{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "***Import needed libraries***"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "import numpy as np\n",
    "import nltk\n",
    "import re\n",
    "import multiprocessing\n",
    "from multiprocessing import Pool\n",
    "import regex"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "**The databases that the code needs during the work:**         \n",
    "1) Key_indications.csv         \n",
    "2) CLINICALTRIALS_ORIGINAL.csv          \n",
    "3) EFO2MESH.csv       \n",
    "4) NCTID_CONDITION_EFO.csv        \n",
    "5) NCT_ID2MOLREGNO.csv        \n",
    "6) EFO2NAME.csv       \n",
    "7) INTERVENTIONS.csv       \n",
    "8) TRIALS_TERMITE.csv      \n",
    "9) TERMITE_TABLE.csv      \n",
    "10) Outcome.csv        \n",
    "11) NOT_MATCHED_WORDS.csv       \n",
    "12) SYNONYMS_FULL_CL.csv        \n",
    "13) tweets_db.csv         \n",
    "14) Phases.csv         "
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# <font color='green'> I. Exctracting information </font>"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Export the needed table with whole tweets, delete the columns that are not needed.       \n",
    "i_table ~ initial table"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "The length of the initial table = 15897\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>TWID</th>\n",
       "      <th>TWEET_ID</th>\n",
       "      <th>TWEET</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>1</td>\n",
       "      <td>986637456241029123</td>\n",
       "      <td>Session on Brexit implications at #DIAEurope20...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2</td>\n",
       "      <td>986605359111565312</td>\n",
       "      <td>Patient Centricity Beyond the Talk session at ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>3</td>\n",
       "      <td>986546919467085825</td>\n",
       "      <td>The FDA approved Rigel's Tavalisse for chronic...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   TWID            TWEET_ID                                              TWEET\n",
       "0     1  986637456241029123  Session on Brexit implications at #DIAEurope20...\n",
       "1     2  986605359111565312  Patient Centricity Beyond the Talk session at ...\n",
       "2     3  986546919467085825  The FDA approved Rigel's Tavalisse for chronic..."
      ]
     },
     "execution_count": 2,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#create a table with names of columns\n",
    "i_table = pd.read_csv(r'tweets_db.csv', encoding='utf8', names=['TWID', 'USER_NAME', 'SCREEN_NAME', 'TWEET_ID', \n",
    "                                                                'TWEET', 'TWEET_URL', 'TWEET_CREATED_AT', \n",
    "                                                                'QUERY_METHOD', 'QUERY_USED', 'INSERTED_AT'])\n",
    "\n",
    "#deleting not necessary columns\n",
    "del i_table['USER_NAME']\n",
    "del i_table['SCREEN_NAME']\n",
    "del i_table['TWEET_URL']\n",
    "del i_table['TWEET_CREATED_AT']\n",
    "del i_table['QUERY_METHOD']\n",
    "del i_table['QUERY_USED']\n",
    "del i_table['INSERTED_AT']\n",
    "\n",
    "print('The length of the initial table =' + ' ' + str(len(i_table)))\n",
    "i_table[:3]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Create new working table where will be relevant tweets from the initial table."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>TWID</th>\n",
       "      <th>TWEET_ID</th>\n",
       "      <th>TWEET</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "Empty DataFrame\n",
       "Columns: [TWID, TWEET_ID, TWEET]\n",
       "Index: []"
      ]
     },
     "execution_count": 3,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "w_table = pd.DataFrame(columns=['TWID', 'TWEET_ID', 'TWEET']) #create new table\n",
    "w_table"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "#fill in the new table with relevant tweets\n",
    "\n",
    "pos = 0 #the position in w_table\n",
    "for i in range(len(i_table)):\n",
    "    trial = re.findall(r'trial', str(i_table.loc[i, 'TWEET']).lower()) #looking for 'trial' in tweet\n",
    "    phase = re.findall(r'phase', str(i_table.loc[i, 'TWEET']).lower()) #looking for 'phase' in trial\n",
    "    ph = re.findall(r'ph\\s?\\d?\\w?\\s', str(i_table.loc[i, 'TWEET']).lower()) #looking for 'ph ' in trial\n",
    "    #if selected words are in tweets we add them into our w_table\n",
    "    if len(trial) > 0 or len(phase) > 0 or len(ph) > 0:\n",
    "        w_table.at[pos, 'TWID'] = i_table.loc[i, 'TWID']\n",
    "        w_table.at[pos, 'TWEET_ID'] = i_table.loc[i, 'TWEET_ID']\n",
    "        w_table.at[pos, 'TWEET']= i_table.loc[i, 'TWEET']\n",
    "        pos += 1"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Lenght of working table is 1131\n"
     ]
    }
   ],
   "source": [
    "print('Lenght of working table is', len(w_table))"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "So we work with the table that looks like this ->"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>TWID</th>\n",
       "      <th>TWEET_ID</th>\n",
       "      <th>TWEET</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>4</td>\n",
       "      <td>986398045897191424</td>\n",
       "      <td>@PoseidaThera present promising results in ini...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>16</td>\n",
       "      <td>986219643881885698</td>\n",
       "      <td>Genentech gains a license option to Kineta's a...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>21</td>\n",
       "      <td>985928258708492288</td>\n",
       "      <td>First-in-human trial with MG7-CART shows effic...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>33</td>\n",
       "      <td>985172281734377473</td>\n",
       "      <td>Roche's CpAM modulator RO7049389 well tolerate...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>40</td>\n",
       "      <td>984750427186126848</td>\n",
       "      <td>Live at #ILC2018 FXR agonist EYP001 from Enyo ...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "  TWID            TWEET_ID                                              TWEET\n",
       "0    4  986398045897191424  @PoseidaThera present promising results in ini...\n",
       "1   16  986219643881885698  Genentech gains a license option to Kineta's a...\n",
       "2   21  985928258708492288  First-in-human trial with MG7-CART shows effic...\n",
       "3   33  985172281734377473  Roche's CpAM modulator RO7049389 well tolerate...\n",
       "4   40  984750427186126848  Live at #ILC2018 FXR agonist EYP001 from Enyo ..."
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "w_table[:5]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## <font color='green'> Phases </font>"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Now we add a column and information about the phases. Running through a table with variants of phases and finding the needed ones.      \n",
    "There are some tweets where is information more than about one phase. Make a column with number of phases."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "phases = pd.read_csv('Phases.csv', encoding='utf8') #open a dataframe with variants of phases\n",
    "del phases['Unnamed: 0']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Variant</th>\n",
       "      <th>Outcome</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>phase 1\\s</td>\n",
       "      <td>Phase 1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>phase 2\\s</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>phase 3\\s</td>\n",
       "      <td>Phase 3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>phase I\\s</td>\n",
       "      <td>Phase 1</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "     Variant  Outcome\n",
       "0  phase 1\\s  Phase 1\n",
       "1  phase 2\\s  Phase 2\n",
       "2  phase 3\\s  Phase 3\n",
       "3  phase I\\s  Phase 1"
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "phases[:4]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [],
   "source": [
    "w_table['PHASE'] = 'Null'\n",
    "w_table['N_PHASES'] = 'Null'"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [],
   "source": [
    "#Find a phase for each tweet\n",
    "for i in range(len(w_table)):\n",
    "    for j in range(len(phases)):\n",
    "        #delete from tweet all the mess\n",
    "        line = str(w_table.loc[i, 'TWEET']).lower().replace('.', ' ').replace(',', ' ').replace('?', ' ').replace(';', ' ')\n",
    "        res = re.findall(str(phases.loc[j, 'Variant']).lower(), line) #search a phase in tweet\n",
    "        if len(res) > 0: #if there is - pick it in a list\n",
    "            w_table.at[i, 'PHASE'] = phases.loc[j, 'Outcome'] # Outcome is a column with the exact form of the phase (ex. Phase 1) "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "The amount tweets without information about phases is 442\n"
     ]
    }
   ],
   "source": [
    "#count how many cells are without phases\n",
    "null_phases = 0 #counter\n",
    "for i in range(len(w_table)):\n",
    "    if str(w_table.loc[i, 'PHASE']) == 'Null': #if there is no phase\n",
    "        null_phases += 1 #add one to counter\n",
    "        \n",
    "print(\"The amount tweets without information about phases is\", null_phases)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [],
   "source": [
    "#count how many phases are in the row\n",
    "#make a separate column with number of phases (N_PHASES)\n",
    "for i in range(len(w_table)):\n",
    "    ph = re.findall(r'\\s\\\\ph\\s', w_table.loc[i, 'TWEET'].lower()) #if there is 'ph'\n",
    "    ph_d = re.findall(r'ph\\d', w_table.loc[i, 'TWEET'].lower()) #if there is 'ph1' or 'ph2' or 'ph3'\n",
    "    p_d = re.findall(r'p(?:i|ii|iii|1|2|3)', w_table.loc[i, 'TWEET'].lower()) #if there is 'p1' or 'pIII' etc\n",
    "    phase = re.findall(r'phase', w_table.loc[i, 'TWEET'].lower()) #if there is simple 'phase'\n",
    "    first_in_tr = re.findall(r'first', w_table.loc[i, 'TWEET'].lower()) #if there is 'first' (first-in-trial, etc)\n",
    "    preclinical_tr = re.findall(r'preclinical trial', w_table.loc[i, 'TWEET'].lower()) #if there is 'preclinical trial'\n",
    "    # the number of phases is the sum of what was found ^\n",
    "    w_table.at[i, 'N_PHASES'] = len(phase) + len(ph) + len(ph_d) + len(p_d) + len(first_in_tr) + len(preclinical_tr)\n",
    "    \n",
    "    #this line is just for other variants\n",
    "    #if there is already found phase by table but not found by this cell just add 1\n",
    "    if w_table.loc[i, 'N_PHASES'] == 0 and w_table.at[i, 'PHASE'] != 'Null':       \n",
    "        w_table.at[i, 'N_PHASES'] = 1"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>TWID</th>\n",
       "      <th>TWEET_ID</th>\n",
       "      <th>TWEET</th>\n",
       "      <th>PHASE</th>\n",
       "      <th>N_PHASES</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>4</td>\n",
       "      <td>986398045897191424</td>\n",
       "      <td>@PoseidaThera present promising results in ini...</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>16</td>\n",
       "      <td>986219643881885698</td>\n",
       "      <td>Genentech gains a license option to Kineta's a...</td>\n",
       "      <td>Null</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "  TWID            TWEET_ID                                              TWEET  \\\n",
       "0    4  986398045897191424  @PoseidaThera present promising results in ini...   \n",
       "1   16  986219643881885698  Genentech gains a license option to Kineta's a...   \n",
       "\n",
       "     PHASE N_PHASES  \n",
       "0  Phase 1        1  \n",
       "1     Null        0  "
      ]
     },
     "execution_count": 13,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "w_table[:2]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## <font color='green'> Synonyms and MOLREGNOs </font>"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [],
   "source": [
    "#create new columns with information about found synonyms and molregno\n",
    "w_table['SYNONYMS'] = 'Null'\n",
    "w_table['MOLREGNO'] = 'Null'"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Import full base of synonyms. During the work we found some mistakes in this table. There were synonyms like today, it, we should delete them."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>MOLREGNO</th>\n",
       "      <th>SYNONYMS</th>\n",
       "      <th>SYN_TYPE</th>\n",
       "      <th>MOLSYN_ID</th>\n",
       "      <th>RES_STEM_ID</th>\n",
       "      <th>MOLECULE_SYNONYM</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>406801</td>\n",
       "      <td>10-METHOXYLUOTONIN A</td>\n",
       "      <td>TRADE_NAME_OLD</td>\n",
       "      <td>409.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>10-Methoxyluotonin A</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>371540</td>\n",
       "      <td>10-METHOXYMETHYLOXY-GINKGOLIDE A</td>\n",
       "      <td>TRADE_NAME_OLD</td>\n",
       "      <td>410.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>10-Methoxymethyloxy-Ginkgolide A</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>510072</td>\n",
       "      <td>10-O-METHYLJERANTININE A</td>\n",
       "      <td>TRADE_NAME_OLD</td>\n",
       "      <td>411.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>10-O-Methyljerantinine A</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   MOLREGNO                          SYNONYMS        SYN_TYPE  MOLSYN_ID  \\\n",
       "0    406801              10-METHOXYLUOTONIN A  TRADE_NAME_OLD      409.0   \n",
       "1    371540  10-METHOXYMETHYLOXY-GINKGOLIDE A  TRADE_NAME_OLD      410.0   \n",
       "2    510072          10-O-METHYLJERANTININE A  TRADE_NAME_OLD      411.0   \n",
       "\n",
       "   RES_STEM_ID                  MOLECULE_SYNONYM  \n",
       "0          NaN              10-Methoxyluotonin A  \n",
       "1          NaN  10-Methoxymethyloxy-Ginkgolide A  \n",
       "2          NaN          10-O-Methyljerantinine A  "
      ]
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "synonyms = pd.read_csv(r'SYNONYMS_FULL_CL.csv', encoding='utf8', names = ['MOLREGNO', 'SYNONYMS', 'SYN_TYPE', 'MOLSYN_ID', 'RES_STEM_ID', 'MOLECULE_SYNONYM'])\n",
    "synonyms[:3]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Length of the initial table with synonyms 661425\n"
     ]
    }
   ],
   "source": [
    "print('Length of the initial table with synonyms', len(synonyms))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Length of clean table with synonyms 661385\n"
     ]
    }
   ],
   "source": [
    "#cleaning the synonyms table\n",
    "mistakes = ['^it$', 'today', 'target', '^dry clear', 'good health', '^at iii$', '^go$', '^may$', 'stop', 'good health'] #list of not relevant for text mining synonyms\n",
    "drop_mistakes = [] #list for indexes to delete\n",
    "\n",
    "for i in range(len(synonyms)): \n",
    "    for j in range(len(mistakes)):\n",
    "        mistake = re.findall(mistakes[j], str(synonyms.loc[i, 'SYNONYMS']).lower()) #look for mistake in synonyms table\n",
    "        if len(mistake) > 0: #if there is\n",
    "            drop_mistakes.append(i) #add the index to the list\n",
    "        \n",
    "synonyms = synonyms.drop(synonyms.index[drop_mistakes]) #drop not relevant synonyms\n",
    "synonyms.index = np.arange(len(synonyms)) #update indexes\n",
    "print('Length of clean table with synonyms', len(synonyms))"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### <font color='green'>Match synonyms with tweets </font>"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [],
   "source": [
    "#Parallelization of the process, making 6 chunks to work with them on different kernels\n",
    "#Make 6 parts of the working table\n",
    "\n",
    "a = w_table[0 : len(w_table) // 6]\n",
    "a.index = np.arange(len(a))\n",
    "\n",
    "b = w_table[len(w_table) // 6 : len(w_table) // 3]\n",
    "b.index = np.arange(len(b))\n",
    "\n",
    "c = w_table[len(w_table) // 3 : len(w_table) // 2]\n",
    "c.index = np.arange(len(c))\n",
    "\n",
    "d = w_table[len(w_table) // 2 : (2 * len(w_table)) // 3]\n",
    "d.index = np.arange(len(d))\n",
    "\n",
    "e = w_table[(2 * len(w_table)) // 3 : (5 * len(w_table)) // 6]\n",
    "e.index = np.arange(len(e))\n",
    "\n",
    "f = w_table[(5 * len(w_table)) // 6 : len(w_table)]\n",
    "f.index = np.arange(len(f)) \n",
    "\n",
    "#list of chunks of the working table that will be run by function\n",
    "chunks = [a, b, c, d, e, f]\n",
    "\n",
    "#number of chunks = number of kernels that is going to use during the process"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [],
   "source": [
    "def find_synonyms(chunk): #function that is used in parallezation and is looking for the synonyms\n",
    "    chunk_copy = chunk #copy to use its' length to work on\n",
    "    for i in range(len(chunk_copy)):\n",
    "        for j in range(len(synonyms)):\n",
    "            #clean synonyms from (+) and so on\n",
    "            syn = synonyms.loc[j, 'SYNONYMS'].lower().replace('+', '').replace(')', '').replace('(', '').replace('[', '').replace(']', '').replace('|', '').replace(',', '').replace('.', '').replace(':', '').replace(';', '').replace('{', '').replace('}', '')\n",
    "            #clean tweet from everything that could prevent matching\n",
    "            tweet = chunk.loc[i, 'TWEET'].lower().replace('?', '').replace('!', '').replace('\\\\', '').replace(\"'\", '').replace('@', ' ').replace('-', '').replace('+', ' ').replace('#', ' ').replace(')', ' ').replace('(', ' ').replace('[', ' ').replace(']', ' ').replace('|', ' ').replace(',', ' ').replace('.', ' ').replace(':', ' ').replace(';', ' ').replace('{', ' ').replace('}', ' ').split()\n",
    "            syn_split = syn.split() #split the word from table with synonyms (to look how many words are in it)\n",
    "            \n",
    "            if len(syn_split) == 1: #if it is one word\n",
    "                if syn.lower() in tweet: #if synonym is in tweet\n",
    "                    if str(chunk.loc[i, 'SYNONYMS']) == 'Null': #if synonyms' cell is empty add the information\n",
    "                        chunk.at[i, 'SYNONYMS'] = synonyms.loc[j, 'SYNONYMS'].upper() \n",
    "                        chunk.at[i, 'MOLREGNO'] = synonyms.loc[j, 'MOLREGNO']\n",
    "                    elif str(chunk.loc[i, 'SYNONYMS']) != 'Null': #if synonyms' cell is full\n",
    "                        new_row = chunk.iloc[i] #create a new row\n",
    "                        chunk = chunk.append(new_row) #add it to the end of the table\n",
    "                        chunk.index = np.arange(len(chunk)) #update the indices\n",
    "                        chunk.at[len(chunk) - 1, 'SYNONYMS'] = synonyms.loc[j, 'SYNONYMS'].upper() #add the synonym to new row\n",
    "                        chunk.at[len(chunk) - 1, 'MOLREGNO'] = synonyms.loc[j, 'MOLREGNO'] #add the molregno to new row \n",
    "\n",
    "            c = 0 #counter       \n",
    "            if len(syn_split) > 1: #if there is more than one word in synonym\n",
    "                for k in range(len(syn_split)): #check if every word is in tweet\n",
    "                    if syn_split[k] in tweet: #if it is in tweet add 1 to counter\n",
    "                        c += 1 \n",
    "                if c == len(syn_split): #if counter is the same as length of synonym\n",
    "                    if str(chunk.loc[i, 'SYNONYMS']) == 'Null': #if synonyms' cell is empty add the information\n",
    "                        chunk.at[i, 'SYNONYMS'] = synonyms.loc[j, 'SYNONYMS'].upper()\n",
    "                        chunk.at[i, 'MOLREGNO'] = synonyms.loc[j, 'MOLREGNO']\n",
    "                    elif str(chunk.loc[i, 'SYNONYMS']) != 'Null': #if synonyms' cell is full\n",
    "                        new_row = chunk.iloc[i] #create a new row\n",
    "                        chunk = chunk.append(new_row) #add it to the end of the table\n",
    "                        chunk.index = np.arange(len(chunk)) #update the indices\n",
    "                        chunk.at[len(chunk) - 1, 'SYNONYMS'] = synonyms.loc[j, 'SYNONYMS'].upper() #add the synonym to new row\n",
    "                        chunk.at[len(chunk) - 1, 'MOLREGNO'] = synonyms.loc[j, 'MOLREGNO'] #add the molregno to new row              \n",
    "    return chunk\n",
    "\n",
    "\n",
    "if __name__ == '__main__': #constructor for parallezation\n",
    "    p = Pool(6) #use 6 kernels to work on them\n",
    "    result = p.map(find_synonyms, chunks) #\n",
    "    #print(result)   #prints the list with updated chunks\n",
    "    \n",
    "    \n",
    "dataframe = w_table[0:0] #make the frame for the main table\n",
    "for i in range(len(result)):\n",
    "        dataframe = dataframe.append(result[i]) #add parts to the main table\n",
    "        \n",
    "        \n",
    "dataframe = dataframe.drop_duplicates(subset=['TWID', 'SYNONYMS', 'MOLREGNO'], keep='first', inplace=False) #delete all duplicates\n",
    "dataframe = dataframe.sort_values(by = ['TWID']) #sort by twids\n",
    "dataframe.index = np.arange(len(dataframe)) #update the indexes"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Length of dataframe now is increased. Now is 1224\n"
     ]
    }
   ],
   "source": [
    "print('Length of dataframe now is increased. Now is', len(dataframe))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>TWID</th>\n",
       "      <th>TWEET_ID</th>\n",
       "      <th>TWEET</th>\n",
       "      <th>PHASE</th>\n",
       "      <th>N_PHASES</th>\n",
       "      <th>SYNONYMS</th>\n",
       "      <th>MOLREGNO</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>4</td>\n",
       "      <td>986398045897191424</td>\n",
       "      <td>@PoseidaThera present promising results in ini...</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>1</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>16</td>\n",
       "      <td>986219643881885698</td>\n",
       "      <td>Genentech gains a license option to Kineta's a...</td>\n",
       "      <td>Null</td>\n",
       "      <td>0</td>\n",
       "      <td>ACETYLCHOLINE</td>\n",
       "      <td>27812</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>16</td>\n",
       "      <td>986219643881885698</td>\n",
       "      <td>Genentech gains a license option to Kineta's a...</td>\n",
       "      <td>Null</td>\n",
       "      <td>0</td>\n",
       "      <td>ACETYLCHOLINE</td>\n",
       "      <td>195974</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>21</td>\n",
       "      <td>985928258708492288</td>\n",
       "      <td>First-in-human trial with MG7-CART shows effic...</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>1</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>33</td>\n",
       "      <td>985172281734377473</td>\n",
       "      <td>Roche's CpAM modulator RO7049389 well tolerate...</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>1</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>40</td>\n",
       "      <td>984750427186126848</td>\n",
       "      <td>Live at #ILC2018 FXR agonist EYP001 from Enyo ...</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>1</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>65</td>\n",
       "      <td>981919705912004609</td>\n",
       "      <td>Boehringer Ingelheim to progress OSE's SIRP-al...</td>\n",
       "      <td>Null</td>\n",
       "      <td>0</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>106</td>\n",
       "      <td>977514137046667265</td>\n",
       "      <td>41 patients have been enrolled in the ongoing ...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>1</td>\n",
       "      <td>BINIMETINIB</td>\n",
       "      <td>1677014</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>106</td>\n",
       "      <td>977514137046667265</td>\n",
       "      <td>41 patients have been enrolled in the ongoing ...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>1</td>\n",
       "      <td>RIBOCICLIB</td>\n",
       "      <td>2039237</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>106</td>\n",
       "      <td>977514137046667265</td>\n",
       "      <td>41 patients have been enrolled in the ongoing ...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>1</td>\n",
       "      <td>RIBOCICLIB</td>\n",
       "      <td>1926959</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "  TWID            TWEET_ID                                              TWEET  \\\n",
       "0    4  986398045897191424  @PoseidaThera present promising results in ini...   \n",
       "1   16  986219643881885698  Genentech gains a license option to Kineta's a...   \n",
       "2   16  986219643881885698  Genentech gains a license option to Kineta's a...   \n",
       "3   21  985928258708492288  First-in-human trial with MG7-CART shows effic...   \n",
       "4   33  985172281734377473  Roche's CpAM modulator RO7049389 well tolerate...   \n",
       "5   40  984750427186126848  Live at #ILC2018 FXR agonist EYP001 from Enyo ...   \n",
       "6   65  981919705912004609  Boehringer Ingelheim to progress OSE's SIRP-al...   \n",
       "7  106  977514137046667265  41 patients have been enrolled in the ongoing ...   \n",
       "8  106  977514137046667265  41 patients have been enrolled in the ongoing ...   \n",
       "9  106  977514137046667265  41 patients have been enrolled in the ongoing ...   \n",
       "\n",
       "     PHASE N_PHASES       SYNONYMS MOLREGNO  \n",
       "0  Phase 1        1           Null     Null  \n",
       "1     Null        0  ACETYLCHOLINE    27812  \n",
       "2     Null        0  ACETYLCHOLINE   195974  \n",
       "3  Phase 1        1           Null     Null  \n",
       "4  Phase 1        1           Null     Null  \n",
       "5  Phase 1        1           Null     Null  \n",
       "6     Null        0           Null     Null  \n",
       "7  Phase 2        1    BINIMETINIB  1677014  \n",
       "8  Phase 2        1     RIBOCICLIB  2039237  \n",
       "9  Phase 2        1     RIBOCICLIB  1926959  "
      ]
     },
     "execution_count": 24,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "dataframe[:10]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {},
   "outputs": [],
   "source": [
    "#to save it to csv for some reason\n",
    "dataframe.to_csv('Working_dataframe_03.csv', sep='\\t', encoding='utf8')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### <font color='indigo'> *Important information about matchings after this process* </font>"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "The amount of synonyms that was added with this table is 400\n",
      "The length of the dataframe is 1224\n",
      "___________\n",
      "The amount of unique tweets that now has synonyms is 307\n",
      "The amount of unique tweets is now 1130\n"
     ]
    }
   ],
   "source": [
    "# The cell to make some conslusion about matching\n",
    "c = 0 \n",
    "indexes_synonyms = ['0'] #the list with indexes of rows where synonyms were added by the table of synonyms\n",
    "\n",
    "for i in range(len(dataframe)):\n",
    "    if (str(dataframe.loc[i, 'SYNONYMS']) != 'Null'):\n",
    "        c += 1\n",
    "\n",
    "for i in range(len(dataframe)): \n",
    "    if (str(dataframe.loc[i, 'SYNONYMS']) != 'Null') and (str(dataframe.loc[i, 'TWID']) not in indexes_synonyms):\n",
    "        indexes_synonyms.append(str(dataframe.loc[i, 'TWID']))\n",
    "\n",
    "uni = 0 #count how many unique twids there are\n",
    "for i in range(1, len(dataframe)):\n",
    "    if str(dataframe.loc[i, 'TWID']) != str(dataframe.loc[i - 1, 'TWID']):\n",
    "        uni += 1\n",
    "        \n",
    "print('The amount of synonyms that was added with this table is', c)\n",
    "print('The length of the dataframe is', len(dataframe))\n",
    "print('___________')\n",
    "print('The amount of unique tweets that now has synonyms is', len(indexes_synonyms) - 1)\n",
    "print('The amount of unique tweets is now', uni)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "metadata": {},
   "outputs": [],
   "source": [
    "#table_with_synonyms_first = dataframe"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>TWID</th>\n",
       "      <th>TWEET_ID</th>\n",
       "      <th>TWEET</th>\n",
       "      <th>PHASE</th>\n",
       "      <th>N_PHASES</th>\n",
       "      <th>SYNONYMS</th>\n",
       "      <th>MOLREGNO</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>4</td>\n",
       "      <td>986398045897191424</td>\n",
       "      <td>@PoseidaThera present promising results in ini...</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>1</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>16</td>\n",
       "      <td>986219643881885698</td>\n",
       "      <td>Genentech gains a license option to Kineta's a...</td>\n",
       "      <td>Null</td>\n",
       "      <td>0</td>\n",
       "      <td>ACETYLCHOLINE</td>\n",
       "      <td>27812</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "  TWID            TWEET_ID                                              TWEET  \\\n",
       "0    4  986398045897191424  @PoseidaThera present promising results in ini...   \n",
       "1   16  986219643881885698  Genentech gains a license option to Kineta's a...   \n",
       "\n",
       "     PHASE N_PHASES       SYNONYMS MOLREGNO  \n",
       "0  Phase 1        1           Null     Null  \n",
       "1     Null        0  ACETYLCHOLINE    27812  "
      ]
     },
     "execution_count": 29,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "dataframe[:2]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### <font color='green'> Matching with the list of acronyms (new column) </font>"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Added information to 42 tweets\n"
     ]
    }
   ],
   "source": [
    "# Names of trials I found:\n",
    "trials = ['HMAXIK', 'APECS', 'BRIGHTE', 'CONTI-PV', 'BISE', 'LMTX', 'COPD', 'APEX', 'AML', 'CAR', 'ADXS-NEO', \n",
    "          'EFFECT-HF', 'AEGIS', 'DLBCL', 'NASH', 'PoC', 'PTGX', 'MPS', 'MATCH', 'ASND', 'GPCR', 'CART', 'SWOG',\n",
    "          'KEYNOTE']\n",
    "\n",
    "dataframe['ACRONYM'] = 'Null' #make a new column to fill there the information about acronyms\n",
    "from_acr = []\n",
    "how_many_acr = 0 #counter\n",
    "for i in range(len(dataframe)):\n",
    "    if str(dataframe.loc[i, 'SYNONYMS']) == 'Null': #if the information about synonyms is not found\n",
    "        #clean the tweet and look there for a acronym\n",
    "        tweet = dataframe.loc[i, 'TWEET'].replace('@', ' ').replace('$', ' ').replace('#', ' ').replace('?', ' ').replace('!', ' ').replace('\\\\', ' ').replace('+', ' ').replace(')', ' ').replace('(', ' ').replace('[', ' ').replace(']', ' ').replace('|', ' ').replace(',', ' ').replace('.', ' ').replace(':', ' ').replace(';', ' ').replace('{', ' ').replace('}', ' ').split()\n",
    "        for j in range(len(trials)):\n",
    "            if trials[j] in tweet: #if trial in tweet\n",
    "                dataframe.at[i, 'ACRONYM'] = trials[j] #add it to a column with acronyms\n",
    "                how_many_acr += 1 #counter + 1\n",
    "                from_acr.append(i) #to know where acronyms were added\n",
    "                \n",
    "print('Added information to', how_many_acr, 'tweets by trials list') "
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### <font color='green'> Matching with regular expressions </font>"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "metadata": {},
   "outputs": [],
   "source": [
    "#list of things I don't want to match by reg_exp, some mess\n",
    "notl = ['vision2016', 'First-in', 'first-in', '11', 'ucel-T', 'icense2016', 'Nonfiction8879', 'califf001', 'bluejaunt100', 'S-like', 'icrobe2018', 'anut-aller', 'muno-oncol', 'sing-remit', '99-100', 'ayed-relea', \n",
    "        'Post-hoc',  'EA2017', 'umab-EU', 'ILC2018', 'oAsia2018', 'EAU18', 'Editor-in', 'ASH2017', 'Paris2017', 'upYby68',\n",
    "        'KhUtk42', 'osis-relat', '4Q17', '9-39', 'Aiims1742', 'non-valvu', 'raft-versu', 'owKWW16', 'rgets17', 'EULAR2018', 'ASCO18', '2017', '2018', '2016', '2015',\n",
    "        'shwin97', 'itor-refra', 'IB-MS', 'CD33-speci', 'aliff001', 'roof-of', 'Chi-Med' 'IWD2018', 'ODlp78', 'ndera07', 'jaunt100', 'ction8879', 'Acc18', 'AACR2018',\n",
    "        'ESMO2017', 'power130', 'Chi-Med', 'EBV-speci', 'HFE-relat', 'asco18', 'gmt9992', 'power150', 'NOP-46', 'rcFq50', '1000', '1539', 'ASCO17', \n",
    "        '4Q2017', 'T1E28', 'anti-P', 'ADXS-NEO', 'HIF-PH', '1Q18', 'RION-1', 'AHA16', 'anti-cance', '2609', 'DWeek2016', 'EAU17', 'qtifA46', 'Zr89', '12019', \n",
    "        'unCD47', 'ash17', 'dime-aviba', 'ntra-abdom', 'eO94', 'JPM18', 'ARVO2018', 'OVWLv30', 'CIMT2018', 'SBS2018', 'gx17', 'b0HKd44', \n",
    "        'l2ovv62', 'CCMID2018', '36-51', 'crobe2018', '5461', '6OGjm11', 'fu27', 'ISSCR2017', 'EULAR2017', 'AAIC17',\n",
    "       'cense2016', 'non-CF', 'mu-opoid', 'ONIS-ANGPT', 'out-of', 'eular2016', 'Lefmk47', '6juOv79', 'WCLC2016', 'EXk61', 'EjOGO57', '4Q16', 'ASCO16', 'cPnY186',\n",
    "       'hBZiu81','24-week', 'Ex-Dezim', 'rate-to', '8E12', 'edge-Based', 'Ado-trast', 'O0nI10', 'ASH2016', 'RSLDN2016', 'ASCO16', 'Pq3fK45', 'ATS2018', 'MOR208', 'IdiFh13', 'ESHG2016', 'non-infer', 'rGEN-X', 'nkle-reduc', 'EANM2016', 'ICTMC2017', 'DDW17', 'SITC2017' 'WIyR70', 'CCMID2017', \n",
    "       'AASLD16', 'TRIMS2016', 'KEYNOTE006', 'TORE-IMI', 'ASCO2018','anti-seizu', 'SITC2017', 'ESHG2017', 'wr4R27', '5126', 'ATS2017', 'BSW17', 'dry-eye', \n",
    "        'AACR18', 'ulse-conti', 'IBIT-MESO', 'FECT-HF',  'JAK1', 'JAK2', 'Ph2', 'Ph1', 'Ph3', 'long-term', 'irst-in', 'some-posit', 'Pre-IND', \n",
    "        'stol-Myers', 'anti-Tau', 'non-cysti', 'GOOD HEALTH', 'tion-resis', 'ment-exper', 'anti-tuber', 'cebo-contr', 'llow-up', 'well-balan', 'irus-based',\n",
    "        'ally-advan', 'avel-time', 'top-line', 'ROS1-posit', 'long-actin', 'cult-to', 'non-syste', 'arly-stage', 'rite-up', 'tice-chang', 'ROVE-IT', 'all-cause',\n",
    "       'uana-Based', 'AP-CBD', 'T-cell', '13-0', 'non-Hodgk', 're-used', 'iRNA-allel', 'Fc-fused', 'mild-to', 'INI1-negat', 'MRI-guide', 'open-label', 're-reead', 'free-rider', \n",
    "        'irst-line', 'non-indus', 'TNBC-MERIT', 'enti-D', 'Wu-Xi', 'ex-someb', 'anut-aller', 'Can-Fite', 'phil-deple', 'anti-multi', 'rass-SPIRE', 'abis-based', 'issi-Thode',\n",
    "        'SIRP-alpha', 'two-trial', 'gram-', '2-trial', 'ngle-arm', 'anti-aging', 'low-dose',\n",
    "        'apid-fire', 'iota-resto', 'New-', 'Anti-aging', 'well-toler', 'mega-round', 'Site-less', 'mega-round', 'go-ahead', 'long-delay', 'CAR-T', 'lash-and', 'DSP-Visul',\n",
    "         'ngle-agent', 'itor-in', 'RET-alter',  'late-stage', 'late-stage', 'ngle-cell', 'ONIS-MAPTR', 'post-marke', 'half-life', 'beta-amylo',\n",
    "        'ncer-fight', 'ET-alter', 'anti-tumor', 'uble-blind', 'irst-time', 'rial-', 'MTL-CEBPA', 'I-bound', 'Mind-contr', 'I-ready', 'mid-stage', 'Mind-contr', 'mega-block', 'High-Perfo',\n",
    "        'anti-TIM', 'Cancer-fight', 'slash-and', 'nowledge-Based', 'rapid-fire', 'proof-of', 'aghrissi-Thode', 'first-in', 'stration-resis', 'immuno-oncol', 'SiRNA-allel', 'Editor-in', 'Immuno-oncol', 'Single-cell', 'crobiota-resto',\n",
    "        'First-time', 'IMPROVE-IT', 'placebo-contr', 'first-line', 'program-']\n",
    "\n",
    "const = 0 #counter\n",
    "\n",
    "for i in range(len(dataframe)):\n",
    "    if str(dataframe.loc[i, 'SYNONYMS']) == 'Null': #suggest that if the synonym is already found it should be a correct synonym\n",
    "        #here are four types of regular expressions\n",
    "        first = re.findall(r'\\w{1,6}\\-\\d{1,9}', str(dataframe.loc[i, 'TWEET'])) \n",
    "        second = re.findall(r'\\w{1,9}\\d{,1}\\-\\d{,3}\\w{,5}\\d{,2}', str(dataframe.loc[i, 'TWEET']))\n",
    "        third = re.findall(r'\\w{,4}\\d?\\w{1,3}?\\-\\w{1,4}\\-\\w{1,7}?\\d{1,3}', str(dataframe.loc[i, 'TWEET']))\n",
    "        fourth = re.findall(r'\\w{2,15}\\-?\\d{2,9}', str(dataframe.loc[i, 'TWEET']))\n",
    "        \n",
    "        #conditions depending on that\n",
    "        #first look at the third regular expression, it is the biggest and the most complicated\n",
    "        if (len(third) > 0) and (third[0] not in notl):\n",
    "            res = third\n",
    "        elif (((len(third) > 0) and (third[0] in notl)) or len(third) == 0)  and (len(second) > 0) and (second[0] not in notl):\n",
    "            res = second\n",
    "        elif (((len(third) > 0) and (third[0] in notl)) or len(third) == 0) and (((len(second) > 0) and (second[0] in notl)) or len(second) == 0) and ((len(first) > 0) and (first[0] not in notl)):\n",
    "            res = first\n",
    "        else:\n",
    "            if len(re.findall(r'\\w\\w\\d\\-\\w\\w\\w\\w', str(dataframe.loc[i, 'TWEET']))) > 0:\n",
    "                res = re.findall(r'\\w\\w\\d\\-\\w\\w\\w\\w', str(dataframe.loc[i, 'TWEET']))\n",
    "            else:\n",
    "                res = fourth\n",
    "\n",
    "        if len(res) > 0:\n",
    "            if (res[0] not in notl) and (len(re.findall('^\\w?\\d{,4}$', res[0])) == 0): #if the word is not in the list of mess and it's not only a digit word\n",
    "                years = ['2014', '2015', '2016', '2017', '2018', '2019', '2020', '2021', '2022'] #to check one more time that the word is not the name of conference (they usually contain the year)\n",
    "                check = 0 #checker\n",
    "                for year in range(len(years)): \n",
    "                    if len(re.findall(years[year], res[0])) > 0: #if there is a year in the word\n",
    "                        check += 1 #increase checker\n",
    "\n",
    "                if (check == 0) and (dataframe.loc[i, 'SYNONYMS'] == 'Null'): #if the checker is not mentioned and the synonyms cell is free\n",
    "                    dataframe.at[i, 'SYNONYMS'] = res[0] #add the information\n",
    "                    dataframe.at[i, 'MOLREGNO'] = 'Not found' \n",
    "                    const += 1 # +1 to counter to know how many words were added by regular expressions"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "How many words were matched by regular expressions 388\n"
     ]
    }
   ],
   "source": [
    "print('How many words were matched by regular expressions', const) "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "The amount of words that were added by regular expressions is 400\n",
      "The length of the dataframe is 1224\n",
      "The amount of unique tweets is now 1130\n",
      "The amount of rows with synonyms is 788\n"
     ]
    }
   ],
   "source": [
    "#The cell for information about what was already done\n",
    "added_by_reg_exp = [] #list of twids of rows that added by regular expressions\n",
    "fromregexp = 0\n",
    "regexp_added_indexes = [] #list of indexes of cells that added by regular expressions\n",
    "inf = 0\n",
    "\n",
    "for i in range(len(dataframe)):\n",
    "    if (dataframe.loc[i, 'SYNONYMS'] != 'Null'):\n",
    "        inf += 1\n",
    "        lenmatched = (len(indexes_synonyms) - 1)\n",
    "        helper = 0\n",
    "        for j in range(len(indexes_synonyms)):\n",
    "            if str(dataframe.loc[i, 'TWID']) != str(indexes_synonyms[j]):\n",
    "                helper += 1\n",
    "                \n",
    "        if helper == lenmatched:\n",
    "            added_by_reg_exp.append(dataframe.loc[i, 'TWID'])\n",
    "            regexp_added_indexes.append(i)\n",
    "            fromregexp += 1\n",
    "\n",
    "uniq = 0 #count how many unique twids there are\n",
    "for i in range(1, len(dataframe)):\n",
    "    if str(dataframe.loc[i, 'TWID']) != str(dataframe.loc[i - 1, 'TWID']):\n",
    "        uniq += 1\n",
    "        \n",
    "print('The amount of words that were added by regular expressions is', fromregexp)\n",
    "print('The length of the dataframe is', len(dataframe))\n",
    "print('The amount of unique tweets is now', uniq)\n",
    "print('The amount of rows with synonyms is', inf)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>TWID</th>\n",
       "      <th>TWEET_ID</th>\n",
       "      <th>TWEET</th>\n",
       "      <th>PHASE</th>\n",
       "      <th>N_PHASES</th>\n",
       "      <th>SYNONYMS</th>\n",
       "      <th>MOLREGNO</th>\n",
       "      <th>ACRONYM</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>4</td>\n",
       "      <td>986398045897191424</td>\n",
       "      <td>@PoseidaThera present promising results in ini...</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>1</td>\n",
       "      <td>P-BCMA-101</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>16</td>\n",
       "      <td>986219643881885698</td>\n",
       "      <td>Genentech gains a license option to Kineta's a...</td>\n",
       "      <td>Null</td>\n",
       "      <td>0</td>\n",
       "      <td>ACETYLCHOLINE</td>\n",
       "      <td>27812</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>16</td>\n",
       "      <td>986219643881885698</td>\n",
       "      <td>Genentech gains a license option to Kineta's a...</td>\n",
       "      <td>Null</td>\n",
       "      <td>0</td>\n",
       "      <td>ACETYLCHOLINE</td>\n",
       "      <td>195974</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>21</td>\n",
       "      <td>985928258708492288</td>\n",
       "      <td>First-in-human trial with MG7-CART shows effic...</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>1</td>\n",
       "      <td>MG7-CART</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>33</td>\n",
       "      <td>985172281734377473</td>\n",
       "      <td>Roche's CpAM modulator RO7049389 well tolerate...</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>1</td>\n",
       "      <td>RO7049389</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>40</td>\n",
       "      <td>984750427186126848</td>\n",
       "      <td>Live at #ILC2018 FXR agonist EYP001 from Enyo ...</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>1</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>65</td>\n",
       "      <td>981919705912004609</td>\n",
       "      <td>Boehringer Ingelheim to progress OSE's SIRP-al...</td>\n",
       "      <td>Null</td>\n",
       "      <td>0</td>\n",
       "      <td>OSE-172</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>106</td>\n",
       "      <td>977514137046667265</td>\n",
       "      <td>41 patients have been enrolled in the ongoing ...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>1</td>\n",
       "      <td>BINIMETINIB</td>\n",
       "      <td>1677014</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>106</td>\n",
       "      <td>977514137046667265</td>\n",
       "      <td>41 patients have been enrolled in the ongoing ...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>1</td>\n",
       "      <td>RIBOCICLIB</td>\n",
       "      <td>2039237</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>106</td>\n",
       "      <td>977514137046667265</td>\n",
       "      <td>41 patients have been enrolled in the ongoing ...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>1</td>\n",
       "      <td>RIBOCICLIB</td>\n",
       "      <td>1926959</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "  TWID            TWEET_ID                                              TWEET  \\\n",
       "0    4  986398045897191424  @PoseidaThera present promising results in ini...   \n",
       "1   16  986219643881885698  Genentech gains a license option to Kineta's a...   \n",
       "2   16  986219643881885698  Genentech gains a license option to Kineta's a...   \n",
       "3   21  985928258708492288  First-in-human trial with MG7-CART shows effic...   \n",
       "4   33  985172281734377473  Roche's CpAM modulator RO7049389 well tolerate...   \n",
       "5   40  984750427186126848  Live at #ILC2018 FXR agonist EYP001 from Enyo ...   \n",
       "6   65  981919705912004609  Boehringer Ingelheim to progress OSE's SIRP-al...   \n",
       "7  106  977514137046667265  41 patients have been enrolled in the ongoing ...   \n",
       "8  106  977514137046667265  41 patients have been enrolled in the ongoing ...   \n",
       "9  106  977514137046667265  41 patients have been enrolled in the ongoing ...   \n",
       "\n",
       "     PHASE N_PHASES       SYNONYMS   MOLREGNO ACRONYM  \n",
       "0  Phase 1        1     P-BCMA-101  Not found    Null  \n",
       "1     Null        0  ACETYLCHOLINE      27812    Null  \n",
       "2     Null        0  ACETYLCHOLINE     195974    Null  \n",
       "3  Phase 1        1       MG7-CART  Not found    Null  \n",
       "4  Phase 1        1      RO7049389  Not found    Null  \n",
       "5  Phase 1        1           Null       Null    Null  \n",
       "6     Null        0        OSE-172  Not found    Null  \n",
       "7  Phase 2        1    BINIMETINIB    1677014    Null  \n",
       "8  Phase 2        1     RIBOCICLIB    2039237    Null  \n",
       "9  Phase 2        1     RIBOCICLIB    1926959    Null  "
      ]
     },
     "execution_count": 34,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "dataframe[:10]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### <font color='green'> Match words that are not matched </font>"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "metadata": {},
   "outputs": [],
   "source": [
    "not_matched = pd.read_csv('NOT_MATCHED_WORDS.csv') #open a table with words that synonyms' table doesn't have + that were not found by anything else\n",
    "not_matched = not_matched['DRUGS']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "The amount of synonyms that were added by this table is 125\n"
     ]
    }
   ],
   "source": [
    "q = 0 #to look how many words were added by this method\n",
    "for i in range(len(dataframe)):\n",
    "    if str(dataframe.loc[i, 'SYNONYMS']) == 'Null': #if the synonym cell is empty\n",
    "        #look in a clean tweet\n",
    "        tweet = dataframe.loc[i, 'TWEET'].lower().replace('-', ' ').replace('@', ' ').replace('$', ' ').replace('#', ' ').replace('?', ' ').replace('!', ' ').replace('\\\\', ' ').replace('+', ' ').replace(')', ' ').replace('(', ' ').replace('[', ' ').replace(']', ' ').replace('|', ' ').replace(',', ' ').replace('.', ' ').replace(':', ' ').replace(';', ' ').replace('{', ' ').replace('}', ' ').split()\n",
    "        for j in range(len(not_matched)): #for the length of the table with not found words\n",
    "            nm = not_matched.loc[j].lower().replace('-', ' ')\n",
    "            nm = nm.split() #there can be not only one word, we need to look for every\n",
    "            x = 0 #counter\n",
    "            for k in range(len(nm)): #for every word in cell from not_matched table\n",
    "                if nm[k] in tweet: #if the word is in tweet\n",
    "                    x += 1 #counter + 1\n",
    "            if len(nm) == x: #if the amount of words in cells is the same as couner (all words are in tweet)\n",
    "                dataframe.at[i, 'SYNONYMS'] = not_matched.loc[j].upper() #add the information to synonyms cell\n",
    "                q += 1 #to look how many words were added by this method\n",
    "                \n",
    "print('The amount of synonyms that were added by this table is', q)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>TWID</th>\n",
       "      <th>TWEET_ID</th>\n",
       "      <th>TWEET</th>\n",
       "      <th>PHASE</th>\n",
       "      <th>N_PHASES</th>\n",
       "      <th>SYNONYMS</th>\n",
       "      <th>MOLREGNO</th>\n",
       "      <th>ACRONYM</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>4</td>\n",
       "      <td>986398045897191424</td>\n",
       "      <td>@PoseidaThera present promising results in ini...</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>1</td>\n",
       "      <td>P-BCMA-101</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>16</td>\n",
       "      <td>986219643881885698</td>\n",
       "      <td>Genentech gains a license option to Kineta's a...</td>\n",
       "      <td>Null</td>\n",
       "      <td>0</td>\n",
       "      <td>ACETYLCHOLINE</td>\n",
       "      <td>27812</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>16</td>\n",
       "      <td>986219643881885698</td>\n",
       "      <td>Genentech gains a license option to Kineta's a...</td>\n",
       "      <td>Null</td>\n",
       "      <td>0</td>\n",
       "      <td>ACETYLCHOLINE</td>\n",
       "      <td>195974</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>21</td>\n",
       "      <td>985928258708492288</td>\n",
       "      <td>First-in-human trial with MG7-CART shows effic...</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>1</td>\n",
       "      <td>MG7-CART</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>33</td>\n",
       "      <td>985172281734377473</td>\n",
       "      <td>Roche's CpAM modulator RO7049389 well tolerate...</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>1</td>\n",
       "      <td>RO7049389</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>40</td>\n",
       "      <td>984750427186126848</td>\n",
       "      <td>Live at #ILC2018 FXR agonist EYP001 from Enyo ...</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>1</td>\n",
       "      <td>EYP001</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>65</td>\n",
       "      <td>981919705912004609</td>\n",
       "      <td>Boehringer Ingelheim to progress OSE's SIRP-al...</td>\n",
       "      <td>Null</td>\n",
       "      <td>0</td>\n",
       "      <td>OSE-172</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>106</td>\n",
       "      <td>977514137046667265</td>\n",
       "      <td>41 patients have been enrolled in the ongoing ...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>1</td>\n",
       "      <td>BINIMETINIB</td>\n",
       "      <td>1677014</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>106</td>\n",
       "      <td>977514137046667265</td>\n",
       "      <td>41 patients have been enrolled in the ongoing ...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>1</td>\n",
       "      <td>RIBOCICLIB</td>\n",
       "      <td>2039237</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>106</td>\n",
       "      <td>977514137046667265</td>\n",
       "      <td>41 patients have been enrolled in the ongoing ...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>1</td>\n",
       "      <td>RIBOCICLIB</td>\n",
       "      <td>1926959</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>116</td>\n",
       "      <td>977140733919547392</td>\n",
       "      <td>The FDA approves Novartis kinase inhibitor nil...</td>\n",
       "      <td>Null</td>\n",
       "      <td>2</td>\n",
       "      <td>NILOTINIB</td>\n",
       "      <td>426660</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>140</td>\n",
       "      <td>976673091500814336</td>\n",
       "      <td>PRN-1008 from Principia Biopharma, a Btk inhib...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>2</td>\n",
       "      <td>PRN-1008</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>141</td>\n",
       "      <td>976672839821611008</td>\n",
       "      <td>Novartis presents LSZ-102, a selective estroge...</td>\n",
       "      <td>Null</td>\n",
       "      <td>1</td>\n",
       "      <td>ESTROGEN</td>\n",
       "      <td>600686</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>177</td>\n",
       "      <td>975811214906478592</td>\n",
       "      <td>Millendo Therapeutics' nevanimibe (ATR-101) re...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>1</td>\n",
       "      <td>ATR-101</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>182</td>\n",
       "      <td>975694542572802049</td>\n",
       "      <td>Positive safety data from an ongoing phase 2 t...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>1</td>\n",
       "      <td>GENE THERAPY</td>\n",
       "      <td>Null</td>\n",
       "      <td>HMAXIK</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>183</td>\n",
       "      <td>975690650514489344</td>\n",
       "      <td>First phase 2 results on GV-1001 in BPH releas...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>2</td>\n",
       "      <td>GV-1001</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>184</td>\n",
       "      <td>975689033983647744</td>\n",
       "      <td>Phase 3 study on vibegron shows good safety an...</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>1</td>\n",
       "      <td>VIBEGRON</td>\n",
       "      <td>1380096</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>195</td>\n",
       "      <td>975490429943721986</td>\n",
       "      <td>Probiodrug introduces PQ-912 in Phase IIa clin...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>1</td>\n",
       "      <td>PQ-912</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>201</td>\n",
       "      <td>975413019047022593</td>\n",
       "      <td>The #FDA recommends #diversity in #clinicaltri...</td>\n",
       "      <td>Null</td>\n",
       "      <td>0</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>203</td>\n",
       "      <td>975374696249163776</td>\n",
       "      <td>Sipuleucel-T mechanism of action disclosed in ...</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>1</td>\n",
       "      <td>ipuleucel-T</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   TWID            TWEET_ID  \\\n",
       "0     4  986398045897191424   \n",
       "1    16  986219643881885698   \n",
       "2    16  986219643881885698   \n",
       "3    21  985928258708492288   \n",
       "4    33  985172281734377473   \n",
       "5    40  984750427186126848   \n",
       "6    65  981919705912004609   \n",
       "7   106  977514137046667265   \n",
       "8   106  977514137046667265   \n",
       "9   106  977514137046667265   \n",
       "10  116  977140733919547392   \n",
       "11  140  976673091500814336   \n",
       "12  141  976672839821611008   \n",
       "13  177  975811214906478592   \n",
       "14  182  975694542572802049   \n",
       "15  183  975690650514489344   \n",
       "16  184  975689033983647744   \n",
       "17  195  975490429943721986   \n",
       "18  201  975413019047022593   \n",
       "19  203  975374696249163776   \n",
       "\n",
       "                                                TWEET    PHASE N_PHASES  \\\n",
       "0   @PoseidaThera present promising results in ini...  Phase 1        1   \n",
       "1   Genentech gains a license option to Kineta's a...     Null        0   \n",
       "2   Genentech gains a license option to Kineta's a...     Null        0   \n",
       "3   First-in-human trial with MG7-CART shows effic...  Phase 1        1   \n",
       "4   Roche's CpAM modulator RO7049389 well tolerate...  Phase 1        1   \n",
       "5   Live at #ILC2018 FXR agonist EYP001 from Enyo ...  Phase 1        1   \n",
       "6   Boehringer Ingelheim to progress OSE's SIRP-al...     Null        0   \n",
       "7   41 patients have been enrolled in the ongoing ...  Phase 2        1   \n",
       "8   41 patients have been enrolled in the ongoing ...  Phase 2        1   \n",
       "9   41 patients have been enrolled in the ongoing ...  Phase 2        1   \n",
       "10  The FDA approves Novartis kinase inhibitor nil...     Null        2   \n",
       "11  PRN-1008 from Principia Biopharma, a Btk inhib...  Phase 2        2   \n",
       "12  Novartis presents LSZ-102, a selective estroge...     Null        1   \n",
       "13  Millendo Therapeutics' nevanimibe (ATR-101) re...  Phase 2        1   \n",
       "14  Positive safety data from an ongoing phase 2 t...  Phase 2        1   \n",
       "15  First phase 2 results on GV-1001 in BPH releas...  Phase 2        2   \n",
       "16  Phase 3 study on vibegron shows good safety an...  Phase 3        1   \n",
       "17  Probiodrug introduces PQ-912 in Phase IIa clin...  Phase 2        1   \n",
       "18  The #FDA recommends #diversity in #clinicaltri...     Null        0   \n",
       "19  Sipuleucel-T mechanism of action disclosed in ...  Phase 1        1   \n",
       "\n",
       "         SYNONYMS   MOLREGNO ACRONYM  \n",
       "0      P-BCMA-101  Not found    Null  \n",
       "1   ACETYLCHOLINE      27812    Null  \n",
       "2   ACETYLCHOLINE     195974    Null  \n",
       "3        MG7-CART  Not found    Null  \n",
       "4       RO7049389  Not found    Null  \n",
       "5          EYP001       Null    Null  \n",
       "6         OSE-172  Not found    Null  \n",
       "7     BINIMETINIB    1677014    Null  \n",
       "8      RIBOCICLIB    2039237    Null  \n",
       "9      RIBOCICLIB    1926959    Null  \n",
       "10      NILOTINIB     426660    Null  \n",
       "11       PRN-1008  Not found    Null  \n",
       "12       ESTROGEN     600686    Null  \n",
       "13        ATR-101  Not found    Null  \n",
       "14   GENE THERAPY       Null  HMAXIK  \n",
       "15        GV-1001  Not found    Null  \n",
       "16       VIBEGRON    1380096    Null  \n",
       "17         PQ-912  Not found    Null  \n",
       "18           Null       Null    Null  \n",
       "19    ipuleucel-T  Not found    Null  "
      ]
     },
     "execution_count": 37,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "dataframe[:20]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "318 1224\n"
     ]
    }
   ],
   "source": [
    "# to look how many words were added by all these matchings\n",
    "a = 0 #counter\n",
    "for i in range(len(dataframe)):\n",
    "    if (str(dataframe.loc[i, 'SYNONYMS']) == 'Null') and (str(dataframe.loc[i, 'ACRONYM']) == 'Null'): \n",
    "        #if there is no information about synonym or acronym\n",
    "        a += 1 #counter +1\n",
    "        \n",
    "print(a, len(dataframe))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "The amount of matched tweets is 74.01960784313727 %\n"
     ]
    }
   ],
   "source": [
    "print('The amount of matched tweets is', (len(dataframe) - a)/len(dataframe) * 100, '%')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### <font color='green'> Deleting not relevant tweets </font>"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "<font color='purple'> **Before** running this part it is **neccessary** to check which tweets are not with any information. While I was running it it showed me that it's a mess or something around this. The ones that were not a mess I added to the list with *not matched words* </font>"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "#you can check by this cell\n",
    "for i in range(len(dataframe)):\n",
    "    if (str(dataframe.loc[i, 'SYNONYMS']) == 'Null') and (str(dataframe.loc[i, 'ACRONYM']) == 'Null'): #if there is no information about synonym or acronym\n",
    "        print(i, dataframe.loc[i. 'TWEET']) #print the tweet\n",
    "        print('______________') #print a separator"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "The amount of tweets without information about synonyms is 290\n"
     ]
    }
   ],
   "source": [
    "delete_tweets = [] #list of indexes of tweets we need to delete\n",
    "empty = 0 #counter\n",
    "for i in range(len(dataframe)):\n",
    "    #if there is no information about synonym or acronym\n",
    "    if str(dataframe.loc[i, 'SYNONYMS']) == 'Null' and str(dataframe.loc[i, 'ACRONYM']) == 'Null':\n",
    "        delete_tweets.append(i) #append index to the list\n",
    "        empty += 1 #add 1 to counter\n",
    "    \n",
    "print('The amount of tweets without information about synonyms is', empty)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "The length of tweets with found synonyms is 934\n"
     ]
    }
   ],
   "source": [
    "dataframe = dataframe.drop(dataframe.index[delete_tweets]) #delete one time all the tweets by indexes\n",
    "dataframe.index = np.arange(len(dataframe)) #update the indexing\n",
    "\n",
    "print('The length of tweets with found synonyms is', len(dataframe))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "The amount of unique tweets is 840\n"
     ]
    }
   ],
   "source": [
    "#check how many unique tweets are still in the table\n",
    "twids_c = 0 #counter\n",
    "for i in range(1, len(dataframe)):\n",
    "    if str(dataframe.loc[i, 'TWID']) != str(dataframe.loc[i - 1, 'TWID']): \n",
    "        twids_c += 1\n",
    "        \n",
    "print('The amount of unique tweets is', twids_c)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>TWID</th>\n",
       "      <th>TWEET_ID</th>\n",
       "      <th>TWEET</th>\n",
       "      <th>PHASE</th>\n",
       "      <th>N_PHASES</th>\n",
       "      <th>SYNONYMS</th>\n",
       "      <th>MOLREGNO</th>\n",
       "      <th>ACRONYM</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>4</td>\n",
       "      <td>986398045897191424</td>\n",
       "      <td>@PoseidaThera present promising results in ini...</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>1</td>\n",
       "      <td>P-BCMA-101</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>16</td>\n",
       "      <td>986219643881885698</td>\n",
       "      <td>Genentech gains a license option to Kineta's a...</td>\n",
       "      <td>Null</td>\n",
       "      <td>0</td>\n",
       "      <td>ACETYLCHOLINE</td>\n",
       "      <td>27812</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>16</td>\n",
       "      <td>986219643881885698</td>\n",
       "      <td>Genentech gains a license option to Kineta's a...</td>\n",
       "      <td>Null</td>\n",
       "      <td>0</td>\n",
       "      <td>ACETYLCHOLINE</td>\n",
       "      <td>195974</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>21</td>\n",
       "      <td>985928258708492288</td>\n",
       "      <td>First-in-human trial with MG7-CART shows effic...</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>1</td>\n",
       "      <td>MG7-CART</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>33</td>\n",
       "      <td>985172281734377473</td>\n",
       "      <td>Roche's CpAM modulator RO7049389 well tolerate...</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>1</td>\n",
       "      <td>RO7049389</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   TWID            TWEET_ID  \\\n",
       "0     4  986398045897191424   \n",
       "1    16  986219643881885698   \n",
       "2    16  986219643881885698   \n",
       "3    21  985928258708492288   \n",
       "4    33  985172281734377473   \n",
       "\n",
       "                                               TWEET    PHASE  N_PHASES  \\\n",
       "0  @PoseidaThera present promising results in ini...  Phase 1         1   \n",
       "1  Genentech gains a license option to Kineta's a...     Null         0   \n",
       "2  Genentech gains a license option to Kineta's a...     Null         0   \n",
       "3  First-in-human trial with MG7-CART shows effic...  Phase 1         1   \n",
       "4  Roche's CpAM modulator RO7049389 well tolerate...  Phase 1         1   \n",
       "\n",
       "        SYNONYMS   MOLREGNO ACRONYM  \n",
       "0     P-BCMA-101  Not found    Null  \n",
       "1  ACETYLCHOLINE      27812    Null  \n",
       "2  ACETYLCHOLINE     195974    Null  \n",
       "3       MG7-CART  Not found    Null  \n",
       "4      RO7049389  Not found    Null  "
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "dataframe[:5]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## <font color='green'> Outcome from the tweet </font>"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>REG_EXP</th>\n",
       "      <th>RESULT</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>shows efficacy</td>\n",
       "      <td>SUCCESS</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>promising results</td>\n",
       "      <td>SUCCESS</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>well tolerated</td>\n",
       "      <td>SUCCESS</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>safe well tolerated</td>\n",
       "      <td>SUCCESS</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "               REG_EXP   RESULT\n",
       "0       shows efficacy  SUCCESS\n",
       "1    promising results  SUCCESS\n",
       "2       well tolerated  SUCCESS\n",
       "3  safe well tolerated  SUCCESS"
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "outcomes = pd.read_csv(r'Outcome.csv', encoding='utf8') #open the table with outcomes\n",
    "outcomes[:4]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "392"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(outcomes)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Matching the outcomes with tweets"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [],
   "source": [
    "ww_table = dataframe #copy to work with\n",
    "\n",
    "for i in range(len(ww_table)): \n",
    "    #clean tweet\n",
    "    ww_table.loc[i, 'TWEET'] =  ww_table.loc[i, 'TWEET'].replace(',', '').replace('.', '').replace(';', '').replace(':', '')\n",
    "    \n",
    "for i in range(len(ww_table)): #for the word in dataframe\n",
    "    for j in range(len(outcomes)): #for the word in table with outcomes\n",
    "        out = outcomes.loc[j, 'REG_EXP'].lower().split() #make a list of words in cell with outcome\n",
    "        tweet = ww_table.loc[i, 'TWEET'].lower().split() #make a list of words in cell with tweet\n",
    "        \n",
    "        counter = 0 #counter\n",
    "        for k in range(len(out)):\n",
    "            if out[k] in tweet: #if the word is in tweet\n",
    "                counter += 1 #add 1 to counter\n",
    "        if counter == len(out): #if all words in tweet\n",
    "            dataframe.at[i, 'OUTCOME'] = outcomes.loc[j, 'RESULT'] #add information about final outcome\n",
    "            dataframe.at[i, 'MATCHED_OUTCOME'] = outcomes.loc[j, 'REG_EXP'] #add information about the reason of decision\n",
    "            \n",
    "            \n",
    "dataframe = dataframe.drop_duplicates() #delete duplicates\n",
    "dataframe = dataframe.fillna('Null') #fill empty cells with 'Null'"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>TWID</th>\n",
       "      <th>TWEET_ID</th>\n",
       "      <th>TWEET</th>\n",
       "      <th>PHASE</th>\n",
       "      <th>N_PHASES</th>\n",
       "      <th>SYNONYMS</th>\n",
       "      <th>MOLREGNO</th>\n",
       "      <th>ACRONYM</th>\n",
       "      <th>OUTCOME</th>\n",
       "      <th>MATCHED_OUTCOME</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>4</td>\n",
       "      <td>986398045897191424</td>\n",
       "      <td>@PoseidaThera present promising results in ini...</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>1</td>\n",
       "      <td>P-BCMA-101</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "      <td>SUCCESS</td>\n",
       "      <td>promising results</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>16</td>\n",
       "      <td>986219643881885698</td>\n",
       "      <td>Genentech gains a license option to Kineta's a...</td>\n",
       "      <td>Null</td>\n",
       "      <td>0</td>\n",
       "      <td>ACETYLCHOLINE</td>\n",
       "      <td>27812</td>\n",
       "      <td>Null</td>\n",
       "      <td>SUCCESS</td>\n",
       "      <td>gains a license</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>16</td>\n",
       "      <td>986219643881885698</td>\n",
       "      <td>Genentech gains a license option to Kineta's a...</td>\n",
       "      <td>Null</td>\n",
       "      <td>0</td>\n",
       "      <td>ACETYLCHOLINE</td>\n",
       "      <td>195974</td>\n",
       "      <td>Null</td>\n",
       "      <td>SUCCESS</td>\n",
       "      <td>gains a license</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>21</td>\n",
       "      <td>985928258708492288</td>\n",
       "      <td>First-in-human trial with MG7-CART shows effic...</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>1</td>\n",
       "      <td>MG7-CART</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "      <td>SUCCESS</td>\n",
       "      <td>shows safety</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>33</td>\n",
       "      <td>985172281734377473</td>\n",
       "      <td>Roche's CpAM modulator RO7049389 well tolerate...</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>1</td>\n",
       "      <td>RO7049389</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "      <td>SUCCESS</td>\n",
       "      <td>well tolerated</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>40</td>\n",
       "      <td>984750427186126848</td>\n",
       "      <td>Live at #ILC2018 FXR agonist EYP001 from Enyo ...</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>1</td>\n",
       "      <td>EYP001</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>IN PROGRESS</td>\n",
       "      <td>In phase live at</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>65</td>\n",
       "      <td>981919705912004609</td>\n",
       "      <td>Boehringer Ingelheim to progress OSE's SIRP-al...</td>\n",
       "      <td>Null</td>\n",
       "      <td>0</td>\n",
       "      <td>OSE-172</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "      <td>IN PROGRESS</td>\n",
       "      <td>to progress for</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>106</td>\n",
       "      <td>977514137046667265</td>\n",
       "      <td>41 patients have been enrolled in the ongoing ...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>1</td>\n",
       "      <td>BINIMETINIB</td>\n",
       "      <td>1677014</td>\n",
       "      <td>Null</td>\n",
       "      <td>IN PROGRESS</td>\n",
       "      <td>in the ongoing phase</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>106</td>\n",
       "      <td>977514137046667265</td>\n",
       "      <td>41 patients have been enrolled in the ongoing ...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>1</td>\n",
       "      <td>RIBOCICLIB</td>\n",
       "      <td>2039237</td>\n",
       "      <td>Null</td>\n",
       "      <td>IN PROGRESS</td>\n",
       "      <td>in the ongoing phase</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>106</td>\n",
       "      <td>977514137046667265</td>\n",
       "      <td>41 patients have been enrolled in the ongoing ...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>1</td>\n",
       "      <td>RIBOCICLIB</td>\n",
       "      <td>1926959</td>\n",
       "      <td>Null</td>\n",
       "      <td>IN PROGRESS</td>\n",
       "      <td>in the ongoing phase</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>116</td>\n",
       "      <td>977140733919547392</td>\n",
       "      <td>The FDA approves Novartis kinase inhibitor nil...</td>\n",
       "      <td>Null</td>\n",
       "      <td>2</td>\n",
       "      <td>NILOTINIB</td>\n",
       "      <td>426660</td>\n",
       "      <td>Null</td>\n",
       "      <td>SUCCESS</td>\n",
       "      <td>FDA approves</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>140</td>\n",
       "      <td>976673091500814336</td>\n",
       "      <td>PRN-1008 from Principia Biopharma a Btk inhibi...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>2</td>\n",
       "      <td>PRN-1008</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "      <td>IN PROGRESS</td>\n",
       "      <td>In phase live at</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>141</td>\n",
       "      <td>976672839821611008</td>\n",
       "      <td>Novartis presents LSZ-102 a selective estrogen...</td>\n",
       "      <td>Null</td>\n",
       "      <td>1</td>\n",
       "      <td>ESTROGEN</td>\n",
       "      <td>600686</td>\n",
       "      <td>Null</td>\n",
       "      <td>IN PROGRESS</td>\n",
       "      <td>Presents in phase live at</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>177</td>\n",
       "      <td>975811214906478592</td>\n",
       "      <td>Millendo Therapeutics' nevanimibe (ATR-101) re...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>1</td>\n",
       "      <td>ATR-101</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "      <td>SUCCESS</td>\n",
       "      <td>reduces 17-hydroxyprogesterone</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>182</td>\n",
       "      <td>975694542572802049</td>\n",
       "      <td>Positive safety data from an ongoing phase 2 t...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>1</td>\n",
       "      <td>GENE THERAPY</td>\n",
       "      <td>Null</td>\n",
       "      <td>HMAXIK</td>\n",
       "      <td>SUCCESS</td>\n",
       "      <td>Positive trial</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>183</td>\n",
       "      <td>975690650514489344</td>\n",
       "      <td>First phase 2 results on GV-1001 in BPH releas...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>2</td>\n",
       "      <td>GV-1001</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "      <td>N/I</td>\n",
       "      <td>released today at</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>184</td>\n",
       "      <td>975689033983647744</td>\n",
       "      <td>Phase 3 study on vibegron shows good safety an...</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>1</td>\n",
       "      <td>VIBEGRON</td>\n",
       "      <td>1380096</td>\n",
       "      <td>Null</td>\n",
       "      <td>SUCCESS</td>\n",
       "      <td>shows safety</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>195</td>\n",
       "      <td>975490429943721986</td>\n",
       "      <td>Probiodrug introduces PQ-912 in Phase IIa clin...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>1</td>\n",
       "      <td>PQ-912</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "      <td>SUCCESS</td>\n",
       "      <td>treating early patients</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>203</td>\n",
       "      <td>975374696249163776</td>\n",
       "      <td>Sipuleucel-T mechanism of action disclosed in ...</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>1</td>\n",
       "      <td>ipuleucel-T</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "      <td>IN PROGRESS</td>\n",
       "      <td>mechanism disclosed</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>208</td>\n",
       "      <td>975080041397792769</td>\n",
       "      <td>Crinetics Pharmaceuticals' CRN-00808 shows pro...</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>1</td>\n",
       "      <td>CRN-00808</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "      <td>SUCCESS</td>\n",
       "      <td>shows promise</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>219</td>\n",
       "      <td>974573688434692096</td>\n",
       "      <td>Less surgical AEs and readmissions in surgery ...</td>\n",
       "      <td>Null</td>\n",
       "      <td>0</td>\n",
       "      <td>SUNITINIB</td>\n",
       "      <td>13048</td>\n",
       "      <td>Null</td>\n",
       "      <td>SUCCESS</td>\n",
       "      <td>Less surgical AEs and readmissions in surgery</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>222</td>\n",
       "      <td>973893417821528065</td>\n",
       "      <td>InCARDA's InRhythm Inhaled Flecainide for card...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>1</td>\n",
       "      <td>FLECAINIDE</td>\n",
       "      <td>27588</td>\n",
       "      <td>Null</td>\n",
       "      <td>SUCCESS</td>\n",
       "      <td>Positive trial</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>226</td>\n",
       "      <td>973584058985918465</td>\n",
       "      <td>#Cristal Therapeutics' nanoproduct CriPec doce...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>2</td>\n",
       "      <td>DOCETAXEL</td>\n",
       "      <td>1927101</td>\n",
       "      <td>Null</td>\n",
       "      <td>SUCCESS</td>\n",
       "      <td>demonstrates efficacy</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>226</td>\n",
       "      <td>973584058985918465</td>\n",
       "      <td>#Cristal Therapeutics' nanoproduct CriPec doce...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>2</td>\n",
       "      <td>TAXOTERE</td>\n",
       "      <td>1927101</td>\n",
       "      <td>Null</td>\n",
       "      <td>SUCCESS</td>\n",
       "      <td>demonstrates efficacy</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>226</td>\n",
       "      <td>973584058985918465</td>\n",
       "      <td>#Cristal Therapeutics' nanoproduct CriPec doce...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>2</td>\n",
       "      <td>TAXOTERE</td>\n",
       "      <td>9097</td>\n",
       "      <td>Null</td>\n",
       "      <td>SUCCESS</td>\n",
       "      <td>demonstrates efficacy</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>231</td>\n",
       "      <td>973515394765000704</td>\n",
       "      <td>Anthera Pharmaceuticals suspended further clin...</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>1</td>\n",
       "      <td>SOLLPURA</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>FAIL</td>\n",
       "      <td>did not meet its primary endpoint</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>258</td>\n",
       "      <td>970630221702615040</td>\n",
       "      <td>Santhera's Raxone shows no efficacy benefit in...</td>\n",
       "      <td>Phase 1/2</td>\n",
       "      <td>1</td>\n",
       "      <td>RAXONE</td>\n",
       "      <td>418736</td>\n",
       "      <td>Null</td>\n",
       "      <td>FAIL</td>\n",
       "      <td>no efficacy benefit</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>260</td>\n",
       "      <td>970593118444752898</td>\n",
       "      <td>The EMA has started an urgent review of BioGen...</td>\n",
       "      <td>Null</td>\n",
       "      <td>0</td>\n",
       "      <td>DACLIZUMAB</td>\n",
       "      <td>675587</td>\n",
       "      <td>Null</td>\n",
       "      <td>IN PROGRESS</td>\n",
       "      <td>has started</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>260</td>\n",
       "      <td>970593118444752898</td>\n",
       "      <td>The EMA has started an urgent review of BioGen...</td>\n",
       "      <td>Null</td>\n",
       "      <td>0</td>\n",
       "      <td>ZINBRYTA</td>\n",
       "      <td>675587</td>\n",
       "      <td>Null</td>\n",
       "      <td>IN PROGRESS</td>\n",
       "      <td>has started</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>274</td>\n",
       "      <td>967237639152787456</td>\n",
       "      <td>Trastuzumab biosimilar from @ Hetero Biopharma...</td>\n",
       "      <td>Null</td>\n",
       "      <td>0</td>\n",
       "      <td>TRASTUZUMAB</td>\n",
       "      <td>675581</td>\n",
       "      <td>Null</td>\n",
       "      <td>SUCCESS</td>\n",
       "      <td>has progressed into clinical trials</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>904</th>\n",
       "      <td>64751</td>\n",
       "      <td>1007241245637447680</td>\n",
       "      <td>Chugai's subcutaneous formulation of tocilizum...</td>\n",
       "      <td>Phase 4</td>\n",
       "      <td>1</td>\n",
       "      <td>ACTEMRA</td>\n",
       "      <td>699373</td>\n",
       "      <td>Null</td>\n",
       "      <td>SUCCESS</td>\n",
       "      <td>demonstrates efficacy</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>905</th>\n",
       "      <td>64751</td>\n",
       "      <td>1007241245637447680</td>\n",
       "      <td>Chugai's subcutaneous formulation of tocilizum...</td>\n",
       "      <td>Phase 4</td>\n",
       "      <td>1</td>\n",
       "      <td>TOCILIZUMAB</td>\n",
       "      <td>699373</td>\n",
       "      <td>Null</td>\n",
       "      <td>SUCCESS</td>\n",
       "      <td>demonstrates efficacy</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>906</th>\n",
       "      <td>64754</td>\n",
       "      <td>1006974738747584513</td>\n",
       "      <td>Corbus Pharmaceuticals' CB2 agonist lenabasum ...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>1</td>\n",
       "      <td>LENABASUM</td>\n",
       "      <td>512450</td>\n",
       "      <td>Null</td>\n",
       "      <td>SUCCESS</td>\n",
       "      <td>demonstrates a favorable long-term safety profile</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>907</th>\n",
       "      <td>64757</td>\n",
       "      <td>1006498575809957888</td>\n",
       "      <td>REGENXBIO earns $100M accelerated license fee ...</td>\n",
       "      <td>Null</td>\n",
       "      <td>1</td>\n",
       "      <td>AVXS-101</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "      <td>IN PROGRESS</td>\n",
       "      <td>Earns fee</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>908</th>\n",
       "      <td>71169</td>\n",
       "      <td>1008815386341576705</td>\n",
       "      <td>Clinical hold lifted on @SolidBioDMD trial for...</td>\n",
       "      <td>Null</td>\n",
       "      <td>0</td>\n",
       "      <td>GENETHERAPY</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>IN PROGRESS</td>\n",
       "      <td>hold on trial</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>909</th>\n",
       "      <td>71177</td>\n",
       "      <td>1008721334027931649</td>\n",
       "      <td>@US_FDA Lifts Clinical Hold on @SolidBioDMD T...</td>\n",
       "      <td>Null</td>\n",
       "      <td>0</td>\n",
       "      <td>GENETHERAPY</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>IN PROGRESS</td>\n",
       "      <td>hold on trial</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>910</th>\n",
       "      <td>71184</td>\n",
       "      <td>1008400157065515010</td>\n",
       "      <td>$TEVA Halts Phase III Trial of Fremanezumab in...</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>1</td>\n",
       "      <td>FREMANEZUMAB</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>FAIL</td>\n",
       "      <td>halts trial</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>911</th>\n",
       "      <td>71206</td>\n",
       "      <td>1007992469328416768</td>\n",
       "      <td>@Vical Halts Development of HSV-2 Vaccine aft...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>1</td>\n",
       "      <td>HSV-2</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "      <td>FAIL</td>\n",
       "      <td>phase failure</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>912</th>\n",
       "      <td>71214</td>\n",
       "      <td>1007728226167328768</td>\n",
       "      <td>Citing likely failure $TEVA halts Phase III tr...</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>1</td>\n",
       "      <td>FREMANEZUMAB</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>FAIL</td>\n",
       "      <td>failure in trial</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>913</th>\n",
       "      <td>71218</td>\n",
       "      <td>1007626689931894784</td>\n",
       "      <td>$TEVA Halts Phase III Trial of Fremanezumab in...</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>1</td>\n",
       "      <td>oowKWW16</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "      <td>FAIL</td>\n",
       "      <td>halts trial</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>914</th>\n",
       "      <td>71239</td>\n",
       "      <td>1007003456375263233</td>\n",
       "      <td>Citing \"oral intolerability\" @flexpharma  halt...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>1</td>\n",
       "      <td>FLX-787</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "      <td>STOPPED</td>\n",
       "      <td>Halts trials</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>915</th>\n",
       "      <td>71268</td>\n",
       "      <td>1006339070421798915</td>\n",
       "      <td>After Phase II failure  @Vical halts developme...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>1</td>\n",
       "      <td>HSV-2</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "      <td>FAIL</td>\n",
       "      <td>phase failure</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>916</th>\n",
       "      <td>71277</td>\n",
       "      <td>1006185066576347136</td>\n",
       "      <td>@Vical Halts Development of HSV-2 Vaccine aft...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>1</td>\n",
       "      <td>HSV-2</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "      <td>FAIL</td>\n",
       "      <td>phase failure</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>917</th>\n",
       "      <td>74381</td>\n",
       "      <td>1009078221005033472</td>\n",
       "      <td>$SRPT I'm impressed\\n$SLDB $PFE\\n\\nA Gene Ther...</td>\n",
       "      <td>Null</td>\n",
       "      <td>0</td>\n",
       "      <td>GENE THERAPY</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>N/I</td>\n",
       "      <td>Appears To Replace</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>918</th>\n",
       "      <td>74611</td>\n",
       "      <td>1006856349492371461</td>\n",
       "      <td>@VRBoombatzMDPhD @mullymt @iangtobin Pretty su...</td>\n",
       "      <td>Null</td>\n",
       "      <td>0</td>\n",
       "      <td>NAPROSYN</td>\n",
       "      <td>51056</td>\n",
       "      <td>Null</td>\n",
       "      <td>MESS</td>\n",
       "      <td>was a blockbuster</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>919</th>\n",
       "      <td>74611</td>\n",
       "      <td>1006856349492371461</td>\n",
       "      <td>@VRBoombatzMDPhD @mullymt @iangtobin Pretty su...</td>\n",
       "      <td>Null</td>\n",
       "      <td>0</td>\n",
       "      <td>MOBIC</td>\n",
       "      <td>20496</td>\n",
       "      <td>Null</td>\n",
       "      <td>MESS</td>\n",
       "      <td>was a blockbuster</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>920</th>\n",
       "      <td>74629</td>\n",
       "      <td>1006687620531933184</td>\n",
       "      <td>@pjobphd Here's my Forbes story on \"The Ultima...</td>\n",
       "      <td>Null</td>\n",
       "      <td>1</td>\n",
       "      <td>5FVl2ovv62</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "      <td>MESS</td>\n",
       "      <td>Forbes story</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>921</th>\n",
       "      <td>74630</td>\n",
       "      <td>1006687454458531841</td>\n",
       "      <td>@skathire @MattFlowers_PhD I think the argumen...</td>\n",
       "      <td>Null</td>\n",
       "      <td>0</td>\n",
       "      <td>ADUCANUMAB</td>\n",
       "      <td>1592358</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>922</th>\n",
       "      <td>74631</td>\n",
       "      <td>1006686951007772674</td>\n",
       "      <td>@pjobphd Oh yes! \\nhttps//tco/5FVl2ovv62</td>\n",
       "      <td>Null</td>\n",
       "      <td>0</td>\n",
       "      <td>5FVl2ovv62</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "      <td>MESS</td>\n",
       "      <td>Oh yes!</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>923</th>\n",
       "      <td>74643</td>\n",
       "      <td>1006647083443638274</td>\n",
       "      <td>@TheAlexKnapp I really hope we can avert nucle...</td>\n",
       "      <td>Null</td>\n",
       "      <td>0</td>\n",
       "      <td>AVERT</td>\n",
       "      <td>365538</td>\n",
       "      <td>Null</td>\n",
       "      <td>MESS</td>\n",
       "      <td>I really hope</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>924</th>\n",
       "      <td>116396</td>\n",
       "      <td>1011617239773208578</td>\n",
       "      <td>Gossamer Bio obtains exclusive license for wor...</td>\n",
       "      <td>Null</td>\n",
       "      <td>1</td>\n",
       "      <td>HIF-1</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "      <td>IN PROGRESS</td>\n",
       "      <td>obtains exclusive license</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>925</th>\n",
       "      <td>116399</td>\n",
       "      <td>1011457286303354880</td>\n",
       "      <td>The potential use of novel [11C]-radiolabeled ...</td>\n",
       "      <td>Null</td>\n",
       "      <td>0</td>\n",
       "      <td>PKG-1</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "      <td>N/I</td>\n",
       "      <td>was discussed</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>926</th>\n",
       "      <td>116409</td>\n",
       "      <td>1010937748306481153</td>\n",
       "      <td>Preclinical data for Glaceum's HSG-4112 curren...</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>1</td>\n",
       "      <td>HSG-4112</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "      <td>IN PROGRESS</td>\n",
       "      <td>support its development</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>927</th>\n",
       "      <td>122871</td>\n",
       "      <td>1012333898615984129</td>\n",
       "      <td>@ArsanisInc Halts Phase II Trial of #Pneumoni...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>1</td>\n",
       "      <td>ASN100</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "      <td>FAIL</td>\n",
       "      <td>halts trial</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>928</th>\n",
       "      <td>122880</td>\n",
       "      <td>1011977695536836608</td>\n",
       "      <td>@Summitplc Plans Cost Cuts Stock Falls 80% af...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>1</td>\n",
       "      <td>EZUTROMID</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>FAIL</td>\n",
       "      <td>trial fails</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>929</th>\n",
       "      <td>122900</td>\n",
       "      <td>1011352104278155264</td>\n",
       "      <td>After Phase II failure @MerrimackPharma scraps...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>1</td>\n",
       "      <td>MM-141</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "      <td>FAIL</td>\n",
       "      <td>phase failure</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>930</th>\n",
       "      <td>122925</td>\n",
       "      <td>1010544287359086593</td>\n",
       "      <td>@US_FDA Lifts Clinical Hold on @SolidBioDMD T...</td>\n",
       "      <td>Null</td>\n",
       "      <td>0</td>\n",
       "      <td>GENETHERAPY</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>IN PROGRESS</td>\n",
       "      <td>hold on trial</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>931</th>\n",
       "      <td>132553</td>\n",
       "      <td>1012453525979267077</td>\n",
       "      <td>Finally Celgene wins Anemia drug luspatercept ...</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>1</td>\n",
       "      <td>LUSPATERCEPT</td>\n",
       "      <td>1592363</td>\n",
       "      <td>Null</td>\n",
       "      <td>SUCCESS</td>\n",
       "      <td>scores in trial</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>932</th>\n",
       "      <td>135766</td>\n",
       "      <td>1012439269128986626</td>\n",
       "      <td>Anticipating failure @ArsanisInc ends Phase II...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>1</td>\n",
       "      <td>ASN100</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "      <td>FAIL</td>\n",
       "      <td>phase failure</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>933</th>\n",
       "      <td>138975</td>\n",
       "      <td>1012504783897362433</td>\n",
       "      <td>RT @adamfeuerstein $XLRN blood disease drug hi...</td>\n",
       "      <td>Null</td>\n",
       "      <td>1</td>\n",
       "      <td>PIVOTAL TRIAL</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>SUCCESS</td>\n",
       "      <td>hits goal in trial</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>934 rows × 10 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "       TWID             TWEET_ID  \\\n",
       "0         4   986398045897191424   \n",
       "1        16   986219643881885698   \n",
       "2        16   986219643881885698   \n",
       "3        21   985928258708492288   \n",
       "4        33   985172281734377473   \n",
       "5        40   984750427186126848   \n",
       "6        65   981919705912004609   \n",
       "7       106   977514137046667265   \n",
       "8       106   977514137046667265   \n",
       "9       106   977514137046667265   \n",
       "10      116   977140733919547392   \n",
       "11      140   976673091500814336   \n",
       "12      141   976672839821611008   \n",
       "13      177   975811214906478592   \n",
       "14      182   975694542572802049   \n",
       "15      183   975690650514489344   \n",
       "16      184   975689033983647744   \n",
       "17      195   975490429943721986   \n",
       "18      203   975374696249163776   \n",
       "19      208   975080041397792769   \n",
       "20      219   974573688434692096   \n",
       "21      222   973893417821528065   \n",
       "22      226   973584058985918465   \n",
       "23      226   973584058985918465   \n",
       "24      226   973584058985918465   \n",
       "25      231   973515394765000704   \n",
       "26      258   970630221702615040   \n",
       "27      260   970593118444752898   \n",
       "28      260   970593118444752898   \n",
       "29      274   967237639152787456   \n",
       "..      ...                  ...   \n",
       "904   64751  1007241245637447680   \n",
       "905   64751  1007241245637447680   \n",
       "906   64754  1006974738747584513   \n",
       "907   64757  1006498575809957888   \n",
       "908   71169  1008815386341576705   \n",
       "909   71177  1008721334027931649   \n",
       "910   71184  1008400157065515010   \n",
       "911   71206  1007992469328416768   \n",
       "912   71214  1007728226167328768   \n",
       "913   71218  1007626689931894784   \n",
       "914   71239  1007003456375263233   \n",
       "915   71268  1006339070421798915   \n",
       "916   71277  1006185066576347136   \n",
       "917   74381  1009078221005033472   \n",
       "918   74611  1006856349492371461   \n",
       "919   74611  1006856349492371461   \n",
       "920   74629  1006687620531933184   \n",
       "921   74630  1006687454458531841   \n",
       "922   74631  1006686951007772674   \n",
       "923   74643  1006647083443638274   \n",
       "924  116396  1011617239773208578   \n",
       "925  116399  1011457286303354880   \n",
       "926  116409  1010937748306481153   \n",
       "927  122871  1012333898615984129   \n",
       "928  122880  1011977695536836608   \n",
       "929  122900  1011352104278155264   \n",
       "930  122925  1010544287359086593   \n",
       "931  132553  1012453525979267077   \n",
       "932  135766  1012439269128986626   \n",
       "933  138975  1012504783897362433   \n",
       "\n",
       "                                                 TWEET      PHASE  N_PHASES  \\\n",
       "0    @PoseidaThera present promising results in ini...    Phase 1         1   \n",
       "1    Genentech gains a license option to Kineta's a...       Null         0   \n",
       "2    Genentech gains a license option to Kineta's a...       Null         0   \n",
       "3    First-in-human trial with MG7-CART shows effic...    Phase 1         1   \n",
       "4    Roche's CpAM modulator RO7049389 well tolerate...    Phase 1         1   \n",
       "5    Live at #ILC2018 FXR agonist EYP001 from Enyo ...    Phase 1         1   \n",
       "6    Boehringer Ingelheim to progress OSE's SIRP-al...       Null         0   \n",
       "7    41 patients have been enrolled in the ongoing ...    Phase 2         1   \n",
       "8    41 patients have been enrolled in the ongoing ...    Phase 2         1   \n",
       "9    41 patients have been enrolled in the ongoing ...    Phase 2         1   \n",
       "10   The FDA approves Novartis kinase inhibitor nil...       Null         2   \n",
       "11   PRN-1008 from Principia Biopharma a Btk inhibi...    Phase 2         2   \n",
       "12   Novartis presents LSZ-102 a selective estrogen...       Null         1   \n",
       "13   Millendo Therapeutics' nevanimibe (ATR-101) re...    Phase 2         1   \n",
       "14   Positive safety data from an ongoing phase 2 t...    Phase 2         1   \n",
       "15   First phase 2 results on GV-1001 in BPH releas...    Phase 2         2   \n",
       "16   Phase 3 study on vibegron shows good safety an...    Phase 3         1   \n",
       "17   Probiodrug introduces PQ-912 in Phase IIa clin...    Phase 2         1   \n",
       "18   Sipuleucel-T mechanism of action disclosed in ...    Phase 1         1   \n",
       "19   Crinetics Pharmaceuticals' CRN-00808 shows pro...    Phase 1         1   \n",
       "20   Less surgical AEs and readmissions in surgery ...       Null         0   \n",
       "21   InCARDA's InRhythm Inhaled Flecainide for card...    Phase 2         1   \n",
       "22   #Cristal Therapeutics' nanoproduct CriPec doce...    Phase 2         2   \n",
       "23   #Cristal Therapeutics' nanoproduct CriPec doce...    Phase 2         2   \n",
       "24   #Cristal Therapeutics' nanoproduct CriPec doce...    Phase 2         2   \n",
       "25   Anthera Pharmaceuticals suspended further clin...    Phase 3         1   \n",
       "26   Santhera's Raxone shows no efficacy benefit in...  Phase 1/2         1   \n",
       "27   The EMA has started an urgent review of BioGen...       Null         0   \n",
       "28   The EMA has started an urgent review of BioGen...       Null         0   \n",
       "29   Trastuzumab biosimilar from @ Hetero Biopharma...       Null         0   \n",
       "..                                                 ...        ...       ...   \n",
       "904  Chugai's subcutaneous formulation of tocilizum...    Phase 4         1   \n",
       "905  Chugai's subcutaneous formulation of tocilizum...    Phase 4         1   \n",
       "906  Corbus Pharmaceuticals' CB2 agonist lenabasum ...    Phase 2         1   \n",
       "907  REGENXBIO earns $100M accelerated license fee ...       Null         1   \n",
       "908  Clinical hold lifted on @SolidBioDMD trial for...       Null         0   \n",
       "909   @US_FDA Lifts Clinical Hold on @SolidBioDMD T...       Null         0   \n",
       "910  $TEVA Halts Phase III Trial of Fremanezumab in...    Phase 3         1   \n",
       "911   @Vical Halts Development of HSV-2 Vaccine aft...    Phase 2         1   \n",
       "912  Citing likely failure $TEVA halts Phase III tr...    Phase 3         1   \n",
       "913  $TEVA Halts Phase III Trial of Fremanezumab in...    Phase 3         1   \n",
       "914  Citing \"oral intolerability\" @flexpharma  halt...    Phase 2         1   \n",
       "915  After Phase II failure  @Vical halts developme...    Phase 2         1   \n",
       "916   @Vical Halts Development of HSV-2 Vaccine aft...    Phase 2         1   \n",
       "917  $SRPT I'm impressed\\n$SLDB $PFE\\n\\nA Gene Ther...       Null         0   \n",
       "918  @VRBoombatzMDPhD @mullymt @iangtobin Pretty su...       Null         0   \n",
       "919  @VRBoombatzMDPhD @mullymt @iangtobin Pretty su...       Null         0   \n",
       "920  @pjobphd Here's my Forbes story on \"The Ultima...       Null         1   \n",
       "921  @skathire @MattFlowers_PhD I think the argumen...       Null         0   \n",
       "922           @pjobphd Oh yes! \\nhttps//tco/5FVl2ovv62       Null         0   \n",
       "923  @TheAlexKnapp I really hope we can avert nucle...       Null         0   \n",
       "924  Gossamer Bio obtains exclusive license for wor...       Null         1   \n",
       "925  The potential use of novel [11C]-radiolabeled ...       Null         0   \n",
       "926  Preclinical data for Glaceum's HSG-4112 curren...    Phase 1         1   \n",
       "927   @ArsanisInc Halts Phase II Trial of #Pneumoni...    Phase 2         1   \n",
       "928   @Summitplc Plans Cost Cuts Stock Falls 80% af...    Phase 2         1   \n",
       "929  After Phase II failure @MerrimackPharma scraps...    Phase 2         1   \n",
       "930   @US_FDA Lifts Clinical Hold on @SolidBioDMD T...       Null         0   \n",
       "931  Finally Celgene wins Anemia drug luspatercept ...    Phase 3         1   \n",
       "932  Anticipating failure @ArsanisInc ends Phase II...    Phase 2         1   \n",
       "933  RT @adamfeuerstein $XLRN blood disease drug hi...       Null         1   \n",
       "\n",
       "          SYNONYMS   MOLREGNO ACRONYM      OUTCOME  \\\n",
       "0       P-BCMA-101  Not found    Null      SUCCESS   \n",
       "1    ACETYLCHOLINE      27812    Null      SUCCESS   \n",
       "2    ACETYLCHOLINE     195974    Null      SUCCESS   \n",
       "3         MG7-CART  Not found    Null      SUCCESS   \n",
       "4        RO7049389  Not found    Null      SUCCESS   \n",
       "5           EYP001       Null    Null  IN PROGRESS   \n",
       "6          OSE-172  Not found    Null  IN PROGRESS   \n",
       "7      BINIMETINIB    1677014    Null  IN PROGRESS   \n",
       "8       RIBOCICLIB    2039237    Null  IN PROGRESS   \n",
       "9       RIBOCICLIB    1926959    Null  IN PROGRESS   \n",
       "10       NILOTINIB     426660    Null      SUCCESS   \n",
       "11        PRN-1008  Not found    Null  IN PROGRESS   \n",
       "12        ESTROGEN     600686    Null  IN PROGRESS   \n",
       "13         ATR-101  Not found    Null      SUCCESS   \n",
       "14    GENE THERAPY       Null  HMAXIK      SUCCESS   \n",
       "15         GV-1001  Not found    Null          N/I   \n",
       "16        VIBEGRON    1380096    Null      SUCCESS   \n",
       "17          PQ-912  Not found    Null      SUCCESS   \n",
       "18     ipuleucel-T  Not found    Null  IN PROGRESS   \n",
       "19       CRN-00808  Not found    Null      SUCCESS   \n",
       "20       SUNITINIB      13048    Null      SUCCESS   \n",
       "21      FLECAINIDE      27588    Null      SUCCESS   \n",
       "22       DOCETAXEL    1927101    Null      SUCCESS   \n",
       "23        TAXOTERE    1927101    Null      SUCCESS   \n",
       "24        TAXOTERE       9097    Null      SUCCESS   \n",
       "25        SOLLPURA       Null    Null         FAIL   \n",
       "26          RAXONE     418736    Null         FAIL   \n",
       "27      DACLIZUMAB     675587    Null  IN PROGRESS   \n",
       "28        ZINBRYTA     675587    Null  IN PROGRESS   \n",
       "29     TRASTUZUMAB     675581    Null      SUCCESS   \n",
       "..             ...        ...     ...          ...   \n",
       "904        ACTEMRA     699373    Null      SUCCESS   \n",
       "905    TOCILIZUMAB     699373    Null      SUCCESS   \n",
       "906      LENABASUM     512450    Null      SUCCESS   \n",
       "907       AVXS-101  Not found    Null  IN PROGRESS   \n",
       "908    GENETHERAPY       Null    Null  IN PROGRESS   \n",
       "909    GENETHERAPY       Null    Null  IN PROGRESS   \n",
       "910   FREMANEZUMAB       Null    Null         FAIL   \n",
       "911          HSV-2  Not found    Null         FAIL   \n",
       "912   FREMANEZUMAB       Null    Null         FAIL   \n",
       "913       oowKWW16  Not found    Null         FAIL   \n",
       "914        FLX-787  Not found    Null      STOPPED   \n",
       "915          HSV-2  Not found    Null         FAIL   \n",
       "916          HSV-2  Not found    Null         FAIL   \n",
       "917   GENE THERAPY       Null    Null          N/I   \n",
       "918       NAPROSYN      51056    Null         MESS   \n",
       "919          MOBIC      20496    Null         MESS   \n",
       "920     5FVl2ovv62  Not found    Null         MESS   \n",
       "921     ADUCANUMAB    1592358    Null         Null   \n",
       "922     5FVl2ovv62  Not found    Null         MESS   \n",
       "923          AVERT     365538    Null         MESS   \n",
       "924          HIF-1  Not found    Null  IN PROGRESS   \n",
       "925          PKG-1  Not found    Null          N/I   \n",
       "926       HSG-4112  Not found    Null  IN PROGRESS   \n",
       "927         ASN100  Not found    Null         FAIL   \n",
       "928      EZUTROMID       Null    Null         FAIL   \n",
       "929         MM-141  Not found    Null         FAIL   \n",
       "930    GENETHERAPY       Null    Null  IN PROGRESS   \n",
       "931   LUSPATERCEPT    1592363    Null      SUCCESS   \n",
       "932         ASN100  Not found    Null         FAIL   \n",
       "933  PIVOTAL TRIAL       Null    Null      SUCCESS   \n",
       "\n",
       "                                       MATCHED_OUTCOME  \n",
       "0                                    promising results  \n",
       "1                                      gains a license  \n",
       "2                                      gains a license  \n",
       "3                                         shows safety  \n",
       "4                                       well tolerated  \n",
       "5                                     In phase live at  \n",
       "6                                      to progress for  \n",
       "7                                 in the ongoing phase  \n",
       "8                                 in the ongoing phase  \n",
       "9                                 in the ongoing phase  \n",
       "10                                        FDA approves  \n",
       "11                                    In phase live at  \n",
       "12                           Presents in phase live at  \n",
       "13                      reduces 17-hydroxyprogesterone  \n",
       "14                                      Positive trial  \n",
       "15                                   released today at  \n",
       "16                                        shows safety  \n",
       "17                             treating early patients  \n",
       "18                                 mechanism disclosed  \n",
       "19                                       shows promise  \n",
       "20       Less surgical AEs and readmissions in surgery  \n",
       "21                                      Positive trial  \n",
       "22                               demonstrates efficacy  \n",
       "23                               demonstrates efficacy  \n",
       "24                               demonstrates efficacy  \n",
       "25                   did not meet its primary endpoint  \n",
       "26                                 no efficacy benefit  \n",
       "27                                         has started  \n",
       "28                                         has started  \n",
       "29                 has progressed into clinical trials  \n",
       "..                                                 ...  \n",
       "904                              demonstrates efficacy  \n",
       "905                              demonstrates efficacy  \n",
       "906  demonstrates a favorable long-term safety profile  \n",
       "907                                          Earns fee  \n",
       "908                                      hold on trial  \n",
       "909                                      hold on trial  \n",
       "910                                        halts trial  \n",
       "911                                      phase failure  \n",
       "912                                   failure in trial  \n",
       "913                                        halts trial  \n",
       "914                                       Halts trials  \n",
       "915                                      phase failure  \n",
       "916                                      phase failure  \n",
       "917                                 Appears To Replace  \n",
       "918                                  was a blockbuster  \n",
       "919                                  was a blockbuster  \n",
       "920                                       Forbes story  \n",
       "921                                               Null  \n",
       "922                                           Oh yes!   \n",
       "923                                      I really hope  \n",
       "924                          obtains exclusive license  \n",
       "925                                      was discussed  \n",
       "926                            support its development  \n",
       "927                                        halts trial  \n",
       "928                                        trial fails  \n",
       "929                                      phase failure  \n",
       "930                                      hold on trial  \n",
       "931                                    scores in trial  \n",
       "932                                      phase failure  \n",
       "933                                 hits goal in trial  \n",
       "\n",
       "[934 rows x 10 columns]"
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "dataframe"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "<font color='purple'> One more time to **check** tweets for relevance because there is still some mess we could not use </font>"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Ex-Dezima CEO co-founds NASH startup flying into Phase IIB with 25 million\n",
      "@BrittanyMeiling\n",
      "https//tco/OVO41lOayo\n",
      "_______________________\n",
      "#3\n",
      "UPDATED Watch out Allergan Revance's wrinkle-reducer beats Botox in PhIII trials\n",
      "-- $AGN responds to the challenge\n",
      "https//tco/oFbEvbb5gr\n",
      "_______________________\n",
      "Watch out Allergan Revance's wrinkle-reducer beats Botox in PhIII trials\n",
      "$RVNC +36%\n",
      "https//tco/oFbEvbb5gr\n",
      "_______________________\n",
      "RT @MaxJacobsEdison I love this reminder of the dangers of subgroup analysis  Apparently in a 17000 patient trial Aspirin had a negativ\n",
      "_______________________\n",
      "#2\n",
      "Innate shares crushed on second big setback for Bristol-Myers partnered lirilumab\n",
      "$BMY $IPH\n",
      "https//tco/aslqF0wWkK\n",
      "_______________________\n",
      "We'll have a truncated report out in just a bit With an annual special\n",
      "Innate shares crushed on second big setback for Bristol-Myers partnered lirilumab\n",
      "$BMY Euronext IPH\n",
      "https//tco/aslqF0wWkK\n",
      "_______________________\n",
      "from weekend bureau\n",
      "Merck KGaA impresses on OA\n",
      "https//tco/ki6OCeS12O\n",
      "NousCom funds 1st trials of neoantigen drugs\n",
      "https//tco/bTtblPUDRJ\n",
      "_______________________\n",
      "Top story\n",
      "Eyeing an #IPO ADC Therapeutics fuels pivotal cancer trials with a $200M mega-round backed by $AZN\n",
      "https//tco/RLHlC4zMd5\n",
      "_______________________\n",
      "In a setback Global Blood Therapeutics scraps IPF program as lead drug flounders in PoC trials\n",
      "$GBT -8%\n",
      "https//tco/uVdo6IL9e4\n",
      "_______________________\n",
      "Eyeing an IPO ADC Therapeutics fuels pivotal cancer trials with a $200M mega-round backed by AstraZeneca\n",
      "$AZN\n",
      "https//tco/RLHlC4zMd5\n",
      "_______________________\n",
      "RT @Aiims1742 @parkerici trial on 1st line chemoRx + aCD40 + Nivolumab in #PancreaticCancer will open @MDAndersonNews next month\n",
      "https//\n",
      "_______________________\n",
      "Join @Clarivate's Head of Clinical Products Gavin Coney &amp Head of Clinical/Regulatory Professional Services Teresa Fishburne for a May 3 #webinar Knowledge-Based Approaches to Decreasing Clinical Attrition Rates\" Register now https//tco/QzrPSNNdf3 \n",
      "\n",
      "#clinicaltrials #pharma https//tco/GmZGxtQ7ED\n",
      "_______________________\n",
      "WEBINAR | Knowledge-Based Approaches to Decreasing Clinical Attrition Rates\n",
      "\n",
      "Join @Clarivate's Chief Scientific Officer Dr Richard K Harrison on May 3 at 9AM ET to discuss factors associated with trial endpoint success &amp more https//tco/QzrPSNNdf3\n",
      "\n",
      "#clinicaltrials #pharma https//tco/MNkTZjnJFb\n",
      "_______________________\n",
      "Last chance! Join @Clarivate's Chief Scientific Officer Dr Richard K Harrison + other industry experts for a #webinar on \"Knowledge-Based Approaches to Decreasing Clinical Attrition Rates\" Register now for the May 3 event https//tco/QzrPSNNdf3\n",
      "\n",
      "#clinicaltrials #pharma https//tco/BJ17ZhQKUf\n",
      "_______________________\n",
      "I found this interesting today --\n",
      "With hits and misses in first pivotal trials J&ampJ confidently maps a path to the FDA with its major depression med esketamine\n",
      "$JNJ\n",
      "https//tco/Ro2g8eHGoZ\n",
      "_______________________\n",
      "With hits and misses in first pivotal trials J&ampJ confidently maps a path to the FDA with its major depression med esketamine\n",
      "$JNJ\n",
      "https//tco/Ro2g8eHGoZ\n",
      "_______________________\n",
      "Top 3 today #1\n",
      "IDO rout Pivotal trials with Bristol-Myers Merck and AstraZeneca dumped in wake of Incyte's PhIII implosion\n",
      "$BMY $MRK $AZN\n",
      "https//tco/RThzDm7K7v\n",
      "_______________________\n",
      " @ferring Gains Option to FKD's Phase III Bladder #Cancer #GeneTherapy Candidate https//tco/4QoNxQWxic https//tco/cvlV1ASeL3\n",
      "_______________________\n",
      "FKD outlicenses option to Phase III bladder #Cancer #genetherapy nadofaragene firadenovec/Syn3 to @ferring  https//tco/4QoNxQWxic https//tco/HUMVZV0JDf\n",
      "_______________________\n",
      " @ferring Gains Option to FKD's Phase III Bladder #Cancer #GeneTherapy Candidate https//tco/4QoNxQWxic\n",
      "_______________________\n",
      "ApolloBio acquires #China region rights to @Tocagen Phase III #Cancer #immunotherapy Toca 511 &amp Toca FC https//tco/sInTQnKwKr\n",
      "_______________________\n",
      " @mpimoph and @AiCuris Launch #Antibacterial Collaboration  https//tco/LHF4hIAUGm https//tco/1Ub0HKd44x\n",
      "_______________________\n",
      "#GeneTherapy Trials for Inherited Form of #Blindness Could Start in Two Years https//tco/g36Yw3OSFT https//tco/TPq3fK45b2\n",
      "_______________________\n",
      "Success of #GeneTherapy in canine model of inherited form of #blindness raises prospect of human trials in less than 2 years https//tco/g36Yw3OSFT\n",
      "_______________________\n",
      "#GeneTherapy Trials for Inherited Form of #Blindness Could Start in Two Years https//tco/g36Yw3OSFT https//tco/tTpxM7IPfb\n",
      "_______________________\n",
      " @NIHsbir awards $28M grant to #PhaseBio toward advancement of lead candidate PB1046 in PAH https//tco/NGLCcciRT4\n",
      "_______________________\n",
      " @MilliporeSigma CEO Udit Batra PhD on #CART #Manufacturing \"The full supply chain is extremely difficult to say the least And we have to work together to simplify it https//tco/dcLospzRcC\n",
      "_______________________\n",
      "Completed Phase I Study to Restore Hearing Using Progenitor Cells https//tco/KoyoI61QHO\n",
      "_______________________\n",
      " @Roche Licenses @ionispharma Antisense HD Therapy Following Groundbreaking Trial https//tco/8gQ0RpROME https//tco/NWx7eSfPAV\n",
      "_______________________\n",
      " @Roche Licenses @ionispharma Antisense HD Therapy Following Groundbreaking Trial https//tco/8gQ0RpROME https//tco/qSqVePmDsU\n",
      "_______________________\n",
      "Improvements to #GeneTherapy #ClinicalTrial Design Benefit Hemophilia #Patients https//tco/K3mtnJqAKa https//tco/teb6OGjm11\n",
      "_______________________\n",
      "Improvements to #GeneTherapy #ClinicalTrial Design Benefit Hemophilia #Patients https//tco/K3mtnJqAKa https//tco/W2se5rUAi4\n",
      "_______________________\n",
      " @MedImmune Phase I-ready reversal agent for blood thinner Brilinta licensed to PhaseBio https//tco/JPZKrd3Rfn\n",
      "_______________________\n",
      " @SangamoTx #Genome Editing Trial Assessing MPS II Candidate Treats First #Patient https//tco/FwKGinnmv2\n",
      "_______________________\n",
      "First patient treated in @SangamoTx #genome editing trial evaluating MPS II candidate https//tco/FwKGinnmv2\n",
      "_______________________\n",
      " @SangamoTx #Genome Editing Trial Assessing MPS II Candidate Treats First #Patient  https//tco/FwKGinnmv2\n",
      "_______________________\n",
      "Preclinical data show that Aduro Biotech's STING agonist ADU-S100 heats up tumors and induce systemic responses showing promise in oncology and TB vaccine development Various ADU-S100 clinical trials in collaboration with Novartis are underway and planned #CIMT2018\n",
      "_______________________\n",
      "\"It's not just the data you need domain expertise to build successful networks in systems biology\"  @JohnQuakenbush Professor @DanaFarber &amp @HarvardChanSPH live at the 2018 Systems Biology Symposium Join his talk via Webex https//tco/LiaHBAYLyk \n",
      "\n",
      "#SBS2018 #pharma https//tco/sEtJoMsxVR\n",
      "_______________________\n",
      "The PM bureau\n",
      "$CELG Fidelity backed -\n",
      "Seattle's Nohla closes $45M to bring novel stem cell treatment for leukemia to late-stage trials\n",
      "https//tco/P4ZiiojQjq\n",
      "_______________________\n",
      "Seattle's Nohla closes $45M to bring novel stem cell treatment for leukemia to late-stage trials\n",
      "@BrittanyMeiling \n",
      "https//tco/P4ZiiojQjq\n",
      "_______________________\n",
      "Great debate earlier in the Clinical trials and studies in COPD poster discussion session hosted by @UTHealthSA's Antonio Anzueto #ATS2018 https//tco/I6B2ge1AJd\n",
      "_______________________\n",
      "Roche adds a stellar round of pivotal data on Hemlibra looking to expand its market for a potential mega-blockbuster\n",
      "$SHPH \n",
      "https//tco/Xig3v6pWXo\n",
      "_______________________\n",
      "Roche adds a stellar round of pivotal data on Hemlibra looking to expand its market for a potential mega-blockbuster\n",
      "$SHPH \n",
      "https//tco/Xig3v6pWXo\n",
      "_______________________\n",
      "CCTG MA31 phase 3 trial of anti-HER2 therapy in first-line HER2+ metastatic breast cancer- elevated pretreatment with serum PD-L1 associated with a shorter overall survival to trastuzumab #ASCO18\n",
      "_______________________\n",
      "Merck's Keytruda builds a commanding lead in frontline lung cancer with data from two more landmark trials\n",
      "$MRK\n",
      "https//tco/jcjLREli9C\n",
      "_______________________\n",
      "#3\n",
      "AstraZeneca writes off its second pivotal COPD trial for Fasenra killing expansion plans\n",
      "$AZN\n",
      "https//tco/L7RKeGttcL\n",
      "_______________________\n",
      "AstraZeneca writes off its second pivotal COPD trial for Fasenra killing expansion plans\n",
      "https//tco/L7RKeGttcL\n",
      "_______________________\n",
      "AstraZeneca writes off its second pivotal COPD trial for Fasenra killing expansion plans\n",
      "$AZN\n",
      "https//tco/L7RKeGttcL\n",
      "_______________________\n",
      "#2\n",
      "Roche's Tecentriq scores again on a pivotal frontline lung cancer trial positioning them against Merck Bristol-Myers\n",
      "https//tco/WIyR70eEcJ\n",
      "_______________________\n",
      "IMpower130 --\n",
      "Roche's Tecentriq scores again on a pivotal frontline lung cancer trial positioning them against Merck Bristol-Myers\n",
      "https//tco/WIyR70eEcJ\n",
      "_______________________\n",
      " @biogen acquires exclusive option for Phase II #stroke candidate TMS-007 https//tco/X10AelRqk1\n",
      "_______________________\n",
      "RT @Aiims1742 Winners &amp losers from #ASCO18 Hopefully patients feel like they won \n",
      "Loved the metformin story - when a trial is well done\n",
      "_______________________\n",
      "RT @smerv Re the metformin trial \"What's also striking is that this non-industry study of a generic drug was more cautious and rigorous t\n",
      "_______________________\n",
      "@DewDiligence Well it's what I think most people say There's been a lot of \"is Keytruda better\" talk but most people I talk to think it's trial design but can't quite explain it\n",
      "_______________________\n",
      "RT @tmprowell TAILORx trial immed practice-changing Pts w/ T1-2 N0 ER+ HER2- node neg BC &amp RS &lt 26 should receive adj endocrine therapy\n",
      "_______________________\n",
      "RT @fischmd MATCH trial results at  #ASCO18 sobering reality of precision guided trial enrollmentnot always a home run https//tco/Pt0\n",
      "_______________________\n",
      "RT @JohnCendpts IMpower130 --\n",
      "Roche's Tecentriq scores again on a pivotal frontline lung cancer trial positioning them against Merck Bri\n",
      "_______________________\n",
      "RT @JohnCendpts IMpower130 --\n",
      "Roche's Tecentriq scores again on a pivotal frontline lung cancer trial positioning them against Merck Bri\n",
      "_______________________\n",
      "RT @sarahzhang Is salt actually bad? \n",
      "The only way settle it is a randomized controlled trial \n",
      "\n",
      "Where can you control what people eat? \n",
      "P\n",
      "_______________________\n",
      "RT @n8pennell IMpower150 trial of atezo + chemo/bev vs chemo/bev with improvement in OS median 192 vs 147 months (HR 078) Also OS bett\n",
      "_______________________\n",
      "Ozanimod metabolite half-life is 10 to 13 days\n",
      "\n",
      "Dose was studied in clinical trials so safety will be characterized But will docs worry about giving a drug where it takes two weeks to get the patient off?\n",
      "\n",
      "What do people particularly docs think? $celg\n",
      "_______________________\n",
      "@varma_ashwin97 They have two candidates But no trials have started\n",
      "_______________________\n",
      "RT @ByJonGardner While we await data from aducanumab don't lose sight of the Alzheimer's prevention trials Readout as early as next year\n",
      "_______________________\n",
      "FDA Panel Votes To Approve Marijuana-Based Drug For Epilepsy $GWPH by @mtindera07 https//tco/uQ6sfN0kCi\n",
      "_______________________\n",
      "@antonioregalado You did more clinical trials It's the Lipitor strategy Wall of data\n",
      "_______________________\n",
      "@antonioregalado You did more clinical trials It's the Lipitor strategy Wall of data\n",
      "_______________________\n",
      "@cecilejanssens @antonioregalado That is not the opinion of anyone who has gone through the PSA/Mammography wars Follow-up diagnostic testing for cancer is unpleasant and has risks False positives are the boogeyman here\n",
      "_______________________\n",
      "RH plugs NCCN SWOG trial to look at chemo sequencing\n",
      "_______________________\n",
      "RT @MaxJacobsEdison Maybe $MRK should rename their Pembro trials from KEYNOTE to PLENARY\n",
      "_______________________\n",
      "@VRBoombatzMDPhD @adamfeuerstein I had Earl Grey last night but today was English Breakfast Currently drinking peppermint It's a well-balanced portfolio\n",
      "_______________________\n",
      "RT @JacobPlieth What about those other $INCY $BMY $NLNK combo trials? My take on today's Echo-301 blow-up via @EPVantage https//tco/KiE\n",
      "_______________________\n",
      "@JohnTuckerPhD @TroKalayjian @JasonCRG @pcbiotech @John_LaMattina On the other hand Vioxx was withdrawn because of data in a study for Alzheimer's\n",
      "_______________________\n",
      "RT @kyleserikawa Really good write-up of this #praluent trial its results and what they may mean for sales and patient health Nice nugg\n",
      "_______________________\n",
      "@skathire @MattFlowers_PhD I think the argument that the backlash against HRT was overdone might be true But I don't think the 'eternal youth' stuff will ever pan out\n",
      "\n",
      "It may be that beta-amyloid is a really tough target to hit and aducanumab will impress I can't believe that an HDL will do anything\n",
      "_______________________\n"
     ]
    }
   ],
   "source": [
    "c = 0 #counter\n",
    "for i in range(len(dataframe)):\n",
    "    if str(dataframe.loc[i, 'OUTCOME']) == 'Null': #if the outcome is empty\n",
    "        print(dataframe.loc[i, 'TWEET']) #print tweet\n",
    "        c += 1 #counter +1\n",
    "        print('_______________________') #print a separator"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "The amount of not relevent tweets now is 74\n"
     ]
    }
   ],
   "source": [
    "print('The amount of not relevent tweets now is', c)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [],
   "source": [
    "#delete these rows\n",
    "mess = [] #the list with indexes of not relevant rows\n",
    "for i in range(len(dataframe)):\n",
    "    if str(dataframe.loc[i, 'OUTCOME']) == 'Null' or str(dataframe.loc[i, 'OUTCOME']) == 'MESS': #if there is no information or there is information that it's a mess\n",
    "        mess.append(i) #add the index to the list\n",
    "        \n",
    "dataframe = dataframe.drop(dataframe.index[mess]) #delete these rows\n",
    "dataframe.index = np.arange(len(dataframe)) #update the indexing"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Now the length of main dataframe is 838\n"
     ]
    }
   ],
   "source": [
    "print('Now the length of main dataframe is', len(dataframe))"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# <font color='green'>  II. Working with tables from termite </font>"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## <font color='green'> Prepare a termite table </font>"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 91,
   "metadata": {},
   "outputs": [],
   "source": [
    "#open tables\n",
    "termite_main_init = pd.read_csv('TERMITE_TABLE.csv', encoding='utf8', names = ['TWID', 'ENTITY_TYPE', 'ENTITY_ID', 'ENTITY_NAME', 'MATCHED_SYN', 'MATCHED_POS', 'SCORE', 'NONAMBIG'])\n",
    "termite_suppl_init = pd.read_csv(r'TRIALS_TERMITE.csv', encoding='utf8', names=['NCT_ID', 'ENTITY_TYPE', 'ENTITY_ID', 'ENTITY_NAME', 'MATCH_SYN', 'MATCH_POS', 'SCORE', 'NONAMBIG'])\n",
    "\n",
    "#create the frames of new ones\n",
    "termite_main = pd.DataFrame(columns=['TWID', 'DRUG', 'DRUG_ID', 'DRUG_SCORE', 'DRUG_NONAMBIG', 'DRUG_NCT_ID', 'DRUG_MATCHED', 'COMPANY', 'COMPANY_ID', 'COMPANY_SCORE', 'COMPANY_NONAMBIG', 'COMPANY_MATCHED', 'INDICATION', 'INDICATION_ID', 'INDICATION_SCORE', 'INDICATION_NONAMBIG', 'INDICATION_NCT_ID', 'INDICATION_MATCHED'])\n",
    "termite_suppl = pd.DataFrame(columns=['INDICATION_ID', 'INDICATION_NAME', 'INDICATION_NCT_ID', 'INDICATION_SCORE', 'INDICATION_NONAMBIG', 'DRUG_ID', 'DRUG_NAME', 'DRUG_NCT_ID', 'DRUG_SCORE', 'DRUG_NONAMBIG'])"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Turn upside down the main table: "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 92,
   "metadata": {},
   "outputs": [],
   "source": [
    "#for the first raw:\n",
    "termite_main.at[0, 'TWID'] = termite_main_init.iloc[0, 0] #add the information about the first tweed\n",
    "if termite_main_init.iloc[0, 1] == 'COMPANY': #if the ENTITY_TYPE is 'company' add information to the company\n",
    "    termite_main.at[0, 'COMPANY'] = termite_main_init.iloc[0, 3]\n",
    "    termite_main.at[0, 'COMPANY_ID'] = termite_main_init.iloc[0, 2]\n",
    "    termite_main.at[0, 'COMPANY_SCORE'] = termite_main_init.iloc[0, 6]\n",
    "    termite_main.at[0, 'COMPANY_NONAMBIG'] = termite_main_init.iloc[0, 7]\n",
    "    termite_main.at[0, 'COMPANY_MATCHED'] = termite_main_init.loc[0, 'MATCHED_SYN']\n",
    "\n",
    "elif termite_main_init.iloc[0, 1] == 'DRUG': #if the ENTITY_TYPE is 'drug' add information to the company\n",
    "    termite_main.at[0, 'DRUG'] = termite_main_init.iloc[0, 3]\n",
    "    termite_main.at[0, 'DRUG_ID'] = termite_main_init.iloc[0, 2]\n",
    "    termite_main.at[0, 'DRUG_SCORE'] = termite_main_init.iloc[0, 6]\n",
    "    termite_main.at[0, 'DRUG_NONAMBIG'] = termite_main_init.iloc[0, 7]\n",
    "    termite_main.at[0, 'DRUG_MATCHED'] = termite_main_init.loc[0, 'MATCHED_SYN']\n",
    "    \n",
    "elif termite_main_init.iloc[0, 1] == 'INDICATION': #if the ENTITY_TYPE is 'indication' add information to the company\n",
    "    termite_main.at[0, 'INDICATION'] = termite_main_init.iloc[0, 3]\n",
    "    termite_main.at[0, 'INDICATION_ID'] = termite_main_init.iloc[0, 2]\n",
    "    termite_main.at[0, 'INDICATION_SCORE'] = termite_main_init.iloc[0, 6]\n",
    "    termite_main.at[0, 'INDICATION_NONAMBIG'] = termite_main_init.iloc[0, 7]\n",
    "    termite_main.at[0, 'INDICATION_MATCHED'] = termite_main_init.loc[0, 'MATCHED_SYN']\n",
    "\n",
    "#for others raws:\n",
    "p = 0 #position in new_termite table\n",
    "for i in range(1, len(termite_main_init)):\n",
    "    if termite_main_init.iloc[i, 0] != termite_main.iloc[p, 0]: #if twid is other\n",
    "        p += 1 #come to next position\n",
    "        termite_main.at[p, 'TWID'] = termite_main_init.iloc[i, 0] #add twid to the table\n",
    "        if termite_main_init.iloc[i, 1] == 'COMPANY': #if the ENTITY_TYPE is 'company' add information to the company\n",
    "            termite_main.at[p, 'COMPANY'] = termite_main_init.iloc[i, 3]\n",
    "            termite_main.at[p, 'COMPANY_ID'] = termite_main_init.iloc[i, 2]\n",
    "            termite_main.at[p, 'COMPANY_SCORE'] = termite_main_init.iloc[i, 6]\n",
    "            termite_main.at[p, 'COMPANY_NONAMBIG'] = termite_main_init.iloc[i, 7]\n",
    "            termite_main.at[p, 'COMPANY_MATCHED'] = termite_main_init.loc[i, 'MATCHED_SYN']\n",
    "\n",
    "        elif termite_main_init.iloc[i, 1] == 'DRUG': #if the ENTITY_TYPE is 'drug' add information to the company\n",
    "            termite_main.at[p, 'DRUG'] = termite_main_init.iloc[i, 3]\n",
    "            termite_main.at[p, 'DRUG_ID'] = termite_main_init.iloc[i, 2]\n",
    "            termite_main.at[p, 'DRUG_SCORE'] = termite_main_init.iloc[i, 6]\n",
    "            termite_main.at[p, 'DRUG_NONAMBIG'] = termite_main_init.iloc[i, 7]\n",
    "            termite_main.at[p, 'DRUG_MATCHED'] = termite_main_init.loc[i, 'MATCHED_SYN']\n",
    "    \n",
    "        elif termite_main_init.iloc[i, 1] == 'INDICATION': #if the ENTITY_TYPE is 'indication' add information to the company\n",
    "            termite_main.at[p, 'INDICATION'] = termite_main_init.iloc[i, 3]\n",
    "            termite_main.at[p, 'INDICATION_ID'] = termite_main_init.iloc[i, 2]\n",
    "            termite_main.at[p, 'INDICATION_SCORE'] = termite_main_init.iloc[i, 6]\n",
    "            termite_main.at[p, 'INDICATION_NONAMBIG'] = termite_main_init.iloc[i, 7]\n",
    "            termite_main.at[p, 'INDICATION_MATCHED'] = termite_main_init.loc[i, 'MATCHED_SYN']\n",
    "    else:\n",
    "        if termite_main_init.iloc[i, 1] == 'COMPANY': #if the ENTITY_TYPE is 'company' add information to the company\n",
    "            termite_main.at[p, 'COMPANY'] = termite_main_init.iloc[i, 3]\n",
    "            termite_main.at[p, 'COMPANY_ID'] = termite_main_init.iloc[i, 2]\n",
    "            termite_main.at[p, 'COMPANY_SCORE'] = termite_main_init.iloc[i, 6]\n",
    "            termite_main.at[p, 'COMPANY_NONAMBIG'] = termite_main_init.iloc[i, 7]\n",
    "            termite_main.at[p, 'COMPANY_MATCHED'] = termite_main_init.loc[i, 'MATCHED_SYN']\n",
    "\n",
    "        elif termite_main_init.iloc[i, 1] == 'DRUG': #if the ENTITY_TYPE is 'drug' add information to the company\n",
    "            termite_main.at[p, 'DRUG'] = termite_main_init.iloc[i, 3]\n",
    "            termite_main.at[p, 'DRUG_ID'] = termite_main_init.iloc[i, 2]\n",
    "            termite_main.at[p, 'DRUG_SCORE'] = termite_main_init.iloc[i, 6]\n",
    "            termite_main.at[p, 'DRUG_NONAMBIG'] = termite_main_init.iloc[i, 7]\n",
    "            termite_main.at[p, 'DRUG_MATCHED'] = termite_main_init.loc[i, 'MATCHED_SYN']\n",
    "    \n",
    "        elif termite_main_init.iloc[i, 1] == 'INDICATION': #if the ENTITY_TYPE is 'indication' add information to the company\n",
    "            termite_main.at[p, 'INDICATION'] = termite_main_init.iloc[i, 3]\n",
    "            termite_main.at[p, 'INDICATION_ID'] = termite_main_init.iloc[i, 2] \n",
    "            termite_main.at[p, 'INDICATION_SCORE'] = termite_main_init.iloc[i, 6]\n",
    "            termite_main.at[p, 'INDICATION_NONAMBIG'] = termite_main_init.iloc[i, 7]\n",
    "            termite_main.at[p, 'INDICATION_MATCHED'] = termite_main_init.loc[i, 'MATCHED_SYN']\n",
    "            \n",
    "termite_main = termite_main.fillna('Null') #fill in empty cells with 'Null'\n",
    "termite_main.index = np.arange(len(termite_main)) #update indexing"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 93,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>TWID</th>\n",
       "      <th>DRUG</th>\n",
       "      <th>DRUG_ID</th>\n",
       "      <th>DRUG_SCORE</th>\n",
       "      <th>DRUG_NONAMBIG</th>\n",
       "      <th>DRUG_NCT_ID</th>\n",
       "      <th>DRUG_MATCHED</th>\n",
       "      <th>COMPANY</th>\n",
       "      <th>COMPANY_ID</th>\n",
       "      <th>COMPANY_SCORE</th>\n",
       "      <th>COMPANY_NONAMBIG</th>\n",
       "      <th>COMPANY_MATCHED</th>\n",
       "      <th>INDICATION</th>\n",
       "      <th>INDICATION_ID</th>\n",
       "      <th>INDICATION_SCORE</th>\n",
       "      <th>INDICATION_NONAMBIG</th>\n",
       "      <th>INDICATION_NCT_ID</th>\n",
       "      <th>INDICATION_MATCHED</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>368</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>AstraZeneca</td>\n",
       "      <td>COMP82</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>AstraZeneca</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>369</td>\n",
       "      <td>Macrilen</td>\n",
       "      <td>SDG00531</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Null</td>\n",
       "      <td>Macrilen</td>\n",
       "      <td>Aeterna Zentaris</td>\n",
       "      <td>COMP25</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Aeterna Zentaris</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>373</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Roche</td>\n",
       "      <td>COMP642</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Chronic Progressive Multiple Sclerosis</td>\n",
       "      <td>D020528</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Null</td>\n",
       "      <td>primary progressive multiple sclerosis</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>374</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Shire Pharmaceuticals</td>\n",
       "      <td>COMP705</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>Shire</td>\n",
       "      <td>Hemophilia A</td>\n",
       "      <td>D006467</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Null</td>\n",
       "      <td>haemophilia A</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>376</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Pharmaxis</td>\n",
       "      <td>COMP91241</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Pharmaxis</td>\n",
       "      <td>Diabetic Retinopathy</td>\n",
       "      <td>D003930</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Null</td>\n",
       "      <td>diabetic retinopathy</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   TWID      DRUG   DRUG_ID DRUG_SCORE DRUG_NONAMBIG DRUG_NCT_ID DRUG_MATCHED  \\\n",
       "0   368      Null      Null       Null          Null        Null         Null   \n",
       "1   369  Macrilen  SDG00531          1             1        Null     Macrilen   \n",
       "2   373      Null      Null       Null          Null        Null         Null   \n",
       "3   374      Null      Null       Null          Null        Null         Null   \n",
       "4   376      Null      Null       Null          Null        Null         Null   \n",
       "\n",
       "                 COMPANY COMPANY_ID COMPANY_SCORE COMPANY_NONAMBIG  \\\n",
       "0            AstraZeneca     COMP82             1                1   \n",
       "1       Aeterna Zentaris     COMP25             1                1   \n",
       "2                  Roche    COMP642             1                1   \n",
       "3  Shire Pharmaceuticals    COMP705             1                0   \n",
       "4              Pharmaxis  COMP91241             1                1   \n",
       "\n",
       "    COMPANY_MATCHED                              INDICATION INDICATION_ID  \\\n",
       "0       AstraZeneca                                    Null          Null   \n",
       "1  Aeterna Zentaris                                    Null          Null   \n",
       "2             Roche  Chronic Progressive Multiple Sclerosis       D020528   \n",
       "3             Shire                            Hemophilia A       D006467   \n",
       "4         Pharmaxis                    Diabetic Retinopathy       D003930   \n",
       "\n",
       "  INDICATION_SCORE INDICATION_NONAMBIG INDICATION_NCT_ID  \\\n",
       "0             Null                Null              Null   \n",
       "1             Null                Null              Null   \n",
       "2                1                   1              Null   \n",
       "3                1                   1              Null   \n",
       "4                1                   1              Null   \n",
       "\n",
       "                       INDICATION_MATCHED  \n",
       "0                                    Null  \n",
       "1                                    Null  \n",
       "2  primary progressive multiple sclerosis  \n",
       "3                           haemophilia A  \n",
       "4                    diabetic retinopathy  "
      ]
     },
     "execution_count": 93,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "termite_main[:5]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Turn upside down the second table"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 94,
   "metadata": {},
   "outputs": [],
   "source": [
    "pos = 0 #position in termite_suppl\n",
    "\n",
    "for i in range(len(termite_suppl_init) - 1): \n",
    "    if termite_suppl_init.loc[i, 'ENTITY_TYPE'] == 'INDICATION': #if the ENTITY_TYPE is indication\n",
    "        #add information about indication\n",
    "        termite_suppl.at[pos, 'INDICATION_ID'] = termite_suppl_init.loc[i, 'ENTITY_ID']\n",
    "        termite_suppl.at[pos, 'INDICATION_NAME'] = termite_suppl_init.loc[i, 'ENTITY_NAME']\n",
    "        termite_suppl.at[pos, 'INDICATION_NCT_ID'] = termite_suppl_init.loc[i, 'NCT_ID']\n",
    "        termite_suppl.at[pos, 'INDICATION_SCORE'] = termite_suppl_init.loc[i, 'SCORE']\n",
    "        termite_suppl.at[pos, 'INDICATION_NONAMBIG'] = termite_suppl_init.loc[i, 'NONAMBIG']\n",
    "        \n",
    "\n",
    "    elif termite_suppl_init.loc[i, 'ENTITY_TYPE'] == 'DRUG': #if the ENTITY_TYPE is drug\n",
    "        #add information about drug\n",
    "        termite_suppl.at[pos, 'DRUG_ID'] = termite_suppl_init.loc[i, 'ENTITY_ID']\n",
    "        termite_suppl.at[pos, 'DRUG_NAME'] = termite_suppl_init.loc[i, 'ENTITY_NAME']\n",
    "        termite_suppl.at[pos, 'DRUG_NCT_ID'] = termite_suppl_init.loc[i, 'NCT_ID']\n",
    "        termite_suppl.at[pos, 'DRUG_SCORE'] = termite_suppl_init.loc[i, 'SCORE']\n",
    "        termite_suppl.at[pos, 'DRUG_NONAMBIG'] = termite_suppl_init.loc[i, 'NONAMBIG']\n",
    "        \n",
    "    if termite_suppl_init.loc[i + 1, 'NCT_ID'] != termite_suppl_init.loc[i, 'NCT_ID']: #if rows are not referred to the same nct_id\n",
    "        pos += 1 #make one step in table\n",
    "        \n",
    "termite_suppl = termite_suppl.fillna('Null') #fill in the empty cells with 'Null'\n",
    "termite_suppl.index = np.arange(len(termite_suppl)) #update the indexing"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 95,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>INDICATION_ID</th>\n",
       "      <th>INDICATION_NAME</th>\n",
       "      <th>INDICATION_NCT_ID</th>\n",
       "      <th>INDICATION_SCORE</th>\n",
       "      <th>INDICATION_NONAMBIG</th>\n",
       "      <th>DRUG_ID</th>\n",
       "      <th>DRUG_NAME</th>\n",
       "      <th>DRUG_NCT_ID</th>\n",
       "      <th>DRUG_SCORE</th>\n",
       "      <th>DRUG_NONAMBIG</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>D010003</td>\n",
       "      <td>Osteoarthritis</td>\n",
       "      <td>NCT00000425</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>D010024</td>\n",
       "      <td>Osteoporosis</td>\n",
       "      <td>NCT00000426</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>D010024</td>\n",
       "      <td>Osteoporosis</td>\n",
       "      <td>NCT00000427</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>CHEMBL870</td>\n",
       "      <td>Alendronate Sodium</td>\n",
       "      <td>NCT00000427</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>D005356</td>\n",
       "      <td>Fibromyalgia</td>\n",
       "      <td>NCT00000428</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>CHEMBL629</td>\n",
       "      <td>Amitriptyline</td>\n",
       "      <td>NCT00000428</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>D001171</td>\n",
       "      <td>Juvenile Arthritis</td>\n",
       "      <td>NCT00000429</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "  INDICATION_ID     INDICATION_NAME INDICATION_NCT_ID INDICATION_SCORE  \\\n",
       "0       D010003      Osteoarthritis       NCT00000425                1   \n",
       "1       D010024        Osteoporosis       NCT00000426                1   \n",
       "2       D010024        Osteoporosis       NCT00000427                1   \n",
       "3       D005356        Fibromyalgia       NCT00000428                1   \n",
       "4       D001171  Juvenile Arthritis       NCT00000429                1   \n",
       "\n",
       "  INDICATION_NONAMBIG    DRUG_ID           DRUG_NAME  DRUG_NCT_ID DRUG_SCORE  \\\n",
       "0                   1       Null                Null         Null       Null   \n",
       "1                   1       Null                Null         Null       Null   \n",
       "2                   1  CHEMBL870  Alendronate Sodium  NCT00000427          1   \n",
       "3                   1  CHEMBL629       Amitriptyline  NCT00000428          1   \n",
       "4                   1       Null                Null         Null       Null   \n",
       "\n",
       "  DRUG_NONAMBIG  \n",
       "0          Null  \n",
       "1          Null  \n",
       "2             1  \n",
       "3             1  \n",
       "4          Null  "
      ]
     },
     "execution_count": 95,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "termite_suppl[:5]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Fill in the main table with the information from the supplementary table. If there is information about the drug in main table but there is no the information about the indication, add the information from the supplementary table about indication in table."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 96,
   "metadata": {},
   "outputs": [],
   "source": [
    "termite = termite_main #make a copy of initial table to work with it, it will be a final termite table"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 97,
   "metadata": {},
   "outputs": [
    {
     "ename": "KeyboardInterrupt",
     "evalue": "",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mKeyboardInterrupt\u001b[0m                         Traceback (most recent call last)",
      "\u001b[0;32m<ipython-input-97-3b09b7a67e60>\u001b[0m in \u001b[0;36m<module>\u001b[0;34m()\u001b[0m\n\u001b[1;32m     12\u001b[0m         \u001b[0;32mfor\u001b[0m \u001b[0mj\u001b[0m \u001b[0;32min\u001b[0m \u001b[0mrange\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mlen\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mtermite_suppl\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     13\u001b[0m             \u001b[0;31m#if there is such drug in supplementary table and in initial there is no indication\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m---> 14\u001b[0;31m             \u001b[0;32mif\u001b[0m \u001b[0;34m(\u001b[0m\u001b[0mstr\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mtermite\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mloc\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0mi\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m'DRUG'\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mlower\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m \u001b[0;34m==\u001b[0m \u001b[0mstr\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mtermite_suppl\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mloc\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0mj\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m'DRUG_NAME'\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mlower\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m)\u001b[0m \u001b[0;32mand\u001b[0m \u001b[0;34m(\u001b[0m\u001b[0mtermite_suppl\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mloc\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0mj\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m'INDICATION_NAME'\u001b[0m\u001b[0;34m]\u001b[0m \u001b[0;34m!=\u001b[0m \u001b[0;34m'Null'\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m     15\u001b[0m                 \u001b[0;31m#fill in the information about indication in main termite table\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     16\u001b[0m                 \u001b[0mtermite\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mat\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0mi\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m'INDICATION_ID'\u001b[0m\u001b[0;34m]\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mtermite_suppl\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mloc\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0mj\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m'INDICATION_ID'\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m/anaconda3/lib/python3.5/site-packages/pandas/core/indexing.py\u001b[0m in \u001b[0;36m__getitem__\u001b[0;34m(self, key)\u001b[0m\n\u001b[1;32m   1466\u001b[0m                         for x in key)\n\u001b[1;32m   1467\u001b[0m             \u001b[0;32mtry\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m-> 1468\u001b[0;31m                 \u001b[0;32mif\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_is_scalar_access\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mkey\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m   1469\u001b[0m                     \u001b[0;32mreturn\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_getitem_scalar\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mkey\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1470\u001b[0m             \u001b[0;32mexcept\u001b[0m \u001b[0;34m(\u001b[0m\u001b[0mKeyError\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mIndexError\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m/anaconda3/lib/python3.5/site-packages/pandas/core/indexing.py\u001b[0m in \u001b[0;36m_is_scalar_access\u001b[0;34m(self, key)\u001b[0m\n\u001b[1;32m   1813\u001b[0m                 \u001b[0;32mreturn\u001b[0m \u001b[0;32mFalse\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1814\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m-> 1815\u001b[0;31m             \u001b[0max\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mobj\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0maxes\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0mi\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m   1816\u001b[0m             \u001b[0;32mif\u001b[0m \u001b[0misinstance\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0max\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mMultiIndex\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1817\u001b[0m                 \u001b[0;32mreturn\u001b[0m \u001b[0;32mFalse\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;31mKeyboardInterrupt\u001b[0m: "
     ]
    }
   ],
   "source": [
    "#add the columns for result of filling in new information\n",
    "termite['RESULT_INDICATION'] = 'Null'\n",
    "termite['RESULT_DRUG'] = 'Null'\n",
    "\n",
    "#update everything\n",
    "termite.index = np.arange(len(termite))\n",
    "termite_suppl.index = np.arange(len(termite_suppl))\n",
    "\n",
    "#the main part of this adding\n",
    "for i in range(len(termite)): \n",
    "    if termite.loc[i, 'DRUG'] != 'Null': #if there is information about drug in initial table\n",
    "        for j in range(len(termite_suppl)):\n",
    "            #if there is such drug in supplementary table and in initial there is no indication\n",
    "            if (str(termite.loc[i, 'DRUG']).lower() == str(termite_suppl.loc[j, 'DRUG_NAME']).lower()) and (termite_suppl.loc[j, 'INDICATION_NAME'] != 'Null'):\n",
    "                #fill in the information about indication in main termite table\n",
    "                termite.at[i, 'INDICATION_ID'] = termite_suppl.loc[j, 'INDICATION_ID']\n",
    "                termite.at[i, 'INDICATION'] = termite_suppl.loc[j, 'INDICATION_NAME']\n",
    "                termite.at[i, 'INDICATION_NCT_ID'] = termite_suppl.loc[j, 'INDICATION_NCT_ID']\n",
    "                termite.at[i, 'INDICATION_SCORE'] = termite_suppl.loc[j, 'INDICATION_SCORE']\n",
    "                termite.at[i, 'INDICATION_NONAMBIG']= termite_suppl.loc[j, 'INDICATION_NONAMBIG']\n",
    "                termite.at[i, 'RESULT_DRUG'] = 'Found'\n",
    "                termite.at[i, 'RESULT_INDICATION'] = 'Filled'\n",
    "\n",
    "                \n",
    "#add columns with NCT_ID and Type of NCT_ID\n",
    "termite['NCT_ID'] = 'Null'\n",
    "termite['TYPE_NCT_ID'] = 'Null'\n",
    "\n",
    "#fill in the information about NCT_ID\n",
    "for i in range(len(termite)):\n",
    "    if termite.loc[i, 'DRUG_NCT_ID'] != 'Null':\n",
    "        termite.at[i, 'NCT_ID'] = termite.loc[i, 'DRUG_NCT_ID']\n",
    "        termite.at[i, 'TYPE_NCT_ID'] = 'Drug'\n",
    "    else:\n",
    "        if termite.loc[i, 'INDICATION_NCT_ID'] != 'Null':\n",
    "            termite.at[i, 'NCT_ID'] = termite.loc[i, 'INDICATION_NCT_ID']\n",
    "            termite.at[i, 'TYPE_NCT_ID'] = 'Indication'  "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "term = termite #make a new table to work with"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "term[:3]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "#delete columns that are not relevant for further matchings\n",
    "del term['DRUG']\n",
    "del term['DRUG_ID']\n",
    "del term['DRUG_SCORE']\n",
    "del term['DRUG_NONAMBIG']\n",
    "del term['DRUG_NCT_ID']\n",
    "del term['DRUG_MATCHED']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "term[:8]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "term.to_csv('termite_new.csv', sep='\\t', encoding='utf8')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## <font color='green'> Join the termite table and the main table </font>"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [],
   "source": [
    "#check the order of columns\n",
    "dataframe = dataframe[['TWID', 'TWEET_ID', 'TWEET', 'SYNONYMS', 'MOLREGNO', 'ACRONYM', 'PHASE', 'N_PHASES', 'OUTCOME', 'MATCHED_OUTCOME']]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>TWID</th>\n",
       "      <th>TWEET_ID</th>\n",
       "      <th>TWEET</th>\n",
       "      <th>SYNONYMS</th>\n",
       "      <th>MOLREGNO</th>\n",
       "      <th>ACRONYM</th>\n",
       "      <th>PHASE</th>\n",
       "      <th>N_PHASES</th>\n",
       "      <th>OUTCOME</th>\n",
       "      <th>MATCHED_OUTCOME</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>4</td>\n",
       "      <td>986398045897191424</td>\n",
       "      <td>@PoseidaThera present promising results in ini...</td>\n",
       "      <td>P-BCMA-101</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>1</td>\n",
       "      <td>SUCCESS</td>\n",
       "      <td>promising results</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>16</td>\n",
       "      <td>986219643881885698</td>\n",
       "      <td>Genentech gains a license option to Kineta's a...</td>\n",
       "      <td>ACETYLCHOLINE</td>\n",
       "      <td>27812</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>0</td>\n",
       "      <td>SUCCESS</td>\n",
       "      <td>gains a license</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>16</td>\n",
       "      <td>986219643881885698</td>\n",
       "      <td>Genentech gains a license option to Kineta's a...</td>\n",
       "      <td>ACETYLCHOLINE</td>\n",
       "      <td>195974</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>0</td>\n",
       "      <td>SUCCESS</td>\n",
       "      <td>gains a license</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   TWID            TWEET_ID  \\\n",
       "0     4  986398045897191424   \n",
       "1    16  986219643881885698   \n",
       "2    16  986219643881885698   \n",
       "\n",
       "                                               TWEET       SYNONYMS  \\\n",
       "0  @PoseidaThera present promising results in ini...     P-BCMA-101   \n",
       "1  Genentech gains a license option to Kineta's a...  ACETYLCHOLINE   \n",
       "2  Genentech gains a license option to Kineta's a...  ACETYLCHOLINE   \n",
       "\n",
       "    MOLREGNO ACRONYM    PHASE  N_PHASES  OUTCOME    MATCHED_OUTCOME  \n",
       "0  Not found    Null  Phase 1         1  SUCCESS  promising results  \n",
       "1      27812    Null     Null         0  SUCCESS    gains a license  \n",
       "2     195974    Null     Null         0  SUCCESS    gains a license  "
      ]
     },
     "execution_count": 19,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "dataframe[:3]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [],
   "source": [
    "#convert the type of cell to do the correct matching\n",
    "dataframe['TWID'] = dataframe['TWID'].astype(np.int64)\n",
    "term['TWID'] = term['TWID'].astype(np.int64)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "The amount of unique tweets now is 750\n"
     ]
    }
   ],
   "source": [
    "uni = 0 #count how many unique twids there are\n",
    "for i in range(1, len(dataframe)):\n",
    "    if str(dataframe.loc[i, 'TWID']) != str(dataframe.loc[i - 1, 'TWID']):\n",
    "        uni += 1\n",
    "        \n",
    "print('The amount of unique tweets now is', uni)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "841\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>TWID</th>\n",
       "      <th>TWEET_ID</th>\n",
       "      <th>TWEET</th>\n",
       "      <th>SYNONYMS</th>\n",
       "      <th>MOLREGNO</th>\n",
       "      <th>ACRONYM</th>\n",
       "      <th>PHASE</th>\n",
       "      <th>N_PHASES</th>\n",
       "      <th>OUTCOME</th>\n",
       "      <th>MATCHED_OUTCOME</th>\n",
       "      <th>COMPANY</th>\n",
       "      <th>COMPANY_ID</th>\n",
       "      <th>COMPANY_SCORE</th>\n",
       "      <th>COMPANY_NONAMBIG</th>\n",
       "      <th>COMPANY_MATCHED</th>\n",
       "      <th>INDICATION</th>\n",
       "      <th>INDICATION_ID</th>\n",
       "      <th>INDICATION_SCORE</th>\n",
       "      <th>INDICATION_NONAMBIG</th>\n",
       "      <th>INDICATION_NCT_ID</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>4</td>\n",
       "      <td>986398045897191424</td>\n",
       "      <td>@PoseidaThera present promising results in ini...</td>\n",
       "      <td>P-BCMA-101</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>1</td>\n",
       "      <td>SUCCESS</td>\n",
       "      <td>promising results</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Multiple Myeloma</td>\n",
       "      <td>D009101</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>16</td>\n",
       "      <td>986219643881885698</td>\n",
       "      <td>Genentech gains a license option to Kineta's a...</td>\n",
       "      <td>ACETYLCHOLINE</td>\n",
       "      <td>27812</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>0</td>\n",
       "      <td>SUCCESS</td>\n",
       "      <td>gains a license</td>\n",
       "      <td>Kineta®</td>\n",
       "      <td>COMP92965</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>AstraZeneca</td>\n",
       "      <td>Chronic Pain</td>\n",
       "      <td>D059350</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   TWID            TWEET_ID  \\\n",
       "0     4  986398045897191424   \n",
       "1    16  986219643881885698   \n",
       "\n",
       "                                               TWEET       SYNONYMS  \\\n",
       "0  @PoseidaThera present promising results in ini...     P-BCMA-101   \n",
       "1  Genentech gains a license option to Kineta's a...  ACETYLCHOLINE   \n",
       "\n",
       "    MOLREGNO ACRONYM    PHASE  N_PHASES  OUTCOME    MATCHED_OUTCOME  COMPANY  \\\n",
       "0  Not found    Null  Phase 1         1  SUCCESS  promising results     Null   \n",
       "1      27812    Null     Null         0  SUCCESS    gains a license  Kineta®   \n",
       "\n",
       "  COMPANY_ID COMPANY_SCORE COMPANY_NONAMBIG COMPANY_MATCHED        INDICATION  \\\n",
       "0       Null          Null             Null            Null  Multiple Myeloma   \n",
       "1  COMP92965             1                1     AstraZeneca      Chronic Pain   \n",
       "\n",
       "  INDICATION_ID INDICATION_SCORE INDICATION_NONAMBIG INDICATION_NCT_ID  \n",
       "0       D009101                1                   1              Null  \n",
       "1       D059350                1                   1              Null  "
      ]
     },
     "execution_count": 22,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "dataframe = pd.merge(dataframe, term, how='left', on='TWID') #connect the main dataframe and the termite table by 'TWID'\n",
    "dataframe.index = np.arange(len(dataframe)) #update the indexing\n",
    "dataframe = dataframe.fillna('Null') #fill in empty places with 'Null'\n",
    "print(len(dataframe)) #length of the dataframe now is\n",
    "dataframe[:2]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# <font color='green'> III. Adding the information from other tables. </font>"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## <font color='green'> Exctracting NCT_ID! </font>"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>NCT_ID</th>\n",
       "      <th>INTERVENTION_TYPE</th>\n",
       "      <th>INTERVENTION_NAME</th>\n",
       "      <th>DESCRIPTIONS</th>\n",
       "      <th>OTHER_NAME</th>\n",
       "      <th>ARM_GROUP_LABEL</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT00003593</td>\n",
       "      <td>Drug</td>\n",
       "      <td>cytarabine</td>\n",
       "      <td>Given IT</td>\n",
       "      <td>cytosine arabinoside;AraC;Cytosar;NSC #063878</td>\n",
       "      <td>Arm A: TMD patients only</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT00003593</td>\n",
       "      <td>Drug</td>\n",
       "      <td>cytarabine</td>\n",
       "      <td>Given IT</td>\n",
       "      <td>cytosine arabinoside;AraC;Cytosar;NSC #063878</td>\n",
       "      <td>Arm B: AML/MDS patients only</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "        NCT_ID INTERVENTION_TYPE INTERVENTION_NAME DESCRIPTIONS  \\\n",
       "0  NCT00003593              Drug        cytarabine     Given IT   \n",
       "1  NCT00003593              Drug        cytarabine     Given IT   \n",
       "\n",
       "                                      OTHER_NAME               ARM_GROUP_LABEL  \n",
       "0  cytosine arabinoside;AraC;Cytosar;NSC #063878      Arm A: TMD patients only  \n",
       "1  cytosine arabinoside;AraC;Cytosar;NSC #063878  Arm B: AML/MDS patients only  "
      ]
     },
     "execution_count": 23,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#open the list with interventions (Paula's table)\n",
    "interventions = pd.read_csv('INTERVENTIONS.csv', names=['NCT_ID', 'INTERVENTION_TYPE', 'INTERVENTION_NAME', \n",
    "                                                        'DESCRIPTIONS', 'OTHER_NAME', 'ARM_GROUP_LABEL'])\n",
    "\n",
    "interventions[:2]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {},
   "outputs": [],
   "source": [
    "dataframe_copy = dataframe #make a copy of main dataframe"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {},
   "outputs": [],
   "source": [
    "dataframe = dataframe_copy"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {},
   "outputs": [],
   "source": [
    "#Parallelization of the process, making 6 chunks to work with them on different kernels\n",
    "#Dividing main table to 6 parts\n",
    "\n",
    "a = dataframe[0 : len(dataframe) // 6]\n",
    "a.index = np.arange(len(a))\n",
    "\n",
    "b = dataframe[len(dataframe) // 6 : len(dataframe) // 3]\n",
    "b.index = np.arange(len(b))\n",
    "\n",
    "c = dataframe[len(dataframe) // 3 : len(dataframe) // 2]\n",
    "c.index = np.arange(len(c))\n",
    "\n",
    "d = dataframe[len(dataframe) // 2 : (2 * len(dataframe)) // 3]\n",
    "d.index = np.arange(len(d))\n",
    "\n",
    "e = dataframe[(2 * len(dataframe)) // 3 : (5 * len(dataframe)) // 6]\n",
    "e.index = np.arange(len(e))\n",
    "\n",
    "f = dataframe[(5 * len(dataframe)) // 6 : len(dataframe)]\n",
    "f.index = np.arange(len(f)) \n",
    "\n",
    "#list of chunks of the working table that will be run by function\n",
    "chunks = [a, b, c, d, e, f]\n",
    "\n",
    "#number of chunks = number of kernels that is going to use during the process"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[     TWID            TWEET_ID  \\\n",
      "0       4  986398045897191424   \n",
      "1      16  986219643881885698   \n",
      "2      16  986219643881885698   \n",
      "3      21  985928258708492288   \n",
      "4      33  985172281734377473   \n",
      "5      40  984750427186126848   \n",
      "6      65  981919705912004609   \n",
      "7     106  977514137046667265   \n",
      "8     106  977514137046667265   \n",
      "9     106  977514137046667265   \n",
      "10    116  977140733919547392   \n",
      "11    140  976673091500814336   \n",
      "12    141  976672839821611008   \n",
      "13    177  975811214906478592   \n",
      "14    182  975694542572802049   \n",
      "15    183  975690650514489344   \n",
      "16    184  975689033983647744   \n",
      "17    195  975490429943721986   \n",
      "18    203  975374696249163776   \n",
      "19    208  975080041397792769   \n",
      "20    219  974573688434692096   \n",
      "21    222  973893417821528065   \n",
      "22    226  973584058985918465   \n",
      "23    226  973584058985918465   \n",
      "24    226  973584058985918465   \n",
      "25    231  973515394765000704   \n",
      "26    258  970630221702615040   \n",
      "27    260  970593118444752898   \n",
      "28    260  970593118444752898   \n",
      "29    274  967237639152787456   \n",
      "..    ...                 ...   \n",
      "110   880  907538089609965568   \n",
      "111   881  907537590043201537   \n",
      "112   885  907258559448088576   \n",
      "113   887  907214352385757184   \n",
      "114   888  907210846551597057   \n",
      "115   892  907134226776166400   \n",
      "116   894  906997311330504704   \n",
      "117   897  906862973448282112   \n",
      "118   901  906576783583203331   \n",
      "119   902  906510794329915392   \n",
      "120   903  906489367081967617   \n",
      "121   922  905791551405776896   \n",
      "122   930  905446474691043330   \n",
      "123   932  905020361133187073   \n",
      "124   939  904644489461026816   \n",
      "125   969  902093522945363968   \n",
      "126   969  902093522945363968   \n",
      "127   972  901814055853318144   \n",
      "128   973  901712186120302592   \n",
      "129   987  900381238766301185   \n",
      "130   989  900370051328393216   \n",
      "131  1016  898403700502175744   \n",
      "132  1021  897448032064610304   \n",
      "133  1034  895596060562919424   \n",
      "134  1039  894868895961690112   \n",
      "135  1040  894867870051708928   \n",
      "136  1041  894850403241734148   \n",
      "137  1055  892593477686616064   \n",
      "138  1056  892593280474546177   \n",
      "139  1059  892360379740954624   \n",
      "\n",
      "                                                 TWEET       SYNONYMS  \\\n",
      "0    @PoseidaThera present promising results in ini...     P-BCMA-101   \n",
      "1    Genentech gains a license option to Kineta's a...  ACETYLCHOLINE   \n",
      "2    Genentech gains a license option to Kineta's a...  ACETYLCHOLINE   \n",
      "3    First-in-human trial with MG7-CART shows effic...       MG7-CART   \n",
      "4    Roche's CpAM modulator RO7049389 well tolerate...      RO7049389   \n",
      "5    Live at #ILC2018 FXR agonist EYP001 from Enyo ...         EYP001   \n",
      "6    Boehringer Ingelheim to progress OSE's SIRP-al...        OSE-172   \n",
      "7    41 patients have been enrolled in the ongoing ...    BINIMETINIB   \n",
      "8    41 patients have been enrolled in the ongoing ...     RIBOCICLIB   \n",
      "9    41 patients have been enrolled in the ongoing ...     RIBOCICLIB   \n",
      "10   The FDA approves Novartis kinase inhibitor nil...      NILOTINIB   \n",
      "11   PRN-1008 from Principia Biopharma a Btk inhibi...       PRN-1008   \n",
      "12   Novartis presents LSZ-102 a selective estrogen...       ESTROGEN   \n",
      "13   Millendo Therapeutics' nevanimibe (ATR-101) re...        ATR-101   \n",
      "14   Positive safety data from an ongoing phase 2 t...   GENE THERAPY   \n",
      "15   First phase 2 results on GV-1001 in BPH releas...        GV-1001   \n",
      "16   Phase 3 study on vibegron shows good safety an...       VIBEGRON   \n",
      "17   Probiodrug introduces PQ-912 in Phase IIa clin...         PQ-912   \n",
      "18   Sipuleucel-T mechanism of action disclosed in ...    ipuleucel-T   \n",
      "19   Crinetics Pharmaceuticals' CRN-00808 shows pro...      CRN-00808   \n",
      "20   Less surgical AEs and readmissions in surgery ...      SUNITINIB   \n",
      "21   InCARDA's InRhythm Inhaled Flecainide for card...     FLECAINIDE   \n",
      "22   #Cristal Therapeutics' nanoproduct CriPec doce...      DOCETAXEL   \n",
      "23   #Cristal Therapeutics' nanoproduct CriPec doce...       TAXOTERE   \n",
      "24   #Cristal Therapeutics' nanoproduct CriPec doce...       TAXOTERE   \n",
      "25   Anthera Pharmaceuticals suspended further clin...       SOLLPURA   \n",
      "26   Santhera's Raxone shows no efficacy benefit in...         RAXONE   \n",
      "27   The EMA has started an urgent review of BioGen...     DACLIZUMAB   \n",
      "28   The EMA has started an urgent review of BioGen...       ZINBRYTA   \n",
      "29   Trastuzumab biosimilar from @ Hetero Biopharma...    TRASTUZUMAB   \n",
      "..                                                 ...            ...   \n",
      "110  Use of benralizumab in uncontrolled asthma sup...   BENRALIZUMAB   \n",
      "111  Positive results of PATHWAY phase III trial on...    TEZEPELUMAB   \n",
      "112  Janssen discontinues phase II development of h...       JNJ-4178   \n",
      "113  Encouraging antitumor activity safety and effi...     DURVALUMAB   \n",
      "114  Phase I data shows new peptide ALM201 has very...         ALM201   \n",
      "115  AZD8871 showed significant bronchodilation in ...        AZD8871   \n",
      "116  First data from MONARCH 3 trial released today...    ABEMACICLIB   \n",
      "117  Phase 3 trials confirm similarity between bios...   astuzumab-EU   \n",
      "118  Phase 1 study of Resminostat/S-1 combination s...            S-1   \n",
      "119  Ganymed's IMAB362 IV injection is well tolerat...        IMAB362   \n",
      "120  Phase III ALUR trial data shows Alectinib redu...      ALECTINIB   \n",
      "121  Daiichi Sankyo and Sanford Burnham Prebys star...        DS-1211   \n",
      "122  Ligand's LGD-6972 shows topline safety &amp ef...       LGD-6972   \n",
      "123  US FDA places clinical hold on Cellectis' UCAR...      UCART-123   \n",
      "124  Midatech files CTA for MTD-201 for carcinoid c...        MTD-201   \n",
      "125  @pfizer presents newest safety data of apixaba...       WARFARIN   \n",
      "126  @pfizer presents newest safety data of apixaba...       APIXABAN   \n",
      "127  @portola_pharma  presents data of the phase 3 ...           Null   \n",
      "128  @sanofi presents newest data from its phase 3 ...     ALIROCUMAB   \n",
      "129  Phase 2 clinical data presented for @LillyPad ...     LY-3202626   \n",
      "130  RT @BioWorld Astellas Pharma's AML trial doses...           Null   \n",
      "131  Tetraphase files MAA for iv eravacycline for c...   ERAVACYCLINE   \n",
      "132  RT @BioWorld $REGN boots suptavumab after phas...     SUPTAVUMAB   \n",
      "133  Galapagos' GLPG-1690 stabilizes disease in pat...      GLPG-1690   \n",
      "134  FUJIFILM Corp begins US phase I trial of anti-...       FF-10101   \n",
      "135  Zynerba Pharmaceuticals ZYN-002 fails to meet ...        ZYN-002   \n",
      "136  Rebiotix's RBX-2660 begins phase III trial for...       RBX-2660   \n",
      "137  Aptinyx's NYX-2925 begins phase II trial for n...       NYX-2925   \n",
      "138  Wakamoto starts phase II trial of WP-1303 (H-1...        WP-1303   \n",
      "139  Glenmark Pharmaceuticals announces positive re...        GBR-830   \n",
      "\n",
      "      MOLREGNO ACRONYM      PHASE  N_PHASES      OUTCOME  \\\n",
      "0    Not found    Null    Phase 1         1      SUCCESS   \n",
      "1        27812    Null       Null         0      SUCCESS   \n",
      "2       195974    Null       Null         0      SUCCESS   \n",
      "3    Not found    Null    Phase 1         1      SUCCESS   \n",
      "4    Not found    Null    Phase 1         1      SUCCESS   \n",
      "5         Null    Null    Phase 1         1  IN PROGRESS   \n",
      "6    Not found    Null       Null         0  IN PROGRESS   \n",
      "7      1677014    Null    Phase 2         1  IN PROGRESS   \n",
      "8      2039237    Null    Phase 2         1  IN PROGRESS   \n",
      "9      1926959    Null    Phase 2         1  IN PROGRESS   \n",
      "10      426660    Null       Null         2      SUCCESS   \n",
      "11   Not found    Null    Phase 2         2  IN PROGRESS   \n",
      "12      600686    Null       Null         1  IN PROGRESS   \n",
      "13   Not found    Null    Phase 2         1      SUCCESS   \n",
      "14        Null  HMAXIK    Phase 2         1      SUCCESS   \n",
      "15   Not found    Null    Phase 2         2          N/I   \n",
      "16     1380096    Null    Phase 3         1      SUCCESS   \n",
      "17   Not found    Null    Phase 2         1      SUCCESS   \n",
      "18   Not found    Null    Phase 1         1  IN PROGRESS   \n",
      "19   Not found    Null    Phase 1         1      SUCCESS   \n",
      "20       13048    Null       Null         0      SUCCESS   \n",
      "21       27588    Null    Phase 2         1      SUCCESS   \n",
      "22     1927101    Null    Phase 2         2      SUCCESS   \n",
      "23     1927101    Null    Phase 2         2      SUCCESS   \n",
      "24        9097    Null    Phase 2         2      SUCCESS   \n",
      "25        Null    Null    Phase 3         1         FAIL   \n",
      "26      418736    Null  Phase 1/2         1         FAIL   \n",
      "27      675587    Null       Null         0  IN PROGRESS   \n",
      "28      675587    Null       Null         0  IN PROGRESS   \n",
      "29      675581    Null       Null         0      SUCCESS   \n",
      "..         ...     ...        ...       ...          ...   \n",
      "110    1121862    Null    Phase 3         1          N/I   \n",
      "111    2039200    Null    Phase 3         1      SUCCESS   \n",
      "112  Not found    Null    Phase 2         1         FAIL   \n",
      "113    1763549    Null       Null         0      SUCCESS   \n",
      "114  Not found    Null    Phase 1         1      SUCCESS   \n",
      "115  Not found    COPD    Phase 2         1      SUCCESS   \n",
      "116    1763572    Null       Null         1          N/I   \n",
      "117  Not found    Null    Phase 3         1  SIM IN COMP   \n",
      "118  Not found    Null    Phase 1         1      SUCCESS   \n",
      "119  Not found    Null    Phase 1         1      SUCCESS   \n",
      "120    1117844    Null    Phase 3         1      SUCCESS   \n",
      "121  Not found    Null    Phase 1         2  IN PROGRESS   \n",
      "122  Not found    Null    Phase 2         1      SUCCESS   \n",
      "123  Not found    Null    Phase 1         1         FAIL   \n",
      "124  Not found    Null    Phase 1         1  IN PROGRESS   \n",
      "125     394165    Null       Null         1      SUCCESS   \n",
      "126     397524    Null       Null         1      SUCCESS   \n",
      "127       Null    APEX    Phase 3         1          N/I   \n",
      "128    1381980    Null    Phase 3         1          N/I   \n",
      "129  Not found    Null    Phase 2         1  IN PROGRESS   \n",
      "130       Null     AML       Null         1  IN PROGRESS   \n",
      "131    1280078    Null       Null         1         FAIL   \n",
      "132    2039298    Null    Phase 3         1         FAIL   \n",
      "133  Not found    Null    Phase 2         1      SUCCESS   \n",
      "134  Not found    Null    Phase 1         1  IN PROGRESS   \n",
      "135  Not found    Null    Phase 2         2         FAIL   \n",
      "136  Not found    Null    Phase 3         1  IN PROGRESS   \n",
      "137  Not found    Null    Phase 2         1  IN PROGRESS   \n",
      "138  Not found    Null    Phase 2         1  IN PROGRESS   \n",
      "139  Not found    Null    Phase 2         2      SUCCESS   \n",
      "\n",
      "                                   MATCHED_OUTCOME       ...       COMPANY_ID  \\\n",
      "0                                promising results       ...             Null   \n",
      "1                                  gains a license       ...        COMP92965   \n",
      "2                                  gains a license       ...        COMP92965   \n",
      "3                                     shows safety       ...             Null   \n",
      "4                                   well tolerated       ...          COMP642   \n",
      "5                                 In phase live at       ...             Null   \n",
      "6                                  to progress for       ...          COMP136   \n",
      "7                             in the ongoing phase       ...             Null   \n",
      "8                             in the ongoing phase       ...             Null   \n",
      "9                             in the ongoing phase       ...             Null   \n",
      "10                                    FDA approves       ...          COMP504   \n",
      "11                                In phase live at       ...             Null   \n",
      "12                       Presents in phase live at       ...          COMP504   \n",
      "13                  reduces 17-hydroxyprogesterone       ...        COMP93860   \n",
      "14                                  Positive trial       ...             Null   \n",
      "15                               released today at       ...             Null   \n",
      "16                                    shows safety       ...             Null   \n",
      "17                         treating early patients       ...        COMP92925   \n",
      "18                             mechanism disclosed       ...             Null   \n",
      "19                                   shows promise       ...             Null   \n",
      "20   Less surgical AEs and readmissions in surgery       ...             Null   \n",
      "21                                  Positive trial       ...             Null   \n",
      "22                           demonstrates efficacy       ...             Null   \n",
      "23                           demonstrates efficacy       ...             Null   \n",
      "24                           demonstrates efficacy       ...             Null   \n",
      "25               did not meet its primary endpoint       ...        COMP90280   \n",
      "26                             no efficacy benefit       ...        COMP91054   \n",
      "27                                     has started       ...          COMP118   \n",
      "28                                     has started       ...          COMP118   \n",
      "29             has progressed into clinical trials       ...             Null   \n",
      "..                                             ...       ...              ...   \n",
      "110                   Studies analysis released at       ...             Null   \n",
      "111                                 Positive trial       ...             Null   \n",
      "112                       discontinues development       ...          COMP354   \n",
      "113                                scores in trial       ...             Null   \n",
      "114                                   shows safety       ...             Null   \n",
      "115                             showed significant       ...             Null   \n",
      "116                                     First data       ...             Null   \n",
      "117                     confirm similarity between       ...             Null   \n",
      "118                               shows OS and PFS       ...             Null   \n",
      "119                                 well tolerated       ...          COMP272   \n",
      "120                    reduces disease progression       ...             Null   \n",
      "121                              Start phase trial       ...          COMP199   \n",
      "122                                   shows safety       ...             Null   \n",
      "123                                 Hold on trials       ...        COMP92339   \n",
      "124                                trial to start        ...             Null   \n",
      "125                           presents safety data       ...             Null   \n",
      "126                           presents safety data       ...             Null   \n",
      "127                    Presents data of trial live       ...             Null   \n",
      "128                     Presents data from program       ...        COMP90647   \n",
      "129                                 data presented       ...             Null   \n",
      "130                            Doses first patient       ...           COMP73   \n",
      "131               files for complicated infections       ...        COMP90755   \n",
      "132                                    boots after       ...             Null   \n",
      "133                             stabilizes disease       ...        COMP90590   \n",
      "134                             begins phase trial       ...             Null   \n",
      "135                                    trial fails       ...             Null   \n",
      "136                             begins phase trial       ...        COMP92376   \n",
      "137                             begins phase trial       ...             Null   \n",
      "138                             starts phase trial       ...             Null   \n",
      "139                                 Positive trial       ...        COMP92688   \n",
      "\n",
      "    COMPANY_SCORE COMPANY_NONAMBIG COMPANY_MATCHED  \\\n",
      "0            Null             Null            Null   \n",
      "1               1                1     AstraZeneca   \n",
      "2               1                1     AstraZeneca   \n",
      "3            Null             Null            Null   \n",
      "4               1                1     AstraZeneca   \n",
      "5            Null             Null            Null   \n",
      "6               1                1     AstraZeneca   \n",
      "7            Null             Null            Null   \n",
      "8            Null             Null            Null   \n",
      "9            Null             Null            Null   \n",
      "10              1                1     AstraZeneca   \n",
      "11           Null             Null            Null   \n",
      "12              1                1     AstraZeneca   \n",
      "13              1                1     AstraZeneca   \n",
      "14           Null             Null            Null   \n",
      "15           Null             Null            Null   \n",
      "16           Null             Null            Null   \n",
      "17              1                1     AstraZeneca   \n",
      "18           Null             Null            Null   \n",
      "19           Null             Null            Null   \n",
      "20           Null             Null            Null   \n",
      "21           Null             Null            Null   \n",
      "22           Null             Null            Null   \n",
      "23           Null             Null            Null   \n",
      "24           Null             Null            Null   \n",
      "25              1                1     AstraZeneca   \n",
      "26              1                1     AstraZeneca   \n",
      "27              1                1     AstraZeneca   \n",
      "28              1                1     AstraZeneca   \n",
      "29           Null             Null            Null   \n",
      "..            ...              ...             ...   \n",
      "110          Null             Null            Null   \n",
      "111          Null             Null            Null   \n",
      "112             1                1     AstraZeneca   \n",
      "113          Null             Null            Null   \n",
      "114          Null             Null            Null   \n",
      "115          Null             Null            Null   \n",
      "116          Null             Null            Null   \n",
      "117          Null             Null            Null   \n",
      "118          Null             Null            Null   \n",
      "119             1                1     AstraZeneca   \n",
      "120          Null             Null            Null   \n",
      "121             1                1     AstraZeneca   \n",
      "122          Null             Null            Null   \n",
      "123             1                1     AstraZeneca   \n",
      "124          Null             Null            Null   \n",
      "125          Null             Null            Null   \n",
      "126          Null             Null            Null   \n",
      "127          Null             Null            Null   \n",
      "128             1                0     AstraZeneca   \n",
      "129          Null             Null            Null   \n",
      "130             1                1     AstraZeneca   \n",
      "131             1                1     AstraZeneca   \n",
      "132          Null             Null            Null   \n",
      "133             1                0     AstraZeneca   \n",
      "134          Null             Null            Null   \n",
      "135          Null             Null            Null   \n",
      "136             1                1     AstraZeneca   \n",
      "137          Null             Null            Null   \n",
      "138          Null             Null            Null   \n",
      "139             1                1     AstraZeneca   \n",
      "\n",
      "                                        INDICATION INDICATION_ID  \\\n",
      "0                                 Multiple Myeloma       D009101   \n",
      "1                                     Chronic Pain       D059350   \n",
      "2                                     Chronic Pain       D059350   \n",
      "3                                 Rectal Neoplasms       D012004   \n",
      "4                                             Null          Null   \n",
      "5                                             Null          Null   \n",
      "6                                        Carcinoma       D002277   \n",
      "7                             Cerebellar Neoplasms       D002528   \n",
      "8                             Cerebellar Neoplasms       D002528   \n",
      "9                             Cerebellar Neoplasms       D002528   \n",
      "10   BCR-ABL Positive Chronic Myelogenous Leukemia       D015464   \n",
      "11                                       Pemphigus       D010392   \n",
      "12                                            Null          Null   \n",
      "13                                 Premature Birth       D047928   \n",
      "14                            Erectile Dysfunction       D007172   \n",
      "15                               Alzheimer Disease       D000544   \n",
      "16                      Overactive Urinary Bladder       D053201   \n",
      "17                               Alzheimer Disease       D000544   \n",
      "18                             Prostatic Neoplasms       D011471   \n",
      "19                                      Acromegaly       D000172   \n",
      "20                                         Thymoma       D013945   \n",
      "21                                Brugada Syndrome       D053840   \n",
      "22                               Stomach Neoplasms       D013274   \n",
      "23                               Stomach Neoplasms       D013274   \n",
      "24                               Stomach Neoplasms       D013274   \n",
      "25                                            Null          Null   \n",
      "26                     Duchenne Muscular Dystrophy       D020388   \n",
      "27          Relapsing-Remitting Multiple Sclerosis       D020529   \n",
      "28          Relapsing-Remitting Multiple Sclerosis       D020529   \n",
      "29                        Nervous System Neoplasms       D009423   \n",
      "..                                             ...           ...   \n",
      "110                                   Eosinophilia       D004802   \n",
      "111                                         Asthma       D001249   \n",
      "112                            Renal Insufficiency       D051437   \n",
      "113                                    Solid Tumor       SDI0034   \n",
      "114                              Ovarian Neoplasms       D010051   \n",
      "115          Chronic Obstructive Pulmonary Disease       D029424   \n",
      "116                        Head and Neck Neoplasms       D006258   \n",
      "117                                           Null          Null   \n",
      "118                        Biliary Tract Neoplasms       D001661   \n",
      "119                         gastric adenocarcinoma       SDI0107   \n",
      "120                  Non-Small-Cell Lung Carcinoma       D002289   \n",
      "121                                           Null          Null   \n",
      "122                              Diabetes Mellitus       D003920   \n",
      "123                          Hematologic Neoplasms       D019337   \n",
      "124                                Carcinoid Tumor       D002276   \n",
      "125                        cardiovascular diseases       D002318   \n",
      "126                        cardiovascular diseases       D002318   \n",
      "127                              Venous Thrombosis       D020246   \n",
      "128                           Hypercholesterolemia       D006937   \n",
      "129                              Alzheimer Disease       D000544   \n",
      "130                                           Null          Null   \n",
      "131                         Chronic Kidney Failure       D007676   \n",
      "132                                           Null          Null   \n",
      "133                  Idiopathic Pulmonary Fibrosis       D054990   \n",
      "134                                      Carcinoma       D002277   \n",
      "135                                       Seizures       D012640   \n",
      "136                 Pseudomembranous Enterocolitis       D004761   \n",
      "137                                   Fibromyalgia       D005356   \n",
      "138                            Ocular Hypertension       D009798   \n",
      "139                                Neurodermatitis       D009450   \n",
      "\n",
      "    INDICATION_SCORE INDICATION_NONAMBIG INDICATION_NCT_ID SYNONYMS_NCT_ID  \n",
      "0                  1                   1              Null     NCT03288493  \n",
      "1                  1                   1              Null     NCT03446612  \n",
      "2                  1                   1              Null     NCT03446612  \n",
      "3                  1                   1              Null     NCT02862704  \n",
      "4               Null                Null              Null     NCT03570658  \n",
      "5               Null                Null              Null     NCT03469583  \n",
      "6                  1                   1              Null             NaN  \n",
      "7                  1                   1       NCT03387020     NCT03158103  \n",
      "8                  1                   1       NCT03387020     NCT03081234  \n",
      "9                  1                   1       NCT03387020     NCT03081234  \n",
      "10                 1                   1       NCT03332511     NCT01535391  \n",
      "11                 1                   1              Null     NCT03395210  \n",
      "12              Null                Null              Null     NCT02835846  \n",
      "13                 1                   1       NCT03433040     NCT03053271  \n",
      "14                 1                   1              Null     NCT03507686  \n",
      "15                 1                   1       NCT03184467     NCT03184467  \n",
      "16                 1                   1       NCT01737684     NCT03492281  \n",
      "17                 1                   1       NCT02389413     NCT02389413  \n",
      "18                 1                   1       NCT03024216     NCT03024216  \n",
      "19                 1                   1              Null     NCT03276858  \n",
      "20                 1                   2       NCT03449173     NCT03379012  \n",
      "21                 1                   1       NCT02302274     NCT03162120  \n",
      "22                 1                   1       NCT03421288     NCT03432780  \n",
      "23                 1                   1       NCT03421288     NCT03432780  \n",
      "24                 1                   1       NCT03421288     NCT03432780  \n",
      "25              Null                Null              Null     NCT02823964  \n",
      "26                 1                   1       NCT02814019     NCT02887443  \n",
      "27                 1                   1       NCT02881567     NCT01064401  \n",
      "28                 1                   1       NCT02881567             NaN  \n",
      "29                 1                   1       NCT03417544     NCT00404066  \n",
      "..               ...                 ...               ...             ...  \n",
      "110                1                   1       NCT03450083     NCT02417961  \n",
      "111                1                   1              Null     NCT03406078  \n",
      "112                1                   1       NCT02961660             NaN  \n",
      "113                1                   1       NCT03394144     NCT02352948  \n",
      "114                1                   1       NCT03427073     NCT03427073  \n",
      "115                1                   1              Null     NCT02573155  \n",
      "116                1                   1       NCT03356587     NCT03155997  \n",
      "117             Null                Null              Null     NCT02187744  \n",
      "118                1                   1              Null     NCT03440437  \n",
      "119                1                   1       NCT01630083     NCT01630083  \n",
      "120                1                   1       NCT03445000     NCT03445000  \n",
      "121             Null                Null              Null             NaN  \n",
      "122                1                   1       NCT02851849     NCT02672839  \n",
      "123                1                   1              Null     NCT03203369  \n",
      "124                1                   1              Null             NaN  \n",
      "125                1                   1       NCT03426033     NCT03395639  \n",
      "126                1                   1       NCT03426033     NCT03129555  \n",
      "127                1                   1              Null     NCT03521635  \n",
      "128                1                   1       NCT03415178     NCT03014830  \n",
      "129                1                   1              Null     NCT03367403  \n",
      "130             Null                Null              Null     NCT03038451  \n",
      "131                1                   1       NCT02135276     NCT03032510  \n",
      "132             Null                Null              Null     NCT02325791  \n",
      "133                1                   1       NCT02738801     NCT03515382  \n",
      "134                1                   1              Null     NCT03194685  \n",
      "135                1                   1              Null             NaN  \n",
      "136                1                   0       NCT03244644     NCT03378167  \n",
      "137                1                   1              Null     NCT03249103  \n",
      "138                1                   1              Null             NaN  \n",
      "139                1                   0              Null             NaN  \n",
      "\n",
      "[140 rows x 21 columns],      TWID            TWEET_ID  \\\n",
      "0    1067  890786380716032000   \n",
      "1    1072  890213870522040322   \n",
      "2    1074  890210096415899649   \n",
      "3    1074  890210096415899649   \n",
      "4    1075  890208837441073152   \n",
      "5    1082  889491609678737408   \n",
      "6    1087  888386831263379456   \n",
      "7    1097  887649643793874945   \n",
      "8    1104  887312251123884033   \n",
      "9    1114  886955701045780480   \n",
      "10   1114  886955701045780480   \n",
      "11   1120  884710616518340608   \n",
      "12   1124  884701927287685120   \n",
      "13   1132  882830764865449985   \n",
      "14   1146  881814116389838849   \n",
      "15   1150  880908414691536897   \n",
      "16   1151  880908410878918656   \n",
      "17   1154  880908409025036288   \n",
      "18   1160  880126147958382600   \n",
      "19   1163  879220946128842752   \n",
      "20   1177  877859844258119680   \n",
      "21   1179  877813897868091393   \n",
      "22   1188  877458307501367296   \n",
      "23   1190  877171367141146625   \n",
      "24   1190  877171367141146625   \n",
      "25   1190  877171367141146625   \n",
      "26   1195  877102212903817216   \n",
      "27   1204  876118964623081472   \n",
      "28   1211  875502584571809793   \n",
      "29   1212  875473238561783808   \n",
      "..    ...                 ...   \n",
      "110  1488  856952342041817089   \n",
      "111  1495  856754529936822272   \n",
      "112  1502  856509280463319041   \n",
      "113  1506  856397320069541888   \n",
      "114  1509  856227666030100482   \n",
      "115  1537  854286063665328128   \n",
      "116  1537  854286063665328128   \n",
      "117  1544  852126638456352771   \n",
      "118  1557  851368212285583360   \n",
      "119  1560  850034277010083840   \n",
      "120  1561  849985040369025025   \n",
      "121  1565  849914685633822720   \n",
      "122  1598  848830884446916608   \n",
      "123  1603  848797772727947265   \n",
      "124  1605  848779093890002944   \n",
      "125  1616  847128732154376193   \n",
      "126  1633  846031294563848194   \n",
      "127  1642  844918129293647873   \n",
      "128  1643  844917883763273728   \n",
      "129  1643  844917883763273728   \n",
      "130  1649  844549905767063552   \n",
      "131  1650  844548182616911873   \n",
      "132  1652  844543744569356289   \n",
      "133  1653  844543644090585088   \n",
      "134  1666  844226289611374592   \n",
      "135  1670  844169826318794754   \n",
      "136  1688  843801423653437440   \n",
      "137  1689  843797638747115520   \n",
      "138  1690  843797571680124928   \n",
      "139  1701  842799704052121600   \n",
      "\n",
      "                                                 TWEET  \\\n",
      "0    Quark's QPI-1002 meets safety and efficacy end...   \n",
      "1    Tetraphase's eravacycline meets primary endpoi...   \n",
      "2    Axsome's AXS-06 (meloxicam and esomeprazole) m...   \n",
      "3    Axsome's AXS-06 (meloxicam and esomeprazole) m...   \n",
      "4    AntriaBio begins phase I trial of AB101 for tr...   \n",
      "5    UCB's bimekizumab safe and effective in phase ...   \n",
      "6    Incyte begins phase III trials of itacitinib f...   \n",
      "7    Amgen/Sanofi's Leukine (recombinant GM-CSF) im...   \n",
      "8    Wave Life Sciences has begun phase Ib/IIa tria...   \n",
      "9    Concomitant use of glycopyrrolate or trospium ...   \n",
      "10   Concomitant use of glycopyrrolate or trospium ...   \n",
      "11   Positive topline phase II results reported for...   \n",
      "12   Prexton starts phase II trial of Foliglurax (P...   \n",
      "13   Zydus's ZYAN-1 begins phase II trial for anemi...   \n",
      "14   Zealand Pharma begins phase 3 trial of dasiglu...   \n",
      "15   Myovant starts phase III trial of relugolix fo...   \n",
      "16   Pharmaleads' oral PL-265 shows promising safet...   \n",
      "17   CytomX's CX-2009 begins phase I/II trial for s...   \n",
      "18   Cellectis begins first in human phase I trial ...   \n",
      "19   Proteostasis Therapeutics files IND with FDA f...   \n",
      "20   Chi-Med's HMPL-453 begins phase I/II trial in ...   \n",
      "21   ImmunoCellular suspends ICT-107 phase III tria...   \n",
      "22   Neurotech's NT-501 reduces progressive loss of...   \n",
      "23   Seattle Genetics stops treatment in all Vadast...   \n",
      "24   Seattle Genetics stops treatment in all Vadast...   \n",
      "25   Seattle Genetics stops treatment in all Vadast...   \n",
      "26   US FDA approves Unum's ACTR-707 IND for B cell...   \n",
      "27   Celgene's CC-220 shows promise in phase IIa tr...   \n",
      "28   Phase 1/2 study using human umbilical cord mes...   \n",
      "29   AbbVie's lutikizumab fails to meet primary end...   \n",
      "..                                                 ...   \n",
      "110  First data on MYSTICOL trial evaluating rimabo...   \n",
      "111  XOMA's X-213 effective in suppressing post-par...   \n",
      "112  ReViral's RV-521 for RSV infection well tolera...   \n",
      "113  Ceftazidime-avibactam active against nosocomia...   \n",
      "114  Neural stem cell based therapy for PD is safe ...   \n",
      "115  OncoMed's tarextumab in combination with etopo...   \n",
      "116  OncoMed's tarextumab in combination with etopo...   \n",
      "117  US FDA clears ArQule's IND for ARQ-531 for B-c...   \n",
      "118  Kura starts phase I trial of KO-947 for cancer...   \n",
      "119  Galapagos earns $10M fee from Gilead triggered...   \n",
      "120  Zavante's Zolyd (fosfomycin inj) not inferior ...   \n",
      "121  Agenus's AutoSynVax begins phase I trial for c...   \n",
      "122  NIAID's VRC-5283 DNA vaccine starts phase II/I...   \n",
      "123  Almirall presented a new series of PI3Kdelta/g...   \n",
      "124  GDC-0077 a promising potent and selective inhi...   \n",
      "125  Calithera to earn $12M fee from Incyte followi...   \n",
      "126  Novel SARDs from GTx show proof of concept &am...   \n",
      "127  US FDA clears Akashi to resume HT-100 (halofug...   \n",
      "128  Intec's AP-CBD/THC (cannabidiol + dronabinol) ...   \n",
      "129  Intec's AP-CBD/THC (cannabidiol + dronabinol) ...   \n",
      "130  @Selvita CLI24-001 phI/II trial of SEL24-B489 ...   \n",
      "131  Galapagos starts phase I trial for GLPG-3067 f...   \n",
      "132  CTD's Trappsol Cyclo begins phase I/II Europea...   \n",
      "133  US FDA accepts Tarrex's TX-803 IND to begin ph...   \n",
      "134  Nektar's NKTR-181 well tolerated and meet prim...   \n",
      "135  @SymicBio planning phase 2b clinical study in ...   \n",
      "136  King's College London sees stable disease in 5...   \n",
      "137  Ergomed starts phase II trial of topical Pepro...   \n",
      "138  Umecrine Cognition's GR-3027 begins phase Ib/I...   \n",
      "139  MASTIFF - a phase I clinical study of MTH1 inh...   \n",
      "\n",
      "                                    SYNONYMS   MOLREGNO ACRONYM      PHASE  \\\n",
      "0                                   QPI-1002  Not found    Null    Phase 2   \n",
      "1                               ERAVACYCLINE    1280078    Null    Phase 3   \n",
      "2                               ESOMEPRAZOLE     675271    Null    Phase 1   \n",
      "3                                  MELOXICAM      20496    Null    Phase 1   \n",
      "4                                      AB101  Not found    Null    Phase 1   \n",
      "5                                BIMEKIZUMAB       Null    Null    Phase 2   \n",
      "6                                 ITACITINIB    1966506    Null    Phase 3   \n",
      "7                                    LEUKINE     675569    Null    Phase 2   \n",
      "8                                 WVE-120101  Not found    Null  Phase 1/2   \n",
      "9                             GLYCOPYRROLATE     674978    Null       Null   \n",
      "10                                  TROSPIUM    1228747    Null       Null   \n",
      "11                                 RALINEPAG    1763566    Null    Phase 2   \n",
      "12                                  PXT-2331  Not found    Null    Phase 2   \n",
      "13                                    ZYAN-1  Not found    Null    Phase 2   \n",
      "14                              DASIGLUCAGON       Null    Null    Phase 3   \n",
      "15                                 RELUGOLIX    1161221    Null    Phase 3   \n",
      "16                                    PL-265  Not found    Null    Phase 1   \n",
      "17                                   CX-2009  Not found    Null  Phase 1/2   \n",
      "18                                 UCART-123  Not found    Null    Phase 1   \n",
      "19                                   PTI-808  Not found    Null    Phase 1   \n",
      "20                                  HMPL-453  Not found    Null  Phase 1/2   \n",
      "21                                   ICT-107  Not found    Null    Phase 3   \n",
      "22                                    NT-501  Not found    Null    Phase 2   \n",
      "23                     VADASTUXIMAB TALIRINE    2197892    Null    Phase 3   \n",
      "24                              VADASTUXIMAB    2197895    Null    Phase 3   \n",
      "25                                  TALIRINE    2197836    Null    Phase 3   \n",
      "26                                 RITUXIMAB     675578    Null    Phase 1   \n",
      "27                                    CC-220  Not found    Null    Phase 2   \n",
      "28   UMBILICAL CORD MESENCHYMAL STROMAL CELL       Null    Null  Phase 1/2   \n",
      "29                               LUTIKIZUMAB       Null    Null    Phase 2   \n",
      "..                                       ...        ...     ...        ...   \n",
      "110                      RIMABOTULINUMTOXINB    1380976    Null       Null   \n",
      "111                                    X-213  Not found    Null    Phase 2   \n",
      "112                                   RV-521  Not found    Null    Phase 2   \n",
      "113                          ftazidime-aviba  Not found    Null    Phase 3   \n",
      "114                                STEM CELL       Null    Null    Phase 1   \n",
      "115                                ETOPOSIDE      68607    Null    Phase 2   \n",
      "116                               TAREXTUMAB    1763550    Null    Phase 2   \n",
      "117                                  ARQ-531  Not found    Null       Null   \n",
      "118                                   KO-947  Not found    Null    Phase 1   \n",
      "119                               FILGOTINIB    1763569    Null    Phase 2   \n",
      "120                               FOSFOMYCIN     581859    Null  Phase 2/3   \n",
      "121                               AUTOSYNVAX       Null    Null    Phase 1   \n",
      "122                                 VRC-5283  Not found    Null       Null   \n",
      "123               PI3KDELTA/GAMMA INHIBITORS       Null    Null       Null   \n",
      "124                                 GDC-0077  Not found    Null    Phase 1   \n",
      "125                                  CB-1158  Not found    Null    Phase 1   \n",
      "126                                    SARDS       Null    Null       Null   \n",
      "127                             HALOFUGINONE     671041    Null       Null   \n",
      "128                              CANNABIDIOL     318390    Null    Phase 1   \n",
      "129                               DRONABINOL       4496    Null    Phase 1   \n",
      "130                                CLI24-001  Not found     AML  Phase 1/2   \n",
      "131                                GLPG-3067  Not found    Null    Phase 1   \n",
      "132                           TRAPPSOL CYCLO       Null    Null  Phase 1/2   \n",
      "133                                   TX-803  Not found    Null    Phase 1   \n",
      "134                                 NKTR-181  Not found    Null    Phase 3   \n",
      "135                                   SB-030  Not found    Null    Phase 2   \n",
      "136                                     Null       Null     CAR       Null   \n",
      "137                                PEPROSTAT       Null    Null    Phase 2   \n",
      "138                                  GR-3027  Not found    Null  Phase 1/2   \n",
      "139                                   TH1579  Not found    Null    Phase 1   \n",
      "\n",
      "     N_PHASES      OUTCOME                             MATCHED_OUTCOME  \\\n",
      "0           2      SUCCESS         meets safety and efficacy endpoints   \n",
      "1           3      SUCCESS                      meets primary endpoint   \n",
      "2           1      SUCCESS                      meets primary endpoint   \n",
      "3           1      SUCCESS                      meets primary endpoint   \n",
      "4           1  IN PROGRESS                          begins phase trial   \n",
      "5           1      SUCCESS                          effective in phase   \n",
      "6           1  IN PROGRESS                         begins phase trials   \n",
      "7           1      SUCCESS                      improves MMSE in trial   \n",
      "8           1  IN PROGRESS                           has begun trials    \n",
      "9           1      SUCCESS                        reduced side effects   \n",
      "10          1      SUCCESS                        reduced side effects   \n",
      "11          1      SUCCESS                              Positive trial   \n",
      "12          1  IN PROGRESS                          starts phase trial   \n",
      "13          1  IN PROGRESS                          begins phase trial   \n",
      "14          2  IN PROGRESS                               Trial planned   \n",
      "15          1  IN PROGRESS                          starts phase trial   \n",
      "16          1      SUCCESS                                shows safety   \n",
      "17          1  IN PROGRESS                          begins phase trial   \n",
      "18          2  IN PROGRESS                          begins phase trial   \n",
      "19          1  IN PROGRESS                             files for phase   \n",
      "20          1  IN PROGRESS                          begins phase trial   \n",
      "21          1      STOPPED               suspends due to lack of funds   \n",
      "22          1      SUCCESS              reduces loss of photoreceptors   \n",
      "23          1         FAIL                             stops treatment   \n",
      "24          1         FAIL                             stops treatment   \n",
      "25          1         FAIL                             stops treatment   \n",
      "26          1      SUCCESS                                FDA approves   \n",
      "27          1      SUCCESS                               shows promise   \n",
      "28          1      SUCCESS             shows safe and efficacy results   \n",
      "29          1         FAIL                                 trial fails   \n",
      "..        ...          ...                                         ...   \n",
      "110         1          N/I                                  First data   \n",
      "111         1      SUCCESS                          effective in phase   \n",
      "112         2  IN PROGRESS                               Trial planned   \n",
      "113         1      SUCCESS               active against according data   \n",
      "114         1      SUCCESS                           safe and feasible   \n",
      "115         1         FAIL                                 trial fails   \n",
      "116         1         FAIL                                 trial fails   \n",
      "117         1  IN PROGRESS                            Clears for trial   \n",
      "118         1  IN PROGRESS                          starts phase trial   \n",
      "119         1  IN PROGRESS                                   Earns fee   \n",
      "120         2          N/I                             not inferior to   \n",
      "121         1  IN PROGRESS                          begins phase trial   \n",
      "122         1  IN PROGRESS                          starts phase trial   \n",
      "123         1          N/I                      presented a new series   \n",
      "124         2      SUCCESS  a promising potent and selective inhibitor   \n",
      "125         1  IN PROGRESS                                    Earn fee   \n",
      "126         1      SUCCESS              show proof of concept efficacy   \n",
      "127         0  IN PROGRESS                                resume study   \n",
      "128         1  IN PROGRESS                          starts phase trial   \n",
      "129         1  IN PROGRESS                          starts phase trial   \n",
      "130         1  IN PROGRESS                              data presented   \n",
      "131         1  IN PROGRESS                          starts phase trial   \n",
      "132         2  IN PROGRESS                          begins phase trial   \n",
      "133         1  IN PROGRESS                             trials to begin   \n",
      "134         1      SUCCESS                              well tolerated   \n",
      "135         1         FAIL                               phase failure   \n",
      "136         0  IN PROGRESS         sees stable disease in 5 of 10 head   \n",
      "137         2  IN PROGRESS                          starts phase trial   \n",
      "138         1  IN PROGRESS                          begins phase trial   \n",
      "139         1  IN PROGRESS                    Clinical study launched    \n",
      "\n",
      "          ...       COMPANY_ID COMPANY_SCORE COMPANY_NONAMBIG COMPANY_MATCHED  \\\n",
      "0         ...        COMP91161             1                0     AstraZeneca   \n",
      "1         ...        COMP90755             1                1     AstraZeneca   \n",
      "2         ...             Null          Null             Null            Null   \n",
      "3         ...             Null          Null             Null            Null   \n",
      "4         ...             Null          Null             Null            Null   \n",
      "5         ...             Null          Null             Null            Null   \n",
      "6         ...          COMP328             1                1     AstraZeneca   \n",
      "7         ...           COMP44             1                1     AstraZeneca   \n",
      "8         ...             Null          Null             Null            Null   \n",
      "9         ...             Null          Null             Null            Null   \n",
      "10        ...             Null          Null             Null            Null   \n",
      "11        ...           COMP64             1                1     AstraZeneca   \n",
      "12        ...             Null          Null             Null            Null   \n",
      "13        ...        COMP90067             1                1     AstraZeneca   \n",
      "14        ...        COMP90172             1                1     AstraZeneca   \n",
      "15        ...             Null          Null             Null            Null   \n",
      "16        ...             Null          Null             Null            Null   \n",
      "17        ...        COMP92918             1                1     AstraZeneca   \n",
      "18        ...        COMP92339             1                1     AstraZeneca   \n",
      "19        ...             Null          Null             Null            Null   \n",
      "20        ...             Null          Null             Null            Null   \n",
      "21        ...             Null          Null             Null            Null   \n",
      "22        ...        COMP93125             1                1     AstraZeneca   \n",
      "23        ...          COMP698             1                1     AstraZeneca   \n",
      "24        ...          COMP698             1                1     AstraZeneca   \n",
      "25        ...          COMP698             1                1     AstraZeneca   \n",
      "26        ...             Null          Null             Null            Null   \n",
      "27        ...          COMP160             1                1     AstraZeneca   \n",
      "28        ...             Null          Null             Null            Null   \n",
      "29        ...        COMP92805             1                1     AstraZeneca   \n",
      "..        ...              ...           ...              ...             ...   \n",
      "110       ...             Null          Null             Null            Null   \n",
      "111       ...          COMP814             1                1     AstraZeneca   \n",
      "112       ...             Null          Null             Null            Null   \n",
      "113       ...           COMP82             1                1     AstraZeneca   \n",
      "114       ...             Null          Null             Null            Null   \n",
      "115       ...        COMP92543             1                1     AstraZeneca   \n",
      "116       ...        COMP92543             1                1     AstraZeneca   \n",
      "117       ...           COMP68             1                1     AstraZeneca   \n",
      "118       ...             Null          Null             Null            Null   \n",
      "119       ...          COMP284             1                1     AstraZeneca   \n",
      "120       ...             Null          Null             Null            Null   \n",
      "121       ...        COMP93963             1                1     AstraZeneca   \n",
      "122       ...             Null          Null             Null            Null   \n",
      "123       ...           COMP36             1                1     AstraZeneca   \n",
      "124       ...          COMP277             1                1     AstraZeneca   \n",
      "125       ...          COMP328             1                1     AstraZeneca   \n",
      "126       ...             Null          Null             Null            Null   \n",
      "127       ...        COMP92958             1                0     AstraZeneca   \n",
      "128       ...             Null          Null             Null            Null   \n",
      "129       ...             Null          Null             Null            Null   \n",
      "130       ...             Null          Null             Null            Null   \n",
      "131       ...        COMP90590             1                0     AstraZeneca   \n",
      "132       ...             Null          Null             Null            Null   \n",
      "133       ...             Null          Null             Null            Null   \n",
      "134       ...          COMP475             1                1     AstraZeneca   \n",
      "135       ...             Null          Null             Null            Null   \n",
      "136       ...             Null          Null             Null            Null   \n",
      "137       ...             Null          Null             Null            Null   \n",
      "138       ...        COMP93944             1                1     AstraZeneca   \n",
      "139       ...             Null          Null             Null            Null   \n",
      "\n",
      "                                 INDICATION INDICATION_ID INDICATION_SCORE  \\\n",
      "0                    Delayed Graft Function       D051799                1   \n",
      "1                    Chronic Kidney Failure       D007676                1   \n",
      "2                             Low Back Pain       D017116                1   \n",
      "3                             Low Back Pain       D017116                1   \n",
      "4                        Metabolic Diseases       D008659                1   \n",
      "5                                 Psoriasis       D011565                1   \n",
      "6                     Graft vs Host Disease       D006086                1   \n",
      "7                           Kidney Diseases       D007674                1   \n",
      "8                        Huntington Disease       D006816                1   \n",
      "9                Overactive Urinary Bladder       D053201                1   \n",
      "10               Overactive Urinary Bladder       D053201                1   \n",
      "11                   Pulmonary Hypertension       D006976                1   \n",
      "12              Secondary Parkinson Disease       D010302                1   \n",
      "13                                   Anemia       D000740                1   \n",
      "14                             Hypoglycemia       D007003                1   \n",
      "15                                Leiomyoma       D007889                1   \n",
      "16                         Neuropathic Pain       DX90161                1   \n",
      "17                              Solid Tumor       SDI0034                1   \n",
      "18                   Acute Myeloid Leukemia       D015470                1   \n",
      "19                          Cystic Fibrosis       D003550                1   \n",
      "20                              Solid Tumor       SDI0034                1   \n",
      "21                              Astrocytoma       D001254                1   \n",
      "22                                 Glaucoma       D005901                1   \n",
      "23                                     Null          Null             Null   \n",
      "24                                     Null          Null             Null   \n",
      "25                                     Null          Null             Null   \n",
      "26                                Carcinoma       D002277                1   \n",
      "27                                     Null          Null             Null   \n",
      "28                                     Null          Null             Null   \n",
      "29                           Osteoarthritis       D010003                1   \n",
      "..                                      ...           ...              ...   \n",
      "110                           Hyperhidrosis       D006945                1   \n",
      "111                                    Null          Null             Null   \n",
      "112  Respiratory Syncytial Virus Infections       D018357                1   \n",
      "113                    Esophageal Achalasia       D004931                1   \n",
      "114                                    Null          Null             Null   \n",
      "115               Small Cell Lung Carcinoma       D055752                1   \n",
      "116               Small Cell Lung Carcinoma       D055752                1   \n",
      "117                              Insulinoma       D007340                1   \n",
      "118                               Carcinoma       D002277                1   \n",
      "119                           Crohn Disease       D003424                1   \n",
      "120       Exocrine Pancreatic Insufficiency       D010188                1   \n",
      "121                               Carcinoma       D002277                1   \n",
      "122                    Zika virus infection       SDI0381                1   \n",
      "123                                    Null          Null             Null   \n",
      "124                                    Null          Null             Null   \n",
      "125                               Carcinoma       D002277                1   \n",
      "126                     Prostatic Neoplasms       D011471                1   \n",
      "127             Duchenne Muscular Dystrophy       D020388                1   \n",
      "128                            Chronic Pain       D059350                1   \n",
      "129                            Chronic Pain       D059350                1   \n",
      "130                                    Null          Null             Null   \n",
      "131                         Cystic Fibrosis       D003550                1   \n",
      "132             Type C Niemann-Pick Disease       D052556                1   \n",
      "133                       Colonic Neoplasms       D003110                1   \n",
      "134                            Chronic Pain       D059350                1   \n",
      "135                                    Null          Null             Null   \n",
      "136                 Head and Neck Neoplasms       D006258                1   \n",
      "137                              Hemorrhage       D006470                1   \n",
      "138                  Hepatic Encephalopathy       D006501                1   \n",
      "139                                    Null          Null             Null   \n",
      "\n",
      "    INDICATION_NONAMBIG INDICATION_NCT_ID SYNONYMS_NCT_ID  \n",
      "0                     1       NCT02610296     NCT03510897  \n",
      "1                     1       NCT02135276     NCT03032510  \n",
      "2                     1       NCT02706054     NCT03006874  \n",
      "3                     1       NCT02706054     NCT03434275  \n",
      "4                     1              Null     NCT03556956  \n",
      "5                     1       NCT03412747     NCT03355573  \n",
      "6                     1              Null     NCT02257619  \n",
      "7                     0       NCT03063242     NCT01265901  \n",
      "8                     1              Null     NCT03225833  \n",
      "9                     1       NCT03109379     NCT03081156  \n",
      "10                    1       NCT03109379     NCT03168828  \n",
      "11                    1       NCT02279745     NCT02279745  \n",
      "12                    0              Null             NaN  \n",
      "13                    1              Null             NaN  \n",
      "14                    1              Null     NCT03378635  \n",
      "15                    1       NCT03412890     NCT03412890  \n",
      "16                    1              Null             NaN  \n",
      "17                    1              Null     NCT03149549  \n",
      "18                    1              Null     NCT03203369  \n",
      "19                    1              Null     NCT03140527  \n",
      "20                    1              Null     NCT03160833  \n",
      "21                    1       NCT02546102     NCT02546102  \n",
      "22                    1       NCT02862938     NCT01530659  \n",
      "23                 Null              Null     NCT02706899  \n",
      "24                 Null              Null     NCT02706899  \n",
      "25                 Null              Null     NCT02706899  \n",
      "26                    1       NCT03352765     NCT03361852  \n",
      "27                 Null              Null     NCT03161483  \n",
      "28                 Null              Null             NaN  \n",
      "29                    1              Null     NCT02384538  \n",
      "..                  ...               ...             ...  \n",
      "110                   1       NCT01930604     NCT01930604  \n",
      "111                Null              Null             NaN  \n",
      "112                   1              Null     NCT03258502  \n",
      "113                   1       NCT03404739     NCT01726023  \n",
      "114                Null              Null     NCT03369275  \n",
      "115                   1       NCT03389087     NCT03382561  \n",
      "116                   1       NCT03389087             NaN  \n",
      "117                   1              Null             NaN  \n",
      "118                   1              Null     NCT03051035  \n",
      "119                   1       NCT03417778     NCT03025308  \n",
      "120                   1       NCT03269994     NCT03151603  \n",
      "121                   1              Null     NCT02992977  \n",
      "122                   1              Null             NaN  \n",
      "123                Null              Null             NaN  \n",
      "124                Null              Null     NCT03006172  \n",
      "125                   1              Null     NCT02903914  \n",
      "126                   1              Null             NaN  \n",
      "127                   1              Null     NCT01847573  \n",
      "128                   1       NCT03215940     NCT03164512  \n",
      "129                   1       NCT03215940     NCT01394185  \n",
      "130                Null              Null             NaN  \n",
      "131                   1              Null     NCT03128606  \n",
      "132                   1              Null     NCT02912793  \n",
      "133                   1              Null             NaN  \n",
      "134                   1       NCT02367820     NCT02367820  \n",
      "135                Null              Null             NaN  \n",
      "136                   1              Null     NCT03425747  \n",
      "137                   1              Null     NCT03131336  \n",
      "138                   1              Null             NaN  \n",
      "139                Null              Null             NaN  \n",
      "\n",
      "[140 rows x 21 columns],      TWID            TWEET_ID  \\\n",
      "0    1705  842712473887100928   \n",
      "1    1715  842428233337397249   \n",
      "2    1729  842009857871953925   \n",
      "3    1746  841241045291606018   \n",
      "4    1758  839436021083230208   \n",
      "5    1758  839436021083230208   \n",
      "6    1758  839436021083230208   \n",
      "7    1758  839436021083230208   \n",
      "8    1758  839436021083230208   \n",
      "9    1767  839014291336376321   \n",
      "10   1779  837264641591894016   \n",
      "11   1791  836468106637647872   \n",
      "12   1797  835101459641315328   \n",
      "13   1809  834378731099545601   \n",
      "14   1810  834377523949481984   \n",
      "15   1812  834377341425954816   \n",
      "16   1835  831850847394893824   \n",
      "17   1839  831476861049794560   \n",
      "18   1842  831448836136542209   \n",
      "19   1843  831448626115153920   \n",
      "20   1849  831081133156626432   \n",
      "21   1852  830028668428709889   \n",
      "22   1852  830028668428709889   \n",
      "23   1857  829289877908946947   \n",
      "24   1868  828554139382657024   \n",
      "25   1881  826754994804183040   \n",
      "26   1892  825641676324495360   \n",
      "27   1893  825331397904654340   \n",
      "28   1901  824212334188969984   \n",
      "29   1905  823846502179028992   \n",
      "..    ...                 ...   \n",
      "110  2183  800073616998232064   \n",
      "111  2187  799717189037105152   \n",
      "112  2187  799717189037105152   \n",
      "113  2187  799717189037105152   \n",
      "114  2187  799717189037105152   \n",
      "115  2191  799235688461762560   \n",
      "116  2193  799199484437823488   \n",
      "117  2193  799199484437823488   \n",
      "118  2194  799197851838513152   \n",
      "119  2201  798950631293665280   \n",
      "120  2205  798685053962158080   \n",
      "121  2205  798685053962158080   \n",
      "122  2208  798669726075404288   \n",
      "123  2210  798663858281811968   \n",
      "124  2211  798644347449184256   \n",
      "125  2218  798595540422426626   \n",
      "126  2222  798484573189337088   \n",
      "127  2228  798355129963454464   \n",
      "128  2243  798105296346357760   \n",
      "129  2243  798105296346357760   \n",
      "130  2255  797985266065547264   \n",
      "131  2261  797887760879206400   \n",
      "132  2261  797887760879206400   \n",
      "133  2268  797619869407555584   \n",
      "134  2275  797149141289799680   \n",
      "135  2285  796300705724104705   \n",
      "136  2288  795962947423989760   \n",
      "137  2290  795946492083044352   \n",
      "138  2304  794105763002191872   \n",
      "139  2306  793805257503453184   \n",
      "\n",
      "                                                 TWEET               SYNONYMS  \\\n",
      "0    Preliminary toxicity results presented from ph...              CETUXIMAB   \n",
      "1    Electrochemotherapy shows an overall tumor res...    ELECTROCHEMOTHERAPY   \n",
      "2    MetrioPharm's MP-1032 shows efficacy and super...                MP-1032   \n",
      "3    TiGenix reports top-line phase I/II results of...              lloCSC-01   \n",
      "4    US FDA clears Glenmark's IND for phase II tria...             TIOTROPIUM   \n",
      "5    US FDA clears Glenmark's IND for phase II tria...             TIOTROPIUM   \n",
      "6    US FDA clears Glenmark's IND for phase II tria...     TIOTROPIUM BROMIDE   \n",
      "7    US FDA clears Glenmark's IND for phase II tria...                BROMIDE   \n",
      "8    US FDA clears Glenmark's IND for phase II tria...                BROMIDE   \n",
      "9    US FDA approves IND for Advaxis and Amgen's pe...                   Null   \n",
      "10   Myovant starts phase III trial of relugolix fo...              RELUGOLIX   \n",
      "11   La Jolla Pharma reports positive results from ...                 LA III   \n",
      "12   Rexahn's Supinoxin (RX-5902) starts phase IIa ...                RX-5902   \n",
      "13   Cidara terminates development of topical biafu...              BIAFUNGIN   \n",
      "14   Apitope 's ATX-MS-1467 shows promising efficac...            ATX-MS-1467   \n",
      "15   Lanthio's MOR-107 begins phase I trial in UK f...                MOR-107   \n",
      "16   Merck's Phase III trial of Verubecestat in Alz...           VERUBECESTAT   \n",
      "17   Vernalis earns $3M fee from Corvus triggered b...                CPI-444   \n",
      "18   Aviragen's vapendavir fails to meet primary ef...             VAPENDAVIR   \n",
      "19   Zosano's M-207 (zolmitriptan) well tolerated &...           ZOLMITRIPTAN   \n",
      "20   PhytoTech Therapeutics begins phase II trial o...                PTL-101   \n",
      "21   US FDA approves Emflaza (deflazacort) for the ...                EMFLAZA   \n",
      "22   US FDA approves Emflaza (deflazacort) for the ...            DEFLAZACORT   \n",
      "23   Vyome's VB-1953 well tolerated and meets pharm...                VB-1953   \n",
      "24   Innate Pharma's lirilumab fails to meet the pr...              LIRILUMAB   \n",
      "25   Dimension's DTX-101 shows preliminary efficacy...                DTX-101   \n",
      "26   Live at #ECCOCongress LOXO Oncology's larotrec...          LAROTRECTINIB   \n",
      "27   Live at #ECCOCongress Phase I/II study results...              MODUFOLIN   \n",
      "28   Health Canada clears ProtoKinetix's PKX-001 CT...                PKX-001   \n",
      "29   Vectura Group receives US IND approval for pha...                 VR-647   \n",
      "..                                                 ...                    ...   \n",
      "110  Taisho discloses clinical data of oral HIF-PH ...             TP-0463518   \n",
      "111  Sevelamer carbonate (Sanofi Genzyme's Renvela)...              SEVELAMER   \n",
      "112  Sevelamer carbonate (Sanofi Genzyme's Renvela)...                RENVELA   \n",
      "113  Sevelamer carbonate (Sanofi Genzyme's Renvela)...                RENVELA   \n",
      "114  Sevelamer carbonate (Sanofi Genzyme's Renvela)...    SEVELAMER CARBONATE   \n",
      "115  Lack of efficacy causes half of phase II and p...                 NATURE   \n",
      "116  Boehringer Ingelheim's bevacizumab biosimilar ...                AVASTIN   \n",
      "117  Boehringer Ingelheim's bevacizumab biosimilar ...            BEVACIZUMAB   \n",
      "118  Imara begins phase I study of IMR-687 for trea...                IMR-687   \n",
      "119  EFFECT-HF trial of Vifor's  iv ferric carboxym...  FERRIC CARBOXYMALTOSE   \n",
      "120  @AstraZeneca drug AZD-7325 increases test stim...                     2H   \n",
      "121  @AstraZeneca drug AZD-7325 increases test stim...                AZD7325   \n",
      "122  @ Rottapharm CR-6086 reduced the release of IL...                CR-6086   \n",
      "123  IONIS-ANGPTL3-LRx was well tolerated and no dr...            IONIS-ANGPT   \n",
      "124  Results of ORION-1 phase II trial of inclisira...             INCLISIRAN   \n",
      "125  SVR12 achieved with 8 or 12 weeks glecaprevir/...               GT1-infe   \n",
      "126  MabVax's MVT-5873 &amp MVT-2163 show interim s...               MVT-5873   \n",
      "127  In phase I trial humanized chimeric antibody a...                 a2AP-I   \n",
      "128  Camurus and Braeburn's long-acting buprenorphi...          BUPRENORPHINE   \n",
      "129  Camurus and Braeburn's long-acting buprenorphi...          BUPRENORPHINE   \n",
      "130  BMS-986165 shows good results for SLE and IBD ...             BMS-986165   \n",
      "131  No added advantage from rifaximin over lactulo...              LACTULOSE   \n",
      "132  No added advantage from rifaximin over lactulo...              RIFAXIMIN   \n",
      "133  Exenatide shows feasibility in more than 90% o...              EXENATIDE   \n",
      "134  PPIs (pantoprazol) reduce significantly the ne...            PANTOPRAZOL   \n",
      "135  US FDA places verbal clinical hold on BioInven...                 BI-505   \n",
      "136  Opexa reduces 40% workforce following negative...                 TCELNA   \n",
      "137  The Medicines Company discontinues development...            CHOLESTEROL   \n",
      "138  Phase I pharmacokinetic safety and immunogenic...              ABATACEPT   \n",
      "139  Gilead's GS-0976 (allosteric ACC inhibitor for...                GS-0976   \n",
      "\n",
      "      MOLREGNO   ACRONYM      PHASE  N_PHASES      OUTCOME  \\\n",
      "0       675579      Null    Phase 3         1         FAIL   \n",
      "1         Null      Null    Phase 2         1          N/I   \n",
      "2    Not found      Null    Phase 2         1      SUCCESS   \n",
      "3    Not found      Null  Phase 1/2         1      SUCCESS   \n",
      "4       675258      Null    Phase 2         2  IN PROGRESS   \n",
      "5      1241099      Null    Phase 2         2  IN PROGRESS   \n",
      "6      1927030      Null    Phase 2         2  IN PROGRESS   \n",
      "7       693811      Null    Phase 2         2  IN PROGRESS   \n",
      "8       308053      Null    Phase 2         2  IN PROGRESS   \n",
      "9         Null  ADXS-NEO       Null         0      SUCCESS   \n",
      "10     1161221      Null    Phase 3         1  IN PROGRESS   \n",
      "11         721      Null    Phase 3         1      SUCCESS   \n",
      "12   Not found      Null    Phase 2         2  IN PROGRESS   \n",
      "13        Null      Null    Phase 2         2         FAIL   \n",
      "14   Not found      Null    Phase 2         2      SUCCESS   \n",
      "15   Not found      Null    Phase 1         1  IN PROGRESS   \n",
      "16     1763563      Null    Phase 3         1         FAIL   \n",
      "17   Not found      Null       Null         2      SUCCESS   \n",
      "18        Null      Null    Phase 2         1         FAIL   \n",
      "19      196215      Null    Phase 1         1      SUCCESS   \n",
      "20   Not found      Null    Phase 2         2  IN PROGRESS   \n",
      "21      675842      Null       Null         0      SUCCESS   \n",
      "22      675842      Null       Null         0      SUCCESS   \n",
      "23   Not found      Null    Phase 1         1      SUCCESS   \n",
      "24     1381940      Null    Phase 2         1         FAIL   \n",
      "25   Not found      Null  Phase 1/2         1      SUCCESS   \n",
      "26     2099025      Null    Phase 1         1  IN PROGRESS   \n",
      "27        Null      Null  Phase 1/2         1  IN PROGRESS   \n",
      "28   Not found      Null  Phase 1/2         1  IN PROGRESS   \n",
      "29   Not found      Null    Phase 1         1  IN PROGRESS   \n",
      "..         ...       ...        ...       ...          ...   \n",
      "110  Not found      Null       Null         0          N/I   \n",
      "111     675749      Null    Phase 2         1      SUCCESS   \n",
      "112     675750      Null    Phase 2         1      SUCCESS   \n",
      "113     675749      Null    Phase 2         1      SUCCESS   \n",
      "114     675750      Null    Phase 2         1      SUCCESS   \n",
      "115    1381144      Null    Phase 3         2         FAIL   \n",
      "116     675483      Null    Phase 1         1  SIM IN COMP   \n",
      "117     675483      Null    Phase 1         1  SIM IN COMP   \n",
      "118  Not found      Null    Phase 1         1  IN PROGRESS   \n",
      "119    1380863      Null       Null         0      SUCCESS   \n",
      "120     694656      Null    Phase 1         1  IN PROGRESS   \n",
      "121    1149947      Null    Phase 1         1  IN PROGRESS   \n",
      "122  Not found      Null       Null         1         FAIL   \n",
      "123  Not found      Null  Phase 1/2         1      SUCCESS   \n",
      "124    2197904      Null    Phase 3         2  IN PROGRESS   \n",
      "125  Not found      Null    Phase 3         2      SUCCESS   \n",
      "126  Not found      Null    Phase 1         1      SUCCESS   \n",
      "127  Not found      Null    Phase 1         1          N/I   \n",
      "128     556608      Null    Phase 3         2      SUCCESS   \n",
      "129     446784      Null    Phase 3         2      SUCCESS   \n",
      "130  Not found      Null    Phase 2         1      SUCCESS   \n",
      "131     699419      Null       Null         0          N/I   \n",
      "132     466768      Null       Null         0          N/I   \n",
      "133     390990      Null       Null         2      SUCCESS   \n",
      "134       Null      Null       Null         1          N/I   \n",
      "135  Not found      Null    Phase 2         1      STOPPED   \n",
      "136    1449231      Null    Phase 2         1         FAIL   \n",
      "137     182921      Null    Phase 2         1         FAIL   \n",
      "138     675774      Null    Phase 1         1  IN PROGRESS   \n",
      "139  Not found      NASH    Phase 2         2      SUCCESS   \n",
      "\n",
      "                                       MATCHED_OUTCOME       ...        \\\n",
      "0                           toxicity results presented       ...         \n",
      "1                           shows response rate of 55%       ...         \n",
      "2                                       shows efficacy       ...         \n",
      "3                             reports top-line results       ...         \n",
      "4                                     Clears for trial       ...         \n",
      "5                                     Clears for trial       ...         \n",
      "6                                     Clears for trial       ...         \n",
      "7                                     Clears for trial       ...         \n",
      "8                                     Clears for trial       ...         \n",
      "9                                         FDA approves       ...         \n",
      "10                                  starts phase trial       ...         \n",
      "11                                      Positive trial       ...         \n",
      "12                                  starts phase trial       ...         \n",
      "13                                    terminates trial       ...         \n",
      "14                                        shows safety       ...         \n",
      "15                                  begins phase trial       ...         \n",
      "16                                    Lack of efficacy       ...         \n",
      "17                                      Positive trial       ...         \n",
      "18                                         fails phase       ...         \n",
      "19                                      well tolerated       ...         \n",
      "20                                  begins phase trial       ...         \n",
      "21                                        FDA approves       ...         \n",
      "22                                        FDA approves       ...         \n",
      "23                              meets primary endpoint       ...         \n",
      "24                                         trial fails       ...         \n",
      "25                                        shows safety       ...         \n",
      "26                                    In phase live at       ...         \n",
      "27                                    In phase live at       ...         \n",
      "28                                    Clears for trial       ...         \n",
      "29                                receives US approval       ...         \n",
      "..                                                 ...       ...         \n",
      "110                                     discloses data       ...         \n",
      "111                                    seen to be safe       ...         \n",
      "112                                    seen to be safe       ...         \n",
      "113                                    seen to be safe       ...         \n",
      "114                                    seen to be safe       ...         \n",
      "115                                   Lack of efficacy       ...         \n",
      "116                        Demonstrates bioequivalence       ...         \n",
      "117                        Demonstrates bioequivalence       ...         \n",
      "118                                       Begins study       ...         \n",
      "119                        met its primary endpoint \\t       ...         \n",
      "120                                   In phase live at       ...         \n",
      "121                                   In phase live at       ...         \n",
      "122                                reduced the release       ...         \n",
      "123                                     well tolerated       ...         \n",
      "124                                      Initiation of       ...         \n",
      "125                          SVR12 achieved in 99-100%       ...         \n",
      "126                                     Show safety PK       ...         \n",
      "127                Reduces alpha2-antiplasmin activity       ...         \n",
      "128                             meets primary endpoint       ...         \n",
      "129                             meets primary endpoint       ...         \n",
      "130                                 shows good results       ...         \n",
      "131                                 No added advantage       ...         \n",
      "132                                 No added advantage       ...         \n",
      "133                                  shows feasibility       ...         \n",
      "134     reduce significantly the need for phlebotomies       ...         \n",
      "135                               places clinical hold       ...         \n",
      "136                             Negative phase results       ...         \n",
      "137                           discontinues development       ...         \n",
      "138                                    Trial initiated       ...         \n",
      "139  achieves significant milestone in phase progress        ...         \n",
      "\n",
      "    COMPANY_ID COMPANY_SCORE COMPANY_NONAMBIG COMPANY_MATCHED  \\\n",
      "0         Null          Null             Null            Null   \n",
      "1         Null          Null             Null            Null   \n",
      "2    COMP90628             1                1     AstraZeneca   \n",
      "3    COMP90119             1                1     AstraZeneca   \n",
      "4    COMP92688             1                1     AstraZeneca   \n",
      "5    COMP92688             1                1     AstraZeneca   \n",
      "6    COMP92688             1                1     AstraZeneca   \n",
      "7    COMP92688             1                1     AstraZeneca   \n",
      "8    COMP92688             1                1     AstraZeneca   \n",
      "9       COMP44             1                1     AstraZeneca   \n",
      "10        Null          Null             Null            Null   \n",
      "11   COMP92521             1                1     AstraZeneca   \n",
      "12   COMP91164             1                1     AstraZeneca   \n",
      "13   COMP92959             1                0     AstraZeneca   \n",
      "14        Null          Null             Null            Null   \n",
      "15        Null          Null             Null            Null   \n",
      "16     COMP435             1                1     AstraZeneca   \n",
      "17     COMP799             1                1     AstraZeneca   \n",
      "18        Null          Null             Null            Null   \n",
      "19   COMP93587             1                1     AstraZeneca   \n",
      "20        Null          Null             Null            Null   \n",
      "21        Null          Null             Null            Null   \n",
      "22        Null          Null             Null            Null   \n",
      "23        Null          Null             Null            Null   \n",
      "24     COMP334             1                1     AstraZeneca   \n",
      "25        Null          Null             Null            Null   \n",
      "26   COMP93848             1                1     AstraZeneca   \n",
      "27        Null          Null             Null            Null   \n",
      "28   COMP92551             1                1     AstraZeneca   \n",
      "29   COMP92352             1                1     AstraZeneca   \n",
      "..         ...           ...              ...             ...   \n",
      "110       Null          Null             Null            Null   \n",
      "111    COMP282             1                1     AstraZeneca   \n",
      "112    COMP282             1                1     AstraZeneca   \n",
      "113    COMP282             1                1     AstraZeneca   \n",
      "114    COMP282             1                1     AstraZeneca   \n",
      "115       Null          Null             Null            Null   \n",
      "116    COMP136             1                1     AstraZeneca   \n",
      "117    COMP136             1                1     AstraZeneca   \n",
      "118       Null          Null             Null            Null   \n",
      "119  COMP92668             1                1     AstraZeneca   \n",
      "120       Null          Null             Null            Null   \n",
      "121       Null          Null             Null            Null   \n",
      "122  COMP93909             1                1     AstraZeneca   \n",
      "123       Null          Null             Null            Null   \n",
      "124       Null          Null             Null            Null   \n",
      "125       Null          Null             Null            Null   \n",
      "126       Null          Null             Null            Null   \n",
      "127       Null          Null             Null            Null   \n",
      "128  COMP92246             1                0     AstraZeneca   \n",
      "129  COMP92246             1                0     AstraZeneca   \n",
      "130       Null          Null             Null            Null   \n",
      "131       Null          Null             Null            Null   \n",
      "132       Null          Null             Null            Null   \n",
      "133       Null          Null             Null            Null   \n",
      "134       Null          Null             Null            Null   \n",
      "135  COMP92400             1                1     AstraZeneca   \n",
      "136  COMP90274             1                1     AstraZeneca   \n",
      "137  COMP92529             1                1     AstraZeneca   \n",
      "138  COMP90048             1                1     AstraZeneca   \n",
      "139    COMP284             1                1     AstraZeneca   \n",
      "\n",
      "                       INDICATION INDICATION_ID INDICATION_SCORE  \\\n",
      "0                       Carcinoma       D002277                1   \n",
      "1         Head and Neck Neoplasms       D006258                1   \n",
      "2                       Psoriasis       D011565                1   \n",
      "3           Myocardial Infarction       D009203                1   \n",
      "4                          Asthma       D001249                1   \n",
      "5                          Asthma       D001249                1   \n",
      "6                          Asthma       D001249                1   \n",
      "7                          Asthma       D001249                1   \n",
      "8                          Asthma       D001249                1   \n",
      "9                       Carcinoma       D002277                1   \n",
      "10                      Leiomyoma       D007889                1   \n",
      "11                    Hypotension       D007022                1   \n",
      "12                    Solid Tumor       SDI0034                1   \n",
      "13                    Candidiasis       D002177                1   \n",
      "14             Multiple Sclerosis       D009103                1   \n",
      "15         Diabetic Nephropathies       D003928                1   \n",
      "16      Mild Cognitive Impairment       D060825                1   \n",
      "17           Renal Cell Carcinoma       D002292                1   \n",
      "18   Respiratory Tract Infections       D012141                1   \n",
      "19             Vascular Headaches       D014653                1   \n",
      "20                       Epilepsy       D004827                1   \n",
      "21    Duchenne Muscular Dystrophy       D020388                1   \n",
      "22    Duchenne Muscular Dystrophy       D020388                1   \n",
      "23                  Acne Vulgaris       D000152                1   \n",
      "24                      Carcinoma       D002277                1   \n",
      "25                   Hemophilia B       D002836                1   \n",
      "26                      Carcinoma       D002277                1   \n",
      "27              Colonic Neoplasms       D003110                1   \n",
      "28       Type 1 Diabetes Mellitus       D003922                1   \n",
      "29                         Asthma       D001249                1   \n",
      "..                            ...           ...              ...   \n",
      "110                        Anemia       D000740                1   \n",
      "111             Hyperphosphatemia       D054559                1   \n",
      "112             Hyperphosphatemia       D054559                1   \n",
      "113             Hyperphosphatemia       D054559                1   \n",
      "114             Hyperphosphatemia       D054559                1   \n",
      "115                          Null          Null             Null   \n",
      "116                 Macular Edema       D008269                1   \n",
      "117                 Macular Edema       D008269                1   \n",
      "118            Sickle Cell Anemia       D000755                1   \n",
      "119                 Heart Failure       D006333                1   \n",
      "120            Fragile X Syndrome       D005600                1   \n",
      "121            Fragile X Syndrome       D005600                1   \n",
      "122                          Null          Null             Null   \n",
      "123                          Null          Null             Null   \n",
      "124          Hypercholesterolemia       D006937                1   \n",
      "125                   Hepatitis C       D006526                1   \n",
      "126          Pancreatic Neoplasms       D010190                1   \n",
      "127                          Null          Null             Null   \n",
      "128                  Chronic Pain       D059350                1   \n",
      "129                  Chronic Pain       D059350                1   \n",
      "130                          Null          Null             Null   \n",
      "131      Irritable Bowel Syndrome       D043183                1   \n",
      "132      Irritable Bowel Syndrome       D043183                1   \n",
      "133                  Hypoglycemia       D007003                1   \n",
      "134               Hemochromatosis       D006432                1   \n",
      "135              Multiple Myeloma       D009101                1   \n",
      "136                       Atrophy       D001284                1   \n",
      "137                          Null          Null             Null   \n",
      "138            Sjogren's Syndrome       D012859                1   \n",
      "139                          Null          Null             Null   \n",
      "\n",
      "    INDICATION_NONAMBIG INDICATION_NCT_ID SYNONYMS_NCT_ID  \n",
      "0                     1       NCT03416153     NCT03391843  \n",
      "1                     1              Null     NCT03448666  \n",
      "2                     1              Null     NCT02908347  \n",
      "3                     1              Null     NCT02439398  \n",
      "4                     1       NCT03376932     NCT03395002  \n",
      "5                     1       NCT03376932     NCT03395002  \n",
      "6                     1       NCT03376932     NCT00565266  \n",
      "7                     1       NCT03376932     NCT00565266  \n",
      "8                     1       NCT03376932     NCT00565266  \n",
      "9                     1              Null     NCT03265080  \n",
      "10                    1       NCT03412890     NCT03412890  \n",
      "11                    1              Null             NaN  \n",
      "12                    1       NCT02003092     NCT02003092  \n",
      "13                    1              Null             NaN  \n",
      "14                    1              Null     NCT01973491  \n",
      "15                    1              Null     NCT03067363  \n",
      "16                    1       NCT01953601     NCT01739348  \n",
      "17                    1              Null     NCT03337698  \n",
      "18                    1       NCT03024177     NCT03024177  \n",
      "19                    1       NCT03377257     NCT02905227  \n",
      "20                    1              Null             NaN  \n",
      "21                    1       NCT02295748             NaN  \n",
      "22                    1       NCT02295748     NCT02286635  \n",
      "23                    1              Null             NaN  \n",
      "24                    1       NCT02399917     NCT02813135  \n",
      "25                    1              Null     NCT02618915  \n",
      "26                    1              Null     NCT03213704  \n",
      "27                    1              Null     NCT02244632  \n",
      "28                    1              Null     NCT03073577  \n",
      "29                    1              Null     NCT03421730  \n",
      "..                  ...               ...             ...  \n",
      "110                   1              Null             NaN  \n",
      "111                   1       NCT03001011     NCT03451019  \n",
      "112                   1       NCT03001011     NCT01308242  \n",
      "113                   1       NCT03001011     NCT01308242  \n",
      "114                   1       NCT03001011     NCT01308242  \n",
      "115                Null              Null     NCT03081949  \n",
      "116                   1       NCT03353324     NCT03390673  \n",
      "117                   1       NCT03353324     NCT03387085  \n",
      "118                   1              Null     NCT02998450  \n",
      "119                   1       NCT03380520     NCT02009943  \n",
      "120                   1       NCT03140813     NCT03051711  \n",
      "121                   1       NCT03140813     NCT03140813  \n",
      "122                Null              Null     NCT03163966  \n",
      "123                Null              Null     NCT03371355  \n",
      "124                   1              Null     NCT03399370  \n",
      "125                   1       NCT03364725             NaN  \n",
      "126                   1              Null     NCT02672917  \n",
      "127                Null              Null             NaN  \n",
      "128                   1       NCT02710526     NCT03026790  \n",
      "129                   1       NCT02710526     NCT03026790  \n",
      "130                Null              Null     NCT03402087  \n",
      "131                   1       NCT03219528     NCT03148002  \n",
      "132                   1       NCT03219528     NCT03069131  \n",
      "133                   1       NCT03373435     NCT03017352  \n",
      "134                   1              Null     NCT01179646  \n",
      "135                   1       NCT01838369     NCT02756728  \n",
      "136                   1       NCT01684761     NCT01684761  \n",
      "137                Null              Null     NCT00272844  \n",
      "138                   1       NCT03411850     NCT00442611  \n",
      "139                Null              Null     NCT02781584  \n",
      "\n",
      "[140 rows x 21 columns],      TWID            TWEET_ID  \\\n",
      "0    2308  793755656234729472   \n",
      "1    2311  793352467110961152   \n",
      "2    2312  793351223457964032   \n",
      "3    2313  793349824020033536   \n",
      "4    2316  793040610060013568   \n",
      "5    2317  792502071647805440   \n",
      "6    2320  792075701323075585   \n",
      "7    2322  791931974327767040   \n",
      "8    2323  791894682280210432   \n",
      "9    2325  791836359149232129   \n",
      "10   2326  791829476074135552   \n",
      "11   2330  791573334479605760   \n",
      "12   2331  791573245279338496   \n",
      "13   2332  791566337424363521   \n",
      "14   2336  791213908883152896   \n",
      "15   2336  791213908883152896   \n",
      "16   2354  789364164485484544   \n",
      "17   2368  788668035275952128   \n",
      "18   2370  788436408587341824   \n",
      "19   2370  788436408587341824   \n",
      "20   2370  788436408587341824   \n",
      "21   2372  788378802577485825   \n",
      "22   2374  788266575656722433   \n",
      "23   2375  788263228220387328   \n",
      "24   2383  787905371750871040   \n",
      "25   2384  787903040976150528   \n",
      "26   2386  787699194437865473   \n",
      "27   2397  786481861904039936   \n",
      "28   2401  786144529615245312   \n",
      "29   2402  786140359386501120   \n",
      "..    ...                 ...   \n",
      "110  2725  762896832070574080   \n",
      "111  2726  762896613627031552   \n",
      "112  2727  762896451831758850   \n",
      "113  2731  761400111456931840   \n",
      "114  2739  760664158714998786   \n",
      "115  2740  760657290257051648   \n",
      "116  2744  760311185975619584   \n",
      "117  2746  760293922643988480   \n",
      "118  2749  759933566792835072   \n",
      "119  2749  759933566792835072   \n",
      "120  2749  759933566792835072   \n",
      "121  2749  759933566792835072   \n",
      "122  2754  758878565232324608   \n",
      "123  2760  758584655239077888   \n",
      "124  2761  758370520723226625   \n",
      "125  2767  758122766788808704   \n",
      "126  2773  757708739948535808   \n",
      "127  2796  753519266188685312   \n",
      "128  2797  753511740898439168   \n",
      "129  2798  753510740674347009   \n",
      "130  2808  752803160679383040   \n",
      "131  2813  752516080552308736   \n",
      "132  2814  752497801070862336   \n",
      "133  2815  752489103598452740   \n",
      "134  2833  751247206825406464   \n",
      "135  2839  750755897194971137   \n",
      "136  2843  750581784837062660   \n",
      "137  2844  750525342817804288   \n",
      "138  2845  750523022398746624   \n",
      "139  2850  750264707999727616   \n",
      "\n",
      "                                                 TWEET  \\\n",
      "0    Palatin's bremelanotide meets coprimary effica...   \n",
      "1    Aclaris Therapeutics submits IND to US FDA for...   \n",
      "2    Vyome Biosciences begins first-in-human phase ...   \n",
      "3    Phase III clinical trial begins in US for Eisa...   \n",
      "4    ReViral begins phase I trial of RV-521 for the...   \n",
      "5    GlaxoSmithKline's gepotidacin safe and effecti...   \n",
      "6    Rebiotix's RBX-2660 effective in phase IIb tri...   \n",
      "7    Alexion's ALXN-1210 begins phase III trials fo...   \n",
      "8    Bird Rock Bio files CTA for namacizumab to sta...   \n",
      "9    Matinas BioPharma's LCNP influenza vaccine pro...   \n",
      "10   Janssen's JNJ-53718678 safe and well tolerated...   \n",
      "11   Selecta starts phase II trial of SEL-212 for g...   \n",
      "12   Entasis' ETX-2514 begins phase I trial for Aci...   \n",
      "13   ProMetic's plasminogen meets primary and secon...   \n",
      "14   Dipexium's Locilex (pexiganan acetate) fails t...   \n",
      "15   Dipexium's Locilex (pexiganan acetate) fails t...   \n",
      "16   MicuRx's MRX-I begins phase III trials for com...   \n",
      "17   Bavarian Nordic's MVA-BN RSV begins phase II t...   \n",
      "18   89Zr ImmunoPET provides valuable data on biodi...   \n",
      "19   89Zr ImmunoPET provides valuable data on biodi...   \n",
      "20   89Zr ImmunoPET provides valuable data on biodi...   \n",
      "21   Apitope regains all rights to its phase II MS ...   \n",
      "22   US FDA places hold on phase 2b trial of Regene...   \n",
      "23   Rational Vaccines' live attenuated herpes vacc...   \n",
      "24   Hua Medicine reports positive phase II results...   \n",
      "25   Clementia Pharmaceuticals' palovarotene demons...   \n",
      "26   Phase II preliminary results show that Zr89-gi...   \n",
      "27   Biocad's BCD-085 starts phase II trial for pso...   \n",
      "28   US FDA clears IND for KemPharm's KP-415 for AD...   \n",
      "29   Exicure's AST-005 shows safety tolerability an...   \n",
      "..                                                 ...   \n",
      "110  Coherus BioSciences' Humira biosimilar CHS-142...   \n",
      "111  ATB-346 from Antibe Therapeutics effective in ...   \n",
      "112  Pfenex's anthrax vaccine Px-563L demonstrates ...   \n",
      "113  Momenta's necuparanib fails to show sufficient...   \n",
      "114  Vaxart's oral norovirus tablet vaccine begins ...   \n",
      "115  PharmaMar starts phase III trial of lurbinecte...   \n",
      "116  Tetraphase's iv TP-6076 begins phase I trial f...   \n",
      "117  Araclon's ABvac40 shows safety and tolerabilit...   \n",
      "118  Edge Therapeutics starts phase III trial of EG...   \n",
      "119  Edge Therapeutics starts phase III trial of EG...   \n",
      "120  Edge Therapeutics starts phase III trial of EG...   \n",
      "121  Edge Therapeutics starts phase III trial of EG...   \n",
      "122  ObsEva starts phase I trial of OBE-022 for pre...   \n",
      "123  US NIAID initiates phase I trial of MVA-BN YF ...   \n",
      "124  Phase 1 results on first-in-class Abeta oligom...   \n",
      "125  Tokai discontinues galeterone's phase III tria...   \n",
      "126  MK-8719 safe and well tolerated in phase 1 stu...   \n",
      "127  TARIS Biomedical begins phase Ib trial of TAR-...   \n",
      "128  Phase I first-in-human trial begins for Aptiny...   \n",
      "129  Enteris BioPharma initiates phase I clinical t...   \n",
      "130  Celldex Therapeutics begins enrollment in phas...   \n",
      "131  Sucampo discontinue cobiprostone development a...   \n",
      "132  AC Immune to receive CHF 14 million milestone ...   \n",
      "133  Diurnal's Infacort meets primary endpoint in p...   \n",
      "134  Protalix starts phase II trial of AIR DNase (P...   \n",
      "135  $10M milestone triggered for 1st patient dosin...   \n",
      "136  Can-Fite's CF-101 fails to meet primary effica...   \n",
      "137  Oryzon selects oral LSD1 inhibitor ORY-3001 as...   \n",
      "138  Nippon Kayaku's NK-105 (paclitaxel micelles) f...   \n",
      "139  Cinfa Biotech's pegfilgrastim biosimilar B-120...   \n",
      "\n",
      "                     SYNONYMS   MOLREGNO ACRONYM              PHASE  N_PHASES  \\\n",
      "0               BREMELANOTIDE    1360388    Null            Phase 3         1   \n",
      "1                   ATI-50001  Not found    Null               Null         0   \n",
      "2                     VB-1953  Not found    Null            Phase 1         2   \n",
      "3                       E2609    2096360    Null            Phase 3         1   \n",
      "4                      RV-521  Not found    Null            Phase 1         1   \n",
      "5                 GEPOTIDACIN    1782495    Null            Phase 2         1   \n",
      "6                    RBX-2660  Not found    Null            Phase 2         1   \n",
      "7                    ALXN1210    2197857    Null            Phase 3         2   \n",
      "8                 NAMACIZUMAB       Null    Null            Phase 1         1   \n",
      "9           INFLUENZA VACCINE       Null    Null  Preclinical trial         1   \n",
      "10               JNJ-53718678  Not found    Null            Phase 1         1   \n",
      "11                    SEL-212  Not found    Null            Phase 2         1   \n",
      "12                   ETX-2514  Not found    Null            Phase 1         1   \n",
      "13                PLASMINOGEN    1380397    Null          Phase 2/3         2   \n",
      "14          PEXIGANAN ACETATE    1380822    Null            Phase 3         1   \n",
      "15                  PEXIGANAN     711762    Null            Phase 3         1   \n",
      "16                      MRX-I  Not found    Null            Phase 3         1   \n",
      "17                     MVA-BN  Not found    Null            Phase 2         1   \n",
      "18               CERGUTUZUMAB    2197886    Null            Phase 1         1   \n",
      "19   CERGUTUZUMAB AMUNALEUKIN    2197889    Null            Phase 1         1   \n",
      "20                      ROCHE     469217    Null            Phase 1         1   \n",
      "21                ATX-MS-1467  Not found    Null            Phase 2         2   \n",
      "22                  FASINUMAB    1381968    Null            Phase 2         1   \n",
      "23                   THERAVAX       Null    Null            Phase 1         1   \n",
      "24                   HMS-5552  Not found    Null            Phase 2         1   \n",
      "25               PALOVAROTENE    1377918    Null            Phase 2         1   \n",
      "26                 Zr89-giren  Not found    Null            Phase 2         1   \n",
      "27                    BCD-085  Not found    Null            Phase 2         1   \n",
      "28                     KP-415  Not found    Null               Null         0   \n",
      "29                    AST-005  Not found    Null            Phase 1         1   \n",
      "..                        ...        ...     ...                ...       ...   \n",
      "110                    HUMIRA     675482    Null            Phase 3         1   \n",
      "111                   ATB-346  Not found    Null            Phase 2         1   \n",
      "112                   Px-563L  Not found    Null            Phase 1         1   \n",
      "113               NECUPARANIB    1763532    Null          Phase 1/2         1   \n",
      "114  NOROVIRUS TABLET VACCINE       Null    Null            Phase 1         1   \n",
      "115                   PM-1183  Not found    Null            Phase 3         1   \n",
      "116                   TP-6076  Not found    Null            Phase 1         2   \n",
      "117                   ABvac40  Not found    Null            Phase 2         2   \n",
      "118                NIMODIPINE     421116    Null            Phase 3         2   \n",
      "119                NIMODIPINE     421116    Null            Phase 3         2   \n",
      "120                NIMODIPINE     365248    Null            Phase 3         2   \n",
      "121                NIMODIPINE     365248    Null            Phase 3         2   \n",
      "122                   OBE-022  Not found    Null            Phase 1         1   \n",
      "123      YELLOW FEVER VACCINE    1381082    Null            Phase 1         1   \n",
      "124                    CT1812  Not found    Null            Phase 1         2   \n",
      "125           astration-resis  Not found    Null            Phase 3         1   \n",
      "126                   MK-8719  Not found    Null            Phase 1         1   \n",
      "127                   TAR-200  Not found    Null            Phase 1         1   \n",
      "128                      NMDA      64776    Null            Phase 1         2   \n",
      "129                TOBRAMYCIN     577488    Null            Phase 1         1   \n",
      "130                     TIM-1  Not found    Null          Phase 1/2         1   \n",
      "131              COBIPROSTONE    1376069    Null            Phase 2         1   \n",
      "132              ANTI-TAU MAB       Null    Null            Phase 1         1   \n",
      "133             PIVOTAL TRIAL       Null    Null            Phase 3         2   \n",
      "134                   PRX-110  Not found    Null            Phase 2         1   \n",
      "135                   HTL1071  Not found    Null            Phase 1         1   \n",
      "136                     CF101    2197744    Null            Phase 2         1   \n",
      "137                  ORY-3001  Not found    Null          Phase 1/2         1   \n",
      "138                PACLITAXEL       8062    Null            Phase 3         1   \n",
      "139             PEGFILGRASTIM     675363    Null               Null         0   \n",
      "\n",
      "         OUTCOME                         MATCHED_OUTCOME       ...        \\\n",
      "0        SUCCESS      meets coprimary efficacy endpoints       ...         \n",
      "1    IN PROGRESS                           Trial planned       ...         \n",
      "2    IN PROGRESS                      begins phase trial       ...         \n",
      "3    IN PROGRESS                      begins phase trial       ...         \n",
      "4    IN PROGRESS                      begins phase trial       ...         \n",
      "5        SUCCESS                      effective in phase       ...         \n",
      "6        SUCCESS                      effective in phase       ...         \n",
      "7    IN PROGRESS                     begins phase trials       ...         \n",
      "8    IN PROGRESS                      Start phase trials       ...         \n",
      "9        SUCCESS                 protects from infection       ...         \n",
      "10       SUCCESS                           safe in trial       ...         \n",
      "11   IN PROGRESS                      starts phase trial       ...         \n",
      "12   IN PROGRESS                      begins phase trial       ...         \n",
      "13       SUCCESS  meets primary and secondary end points       ...         \n",
      "14          FAIL                             trial fails       ...         \n",
      "15          FAIL                             trial fails       ...         \n",
      "16   IN PROGRESS                     begins phase trials       ...         \n",
      "17   IN PROGRESS                      begins phase trial       ...         \n",
      "18           N/I                  Provides valuable data       ...         \n",
      "19           N/I                  Provides valuable data       ...         \n",
      "20           N/I                  Provides valuable data       ...         \n",
      "21           N/I                      Regains all rights       ...         \n",
      "22   IN PROGRESS                           hold on trial       ...         \n",
      "23       SUCCESS                           safe in trial       ...         \n",
      "24       SUCCESS                          Positive trial       ...         \n",
      "25       SUCCESS                          Positive trial       ...         \n",
      "26           N/I                preliminary results show       ...         \n",
      "27   IN PROGRESS                      starts phase trial       ...         \n",
      "28   IN PROGRESS                   start clinical trials       ...         \n",
      "29       SUCCESS                            shows safety       ...         \n",
      "..           ...                                     ...       ...         \n",
      "110      SUCCESS              meets equivalence endpoint       ...         \n",
      "111      SUCCESS                      effective in phase       ...         \n",
      "112      SUCCESS                      Tolerable in trial       ...         \n",
      "113         FAIL                             trial fails       ...         \n",
      "114  IN PROGRESS                      begins phase trial       ...         \n",
      "115  IN PROGRESS                      starts phase trial       ...         \n",
      "116  IN PROGRESS                      begins phase trial       ...         \n",
      "117      SUCCESS                            shows safety       ...         \n",
      "118  IN PROGRESS                      starts phase trial       ...         \n",
      "119  IN PROGRESS                      starts phase trial       ...         \n",
      "120  IN PROGRESS                      starts phase trial       ...         \n",
      "121  IN PROGRESS                      starts phase trial       ...         \n",
      "122  IN PROGRESS                      starts phase trial       ...         \n",
      "123  IN PROGRESS                         initiates trial       ...         \n",
      "124          N/I                       results disclosed       ...         \n",
      "125         FAIL                            discontinues       ...         \n",
      "126      SUCCESS                     safe well tolerated       ...         \n",
      "127  IN PROGRESS                      begins phase trial       ...         \n",
      "128  IN PROGRESS                      begins phase trial       ...         \n",
      "129  IN PROGRESS                         initiates trial       ...         \n",
      "130  IN PROGRESS                      begins phase trial       ...         \n",
      "131         FAIL                 discontinue development       ...         \n",
      "132  IN PROGRESS                         initiates trial       ...         \n",
      "133      SUCCESS                  meets primary endpoint       ...         \n",
      "134  IN PROGRESS                      starts phase trial       ...         \n",
      "135          N/I                     milestone triggered       ...         \n",
      "136         FAIL                             trial fails       ...         \n",
      "137  IN PROGRESS                      Start phase trials       ...         \n",
      "138         FAIL                             trial fails       ...         \n",
      "139      SUCCESS              meets equivalence endpoint       ...         \n",
      "\n",
      "    COMPANY_ID COMPANY_SCORE COMPANY_NONAMBIG COMPANY_MATCHED  \\\n",
      "0         Null          Null             Null            Null   \n",
      "1    COMP93609             1                1     AstraZeneca   \n",
      "2         Null          Null             Null            Null   \n",
      "3      COMP118             1                1     AstraZeneca   \n",
      "4         Null          Null             Null            Null   \n",
      "5      COMP286             1                1     AstraZeneca   \n",
      "6    COMP92376             1                1     AstraZeneca   \n",
      "7       COMP30             1                1     AstraZeneca   \n",
      "8    COMP93691             1                1     AstraZeneca   \n",
      "9         Null          Null             Null            Null   \n",
      "10     COMP354             1                1     AstraZeneca   \n",
      "11        Null          Null             Null            Null   \n",
      "12        Null          Null             Null            Null   \n",
      "13   COMP90671             1                1     AstraZeneca   \n",
      "14   COMP91194             1                1     AstraZeneca   \n",
      "15   COMP91194             1                1     AstraZeneca   \n",
      "16   COMP90957             1                1     AstraZeneca   \n",
      "17   COMP93676             1                1     AstraZeneca   \n",
      "18        Null          Null             Null            Null   \n",
      "19        Null          Null             Null            Null   \n",
      "20        Null          Null             Null            Null   \n",
      "21     COMP441             1                1     AstraZeneca   \n",
      "22   COMP90037             1                1     AstraZeneca   \n",
      "23        Null          Null             Null            Null   \n",
      "24        Null          Null             Null            Null   \n",
      "25   COMP92796             1                1     AstraZeneca   \n",
      "26        Null          Null             Null            Null   \n",
      "27        Null          Null             Null            Null   \n",
      "28   COMP93831             1                1     AstraZeneca   \n",
      "29   COMP93768             1                1     AstraZeneca   \n",
      "..         ...           ...              ...             ...   \n",
      "110  COMP90941             1                1     AstraZeneca   \n",
      "111  COMP92830             1                1     AstraZeneca   \n",
      "112       Null          Null             Null            Null   \n",
      "113  COMP90053             1                0     AstraZeneca   \n",
      "114  COMP93948             1                1     AstraZeneca   \n",
      "115  COMP93889             1                1     AstraZeneca   \n",
      "116  COMP90755             1                1     AstraZeneca   \n",
      "117       Null          Null             Null            Null   \n",
      "118       Null          Null             Null            Null   \n",
      "119  COMP92360             1                1     AstraZeneca   \n",
      "120       Null          Null             Null            Null   \n",
      "121  COMP92360             1                1     AstraZeneca   \n",
      "122  COMP93456             1                1     AstraZeneca   \n",
      "123  COMP93676             1                1     AstraZeneca   \n",
      "124       Null          Null             Null            Null   \n",
      "125  COMP91140             1                0     AstraZeneca   \n",
      "126       Null          Null             Null            Null   \n",
      "127  COMP93188             1                1     AstraZeneca   \n",
      "128       Null          Null             Null            Null   \n",
      "129       Null          Null             Null            Null   \n",
      "130  COMP90057             1                1     AstraZeneca   \n",
      "131  COMP90477             1                1     AstraZeneca   \n",
      "132    COMP277             1                1     AstraZeneca   \n",
      "133       Null          Null             Null            Null   \n",
      "134  COMP90672             1                1     AstraZeneca   \n",
      "135     COMP82             1                1     AstraZeneca   \n",
      "136  COMP92837             1                0     AstraZeneca   \n",
      "137       Null          Null             Null            Null   \n",
      "138    COMP491             1                1     AstraZeneca   \n",
      "139       Null          Null             Null            Null   \n",
      "\n",
      "                                        INDICATION INDICATION_ID  \\\n",
      "0                Hypoactive sexual desire disorder       SDI0266   \n",
      "1                                         Alopecia       D000505   \n",
      "2                                    Acne Vulgaris       D000152   \n",
      "3                                Alzheimer Disease       D000544   \n",
      "4           Respiratory Syncytial Virus Infections       D018357   \n",
      "5                                        Gonorrhea       D006069   \n",
      "6                   Pseudomembranous Enterocolitis       D004761   \n",
      "7               Atypical Hemolytic Uremic Syndrome       D065766   \n",
      "8                                         Fibrosis       D005355   \n",
      "9                                      influenza A       D007251   \n",
      "10                                            Null          Null   \n",
      "11                                            Gout       D006073   \n",
      "12                                            Null          Null   \n",
      "13                                            Null          Null   \n",
      "14                                   Diabetic Foot       D017719   \n",
      "15                                   Diabetic Foot       D017719   \n",
      "16                                            Null          Null   \n",
      "17                                        Orthopox       DX90099   \n",
      "18                                            Null          Null   \n",
      "19                                            Null          Null   \n",
      "20                                            Null          Null   \n",
      "21                                            Null          Null   \n",
      "22                             Knee Osteoarthritis       D020370   \n",
      "23                                            Null          Null   \n",
      "24                               Diabetes Mellitus       D003920   \n",
      "25                   Multiple Hereditary Exostoses       D005097   \n",
      "26                            Renal Cell Carcinoma       D002292   \n",
      "27                                       Psoriasis       D011565   \n",
      "28   Attention Deficit Disorder with Hyperactivity       D001289   \n",
      "29                                       Psoriasis       D011565   \n",
      "..                                             ...           ...   \n",
      "110                                      Psoriasis       D011565   \n",
      "111                                   Chronic Pain       D059350   \n",
      "112                                        Anthrax       D000881   \n",
      "113                            Neoplasm Metastasis       D009362   \n",
      "114                                           Null          Null   \n",
      "115                      Small Cell Lung Carcinoma       D055752   \n",
      "116                           Bacterial Infections       D001424   \n",
      "117                              Alzheimer Disease       D000544   \n",
      "118                        Subarachnoid Hemorrhage       D013345   \n",
      "119                                           Null          Null   \n",
      "120                        Subarachnoid Hemorrhage       D013345   \n",
      "121                                           Null          Null   \n",
      "122                      Premature Obstetric Labor       D007752   \n",
      "123                                       Orthopox       DX90099   \n",
      "124                                           Null          Null   \n",
      "125                            Prostatic Neoplasms       D011471   \n",
      "126                                           Null          Null   \n",
      "127                                      Carcinoma       D002277   \n",
      "128                                           Null          Null   \n",
      "129                                Cystic Fibrosis       D003550   \n",
      "130                           Renal Cell Carcinoma       D002292   \n",
      "131                                     Stomatitis       D013280   \n",
      "132                              Alzheimer Disease       D000544   \n",
      "133                          Adrenal Insufficiency       D000309   \n",
      "134                                Cystic Fibrosis       D003550   \n",
      "135                                      Carcinoma       D002277   \n",
      "136                                      Psoriasis       D011565   \n",
      "137                                           Null          Null   \n",
      "138                          Prostatic Hyperplasia       D011470   \n",
      "139                               Breast Neoplasms       D001943   \n",
      "\n",
      "    INDICATION_SCORE INDICATION_NONAMBIG INDICATION_NCT_ID SYNONYMS_NCT_ID  \n",
      "0                  1                   1       NCT02338960     NCT02338960  \n",
      "1                  1                   2              Null             NaN  \n",
      "2                  1                   1              Null             NaN  \n",
      "3                  1                   1              Null     NCT03055962  \n",
      "4                  1                   1              Null     NCT03258502  \n",
      "5                  1                   1       NCT02294682     NCT03562117  \n",
      "6                  1                   0       NCT03244644     NCT03378167  \n",
      "7                  1                   1              Null     NCT02605993  \n",
      "8                  1                   1              Null             NaN  \n",
      "9                  1                   1              Null     NCT03163342  \n",
      "10              Null                Null              Null     NCT03379675  \n",
      "11                 1                   1              Null     NCT02959918  \n",
      "12              Null                Null              Null     NCT03303924  \n",
      "13              Null                Null              Null     NCT01554956  \n",
      "14                 1                   1              Null             NaN  \n",
      "15                 1                   1              Null     NCT01590758  \n",
      "16              Null                Null              Null     NCT02269319  \n",
      "17                 1                   1       NCT02977715     NCT03493945  \n",
      "18              Null                Null              Null     NCT02350673  \n",
      "19              Null                Null              Null     NCT02350673  \n",
      "20              Null                Null              Null     NCT03448666  \n",
      "21              Null                Null              Null     NCT01973491  \n",
      "22                 1                   1       NCT03304379     NCT03161093  \n",
      "23              Null                Null              Null             NaN  \n",
      "24                 1                   1       NCT03173391     NCT03173391  \n",
      "25                 1                   1       NCT03442985     NCT03442985  \n",
      "26                 1                   1       NCT02883153             NaN  \n",
      "27                 1                   1              Null     NCT03390101  \n",
      "28                 1                   0              Null     NCT03460652  \n",
      "29                 1                   1              Null             NaN  \n",
      "..               ...                 ...               ...             ...  \n",
      "110                1                   1       NCT03316781     NCT03014947  \n",
      "111                1                   1       NCT03220633     NCT03291418  \n",
      "112                1                   1       NCT00119067     NCT02655549  \n",
      "113                1                   1              Null     NCT01621243  \n",
      "114             Null                Null              Null             NaN  \n",
      "115                1                   1              Null             NaN  \n",
      "116                1                   1              Null             NaN  \n",
      "117                1                   1              Null     NCT03461276  \n",
      "118                1                   1       NCT02893826     NCT03150524  \n",
      "119             Null                Null              Null     NCT03150524  \n",
      "120                1                   1       NCT02893826     NCT03150524  \n",
      "121             Null                Null              Null     NCT03150524  \n",
      "122                1                   1              Null     NCT03369262  \n",
      "123                1                   1       NCT02977715     NCT03116802  \n",
      "124             Null                Null              Null     NCT03493282  \n",
      "125                1                   1       NCT02438007             NaN  \n",
      "126             Null                Null              Null             NaN  \n",
      "127                1                   1       NCT03451773     NCT03404791  \n",
      "128             Null                Null              Null     NCT02437344  \n",
      "129                1                   1       NCT03341741     NCT02873806  \n",
      "130                1                   1              Null             NaN  \n",
      "131                1                   1       NCT02542215     NCT02542215  \n",
      "132                1                   1              Null             NaN  \n",
      "133                1                   1              Null             NaN  \n",
      "134                1                   1              Null             NaN  \n",
      "135                1                   1              Null             NaN  \n",
      "136                1                   1       NCT03168256     NCT03168256  \n",
      "137             Null                Null              Null             NaN  \n",
      "138                1                   2       NCT03423979     NCT03387085  \n",
      "139                1                   1       NCT03376503     NCT00404066  \n",
      "\n",
      "[140 rows x 21 columns],       TWID            TWEET_ID  \\\n",
      "0     2852  750259163033432064   \n",
      "1     2856  750139498546081792   \n",
      "2     2869  748809687643021312   \n",
      "3     2875  748131406232985600   \n",
      "4     2882  747739017584742400   \n",
      "5     2884  747731271959318529   \n",
      "6     2894  746298848826503168   \n",
      "7     2895  746286834687352832   \n",
      "8     2899  745898778931109893   \n",
      "9     2904  745565391762632704   \n",
      "10    2906  745480905133699072   \n",
      "11    2911  745196918591070208   \n",
      "12    2913  745185212372418560   \n",
      "13    2914  745171644675567616   \n",
      "14    2919  744828585010143232   \n",
      "15    2920  744816995846107136   \n",
      "16    2921  744815279411073028   \n",
      "17    2931  743386006402048000   \n",
      "18    2932  743381252707856384   \n",
      "19    2932  743381252707856384   \n",
      "20    2932  743381252707856384   \n",
      "21    2945  742661115532972032   \n",
      "22    2946  742658898914639872   \n",
      "23    2947  742656369510219777   \n",
      "24    2948  742652933590900736   \n",
      "25    2963  741568485025796096   \n",
      "26    2964  741567279050149888   \n",
      "27    2973  741208998939136000   \n",
      "28    2975  741208257214177281   \n",
      "29    2977  741198668490002433   \n",
      "..     ...                 ...   \n",
      "110   6186  921459906804363265   \n",
      "111   6196  921337019594346497   \n",
      "112   6201  921134119240785922   \n",
      "113   6204  921117650608115714   \n",
      "114   6421  916224030503555072   \n",
      "115   6482  990698008667975682   \n",
      "116   6492  989591543181905921   \n",
      "117   6503  989322226259329024   \n",
      "118   6504  989276575773462529   \n",
      "119   6511  988994961277358081   \n",
      "120   6516  988846800181350400   \n",
      "121   6519  988718756707885056   \n",
      "122   6519  988718756707885056   \n",
      "123   6527  988452592014561280   \n",
      "124   6536  988015852086874112   \n",
      "125   6536  988015852086874112   \n",
      "126   6536  988015852086874112   \n",
      "127   6537  988010121203802112   \n",
      "128   6537  988010121203802112   \n",
      "129   9735  989198012986593285   \n",
      "130   9742  989135291565903873   \n",
      "131  12910  992218379149889536   \n",
      "132  12927  991337132642979840   \n",
      "133  16248  991311142625652737   \n",
      "134  19304  994947253776330753   \n",
      "135  19312  994682264528224256   \n",
      "136  19430  991798269239062528   \n",
      "137  19430  991798269239062528   \n",
      "138  19477  990612942524690432   \n",
      "139  19522  989608833084477440   \n",
      "\n",
      "                                                 TWEET               SYNONYMS  \\\n",
      "0    US FDA approves IND for Biohaven Pharmaceutica...               BHV-4157   \n",
      "1    GlaxoSmithKline's GSK-3359609 begins phase I t...            GSK-3359609   \n",
      "2    ImmBio's PnuBioVax vaccine safe well tolerated...      PNUBIOVAX VACCINE   \n",
      "3    AstraZeneca's benralizumab reduces asthma exac...           BENRALIZUMAB   \n",
      "4    US FDA places clinical hold on RG-101's IND fo...                 RG-101   \n",
      "5    AstraZeneca's eosinophil-depleting asthma drug...           BENRALIZUMAB   \n",
      "6    VBI's VBI-1501 starts phase I trial in Canada ...               VBI-1501   \n",
      "7    Apellis' APL-2 shows safety tolerability &amp ...                  APL-2   \n",
      "8    Spring Bank's SB-9200 begins phase II global t...                SB-9200   \n",
      "9    Frontier Biotech's AB-001 shows safety and eff...                 AB-001   \n",
      "10     Curis starts phase I trial of CA-170 for cancer                 CA-170   \n",
      "11   ApeX files IND to start phase I US trial of AP...               APX-3330   \n",
      "12   Inovio and GeneOne get green light to start ph...               GLS-5700   \n",
      "13   US FDA clears Sangamo's IND for SB-913 phase I...                 SB-913   \n",
      "14   TiGenix's AlloCSC-01 shows interim acute &amp ...             AlloCSC-01   \n",
      "15   Nippon Chemiphar and Kyusyu University start p...                NC-2600   \n",
      "16   Poxel's oral type 2 diabetes candidate PXL-770...                PXL-770   \n",
      "17   Zenith Epigenetics' ZEN-3694 begins phase I tr...               ZEN-3694   \n",
      "18   Cellceutix starts phase II trial of topical br...               PMX30063   \n",
      "19   Cellceutix starts phase II trial of topical br...               PMX30063   \n",
      "20   Cellceutix starts phase II trial of topical br...             BRILACIDIN   \n",
      "21   Tyme's SM-88 begins phase Ib/II trial for pros...                  SM-88   \n",
      "22   Fibrocell's FCX-007 starts phase I/II trial fo...                FCX-007   \n",
      "23   Marinus' ganaxolone capsules fail to meet effi...             GANAXOLONE   \n",
      "24   Eleven Biotherapeutics files US IND to start p...                EBI-031   \n",
      "25   Short term treatment with Gilead's GS5745 well...                 GS5745   \n",
      "26   Sirukumab efficacy in phase 3 study in active ...              SIRUKUMAB   \n",
      "27   Macrogenics presents good phase 1 safety data ...            MACROGENICS   \n",
      "28   Phase 1 data for BIOCAD's BCD-085 shows safety...                BCD-085   \n",
      "29   Theravance's TD-1473 safe &amp well tolerated ...                TD-1473   \n",
      "..                                                 ...                    ...   \n",
      "110  Top story --\\nUPDATED Celgene's $710M deal on ...              MONGERSEN   \n",
      "111  UPDATED Celgene's $710M deal on mongersen impl...              MONGERSEN   \n",
      "112  UPDATED Celgene's $710M deal on mongersen impl...              MONGERSEN   \n",
      "113  Celgene's $710M deal on mongersen implodes as ...              MONGERSEN   \n",
      "114  In a setback Bayer J&ampJ say their big PhIII ...                XARELTO   \n",
      "115  Live at #ARVO2018 Topivert present phase 2 dat...                TOP1630   \n",
      "116  Phase 2b results on Neuraltus' NP-001 have jus...                 NP-001   \n",
      "117  PROMISE-2 Trial reveals that single dose of ep...            EPTINEZUMAB   \n",
      "118  STRIVE phase 3 trial results show AVXS-101 an ...               AVXS-101   \n",
      "119  Results from EVOLVE MS-1 trial show ALKS-8700 ...               ALKS8700   \n",
      "120  Oral venglustat has favorable safety and toler...                   GL-1   \n",
      "121  Contezolid Acefosamil (MRX-4 MicuRx Pharmaceut...  CONTEZOLID ACEFOSAMIL   \n",
      "122  Contezolid Acefosamil (MRX-4 MicuRx Pharmaceut...             CONTEZOLID   \n",
      "123  R21 an improved RTSS-like Plasmodium falcipari...                    R21   \n",
      "124  First efficacy and safety data from the phase ...               IMIPENEM   \n",
      "125  First efficacy and safety data from the phase ...               IMIPENEM   \n",
      "126  First efficacy and safety data from the phase ...               COLISTIN   \n",
      "127  Actelion  antibiotic Cadazolid demonstrates no...              CADAZOLID   \n",
      "128  Actelion  antibiotic Cadazolid demonstrates no...             VANCOMYCIN   \n",
      "129  After mega-round investment ADC Therapeutics c...                   HER2   \n",
      "130  After mega-round investment ADC Therapeutics c...                   HER2   \n",
      "131  Live at #ARVO2018 phase I/II data for DSP-Visu...             PREDNISONE   \n",
      "132  AbbVie has filed risankizumab in the EU for mo...           RISANKIZUMAB   \n",
      "133  It's bad --\\nIDO rout Bristol-Myers Merck and ...          Bristol-Myers   \n",
      "134   @AstraZeneca Weighs Expanding Fasenra to #COP...                FASENRA   \n",
      "135  WIth planned $16B $ARMO acquisition @LillyPad ...                 AM0010   \n",
      "136  Study by @TheCrick investigators may explain w...              LAPATINIB   \n",
      "137  Study by @TheCrick investigators may explain w...              LAPATINIB   \n",
      "138  Neuraltus Weighs Future of Lead Candidate NP00...                  NP001   \n",
      "139  Neuraltus lead candidate NP001 fails confirmat...                  NP001   \n",
      "\n",
      "      MOLREGNO ACRONYM      PHASE  N_PHASES      OUTCOME  \\\n",
      "0    Not found    Null    Phase 3         3      SUCCESS   \n",
      "1    Not found    Null    Phase 1         1  IN PROGRESS   \n",
      "2         Null    Null    Phase 1         1      SUCCESS   \n",
      "3      1121862    Null    Phase 3         1      SUCCESS   \n",
      "4    Not found    Null    Phase 1         1      STOPPED   \n",
      "5      1121862    Null    Phase 3         1      SUCCESS   \n",
      "6    Not found    Null    Phase 1         1  IN PROGRESS   \n",
      "7    Not found    Null    Phase 1         1      SUCCESS   \n",
      "8    Not found    Null    Phase 2         1  IN PROGRESS   \n",
      "9    Not found    Null    Phase 2         1      SUCCESS   \n",
      "10   Not found    Null    Phase 1         1  IN PROGRESS   \n",
      "11   Not found    Null    Phase 1         1  IN PROGRESS   \n",
      "12   Not found    Null    Phase 1         1  IN PROGRESS   \n",
      "13   Not found    Null  Phase 1/2         1  IN PROGRESS   \n",
      "14   Not found    Null  Phase 1/2         1      SUCCESS   \n",
      "15   Not found    Null    Phase 1         2  IN PROGRESS   \n",
      "16   Not found    Null    Phase 1         1      SUCCESS   \n",
      "17   Not found    Null    Phase 1         2  IN PROGRESS   \n",
      "18     1449217    Null    Phase 2         2  IN PROGRESS   \n",
      "19     1449224    Null    Phase 2         2  IN PROGRESS   \n",
      "20     1449217    Null    Phase 2         2  IN PROGRESS   \n",
      "21   Not found    Null  Phase 1/2         1  IN PROGRESS   \n",
      "22   Not found    Null  Phase 1/2         2  IN PROGRESS   \n",
      "23      992582    Null    Phase 3         1         FAIL   \n",
      "24   Not found    Null    Phase 1         1  IN PROGRESS   \n",
      "25   Not found    Null    Phase 1         1  IN PROGRESS   \n",
      "26     1121942    Null    Phase 3         1  IN PROGRESS   \n",
      "27     1927222    Null    Phase 1         1      SUCCESS   \n",
      "28   Not found    Null    Phase 1         1      SUCCESS   \n",
      "29   Not found    Null    Phase 1         2  IN PROGRESS   \n",
      "..         ...     ...        ...       ...          ...   \n",
      "110       Null    Null    Phase 3         1         FAIL   \n",
      "111       Null    Null    Phase 3         1         FAIL   \n",
      "112       Null    Null    Phase 3         1         FAIL   \n",
      "113       Null    Null    Phase 3         1         FAIL   \n",
      "114     328601    Null    Phase 3         1         FAIL   \n",
      "115       Null    Null    Phase 2         3  IN PROGRESS   \n",
      "116  Not found    Null    Phase 2         1          N/I   \n",
      "117    2096371    Null       Null         0      SUCCESS   \n",
      "118  Not found    Null    Phase 3         2      SUCCESS   \n",
      "119    2197815    Null       Null         0      SUCCESS   \n",
      "120  Not found    Null    Phase 2         2      SUCCESS   \n",
      "121    2197837    Null    Phase 1         1      SUCCESS   \n",
      "122    1757906    Null    Phase 1         1      SUCCESS   \n",
      "123       Null    Null    Phase 2         1  IN PROGRESS   \n",
      "124      43934    Null    Phase 3         2          N/I   \n",
      "125     610112    Null    Phase 3         2          N/I   \n",
      "126    1451060    Null    Phase 3         2          N/I   \n",
      "127    2039347    Null       Null         0         FAIL   \n",
      "128      70140    Null       Null         0         FAIL   \n",
      "129       Null    Null    Phase 1         1      STOPPED   \n",
      "130       Null    Null    Phase 1         1      STOPPED   \n",
      "131      27229    Null  Phase 1/2         1  IN PROGRESS   \n",
      "132    2197900    Null    Phase 3         2      STOPPED   \n",
      "133  Not found    Null       Null         2         FAIL   \n",
      "134    1121862    Null    Phase 3         1         FAIL   \n",
      "135    2197863    Null    Phase 3         2  IN PROGRESS   \n",
      "136      14805    Null       Null         0         FAIL   \n",
      "137     675130    Null       Null         0         FAIL   \n",
      "138  Not found    Null    Phase 2         1         FAIL   \n",
      "139  Not found    Null    Phase 2         1         FAIL   \n",
      "\n",
      "                            MATCHED_OUTCOME       ...       COMPANY_ID  \\\n",
      "0                              FDA approves       ...        COMP92800   \n",
      "1                        begins phase trial       ...          COMP286   \n",
      "2                             safe in trial       ...             Null   \n",
      "3          reduces asthma exacerbation rate       ...           COMP82   \n",
      "4                      places clinical hold       ...             Null   \n",
      "5          reduces asthma exacerbation rate       ...           COMP82   \n",
      "6                        starts phase trial       ...             Null   \n",
      "7                           shows reduction       ...        COMP93236   \n",
      "8                        begins phase trial       ...        COMP91236   \n",
      "9                              shows safety       ...             Null   \n",
      "10                       starts phase trial       ...          COMP191   \n",
      "11                        Start phase trial       ...             Null   \n",
      "12                              Begin trial       ...        COMP90462   \n",
      "13                         Clears for trial       ...          COMP656   \n",
      "14                             shows safety       ...        COMP90119   \n",
      "15                        Start phase trial       ...          COMP490   \n",
      "16                            safe in trial       ...        COMP93895   \n",
      "17                       begins phase trial       ...             Null   \n",
      "18                       starts phase trial       ...        COMP90493   \n",
      "19                       starts phase trial       ...        COMP90493   \n",
      "20                       starts phase trial       ...        COMP90493   \n",
      "21                       begins phase trial       ...             Null   \n",
      "22                       starts phase trial       ...        COMP90898   \n",
      "23           fail to meet efficacy endpoint       ...             Null   \n",
      "24                        Start phase trial       ...        COMP92771   \n",
      "25                         In phase live at       ...          COMP284   \n",
      "26                         In phase live at       ...             Null   \n",
      "27                     presents safety data       ...          COMP415   \n",
      "28                             shows safety       ...             Null   \n",
      "29                              Begin trial       ...        COMP90012   \n",
      "..                                      ...       ...              ...   \n",
      "110                                implodes       ...          COMP160   \n",
      "111                                implodes       ...          COMP160   \n",
      "112                                implodes       ...          COMP160   \n",
      "113                                implodes       ...          COMP160   \n",
      "114                            Trial failed       ...          COMP105   \n",
      "115                        In phase live at       ...        COMP93550   \n",
      "116                       Results presented       ...        COMP90982   \n",
      "117                   Reduces migraine days       ...             Null   \n",
      "118                         scores in trial       ...        COMP92701   \n",
      "119  relapsing remitting multiple sclerosis       ...             Null   \n",
      "120                          Safety profile       ...             Null   \n",
      "121                            shows safety       ...        COMP90957   \n",
      "122                            shows safety       ...        COMP90957   \n",
      "123                         Being developed       ...        COMP90137   \n",
      "124                              First data       ...          COMP435   \n",
      "125                              First data       ...          COMP435   \n",
      "126                              First data       ...          COMP435   \n",
      "127            demonstrates non-inferiority       ...           COMP19   \n",
      "128            demonstrates non-inferiority       ...           COMP19   \n",
      "129                              Cans trial       ...        COMP93613   \n",
      "130                              Cans trial       ...        COMP93613   \n",
      "131                        In phase live at       ...             Null   \n",
      "132                               Has filed       ...        COMP92805   \n",
      "133                             dump trials       ...           COMP82   \n",
      "134                           phase failure       ...             Null   \n",
      "135                            planned $16B       ...             Null   \n",
      "136                              why failed       ...             Null   \n",
      "137                              why failed       ...             Null   \n",
      "138                        failure in trial       ...        COMP90982   \n",
      "139                             trial fails       ...        COMP90982   \n",
      "\n",
      "    COMPANY_SCORE COMPANY_NONAMBIG COMPANY_MATCHED  \\\n",
      "0               1                1     AstraZeneca   \n",
      "1               1                1     AstraZeneca   \n",
      "2            Null             Null            Null   \n",
      "3               1                1     AstraZeneca   \n",
      "4            Null             Null            Null   \n",
      "5               1                1     AstraZeneca   \n",
      "6            Null             Null            Null   \n",
      "7               1                1     AstraZeneca   \n",
      "8               1                1     AstraZeneca   \n",
      "9            Null             Null            Null   \n",
      "10              1                1     AstraZeneca   \n",
      "11           Null             Null            Null   \n",
      "12              1                1     AstraZeneca   \n",
      "13              1                0     AstraZeneca   \n",
      "14              1                1     AstraZeneca   \n",
      "15              1                1     AstraZeneca   \n",
      "16              1                1     AstraZeneca   \n",
      "17           Null             Null            Null   \n",
      "18              1                1     AstraZeneca   \n",
      "19              1                1     AstraZeneca   \n",
      "20              1                1     AstraZeneca   \n",
      "21           Null             Null            Null   \n",
      "22              1                1     AstraZeneca   \n",
      "23           Null             Null            Null   \n",
      "24              1                1     AstraZeneca   \n",
      "25              1                1     AstraZeneca   \n",
      "26           Null             Null            Null   \n",
      "27              1                1     AstraZeneca   \n",
      "28           Null             Null            Null   \n",
      "29              1                1     AstraZeneca   \n",
      "..            ...              ...             ...   \n",
      "110             1                1     AstraZeneca   \n",
      "111             1                1     AstraZeneca   \n",
      "112             1                1     AstraZeneca   \n",
      "113             1                1     AstraZeneca   \n",
      "114             1                1     AstraZeneca   \n",
      "115             1                1     AstraZeneca   \n",
      "116             1                1     AstraZeneca   \n",
      "117          Null             Null            Null   \n",
      "118             1                1     AstraZeneca   \n",
      "119          Null             Null            Null   \n",
      "120          Null             Null            Null   \n",
      "121             1                1     AstraZeneca   \n",
      "122             1                1     AstraZeneca   \n",
      "123             1                1     AstraZeneca   \n",
      "124             1                1     AstraZeneca   \n",
      "125             1                1     AstraZeneca   \n",
      "126             1                1     AstraZeneca   \n",
      "127             1                1     AstraZeneca   \n",
      "128             1                1     AstraZeneca   \n",
      "129             1                1     AstraZeneca   \n",
      "130             1                1     AstraZeneca   \n",
      "131          Null             Null            Null   \n",
      "132             1                1     AstraZeneca   \n",
      "133             1                1     AstraZeneca   \n",
      "134          Null             Null            Null   \n",
      "135          Null             Null            Null   \n",
      "136          Null             Null            Null   \n",
      "137          Null             Null            Null   \n",
      "138             1                1     AstraZeneca   \n",
      "139             1                1     AstraZeneca   \n",
      "\n",
      "                                   INDICATION INDICATION_ID INDICATION_SCORE  \\\n",
      "0                     Spinocerebellar Ataxias       D020754                1   \n",
      "1                                 Solid Tumor       SDI0034                1   \n",
      "2                                        Null          Null             Null   \n",
      "3                                Eosinophilia       D004802                1   \n",
      "4                                    Jaundice       D007565                1   \n",
      "5                                Eosinophilia       D004802                1   \n",
      "6                  Cytomegalovirus Infections       D003586                1   \n",
      "7                   Paroxysmal Hemoglobinuria       D006457                1   \n",
      "8                                   Hepatitis       D006505                1   \n",
      "9                               Low Back Pain       D017116                1   \n",
      "10                                  Carcinoma       D002277                1   \n",
      "11                                  Carcinoma       D002277                1   \n",
      "12                       Zika Virus Infection       DX90254                1   \n",
      "13                   Mucopolysaccharidosis II       D016532                1   \n",
      "14                      Myocardial Infarction       D009203                1   \n",
      "15                           Neuropathic Pain       DX90161                1   \n",
      "16                   Type 2 Diabetes Mellitus       D003924                1   \n",
      "17   Castration-Resistant Prostatic Neoplasms       D064129                1   \n",
      "18                                  Mucositis       D052016                1   \n",
      "19                                  Mucositis       D052016                1   \n",
      "20                                  Mucositis       D052016                1   \n",
      "21                        Prostatic Neoplasms       D011471                1   \n",
      "22          Epidermolysis Bullosa Dystrophica       D016108                1   \n",
      "23                             Mood Disorders       D019964                1   \n",
      "24                                       Null          Null             Null   \n",
      "25                         Ulcerative Colitis       D003093                1   \n",
      "26                     Polymyalgia Rheumatica       D011111                1   \n",
      "27                                Hepatitis A       D006506                1   \n",
      "28                                       Null          Null             Null   \n",
      "29                               Inflammation       D007249                1   \n",
      "..                                        ...           ...              ...   \n",
      "110                             Crohn Disease       D003424                1   \n",
      "111                             Crohn Disease       D003424                1   \n",
      "112                             Crohn Disease       D003424                1   \n",
      "113                             Crohn Disease       D003424                1   \n",
      "114                   Postthrombotic Syndrome       D054070                1   \n",
      "115                             Xerophthalmia       D014985                1   \n",
      "116                         Alzheimer Disease       D000544                1   \n",
      "117                        Migraine Disorders       D008881                1   \n",
      "118                                      Null          Null             Null   \n",
      "119    Relapsing-Remitting Multiple Sclerosis       D020529                1   \n",
      "120                                      Null          Null             Null   \n",
      "121                                      Null          Null             Null   \n",
      "122                                      Null          Null             Null   \n",
      "123                                   Malaria       D008288                1   \n",
      "124                                 Carcinoma       D002277                1   \n",
      "125                                 Carcinoma       D002277                1   \n",
      "126                                 Carcinoma       D002277                1   \n",
      "127            Pseudomembranous Enterocolitis       D004761                1   \n",
      "128            Pseudomembranous Enterocolitis       D004761                1   \n",
      "129                                      Null          Null             Null   \n",
      "130                                      Null          Null             Null   \n",
      "131                                 Carcinoma       D002277                1   \n",
      "132                                 Psoriasis       D011565                1   \n",
      "133                                      Null          Null             Null   \n",
      "134     Chronic Obstructive Pulmonary Disease       D029424                1   \n",
      "135                                 Carcinoma       D002277                1   \n",
      "136                         Colonic Neoplasms       D003110                1   \n",
      "137                         Colonic Neoplasms       D003110                1   \n",
      "138                         Alzheimer Disease       D000544                1   \n",
      "139                         Alzheimer Disease       D000544                1   \n",
      "\n",
      "    INDICATION_NONAMBIG INDICATION_NCT_ID SYNONYMS_NCT_ID  \n",
      "0                     1              Null     NCT02960893  \n",
      "1                     1              Null     NCT02723955  \n",
      "2                  Null              Null             NaN  \n",
      "3                     1       NCT03450083     NCT02417961  \n",
      "4                     1              Null     NCT02591199  \n",
      "5                     1       NCT03450083     NCT02417961  \n",
      "6                     1              Null     NCT02826798  \n",
      "7                     1              Null     NCT03453619  \n",
      "8                     1       NCT02751996     NCT02751996  \n",
      "9                     1       NCT02436824     NCT03474640  \n",
      "10                    1              Null     NCT02812875  \n",
      "11                    1              Null     NCT03375086  \n",
      "12                    1              Null     NCT02809443  \n",
      "13                    1       NCT03359213     NCT03041324  \n",
      "14                    1              Null     NCT02439398  \n",
      "15                    1              Null             NaN  \n",
      "16                    1              Null     NCT03395470  \n",
      "17                    1              Null             NaN  \n",
      "18                    1       NCT02324335     NCT02324335  \n",
      "19                    1       NCT02324335     NCT02324335  \n",
      "20                    1       NCT02324335     NCT02324335  \n",
      "21                    1              Null     NCT03512756  \n",
      "22                    1              Null     NCT02810951  \n",
      "23                    1       NCT03228394     NCT03460756  \n",
      "24                 Null              Null     NCT02842541  \n",
      "25                    1       NCT02520284     NCT02759562  \n",
      "26                    1       NCT02899026     NCT00718718  \n",
      "27                    1       NCT02376036             NaN  \n",
      "28                 Null              Null     NCT03390101  \n",
      "29                    1              Null     NCT03555617  \n",
      "..                  ...               ...             ...  \n",
      "110                   1              Null     NCT02641392  \n",
      "111                   1              Null     NCT02641392  \n",
      "112                   1              Null     NCT02641392  \n",
      "113                   1              Null     NCT02641392  \n",
      "114                   1       NCT03413618     NCT03428373  \n",
      "115                   1              Null     NCT03088605  \n",
      "116                   1       NCT03179501     NCT02794857  \n",
      "117                   1              Null     NCT02985398  \n",
      "118                Null              Null     NCT03381729  \n",
      "119                   1              Null             NaN  \n",
      "120                Null              Null     NCT02656394  \n",
      "121                Null              Null             NaN  \n",
      "122                Null              Null             NaN  \n",
      "123                   1              Null     NCT02983045  \n",
      "124                   1       NCT03397914     NCT03159078  \n",
      "125                   1       NCT03397914     NCT03159078  \n",
      "126                   1       NCT03397914     NCT03397914  \n",
      "127                   0       NCT02053181     NCT03105479  \n",
      "128                   0       NCT02053181     NCT02137668  \n",
      "129                Null              Null     NCT03199885  \n",
      "130                Null              Null     NCT03199885  \n",
      "131                   1       NCT03419234     NCT01393730  \n",
      "132                   1              Null     NCT03047395  \n",
      "133                Null              Null     NCT02582697  \n",
      "134                   1              Null     NCT03473977  \n",
      "135                   1              Null     NCT03382899  \n",
      "136                   1       NCT03225937     NCT00404066  \n",
      "137                   1       NCT03225937     NCT00404066  \n",
      "138                   1       NCT03179501     NCT02794857  \n",
      "139                   1       NCT03179501     NCT02794857  \n",
      "\n",
      "[140 rows x 21 columns],        TWID             TWEET_ID  \\\n",
      "0     19526   989502325533310976   \n",
      "1     19565   988521674436960258   \n",
      "2     19712   985222431202795521   \n",
      "3     19772   983810627549519873   \n",
      "4     19778   983712108683644928   \n",
      "5     19796   983048102453137408   \n",
      "6     19830   982361076615516161   \n",
      "7     19830   982361076615516161   \n",
      "8     19836   982255437188775937   \n",
      "9     19920   980103708926205952   \n",
      "10    19944   979477107951665152   \n",
      "11    19983   978374808546234368   \n",
      "12    19989   978276849401958400   \n",
      "13    20052   976593086766821376   \n",
      "14    20052   976593086766821376   \n",
      "15    20091   975407757665939457   \n",
      "16    20105   975090674000453633   \n",
      "17    20140   974388561540763648   \n",
      "18    20147   974290518439014401   \n",
      "19    20155   974026162337931265   \n",
      "20    20162   973920984309825536   \n",
      "21    20171   973648680942268416   \n",
      "22    20556   962437291070418944   \n",
      "23    20568   962346702672945152   \n",
      "24    20607   961257229285457926   \n",
      "25    20626   960536049276596224   \n",
      "26    20755   957650758559784960   \n",
      "27    20798   956661743325007872   \n",
      "28    20804   956553847912255489   \n",
      "29    21079   949474368874274817   \n",
      "..      ...                  ...   \n",
      "111   64741  1007611641922453509   \n",
      "112   64742  1007592590017953793   \n",
      "113   64743  1007588747297349632   \n",
      "114   64748  1007261024792338432   \n",
      "115   64749  1007257361088745473   \n",
      "116   64749  1007257361088745473   \n",
      "117   64751  1007241245637447680   \n",
      "118   64751  1007241245637447680   \n",
      "119   64754  1006974738747584513   \n",
      "120   64757  1006498575809957888   \n",
      "121   71169  1008815386341576705   \n",
      "122   71177  1008721334027931649   \n",
      "123   71184  1008400157065515010   \n",
      "124   71206  1007992469328416768   \n",
      "125   71214  1007728226167328768   \n",
      "126   71218  1007626689931894784   \n",
      "127   71239  1007003456375263233   \n",
      "128   71268  1006339070421798915   \n",
      "129   71277  1006185066576347136   \n",
      "130   74381  1009078221005033472   \n",
      "131  116396  1011617239773208578   \n",
      "132  116399  1011457286303354880   \n",
      "133  116409  1010937748306481153   \n",
      "134  122871  1012333898615984129   \n",
      "135  122880  1011977695536836608   \n",
      "136  122900  1011352104278155264   \n",
      "137  122925  1010544287359086593   \n",
      "138  132553  1012453525979267077   \n",
      "139  135766  1012439269128986626   \n",
      "140  138975  1012504783897362433   \n",
      "\n",
      "                                                 TWEET  \\\n",
      "0     Neuraltus Weighs Future of Lead Candidate NP0...   \n",
      "1    After a failed Phase IIb trial and a Phase III...   \n",
      "2    vTv Therapeutics ($VTVT) Halts Trials of #Alzh...   \n",
      "3    Shares of vTv Therapeutics ($VTVT) plunge afte...   \n",
      "4    vTv Therapeutics ($VTVT) Halts Trials of #Alzh...   \n",
      "5     @Incyte @Merck Halt Phase III #ClinicalTrial ...   \n",
      "6    Phase III trial failure for @Incyte's Epacados...   \n",
      "7    Phase III trial failure for @Incyte's Epacados...   \n",
      "8     @Incyte @Merck Halt Phase III #ClinicalTrial ...   \n",
      "9     @AblynxABLX and Protagonist Therapeutics ($PT...   \n",
      "10   Citing adverse events in first patient dosed @...   \n",
      "11    @AblynxABLX #Lupus candidate Protagonist Ther...   \n",
      "12    @AblynxABLX and  Protagonist Therapeutics ($P...   \n",
      "13   #MuscularDystrophy progression slowed by tamox...   \n",
      "14   #MuscularDystrophy progression slowed by tamox...   \n",
      "15    @US_FDA Places Full Clinical Hold on @SolidBi...   \n",
      "16   Auris Medical ($EARS) #Tinnitus Candidate Keyz...   \n",
      "17   Full clinical hold placed on @SolidBioDMD tria...   \n",
      "18    @US_FDA Places Full Clinical Hold on @SolidBi...   \n",
      "19   For the second time in 19 months Auris Medical...   \n",
      "20   Auris Medical ($EARS) #Tinnitus Candidate Keyz...   \n",
      "21   $TEVA returns Phase I-bound GPCR candidate to ...   \n",
      "22   @biogen Halts Development of #Tysabri for Acut...   \n",
      "23    @EyeGatePharma Eye Treatment EGP-437 Fails Ph...   \n",
      "24    @biogen Halts Development of #Tysabri for Acu...   \n",
      "25    @EyeGatePharma Eye Treatment EGP-437 Fails Ph...   \n",
      "26   #Alzheimers Amyloid Drug Fails to Slow Cogniti...   \n",
      "27   In clinical trial solanezumab did not signific...   \n",
      "28   #Alzheimers Amyloid Drug Fails to Slow Cogniti...   \n",
      "29    @Shireplc wins FDA Breakthrough Therapy Desig...   \n",
      "..                                                 ...   \n",
      "111  A post hoc analysis from three phase III studi...   \n",
      "112  Stemline Therapeutics' SL-401 an anti-CD123 bi...   \n",
      "113  Vernalis ends $100M Tris Pharma agreement cove...   \n",
      "114  Amgen's Fc-fused IL-2 mutein AMG-592 achieves ...   \n",
      "115  Novartis' canakinumab (Ilaris) achieves the pr...   \n",
      "116  Novartis' canakinumab (Ilaris) achieves the pr...   \n",
      "117  Chugai's subcutaneous formulation of tocilizum...   \n",
      "118  Chugai's subcutaneous formulation of tocilizum...   \n",
      "119  Corbus Pharmaceuticals' CB2 agonist lenabasum ...   \n",
      "120  REGENXBIO earns $100M accelerated license fee ...   \n",
      "121  Clinical hold lifted on @SolidBioDMD trial for...   \n",
      "122   @US_FDA Lifts Clinical Hold on @SolidBioDMD T...   \n",
      "123  $TEVA Halts Phase III Trial of Fremanezumab in...   \n",
      "124   @Vical Halts Development of HSV-2 Vaccine aft...   \n",
      "125  Citing likely failure $TEVA halts Phase III tr...   \n",
      "126  $TEVA Halts Phase III Trial of Fremanezumab in...   \n",
      "127  Citing \"oral intolerability\" @flexpharma  halt...   \n",
      "128  After Phase II failure  @Vical halts developme...   \n",
      "129   @Vical Halts Development of HSV-2 Vaccine aft...   \n",
      "130  $SRPT I'm impressed\\n$SLDB $PFE\\n\\nA Gene Ther...   \n",
      "131  Gossamer Bio obtains exclusive license for wor...   \n",
      "132  The potential use of novel [11C]-radiolabeled ...   \n",
      "133  Preclinical data for Glaceum's HSG-4112 curren...   \n",
      "134   @ArsanisInc Halts Phase II Trial of #Pneumoni...   \n",
      "135   @Summitplc Plans Cost Cuts Stock Falls 80% af...   \n",
      "136  After Phase II failure @MerrimackPharma scraps...   \n",
      "137   @US_FDA Lifts Clinical Hold on @SolidBioDMD T...   \n",
      "138  Finally Celgene wins Anemia drug luspatercept ...   \n",
      "139  Anticipating failure @ArsanisInc ends Phase II...   \n",
      "140  RT @adamfeuerstein $XLRN blood disease drug hi...   \n",
      "\n",
      "                    SYNONYMS   MOLREGNO ACRONYM    PHASE  N_PHASES  \\\n",
      "0                      NP001  Not found    Null  Phase 2         1   \n",
      "1                AMYLOIDOSIS       Null    Null  Phase 3         2   \n",
      "2                 AZELIRAGON    2197800    Null  Phase 3         1   \n",
      "3                 AZELIRAGON    2197800    Null  Phase 3         1   \n",
      "4                 AZELIRAGON    2197800    Null  Phase 3         1   \n",
      "5       EPACADOSTAT/KEYTRUDA       Null    Null  Phase 3         1   \n",
      "6                EPACADOSTAT    1927218    Null  Phase 3         1   \n",
      "7                   KEYTRUDA    1626777    Null  Phase 3         1   \n",
      "8       EPACADOSTAT/KEYTRUDA       Null    Null  Phase 3         1   \n",
      "9                       Null       Null    PTGX  Phase 2         1   \n",
      "10                    RXC004  Not found    Null     Null         1   \n",
      "11                      Null       Null    PTGX     Null         0   \n",
      "12                      Null       Null    PTGX  Phase 2         1   \n",
      "13                RALOXIFENE       6914    Null     Null         0   \n",
      "14                 TAMOXIFEN       6968    Null     Null         0   \n",
      "15               GENETHERAPY       Null    Null     Null         0   \n",
      "16                  KEYZILEN       Null    Null  Phase 3         1   \n",
      "17               GENETHERAPY       Null    Null     Null         2   \n",
      "18               GENETHERAPY       Null    Null     Null         0   \n",
      "19                  KEYZILEN       Null    Null  Phase 3         1   \n",
      "20                  KEYZILEN       Null    Null  Phase 3         1   \n",
      "21                      Null       Null    GPCR     Null         1   \n",
      "22                   TYSABRI     675488    Null  Phase 2         1   \n",
      "23                -EGP437.00  Not found    Null  Phase 2         1   \n",
      "24                   TYSABRI     675488    Null  Phase 2         1   \n",
      "25                -EGP437.00  Not found    Null  Phase 2         1   \n",
      "26   ALZHEIMERS AMYLOID DRUG       Null    Null     Null         0   \n",
      "27               SOLANEZUMAB    1121943    Null     Null         0   \n",
      "28   ALZHEIMERS AMYLOID DRUG       Null    Null     Null         0   \n",
      "29                 MARIBAVIR     519284    Null  Phase 3         1   \n",
      "..                       ...        ...     ...      ...       ...   \n",
      "111                ISONIAZID       4941    Null  Phase 3         1   \n",
      "112                   SL-401  Not found    Null     Null         0   \n",
      "113                   CCP-07  Not found    Null  Phase 1         1   \n",
      "114                     IL-2  Not found    Null  Phase 1         3   \n",
      "115              CANAKINUMAB     675785    Null  Phase 3         1   \n",
      "116                   ILARIS     675785    Null  Phase 3         1   \n",
      "117                  ACTEMRA     699373    Null  Phase 4         1   \n",
      "118              TOCILIZUMAB     699373    Null  Phase 4         1   \n",
      "119                LENABASUM     512450    Null  Phase 2         1   \n",
      "120                 AVXS-101  Not found    Null     Null         1   \n",
      "121              GENETHERAPY       Null    Null     Null         0   \n",
      "122              GENETHERAPY       Null    Null     Null         0   \n",
      "123             FREMANEZUMAB       Null    Null  Phase 3         1   \n",
      "124                    HSV-2  Not found    Null  Phase 2         1   \n",
      "125             FREMANEZUMAB       Null    Null  Phase 3         1   \n",
      "126                 oowKWW16  Not found    Null  Phase 3         1   \n",
      "127                  FLX-787  Not found    Null  Phase 2         1   \n",
      "128                    HSV-2  Not found    Null  Phase 2         1   \n",
      "129                    HSV-2  Not found    Null  Phase 2         1   \n",
      "130             GENE THERAPY       Null    Null     Null         0   \n",
      "131                    HIF-1  Not found    Null     Null         1   \n",
      "132                    PKG-1  Not found    Null     Null         0   \n",
      "133                 HSG-4112  Not found    Null  Phase 1         1   \n",
      "134                   ASN100  Not found    Null  Phase 2         1   \n",
      "135                EZUTROMID       Null    Null  Phase 2         1   \n",
      "136                   MM-141  Not found    Null  Phase 2         1   \n",
      "137              GENETHERAPY       Null    Null     Null         0   \n",
      "138             LUSPATERCEPT    1592363    Null  Phase 3         1   \n",
      "139                   ASN100  Not found    Null  Phase 2         1   \n",
      "140            PIVOTAL TRIAL       Null    Null     Null         1   \n",
      "\n",
      "         OUTCOME                                    MATCHED_OUTCOME  \\\n",
      "0           FAIL                                   failure in trial   \n",
      "1           FAIL                                       Trial failed   \n",
      "2        STOPPED                                       Halts trials   \n",
      "3           FAIL                                      phase failure   \n",
      "4        STOPPED                                       Halts trials   \n",
      "5           FAIL                                        fails phase   \n",
      "6           FAIL                                   failure in trial   \n",
      "7           FAIL                                   failure in trial   \n",
      "8           FAIL                                        fails phase   \n",
      "9           FAIL                                     Phase failures   \n",
      "10   IN PROGRESS                                 Patient enrollment   \n",
      "11          FAIL                               disappoint in trials   \n",
      "12          FAIL                                     Phase failures   \n",
      "13       SUCCESS                              progression slowed by   \n",
      "14       SUCCESS                              progression slowed by   \n",
      "15       STOPPED                               places clinical hold   \n",
      "16          FAIL                                        trial fails   \n",
      "17   IN PROGRESS                                      hold on trial   \n",
      "18       STOPPED                               places clinical hold   \n",
      "19          FAIL                                        fails phase   \n",
      "20          FAIL                                        trial fails   \n",
      "21   IN PROGRESS                            Returns phase candidate   \n",
      "22          FAIL                                      phase failure   \n",
      "23          FAIL                                        trial fails   \n",
      "24          FAIL                                      phase failure   \n",
      "25          FAIL                                        trial fails   \n",
      "26          FAIL                                         drug fails   \n",
      "27       SUCCESS       did not significantly slow cognitive decline   \n",
      "28          FAIL                                         drug fails   \n",
      "29       SUCCESS                                 Wins FDA for phase   \n",
      "..           ...                                                ...   \n",
      "111      SUCCESS                    demonstrates the hepatic safety   \n",
      "112  IN PROGRESS                                      Trial planned   \n",
      "113          N/I                                     ends agreement   \n",
      "114  IN PROGRESS                achieves a dose-dependent expansion   \n",
      "115      SUCCESS                      achieves the primary endpoint   \n",
      "116      SUCCESS                      achieves the primary endpoint   \n",
      "117      SUCCESS                              demonstrates efficacy   \n",
      "118      SUCCESS                              demonstrates efficacy   \n",
      "119      SUCCESS  demonstrates a favorable long-term safety profile   \n",
      "120  IN PROGRESS                                          Earns fee   \n",
      "121  IN PROGRESS                                      hold on trial   \n",
      "122  IN PROGRESS                                      hold on trial   \n",
      "123         FAIL                                        halts trial   \n",
      "124         FAIL                                      phase failure   \n",
      "125         FAIL                                   failure in trial   \n",
      "126         FAIL                                        halts trial   \n",
      "127      STOPPED                                       Halts trials   \n",
      "128         FAIL                                      phase failure   \n",
      "129         FAIL                                      phase failure   \n",
      "130          N/I                                 Appears To Replace   \n",
      "131  IN PROGRESS                          obtains exclusive license   \n",
      "132          N/I                                      was discussed   \n",
      "133  IN PROGRESS                            support its development   \n",
      "134         FAIL                                        halts trial   \n",
      "135         FAIL                                        trial fails   \n",
      "136         FAIL                                      phase failure   \n",
      "137  IN PROGRESS                                      hold on trial   \n",
      "138      SUCCESS                                    scores in trial   \n",
      "139         FAIL                                      phase failure   \n",
      "140      SUCCESS                                 hits goal in trial   \n",
      "\n",
      "          ...       COMPANY_ID COMPANY_SCORE COMPANY_NONAMBIG COMPANY_MATCHED  \\\n",
      "0         ...        COMP90982             1                1     AstraZeneca   \n",
      "1         ...             Null          Null             Null            Null   \n",
      "2         ...        COMP93953             1                1     AstraZeneca   \n",
      "3         ...        COMP93953             1                1     AstraZeneca   \n",
      "4         ...        COMP93953             1                1     AstraZeneca   \n",
      "5         ...          COMP328             1                1     AstraZeneca   \n",
      "6         ...             Null          Null             Null            Null   \n",
      "7         ...             Null          Null             Null            Null   \n",
      "8         ...          COMP328             1                1     AstraZeneca   \n",
      "9         ...        COMP92346             1                1     AstraZeneca   \n",
      "10        ...             Null          Null             Null            Null   \n",
      "11        ...        COMP92346             1                1     AstraZeneca   \n",
      "12        ...        COMP92346             1                1     AstraZeneca   \n",
      "13        ...             Null          Null             Null            Null   \n",
      "14        ...             Null          Null             Null            Null   \n",
      "15        ...             Null          Null             Null            Null   \n",
      "16        ...             Null          Null             Null            Null   \n",
      "17        ...             Null          Null             Null            Null   \n",
      "18        ...             Null          Null             Null            Null   \n",
      "19        ...             Null          Null             Null            Null   \n",
      "20        ...             Null          Null             Null            Null   \n",
      "21        ...          COMP714             1                1     AstraZeneca   \n",
      "22        ...             Null          Null             Null            Null   \n",
      "23        ...             Null          Null             Null            Null   \n",
      "24        ...             Null          Null             Null            Null   \n",
      "25        ...             Null          Null             Null            Null   \n",
      "26        ...             Null          Null             Null            Null   \n",
      "27        ...             Null          Null             Null            Null   \n",
      "28        ...             Null          Null             Null            Null   \n",
      "29        ...             Null          Null             Null            Null   \n",
      "..        ...              ...           ...              ...             ...   \n",
      "111       ...          COMP234             1                1     AstraZeneca   \n",
      "112       ...        COMP90706             1                1     AstraZeneca   \n",
      "113       ...          COMP799             1                1     AstraZeneca   \n",
      "114       ...           COMP44             1                1     AstraZeneca   \n",
      "115       ...          COMP504             1                1     AstraZeneca   \n",
      "116       ...          COMP504             1                1     AstraZeneca   \n",
      "117       ...          COMP642             1                1     AstraZeneca   \n",
      "118       ...          COMP642             1                1     AstraZeneca   \n",
      "119       ...        COMP92922             1                1     AstraZeneca   \n",
      "120       ...          COMP504             1                1     AstraZeneca   \n",
      "121       ...             Null          Null             Null            Null   \n",
      "122       ...             Null          Null             Null            Null   \n",
      "123       ...          COMP765             1                1     AstraZeneca   \n",
      "124       ...             Null          Null             Null            Null   \n",
      "125       ...          COMP765             1                1     AstraZeneca   \n",
      "126       ...          COMP765             1                1     AstraZeneca   \n",
      "127       ...             Null          Null             Null            Null   \n",
      "128       ...             Null          Null             Null            Null   \n",
      "129       ...             Null          Null             Null            Null   \n",
      "130       ...             Null          Null             Null            Null   \n",
      "131       ...        COMP93227             1                1     AstraZeneca   \n",
      "132       ...             Null          Null             Null            Null   \n",
      "133       ...             Null          Null             Null            Null   \n",
      "134       ...             Null          Null             Null            Null   \n",
      "135       ...             Null          Null             Null            Null   \n",
      "136       ...             Null          Null             Null            Null   \n",
      "137       ...             Null          Null             Null            Null   \n",
      "138       ...          COMP160             1                1     AstraZeneca   \n",
      "139       ...             Null          Null             Null            Null   \n",
      "140       ...             Null          Null             Null            Null   \n",
      "\n",
      "                        INDICATION INDICATION_ID INDICATION_SCORE  \\\n",
      "0                Alzheimer Disease       D000544                1   \n",
      "1     Primary Systemic Amyloidosis       DX90345                1   \n",
      "2                Alzheimer Disease       D000544                1   \n",
      "3                Alzheimer Disease       D000544                1   \n",
      "4                Alzheimer Disease       D000544                1   \n",
      "5         Female Genital Neoplasms       D005833                1   \n",
      "6         Female Genital Neoplasms       D005833                1   \n",
      "7         Female Genital Neoplasms       D005833                1   \n",
      "8         Female Genital Neoplasms       D005833                1   \n",
      "9                             Null          Null             Null   \n",
      "10                       Carcinoma       D002277                1   \n",
      "11    Systemic Lupus Erythematosus       D008180                1   \n",
      "12                            Null          Null             Null   \n",
      "13                   Schizophrenia       D012559                1   \n",
      "14                   Schizophrenia       D012559                1   \n",
      "15                            Null          Null             Null   \n",
      "16                        Tinnitus       D014012                1   \n",
      "17                            Null          Null             Null   \n",
      "18                            Null          Null             Null   \n",
      "19                        Tinnitus       D014012                1   \n",
      "20                        Tinnitus       D014012                1   \n",
      "21                            Null          Null             Null   \n",
      "22                        Seizures       D012640                1   \n",
      "23                Anterior Uveitis       D014606                1   \n",
      "24                        Seizures       D012640                1   \n",
      "25                Anterior Uveitis       D014606                1   \n",
      "26       Mild Cognitive Impairment       D060825                1   \n",
      "27               Alzheimer Disease       D000544                1   \n",
      "28       Mild Cognitive Impairment       D060825                1   \n",
      "29      Cytomegalovirus Infections       D003586                1   \n",
      "..                             ...           ...              ...   \n",
      "111                   Tuberculosis       D014376                1   \n",
      "112                      Carcinoma       D002277                1   \n",
      "113                          Cough       D003371                1   \n",
      "114                           Null          Null             Null   \n",
      "115  Non-Small-Cell Lung Carcinoma       D002289                1   \n",
      "116  Non-Small-Cell Lung Carcinoma       D002289                1   \n",
      "117           Neuromyelitis Optica       D009471                1   \n",
      "118           Neuromyelitis Optica       D009471                1   \n",
      "119           Systemic Scleroderma       D012595                1   \n",
      "120        Spinal Muscular Atrophy       D009134                1   \n",
      "121                           Null          Null             Null   \n",
      "122                           Null          Null             Null   \n",
      "123               Cluster Headache       D003027                1   \n",
      "124    Herpes Simplex Encephalitis       D020803                1   \n",
      "125               Cluster Headache       D003027                1   \n",
      "126               Cluster Headache       D003027                1   \n",
      "127                           Null          Null             Null   \n",
      "128    Herpes Simplex Encephalitis       D020803                1   \n",
      "129    Herpes Simplex Encephalitis       D020803                1   \n",
      "130           Muscular Dystrophies       D009136                1   \n",
      "131                           Null          Null             Null   \n",
      "132                   Chronic Pain       D059350                1   \n",
      "133                        Obesity       D009765                1   \n",
      "134       Staphylococcal Pneumonia       D011023                1   \n",
      "135                           Null          Null             Null   \n",
      "136       Hepatocellular Carcinoma       D006528                1   \n",
      "137                           Null          Null             Null   \n",
      "138                    Thalassemia       D013789                1   \n",
      "139       Staphylococcal Pneumonia       D011023                1   \n",
      "140           Hematologic Diseases       D006402                1   \n",
      "\n",
      "    INDICATION_NONAMBIG INDICATION_NCT_ID SYNONYMS_NCT_ID  \n",
      "0                     1       NCT03179501     NCT02794857  \n",
      "1                     1              Null             NaN  \n",
      "2                     1              Null     NCT02916056  \n",
      "3                     1              Null     NCT02916056  \n",
      "4                     1              Null     NCT02916056  \n",
      "5                     1       NCT03425565             NaN  \n",
      "6                     1       NCT03425565     NCT03085914  \n",
      "7                     1       NCT03425565     NCT03362060  \n",
      "8                     1       NCT03425565             NaN  \n",
      "9                  Null              Null             NaN  \n",
      "10                    1              Null     NCT03447470  \n",
      "11                    0              Null             NaN  \n",
      "12                 Null              Null             NaN  \n",
      "13                    1       NCT03418831     NCT03006003  \n",
      "14                    1       NCT03418831     NCT03382834  \n",
      "15                 Null              Null     NCT01906541  \n",
      "16                    1              Null             NaN  \n",
      "17                 Null              Null     NCT01906541  \n",
      "18                 Null              Null     NCT01906541  \n",
      "19                    1              Null             NaN  \n",
      "20                    1              Null             NaN  \n",
      "21                 Null              Null             NaN  \n",
      "22                    1       NCT03283371     NCT03093064  \n",
      "23                    1       NCT00694135             NaN  \n",
      "24                    1       NCT03283371     NCT03093064  \n",
      "25                    1       NCT00694135             NaN  \n",
      "26                    1              Null             NaN  \n",
      "27                    1       NCT02760602     NCT01127633  \n",
      "28                    1              Null             NaN  \n",
      "29                    1       NCT01611974     NCT02931539  \n",
      "..                  ...               ...             ...  \n",
      "111                   1       NCT03334734     NCT00931736  \n",
      "112                   1       NCT03113643     NCT02270463  \n",
      "113                   1              Null             NaN  \n",
      "114                Null              Null     NCT03450122  \n",
      "115                   1       NCT03447769     NCT02204293  \n",
      "116                   1       NCT03447769     NCT02204293  \n",
      "117                   2       NCT03350633     NCT01532869  \n",
      "118                   2       NCT03350633     NCT01532869  \n",
      "119                   1              Null     NCT03451045  \n",
      "120                   1              Null     NCT03381729  \n",
      "121                Null              Null     NCT01906541  \n",
      "122                Null              Null     NCT01906541  \n",
      "123                   1              Null     NCT02945046  \n",
      "124                   0              Null             NaN  \n",
      "125                   1              Null     NCT02945046  \n",
      "126                   1              Null             NaN  \n",
      "127                Null              Null     NCT03338114  \n",
      "128                   0              Null             NaN  \n",
      "129                   0              Null             NaN  \n",
      "130                   1              Null     NCT03507686  \n",
      "131                Null              Null     NCT00466583  \n",
      "132                   1              Null             NaN  \n",
      "133                   1              Null             NaN  \n",
      "134                   1       NCT02940626     NCT02940626  \n",
      "135                Null              Null     NCT02858362  \n",
      "136                   1       NCT01733004     NCT02538627  \n",
      "137                Null              Null     NCT01906541  \n",
      "138                   1       NCT03342404     NCT03342404  \n",
      "139                   1       NCT02940626     NCT02940626  \n",
      "140                   1              Null             NaN  \n",
      "\n",
      "[141 rows x 21 columns]]\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/anaconda3/lib/python3.5/site-packages/pandas/core/frame.py:6211: FutureWarning: Sorting because non-concatenation axis is not aligned. A future version\n",
      "of pandas will change to not sort by default.\n",
      "\n",
      "To accept the future behavior, pass 'sort=False'.\n",
      "\n",
      "To retain the current behavior and silence the warning, pass 'sort=True'.\n",
      "\n",
      "  sort=sort)\n",
      "Process ForkPoolWorker-6:\n",
      "Process ForkPoolWorker-5:\n",
      "Process ForkPoolWorker-3:\n",
      "Process ForkPoolWorker-2:\n",
      "Process ForkPoolWorker-4:\n",
      "Process ForkPoolWorker-1:\n",
      "Traceback (most recent call last):\n",
      "Traceback (most recent call last):\n",
      "Traceback (most recent call last):\n",
      "Traceback (most recent call last):\n",
      "Traceback (most recent call last):\n",
      "  File \"/anaconda3/lib/python3.5/multiprocessing/process.py\", line 254, in _bootstrap\n",
      "    self.run()\n",
      "  File \"/anaconda3/lib/python3.5/multiprocessing/process.py\", line 254, in _bootstrap\n",
      "    self.run()\n",
      "Traceback (most recent call last):\n",
      "  File \"/anaconda3/lib/python3.5/multiprocessing/process.py\", line 254, in _bootstrap\n",
      "    self.run()\n",
      "  File \"/anaconda3/lib/python3.5/multiprocessing/process.py\", line 254, in _bootstrap\n",
      "    self.run()\n",
      "  File \"/anaconda3/lib/python3.5/multiprocessing/process.py\", line 254, in _bootstrap\n",
      "    self.run()\n",
      "  File \"/anaconda3/lib/python3.5/multiprocessing/process.py\", line 254, in _bootstrap\n",
      "    self.run()\n",
      "  File \"/anaconda3/lib/python3.5/multiprocessing/process.py\", line 93, in run\n",
      "    self._target(*self._args, **self._kwargs)\n",
      "  File \"/anaconda3/lib/python3.5/multiprocessing/process.py\", line 93, in run\n",
      "    self._target(*self._args, **self._kwargs)\n",
      "  File \"/anaconda3/lib/python3.5/multiprocessing/process.py\", line 93, in run\n",
      "    self._target(*self._args, **self._kwargs)\n",
      "  File \"/anaconda3/lib/python3.5/multiprocessing/process.py\", line 93, in run\n",
      "    self._target(*self._args, **self._kwargs)\n",
      "  File \"/anaconda3/lib/python3.5/multiprocessing/process.py\", line 93, in run\n",
      "    self._target(*self._args, **self._kwargs)\n",
      "  File \"/anaconda3/lib/python3.5/multiprocessing/process.py\", line 93, in run\n",
      "    self._target(*self._args, **self._kwargs)\n",
      "  File \"/anaconda3/lib/python3.5/multiprocessing/pool.py\", line 108, in worker\n",
      "    task = get()\n",
      "  File \"/anaconda3/lib/python3.5/multiprocessing/pool.py\", line 108, in worker\n",
      "    task = get()\n",
      "  File \"/anaconda3/lib/python3.5/multiprocessing/pool.py\", line 108, in worker\n",
      "    task = get()\n",
      "  File \"/anaconda3/lib/python3.5/multiprocessing/pool.py\", line 108, in worker\n",
      "    task = get()\n",
      "  File \"/anaconda3/lib/python3.5/multiprocessing/pool.py\", line 108, in worker\n",
      "    task = get()\n",
      "  File \"/anaconda3/lib/python3.5/multiprocessing/queues.py\", line 342, in get\n",
      "    with self._rlock:\n",
      "  File \"/anaconda3/lib/python3.5/multiprocessing/queues.py\", line 342, in get\n",
      "    with self._rlock:\n",
      "  File \"/anaconda3/lib/python3.5/multiprocessing/pool.py\", line 108, in worker\n",
      "    task = get()\n",
      "  File \"/anaconda3/lib/python3.5/multiprocessing/queues.py\", line 342, in get\n",
      "    with self._rlock:\n",
      "  File \"/anaconda3/lib/python3.5/multiprocessing/synchronize.py\", line 96, in __enter__\n",
      "    return self._semlock.__enter__()\n",
      "  File \"/anaconda3/lib/python3.5/multiprocessing/synchronize.py\", line 96, in __enter__\n",
      "    return self._semlock.__enter__()\n",
      "  File \"/anaconda3/lib/python3.5/multiprocessing/queues.py\", line 343, in get\n",
      "    res = self._reader.recv_bytes()\n",
      "  File \"/anaconda3/lib/python3.5/multiprocessing/synchronize.py\", line 96, in __enter__\n",
      "    return self._semlock.__enter__()\n",
      "KeyboardInterrupt\n",
      "  File \"/anaconda3/lib/python3.5/multiprocessing/queues.py\", line 342, in get\n",
      "    with self._rlock:\n",
      "KeyboardInterrupt\n",
      "  File \"/anaconda3/lib/python3.5/multiprocessing/connection.py\", line 216, in recv_bytes\n",
      "    buf = self._recv_bytes(maxlength)\n",
      "KeyboardInterrupt\n",
      "  File \"/anaconda3/lib/python3.5/multiprocessing/connection.py\", line 407, in _recv_bytes\n",
      "    buf = self._recv(4)\n",
      "  File \"/anaconda3/lib/python3.5/multiprocessing/synchronize.py\", line 96, in __enter__\n",
      "    return self._semlock.__enter__()\n",
      "  File \"/anaconda3/lib/python3.5/multiprocessing/queues.py\", line 342, in get\n",
      "    with self._rlock:\n",
      "  File \"/anaconda3/lib/python3.5/multiprocessing/connection.py\", line 379, in _recv\n",
      "    chunk = read(handle, remaining)\n",
      "KeyboardInterrupt\n",
      "  File \"/anaconda3/lib/python3.5/multiprocessing/synchronize.py\", line 96, in __enter__\n",
      "    return self._semlock.__enter__()\n",
      "KeyboardInterrupt\n",
      "KeyboardInterrupt\n"
     ]
    }
   ],
   "source": [
    "def look_interventions(chunk): #function itself\n",
    "    for i in range(len(chunk)): #for every word from the part of main table\n",
    "        for j in range(len(interventions)): #for all the words from table with interventions\n",
    "            if str(chunk.loc[i, 'SYNONYMS']) != 'Null': #if there is synonym\n",
    "                #try to find it in 'INTERVENTION_NAME' or 'OTHER_NAME' column from interventions table\n",
    "                res_1 = re.findall(str(chunk.loc[i, 'SYNONYMS']).lower().replace('-', ''), str(interventions.loc[j,'INTERVENTION_NAME']).lower().replace('-', ''))\n",
    "                res_2 = re.findall(str(chunk.loc[i, 'SYNONYMS']).lower().replace('-', ''), str(interventions.loc[j,'OTHER_NAME']).lower().replace('-', ''))\n",
    "                if len(res_1) > 0 or len(res_2) > 0: #if found\n",
    "                    chunk.at[i, 'SYNONYMS_NCT_ID'] = interventions.loc[j, 'NCT_ID'] #add the nct_id to a new column to main dataset\n",
    "            elif str(chunk.loc[i, 'ACRONYM']) != 'Null': #if there is acronym\n",
    "                #try to find it in 'INTERVENTION_NAME' or 'OTHER_NAME' column from interventions table\n",
    "                res_1 = re.findall(str(chunk.loc[i, 'ACRONYM']).lower().replace('-', ''), str(interventions.loc[j,'INTERVENTION_NAME']).lower().replace('-', ''))\n",
    "                res_2 = re.findall(str(chunk.loc[i, 'ACRONYM']).lower().replace('-', ''), str(interventions.loc[j,'OTHER_NAME']).lower().replace('-', ''))\n",
    "                if len(res_1) > 0 or len(res_2) > 0: #if found\n",
    "                    chunk.at[i, 'SYNONYMS_NCT_ID'] = interventions.loc[j, 'NCT_ID'] #add the information (nct_id)\n",
    "    return chunk\n",
    "\n",
    "if __name__ == '__main__': #constructor for parallezation\n",
    "    p = Pool(6) #use 6 kernels to work on them\n",
    "    look = p.map(look_interventions, chunks) #function to do what I need\n",
    "    print(look) \n",
    "    \n",
    "dataframe = dataframe[0:0] #create a frame for the main table\n",
    "for l in range(len(look)):\n",
    "    dataframe = dataframe.append(look[l]) #add all updated parts to the main table\n",
    "    \n",
    "dataframe.index = np.arange(len(dataframe)) #update the indexes\n",
    "dataframe = dataframe.fillna('Null') #fill in empty cells"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 58,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>TWID</th>\n",
       "      <th>TWEET_ID</th>\n",
       "      <th>TWEET</th>\n",
       "      <th>SYNONYMS</th>\n",
       "      <th>MOLREGNO</th>\n",
       "      <th>ACRONYM</th>\n",
       "      <th>SYNONYMS_NCT_ID</th>\n",
       "      <th>PHASE</th>\n",
       "      <th>N_PHASES</th>\n",
       "      <th>OUTCOME</th>\n",
       "      <th>MATCHED_OUTCOME</th>\n",
       "      <th>COMPANY</th>\n",
       "      <th>COMPANY_ID</th>\n",
       "      <th>COMPANY_MATCHED</th>\n",
       "      <th>COMPANY_NONAMBIG</th>\n",
       "      <th>COMPANY_SCORE</th>\n",
       "      <th>INDICATION</th>\n",
       "      <th>INDICATION_ID</th>\n",
       "      <th>INDICATION_NONAMBIG</th>\n",
       "      <th>INDICATION_SCORE</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>4</td>\n",
       "      <td>986398045897191424</td>\n",
       "      <td>@PoseidaThera present promising results in ini...</td>\n",
       "      <td>P-BCMA-101</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT03288493</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>1</td>\n",
       "      <td>SUCCESS</td>\n",
       "      <td>promising results</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Multiple Myeloma</td>\n",
       "      <td>D009101</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>16</td>\n",
       "      <td>986219643881885698</td>\n",
       "      <td>Genentech gains a license option to Kineta's a...</td>\n",
       "      <td>ACETYLCHOLINE</td>\n",
       "      <td>27812</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT03446612</td>\n",
       "      <td>Null</td>\n",
       "      <td>0</td>\n",
       "      <td>SUCCESS</td>\n",
       "      <td>gains a license</td>\n",
       "      <td>Kineta®</td>\n",
       "      <td>COMP92965</td>\n",
       "      <td>AstraZeneca</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Chronic Pain</td>\n",
       "      <td>D059350</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   TWID            TWEET_ID  \\\n",
       "0     4  986398045897191424   \n",
       "1    16  986219643881885698   \n",
       "\n",
       "                                               TWEET       SYNONYMS  \\\n",
       "0  @PoseidaThera present promising results in ini...     P-BCMA-101   \n",
       "1  Genentech gains a license option to Kineta's a...  ACETYLCHOLINE   \n",
       "\n",
       "    MOLREGNO ACRONYM SYNONYMS_NCT_ID    PHASE  N_PHASES  OUTCOME  \\\n",
       "0  Not found    Null     NCT03288493  Phase 1         1  SUCCESS   \n",
       "1      27812    Null     NCT03446612     Null         0  SUCCESS   \n",
       "\n",
       "     MATCHED_OUTCOME  COMPANY COMPANY_ID COMPANY_MATCHED COMPANY_NONAMBIG  \\\n",
       "0  promising results     Null       Null            Null             Null   \n",
       "1    gains a license  Kineta®  COMP92965     AstraZeneca                1   \n",
       "\n",
       "  COMPANY_SCORE        INDICATION INDICATION_ID INDICATION_NONAMBIG  \\\n",
       "0          Null  Multiple Myeloma       D009101                   1   \n",
       "1             1      Chronic Pain       D059350                   1   \n",
       "\n",
       "  INDICATION_SCORE  \n",
       "0                1  \n",
       "1                1  "
      ]
     },
     "execution_count": 58,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "dataframe[:2]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "metadata": {},
   "outputs": [],
   "source": [
    "#order of columns\n",
    "dataframe = dataframe[['TWID', 'TWEET_ID', 'TWEET', 'SYNONYMS', 'MOLREGNO', 'ACRONYM', 'SYNONYMS_NCT_ID', \n",
    "                       'PHASE', 'N_PHASES', 'OUTCOME', 'MATCHED_OUTCOME', 'COMPANY', 'COMPANY_ID',\n",
    "                       'COMPANY_MATCHED', 'COMPANY_NONAMBIG', 'COMPANY_SCORE', 'INDICATION', 'INDICATION_ID',\n",
    "                       'INDICATION_NONAMBIG', 'INDICATION_SCORE']]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "During the work with intervention names were found 657 words\n",
      "Not found 184 words\n",
      "The length of the table is 841\n"
     ]
    }
   ],
   "source": [
    "#cell to have some new updated information about what was made with the table\n",
    "found = 0 #counter for found words\n",
    "not_found = 0 #counter for not found words\n",
    "dataframe.index = np.arange(len(dataframe)) #update the indexing\n",
    "\n",
    "for i in range(len(dataframe)):\n",
    "    if str(dataframe.loc[i, 'SYNONYMS_NCT_ID']) != 'Null': #if there is information about nct_id\n",
    "        found += 1 #add 1 to the first counter\n",
    "    else: #if no information\n",
    "        not_found += 1 #add the information to the other counter\n",
    "        \n",
    "print('During the work with intervention names were found', found, 'words')\n",
    "print('Not found', not_found, 'words')\n",
    "print('The length of the table is', len(dataframe))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>TWID</th>\n",
       "      <th>TWEET_ID</th>\n",
       "      <th>TWEET</th>\n",
       "      <th>SYNONYMS</th>\n",
       "      <th>MOLREGNO</th>\n",
       "      <th>ACRONYM</th>\n",
       "      <th>SYNONYMS_NCT_ID</th>\n",
       "      <th>PHASE</th>\n",
       "      <th>N_PHASES</th>\n",
       "      <th>OUTCOME</th>\n",
       "      <th>MATCHED_OUTCOME</th>\n",
       "      <th>COMPANY</th>\n",
       "      <th>COMPANY_ID</th>\n",
       "      <th>COMPANY_MATCHED</th>\n",
       "      <th>COMPANY_NONAMBIG</th>\n",
       "      <th>COMPANY_SCORE</th>\n",
       "      <th>INDICATION</th>\n",
       "      <th>INDICATION_ID</th>\n",
       "      <th>INDICATION_NONAMBIG</th>\n",
       "      <th>INDICATION_SCORE</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>4</td>\n",
       "      <td>986398045897191424</td>\n",
       "      <td>@PoseidaThera present promising results in ini...</td>\n",
       "      <td>P-BCMA-101</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT03288493</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>1</td>\n",
       "      <td>SUCCESS</td>\n",
       "      <td>promising results</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Multiple Myeloma</td>\n",
       "      <td>D009101</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>16</td>\n",
       "      <td>986219643881885698</td>\n",
       "      <td>Genentech gains a license option to Kineta's a...</td>\n",
       "      <td>ACETYLCHOLINE</td>\n",
       "      <td>27812</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT03446612</td>\n",
       "      <td>Null</td>\n",
       "      <td>0</td>\n",
       "      <td>SUCCESS</td>\n",
       "      <td>gains a license</td>\n",
       "      <td>Kineta®</td>\n",
       "      <td>COMP92965</td>\n",
       "      <td>AstraZeneca</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Chronic Pain</td>\n",
       "      <td>D059350</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>16</td>\n",
       "      <td>986219643881885698</td>\n",
       "      <td>Genentech gains a license option to Kineta's a...</td>\n",
       "      <td>ACETYLCHOLINE</td>\n",
       "      <td>195974</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT03446612</td>\n",
       "      <td>Null</td>\n",
       "      <td>0</td>\n",
       "      <td>SUCCESS</td>\n",
       "      <td>gains a license</td>\n",
       "      <td>Kineta®</td>\n",
       "      <td>COMP92965</td>\n",
       "      <td>AstraZeneca</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Chronic Pain</td>\n",
       "      <td>D059350</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>21</td>\n",
       "      <td>985928258708492288</td>\n",
       "      <td>First-in-human trial with MG7-CART shows effic...</td>\n",
       "      <td>MG7-CART</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT02862704</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>1</td>\n",
       "      <td>SUCCESS</td>\n",
       "      <td>shows safety</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Rectal Neoplasms</td>\n",
       "      <td>D012004</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   TWID            TWEET_ID  \\\n",
       "0     4  986398045897191424   \n",
       "1    16  986219643881885698   \n",
       "2    16  986219643881885698   \n",
       "3    21  985928258708492288   \n",
       "\n",
       "                                               TWEET       SYNONYMS  \\\n",
       "0  @PoseidaThera present promising results in ini...     P-BCMA-101   \n",
       "1  Genentech gains a license option to Kineta's a...  ACETYLCHOLINE   \n",
       "2  Genentech gains a license option to Kineta's a...  ACETYLCHOLINE   \n",
       "3  First-in-human trial with MG7-CART shows effic...       MG7-CART   \n",
       "\n",
       "    MOLREGNO ACRONYM SYNONYMS_NCT_ID    PHASE  N_PHASES  OUTCOME  \\\n",
       "0  Not found    Null     NCT03288493  Phase 1         1  SUCCESS   \n",
       "1      27812    Null     NCT03446612     Null         0  SUCCESS   \n",
       "2     195974    Null     NCT03446612     Null         0  SUCCESS   \n",
       "3  Not found    Null     NCT02862704  Phase 1         1  SUCCESS   \n",
       "\n",
       "     MATCHED_OUTCOME  COMPANY COMPANY_ID COMPANY_MATCHED COMPANY_NONAMBIG  \\\n",
       "0  promising results     Null       Null            Null             Null   \n",
       "1    gains a license  Kineta®  COMP92965     AstraZeneca                1   \n",
       "2    gains a license  Kineta®  COMP92965     AstraZeneca                1   \n",
       "3       shows safety     Null       Null            Null             Null   \n",
       "\n",
       "  COMPANY_SCORE        INDICATION INDICATION_ID INDICATION_NONAMBIG  \\\n",
       "0          Null  Multiple Myeloma       D009101                   1   \n",
       "1             1      Chronic Pain       D059350                   1   \n",
       "2             1      Chronic Pain       D059350                   1   \n",
       "3          Null  Rectal Neoplasms       D012004                   1   \n",
       "\n",
       "  INDICATION_SCORE  \n",
       "0                1  \n",
       "1                1  \n",
       "2                1  \n",
       "3                1  "
      ]
     },
     "execution_count": 30,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "dataframe[:4]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## <font color='green'> Matching with other datasets: *INTERVENTIONS, EFO2NAME, NCT_ID2MOLREGNO, NCTID_CONDITION_EFO* </font>"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "metadata": {},
   "outputs": [],
   "source": [
    "#open datasets I need\n",
    "interventions = pd.read_csv('INTERVENTIONS.csv', names=['NCT_ID', 'INTERVENTION_TYPE', 'INTERVENTION_NAME', \n",
    "                                                        'DESCRIPTIONS', 'OTHER_NAME', 'ARM_GROUP_LABEL'])\n",
    "\n",
    "efo2name = pd.read_csv('EFO2NAME.csv', names=['EFO_ID', 'NAME_TERM'])\n",
    "\n",
    "NCT_ID2MOLREGNO = pd.read_csv('NCT_ID2MOLREGNO.csv', names=['NCT_ID', 'MOLREGNO', 'INTERVENTION_NAME',\n",
    "                                                            'ARM_GROUP_TYPE', 'ARM_GROUP_LABEL', 'FOR_DICTIONARY'])\n",
    "\n",
    "NCTID_CONDITION_EFO = pd.read_csv('NCTID_CONDITION_EFO.csv', names=['NCT_ID', 'EFO_ID', 'CONDITION', 'REDUNDANT', \n",
    "                                                                    'FOR_AUTOMATIC_MAPPING', 'IS_INDICATION'])\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 250,
   "metadata": {},
   "outputs": [],
   "source": [
    "df = dataframe #make a copy\n",
    "df = df.rename(columns={'SYNONYMS_NCT_ID':'NCT_ID'}) #rename columns\n",
    "df = df.rename(columns={'MOLREGNO': 'MOLREGNO_1'})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 251,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "841"
      ]
     },
     "execution_count": 251,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(df)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 252,
   "metadata": {},
   "outputs": [],
   "source": [
    "#Now we work only with rows that have NCT_ID\n",
    "clean = df #copy\n",
    "\n",
    "nt = [] #list with indexes of not relevant rows\n",
    "\n",
    "for i in range(len(clean)):\n",
    "    if str(clean.loc[i, 'NCT_ID']) == 'Null': #if there is no information about NCT_ID\n",
    "        nt.append(i) #add the index\n",
    "\n",
    "#clean = clean.drop(clean.index[nt])\n",
    "clean.index = np.arange(len(clean))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 253,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "841"
      ]
     },
     "execution_count": 253,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(clean)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 254,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1958\n"
     ]
    }
   ],
   "source": [
    "df = pd.merge(clean, interventions, how='left', on='NCT_ID') #connect dataframe with interventions table\n",
    "\n",
    "df = df.fillna('Null') #fill in empty cells\n",
    "del df['ARM_GROUP_LABEL'] #delete 'ARM_GROUP_LABEL' column\n",
    "df = df.drop_duplicates() #delete duplicates\n",
    "df.index = np.arange(len(df)) #update indexing\n",
    "print(len(df))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 255,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>TWID</th>\n",
       "      <th>TWEET_ID</th>\n",
       "      <th>TWEET</th>\n",
       "      <th>SYNONYMS</th>\n",
       "      <th>MOLREGNO_1</th>\n",
       "      <th>ACRONYM</th>\n",
       "      <th>NCT_ID</th>\n",
       "      <th>PHASE</th>\n",
       "      <th>N_PHASES</th>\n",
       "      <th>OUTCOME</th>\n",
       "      <th>...</th>\n",
       "      <th>COMPANY_NONAMBIG</th>\n",
       "      <th>COMPANY_SCORE</th>\n",
       "      <th>INDICATION</th>\n",
       "      <th>INDICATION_ID</th>\n",
       "      <th>INDICATION_NONAMBIG</th>\n",
       "      <th>INDICATION_SCORE</th>\n",
       "      <th>INTERVENTION_TYPE</th>\n",
       "      <th>INTERVENTION_NAME</th>\n",
       "      <th>DESCRIPTIONS</th>\n",
       "      <th>OTHER_NAME</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>4</td>\n",
       "      <td>986398045897191424</td>\n",
       "      <td>@PoseidaThera present promising results in ini...</td>\n",
       "      <td>P-BCMA-101</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT03288493</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>1</td>\n",
       "      <td>SUCCESS</td>\n",
       "      <td>...</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Multiple Myeloma</td>\n",
       "      <td>D009101</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Biological</td>\n",
       "      <td>P-BCMA-101 CAR-T cells</td>\n",
       "      <td>P-BCMA-101 is an autologous, principally Tscm,...</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>16</td>\n",
       "      <td>986219643881885698</td>\n",
       "      <td>Genentech gains a license option to Kineta's a...</td>\n",
       "      <td>ACETYLCHOLINE</td>\n",
       "      <td>27812</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT03446612</td>\n",
       "      <td>Null</td>\n",
       "      <td>0</td>\n",
       "      <td>SUCCESS</td>\n",
       "      <td>...</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Chronic Pain</td>\n",
       "      <td>D059350</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Drug</td>\n",
       "      <td>L-N-monomethyl arginine citrate (L-NMMA)</td>\n",
       "      <td>L-N-monomethyl arginine citrate will be used a...</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>16</td>\n",
       "      <td>986219643881885698</td>\n",
       "      <td>Genentech gains a license option to Kineta's a...</td>\n",
       "      <td>ACETYLCHOLINE</td>\n",
       "      <td>27812</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT03446612</td>\n",
       "      <td>Null</td>\n",
       "      <td>0</td>\n",
       "      <td>SUCCESS</td>\n",
       "      <td>...</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Chronic Pain</td>\n",
       "      <td>D059350</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Drug</td>\n",
       "      <td>Daprodustat</td>\n",
       "      <td>Daprodustat will be available as 1 mg, 2 mg an...</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>16</td>\n",
       "      <td>986219643881885698</td>\n",
       "      <td>Genentech gains a license option to Kineta's a...</td>\n",
       "      <td>ACETYLCHOLINE</td>\n",
       "      <td>27812</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT03446612</td>\n",
       "      <td>Null</td>\n",
       "      <td>0</td>\n",
       "      <td>SUCCESS</td>\n",
       "      <td>...</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Chronic Pain</td>\n",
       "      <td>D059350</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Drug</td>\n",
       "      <td>Darbepoetin alfa (Aranesp)</td>\n",
       "      <td>Darbepoetin alfa will be given as solution for...</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>16</td>\n",
       "      <td>986219643881885698</td>\n",
       "      <td>Genentech gains a license option to Kineta's a...</td>\n",
       "      <td>ACETYLCHOLINE</td>\n",
       "      <td>27812</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT03446612</td>\n",
       "      <td>Null</td>\n",
       "      <td>0</td>\n",
       "      <td>SUCCESS</td>\n",
       "      <td>...</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Chronic Pain</td>\n",
       "      <td>D059350</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Drug</td>\n",
       "      <td>Acetylcholine</td>\n",
       "      <td>Acetylcholine will be used as a challenge agen...</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>16</td>\n",
       "      <td>986219643881885698</td>\n",
       "      <td>Genentech gains a license option to Kineta's a...</td>\n",
       "      <td>ACETYLCHOLINE</td>\n",
       "      <td>27812</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT03446612</td>\n",
       "      <td>Null</td>\n",
       "      <td>0</td>\n",
       "      <td>SUCCESS</td>\n",
       "      <td>...</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Chronic Pain</td>\n",
       "      <td>D059350</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Drug</td>\n",
       "      <td>Sodium nitroprusside</td>\n",
       "      <td>Sodium nitroprusside will be used as a challen...</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>16</td>\n",
       "      <td>986219643881885698</td>\n",
       "      <td>Genentech gains a license option to Kineta's a...</td>\n",
       "      <td>ACETYLCHOLINE</td>\n",
       "      <td>195974</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT03446612</td>\n",
       "      <td>Null</td>\n",
       "      <td>0</td>\n",
       "      <td>SUCCESS</td>\n",
       "      <td>...</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Chronic Pain</td>\n",
       "      <td>D059350</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Drug</td>\n",
       "      <td>L-N-monomethyl arginine citrate (L-NMMA)</td>\n",
       "      <td>L-N-monomethyl arginine citrate will be used a...</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>16</td>\n",
       "      <td>986219643881885698</td>\n",
       "      <td>Genentech gains a license option to Kineta's a...</td>\n",
       "      <td>ACETYLCHOLINE</td>\n",
       "      <td>195974</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT03446612</td>\n",
       "      <td>Null</td>\n",
       "      <td>0</td>\n",
       "      <td>SUCCESS</td>\n",
       "      <td>...</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Chronic Pain</td>\n",
       "      <td>D059350</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Drug</td>\n",
       "      <td>Daprodustat</td>\n",
       "      <td>Daprodustat will be available as 1 mg, 2 mg an...</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>16</td>\n",
       "      <td>986219643881885698</td>\n",
       "      <td>Genentech gains a license option to Kineta's a...</td>\n",
       "      <td>ACETYLCHOLINE</td>\n",
       "      <td>195974</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT03446612</td>\n",
       "      <td>Null</td>\n",
       "      <td>0</td>\n",
       "      <td>SUCCESS</td>\n",
       "      <td>...</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Chronic Pain</td>\n",
       "      <td>D059350</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Drug</td>\n",
       "      <td>Darbepoetin alfa (Aranesp)</td>\n",
       "      <td>Darbepoetin alfa will be given as solution for...</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>16</td>\n",
       "      <td>986219643881885698</td>\n",
       "      <td>Genentech gains a license option to Kineta's a...</td>\n",
       "      <td>ACETYLCHOLINE</td>\n",
       "      <td>195974</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT03446612</td>\n",
       "      <td>Null</td>\n",
       "      <td>0</td>\n",
       "      <td>SUCCESS</td>\n",
       "      <td>...</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Chronic Pain</td>\n",
       "      <td>D059350</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Drug</td>\n",
       "      <td>Acetylcholine</td>\n",
       "      <td>Acetylcholine will be used as a challenge agen...</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>16</td>\n",
       "      <td>986219643881885698</td>\n",
       "      <td>Genentech gains a license option to Kineta's a...</td>\n",
       "      <td>ACETYLCHOLINE</td>\n",
       "      <td>195974</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT03446612</td>\n",
       "      <td>Null</td>\n",
       "      <td>0</td>\n",
       "      <td>SUCCESS</td>\n",
       "      <td>...</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Chronic Pain</td>\n",
       "      <td>D059350</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Drug</td>\n",
       "      <td>Sodium nitroprusside</td>\n",
       "      <td>Sodium nitroprusside will be used as a challen...</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>21</td>\n",
       "      <td>985928258708492288</td>\n",
       "      <td>First-in-human trial with MG7-CART shows effic...</td>\n",
       "      <td>MG7-CART</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT02862704</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>1</td>\n",
       "      <td>SUCCESS</td>\n",
       "      <td>...</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Rectal Neoplasms</td>\n",
       "      <td>D012004</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Biological</td>\n",
       "      <td>MG7-CART</td>\n",
       "      <td>Ultrasound-guided intra-tumor injection as the...</td>\n",
       "      <td>Ultrasound-guided Intra-tumor Infusion of MG7-...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>33</td>\n",
       "      <td>985172281734377473</td>\n",
       "      <td>Roche's CpAM modulator RO7049389 well tolerate...</td>\n",
       "      <td>RO7049389</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT03570658</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>1</td>\n",
       "      <td>SUCCESS</td>\n",
       "      <td>...</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Drug</td>\n",
       "      <td>RO7049389</td>\n",
       "      <td>RO7049389 will be administered orally either a...</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>33</td>\n",
       "      <td>985172281734377473</td>\n",
       "      <td>Roche's CpAM modulator RO7049389 well tolerate...</td>\n",
       "      <td>RO7049389</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT03570658</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>1</td>\n",
       "      <td>SUCCESS</td>\n",
       "      <td>...</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Drug</td>\n",
       "      <td>Placebo</td>\n",
       "      <td>Placebo will be administered orally at a dose ...</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>40</td>\n",
       "      <td>984750427186126848</td>\n",
       "      <td>Live at #ILC2018 FXR agonist EYP001 from Enyo ...</td>\n",
       "      <td>EYP001</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT03469583</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>1</td>\n",
       "      <td>IN PROGRESS</td>\n",
       "      <td>...</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Drug</td>\n",
       "      <td>EYP001</td>\n",
       "      <td>EYP001 self administered capsules, morning, wi...</td>\n",
       "      <td>EYP001a</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>40</td>\n",
       "      <td>984750427186126848</td>\n",
       "      <td>Live at #ILC2018 FXR agonist EYP001 from Enyo ...</td>\n",
       "      <td>EYP001</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT03469583</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>1</td>\n",
       "      <td>IN PROGRESS</td>\n",
       "      <td>...</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Drug</td>\n",
       "      <td>Entecavir 1 MG</td>\n",
       "      <td>Entecavir self administered tablets, morning, ...</td>\n",
       "      <td>ETV</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>65</td>\n",
       "      <td>981919705912004609</td>\n",
       "      <td>Boehringer Ingelheim to progress OSE's SIRP-al...</td>\n",
       "      <td>OSE-172</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>0</td>\n",
       "      <td>IN PROGRESS</td>\n",
       "      <td>...</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Carcinoma</td>\n",
       "      <td>D002277</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>106</td>\n",
       "      <td>977514137046667265</td>\n",
       "      <td>41 patients have been enrolled in the ongoing ...</td>\n",
       "      <td>BINIMETINIB</td>\n",
       "      <td>1677014</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT03158103</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>1</td>\n",
       "      <td>IN PROGRESS</td>\n",
       "      <td>...</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Cerebellar Neoplasms</td>\n",
       "      <td>D002528</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Drug</td>\n",
       "      <td>MEK162</td>\n",
       "      <td>MEK162 at 30mg twice daily</td>\n",
       "      <td>Binimetinib</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>106</td>\n",
       "      <td>977514137046667265</td>\n",
       "      <td>41 patients have been enrolled in the ongoing ...</td>\n",
       "      <td>BINIMETINIB</td>\n",
       "      <td>1677014</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT03158103</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>1</td>\n",
       "      <td>IN PROGRESS</td>\n",
       "      <td>...</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Cerebellar Neoplasms</td>\n",
       "      <td>D002528</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Drug</td>\n",
       "      <td>Pexidartinib</td>\n",
       "      <td>pexidartinib 600mg daily (400mg in the morning...</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>106</td>\n",
       "      <td>977514137046667265</td>\n",
       "      <td>41 patients have been enrolled in the ongoing ...</td>\n",
       "      <td>RIBOCICLIB</td>\n",
       "      <td>2039237</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT03081234</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>1</td>\n",
       "      <td>IN PROGRESS</td>\n",
       "      <td>...</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Cerebellar Neoplasms</td>\n",
       "      <td>D002528</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Drug</td>\n",
       "      <td>Ribociclib</td>\n",
       "      <td>Ribociclib 600 mg daily on days 1 to 21 of a 2...</td>\n",
       "      <td>LEE011</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>106</td>\n",
       "      <td>977514137046667265</td>\n",
       "      <td>41 patients have been enrolled in the ongoing ...</td>\n",
       "      <td>RIBOCICLIB</td>\n",
       "      <td>2039237</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT03081234</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>1</td>\n",
       "      <td>IN PROGRESS</td>\n",
       "      <td>...</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Cerebellar Neoplasms</td>\n",
       "      <td>D002528</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Drug</td>\n",
       "      <td>Placebo</td>\n",
       "      <td>Placebo 600 mg daily on days 1 to 21 of a 28-d...</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>106</td>\n",
       "      <td>977514137046667265</td>\n",
       "      <td>41 patients have been enrolled in the ongoing ...</td>\n",
       "      <td>RIBOCICLIB</td>\n",
       "      <td>2039237</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT03081234</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>1</td>\n",
       "      <td>IN PROGRESS</td>\n",
       "      <td>...</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Cerebellar Neoplasms</td>\n",
       "      <td>D002528</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Drug</td>\n",
       "      <td>Adjuvant endocrine therapy</td>\n",
       "      <td>Tamoxifen 20 mg daily, or letrozole 2.5 mg dai...</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>106</td>\n",
       "      <td>977514137046667265</td>\n",
       "      <td>41 patients have been enrolled in the ongoing ...</td>\n",
       "      <td>RIBOCICLIB</td>\n",
       "      <td>1926959</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT03081234</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>1</td>\n",
       "      <td>IN PROGRESS</td>\n",
       "      <td>...</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Cerebellar Neoplasms</td>\n",
       "      <td>D002528</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Drug</td>\n",
       "      <td>Ribociclib</td>\n",
       "      <td>Ribociclib 600 mg daily on days 1 to 21 of a 2...</td>\n",
       "      <td>LEE011</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>106</td>\n",
       "      <td>977514137046667265</td>\n",
       "      <td>41 patients have been enrolled in the ongoing ...</td>\n",
       "      <td>RIBOCICLIB</td>\n",
       "      <td>1926959</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT03081234</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>1</td>\n",
       "      <td>IN PROGRESS</td>\n",
       "      <td>...</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Cerebellar Neoplasms</td>\n",
       "      <td>D002528</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Drug</td>\n",
       "      <td>Placebo</td>\n",
       "      <td>Placebo 600 mg daily on days 1 to 21 of a 28-d...</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>106</td>\n",
       "      <td>977514137046667265</td>\n",
       "      <td>41 patients have been enrolled in the ongoing ...</td>\n",
       "      <td>RIBOCICLIB</td>\n",
       "      <td>1926959</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT03081234</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>1</td>\n",
       "      <td>IN PROGRESS</td>\n",
       "      <td>...</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Cerebellar Neoplasms</td>\n",
       "      <td>D002528</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Drug</td>\n",
       "      <td>Adjuvant endocrine therapy</td>\n",
       "      <td>Tamoxifen 20 mg daily, or letrozole 2.5 mg dai...</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>116</td>\n",
       "      <td>977140733919547392</td>\n",
       "      <td>The FDA approves Novartis kinase inhibitor nil...</td>\n",
       "      <td>NILOTINIB</td>\n",
       "      <td>426660</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT01535391</td>\n",
       "      <td>Null</td>\n",
       "      <td>2</td>\n",
       "      <td>SUCCESS</td>\n",
       "      <td>...</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>BCR-ABL Positive Chronic Myelogenous Leukemia</td>\n",
       "      <td>D015464</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Drug</td>\n",
       "      <td>Nilotinib</td>\n",
       "      <td>Administered orally at the dose of 300 mg twic...</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>140</td>\n",
       "      <td>976673091500814336</td>\n",
       "      <td>PRN-1008 from Principia Biopharma a Btk inhibi...</td>\n",
       "      <td>PRN-1008</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT03395210</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>2</td>\n",
       "      <td>IN PROGRESS</td>\n",
       "      <td>...</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Pemphigus</td>\n",
       "      <td>D010392</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Drug</td>\n",
       "      <td>PRN1008</td>\n",
       "      <td>BTK inhibitor</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>141</td>\n",
       "      <td>976672839821611008</td>\n",
       "      <td>Novartis presents LSZ-102 a selective estrogen...</td>\n",
       "      <td>ESTROGEN</td>\n",
       "      <td>600686</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT02835846</td>\n",
       "      <td>Null</td>\n",
       "      <td>1</td>\n",
       "      <td>IN PROGRESS</td>\n",
       "      <td>...</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Drug</td>\n",
       "      <td>Estrogen Cream</td>\n",
       "      <td>Participants are provided a vaginal estrogen c...</td>\n",
       "      <td>Premarin Cream®</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>177</td>\n",
       "      <td>975811214906478592</td>\n",
       "      <td>Millendo Therapeutics' nevanimibe (ATR-101) re...</td>\n",
       "      <td>ATR-101</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT03053271</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>1</td>\n",
       "      <td>SUCCESS</td>\n",
       "      <td>...</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Premature Birth</td>\n",
       "      <td>D047928</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Drug</td>\n",
       "      <td>ATR-101</td>\n",
       "      <td>During the 4-week randomized withdrawal period...</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>177</td>\n",
       "      <td>975811214906478592</td>\n",
       "      <td>Millendo Therapeutics' nevanimibe (ATR-101) re...</td>\n",
       "      <td>ATR-101</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT03053271</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>1</td>\n",
       "      <td>SUCCESS</td>\n",
       "      <td>...</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Premature Birth</td>\n",
       "      <td>D047928</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Drug</td>\n",
       "      <td>Placebos</td>\n",
       "      <td>During the 4-week randomized withdrawal period...</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1928</th>\n",
       "      <td>71177</td>\n",
       "      <td>1008721334027931649</td>\n",
       "      <td>@US_FDA Lifts Clinical Hold on @SolidBioDMD T...</td>\n",
       "      <td>GENETHERAPY</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT01906541</td>\n",
       "      <td>Null</td>\n",
       "      <td>0</td>\n",
       "      <td>IN PROGRESS</td>\n",
       "      <td>...</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Genetic</td>\n",
       "      <td>ex-vivo gene-therapy</td>\n",
       "      <td>transplantation autologous CD34+ cells, transd...</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1929</th>\n",
       "      <td>71184</td>\n",
       "      <td>1008400157065515010</td>\n",
       "      <td>$TEVA Halts Phase III Trial of Fremanezumab in...</td>\n",
       "      <td>FREMANEZUMAB</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT02945046</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>1</td>\n",
       "      <td>FAIL</td>\n",
       "      <td>...</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Cluster Headache</td>\n",
       "      <td>D003027</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Drug</td>\n",
       "      <td>Placebo</td>\n",
       "      <td>Matching placebo</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1930</th>\n",
       "      <td>71184</td>\n",
       "      <td>1008400157065515010</td>\n",
       "      <td>$TEVA Halts Phase III Trial of Fremanezumab in...</td>\n",
       "      <td>FREMANEZUMAB</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT02945046</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>1</td>\n",
       "      <td>FAIL</td>\n",
       "      <td>...</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Cluster Headache</td>\n",
       "      <td>D003027</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Drug</td>\n",
       "      <td>Fremanezumab - A</td>\n",
       "      <td>iv infusion</td>\n",
       "      <td>TEV-48125</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1931</th>\n",
       "      <td>71184</td>\n",
       "      <td>1008400157065515010</td>\n",
       "      <td>$TEVA Halts Phase III Trial of Fremanezumab in...</td>\n",
       "      <td>FREMANEZUMAB</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT02945046</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>1</td>\n",
       "      <td>FAIL</td>\n",
       "      <td>...</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Cluster Headache</td>\n",
       "      <td>D003027</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Drug</td>\n",
       "      <td>Fremanezumab - B</td>\n",
       "      <td>iv infusion</td>\n",
       "      <td>TEV-48125</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1932</th>\n",
       "      <td>71206</td>\n",
       "      <td>1007992469328416768</td>\n",
       "      <td>@Vical Halts Development of HSV-2 Vaccine aft...</td>\n",
       "      <td>HSV-2</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>1</td>\n",
       "      <td>FAIL</td>\n",
       "      <td>...</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Herpes Simplex Encephalitis</td>\n",
       "      <td>D020803</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1933</th>\n",
       "      <td>71214</td>\n",
       "      <td>1007728226167328768</td>\n",
       "      <td>Citing likely failure $TEVA halts Phase III tr...</td>\n",
       "      <td>FREMANEZUMAB</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT02945046</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>1</td>\n",
       "      <td>FAIL</td>\n",
       "      <td>...</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Cluster Headache</td>\n",
       "      <td>D003027</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Drug</td>\n",
       "      <td>Placebo</td>\n",
       "      <td>Matching placebo</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1934</th>\n",
       "      <td>71214</td>\n",
       "      <td>1007728226167328768</td>\n",
       "      <td>Citing likely failure $TEVA halts Phase III tr...</td>\n",
       "      <td>FREMANEZUMAB</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT02945046</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>1</td>\n",
       "      <td>FAIL</td>\n",
       "      <td>...</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Cluster Headache</td>\n",
       "      <td>D003027</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Drug</td>\n",
       "      <td>Fremanezumab - A</td>\n",
       "      <td>iv infusion</td>\n",
       "      <td>TEV-48125</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1935</th>\n",
       "      <td>71214</td>\n",
       "      <td>1007728226167328768</td>\n",
       "      <td>Citing likely failure $TEVA halts Phase III tr...</td>\n",
       "      <td>FREMANEZUMAB</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT02945046</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>1</td>\n",
       "      <td>FAIL</td>\n",
       "      <td>...</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Cluster Headache</td>\n",
       "      <td>D003027</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Drug</td>\n",
       "      <td>Fremanezumab - B</td>\n",
       "      <td>iv infusion</td>\n",
       "      <td>TEV-48125</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1936</th>\n",
       "      <td>71218</td>\n",
       "      <td>1007626689931894784</td>\n",
       "      <td>$TEVA Halts Phase III Trial of Fremanezumab in...</td>\n",
       "      <td>oowKWW16</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>1</td>\n",
       "      <td>FAIL</td>\n",
       "      <td>...</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Cluster Headache</td>\n",
       "      <td>D003027</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1937</th>\n",
       "      <td>71239</td>\n",
       "      <td>1007003456375263233</td>\n",
       "      <td>Citing \"oral intolerability\" @flexpharma  halt...</td>\n",
       "      <td>FLX-787</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT03338114</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>1</td>\n",
       "      <td>STOPPED</td>\n",
       "      <td>...</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Drug</td>\n",
       "      <td>FLX-787-ODT (orally disintigrating tablet)</td>\n",
       "      <td>Oral Disintegrating Tablet</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1938</th>\n",
       "      <td>71268</td>\n",
       "      <td>1006339070421798915</td>\n",
       "      <td>After Phase II failure  @Vical halts developme...</td>\n",
       "      <td>HSV-2</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>1</td>\n",
       "      <td>FAIL</td>\n",
       "      <td>...</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Herpes Simplex Encephalitis</td>\n",
       "      <td>D020803</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1939</th>\n",
       "      <td>71277</td>\n",
       "      <td>1006185066576347136</td>\n",
       "      <td>@Vical Halts Development of HSV-2 Vaccine aft...</td>\n",
       "      <td>HSV-2</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>1</td>\n",
       "      <td>FAIL</td>\n",
       "      <td>...</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Herpes Simplex Encephalitis</td>\n",
       "      <td>D020803</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1940</th>\n",
       "      <td>74381</td>\n",
       "      <td>1009078221005033472</td>\n",
       "      <td>$SRPT I'm impressed\\n$SLDB $PFE\\n\\nA Gene Ther...</td>\n",
       "      <td>GENE THERAPY</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT03507686</td>\n",
       "      <td>Null</td>\n",
       "      <td>0</td>\n",
       "      <td>N/I</td>\n",
       "      <td>...</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Muscular Dystrophies</td>\n",
       "      <td>D009136</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Drug</td>\n",
       "      <td>AAV2-REP1</td>\n",
       "      <td>Sub-retinal injection of AAV2-REP1 after vitre...</td>\n",
       "      <td>Gene Therapy</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1941</th>\n",
       "      <td>116396</td>\n",
       "      <td>1011617239773208578</td>\n",
       "      <td>Gossamer Bio obtains exclusive license for wor...</td>\n",
       "      <td>HIF-1</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT00466583</td>\n",
       "      <td>Null</td>\n",
       "      <td>1</td>\n",
       "      <td>IN PROGRESS</td>\n",
       "      <td>...</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Drug</td>\n",
       "      <td>Intravenous EZN-2968 (anti-HIF-1a LNA AS-ODN)</td>\n",
       "      <td>IV infusion of EZN 2968 given in 6 week cycles...</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1942</th>\n",
       "      <td>116399</td>\n",
       "      <td>1011457286303354880</td>\n",
       "      <td>The potential use of novel [11C]-radiolabeled ...</td>\n",
       "      <td>PKG-1</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>0</td>\n",
       "      <td>N/I</td>\n",
       "      <td>...</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Chronic Pain</td>\n",
       "      <td>D059350</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1943</th>\n",
       "      <td>116409</td>\n",
       "      <td>1010937748306481153</td>\n",
       "      <td>Preclinical data for Glaceum's HSG-4112 curren...</td>\n",
       "      <td>HSG-4112</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>1</td>\n",
       "      <td>IN PROGRESS</td>\n",
       "      <td>...</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Obesity</td>\n",
       "      <td>D009765</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1944</th>\n",
       "      <td>122871</td>\n",
       "      <td>1012333898615984129</td>\n",
       "      <td>@ArsanisInc Halts Phase II Trial of #Pneumoni...</td>\n",
       "      <td>ASN100</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT02940626</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>1</td>\n",
       "      <td>FAIL</td>\n",
       "      <td>...</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Staphylococcal Pneumonia</td>\n",
       "      <td>D011023</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Drug</td>\n",
       "      <td>ASN100</td>\n",
       "      <td>monoclonal antibody combination of ASN-1 and A...</td>\n",
       "      <td>ASN-1 and ASN-2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1945</th>\n",
       "      <td>122871</td>\n",
       "      <td>1012333898615984129</td>\n",
       "      <td>@ArsanisInc Halts Phase II Trial of #Pneumoni...</td>\n",
       "      <td>ASN100</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT02940626</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>1</td>\n",
       "      <td>FAIL</td>\n",
       "      <td>...</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Staphylococcal Pneumonia</td>\n",
       "      <td>D011023</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Drug</td>\n",
       "      <td>Placebo</td>\n",
       "      <td>Placebo</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1946</th>\n",
       "      <td>122880</td>\n",
       "      <td>1011977695536836608</td>\n",
       "      <td>@Summitplc Plans Cost Cuts Stock Falls 80% af...</td>\n",
       "      <td>EZUTROMID</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT02858362</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>1</td>\n",
       "      <td>FAIL</td>\n",
       "      <td>...</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Drug</td>\n",
       "      <td>ezutromid</td>\n",
       "      <td>oral suspension</td>\n",
       "      <td>SMTC1100</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1947</th>\n",
       "      <td>122900</td>\n",
       "      <td>1011352104278155264</td>\n",
       "      <td>After Phase II failure @MerrimackPharma scraps...</td>\n",
       "      <td>MM-141</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT02538627</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>1</td>\n",
       "      <td>FAIL</td>\n",
       "      <td>...</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Hepatocellular Carcinoma</td>\n",
       "      <td>D006528</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Drug</td>\n",
       "      <td>MM-151</td>\n",
       "      <td>MM-151</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1948</th>\n",
       "      <td>122900</td>\n",
       "      <td>1011352104278155264</td>\n",
       "      <td>After Phase II failure @MerrimackPharma scraps...</td>\n",
       "      <td>MM-141</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT02538627</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>1</td>\n",
       "      <td>FAIL</td>\n",
       "      <td>...</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Hepatocellular Carcinoma</td>\n",
       "      <td>D006528</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Drug</td>\n",
       "      <td>MM-121</td>\n",
       "      <td>MM-121</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1949</th>\n",
       "      <td>122900</td>\n",
       "      <td>1011352104278155264</td>\n",
       "      <td>After Phase II failure @MerrimackPharma scraps...</td>\n",
       "      <td>MM-141</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT02538627</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>1</td>\n",
       "      <td>FAIL</td>\n",
       "      <td>...</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Hepatocellular Carcinoma</td>\n",
       "      <td>D006528</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Drug</td>\n",
       "      <td>MM-141</td>\n",
       "      <td>MM-141</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1950</th>\n",
       "      <td>122900</td>\n",
       "      <td>1011352104278155264</td>\n",
       "      <td>After Phase II failure @MerrimackPharma scraps...</td>\n",
       "      <td>MM-141</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT02538627</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>1</td>\n",
       "      <td>FAIL</td>\n",
       "      <td>...</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Hepatocellular Carcinoma</td>\n",
       "      <td>D006528</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Drug</td>\n",
       "      <td>trametinib</td>\n",
       "      <td>trametininb</td>\n",
       "      <td>MEKINIST</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1951</th>\n",
       "      <td>122925</td>\n",
       "      <td>1010544287359086593</td>\n",
       "      <td>@US_FDA Lifts Clinical Hold on @SolidBioDMD T...</td>\n",
       "      <td>GENETHERAPY</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT01906541</td>\n",
       "      <td>Null</td>\n",
       "      <td>0</td>\n",
       "      <td>IN PROGRESS</td>\n",
       "      <td>...</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Genetic</td>\n",
       "      <td>ex-vivo gene-therapy</td>\n",
       "      <td>transplantation autologous CD34+ cells, transd...</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1952</th>\n",
       "      <td>132553</td>\n",
       "      <td>1012453525979267077</td>\n",
       "      <td>Finally Celgene wins Anemia drug luspatercept ...</td>\n",
       "      <td>LUSPATERCEPT</td>\n",
       "      <td>1592363</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT03342404</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>1</td>\n",
       "      <td>SUCCESS</td>\n",
       "      <td>...</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Thalassemia</td>\n",
       "      <td>D013789</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Drug</td>\n",
       "      <td>Luspatercept</td>\n",
       "      <td>Subjects will start with luspatercept at 1 mg/...</td>\n",
       "      <td>ACE-536</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1953</th>\n",
       "      <td>132553</td>\n",
       "      <td>1012453525979267077</td>\n",
       "      <td>Finally Celgene wins Anemia drug luspatercept ...</td>\n",
       "      <td>LUSPATERCEPT</td>\n",
       "      <td>1592363</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT03342404</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>1</td>\n",
       "      <td>SUCCESS</td>\n",
       "      <td>...</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Thalassemia</td>\n",
       "      <td>D013789</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Other</td>\n",
       "      <td>Placebo</td>\n",
       "      <td>Placebo, Subcutaneous, every 21 days</td>\n",
       "      <td>normal saline</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1954</th>\n",
       "      <td>132553</td>\n",
       "      <td>1012453525979267077</td>\n",
       "      <td>Finally Celgene wins Anemia drug luspatercept ...</td>\n",
       "      <td>LUSPATERCEPT</td>\n",
       "      <td>1592363</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT03342404</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>1</td>\n",
       "      <td>SUCCESS</td>\n",
       "      <td>...</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Thalassemia</td>\n",
       "      <td>D013789</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Other</td>\n",
       "      <td>Best Supportive Care (BSC)</td>\n",
       "      <td>Best Supportive Care (BSC)</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1955</th>\n",
       "      <td>135766</td>\n",
       "      <td>1012439269128986626</td>\n",
       "      <td>Anticipating failure @ArsanisInc ends Phase II...</td>\n",
       "      <td>ASN100</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT02940626</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>1</td>\n",
       "      <td>FAIL</td>\n",
       "      <td>...</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Staphylococcal Pneumonia</td>\n",
       "      <td>D011023</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Drug</td>\n",
       "      <td>ASN100</td>\n",
       "      <td>monoclonal antibody combination of ASN-1 and A...</td>\n",
       "      <td>ASN-1 and ASN-2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1956</th>\n",
       "      <td>135766</td>\n",
       "      <td>1012439269128986626</td>\n",
       "      <td>Anticipating failure @ArsanisInc ends Phase II...</td>\n",
       "      <td>ASN100</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT02940626</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>1</td>\n",
       "      <td>FAIL</td>\n",
       "      <td>...</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Staphylococcal Pneumonia</td>\n",
       "      <td>D011023</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Drug</td>\n",
       "      <td>Placebo</td>\n",
       "      <td>Placebo</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1957</th>\n",
       "      <td>138975</td>\n",
       "      <td>1012504783897362433</td>\n",
       "      <td>RT @adamfeuerstein $XLRN blood disease drug hi...</td>\n",
       "      <td>PIVOTAL TRIAL</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>1</td>\n",
       "      <td>SUCCESS</td>\n",
       "      <td>...</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Hematologic Diseases</td>\n",
       "      <td>D006402</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>1958 rows × 24 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "        TWID             TWEET_ID  \\\n",
       "0          4   986398045897191424   \n",
       "1         16   986219643881885698   \n",
       "2         16   986219643881885698   \n",
       "3         16   986219643881885698   \n",
       "4         16   986219643881885698   \n",
       "5         16   986219643881885698   \n",
       "6         16   986219643881885698   \n",
       "7         16   986219643881885698   \n",
       "8         16   986219643881885698   \n",
       "9         16   986219643881885698   \n",
       "10        16   986219643881885698   \n",
       "11        21   985928258708492288   \n",
       "12        33   985172281734377473   \n",
       "13        33   985172281734377473   \n",
       "14        40   984750427186126848   \n",
       "15        40   984750427186126848   \n",
       "16        65   981919705912004609   \n",
       "17       106   977514137046667265   \n",
       "18       106   977514137046667265   \n",
       "19       106   977514137046667265   \n",
       "20       106   977514137046667265   \n",
       "21       106   977514137046667265   \n",
       "22       106   977514137046667265   \n",
       "23       106   977514137046667265   \n",
       "24       106   977514137046667265   \n",
       "25       116   977140733919547392   \n",
       "26       140   976673091500814336   \n",
       "27       141   976672839821611008   \n",
       "28       177   975811214906478592   \n",
       "29       177   975811214906478592   \n",
       "...      ...                  ...   \n",
       "1928   71177  1008721334027931649   \n",
       "1929   71184  1008400157065515010   \n",
       "1930   71184  1008400157065515010   \n",
       "1931   71184  1008400157065515010   \n",
       "1932   71206  1007992469328416768   \n",
       "1933   71214  1007728226167328768   \n",
       "1934   71214  1007728226167328768   \n",
       "1935   71214  1007728226167328768   \n",
       "1936   71218  1007626689931894784   \n",
       "1937   71239  1007003456375263233   \n",
       "1938   71268  1006339070421798915   \n",
       "1939   71277  1006185066576347136   \n",
       "1940   74381  1009078221005033472   \n",
       "1941  116396  1011617239773208578   \n",
       "1942  116399  1011457286303354880   \n",
       "1943  116409  1010937748306481153   \n",
       "1944  122871  1012333898615984129   \n",
       "1945  122871  1012333898615984129   \n",
       "1946  122880  1011977695536836608   \n",
       "1947  122900  1011352104278155264   \n",
       "1948  122900  1011352104278155264   \n",
       "1949  122900  1011352104278155264   \n",
       "1950  122900  1011352104278155264   \n",
       "1951  122925  1010544287359086593   \n",
       "1952  132553  1012453525979267077   \n",
       "1953  132553  1012453525979267077   \n",
       "1954  132553  1012453525979267077   \n",
       "1955  135766  1012439269128986626   \n",
       "1956  135766  1012439269128986626   \n",
       "1957  138975  1012504783897362433   \n",
       "\n",
       "                                                  TWEET       SYNONYMS  \\\n",
       "0     @PoseidaThera present promising results in ini...     P-BCMA-101   \n",
       "1     Genentech gains a license option to Kineta's a...  ACETYLCHOLINE   \n",
       "2     Genentech gains a license option to Kineta's a...  ACETYLCHOLINE   \n",
       "3     Genentech gains a license option to Kineta's a...  ACETYLCHOLINE   \n",
       "4     Genentech gains a license option to Kineta's a...  ACETYLCHOLINE   \n",
       "5     Genentech gains a license option to Kineta's a...  ACETYLCHOLINE   \n",
       "6     Genentech gains a license option to Kineta's a...  ACETYLCHOLINE   \n",
       "7     Genentech gains a license option to Kineta's a...  ACETYLCHOLINE   \n",
       "8     Genentech gains a license option to Kineta's a...  ACETYLCHOLINE   \n",
       "9     Genentech gains a license option to Kineta's a...  ACETYLCHOLINE   \n",
       "10    Genentech gains a license option to Kineta's a...  ACETYLCHOLINE   \n",
       "11    First-in-human trial with MG7-CART shows effic...       MG7-CART   \n",
       "12    Roche's CpAM modulator RO7049389 well tolerate...      RO7049389   \n",
       "13    Roche's CpAM modulator RO7049389 well tolerate...      RO7049389   \n",
       "14    Live at #ILC2018 FXR agonist EYP001 from Enyo ...         EYP001   \n",
       "15    Live at #ILC2018 FXR agonist EYP001 from Enyo ...         EYP001   \n",
       "16    Boehringer Ingelheim to progress OSE's SIRP-al...        OSE-172   \n",
       "17    41 patients have been enrolled in the ongoing ...    BINIMETINIB   \n",
       "18    41 patients have been enrolled in the ongoing ...    BINIMETINIB   \n",
       "19    41 patients have been enrolled in the ongoing ...     RIBOCICLIB   \n",
       "20    41 patients have been enrolled in the ongoing ...     RIBOCICLIB   \n",
       "21    41 patients have been enrolled in the ongoing ...     RIBOCICLIB   \n",
       "22    41 patients have been enrolled in the ongoing ...     RIBOCICLIB   \n",
       "23    41 patients have been enrolled in the ongoing ...     RIBOCICLIB   \n",
       "24    41 patients have been enrolled in the ongoing ...     RIBOCICLIB   \n",
       "25    The FDA approves Novartis kinase inhibitor nil...      NILOTINIB   \n",
       "26    PRN-1008 from Principia Biopharma a Btk inhibi...       PRN-1008   \n",
       "27    Novartis presents LSZ-102 a selective estrogen...       ESTROGEN   \n",
       "28    Millendo Therapeutics' nevanimibe (ATR-101) re...        ATR-101   \n",
       "29    Millendo Therapeutics' nevanimibe (ATR-101) re...        ATR-101   \n",
       "...                                                 ...            ...   \n",
       "1928   @US_FDA Lifts Clinical Hold on @SolidBioDMD T...    GENETHERAPY   \n",
       "1929  $TEVA Halts Phase III Trial of Fremanezumab in...   FREMANEZUMAB   \n",
       "1930  $TEVA Halts Phase III Trial of Fremanezumab in...   FREMANEZUMAB   \n",
       "1931  $TEVA Halts Phase III Trial of Fremanezumab in...   FREMANEZUMAB   \n",
       "1932   @Vical Halts Development of HSV-2 Vaccine aft...          HSV-2   \n",
       "1933  Citing likely failure $TEVA halts Phase III tr...   FREMANEZUMAB   \n",
       "1934  Citing likely failure $TEVA halts Phase III tr...   FREMANEZUMAB   \n",
       "1935  Citing likely failure $TEVA halts Phase III tr...   FREMANEZUMAB   \n",
       "1936  $TEVA Halts Phase III Trial of Fremanezumab in...       oowKWW16   \n",
       "1937  Citing \"oral intolerability\" @flexpharma  halt...        FLX-787   \n",
       "1938  After Phase II failure  @Vical halts developme...          HSV-2   \n",
       "1939   @Vical Halts Development of HSV-2 Vaccine aft...          HSV-2   \n",
       "1940  $SRPT I'm impressed\\n$SLDB $PFE\\n\\nA Gene Ther...   GENE THERAPY   \n",
       "1941  Gossamer Bio obtains exclusive license for wor...          HIF-1   \n",
       "1942  The potential use of novel [11C]-radiolabeled ...          PKG-1   \n",
       "1943  Preclinical data for Glaceum's HSG-4112 curren...       HSG-4112   \n",
       "1944   @ArsanisInc Halts Phase II Trial of #Pneumoni...         ASN100   \n",
       "1945   @ArsanisInc Halts Phase II Trial of #Pneumoni...         ASN100   \n",
       "1946   @Summitplc Plans Cost Cuts Stock Falls 80% af...      EZUTROMID   \n",
       "1947  After Phase II failure @MerrimackPharma scraps...         MM-141   \n",
       "1948  After Phase II failure @MerrimackPharma scraps...         MM-141   \n",
       "1949  After Phase II failure @MerrimackPharma scraps...         MM-141   \n",
       "1950  After Phase II failure @MerrimackPharma scraps...         MM-141   \n",
       "1951   @US_FDA Lifts Clinical Hold on @SolidBioDMD T...    GENETHERAPY   \n",
       "1952  Finally Celgene wins Anemia drug luspatercept ...   LUSPATERCEPT   \n",
       "1953  Finally Celgene wins Anemia drug luspatercept ...   LUSPATERCEPT   \n",
       "1954  Finally Celgene wins Anemia drug luspatercept ...   LUSPATERCEPT   \n",
       "1955  Anticipating failure @ArsanisInc ends Phase II...         ASN100   \n",
       "1956  Anticipating failure @ArsanisInc ends Phase II...         ASN100   \n",
       "1957  RT @adamfeuerstein $XLRN blood disease drug hi...  PIVOTAL TRIAL   \n",
       "\n",
       "     MOLREGNO_1 ACRONYM       NCT_ID    PHASE  N_PHASES      OUTCOME  \\\n",
       "0     Not found    Null  NCT03288493  Phase 1         1      SUCCESS   \n",
       "1         27812    Null  NCT03446612     Null         0      SUCCESS   \n",
       "2         27812    Null  NCT03446612     Null         0      SUCCESS   \n",
       "3         27812    Null  NCT03446612     Null         0      SUCCESS   \n",
       "4         27812    Null  NCT03446612     Null         0      SUCCESS   \n",
       "5         27812    Null  NCT03446612     Null         0      SUCCESS   \n",
       "6        195974    Null  NCT03446612     Null         0      SUCCESS   \n",
       "7        195974    Null  NCT03446612     Null         0      SUCCESS   \n",
       "8        195974    Null  NCT03446612     Null         0      SUCCESS   \n",
       "9        195974    Null  NCT03446612     Null         0      SUCCESS   \n",
       "10       195974    Null  NCT03446612     Null         0      SUCCESS   \n",
       "11    Not found    Null  NCT02862704  Phase 1         1      SUCCESS   \n",
       "12    Not found    Null  NCT03570658  Phase 1         1      SUCCESS   \n",
       "13    Not found    Null  NCT03570658  Phase 1         1      SUCCESS   \n",
       "14         Null    Null  NCT03469583  Phase 1         1  IN PROGRESS   \n",
       "15         Null    Null  NCT03469583  Phase 1         1  IN PROGRESS   \n",
       "16    Not found    Null         Null     Null         0  IN PROGRESS   \n",
       "17      1677014    Null  NCT03158103  Phase 2         1  IN PROGRESS   \n",
       "18      1677014    Null  NCT03158103  Phase 2         1  IN PROGRESS   \n",
       "19      2039237    Null  NCT03081234  Phase 2         1  IN PROGRESS   \n",
       "20      2039237    Null  NCT03081234  Phase 2         1  IN PROGRESS   \n",
       "21      2039237    Null  NCT03081234  Phase 2         1  IN PROGRESS   \n",
       "22      1926959    Null  NCT03081234  Phase 2         1  IN PROGRESS   \n",
       "23      1926959    Null  NCT03081234  Phase 2         1  IN PROGRESS   \n",
       "24      1926959    Null  NCT03081234  Phase 2         1  IN PROGRESS   \n",
       "25       426660    Null  NCT01535391     Null         2      SUCCESS   \n",
       "26    Not found    Null  NCT03395210  Phase 2         2  IN PROGRESS   \n",
       "27       600686    Null  NCT02835846     Null         1  IN PROGRESS   \n",
       "28    Not found    Null  NCT03053271  Phase 2         1      SUCCESS   \n",
       "29    Not found    Null  NCT03053271  Phase 2         1      SUCCESS   \n",
       "...         ...     ...          ...      ...       ...          ...   \n",
       "1928       Null    Null  NCT01906541     Null         0  IN PROGRESS   \n",
       "1929       Null    Null  NCT02945046  Phase 3         1         FAIL   \n",
       "1930       Null    Null  NCT02945046  Phase 3         1         FAIL   \n",
       "1931       Null    Null  NCT02945046  Phase 3         1         FAIL   \n",
       "1932  Not found    Null         Null  Phase 2         1         FAIL   \n",
       "1933       Null    Null  NCT02945046  Phase 3         1         FAIL   \n",
       "1934       Null    Null  NCT02945046  Phase 3         1         FAIL   \n",
       "1935       Null    Null  NCT02945046  Phase 3         1         FAIL   \n",
       "1936  Not found    Null         Null  Phase 3         1         FAIL   \n",
       "1937  Not found    Null  NCT03338114  Phase 2         1      STOPPED   \n",
       "1938  Not found    Null         Null  Phase 2         1         FAIL   \n",
       "1939  Not found    Null         Null  Phase 2         1         FAIL   \n",
       "1940       Null    Null  NCT03507686     Null         0          N/I   \n",
       "1941  Not found    Null  NCT00466583     Null         1  IN PROGRESS   \n",
       "1942  Not found    Null         Null     Null         0          N/I   \n",
       "1943  Not found    Null         Null  Phase 1         1  IN PROGRESS   \n",
       "1944  Not found    Null  NCT02940626  Phase 2         1         FAIL   \n",
       "1945  Not found    Null  NCT02940626  Phase 2         1         FAIL   \n",
       "1946       Null    Null  NCT02858362  Phase 2         1         FAIL   \n",
       "1947  Not found    Null  NCT02538627  Phase 2         1         FAIL   \n",
       "1948  Not found    Null  NCT02538627  Phase 2         1         FAIL   \n",
       "1949  Not found    Null  NCT02538627  Phase 2         1         FAIL   \n",
       "1950  Not found    Null  NCT02538627  Phase 2         1         FAIL   \n",
       "1951       Null    Null  NCT01906541     Null         0  IN PROGRESS   \n",
       "1952    1592363    Null  NCT03342404  Phase 3         1      SUCCESS   \n",
       "1953    1592363    Null  NCT03342404  Phase 3         1      SUCCESS   \n",
       "1954    1592363    Null  NCT03342404  Phase 3         1      SUCCESS   \n",
       "1955  Not found    Null  NCT02940626  Phase 2         1         FAIL   \n",
       "1956  Not found    Null  NCT02940626  Phase 2         1         FAIL   \n",
       "1957       Null    Null         Null     Null         1      SUCCESS   \n",
       "\n",
       "                            ...                         COMPANY_NONAMBIG  \\\n",
       "0                           ...                                     Null   \n",
       "1                           ...                                        1   \n",
       "2                           ...                                        1   \n",
       "3                           ...                                        1   \n",
       "4                           ...                                        1   \n",
       "5                           ...                                        1   \n",
       "6                           ...                                        1   \n",
       "7                           ...                                        1   \n",
       "8                           ...                                        1   \n",
       "9                           ...                                        1   \n",
       "10                          ...                                        1   \n",
       "11                          ...                                     Null   \n",
       "12                          ...                                        1   \n",
       "13                          ...                                        1   \n",
       "14                          ...                                     Null   \n",
       "15                          ...                                     Null   \n",
       "16                          ...                                        1   \n",
       "17                          ...                                     Null   \n",
       "18                          ...                                     Null   \n",
       "19                          ...                                     Null   \n",
       "20                          ...                                     Null   \n",
       "21                          ...                                     Null   \n",
       "22                          ...                                     Null   \n",
       "23                          ...                                     Null   \n",
       "24                          ...                                     Null   \n",
       "25                          ...                                        1   \n",
       "26                          ...                                     Null   \n",
       "27                          ...                                        1   \n",
       "28                          ...                                        1   \n",
       "29                          ...                                        1   \n",
       "...                         ...                                      ...   \n",
       "1928                        ...                                     Null   \n",
       "1929                        ...                                        1   \n",
       "1930                        ...                                        1   \n",
       "1931                        ...                                        1   \n",
       "1932                        ...                                     Null   \n",
       "1933                        ...                                        1   \n",
       "1934                        ...                                        1   \n",
       "1935                        ...                                        1   \n",
       "1936                        ...                                        1   \n",
       "1937                        ...                                     Null   \n",
       "1938                        ...                                     Null   \n",
       "1939                        ...                                     Null   \n",
       "1940                        ...                                     Null   \n",
       "1941                        ...                                        1   \n",
       "1942                        ...                                     Null   \n",
       "1943                        ...                                     Null   \n",
       "1944                        ...                                     Null   \n",
       "1945                        ...                                     Null   \n",
       "1946                        ...                                     Null   \n",
       "1947                        ...                                     Null   \n",
       "1948                        ...                                     Null   \n",
       "1949                        ...                                     Null   \n",
       "1950                        ...                                     Null   \n",
       "1951                        ...                                     Null   \n",
       "1952                        ...                                        1   \n",
       "1953                        ...                                        1   \n",
       "1954                        ...                                        1   \n",
       "1955                        ...                                     Null   \n",
       "1956                        ...                                     Null   \n",
       "1957                        ...                                     Null   \n",
       "\n",
       "     COMPANY_SCORE                                     INDICATION  \\\n",
       "0             Null                               Multiple Myeloma   \n",
       "1                1                                   Chronic Pain   \n",
       "2                1                                   Chronic Pain   \n",
       "3                1                                   Chronic Pain   \n",
       "4                1                                   Chronic Pain   \n",
       "5                1                                   Chronic Pain   \n",
       "6                1                                   Chronic Pain   \n",
       "7                1                                   Chronic Pain   \n",
       "8                1                                   Chronic Pain   \n",
       "9                1                                   Chronic Pain   \n",
       "10               1                                   Chronic Pain   \n",
       "11            Null                               Rectal Neoplasms   \n",
       "12               1                                           Null   \n",
       "13               1                                           Null   \n",
       "14            Null                                           Null   \n",
       "15            Null                                           Null   \n",
       "16               1                                      Carcinoma   \n",
       "17            Null                           Cerebellar Neoplasms   \n",
       "18            Null                           Cerebellar Neoplasms   \n",
       "19            Null                           Cerebellar Neoplasms   \n",
       "20            Null                           Cerebellar Neoplasms   \n",
       "21            Null                           Cerebellar Neoplasms   \n",
       "22            Null                           Cerebellar Neoplasms   \n",
       "23            Null                           Cerebellar Neoplasms   \n",
       "24            Null                           Cerebellar Neoplasms   \n",
       "25               1  BCR-ABL Positive Chronic Myelogenous Leukemia   \n",
       "26            Null                                      Pemphigus   \n",
       "27               1                                           Null   \n",
       "28               1                                Premature Birth   \n",
       "29               1                                Premature Birth   \n",
       "...            ...                                            ...   \n",
       "1928          Null                                           Null   \n",
       "1929             1                               Cluster Headache   \n",
       "1930             1                               Cluster Headache   \n",
       "1931             1                               Cluster Headache   \n",
       "1932          Null                    Herpes Simplex Encephalitis   \n",
       "1933             1                               Cluster Headache   \n",
       "1934             1                               Cluster Headache   \n",
       "1935             1                               Cluster Headache   \n",
       "1936             1                               Cluster Headache   \n",
       "1937          Null                                           Null   \n",
       "1938          Null                    Herpes Simplex Encephalitis   \n",
       "1939          Null                    Herpes Simplex Encephalitis   \n",
       "1940          Null                           Muscular Dystrophies   \n",
       "1941             1                                           Null   \n",
       "1942          Null                                   Chronic Pain   \n",
       "1943          Null                                        Obesity   \n",
       "1944          Null                       Staphylococcal Pneumonia   \n",
       "1945          Null                       Staphylococcal Pneumonia   \n",
       "1946          Null                                           Null   \n",
       "1947          Null                       Hepatocellular Carcinoma   \n",
       "1948          Null                       Hepatocellular Carcinoma   \n",
       "1949          Null                       Hepatocellular Carcinoma   \n",
       "1950          Null                       Hepatocellular Carcinoma   \n",
       "1951          Null                                           Null   \n",
       "1952             1                                    Thalassemia   \n",
       "1953             1                                    Thalassemia   \n",
       "1954             1                                    Thalassemia   \n",
       "1955          Null                       Staphylococcal Pneumonia   \n",
       "1956          Null                       Staphylococcal Pneumonia   \n",
       "1957          Null                           Hematologic Diseases   \n",
       "\n",
       "     INDICATION_ID INDICATION_NONAMBIG INDICATION_SCORE INTERVENTION_TYPE  \\\n",
       "0          D009101                   1                1        Biological   \n",
       "1          D059350                   1                1              Drug   \n",
       "2          D059350                   1                1              Drug   \n",
       "3          D059350                   1                1              Drug   \n",
       "4          D059350                   1                1              Drug   \n",
       "5          D059350                   1                1              Drug   \n",
       "6          D059350                   1                1              Drug   \n",
       "7          D059350                   1                1              Drug   \n",
       "8          D059350                   1                1              Drug   \n",
       "9          D059350                   1                1              Drug   \n",
       "10         D059350                   1                1              Drug   \n",
       "11         D012004                   1                1        Biological   \n",
       "12            Null                Null             Null              Drug   \n",
       "13            Null                Null             Null              Drug   \n",
       "14            Null                Null             Null              Drug   \n",
       "15            Null                Null             Null              Drug   \n",
       "16         D002277                   1                1              Null   \n",
       "17         D002528                   1                1              Drug   \n",
       "18         D002528                   1                1              Drug   \n",
       "19         D002528                   1                1              Drug   \n",
       "20         D002528                   1                1              Drug   \n",
       "21         D002528                   1                1              Drug   \n",
       "22         D002528                   1                1              Drug   \n",
       "23         D002528                   1                1              Drug   \n",
       "24         D002528                   1                1              Drug   \n",
       "25         D015464                   1                1              Drug   \n",
       "26         D010392                   1                1              Drug   \n",
       "27            Null                Null             Null              Drug   \n",
       "28         D047928                   1                1              Drug   \n",
       "29         D047928                   1                1              Drug   \n",
       "...            ...                 ...              ...               ...   \n",
       "1928          Null                Null             Null           Genetic   \n",
       "1929       D003027                   1                1              Drug   \n",
       "1930       D003027                   1                1              Drug   \n",
       "1931       D003027                   1                1              Drug   \n",
       "1932       D020803                   0                1              Null   \n",
       "1933       D003027                   1                1              Drug   \n",
       "1934       D003027                   1                1              Drug   \n",
       "1935       D003027                   1                1              Drug   \n",
       "1936       D003027                   1                1              Null   \n",
       "1937          Null                Null             Null              Drug   \n",
       "1938       D020803                   0                1              Null   \n",
       "1939       D020803                   0                1              Null   \n",
       "1940       D009136                   1                1              Drug   \n",
       "1941          Null                Null             Null              Drug   \n",
       "1942       D059350                   1                1              Null   \n",
       "1943       D009765                   1                1              Null   \n",
       "1944       D011023                   1                1              Drug   \n",
       "1945       D011023                   1                1              Drug   \n",
       "1946          Null                Null             Null              Drug   \n",
       "1947       D006528                   1                1              Drug   \n",
       "1948       D006528                   1                1              Drug   \n",
       "1949       D006528                   1                1              Drug   \n",
       "1950       D006528                   1                1              Drug   \n",
       "1951          Null                Null             Null           Genetic   \n",
       "1952       D013789                   1                1              Drug   \n",
       "1953       D013789                   1                1             Other   \n",
       "1954       D013789                   1                1             Other   \n",
       "1955       D011023                   1                1              Drug   \n",
       "1956       D011023                   1                1              Drug   \n",
       "1957       D006402                   1                1              Null   \n",
       "\n",
       "                                  INTERVENTION_NAME  \\\n",
       "0                            P-BCMA-101 CAR-T cells   \n",
       "1          L-N-monomethyl arginine citrate (L-NMMA)   \n",
       "2                                       Daprodustat   \n",
       "3                        Darbepoetin alfa (Aranesp)   \n",
       "4                                     Acetylcholine   \n",
       "5                              Sodium nitroprusside   \n",
       "6          L-N-monomethyl arginine citrate (L-NMMA)   \n",
       "7                                       Daprodustat   \n",
       "8                        Darbepoetin alfa (Aranesp)   \n",
       "9                                     Acetylcholine   \n",
       "10                             Sodium nitroprusside   \n",
       "11                                         MG7-CART   \n",
       "12                                        RO7049389   \n",
       "13                                          Placebo   \n",
       "14                                           EYP001   \n",
       "15                                   Entecavir 1 MG   \n",
       "16                                             Null   \n",
       "17                                           MEK162   \n",
       "18                                     Pexidartinib   \n",
       "19                                       Ribociclib   \n",
       "20                                          Placebo   \n",
       "21                       Adjuvant endocrine therapy   \n",
       "22                                       Ribociclib   \n",
       "23                                          Placebo   \n",
       "24                       Adjuvant endocrine therapy   \n",
       "25                                        Nilotinib   \n",
       "26                                          PRN1008   \n",
       "27                                   Estrogen Cream   \n",
       "28                                          ATR-101   \n",
       "29                                         Placebos   \n",
       "...                                             ...   \n",
       "1928                           ex-vivo gene-therapy   \n",
       "1929                                        Placebo   \n",
       "1930                               Fremanezumab - A   \n",
       "1931                               Fremanezumab - B   \n",
       "1932                                           Null   \n",
       "1933                                        Placebo   \n",
       "1934                               Fremanezumab - A   \n",
       "1935                               Fremanezumab - B   \n",
       "1936                                           Null   \n",
       "1937     FLX-787-ODT (orally disintigrating tablet)   \n",
       "1938                                           Null   \n",
       "1939                                           Null   \n",
       "1940                                      AAV2-REP1   \n",
       "1941  Intravenous EZN-2968 (anti-HIF-1a LNA AS-ODN)   \n",
       "1942                                           Null   \n",
       "1943                                           Null   \n",
       "1944                                         ASN100   \n",
       "1945                                        Placebo   \n",
       "1946                                      ezutromid   \n",
       "1947                                         MM-151   \n",
       "1948                                         MM-121   \n",
       "1949                                         MM-141   \n",
       "1950                                     trametinib   \n",
       "1951                           ex-vivo gene-therapy   \n",
       "1952                                   Luspatercept   \n",
       "1953                                        Placebo   \n",
       "1954                     Best Supportive Care (BSC)   \n",
       "1955                                         ASN100   \n",
       "1956                                        Placebo   \n",
       "1957                                           Null   \n",
       "\n",
       "                                           DESCRIPTIONS  \\\n",
       "0     P-BCMA-101 is an autologous, principally Tscm,...   \n",
       "1     L-N-monomethyl arginine citrate will be used a...   \n",
       "2     Daprodustat will be available as 1 mg, 2 mg an...   \n",
       "3     Darbepoetin alfa will be given as solution for...   \n",
       "4     Acetylcholine will be used as a challenge agen...   \n",
       "5     Sodium nitroprusside will be used as a challen...   \n",
       "6     L-N-monomethyl arginine citrate will be used a...   \n",
       "7     Daprodustat will be available as 1 mg, 2 mg an...   \n",
       "8     Darbepoetin alfa will be given as solution for...   \n",
       "9     Acetylcholine will be used as a challenge agen...   \n",
       "10    Sodium nitroprusside will be used as a challen...   \n",
       "11    Ultrasound-guided intra-tumor injection as the...   \n",
       "12    RO7049389 will be administered orally either a...   \n",
       "13    Placebo will be administered orally at a dose ...   \n",
       "14    EYP001 self administered capsules, morning, wi...   \n",
       "15    Entecavir self administered tablets, morning, ...   \n",
       "16                                                 Null   \n",
       "17                           MEK162 at 30mg twice daily   \n",
       "18    pexidartinib 600mg daily (400mg in the morning...   \n",
       "19    Ribociclib 600 mg daily on days 1 to 21 of a 2...   \n",
       "20    Placebo 600 mg daily on days 1 to 21 of a 28-d...   \n",
       "21    Tamoxifen 20 mg daily, or letrozole 2.5 mg dai...   \n",
       "22    Ribociclib 600 mg daily on days 1 to 21 of a 2...   \n",
       "23    Placebo 600 mg daily on days 1 to 21 of a 28-d...   \n",
       "24    Tamoxifen 20 mg daily, or letrozole 2.5 mg dai...   \n",
       "25    Administered orally at the dose of 300 mg twic...   \n",
       "26                                        BTK inhibitor   \n",
       "27    Participants are provided a vaginal estrogen c...   \n",
       "28    During the 4-week randomized withdrawal period...   \n",
       "29    During the 4-week randomized withdrawal period...   \n",
       "...                                                 ...   \n",
       "1928  transplantation autologous CD34+ cells, transd...   \n",
       "1929                                   Matching placebo   \n",
       "1930                                        iv infusion   \n",
       "1931                                        iv infusion   \n",
       "1932                                               Null   \n",
       "1933                                   Matching placebo   \n",
       "1934                                        iv infusion   \n",
       "1935                                        iv infusion   \n",
       "1936                                               Null   \n",
       "1937                         Oral Disintegrating Tablet   \n",
       "1938                                               Null   \n",
       "1939                                               Null   \n",
       "1940  Sub-retinal injection of AAV2-REP1 after vitre...   \n",
       "1941  IV infusion of EZN 2968 given in 6 week cycles...   \n",
       "1942                                               Null   \n",
       "1943                                               Null   \n",
       "1944  monoclonal antibody combination of ASN-1 and A...   \n",
       "1945                                            Placebo   \n",
       "1946                                    oral suspension   \n",
       "1947                                             MM-151   \n",
       "1948                                             MM-121   \n",
       "1949                                             MM-141   \n",
       "1950                                        trametininb   \n",
       "1951  transplantation autologous CD34+ cells, transd...   \n",
       "1952  Subjects will start with luspatercept at 1 mg/...   \n",
       "1953               Placebo, Subcutaneous, every 21 days   \n",
       "1954                         Best Supportive Care (BSC)   \n",
       "1955  monoclonal antibody combination of ASN-1 and A...   \n",
       "1956                                            Placebo   \n",
       "1957                                               Null   \n",
       "\n",
       "                                             OTHER_NAME  \n",
       "0                                                  Null  \n",
       "1                                                  Null  \n",
       "2                                                  Null  \n",
       "3                                                  Null  \n",
       "4                                                  Null  \n",
       "5                                                  Null  \n",
       "6                                                  Null  \n",
       "7                                                  Null  \n",
       "8                                                  Null  \n",
       "9                                                  Null  \n",
       "10                                                 Null  \n",
       "11    Ultrasound-guided Intra-tumor Infusion of MG7-...  \n",
       "12                                                 Null  \n",
       "13                                                 Null  \n",
       "14                                              EYP001a  \n",
       "15                                                  ETV  \n",
       "16                                                 Null  \n",
       "17                                          Binimetinib  \n",
       "18                                                 Null  \n",
       "19                                               LEE011  \n",
       "20                                                 Null  \n",
       "21                                                 Null  \n",
       "22                                               LEE011  \n",
       "23                                                 Null  \n",
       "24                                                 Null  \n",
       "25                                                 Null  \n",
       "26                                                 Null  \n",
       "27                                      Premarin Cream®  \n",
       "28                                                 Null  \n",
       "29                                                 Null  \n",
       "...                                                 ...  \n",
       "1928                                               Null  \n",
       "1929                                               Null  \n",
       "1930                                          TEV-48125  \n",
       "1931                                          TEV-48125  \n",
       "1932                                               Null  \n",
       "1933                                               Null  \n",
       "1934                                          TEV-48125  \n",
       "1935                                          TEV-48125  \n",
       "1936                                               Null  \n",
       "1937                                               Null  \n",
       "1938                                               Null  \n",
       "1939                                               Null  \n",
       "1940                                       Gene Therapy  \n",
       "1941                                               Null  \n",
       "1942                                               Null  \n",
       "1943                                               Null  \n",
       "1944                                    ASN-1 and ASN-2  \n",
       "1945                                               Null  \n",
       "1946                                           SMTC1100  \n",
       "1947                                               Null  \n",
       "1948                                               Null  \n",
       "1949                                               Null  \n",
       "1950                                           MEKINIST  \n",
       "1951                                               Null  \n",
       "1952                                            ACE-536  \n",
       "1953                                      normal saline  \n",
       "1954                                               Null  \n",
       "1955                                    ASN-1 and ASN-2  \n",
       "1956                                               Null  \n",
       "1957                                               Null  \n",
       "\n",
       "[1958 rows x 24 columns]"
      ]
     },
     "execution_count": 255,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "There appeared rows that contain information about the same NCT_ID but the other drug. So this is why we should delete not relevant ones."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 256,
   "metadata": {},
   "outputs": [],
   "source": [
    "df['INDIC_INTERVENTIONS'] = 'False' #new column for the result"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 257,
   "metadata": {},
   "outputs": [],
   "source": [
    "#Parallelization of the process, making 6 chunks to work with them on different kernels\n",
    "#Make 6 parts of the working table\n",
    "\n",
    "a = df[0 : len(df) // 6]\n",
    "a.index = np.arange(len(a))\n",
    "\n",
    "b = df[len(df) // 6 : len(df) // 3]\n",
    "b.index = np.arange(len(b))\n",
    "\n",
    "c = df[len(df) // 3 : len(df) // 2]\n",
    "c.index = np.arange(len(c))\n",
    "\n",
    "d = df[len(df) // 2 : (2 * len(df)) // 3]\n",
    "d.index = np.arange(len(d))\n",
    "\n",
    "e = df[(2 * len(df)) // 3 : (5 * len(df)) // 6]\n",
    "e.index = np.arange(len(e))\n",
    "\n",
    "f = df[(5 * len(df)) // 6 : len(df)]\n",
    "f.index = np.arange(len(f)) \n",
    "\n",
    "#list of chunks of the working table that will be run by function\n",
    "chunks = [a, b, c, d, e, f]\n",
    "\n",
    "#number of chunks = number of kernels that is going to use during the process"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 258,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[     TWID            TWEET_ID  \\\n",
      "0       4  986398045897191424   \n",
      "1      16  986219643881885698   \n",
      "2      16  986219643881885698   \n",
      "3      16  986219643881885698   \n",
      "4      16  986219643881885698   \n",
      "5      16  986219643881885698   \n",
      "6      16  986219643881885698   \n",
      "7      16  986219643881885698   \n",
      "8      16  986219643881885698   \n",
      "9      16  986219643881885698   \n",
      "10     16  986219643881885698   \n",
      "11     21  985928258708492288   \n",
      "12     33  985172281734377473   \n",
      "13     33  985172281734377473   \n",
      "14     40  984750427186126848   \n",
      "15     40  984750427186126848   \n",
      "16     65  981919705912004609   \n",
      "17    106  977514137046667265   \n",
      "18    106  977514137046667265   \n",
      "19    106  977514137046667265   \n",
      "20    106  977514137046667265   \n",
      "21    106  977514137046667265   \n",
      "22    106  977514137046667265   \n",
      "23    106  977514137046667265   \n",
      "24    106  977514137046667265   \n",
      "25    116  977140733919547392   \n",
      "26    140  976673091500814336   \n",
      "27    141  976672839821611008   \n",
      "28    177  975811214906478592   \n",
      "29    177  975811214906478592   \n",
      "..    ...                 ...   \n",
      "296  1041  894850403241734148   \n",
      "297  1041  894850403241734148   \n",
      "298  1055  892593477686616064   \n",
      "299  1055  892593477686616064   \n",
      "300  1056  892593280474546177   \n",
      "301  1059  892360379740954624   \n",
      "302  1067  890786380716032000   \n",
      "303  1067  890786380716032000   \n",
      "304  1072  890213870522040322   \n",
      "305  1072  890213870522040322   \n",
      "306  1072  890213870522040322   \n",
      "307  1072  890213870522040322   \n",
      "308  1074  890210096415899649   \n",
      "309  1074  890210096415899649   \n",
      "310  1074  890210096415899649   \n",
      "311  1074  890210096415899649   \n",
      "312  1074  890210096415899649   \n",
      "313  1075  890208837441073152   \n",
      "314  1082  889491609678737408   \n",
      "315  1087  888386831263379456   \n",
      "316  1087  888386831263379456   \n",
      "317  1097  887649643793874945   \n",
      "318  1097  887649643793874945   \n",
      "319  1097  887649643793874945   \n",
      "320  1097  887649643793874945   \n",
      "321  1104  887312251123884033   \n",
      "322  1104  887312251123884033   \n",
      "323  1114  886955701045780480   \n",
      "324  1114  886955701045780480   \n",
      "325  1120  884710616518340608   \n",
      "\n",
      "                                                 TWEET        SYNONYMS  \\\n",
      "0    @PoseidaThera present promising results in ini...      P-BCMA-101   \n",
      "1    Genentech gains a license option to Kineta's a...   ACETYLCHOLINE   \n",
      "2    Genentech gains a license option to Kineta's a...   ACETYLCHOLINE   \n",
      "3    Genentech gains a license option to Kineta's a...   ACETYLCHOLINE   \n",
      "4    Genentech gains a license option to Kineta's a...   ACETYLCHOLINE   \n",
      "5    Genentech gains a license option to Kineta's a...   ACETYLCHOLINE   \n",
      "6    Genentech gains a license option to Kineta's a...   ACETYLCHOLINE   \n",
      "7    Genentech gains a license option to Kineta's a...   ACETYLCHOLINE   \n",
      "8    Genentech gains a license option to Kineta's a...   ACETYLCHOLINE   \n",
      "9    Genentech gains a license option to Kineta's a...   ACETYLCHOLINE   \n",
      "10   Genentech gains a license option to Kineta's a...   ACETYLCHOLINE   \n",
      "11   First-in-human trial with MG7-CART shows effic...        MG7-CART   \n",
      "12   Roche's CpAM modulator RO7049389 well tolerate...       RO7049389   \n",
      "13   Roche's CpAM modulator RO7049389 well tolerate...       RO7049389   \n",
      "14   Live at #ILC2018 FXR agonist EYP001 from Enyo ...          EYP001   \n",
      "15   Live at #ILC2018 FXR agonist EYP001 from Enyo ...          EYP001   \n",
      "16   Boehringer Ingelheim to progress OSE's SIRP-al...         OSE-172   \n",
      "17   41 patients have been enrolled in the ongoing ...     BINIMETINIB   \n",
      "18   41 patients have been enrolled in the ongoing ...     BINIMETINIB   \n",
      "19   41 patients have been enrolled in the ongoing ...      RIBOCICLIB   \n",
      "20   41 patients have been enrolled in the ongoing ...      RIBOCICLIB   \n",
      "21   41 patients have been enrolled in the ongoing ...      RIBOCICLIB   \n",
      "22   41 patients have been enrolled in the ongoing ...      RIBOCICLIB   \n",
      "23   41 patients have been enrolled in the ongoing ...      RIBOCICLIB   \n",
      "24   41 patients have been enrolled in the ongoing ...      RIBOCICLIB   \n",
      "25   The FDA approves Novartis kinase inhibitor nil...       NILOTINIB   \n",
      "26   PRN-1008 from Principia Biopharma a Btk inhibi...        PRN-1008   \n",
      "27   Novartis presents LSZ-102 a selective estrogen...        ESTROGEN   \n",
      "28   Millendo Therapeutics' nevanimibe (ATR-101) re...         ATR-101   \n",
      "29   Millendo Therapeutics' nevanimibe (ATR-101) re...         ATR-101   \n",
      "..                                                 ...             ...   \n",
      "296  Rebiotix's RBX-2660 begins phase III trial for...        RBX-2660   \n",
      "297  Rebiotix's RBX-2660 begins phase III trial for...        RBX-2660   \n",
      "298  Aptinyx's NYX-2925 begins phase II trial for n...        NYX-2925   \n",
      "299  Aptinyx's NYX-2925 begins phase II trial for n...        NYX-2925   \n",
      "300  Wakamoto starts phase II trial of WP-1303 (H-1...         WP-1303   \n",
      "301  Glenmark Pharmaceuticals announces positive re...         GBR-830   \n",
      "302  Quark's QPI-1002 meets safety and efficacy end...        QPI-1002   \n",
      "303  Quark's QPI-1002 meets safety and efficacy end...        QPI-1002   \n",
      "304  Tetraphase's eravacycline meets primary endpoi...    ERAVACYCLINE   \n",
      "305  Tetraphase's eravacycline meets primary endpoi...    ERAVACYCLINE   \n",
      "306  Tetraphase's eravacycline meets primary endpoi...    ERAVACYCLINE   \n",
      "307  Tetraphase's eravacycline meets primary endpoi...    ERAVACYCLINE   \n",
      "308  Axsome's AXS-06 (meloxicam and esomeprazole) m...    ESOMEPRAZOLE   \n",
      "309  Axsome's AXS-06 (meloxicam and esomeprazole) m...    ESOMEPRAZOLE   \n",
      "310  Axsome's AXS-06 (meloxicam and esomeprazole) m...    ESOMEPRAZOLE   \n",
      "311  Axsome's AXS-06 (meloxicam and esomeprazole) m...       MELOXICAM   \n",
      "312  Axsome's AXS-06 (meloxicam and esomeprazole) m...       MELOXICAM   \n",
      "313  AntriaBio begins phase I trial of AB101 for tr...           AB101   \n",
      "314  UCB's bimekizumab safe and effective in phase ...     BIMEKIZUMAB   \n",
      "315  Incyte begins phase III trials of itacitinib f...      ITACITINIB   \n",
      "316  Incyte begins phase III trials of itacitinib f...      ITACITINIB   \n",
      "317  Amgen/Sanofi's Leukine (recombinant GM-CSF) im...         LEUKINE   \n",
      "318  Amgen/Sanofi's Leukine (recombinant GM-CSF) im...         LEUKINE   \n",
      "319  Amgen/Sanofi's Leukine (recombinant GM-CSF) im...         LEUKINE   \n",
      "320  Amgen/Sanofi's Leukine (recombinant GM-CSF) im...         LEUKINE   \n",
      "321  Wave Life Sciences has begun phase Ib/IIa tria...      WVE-120101   \n",
      "322  Wave Life Sciences has begun phase Ib/IIa tria...      WVE-120101   \n",
      "323  Concomitant use of glycopyrrolate or trospium ...  GLYCOPYRROLATE   \n",
      "324  Concomitant use of glycopyrrolate or trospium ...        TROSPIUM   \n",
      "325  Positive topline phase II results reported for...       RALINEPAG   \n",
      "\n",
      "    MOLREGNO_1 ACRONYM       NCT_ID      PHASE  N_PHASES      OUTCOME  \\\n",
      "0    Not found    Null  NCT03288493    Phase 1         1      SUCCESS   \n",
      "1        27812    Null  NCT03446612       Null         0      SUCCESS   \n",
      "2        27812    Null  NCT03446612       Null         0      SUCCESS   \n",
      "3        27812    Null  NCT03446612       Null         0      SUCCESS   \n",
      "4        27812    Null  NCT03446612       Null         0      SUCCESS   \n",
      "5        27812    Null  NCT03446612       Null         0      SUCCESS   \n",
      "6       195974    Null  NCT03446612       Null         0      SUCCESS   \n",
      "7       195974    Null  NCT03446612       Null         0      SUCCESS   \n",
      "8       195974    Null  NCT03446612       Null         0      SUCCESS   \n",
      "9       195974    Null  NCT03446612       Null         0      SUCCESS   \n",
      "10      195974    Null  NCT03446612       Null         0      SUCCESS   \n",
      "11   Not found    Null  NCT02862704    Phase 1         1      SUCCESS   \n",
      "12   Not found    Null  NCT03570658    Phase 1         1      SUCCESS   \n",
      "13   Not found    Null  NCT03570658    Phase 1         1      SUCCESS   \n",
      "14        Null    Null  NCT03469583    Phase 1         1  IN PROGRESS   \n",
      "15        Null    Null  NCT03469583    Phase 1         1  IN PROGRESS   \n",
      "16   Not found    Null         Null       Null         0  IN PROGRESS   \n",
      "17     1677014    Null  NCT03158103    Phase 2         1  IN PROGRESS   \n",
      "18     1677014    Null  NCT03158103    Phase 2         1  IN PROGRESS   \n",
      "19     2039237    Null  NCT03081234    Phase 2         1  IN PROGRESS   \n",
      "20     2039237    Null  NCT03081234    Phase 2         1  IN PROGRESS   \n",
      "21     2039237    Null  NCT03081234    Phase 2         1  IN PROGRESS   \n",
      "22     1926959    Null  NCT03081234    Phase 2         1  IN PROGRESS   \n",
      "23     1926959    Null  NCT03081234    Phase 2         1  IN PROGRESS   \n",
      "24     1926959    Null  NCT03081234    Phase 2         1  IN PROGRESS   \n",
      "25      426660    Null  NCT01535391       Null         2      SUCCESS   \n",
      "26   Not found    Null  NCT03395210    Phase 2         2  IN PROGRESS   \n",
      "27      600686    Null  NCT02835846       Null         1  IN PROGRESS   \n",
      "28   Not found    Null  NCT03053271    Phase 2         1      SUCCESS   \n",
      "29   Not found    Null  NCT03053271    Phase 2         1      SUCCESS   \n",
      "..         ...     ...          ...        ...       ...          ...   \n",
      "296  Not found    Null  NCT03378167    Phase 3         1  IN PROGRESS   \n",
      "297  Not found    Null  NCT03378167    Phase 3         1  IN PROGRESS   \n",
      "298  Not found    Null  NCT03249103    Phase 2         1  IN PROGRESS   \n",
      "299  Not found    Null  NCT03249103    Phase 2         1  IN PROGRESS   \n",
      "300  Not found    Null         Null    Phase 2         1  IN PROGRESS   \n",
      "301  Not found    Null         Null    Phase 2         2      SUCCESS   \n",
      "302  Not found    Null  NCT03510897    Phase 2         2      SUCCESS   \n",
      "303  Not found    Null  NCT03510897    Phase 2         2      SUCCESS   \n",
      "304    1280078    Null  NCT03032510    Phase 3         3      SUCCESS   \n",
      "305    1280078    Null  NCT03032510    Phase 3         3      SUCCESS   \n",
      "306    1280078    Null  NCT03032510    Phase 3         3      SUCCESS   \n",
      "307    1280078    Null  NCT03032510    Phase 3         3      SUCCESS   \n",
      "308     675271    Null  NCT03006874    Phase 1         1      SUCCESS   \n",
      "309     675271    Null  NCT03006874    Phase 1         1      SUCCESS   \n",
      "310     675271    Null  NCT03006874    Phase 1         1      SUCCESS   \n",
      "311      20496    Null  NCT03434275    Phase 1         1      SUCCESS   \n",
      "312      20496    Null  NCT03434275    Phase 1         1      SUCCESS   \n",
      "313  Not found    Null  NCT03556956    Phase 1         1  IN PROGRESS   \n",
      "314       Null    Null  NCT03355573    Phase 2         1      SUCCESS   \n",
      "315    1966506    Null  NCT02257619    Phase 3         1  IN PROGRESS   \n",
      "316    1966506    Null  NCT02257619    Phase 3         1  IN PROGRESS   \n",
      "317     675569    Null  NCT01265901    Phase 2         1      SUCCESS   \n",
      "318     675569    Null  NCT01265901    Phase 2         1      SUCCESS   \n",
      "319     675569    Null  NCT01265901    Phase 2         1      SUCCESS   \n",
      "320     675569    Null  NCT01265901    Phase 2         1      SUCCESS   \n",
      "321  Not found    Null  NCT03225833  Phase 1/2         1  IN PROGRESS   \n",
      "322  Not found    Null  NCT03225833  Phase 1/2         1  IN PROGRESS   \n",
      "323     674978    Null  NCT03081156       Null         1      SUCCESS   \n",
      "324    1228747    Null  NCT03168828       Null         1      SUCCESS   \n",
      "325    1763566    Null  NCT02279745    Phase 2         1      SUCCESS   \n",
      "\n",
      "            ...         COMPANY_SCORE  \\\n",
      "0           ...                  Null   \n",
      "1           ...                     1   \n",
      "2           ...                     1   \n",
      "3           ...                     1   \n",
      "4           ...                     1   \n",
      "5           ...                     1   \n",
      "6           ...                     1   \n",
      "7           ...                     1   \n",
      "8           ...                     1   \n",
      "9           ...                     1   \n",
      "10          ...                     1   \n",
      "11          ...                  Null   \n",
      "12          ...                     1   \n",
      "13          ...                     1   \n",
      "14          ...                  Null   \n",
      "15          ...                  Null   \n",
      "16          ...                     1   \n",
      "17          ...                  Null   \n",
      "18          ...                  Null   \n",
      "19          ...                  Null   \n",
      "20          ...                  Null   \n",
      "21          ...                  Null   \n",
      "22          ...                  Null   \n",
      "23          ...                  Null   \n",
      "24          ...                  Null   \n",
      "25          ...                     1   \n",
      "26          ...                  Null   \n",
      "27          ...                     1   \n",
      "28          ...                     1   \n",
      "29          ...                     1   \n",
      "..          ...                   ...   \n",
      "296         ...                     1   \n",
      "297         ...                     1   \n",
      "298         ...                  Null   \n",
      "299         ...                  Null   \n",
      "300         ...                  Null   \n",
      "301         ...                     1   \n",
      "302         ...                     1   \n",
      "303         ...                     1   \n",
      "304         ...                     1   \n",
      "305         ...                     1   \n",
      "306         ...                     1   \n",
      "307         ...                     1   \n",
      "308         ...                  Null   \n",
      "309         ...                  Null   \n",
      "310         ...                  Null   \n",
      "311         ...                  Null   \n",
      "312         ...                  Null   \n",
      "313         ...                  Null   \n",
      "314         ...                  Null   \n",
      "315         ...                     1   \n",
      "316         ...                     1   \n",
      "317         ...                     1   \n",
      "318         ...                     1   \n",
      "319         ...                     1   \n",
      "320         ...                     1   \n",
      "321         ...                  Null   \n",
      "322         ...                  Null   \n",
      "323         ...                  Null   \n",
      "324         ...                  Null   \n",
      "325         ...                     1   \n",
      "\n",
      "                                        INDICATION INDICATION_ID  \\\n",
      "0                                 Multiple Myeloma       D009101   \n",
      "1                                     Chronic Pain       D059350   \n",
      "2                                     Chronic Pain       D059350   \n",
      "3                                     Chronic Pain       D059350   \n",
      "4                                     Chronic Pain       D059350   \n",
      "5                                     Chronic Pain       D059350   \n",
      "6                                     Chronic Pain       D059350   \n",
      "7                                     Chronic Pain       D059350   \n",
      "8                                     Chronic Pain       D059350   \n",
      "9                                     Chronic Pain       D059350   \n",
      "10                                    Chronic Pain       D059350   \n",
      "11                                Rectal Neoplasms       D012004   \n",
      "12                                            Null          Null   \n",
      "13                                            Null          Null   \n",
      "14                                            Null          Null   \n",
      "15                                            Null          Null   \n",
      "16                                       Carcinoma       D002277   \n",
      "17                            Cerebellar Neoplasms       D002528   \n",
      "18                            Cerebellar Neoplasms       D002528   \n",
      "19                            Cerebellar Neoplasms       D002528   \n",
      "20                            Cerebellar Neoplasms       D002528   \n",
      "21                            Cerebellar Neoplasms       D002528   \n",
      "22                            Cerebellar Neoplasms       D002528   \n",
      "23                            Cerebellar Neoplasms       D002528   \n",
      "24                            Cerebellar Neoplasms       D002528   \n",
      "25   BCR-ABL Positive Chronic Myelogenous Leukemia       D015464   \n",
      "26                                       Pemphigus       D010392   \n",
      "27                                            Null          Null   \n",
      "28                                 Premature Birth       D047928   \n",
      "29                                 Premature Birth       D047928   \n",
      "..                                             ...           ...   \n",
      "296                 Pseudomembranous Enterocolitis       D004761   \n",
      "297                 Pseudomembranous Enterocolitis       D004761   \n",
      "298                                   Fibromyalgia       D005356   \n",
      "299                                   Fibromyalgia       D005356   \n",
      "300                            Ocular Hypertension       D009798   \n",
      "301                                Neurodermatitis       D009450   \n",
      "302                         Delayed Graft Function       D051799   \n",
      "303                         Delayed Graft Function       D051799   \n",
      "304                         Chronic Kidney Failure       D007676   \n",
      "305                         Chronic Kidney Failure       D007676   \n",
      "306                         Chronic Kidney Failure       D007676   \n",
      "307                         Chronic Kidney Failure       D007676   \n",
      "308                                  Low Back Pain       D017116   \n",
      "309                                  Low Back Pain       D017116   \n",
      "310                                  Low Back Pain       D017116   \n",
      "311                                  Low Back Pain       D017116   \n",
      "312                                  Low Back Pain       D017116   \n",
      "313                             Metabolic Diseases       D008659   \n",
      "314                                      Psoriasis       D011565   \n",
      "315                          Graft vs Host Disease       D006086   \n",
      "316                          Graft vs Host Disease       D006086   \n",
      "317                                Kidney Diseases       D007674   \n",
      "318                                Kidney Diseases       D007674   \n",
      "319                                Kidney Diseases       D007674   \n",
      "320                                Kidney Diseases       D007674   \n",
      "321                             Huntington Disease       D006816   \n",
      "322                             Huntington Disease       D006816   \n",
      "323                     Overactive Urinary Bladder       D053201   \n",
      "324                     Overactive Urinary Bladder       D053201   \n",
      "325                         Pulmonary Hypertension       D006976   \n",
      "\n",
      "    INDICATION_NONAMBIG INDICATION_SCORE INTERVENTION_TYPE  \\\n",
      "0                     1                1        Biological   \n",
      "1                     1                1              Drug   \n",
      "2                     1                1              Drug   \n",
      "3                     1                1              Drug   \n",
      "4                     1                1              Drug   \n",
      "5                     1                1              Drug   \n",
      "6                     1                1              Drug   \n",
      "7                     1                1              Drug   \n",
      "8                     1                1              Drug   \n",
      "9                     1                1              Drug   \n",
      "10                    1                1              Drug   \n",
      "11                    1                1        Biological   \n",
      "12                 Null             Null              Drug   \n",
      "13                 Null             Null              Drug   \n",
      "14                 Null             Null              Drug   \n",
      "15                 Null             Null              Drug   \n",
      "16                    1                1              Null   \n",
      "17                    1                1              Drug   \n",
      "18                    1                1              Drug   \n",
      "19                    1                1              Drug   \n",
      "20                    1                1              Drug   \n",
      "21                    1                1              Drug   \n",
      "22                    1                1              Drug   \n",
      "23                    1                1              Drug   \n",
      "24                    1                1              Drug   \n",
      "25                    1                1              Drug   \n",
      "26                    1                1              Drug   \n",
      "27                 Null             Null              Drug   \n",
      "28                    1                1              Drug   \n",
      "29                    1                1              Drug   \n",
      "..                  ...              ...               ...   \n",
      "296                   0                1        Biological   \n",
      "297                   0                1        Biological   \n",
      "298                   1                1              Drug   \n",
      "299                   1                1              Drug   \n",
      "300                   1                1              Null   \n",
      "301                   0                1              Null   \n",
      "302                   1                1              Drug   \n",
      "303                   1                1              Drug   \n",
      "304                   1                1              Drug   \n",
      "305                   1                1              Drug   \n",
      "306                   1                1              Drug   \n",
      "307                   1                1              Drug   \n",
      "308                   1                1              Drug   \n",
      "309                   1                1              Drug   \n",
      "310                   1                1              Drug   \n",
      "311                   1                1              Drug   \n",
      "312                   1                1              Drug   \n",
      "313                   1                1              Drug   \n",
      "314                   1                1              Drug   \n",
      "315                   1                1              Drug   \n",
      "316                   1                1              Drug   \n",
      "317                   0                1              Drug   \n",
      "318                   0                1        Biological   \n",
      "319                   0                1              Drug   \n",
      "320                   0                1              Drug   \n",
      "321                   1                1              Drug   \n",
      "322                   1                1              Drug   \n",
      "323                   1                1              Drug   \n",
      "324                   1                1              Drug   \n",
      "325                   1                1              Drug   \n",
      "\n",
      "                                     INTERVENTION_NAME  \\\n",
      "0                               P-BCMA-101 CAR-T cells   \n",
      "1             L-N-monomethyl arginine citrate (L-NMMA)   \n",
      "2                                          Daprodustat   \n",
      "3                           Darbepoetin alfa (Aranesp)   \n",
      "4                                        Acetylcholine   \n",
      "5                                 Sodium nitroprusside   \n",
      "6             L-N-monomethyl arginine citrate (L-NMMA)   \n",
      "7                                          Daprodustat   \n",
      "8                           Darbepoetin alfa (Aranesp)   \n",
      "9                                        Acetylcholine   \n",
      "10                                Sodium nitroprusside   \n",
      "11                                            MG7-CART   \n",
      "12                                           RO7049389   \n",
      "13                                             Placebo   \n",
      "14                                              EYP001   \n",
      "15                                      Entecavir 1 MG   \n",
      "16                                                Null   \n",
      "17                                              MEK162   \n",
      "18                                        Pexidartinib   \n",
      "19                                          Ribociclib   \n",
      "20                                             Placebo   \n",
      "21                          Adjuvant endocrine therapy   \n",
      "22                                          Ribociclib   \n",
      "23                                             Placebo   \n",
      "24                          Adjuvant endocrine therapy   \n",
      "25                                           Nilotinib   \n",
      "26                                             PRN1008   \n",
      "27                                      Estrogen Cream   \n",
      "28                                             ATR-101   \n",
      "29                                            Placebos   \n",
      "..                                                 ...   \n",
      "296                                         MICROBIOTA   \n",
      "297                                            PLACEBO   \n",
      "298                               Placebo oral capsule   \n",
      "299                                           NYX-2925   \n",
      "300                                               Null   \n",
      "301                                               Null   \n",
      "302                                           QPI-1002   \n",
      "303                                            Placebo   \n",
      "304                                       Eravacycline   \n",
      "305                                          Ertapenem   \n",
      "306                                            Placebo   \n",
      "307                                       Levofloxacin   \n",
      "308                                  CJ-12420 100mg QD   \n",
      "309                                  Esomeprazole 40mg   \n",
      "310                                   CJ-12420 50mg QD   \n",
      "311                                              N1539   \n",
      "312                                            Placebo   \n",
      "313                                          Masitinib   \n",
      "314                                        Bimekizumab   \n",
      "315                                         Itacitinib   \n",
      "316                                          docetaxel   \n",
      "317                                          Sunitinib   \n",
      "318                                             GM-CSF   \n",
      "319                                   Cyclophosphamide   \n",
      "320                                             IMA901   \n",
      "321                                         WVE-120101   \n",
      "322                                            Placebo   \n",
      "323                        Glycopyrrolate / Formeterol   \n",
      "324  Trospium-Releasing Intravesical System (TAR-30...   \n",
      "325                                             APD811   \n",
      "\n",
      "                                          DESCRIPTIONS  \\\n",
      "0    P-BCMA-101 is an autologous, principally Tscm,...   \n",
      "1    L-N-monomethyl arginine citrate will be used a...   \n",
      "2    Daprodustat will be available as 1 mg, 2 mg an...   \n",
      "3    Darbepoetin alfa will be given as solution for...   \n",
      "4    Acetylcholine will be used as a challenge agen...   \n",
      "5    Sodium nitroprusside will be used as a challen...   \n",
      "6    L-N-monomethyl arginine citrate will be used a...   \n",
      "7    Daprodustat will be available as 1 mg, 2 mg an...   \n",
      "8    Darbepoetin alfa will be given as solution for...   \n",
      "9    Acetylcholine will be used as a challenge agen...   \n",
      "10   Sodium nitroprusside will be used as a challen...   \n",
      "11   Ultrasound-guided intra-tumor injection as the...   \n",
      "12   RO7049389 will be administered orally either a...   \n",
      "13   Placebo will be administered orally at a dose ...   \n",
      "14   EYP001 self administered capsules, morning, wi...   \n",
      "15   Entecavir self administered tablets, morning, ...   \n",
      "16                                                Null   \n",
      "17                          MEK162 at 30mg twice daily   \n",
      "18   pexidartinib 600mg daily (400mg in the morning...   \n",
      "19   Ribociclib 600 mg daily on days 1 to 21 of a 2...   \n",
      "20   Placebo 600 mg daily on days 1 to 21 of a 28-d...   \n",
      "21   Tamoxifen 20 mg daily, or letrozole 2.5 mg dai...   \n",
      "22   Ribociclib 600 mg daily on days 1 to 21 of a 2...   \n",
      "23   Placebo 600 mg daily on days 1 to 21 of a 28-d...   \n",
      "24   Tamoxifen 20 mg daily, or letrozole 2.5 mg dai...   \n",
      "25   Administered orally at the dose of 300 mg twic...   \n",
      "26                                       BTK inhibitor   \n",
      "27   Participants are provided a vaginal estrogen c...   \n",
      "28   During the 4-week randomized withdrawal period...   \n",
      "29   During the 4-week randomized withdrawal period...   \n",
      "..                                                 ...   \n",
      "296  Fecal microbiota enema (RBX2660) infused via c...   \n",
      "297  Placebo enema (Normal Saline) infused via colo...   \n",
      "298                         Matching placebo capsules.   \n",
      "299  NYX-2925 is a novel small molecule that modula...   \n",
      "300                                               Null   \n",
      "301                                               Null   \n",
      "302                                       IV injection   \n",
      "303                                    isotonic saline   \n",
      "304                                               Null   \n",
      "305                                               Null   \n",
      "306                                               Null   \n",
      "307                                               Null   \n",
      "308  CJ-12420 100mg tablets will be orally administ...   \n",
      "309  Esomeprazole 40mg tablets will be orally admin...   \n",
      "310  CJ-12420 50mg tablets will be orally administe...   \n",
      "311                                         Once Daily   \n",
      "312                                         Once Daily   \n",
      "313                          Tyrosine kinase inhibitor   \n",
      "314                Bimekizumab at a prespecified dose.   \n",
      "315  Itacitinib tablets administered orally at 400 ...   \n",
      "316  Administered as an intravenous infusion in the...   \n",
      "317                                      As per label.   \n",
      "318       Intradermal injection of GM-CSF as adjuvant.   \n",
      "319  One single low-dose i.v. infusion prior to the...   \n",
      "320      Intradermal vaccinations with IMA901 vaccine.   \n",
      "321  WVE-120101 is a stereopure antisense oligonucl...   \n",
      "322                               0.9% Sodium Chloride   \n",
      "323                                 Exercise Tolerance   \n",
      "324  TAR-302-5018 is a passive, nonresorbable trosp...   \n",
      "325                                               Null   \n",
      "\n",
      "                                            OTHER_NAME INDIC_INTERVENTIONS  \n",
      "0                                                 Null                True  \n",
      "1                                                 Null               False  \n",
      "2                                                 Null               False  \n",
      "3                                                 Null               False  \n",
      "4                                                 Null                True  \n",
      "5                                                 Null               False  \n",
      "6                                                 Null               False  \n",
      "7                                                 Null               False  \n",
      "8                                                 Null               False  \n",
      "9                                                 Null                True  \n",
      "10                                                Null               False  \n",
      "11   Ultrasound-guided Intra-tumor Infusion of MG7-...                True  \n",
      "12                                                Null                True  \n",
      "13                                                Null               False  \n",
      "14                                             EYP001a                True  \n",
      "15                                                 ETV               False  \n",
      "16                                                Null               False  \n",
      "17                                         Binimetinib                True  \n",
      "18                                                Null               False  \n",
      "19                                              LEE011                True  \n",
      "20                                                Null               False  \n",
      "21                                                Null               False  \n",
      "22                                              LEE011                True  \n",
      "23                                                Null               False  \n",
      "24                                                Null               False  \n",
      "25                                                Null                True  \n",
      "26                                                Null                True  \n",
      "27                                     Premarin Cream®                True  \n",
      "28                                                Null                True  \n",
      "29                                                Null               False  \n",
      "..                                                 ...                 ...  \n",
      "296        RBX2660;RBX7455;Fecal microbiota transplant                True  \n",
      "297                                               Null               False  \n",
      "298                                               Null               False  \n",
      "299                                               Null                True  \n",
      "300                                               Null               False  \n",
      "301                                               Null               False  \n",
      "302                                               Null                True  \n",
      "303                                               Null               False  \n",
      "304                                             TP-434                True  \n",
      "305                                             Invanz               False  \n",
      "306                                               Null               False  \n",
      "307                                           Levaquin               False  \n",
      "308                                    Tegoprazan Tab.               False  \n",
      "309                                        Nexium Tab.                True  \n",
      "310                                    Tegoprazan Tab.               False  \n",
      "311                              Intravenous meloxicam                True  \n",
      "312                                Intravenous placebo               False  \n",
      "313                                             AB1010                True  \n",
      "314                                            UCB4940                True  \n",
      "315                                         INCB039110                True  \n",
      "316                                               Null               False  \n",
      "317                                             Sutent               False  \n",
      "318  Granulocyte macrophage-colony stimulating fact...                True  \n",
      "319                Endoxan (EU name);Cytoxan (US name)               False  \n",
      "320                                     IMA901 Vaccine               False  \n",
      "321                                               Null                True  \n",
      "322                                               Null               False  \n",
      "323                                Bevespi Aeerosphere                True  \n",
      "324                                               Null                True  \n",
      "325                                          Ralinepag                True  \n",
      "\n",
      "[326 rows x 25 columns],      TWID            TWEET_ID  \\\n",
      "0    1124  884701927287685120   \n",
      "1    1132  882830764865449985   \n",
      "2    1146  881814116389838849   \n",
      "3    1146  881814116389838849   \n",
      "4    1146  881814116389838849   \n",
      "5    1150  880908414691536897   \n",
      "6    1150  880908414691536897   \n",
      "7    1151  880908410878918656   \n",
      "8    1154  880908409025036288   \n",
      "9    1160  880126147958382600   \n",
      "10   1163  879220946128842752   \n",
      "11   1163  879220946128842752   \n",
      "12   1163  879220946128842752   \n",
      "13   1177  877859844258119680   \n",
      "14   1179  877813897868091393   \n",
      "15   1179  877813897868091393   \n",
      "16   1188  877458307501367296   \n",
      "17   1190  877171367141146625   \n",
      "18   1190  877171367141146625   \n",
      "19   1190  877171367141146625   \n",
      "20   1190  877171367141146625   \n",
      "21   1190  877171367141146625   \n",
      "22   1190  877171367141146625   \n",
      "23   1190  877171367141146625   \n",
      "24   1190  877171367141146625   \n",
      "25   1190  877171367141146625   \n",
      "26   1195  877102212903817216   \n",
      "27   1195  877102212903817216   \n",
      "28   1204  876118964623081472   \n",
      "29   1204  876118964623081472   \n",
      "..    ...                 ...   \n",
      "296  1729  842009857871953925   \n",
      "297  1729  842009857871953925   \n",
      "298  1746  841241045291606018   \n",
      "299  1746  841241045291606018   \n",
      "300  1758  839436021083230208   \n",
      "301  1758  839436021083230208   \n",
      "302  1758  839436021083230208   \n",
      "303  1758  839436021083230208   \n",
      "304  1758  839436021083230208   \n",
      "305  1758  839436021083230208   \n",
      "306  1758  839436021083230208   \n",
      "307  1758  839436021083230208   \n",
      "308  1758  839436021083230208   \n",
      "309  1758  839436021083230208   \n",
      "310  1758  839436021083230208   \n",
      "311  1758  839436021083230208   \n",
      "312  1758  839436021083230208   \n",
      "313  1758  839436021083230208   \n",
      "314  1758  839436021083230208   \n",
      "315  1767  839014291336376321   \n",
      "316  1779  837264641591894016   \n",
      "317  1779  837264641591894016   \n",
      "318  1791  836468106637647872   \n",
      "319  1797  835101459641315328   \n",
      "320  1809  834378731099545601   \n",
      "321  1810  834377523949481984   \n",
      "322  1812  834377341425954816   \n",
      "323  1812  834377341425954816   \n",
      "324  1812  834377341425954816   \n",
      "325  1835  831850847394893824   \n",
      "\n",
      "                                                 TWEET               SYNONYMS  \\\n",
      "0    Prexton starts phase II trial of Foliglurax (P...               PXT-2331   \n",
      "1    Zydus's ZYAN-1 begins phase II trial for anemi...                 ZYAN-1   \n",
      "2    Zealand Pharma begins phase 3 trial of dasiglu...           DASIGLUCAGON   \n",
      "3    Zealand Pharma begins phase 3 trial of dasiglu...           DASIGLUCAGON   \n",
      "4    Zealand Pharma begins phase 3 trial of dasiglu...           DASIGLUCAGON   \n",
      "5    Myovant starts phase III trial of relugolix fo...              RELUGOLIX   \n",
      "6    Myovant starts phase III trial of relugolix fo...              RELUGOLIX   \n",
      "7    Pharmaleads' oral PL-265 shows promising safet...                 PL-265   \n",
      "8    CytomX's CX-2009 begins phase I/II trial for s...                CX-2009   \n",
      "9    Cellectis begins first in human phase I trial ...              UCART-123   \n",
      "10   Proteostasis Therapeutics files IND with FDA f...                PTI-808   \n",
      "11   Proteostasis Therapeutics files IND with FDA f...                PTI-808   \n",
      "12   Proteostasis Therapeutics files IND with FDA f...                PTI-808   \n",
      "13   Chi-Med's HMPL-453 begins phase I/II trial in ...               HMPL-453   \n",
      "14   ImmunoCellular suspends ICT-107 phase III tria...                ICT-107   \n",
      "15   ImmunoCellular suspends ICT-107 phase III tria...                ICT-107   \n",
      "16   Neurotech's NT-501 reduces progressive loss of...                 NT-501   \n",
      "17   Seattle Genetics stops treatment in all Vadast...  VADASTUXIMAB TALIRINE   \n",
      "18   Seattle Genetics stops treatment in all Vadast...  VADASTUXIMAB TALIRINE   \n",
      "19   Seattle Genetics stops treatment in all Vadast...  VADASTUXIMAB TALIRINE   \n",
      "20   Seattle Genetics stops treatment in all Vadast...           VADASTUXIMAB   \n",
      "21   Seattle Genetics stops treatment in all Vadast...           VADASTUXIMAB   \n",
      "22   Seattle Genetics stops treatment in all Vadast...           VADASTUXIMAB   \n",
      "23   Seattle Genetics stops treatment in all Vadast...               TALIRINE   \n",
      "24   Seattle Genetics stops treatment in all Vadast...               TALIRINE   \n",
      "25   Seattle Genetics stops treatment in all Vadast...               TALIRINE   \n",
      "26   US FDA approves Unum's ACTR-707 IND for B cell...              RITUXIMAB   \n",
      "27   US FDA approves Unum's ACTR-707 IND for B cell...              RITUXIMAB   \n",
      "28   Celgene's CC-220 shows promise in phase IIa tr...                 CC-220   \n",
      "29   Celgene's CC-220 shows promise in phase IIa tr...                 CC-220   \n",
      "..                                                 ...                    ...   \n",
      "296  MetrioPharm's MP-1032 shows efficacy and super...                MP-1032   \n",
      "297  MetrioPharm's MP-1032 shows efficacy and super...                MP-1032   \n",
      "298  TiGenix reports top-line phase I/II results of...              lloCSC-01   \n",
      "299  TiGenix reports top-line phase I/II results of...              lloCSC-01   \n",
      "300  US FDA clears Glenmark's IND for phase II tria...             TIOTROPIUM   \n",
      "301  US FDA clears Glenmark's IND for phase II tria...             TIOTROPIUM   \n",
      "302  US FDA clears Glenmark's IND for phase II tria...             TIOTROPIUM   \n",
      "303  US FDA clears Glenmark's IND for phase II tria...             TIOTROPIUM   \n",
      "304  US FDA clears Glenmark's IND for phase II tria...             TIOTROPIUM   \n",
      "305  US FDA clears Glenmark's IND for phase II tria...             TIOTROPIUM   \n",
      "306  US FDA clears Glenmark's IND for phase II tria...     TIOTROPIUM BROMIDE   \n",
      "307  US FDA clears Glenmark's IND for phase II tria...     TIOTROPIUM BROMIDE   \n",
      "308  US FDA clears Glenmark's IND for phase II tria...     TIOTROPIUM BROMIDE   \n",
      "309  US FDA clears Glenmark's IND for phase II tria...                BROMIDE   \n",
      "310  US FDA clears Glenmark's IND for phase II tria...                BROMIDE   \n",
      "311  US FDA clears Glenmark's IND for phase II tria...                BROMIDE   \n",
      "312  US FDA clears Glenmark's IND for phase II tria...                BROMIDE   \n",
      "313  US FDA clears Glenmark's IND for phase II tria...                BROMIDE   \n",
      "314  US FDA clears Glenmark's IND for phase II tria...                BROMIDE   \n",
      "315  US FDA approves IND for Advaxis and Amgen's pe...                   Null   \n",
      "316  Myovant starts phase III trial of relugolix fo...              RELUGOLIX   \n",
      "317  Myovant starts phase III trial of relugolix fo...              RELUGOLIX   \n",
      "318  La Jolla Pharma reports positive results from ...                 LA III   \n",
      "319  Rexahn's Supinoxin (RX-5902) starts phase IIa ...                RX-5902   \n",
      "320  Cidara terminates development of topical biafu...              BIAFUNGIN   \n",
      "321  Apitope 's ATX-MS-1467 shows promising efficac...            ATX-MS-1467   \n",
      "322  Lanthio's MOR-107 begins phase I trial in UK f...                MOR-107   \n",
      "323  Lanthio's MOR-107 begins phase I trial in UK f...                MOR-107   \n",
      "324  Lanthio's MOR-107 begins phase I trial in UK f...                MOR-107   \n",
      "325  Merck's Phase III trial of Verubecestat in Alz...           VERUBECESTAT   \n",
      "\n",
      "    MOLREGNO_1   ACRONYM       NCT_ID      PHASE  N_PHASES      OUTCOME  \\\n",
      "0    Not found      Null         Null    Phase 2         1  IN PROGRESS   \n",
      "1    Not found      Null         Null    Phase 2         1  IN PROGRESS   \n",
      "2         Null      Null  NCT03378635    Phase 3         2  IN PROGRESS   \n",
      "3         Null      Null  NCT03378635    Phase 3         2  IN PROGRESS   \n",
      "4         Null      Null  NCT03378635    Phase 3         2  IN PROGRESS   \n",
      "5      1161221      Null  NCT03412890    Phase 3         1  IN PROGRESS   \n",
      "6      1161221      Null  NCT03412890    Phase 3         1  IN PROGRESS   \n",
      "7    Not found      Null         Null    Phase 1         1      SUCCESS   \n",
      "8    Not found      Null  NCT03149549  Phase 1/2         1  IN PROGRESS   \n",
      "9    Not found      Null  NCT03203369    Phase 1         2  IN PROGRESS   \n",
      "10   Not found      Null  NCT03140527    Phase 1         1  IN PROGRESS   \n",
      "11   Not found      Null  NCT03140527    Phase 1         1  IN PROGRESS   \n",
      "12   Not found      Null  NCT03140527    Phase 1         1  IN PROGRESS   \n",
      "13   Not found      Null  NCT03160833  Phase 1/2         1  IN PROGRESS   \n",
      "14   Not found      Null  NCT02546102    Phase 3         1      STOPPED   \n",
      "15   Not found      Null  NCT02546102    Phase 3         1      STOPPED   \n",
      "16   Not found      Null  NCT01530659    Phase 2         1      SUCCESS   \n",
      "17     2197892      Null  NCT02706899    Phase 3         1         FAIL   \n",
      "18     2197892      Null  NCT02706899    Phase 3         1         FAIL   \n",
      "19     2197892      Null  NCT02706899    Phase 3         1         FAIL   \n",
      "20     2197895      Null  NCT02706899    Phase 3         1         FAIL   \n",
      "21     2197895      Null  NCT02706899    Phase 3         1         FAIL   \n",
      "22     2197895      Null  NCT02706899    Phase 3         1         FAIL   \n",
      "23     2197836      Null  NCT02706899    Phase 3         1         FAIL   \n",
      "24     2197836      Null  NCT02706899    Phase 3         1         FAIL   \n",
      "25     2197836      Null  NCT02706899    Phase 3         1         FAIL   \n",
      "26      675578      Null  NCT03361852    Phase 1         1      SUCCESS   \n",
      "27      675578      Null  NCT03361852    Phase 1         1      SUCCESS   \n",
      "28   Not found      Null  NCT03161483    Phase 2         1      SUCCESS   \n",
      "29   Not found      Null  NCT03161483    Phase 2         1      SUCCESS   \n",
      "..         ...       ...          ...        ...       ...          ...   \n",
      "296  Not found      Null  NCT02908347    Phase 2         1      SUCCESS   \n",
      "297  Not found      Null  NCT02908347    Phase 2         1      SUCCESS   \n",
      "298  Not found      Null  NCT02439398  Phase 1/2         1      SUCCESS   \n",
      "299  Not found      Null  NCT02439398  Phase 1/2         1      SUCCESS   \n",
      "300     675258      Null  NCT03395002    Phase 2         2  IN PROGRESS   \n",
      "301     675258      Null  NCT03395002    Phase 2         2  IN PROGRESS   \n",
      "302     675258      Null  NCT03395002    Phase 2         2  IN PROGRESS   \n",
      "303    1241099      Null  NCT03395002    Phase 2         2  IN PROGRESS   \n",
      "304    1241099      Null  NCT03395002    Phase 2         2  IN PROGRESS   \n",
      "305    1241099      Null  NCT03395002    Phase 2         2  IN PROGRESS   \n",
      "306    1927030      Null  NCT00565266    Phase 2         2  IN PROGRESS   \n",
      "307    1927030      Null  NCT00565266    Phase 2         2  IN PROGRESS   \n",
      "308    1927030      Null  NCT00565266    Phase 2         2  IN PROGRESS   \n",
      "309     693811      Null  NCT00565266    Phase 2         2  IN PROGRESS   \n",
      "310     693811      Null  NCT00565266    Phase 2         2  IN PROGRESS   \n",
      "311     693811      Null  NCT00565266    Phase 2         2  IN PROGRESS   \n",
      "312     308053      Null  NCT00565266    Phase 2         2  IN PROGRESS   \n",
      "313     308053      Null  NCT00565266    Phase 2         2  IN PROGRESS   \n",
      "314     308053      Null  NCT00565266    Phase 2         2  IN PROGRESS   \n",
      "315       Null  ADXS-NEO  NCT03265080       Null         0      SUCCESS   \n",
      "316    1161221      Null  NCT03412890    Phase 3         1  IN PROGRESS   \n",
      "317    1161221      Null  NCT03412890    Phase 3         1  IN PROGRESS   \n",
      "318        721      Null         Null    Phase 3         1      SUCCESS   \n",
      "319  Not found      Null  NCT02003092    Phase 2         2  IN PROGRESS   \n",
      "320       Null      Null         Null    Phase 2         2         FAIL   \n",
      "321  Not found      Null  NCT01973491    Phase 2         2      SUCCESS   \n",
      "322  Not found      Null  NCT03067363    Phase 1         1  IN PROGRESS   \n",
      "323  Not found      Null  NCT03067363    Phase 1         1  IN PROGRESS   \n",
      "324  Not found      Null  NCT03067363    Phase 1         1  IN PROGRESS   \n",
      "325    1763563      Null  NCT01739348    Phase 3         1         FAIL   \n",
      "\n",
      "            ...         COMPANY_SCORE                   INDICATION  \\\n",
      "0           ...                  Null  Secondary Parkinson Disease   \n",
      "1           ...                     1                       Anemia   \n",
      "2           ...                     1                 Hypoglycemia   \n",
      "3           ...                     1                 Hypoglycemia   \n",
      "4           ...                     1                 Hypoglycemia   \n",
      "5           ...                  Null                    Leiomyoma   \n",
      "6           ...                  Null                    Leiomyoma   \n",
      "7           ...                  Null             Neuropathic Pain   \n",
      "8           ...                     1                  Solid Tumor   \n",
      "9           ...                     1       Acute Myeloid Leukemia   \n",
      "10          ...                  Null              Cystic Fibrosis   \n",
      "11          ...                  Null              Cystic Fibrosis   \n",
      "12          ...                  Null              Cystic Fibrosis   \n",
      "13          ...                  Null                  Solid Tumor   \n",
      "14          ...                  Null                  Astrocytoma   \n",
      "15          ...                  Null                  Astrocytoma   \n",
      "16          ...                     1                     Glaucoma   \n",
      "17          ...                     1                         Null   \n",
      "18          ...                     1                         Null   \n",
      "19          ...                     1                         Null   \n",
      "20          ...                     1                         Null   \n",
      "21          ...                     1                         Null   \n",
      "22          ...                     1                         Null   \n",
      "23          ...                     1                         Null   \n",
      "24          ...                     1                         Null   \n",
      "25          ...                     1                         Null   \n",
      "26          ...                  Null                    Carcinoma   \n",
      "27          ...                  Null                    Carcinoma   \n",
      "28          ...                     1                         Null   \n",
      "29          ...                     1                         Null   \n",
      "..          ...                   ...                          ...   \n",
      "296         ...                     1                    Psoriasis   \n",
      "297         ...                     1                    Psoriasis   \n",
      "298         ...                     1        Myocardial Infarction   \n",
      "299         ...                     1        Myocardial Infarction   \n",
      "300         ...                     1                       Asthma   \n",
      "301         ...                     1                       Asthma   \n",
      "302         ...                     1                       Asthma   \n",
      "303         ...                     1                       Asthma   \n",
      "304         ...                     1                       Asthma   \n",
      "305         ...                     1                       Asthma   \n",
      "306         ...                     1                       Asthma   \n",
      "307         ...                     1                       Asthma   \n",
      "308         ...                     1                       Asthma   \n",
      "309         ...                     1                       Asthma   \n",
      "310         ...                     1                       Asthma   \n",
      "311         ...                     1                       Asthma   \n",
      "312         ...                     1                       Asthma   \n",
      "313         ...                     1                       Asthma   \n",
      "314         ...                     1                       Asthma   \n",
      "315         ...                     1                    Carcinoma   \n",
      "316         ...                  Null                    Leiomyoma   \n",
      "317         ...                  Null                    Leiomyoma   \n",
      "318         ...                     1                  Hypotension   \n",
      "319         ...                     1                  Solid Tumor   \n",
      "320         ...                     1                  Candidiasis   \n",
      "321         ...                  Null           Multiple Sclerosis   \n",
      "322         ...                  Null       Diabetic Nephropathies   \n",
      "323         ...                  Null       Diabetic Nephropathies   \n",
      "324         ...                  Null       Diabetic Nephropathies   \n",
      "325         ...                     1    Mild Cognitive Impairment   \n",
      "\n",
      "    INDICATION_ID INDICATION_NONAMBIG INDICATION_SCORE INTERVENTION_TYPE  \\\n",
      "0         D010302                   0                1              Null   \n",
      "1         D000740                   1                1              Null   \n",
      "2         D007003                   1                1              Drug   \n",
      "3         D007003                   1                1              Drug   \n",
      "4         D007003                   1                1              Drug   \n",
      "5         D007889                   1                1              Drug   \n",
      "6         D007889                   1                1              Drug   \n",
      "7         DX90161                   1                1              Null   \n",
      "8         SDI0034                   1                1              Drug   \n",
      "9         D015470                   1                1        Biological   \n",
      "10        D003550                   1                1              Drug   \n",
      "11        D003550                   1                1              Drug   \n",
      "12        D003550                   1                1              Drug   \n",
      "13        SDI0034                   1                1              Drug   \n",
      "14        D001254                   1                1        Biological   \n",
      "15        D001254                   1                1        Biological   \n",
      "16        D005901                   1                1              Drug   \n",
      "17           Null                Null             Null              Drug   \n",
      "18           Null                Null             Null              Drug   \n",
      "19           Null                Null             Null              Drug   \n",
      "20           Null                Null             Null              Drug   \n",
      "21           Null                Null             Null              Drug   \n",
      "22           Null                Null             Null              Drug   \n",
      "23           Null                Null             Null              Drug   \n",
      "24           Null                Null             Null              Drug   \n",
      "25           Null                Null             Null              Drug   \n",
      "26        D002277                   1                1              Drug   \n",
      "27        D002277                   1                1        Biological   \n",
      "28           Null                Null             Null              Drug   \n",
      "29           Null                Null             Null              Drug   \n",
      "..            ...                 ...              ...               ...   \n",
      "296       D011565                   1                1              Drug   \n",
      "297       D011565                   1                1              Drug   \n",
      "298       D009203                   1                1             Other   \n",
      "299       D009203                   1                1        Biological   \n",
      "300       D001249                   1                1              Drug   \n",
      "301       D001249                   1                1              Drug   \n",
      "302       D001249                   1                1              Drug   \n",
      "303       D001249                   1                1              Drug   \n",
      "304       D001249                   1                1              Drug   \n",
      "305       D001249                   1                1              Drug   \n",
      "306       D001249                   1                1              Drug   \n",
      "307       D001249                   1                1              Drug   \n",
      "308       D001249                   1                1              Drug   \n",
      "309       D001249                   1                1              Drug   \n",
      "310       D001249                   1                1              Drug   \n",
      "311       D001249                   1                1              Drug   \n",
      "312       D001249                   1                1              Drug   \n",
      "313       D001249                   1                1              Drug   \n",
      "314       D001249                   1                1              Drug   \n",
      "315       D002277                   1                1        Biological   \n",
      "316       D007889                   1                1              Drug   \n",
      "317       D007889                   1                1              Drug   \n",
      "318       D007022                   1                1              Null   \n",
      "319       SDI0034                   1                1              Drug   \n",
      "320       D002177                   1                1              Null   \n",
      "321       D009103                   1                1              Drug   \n",
      "322       D003928                   1                1              Drug   \n",
      "323       D003928                   1                1              Drug   \n",
      "324       D003928                   1                1             Other   \n",
      "325       D060825                   1                1              Drug   \n",
      "\n",
      "                                     INTERVENTION_NAME  \\\n",
      "0                                                 Null   \n",
      "1                                                 Null   \n",
      "2                                         Dasiglucagon   \n",
      "3                                             GlucaGen   \n",
      "4                                              Placebo   \n",
      "5                           Low-Dose Hormonal Add-Back   \n",
      "6                                            Relugolix   \n",
      "7                                                 Null   \n",
      "8                                              CX-2009   \n",
      "9                                             UCART123   \n",
      "10                                             PTI-801   \n",
      "11                                             Placebo   \n",
      "12                                             PTI-808   \n",
      "13                                            HMPL-453   \n",
      "14                                             ICT-107   \n",
      "15                                             Placebo   \n",
      "16                                              NT-501   \n",
      "17                               vadastuximab talirine   \n",
      "18                                         Azacitidine   \n",
      "19                                   Placebo (for 33A)   \n",
      "20                               vadastuximab talirine   \n",
      "21                                         Azacitidine   \n",
      "22                                   Placebo (for 33A)   \n",
      "23                               vadastuximab talirine   \n",
      "24                                         Azacitidine   \n",
      "25                                   Placebo (for 33A)   \n",
      "26                                           Rituximab   \n",
      "27                                             Neo Vax   \n",
      "28                                              CC-220   \n",
      "29                                              CC-220   \n",
      "..                                                 ...   \n",
      "296                                            Placebo   \n",
      "297                                             MP1032   \n",
      "298                         Human Serum Albumin-HSA 5%   \n",
      "299         Allogeneic human cardiac stem cells (CSCs)   \n",
      "300  Tiotropium/Salmeterol/Fluticasone 9/50/500 mcg...   \n",
      "301                Tiotropium 18 mcg Inhalation Powder   \n",
      "302  Salmeterol/Fluticasone 50/500 mcg Inhalation P...   \n",
      "303  Tiotropium/Salmeterol/Fluticasone 9/50/500 mcg...   \n",
      "304                Tiotropium 18 mcg Inhalation Powder   \n",
      "305  Salmeterol/Fluticasone 50/500 mcg Inhalation P...   \n",
      "306                                 tiotropium bromide   \n",
      "307                               salmeterol xinafoate   \n",
      "308                        beclomethasone dipropionate   \n",
      "309                                 tiotropium bromide   \n",
      "310                               salmeterol xinafoate   \n",
      "311                        beclomethasone dipropionate   \n",
      "312                                 tiotropium bromide   \n",
      "313                               salmeterol xinafoate   \n",
      "314                        beclomethasone dipropionate   \n",
      "315                                           ADXS-NEO   \n",
      "316                         Low-Dose Hormonal Add-Back   \n",
      "317                                          Relugolix   \n",
      "318                                               Null   \n",
      "319                                            RX-5902   \n",
      "320                                               Null   \n",
      "321                                        ATX-MS-1467   \n",
      "322                                             MOR107   \n",
      "323                                            Placebo   \n",
      "324                                    Low sodium diet   \n",
      "325                  Verubecestat (Part I and Part II)   \n",
      "\n",
      "                                          DESCRIPTIONS  \\\n",
      "0                                                 Null   \n",
      "1                                                 Null   \n",
      "2                                      Glucagon analog   \n",
      "3                                      Native glucagon   \n",
      "4                             Placebo for dasiglucagon   \n",
      "5    Over-encapsulated estradiol 1.0 mg and norethi...   \n",
      "6    Relugolix 40 mg tablet administered orally onc...   \n",
      "7                                                 Null   \n",
      "8                                  CX-2009 Monotherapy   \n",
      "9    Allogeneic engineered T-cells expressing anti-...   \n",
      "10                                              Active   \n",
      "11                                             Placebo   \n",
      "12                                              Active   \n",
      "13                                 oral administrative   \n",
      "14   Autologous dendritic cells pulsed with peptide...   \n",
      "15                                                Null   \n",
      "16   Study participants will undergo surgery to hav...   \n",
      "17                                                Null   \n",
      "18   azacitidine 75 mg/m2 given intravenously or su...   \n",
      "19   Placebo supplied in single-use vials matching 33A   \n",
      "20                                                Null   \n",
      "21   azacitidine 75 mg/m2 given intravenously or su...   \n",
      "22   Placebo supplied in single-use vials matching 33A   \n",
      "23                                                Null   \n",
      "24   azacitidine 75 mg/m2 given intravenously or su...   \n",
      "25   Placebo supplied in single-use vials matching 33A   \n",
      "26   Rituximab is classified as a monoclonal antibo...   \n",
      "27   Neo Vax is an experimental \"viral mimic\" and a...   \n",
      "28                                       0.45 mg QD PO   \n",
      "29                                        0.3 mg QD PO   \n",
      "..                                                 ...   \n",
      "296   hard gelatine capsules without active ingredient   \n",
      "297  hard gelatine capsules containing 50mg MP1032 ...   \n",
      "298  Human Serum Albumin (HSA) is a well-known phys...   \n",
      "299  Allogeneic human CSCs is a new cell medicine b...   \n",
      "300  Tiotropium/Salmeterol/Fluticasone 9/50/500 mcg...   \n",
      "301  Tiotropium 18 mcg Inhalation Powder (1 puff) o...   \n",
      "302  Salmeterol/Fluticasone 50/500 mcg Inhalation P...   \n",
      "303  Tiotropium/Salmeterol/Fluticasone 9/50/500 mcg...   \n",
      "304  Tiotropium 18 mcg Inhalation Powder (1 puff) o...   \n",
      "305  Salmeterol/Fluticasone 50/500 mcg Inhalation P...   \n",
      "306  tiotropium bromide inhalation powder 18 mcg on...   \n",
      "307  salmeterol xinafoate inhalation powder 50 mcg ...   \n",
      "308  beclomethasone dipropionate 80 mcg twice daily...   \n",
      "309  tiotropium bromide inhalation powder 18 mcg on...   \n",
      "310  salmeterol xinafoate inhalation powder 50 mcg ...   \n",
      "311  beclomethasone dipropionate 80 mcg twice daily...   \n",
      "312  tiotropium bromide inhalation powder 18 mcg on...   \n",
      "313  salmeterol xinafoate inhalation powder 50 mcg ...   \n",
      "314  beclomethasone dipropionate 80 mcg twice daily...   \n",
      "315  Biopsy, blood draws, CT scans, trial product a...   \n",
      "316  Over-encapsulated estradiol 1.0 mg and norethi...   \n",
      "317  Relugolix 40 mg tablet administered orally onc...   \n",
      "318                                               Null   \n",
      "319                              escalating doses (mg)   \n",
      "320                                               Null   \n",
      "321  Subjects will receive ATX-MS-1467 50 microgram...   \n",
      "322                      MOR107 solution for injection   \n",
      "323  Solution for injection manufactured to match M...   \n",
      "324  Diet designed to restrict sodium intake to 40 ...   \n",
      "325  Single 12 mg verubecestat tablet once daily, t...   \n",
      "\n",
      "                                     OTHER_NAME INDIC_INTERVENTIONS  \n",
      "0                                          Null               False  \n",
      "1                                          Null               False  \n",
      "2                                        ZP4207                True  \n",
      "3                              GlucaGen HypoKit               False  \n",
      "4                      Placebo for dasiglucagon                True  \n",
      "5                                          Null               False  \n",
      "6                                          Null                True  \n",
      "7                                          Null               False  \n",
      "8                                          Null                True  \n",
      "9                                          Null                True  \n",
      "10                                         Null               False  \n",
      "11                                         Null               False  \n",
      "12                                         Null                True  \n",
      "13                                         Null                True  \n",
      "14                                         Null                True  \n",
      "15                                         Null               False  \n",
      "16         CNTF, Encapsulated Cell Therapy, ECT                True  \n",
      "17                                33A;SGN-CD33A                True  \n",
      "18                                         Null               False  \n",
      "19                                         Null               False  \n",
      "20                                33A;SGN-CD33A                True  \n",
      "21                                         Null               False  \n",
      "22                                         Null               False  \n",
      "23                                33A;SGN-CD33A                True  \n",
      "24                                         Null               False  \n",
      "25                                         Null               False  \n",
      "26                                      Rituxan                True  \n",
      "27                                         Null               False  \n",
      "28                                         Null                True  \n",
      "29                                         Null                True  \n",
      "..                                          ...                 ...  \n",
      "296                                        Null               False  \n",
      "297                                        Null                True  \n",
      "298                                        Null               False  \n",
      "299                                  AlloCSC-01                True  \n",
      "300       Saltif 9/50/500 mcg Inhalation Powder                True  \n",
      "301            Spiriva 18 mcg Inhalation Powder                True  \n",
      "302  Seretide Diskus® 500 mcg Inhalation Powder               False  \n",
      "303       Saltif 9/50/500 mcg Inhalation Powder                True  \n",
      "304            Spiriva 18 mcg Inhalation Powder                True  \n",
      "305  Seretide Diskus® 500 mcg Inhalation Powder               False  \n",
      "306                        SPIRIVA® HandiHaler®                True  \n",
      "307                           Serevent® Diskus®               False  \n",
      "308                    QVAR® Inhalation Aerosol               False  \n",
      "309                        SPIRIVA® HandiHaler®                True  \n",
      "310                           Serevent® Diskus®               False  \n",
      "311                    QVAR® Inhalation Aerosol               False  \n",
      "312                        SPIRIVA® HandiHaler®                True  \n",
      "313                           Serevent® Diskus®               False  \n",
      "314                    QVAR® Inhalation Aerosol               False  \n",
      "315                                        Null                True  \n",
      "316                                        Null               False  \n",
      "317                                        Null                True  \n",
      "318                                        Null               False  \n",
      "319                                  Supinoxin™                True  \n",
      "320                                        Null               False  \n",
      "321                         M2736;IL-10 Inducer                True  \n",
      "322                                       LP2-3                True  \n",
      "323                        Placebo (for MOR107)                True  \n",
      "324                                        Null               False  \n",
      "325                                  SCH 900931                True  \n",
      "\n",
      "[326 rows x 25 columns],      TWID            TWEET_ID  \\\n",
      "0    1835  831850847394893824   \n",
      "1    1835  831850847394893824   \n",
      "2    1835  831850847394893824   \n",
      "3    1835  831850847394893824   \n",
      "4    1839  831476861049794560   \n",
      "5    1839  831476861049794560   \n",
      "6    1839  831476861049794560   \n",
      "7    1839  831476861049794560   \n",
      "8    1839  831476861049794560   \n",
      "9    1839  831476861049794560   \n",
      "10   1839  831476861049794560   \n",
      "11   1839  831476861049794560   \n",
      "12   1839  831476861049794560   \n",
      "13   1839  831476861049794560   \n",
      "14   1842  831448836136542209   \n",
      "15   1842  831448836136542209   \n",
      "16   1843  831448626115153920   \n",
      "17   1849  831081133156626432   \n",
      "18   1852  830028668428709889   \n",
      "19   1852  830028668428709889   \n",
      "20   1852  830028668428709889   \n",
      "21   1857  829289877908946947   \n",
      "22   1868  828554139382657024   \n",
      "23   1868  828554139382657024   \n",
      "24   1868  828554139382657024   \n",
      "25   1868  828554139382657024   \n",
      "26   1868  828554139382657024   \n",
      "27   1868  828554139382657024   \n",
      "28   1868  828554139382657024   \n",
      "29   1868  828554139382657024   \n",
      "..    ...                 ...   \n",
      "297  2228  798355129963454464   \n",
      "298  2243  798105296346357760   \n",
      "299  2243  798105296346357760   \n",
      "300  2243  798105296346357760   \n",
      "301  2243  798105296346357760   \n",
      "302  2243  798105296346357760   \n",
      "303  2243  798105296346357760   \n",
      "304  2255  797985266065547264   \n",
      "305  2255  797985266065547264   \n",
      "306  2255  797985266065547264   \n",
      "307  2261  797887760879206400   \n",
      "308  2261  797887760879206400   \n",
      "309  2261  797887760879206400   \n",
      "310  2261  797887760879206400   \n",
      "311  2268  797619869407555584   \n",
      "312  2268  797619869407555584   \n",
      "313  2275  797149141289799680   \n",
      "314  2285  796300705724104705   \n",
      "315  2285  796300705724104705   \n",
      "316  2285  796300705724104705   \n",
      "317  2288  795962947423989760   \n",
      "318  2288  795962947423989760   \n",
      "319  2290  795946492083044352   \n",
      "320  2304  794105763002191872   \n",
      "321  2304  794105763002191872   \n",
      "322  2306  793805257503453184   \n",
      "323  2306  793805257503453184   \n",
      "324  2306  793805257503453184   \n",
      "325  2306  793805257503453184   \n",
      "326  2308  793755656234729472   \n",
      "\n",
      "                                                 TWEET       SYNONYMS  \\\n",
      "0    Merck's Phase III trial of Verubecestat in Alz...   VERUBECESTAT   \n",
      "1    Merck's Phase III trial of Verubecestat in Alz...   VERUBECESTAT   \n",
      "2    Merck's Phase III trial of Verubecestat in Alz...   VERUBECESTAT   \n",
      "3    Merck's Phase III trial of Verubecestat in Alz...   VERUBECESTAT   \n",
      "4    Vernalis earns $3M fee from Corvus triggered b...        CPI-444   \n",
      "5    Vernalis earns $3M fee from Corvus triggered b...        CPI-444   \n",
      "6    Vernalis earns $3M fee from Corvus triggered b...        CPI-444   \n",
      "7    Vernalis earns $3M fee from Corvus triggered b...        CPI-444   \n",
      "8    Vernalis earns $3M fee from Corvus triggered b...        CPI-444   \n",
      "9    Vernalis earns $3M fee from Corvus triggered b...        CPI-444   \n",
      "10   Vernalis earns $3M fee from Corvus triggered b...        CPI-444   \n",
      "11   Vernalis earns $3M fee from Corvus triggered b...        CPI-444   \n",
      "12   Vernalis earns $3M fee from Corvus triggered b...        CPI-444   \n",
      "13   Vernalis earns $3M fee from Corvus triggered b...        CPI-444   \n",
      "14   Aviragen's vapendavir fails to meet primary ef...     VAPENDAVIR   \n",
      "15   Aviragen's vapendavir fails to meet primary ef...     VAPENDAVIR   \n",
      "16   Zosano's M-207 (zolmitriptan) well tolerated &...   ZOLMITRIPTAN   \n",
      "17   PhytoTech Therapeutics begins phase II trial o...        PTL-101   \n",
      "18   US FDA approves Emflaza (deflazacort) for the ...        EMFLAZA   \n",
      "19   US FDA approves Emflaza (deflazacort) for the ...    DEFLAZACORT   \n",
      "20   US FDA approves Emflaza (deflazacort) for the ...    DEFLAZACORT   \n",
      "21   Vyome's VB-1953 well tolerated and meets pharm...        VB-1953   \n",
      "22   Innate Pharma's lirilumab fails to meet the pr...      LIRILUMAB   \n",
      "23   Innate Pharma's lirilumab fails to meet the pr...      LIRILUMAB   \n",
      "24   Innate Pharma's lirilumab fails to meet the pr...      LIRILUMAB   \n",
      "25   Innate Pharma's lirilumab fails to meet the pr...      LIRILUMAB   \n",
      "26   Innate Pharma's lirilumab fails to meet the pr...      LIRILUMAB   \n",
      "27   Innate Pharma's lirilumab fails to meet the pr...      LIRILUMAB   \n",
      "28   Innate Pharma's lirilumab fails to meet the pr...      LIRILUMAB   \n",
      "29   Innate Pharma's lirilumab fails to meet the pr...      LIRILUMAB   \n",
      "..                                                 ...            ...   \n",
      "297  In phase I trial humanized chimeric antibody a...         a2AP-I   \n",
      "298  Camurus and Braeburn's long-acting buprenorphi...  BUPRENORPHINE   \n",
      "299  Camurus and Braeburn's long-acting buprenorphi...  BUPRENORPHINE   \n",
      "300  Camurus and Braeburn's long-acting buprenorphi...  BUPRENORPHINE   \n",
      "301  Camurus and Braeburn's long-acting buprenorphi...  BUPRENORPHINE   \n",
      "302  Camurus and Braeburn's long-acting buprenorphi...  BUPRENORPHINE   \n",
      "303  Camurus and Braeburn's long-acting buprenorphi...  BUPRENORPHINE   \n",
      "304  BMS-986165 shows good results for SLE and IBD ...     BMS-986165   \n",
      "305  BMS-986165 shows good results for SLE and IBD ...     BMS-986165   \n",
      "306  BMS-986165 shows good results for SLE and IBD ...     BMS-986165   \n",
      "307  No added advantage from rifaximin over lactulo...      LACTULOSE   \n",
      "308  No added advantage from rifaximin over lactulo...      LACTULOSE   \n",
      "309  No added advantage from rifaximin over lactulo...      RIFAXIMIN   \n",
      "310  No added advantage from rifaximin over lactulo...      RIFAXIMIN   \n",
      "311  Exenatide shows feasibility in more than 90% o...      EXENATIDE   \n",
      "312  Exenatide shows feasibility in more than 90% o...      EXENATIDE   \n",
      "313  PPIs (pantoprazol) reduce significantly the ne...    PANTOPRAZOL   \n",
      "314  US FDA places verbal clinical hold on BioInven...         BI-505   \n",
      "315  US FDA places verbal clinical hold on BioInven...         BI-505   \n",
      "316  US FDA places verbal clinical hold on BioInven...         BI-505   \n",
      "317  Opexa reduces 40% workforce following negative...         TCELNA   \n",
      "318  Opexa reduces 40% workforce following negative...         TCELNA   \n",
      "319  The Medicines Company discontinues development...    CHOLESTEROL   \n",
      "320  Phase I pharmacokinetic safety and immunogenic...      ABATACEPT   \n",
      "321  Phase I pharmacokinetic safety and immunogenic...      ABATACEPT   \n",
      "322  Gilead's GS-0976 (allosteric ACC inhibitor for...        GS-0976   \n",
      "323  Gilead's GS-0976 (allosteric ACC inhibitor for...        GS-0976   \n",
      "324  Gilead's GS-0976 (allosteric ACC inhibitor for...        GS-0976   \n",
      "325  Gilead's GS-0976 (allosteric ACC inhibitor for...        GS-0976   \n",
      "326  Palatin's bremelanotide meets coprimary effica...  BREMELANOTIDE   \n",
      "\n",
      "    MOLREGNO_1 ACRONYM       NCT_ID    PHASE  N_PHASES      OUTCOME  \\\n",
      "0      1763563    Null  NCT01739348  Phase 3         1         FAIL   \n",
      "1      1763563    Null  NCT01739348  Phase 3         1         FAIL   \n",
      "2      1763563    Null  NCT01739348  Phase 3         1         FAIL   \n",
      "3      1763563    Null  NCT01739348  Phase 3         1         FAIL   \n",
      "4    Not found    Null  NCT03337698     Null         2      SUCCESS   \n",
      "5    Not found    Null  NCT03337698     Null         2      SUCCESS   \n",
      "6    Not found    Null  NCT03337698     Null         2      SUCCESS   \n",
      "7    Not found    Null  NCT03337698     Null         2      SUCCESS   \n",
      "8    Not found    Null  NCT03337698     Null         2      SUCCESS   \n",
      "9    Not found    Null  NCT03337698     Null         2      SUCCESS   \n",
      "10   Not found    Null  NCT03337698     Null         2      SUCCESS   \n",
      "11   Not found    Null  NCT03337698     Null         2      SUCCESS   \n",
      "12   Not found    Null  NCT03337698     Null         2      SUCCESS   \n",
      "13   Not found    Null  NCT03337698     Null         2      SUCCESS   \n",
      "14        Null    Null  NCT03024177  Phase 2         1         FAIL   \n",
      "15        Null    Null  NCT03024177  Phase 2         1         FAIL   \n",
      "16      196215    Null  NCT02905227  Phase 1         1      SUCCESS   \n",
      "17   Not found    Null         Null  Phase 2         2  IN PROGRESS   \n",
      "18      675842    Null         Null     Null         0      SUCCESS   \n",
      "19      675842    Null  NCT02286635     Null         0      SUCCESS   \n",
      "20      675842    Null  NCT02286635     Null         0      SUCCESS   \n",
      "21   Not found    Null         Null  Phase 1         1      SUCCESS   \n",
      "22     1381940    Null  NCT02813135  Phase 2         1         FAIL   \n",
      "23     1381940    Null  NCT02813135  Phase 2         1         FAIL   \n",
      "24     1381940    Null  NCT02813135  Phase 2         1         FAIL   \n",
      "25     1381940    Null  NCT02813135  Phase 2         1         FAIL   \n",
      "26     1381940    Null  NCT02813135  Phase 2         1         FAIL   \n",
      "27     1381940    Null  NCT02813135  Phase 2         1         FAIL   \n",
      "28     1381940    Null  NCT02813135  Phase 2         1         FAIL   \n",
      "29     1381940    Null  NCT02813135  Phase 2         1         FAIL   \n",
      "..         ...     ...          ...      ...       ...          ...   \n",
      "297  Not found    Null         Null  Phase 1         1          N/I   \n",
      "298     556608    Null  NCT03026790  Phase 3         2      SUCCESS   \n",
      "299     556608    Null  NCT03026790  Phase 3         2      SUCCESS   \n",
      "300     556608    Null  NCT03026790  Phase 3         2      SUCCESS   \n",
      "301     446784    Null  NCT03026790  Phase 3         2      SUCCESS   \n",
      "302     446784    Null  NCT03026790  Phase 3         2      SUCCESS   \n",
      "303     446784    Null  NCT03026790  Phase 3         2      SUCCESS   \n",
      "304  Not found    Null  NCT03402087  Phase 2         1      SUCCESS   \n",
      "305  Not found    Null  NCT03402087  Phase 2         1      SUCCESS   \n",
      "306  Not found    Null  NCT03402087  Phase 2         1      SUCCESS   \n",
      "307     699419    Null  NCT03148002     Null         0          N/I   \n",
      "308     699419    Null  NCT03148002     Null         0          N/I   \n",
      "309     466768    Null  NCT03069131     Null         0          N/I   \n",
      "310     466768    Null  NCT03069131     Null         0          N/I   \n",
      "311     390990    Null  NCT03017352     Null         2      SUCCESS   \n",
      "312     390990    Null  NCT03017352     Null         2      SUCCESS   \n",
      "313       Null    Null  NCT01179646     Null         1          N/I   \n",
      "314  Not found    Null  NCT02756728  Phase 2         1      STOPPED   \n",
      "315  Not found    Null  NCT02756728  Phase 2         1      STOPPED   \n",
      "316  Not found    Null  NCT02756728  Phase 2         1      STOPPED   \n",
      "317    1449231    Null  NCT01684761  Phase 2         1         FAIL   \n",
      "318    1449231    Null  NCT01684761  Phase 2         1         FAIL   \n",
      "319     182921    Null  NCT00272844  Phase 2         1         FAIL   \n",
      "320     675774    Null  NCT00442611  Phase 1         1  IN PROGRESS   \n",
      "321     675774    Null  NCT00442611  Phase 1         1  IN PROGRESS   \n",
      "322  Not found    NASH  NCT02781584  Phase 2         2      SUCCESS   \n",
      "323  Not found    NASH  NCT02781584  Phase 2         2      SUCCESS   \n",
      "324  Not found    NASH  NCT02781584  Phase 2         2      SUCCESS   \n",
      "325  Not found    NASH  NCT02781584  Phase 2         2      SUCCESS   \n",
      "326    1360388    Null  NCT02338960  Phase 3         1      SUCCESS   \n",
      "\n",
      "            ...         COMPANY_SCORE                         INDICATION  \\\n",
      "0           ...                     1          Mild Cognitive Impairment   \n",
      "1           ...                     1          Mild Cognitive Impairment   \n",
      "2           ...                     1          Mild Cognitive Impairment   \n",
      "3           ...                     1          Mild Cognitive Impairment   \n",
      "4           ...                     1               Renal Cell Carcinoma   \n",
      "5           ...                     1               Renal Cell Carcinoma   \n",
      "6           ...                     1               Renal Cell Carcinoma   \n",
      "7           ...                     1               Renal Cell Carcinoma   \n",
      "8           ...                     1               Renal Cell Carcinoma   \n",
      "9           ...                     1               Renal Cell Carcinoma   \n",
      "10          ...                     1               Renal Cell Carcinoma   \n",
      "11          ...                     1               Renal Cell Carcinoma   \n",
      "12          ...                     1               Renal Cell Carcinoma   \n",
      "13          ...                     1               Renal Cell Carcinoma   \n",
      "14          ...                  Null       Respiratory Tract Infections   \n",
      "15          ...                  Null       Respiratory Tract Infections   \n",
      "16          ...                     1                 Vascular Headaches   \n",
      "17          ...                  Null                           Epilepsy   \n",
      "18          ...                  Null        Duchenne Muscular Dystrophy   \n",
      "19          ...                  Null        Duchenne Muscular Dystrophy   \n",
      "20          ...                  Null        Duchenne Muscular Dystrophy   \n",
      "21          ...                  Null                      Acne Vulgaris   \n",
      "22          ...                     1                          Carcinoma   \n",
      "23          ...                     1                          Carcinoma   \n",
      "24          ...                     1                          Carcinoma   \n",
      "25          ...                     1                          Carcinoma   \n",
      "26          ...                     1                          Carcinoma   \n",
      "27          ...                     1                          Carcinoma   \n",
      "28          ...                     1                          Carcinoma   \n",
      "29          ...                     1                          Carcinoma   \n",
      "..          ...                   ...                                ...   \n",
      "297         ...                  Null                               Null   \n",
      "298         ...                     1                       Chronic Pain   \n",
      "299         ...                     1                       Chronic Pain   \n",
      "300         ...                     1                       Chronic Pain   \n",
      "301         ...                     1                       Chronic Pain   \n",
      "302         ...                     1                       Chronic Pain   \n",
      "303         ...                     1                       Chronic Pain   \n",
      "304         ...                  Null                               Null   \n",
      "305         ...                  Null                               Null   \n",
      "306         ...                  Null                               Null   \n",
      "307         ...                  Null           Irritable Bowel Syndrome   \n",
      "308         ...                  Null           Irritable Bowel Syndrome   \n",
      "309         ...                  Null           Irritable Bowel Syndrome   \n",
      "310         ...                  Null           Irritable Bowel Syndrome   \n",
      "311         ...                  Null                       Hypoglycemia   \n",
      "312         ...                  Null                       Hypoglycemia   \n",
      "313         ...                  Null                    Hemochromatosis   \n",
      "314         ...                     1                   Multiple Myeloma   \n",
      "315         ...                     1                   Multiple Myeloma   \n",
      "316         ...                     1                   Multiple Myeloma   \n",
      "317         ...                     1                            Atrophy   \n",
      "318         ...                     1                            Atrophy   \n",
      "319         ...                     1                               Null   \n",
      "320         ...                     1                 Sjogren's Syndrome   \n",
      "321         ...                     1                 Sjogren's Syndrome   \n",
      "322         ...                     1                               Null   \n",
      "323         ...                     1                               Null   \n",
      "324         ...                     1                               Null   \n",
      "325         ...                     1                               Null   \n",
      "326         ...                  Null  Hypoactive sexual desire disorder   \n",
      "\n",
      "    INDICATION_ID INDICATION_NONAMBIG INDICATION_SCORE INTERVENTION_TYPE  \\\n",
      "0         D060825                   1                1              Drug   \n",
      "1         D060825                   1                1              Drug   \n",
      "2         D060825                   1                1              Drug   \n",
      "3         D060825                   1                1              Drug   \n",
      "4         D002292                   1                1              Drug   \n",
      "5         D002292                   1                1              Drug   \n",
      "6         D002292                   1                1              Drug   \n",
      "7         D002292                   1                1              Drug   \n",
      "8         D002292                   1                1              Drug   \n",
      "9         D002292                   1                1              Drug   \n",
      "10        D002292                   1                1              Drug   \n",
      "11        D002292                   1                1              Drug   \n",
      "12        D002292                   1                1              Drug   \n",
      "13        D002292                   1                1              Drug   \n",
      "14        D012141                   1                1              Drug   \n",
      "15        D012141                   1                1              Drug   \n",
      "16        D014653                   1                1              Drug   \n",
      "17        D004827                   1                1              Null   \n",
      "18        D020388                   1                1              Null   \n",
      "19        D020388                   1                1              Drug   \n",
      "20        D020388                   1                1              Drug   \n",
      "21        D000152                   1                1              Null   \n",
      "22        D002277                   1                1              Drug   \n",
      "23        D002277                   1                1              Drug   \n",
      "24        D002277                   1                1              Drug   \n",
      "25        D002277                   1                1              Drug   \n",
      "26        D002277                   1                1              Drug   \n",
      "27        D002277                   1                1              Drug   \n",
      "28        D002277                   1                1              Drug   \n",
      "29        D002277                   1                1              Drug   \n",
      "..            ...                 ...              ...               ...   \n",
      "297          Null                Null             Null              Null   \n",
      "298       D059350                   1                1             Other   \n",
      "299       D059350                   1                1             Other   \n",
      "300       D059350                   1                1              Drug   \n",
      "301       D059350                   1                1             Other   \n",
      "302       D059350                   1                1             Other   \n",
      "303       D059350                   1                1              Drug   \n",
      "304          Null                Null             Null              Drug   \n",
      "305          Null                Null             Null              Drug   \n",
      "306          Null                Null             Null              Drug   \n",
      "307       D043183                   1                1              Drug   \n",
      "308       D043183                   1                1              Drug   \n",
      "309       D043183                   1                1              Drug   \n",
      "310       D043183                   1                1             Other   \n",
      "311       D007003                   1                1              Drug   \n",
      "312       D007003                   1                1              Drug   \n",
      "313       D006432                   1                1              Drug   \n",
      "314       D009101                   1                1        Biological   \n",
      "315       D009101                   1                1             Other   \n",
      "316       D009101                   1                1             Other   \n",
      "317       D001284                   1                1        Biological   \n",
      "318       D001284                   1                1        Biological   \n",
      "319          Null                Null             Null              Drug   \n",
      "320       D012859                   1                1              Drug   \n",
      "321       D012859                   1                1              Drug   \n",
      "322          Null                Null             Null              Drug   \n",
      "323          Null                Null             Null              Drug   \n",
      "324          Null                Null             Null              Drug   \n",
      "325          Null                Null             Null              Drug   \n",
      "326       SDI0266                   1                1              Drug   \n",
      "\n",
      "                                     INTERVENTION_NAME  \\\n",
      "0                    Verubecestat (Part I and Part II)   \n",
      "1                    Verubecestat (Part I and Part II)   \n",
      "2                                     Placebo (Part I)   \n",
      "3                               Verubecestat (Part II)   \n",
      "4                                            Docetaxel   \n",
      "5                                           Pemetrexed   \n",
      "6                                          Carboplatin   \n",
      "7                                          Gemcitabine   \n",
      "8                                         Atezolizumab   \n",
      "9                                          Cobimetinib   \n",
      "10                                           RO6958688   \n",
      "11                                             BL-8040   \n",
      "12                                        Tazemetostat   \n",
      "13                                             CPI-444   \n",
      "14                                          Vapendavir   \n",
      "15                                 Placebo Oral Tablet   \n",
      "16            CVT-427 (zolmitriptan inhalation powder)   \n",
      "17                                                Null   \n",
      "18                                                Null   \n",
      "19                      Deflazacort and Clarithromycin   \n",
      "20                            Deflazacort and rifampin   \n",
      "21                                                Null   \n",
      "22                                          Ribociclib   \n",
      "23                                           Topotecan   \n",
      "24                                        Temozolomide   \n",
      "25                                          Everolimus   \n",
      "26                                             AZD1775   \n",
      "27                                         Carboplatin   \n",
      "28                                            Olaparib   \n",
      "29                                          Irinotecan   \n",
      "..                                                 ...   \n",
      "297                                               Null   \n",
      "298                              Medication management   \n",
      "299                Non-pharmacological pain management   \n",
      "300                             Buprenorphine-Naloxone   \n",
      "301                              Medication management   \n",
      "302                Non-pharmacological pain management   \n",
      "303                             Buprenorphine-Naloxone   \n",
      "304                                       Methotrexate   \n",
      "305                                         Leucovorin   \n",
      "306                                         BMS-986165   \n",
      "307           Current Bowel Protocol (senna/lactulose)   \n",
      "308                 PEG Bowel Protocol (PEG/lactulose)   \n",
      "309                                          Rifaximin   \n",
      "310                                            Placebo   \n",
      "311                                          Exenatide   \n",
      "312                                           Placebos   \n",
      "313  Pantoprazole 40 mg DR Tablet vs. Protonix 40 m...   \n",
      "314                                             BI-505   \n",
      "315                                High dose melphalan   \n",
      "316               Autologous stem cell transplantation   \n",
      "317                                             Tcelna   \n",
      "318                                            Placebo   \n",
      "319       crystalline cholesterol oil-based suspension   \n",
      "320                                          Abatacept   \n",
      "321                                            Placebo   \n",
      "322                                                SEL   \n",
      "323                                            GS-0976   \n",
      "324                                            GS-9674   \n",
      "325                                        Fenofibrate   \n",
      "326                                      Bremelanotide   \n",
      "\n",
      "                                          DESCRIPTIONS  \\\n",
      "0    Single 40 mg verubecestat tablet once daily, t...   \n",
      "1    Single 60 or 40 mg verubecestat tablet once da...   \n",
      "2    Single placebo tablet matching verubecestat tr...   \n",
      "3    Single 40 mg verubecestat tablet once daily, t...   \n",
      "4    Docetaxel is administered by IV on day 1 of ea...   \n",
      "5    Pemetrexed is administered by IV on Day 1 of a...   \n",
      "6    Carboplatin is administered by IV on day 1 of ...   \n",
      "7    Gemcitabine is administered by IV on Days 1 an...   \n",
      "8    Atezolizumab is administered by IV on Day 1 of...   \n",
      "9    Cobimetinib is administered orally on days 1-2...   \n",
      "10   Cycle 1:\\nRO6958688 is administered by IV infu...   \n",
      "11   BL-8040 is administered by subcutaneous inject...   \n",
      "12   Tazemetostat is administered orally twice dail...   \n",
      "13   CPI-444 is administered orally twice daily on ...   \n",
      "14                          Vapendavir Tablets, 264 mg   \n",
      "15                  Vapendavir 264 mg matching tablets   \n",
      "16   Each subject received 2 self-administered dose...   \n",
      "17                                                Null   \n",
      "18                                                Null   \n",
      "19   Deflazacort, a glucocorticoid with anti-inflam...   \n",
      "20   Deflazacort, a glucocorticoid with anti-inflam...   \n",
      "21                                                Null   \n",
      "22                                                Null   \n",
      "23                                                Null   \n",
      "24                                                Null   \n",
      "25                                                Null   \n",
      "26                                                Null   \n",
      "27                                                Null   \n",
      "28                                                Null   \n",
      "29                                                Null   \n",
      "..                                                 ...   \n",
      "297                                               Null   \n",
      "298  Individualized management of medications for pain   \n",
      "299  Individualized management of non-medication pa...   \n",
      "300  Option of using buprenorphine-naloxone to assi...   \n",
      "301  Individualized management of medications for pain   \n",
      "302  Individualized management of non-medication pa...   \n",
      "303  Option of using buprenorphine-naloxone to assi...   \n",
      "304                   Specified dose on specified days   \n",
      "305                   Specified dose on specified days   \n",
      "306                   Specified dose on specified days   \n",
      "307                   Stimulant and Osmotic Laxatives.   \n",
      "308                                 Osmotic Laxatives.   \n",
      "309  twice daily administration of 1 tablet contain...   \n",
      "310  twice daily administration of 1 rifaximin plac...   \n",
      "311                                               Null   \n",
      "312                                               Null   \n",
      "313                     Single dose crossover BE study   \n",
      "314  Treatment with BI-505 10 mg/kg bi-weekly infus...   \n",
      "315                          High dose melphalan (HDM)   \n",
      "316        Autologous stem cell transplantation (ASCT)   \n",
      "317  Autologous pool of myelin reactive T-cells (MR...   \n",
      "318  2 ml of Tcelna excipients, prepared daily as i...   \n",
      "319  200 mg/mL suspension of crystalline cholestero...   \n",
      "320                                               Null   \n",
      "321                                               Null   \n",
      "322                     Administered orally once daily   \n",
      "323                     Administered orally once daily   \n",
      "324                     Administered orally once daily   \n",
      "325                     Administered orally once daily   \n",
      "326  A melanocortin agonist and synthetic peptide a...   \n",
      "\n",
      "                                            OTHER_NAME INDIC_INTERVENTIONS  \n",
      "0                                           SCH 900931                True  \n",
      "1                                           SCH 900931                True  \n",
      "2                                                 Null               False  \n",
      "3                                           SCH 900931                True  \n",
      "4                                                 Null               False  \n",
      "5                                                 Null               False  \n",
      "6                                                 Null               False  \n",
      "7                                                 Null               False  \n",
      "8                                                 Null               False  \n",
      "9                                                 Null               False  \n",
      "10                                                Null               False  \n",
      "11                                                Null               False  \n",
      "12                                                Null               False  \n",
      "13                                                Null                True  \n",
      "14                                              BTA798                True  \n",
      "15                                                Null               False  \n",
      "16                                                Null                True  \n",
      "17                                                Null               False  \n",
      "18                                                Null               False  \n",
      "19                                              biaxin                True  \n",
      "20                                                 DFZ                True  \n",
      "21                                                Null               False  \n",
      "22                                                Null               False  \n",
      "23                                                Null               False  \n",
      "24                                                Null               False  \n",
      "25                                                Null               False  \n",
      "26                                                Null               False  \n",
      "27                                                Null               False  \n",
      "28                                                Null               False  \n",
      "29                                                Null               False  \n",
      "..                                                 ...                 ...  \n",
      "297                                               Null               False  \n",
      "298                                               Null               False  \n",
      "299                                               Null               False  \n",
      "300                                               Null                True  \n",
      "301                                               Null               False  \n",
      "302                                               Null               False  \n",
      "303                                               Null                True  \n",
      "304                                                MTX               False  \n",
      "305                                                LEU               False  \n",
      "306                                               Null                True  \n",
      "307  Senna;Lactulose;Sennosides;DIN 02242814;DIN: 0...                True  \n",
      "308  PEG;Lax-A-Day;Pegalax;DIN: 02328232;Restoralax...                True  \n",
      "309                                               Null                True  \n",
      "310                                               Null               False  \n",
      "311                                             Byetta                True  \n",
      "312                                               Null               False  \n",
      "313   Protonix 40 mg DR Tablet (Wyeth Pharmaceuticals)                True  \n",
      "314                                               Null                True  \n",
      "315                                               Null               False  \n",
      "316                                               Null               False  \n",
      "317                                               Null                True  \n",
      "318                                               Null               False  \n",
      "319                                               Null                True  \n",
      "320                                               Null                True  \n",
      "321                                               Null               False  \n",
      "322                                            GS-4997               False  \n",
      "323                                               Null                True  \n",
      "324                                               Null               False  \n",
      "325                                               Null               False  \n",
      "326                                         BMT;PT-141                True  \n",
      "\n",
      "[327 rows x 25 columns],      TWID            TWEET_ID  \\\n",
      "0    2308  793755656234729472   \n",
      "1    2311  793352467110961152   \n",
      "2    2312  793351223457964032   \n",
      "3    2313  793349824020033536   \n",
      "4    2313  793349824020033536   \n",
      "5    2316  793040610060013568   \n",
      "6    2316  793040610060013568   \n",
      "7    2317  792502071647805440   \n",
      "8    2320  792075701323075585   \n",
      "9    2320  792075701323075585   \n",
      "10   2322  791931974327767040   \n",
      "11   2323  791894682280210432   \n",
      "12   2325  791836359149232129   \n",
      "13   2326  791829476074135552   \n",
      "14   2326  791829476074135552   \n",
      "15   2326  791829476074135552   \n",
      "16   2330  791573334479605760   \n",
      "17   2330  791573334479605760   \n",
      "18   2330  791573334479605760   \n",
      "19   2331  791573245279338496   \n",
      "20   2332  791566337424363521   \n",
      "21   2336  791213908883152896   \n",
      "22   2336  791213908883152896   \n",
      "23   2336  791213908883152896   \n",
      "24   2336  791213908883152896   \n",
      "25   2354  789364164485484544   \n",
      "26   2354  789364164485484544   \n",
      "27   2368  788668035275952128   \n",
      "28   2368  788668035275952128   \n",
      "29   2368  788668035275952128   \n",
      "..    ...                 ...   \n",
      "296  2845  750523022398746624   \n",
      "297  2845  750523022398746624   \n",
      "298  2845  750523022398746624   \n",
      "299  2845  750523022398746624   \n",
      "300  2845  750523022398746624   \n",
      "301  2850  750264707999727616   \n",
      "302  2850  750264707999727616   \n",
      "303  2850  750264707999727616   \n",
      "304  2850  750264707999727616   \n",
      "305  2850  750264707999727616   \n",
      "306  2850  750264707999727616   \n",
      "307  2850  750264707999727616   \n",
      "308  2850  750264707999727616   \n",
      "309  2852  750259163033432064   \n",
      "310  2852  750259163033432064   \n",
      "311  2856  750139498546081792   \n",
      "312  2856  750139498546081792   \n",
      "313  2869  748809687643021312   \n",
      "314  2875  748131406232985600   \n",
      "315  2882  747739017584742400   \n",
      "316  2882  747739017584742400   \n",
      "317  2882  747739017584742400   \n",
      "318  2882  747739017584742400   \n",
      "319  2884  747731271959318529   \n",
      "320  2894  746298848826503168   \n",
      "321  2894  746298848826503168   \n",
      "322  2894  746298848826503168   \n",
      "323  2894  746298848826503168   \n",
      "324  2894  746298848826503168   \n",
      "325  2895  746286834687352832   \n",
      "\n",
      "                                                 TWEET           SYNONYMS  \\\n",
      "0    Palatin's bremelanotide meets coprimary effica...      BREMELANOTIDE   \n",
      "1    Aclaris Therapeutics submits IND to US FDA for...          ATI-50001   \n",
      "2    Vyome Biosciences begins first-in-human phase ...            VB-1953   \n",
      "3    Phase III clinical trial begins in US for Eisa...              E2609   \n",
      "4    Phase III clinical trial begins in US for Eisa...              E2609   \n",
      "5    ReViral begins phase I trial of RV-521 for the...             RV-521   \n",
      "6    ReViral begins phase I trial of RV-521 for the...             RV-521   \n",
      "7    GlaxoSmithKline's gepotidacin safe and effecti...        GEPOTIDACIN   \n",
      "8    Rebiotix's RBX-2660 effective in phase IIb tri...           RBX-2660   \n",
      "9    Rebiotix's RBX-2660 effective in phase IIb tri...           RBX-2660   \n",
      "10   Alexion's ALXN-1210 begins phase III trials fo...           ALXN1210   \n",
      "11   Bird Rock Bio files CTA for namacizumab to sta...        NAMACIZUMAB   \n",
      "12   Matinas BioPharma's LCNP influenza vaccine pro...  INFLUENZA VACCINE   \n",
      "13   Janssen's JNJ-53718678 safe and well tolerated...       JNJ-53718678   \n",
      "14   Janssen's JNJ-53718678 safe and well tolerated...       JNJ-53718678   \n",
      "15   Janssen's JNJ-53718678 safe and well tolerated...       JNJ-53718678   \n",
      "16   Selecta starts phase II trial of SEL-212 for g...            SEL-212   \n",
      "17   Selecta starts phase II trial of SEL-212 for g...            SEL-212   \n",
      "18   Selecta starts phase II trial of SEL-212 for g...            SEL-212   \n",
      "19   Entasis' ETX-2514 begins phase I trial for Aci...           ETX-2514   \n",
      "20   ProMetic's plasminogen meets primary and secon...        PLASMINOGEN   \n",
      "21   Dipexium's Locilex (pexiganan acetate) fails t...  PEXIGANAN ACETATE   \n",
      "22   Dipexium's Locilex (pexiganan acetate) fails t...          PEXIGANAN   \n",
      "23   Dipexium's Locilex (pexiganan acetate) fails t...          PEXIGANAN   \n",
      "24   Dipexium's Locilex (pexiganan acetate) fails t...          PEXIGANAN   \n",
      "25   MicuRx's MRX-I begins phase III trials for com...              MRX-I   \n",
      "26   MicuRx's MRX-I begins phase III trials for com...              MRX-I   \n",
      "27   Bavarian Nordic's MVA-BN RSV begins phase II t...             MVA-BN   \n",
      "28   Bavarian Nordic's MVA-BN RSV begins phase II t...             MVA-BN   \n",
      "29   Bavarian Nordic's MVA-BN RSV begins phase II t...             MVA-BN   \n",
      "..                                                 ...                ...   \n",
      "296  Nippon Kayaku's NK-105 (paclitaxel micelles) f...         PACLITAXEL   \n",
      "297  Nippon Kayaku's NK-105 (paclitaxel micelles) f...         PACLITAXEL   \n",
      "298  Nippon Kayaku's NK-105 (paclitaxel micelles) f...         PACLITAXEL   \n",
      "299  Nippon Kayaku's NK-105 (paclitaxel micelles) f...         PACLITAXEL   \n",
      "300  Nippon Kayaku's NK-105 (paclitaxel micelles) f...         PACLITAXEL   \n",
      "301  Cinfa Biotech's pegfilgrastim biosimilar B-120...      PEGFILGRASTIM   \n",
      "302  Cinfa Biotech's pegfilgrastim biosimilar B-120...      PEGFILGRASTIM   \n",
      "303  Cinfa Biotech's pegfilgrastim biosimilar B-120...      PEGFILGRASTIM   \n",
      "304  Cinfa Biotech's pegfilgrastim biosimilar B-120...      PEGFILGRASTIM   \n",
      "305  Cinfa Biotech's pegfilgrastim biosimilar B-120...      PEGFILGRASTIM   \n",
      "306  Cinfa Biotech's pegfilgrastim biosimilar B-120...      PEGFILGRASTIM   \n",
      "307  Cinfa Biotech's pegfilgrastim biosimilar B-120...      PEGFILGRASTIM   \n",
      "308  Cinfa Biotech's pegfilgrastim biosimilar B-120...      PEGFILGRASTIM   \n",
      "309  US FDA approves IND for Biohaven Pharmaceutica...           BHV-4157   \n",
      "310  US FDA approves IND for Biohaven Pharmaceutica...           BHV-4157   \n",
      "311  GlaxoSmithKline's GSK-3359609 begins phase I t...        GSK-3359609   \n",
      "312  GlaxoSmithKline's GSK-3359609 begins phase I t...        GSK-3359609   \n",
      "313  ImmBio's PnuBioVax vaccine safe well tolerated...  PNUBIOVAX VACCINE   \n",
      "314  AstraZeneca's benralizumab reduces asthma exac...       BENRALIZUMAB   \n",
      "315  US FDA places clinical hold on RG-101's IND fo...             RG-101   \n",
      "316  US FDA places clinical hold on RG-101's IND fo...             RG-101   \n",
      "317  US FDA places clinical hold on RG-101's IND fo...             RG-101   \n",
      "318  US FDA places clinical hold on RG-101's IND fo...             RG-101   \n",
      "319  AstraZeneca's eosinophil-depleting asthma drug...       BENRALIZUMAB   \n",
      "320  VBI's VBI-1501 starts phase I trial in Canada ...           VBI-1501   \n",
      "321  VBI's VBI-1501 starts phase I trial in Canada ...           VBI-1501   \n",
      "322  VBI's VBI-1501 starts phase I trial in Canada ...           VBI-1501   \n",
      "323  VBI's VBI-1501 starts phase I trial in Canada ...           VBI-1501   \n",
      "324  VBI's VBI-1501 starts phase I trial in Canada ...           VBI-1501   \n",
      "325  Apellis' APL-2 shows safety tolerability &amp ...              APL-2   \n",
      "\n",
      "    MOLREGNO_1 ACRONYM       NCT_ID              PHASE  N_PHASES      OUTCOME  \\\n",
      "0      1360388    Null  NCT02338960            Phase 3         1      SUCCESS   \n",
      "1    Not found    Null         Null               Null         0  IN PROGRESS   \n",
      "2    Not found    Null         Null            Phase 1         2  IN PROGRESS   \n",
      "3      2096360    Null  NCT03055962            Phase 3         1  IN PROGRESS   \n",
      "4      2096360    Null  NCT03055962            Phase 3         1  IN PROGRESS   \n",
      "5    Not found    Null  NCT03258502            Phase 1         1  IN PROGRESS   \n",
      "6    Not found    Null  NCT03258502            Phase 1         1  IN PROGRESS   \n",
      "7      1782495    Null  NCT03562117            Phase 2         1      SUCCESS   \n",
      "8    Not found    Null  NCT03378167            Phase 2         1      SUCCESS   \n",
      "9    Not found    Null  NCT03378167            Phase 2         1      SUCCESS   \n",
      "10     2197857    Null  NCT02605993            Phase 3         2  IN PROGRESS   \n",
      "11        Null    Null         Null            Phase 1         1  IN PROGRESS   \n",
      "12        Null    Null  NCT03163342  Preclinical trial         1      SUCCESS   \n",
      "13   Not found    Null  NCT03379675            Phase 1         1      SUCCESS   \n",
      "14   Not found    Null  NCT03379675            Phase 1         1      SUCCESS   \n",
      "15   Not found    Null  NCT03379675            Phase 1         1      SUCCESS   \n",
      "16   Not found    Null  NCT02959918            Phase 2         1  IN PROGRESS   \n",
      "17   Not found    Null  NCT02959918            Phase 2         1  IN PROGRESS   \n",
      "18   Not found    Null  NCT02959918            Phase 2         1  IN PROGRESS   \n",
      "19   Not found    Null  NCT03303924            Phase 1         1  IN PROGRESS   \n",
      "20     1380397    Null  NCT01554956          Phase 2/3         2      SUCCESS   \n",
      "21     1380822    Null         Null            Phase 3         1         FAIL   \n",
      "22      711762    Null  NCT01590758            Phase 3         1         FAIL   \n",
      "23      711762    Null  NCT01590758            Phase 3         1         FAIL   \n",
      "24      711762    Null  NCT01590758            Phase 3         1         FAIL   \n",
      "25   Not found    Null  NCT02269319            Phase 3         1  IN PROGRESS   \n",
      "26   Not found    Null  NCT02269319            Phase 3         1  IN PROGRESS   \n",
      "27   Not found    Null  NCT03493945            Phase 2         1  IN PROGRESS   \n",
      "28   Not found    Null  NCT03493945            Phase 2         1  IN PROGRESS   \n",
      "29   Not found    Null  NCT03493945            Phase 2         1  IN PROGRESS   \n",
      "..         ...     ...          ...                ...       ...          ...   \n",
      "296       8062    Null  NCT03387085            Phase 3         1         FAIL   \n",
      "297       8062    Null  NCT03387085            Phase 3         1         FAIL   \n",
      "298       8062    Null  NCT03387085            Phase 3         1         FAIL   \n",
      "299       8062    Null  NCT03387085            Phase 3         1         FAIL   \n",
      "300       8062    Null  NCT03387085            Phase 3         1         FAIL   \n",
      "301     675363    Null  NCT00404066               Null         0      SUCCESS   \n",
      "302     675363    Null  NCT00404066               Null         0      SUCCESS   \n",
      "303     675363    Null  NCT00404066               Null         0      SUCCESS   \n",
      "304     675363    Null  NCT00404066               Null         0      SUCCESS   \n",
      "305     675363    Null  NCT00404066               Null         0      SUCCESS   \n",
      "306     675363    Null  NCT00404066               Null         0      SUCCESS   \n",
      "307     675363    Null  NCT00404066               Null         0      SUCCESS   \n",
      "308     675363    Null  NCT00404066               Null         0      SUCCESS   \n",
      "309  Not found    Null  NCT02960893            Phase 3         3      SUCCESS   \n",
      "310  Not found    Null  NCT02960893            Phase 3         3      SUCCESS   \n",
      "311  Not found    Null  NCT02723955            Phase 1         1  IN PROGRESS   \n",
      "312  Not found    Null  NCT02723955            Phase 1         1  IN PROGRESS   \n",
      "313       Null    Null         Null            Phase 1         1      SUCCESS   \n",
      "314    1121862    Null  NCT02417961            Phase 3         1      SUCCESS   \n",
      "315  Not found    Null  NCT02591199            Phase 1         1      STOPPED   \n",
      "316  Not found    Null  NCT02591199            Phase 1         1      STOPPED   \n",
      "317  Not found    Null  NCT02591199            Phase 1         1      STOPPED   \n",
      "318  Not found    Null  NCT02591199            Phase 1         1      STOPPED   \n",
      "319    1121862    Null  NCT02417961            Phase 3         1      SUCCESS   \n",
      "320  Not found    Null  NCT02826798            Phase 1         1  IN PROGRESS   \n",
      "321  Not found    Null  NCT02826798            Phase 1         1  IN PROGRESS   \n",
      "322  Not found    Null  NCT02826798            Phase 1         1  IN PROGRESS   \n",
      "323  Not found    Null  NCT02826798            Phase 1         1  IN PROGRESS   \n",
      "324  Not found    Null  NCT02826798            Phase 1         1  IN PROGRESS   \n",
      "325  Not found    Null  NCT03453619            Phase 1         1      SUCCESS   \n",
      "\n",
      "            ...         COMPANY_SCORE                              INDICATION  \\\n",
      "0           ...                  Null       Hypoactive sexual desire disorder   \n",
      "1           ...                     1                                Alopecia   \n",
      "2           ...                  Null                           Acne Vulgaris   \n",
      "3           ...                     1                       Alzheimer Disease   \n",
      "4           ...                     1                       Alzheimer Disease   \n",
      "5           ...                  Null  Respiratory Syncytial Virus Infections   \n",
      "6           ...                  Null  Respiratory Syncytial Virus Infections   \n",
      "7           ...                     1                               Gonorrhea   \n",
      "8           ...                     1          Pseudomembranous Enterocolitis   \n",
      "9           ...                     1          Pseudomembranous Enterocolitis   \n",
      "10          ...                     1      Atypical Hemolytic Uremic Syndrome   \n",
      "11          ...                     1                                Fibrosis   \n",
      "12          ...                  Null                             influenza A   \n",
      "13          ...                     1                                    Null   \n",
      "14          ...                     1                                    Null   \n",
      "15          ...                     1                                    Null   \n",
      "16          ...                  Null                                    Gout   \n",
      "17          ...                  Null                                    Gout   \n",
      "18          ...                  Null                                    Gout   \n",
      "19          ...                  Null                                    Null   \n",
      "20          ...                     1                                    Null   \n",
      "21          ...                     1                           Diabetic Foot   \n",
      "22          ...                     1                           Diabetic Foot   \n",
      "23          ...                     1                           Diabetic Foot   \n",
      "24          ...                     1                           Diabetic Foot   \n",
      "25          ...                     1                                    Null   \n",
      "26          ...                     1                                    Null   \n",
      "27          ...                     1                                Orthopox   \n",
      "28          ...                     1                                Orthopox   \n",
      "29          ...                     1                                Orthopox   \n",
      "..          ...                   ...                                     ...   \n",
      "296         ...                     1                   Prostatic Hyperplasia   \n",
      "297         ...                     1                   Prostatic Hyperplasia   \n",
      "298         ...                     1                   Prostatic Hyperplasia   \n",
      "299         ...                     1                   Prostatic Hyperplasia   \n",
      "300         ...                     1                   Prostatic Hyperplasia   \n",
      "301         ...                  Null                        Breast Neoplasms   \n",
      "302         ...                  Null                        Breast Neoplasms   \n",
      "303         ...                  Null                        Breast Neoplasms   \n",
      "304         ...                  Null                        Breast Neoplasms   \n",
      "305         ...                  Null                        Breast Neoplasms   \n",
      "306         ...                  Null                        Breast Neoplasms   \n",
      "307         ...                  Null                        Breast Neoplasms   \n",
      "308         ...                  Null                        Breast Neoplasms   \n",
      "309         ...                     1                 Spinocerebellar Ataxias   \n",
      "310         ...                     1                 Spinocerebellar Ataxias   \n",
      "311         ...                     1                             Solid Tumor   \n",
      "312         ...                     1                             Solid Tumor   \n",
      "313         ...                  Null                                    Null   \n",
      "314         ...                     1                            Eosinophilia   \n",
      "315         ...                  Null                                Jaundice   \n",
      "316         ...                  Null                                Jaundice   \n",
      "317         ...                  Null                                Jaundice   \n",
      "318         ...                  Null                                Jaundice   \n",
      "319         ...                     1                            Eosinophilia   \n",
      "320         ...                  Null              Cytomegalovirus Infections   \n",
      "321         ...                  Null              Cytomegalovirus Infections   \n",
      "322         ...                  Null              Cytomegalovirus Infections   \n",
      "323         ...                  Null              Cytomegalovirus Infections   \n",
      "324         ...                  Null              Cytomegalovirus Infections   \n",
      "325         ...                     1               Paroxysmal Hemoglobinuria   \n",
      "\n",
      "    INDICATION_ID INDICATION_NONAMBIG INDICATION_SCORE INTERVENTION_TYPE  \\\n",
      "0         SDI0266                   1                1              Drug   \n",
      "1         D000505                   2                1              Null   \n",
      "2         D000152                   1                1              Null   \n",
      "3         D000544                   1                1              Drug   \n",
      "4         D000544                   1                1              Drug   \n",
      "5         D018357                   1                1              Drug   \n",
      "6         D018357                   1                1              Drug   \n",
      "7         D006069                   1                1              Drug   \n",
      "8         D004761                   0                1        Biological   \n",
      "9         D004761                   0                1        Biological   \n",
      "10        D065766                   1                1        Biological   \n",
      "11        D005355                   1                1              Null   \n",
      "12        D007251                   1                1        Biological   \n",
      "13           Null                Null             Null              Drug   \n",
      "14           Null                Null             Null              Drug   \n",
      "15           Null                Null             Null              Drug   \n",
      "16        D006073                   1                1              Drug   \n",
      "17        D006073                   1                1              Drug   \n",
      "18        D006073                   1                1              Drug   \n",
      "19           Null                Null             Null              Drug   \n",
      "20           Null                Null             Null        Biological   \n",
      "21        D017719                   1                1              Null   \n",
      "22        D017719                   1                1              Drug   \n",
      "23        D017719                   1                1              Drug   \n",
      "24        D017719                   1                1             Other   \n",
      "25           Null                Null             Null              Drug   \n",
      "26           Null                Null             Null              Drug   \n",
      "27        DX90099                   1                1        Biological   \n",
      "28        DX90099                   1                1              Drug   \n",
      "29        DX90099                   1                1        Biological   \n",
      "..            ...                 ...              ...               ...   \n",
      "296       D011470                   2                1              Drug   \n",
      "297       D011470                   2                1              Drug   \n",
      "298       D011470                   2                1              Drug   \n",
      "299       D011470                   2                1              Drug   \n",
      "300       D011470                   2                1         Procedure   \n",
      "301       D001943                   1                1              Drug   \n",
      "302       D001943                   1                1              Drug   \n",
      "303       D001943                   1                1              Drug   \n",
      "304       D001943                   1                1              Drug   \n",
      "305       D001943                   1                1              Drug   \n",
      "306       D001943                   1                1              Drug   \n",
      "307       D001943                   1                1              Drug   \n",
      "308       D001943                   1                1              Drug   \n",
      "309       D020754                   1                1              Drug   \n",
      "310       D020754                   1                1              Drug   \n",
      "311       SDI0034                   1                1              Drug   \n",
      "312       SDI0034                   1                1              Drug   \n",
      "313          Null                Null             Null              Null   \n",
      "314       D004802                   1                1        Biological   \n",
      "315       D007565                   1                1              Drug   \n",
      "316       D007565                   1                1              Drug   \n",
      "317       D007565                   1                1              Drug   \n",
      "318       D007565                   1                1              Drug   \n",
      "319       D004802                   1                1        Biological   \n",
      "320       D003586                   1                1              Drug   \n",
      "321       D003586                   1                1              Drug   \n",
      "322       D003586                   1                1              Drug   \n",
      "323       D003586                   1                1              Drug   \n",
      "324       D003586                   1                1              Drug   \n",
      "325       D006457                   1                1              Drug   \n",
      "\n",
      "                       INTERVENTION_NAME  \\\n",
      "0                                Placebo   \n",
      "1                                   Null   \n",
      "2                                   Null   \n",
      "3                                  E2609   \n",
      "4                                Placebo   \n",
      "5                                  RV521   \n",
      "6                                Placebo   \n",
      "7                            Gepotidacin   \n",
      "8                             MICROBIOTA   \n",
      "9                                PLACEBO   \n",
      "10                              ALXN1210   \n",
      "11                                  Null   \n",
      "12   Licensed seasonal influenza vaccine   \n",
      "13                   JNJ-53718678 500 mg   \n",
      "14                    JNJ-53718678 80 mg   \n",
      "15                               Placebo   \n",
      "16                               SEL-037   \n",
      "17                               SEL-212   \n",
      "18               SVP-rapamycin (SEL-110)   \n",
      "19                 ETX2514 and sulbactam   \n",
      "20                     Human Plasminogen   \n",
      "21                                  Null   \n",
      "22          Topical pexiganan cream 0.8%   \n",
      "23                 Topical placebo cream   \n",
      "24                   Standard wound care   \n",
      "25                                 MRX-I   \n",
      "26                             Linezolid   \n",
      "27                                 M7824   \n",
      "28                               ALT-803   \n",
      "29                      MVA-BN-Brachyury   \n",
      "..                                   ...   \n",
      "296                     Cyclophosphamide   \n",
      "297                         Fluorouracil   \n",
      "298                           Leucovorin   \n",
      "299                       nab-Paclitaxel   \n",
      "300                                 SBRT   \n",
      "301                            Docetaxel   \n",
      "302                            Lapatinib   \n",
      "303                          Doxorubicin   \n",
      "304                     Cyclophosphamide   \n",
      "305                        Pegfilgrastim   \n",
      "306                           Filgrastim   \n",
      "307                        Dexamethasone   \n",
      "308                          Trastuzumab   \n",
      "309                             BHV-4157   \n",
      "310                   Placebo Comparator   \n",
      "311               GSK3359609 IV infusion   \n",
      "312     Pembrolizumab 200 mg IV infusion   \n",
      "313                                 Null   \n",
      "314                         Benralizumab   \n",
      "315                               URG101   \n",
      "316                              Placebo   \n",
      "317                            Lidocaine   \n",
      "318                              Heparin   \n",
      "319                         Benralizumab   \n",
      "320                              Placebo   \n",
      "321                            VBI-1501A   \n",
      "322                             VBI-1501   \n",
      "323                            VBI-1501A   \n",
      "324                            VBI-1501A   \n",
      "325                                APL-2   \n",
      "\n",
      "                                          DESCRIPTIONS  \\\n",
      "0                                              Placebo   \n",
      "1                                                 Null   \n",
      "2                                                 Null   \n",
      "3                                               tablet   \n",
      "4                                               tablet   \n",
      "5                               RV521 drug in capsules   \n",
      "6                                  Placebo in capsules   \n",
      "7    It is an immediate-release tablet (1500 mg (2 ...   \n",
      "8    Fecal microbiota enema (RBX2660) infused via c...   \n",
      "9    Placebo enema (Normal Saline) infused via colo...   \n",
      "10                                                Null   \n",
      "11                                                Null   \n",
      "12   20 healthy subjects will be enrolled and recei...   \n",
      "13   Participants will receive 500 mg dose of JNJ-5...   \n",
      "14   Participants will receive 80 mg dose of JNJ-53...   \n",
      "15   In treatment B, participants will receive matc...   \n",
      "16                                   SEL-037, biologic   \n",
      "17                                             SEL-212   \n",
      "18                                                Null   \n",
      "19   Each subject will receive three doses of of ET...   \n",
      "20                                           Eye Drops   \n",
      "21                                                Null   \n",
      "22                                14 days of treatment   \n",
      "23                                14 days of treatment   \n",
      "24                                14 days of treatment   \n",
      "25      Oral MRX-I 800mg given twice a day for 10 days   \n",
      "26   Oral linezolid 600mg given twice a day for 10 ...   \n",
      "27                      1,200 mg IV once every 2 weeks   \n",
      "28              8-15 mcg/kg subcutaneous every 2 weeks   \n",
      "29   MVA-BN-Brachyury will be administered subcutan...   \n",
      "..                                                 ...   \n",
      "296  2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2...   \n",
      "297               5-fluoro-2,4 (1H,3H)-pyrimidinedione   \n",
      "298  L-Glutamic acid, N-[4-[[(2-amino-5-formyl-1,4,...   \n",
      "299  Benzenepropanoic acid, β-(benzoylamino)-α-hydr...   \n",
      "300                Stereotactic Body Radiation Therapy   \n",
      "301  100 mg/m2, intravenously every 3 weeks for 4 c...   \n",
      "302  1250 mg, tablets, oral daily during treatment ...   \n",
      "303  60 mg/m2, intravenously every 2 weeks for 4 cy...   \n",
      "304  600 mg/m2, intravenously every 2 weeks for 4 c...   \n",
      "305  6 mg, subcutaneously on day 2 of all cytotoxic...   \n",
      "306  300 or 480 mcg, subcutaneously on days 3 to 10...   \n",
      "307  8 mg, oral taken twice a day for 3 days starti...   \n",
      "308  Loading dose 8 mg/kg, then 6 mg/kg, intravenou...   \n",
      "309                                   140mg capsule QD   \n",
      "310                                               Null   \n",
      "311  GSK3359609 will be administered intravenously ...   \n",
      "312  Pembrolizumab 200 mg will be intravenously adm...   \n",
      "313                                               Null   \n",
      "314  Benralizumab administered subcutaneously every...   \n",
      "315                                               Null   \n",
      "316                                               Null   \n",
      "317                                               Null   \n",
      "318                                               Null   \n",
      "319  Benralizumab administered subcutaneously every...   \n",
      "320  buffer/sucrose used for VBI-1501 suspension- a...   \n",
      "321  VBI-1501A: 2.0 μg with alum-administered as a ...   \n",
      "322  VBI-1501: 1.0 μg without alum-administered as ...   \n",
      "323  VBI-1501A: 0.5 μg with alum-administered as a ...   \n",
      "324  VBI-1501A: 1.0 μg with alum with alum-administ...   \n",
      "325  APL-2 is a C3 complement mediator administered...   \n",
      "\n",
      "                                            OTHER_NAME INDIC_INTERVENTIONS  \n",
      "0                                                 Null               False  \n",
      "1                                                 Null               False  \n",
      "2                                                 Null               False  \n",
      "3                                                 Null                True  \n",
      "4                                                 Null               False  \n",
      "5                                                 Null                True  \n",
      "6                                                 Null               False  \n",
      "7                                                 Null                True  \n",
      "8          RBX2660;RBX7455;Fecal microbiota transplant                True  \n",
      "9                                                 Null               False  \n",
      "10                                                Null                True  \n",
      "11                                                Null               False  \n",
      "12                                                Null                True  \n",
      "13                                                Null                True  \n",
      "14                                                Null                True  \n",
      "15                                                Null               False  \n",
      "16                                         pegsiticase               False  \n",
      "17                                                Null                True  \n",
      "18                                                Null               False  \n",
      "19                                                Null                True  \n",
      "20                                                Null                True  \n",
      "21                                                Null               False  \n",
      "22                                              MSI-78                True  \n",
      "23                                                Null               False  \n",
      "24                                                Null               False  \n",
      "25                                                Null                True  \n",
      "26                                               Zyvox               False  \n",
      "27                                                Null               False  \n",
      "28                                                Null               False  \n",
      "29                                                Null                True  \n",
      "..                                                 ...                 ...  \n",
      "296                                               Null               False  \n",
      "297                                               Null               False  \n",
      "298                                               Null               False  \n",
      "299                                               Null                True  \n",
      "300                                               Null               False  \n",
      "301                                           Taxotere               False  \n",
      "302                                           GW572016               False  \n",
      "303                            Adriamycin;Adriablastin               False  \n",
      "304                                       Cytoxan;ASTA               False  \n",
      "305                                           Neulasta                True  \n",
      "306  Neupogen;Granulocyte Colony-Stimulating Factor...               False  \n",
      "307                                            Adexone               False  \n",
      "308                                          Herceptin               False  \n",
      "309                                               Null                True  \n",
      "310                                               Null               False  \n",
      "311                                               Null                True  \n",
      "312                                               Null               False  \n",
      "313                                               Null               False  \n",
      "314                                               Null                True  \n",
      "315                                               Null                True  \n",
      "316                                               Null               False  \n",
      "317                                               Null               False  \n",
      "318                                               Null               False  \n",
      "319                                               Null                True  \n",
      "320                                               Null               False  \n",
      "321                                               Null                True  \n",
      "322                                               Null                True  \n",
      "323                                               Null                True  \n",
      "324                                               Null                True  \n",
      "325                                               Null                True  \n",
      "\n",
      "[326 rows x 25 columns],       TWID            TWEET_ID  \\\n",
      "0     2899  745898778931109893   \n",
      "1     2899  745898778931109893   \n",
      "2     2899  745898778931109893   \n",
      "3     2904  745565391762632704   \n",
      "4     2906  745480905133699072   \n",
      "5     2911  745196918591070208   \n",
      "6     2913  745185212372418560   \n",
      "7     2914  745171644675567616   \n",
      "8     2919  744828585010143232   \n",
      "9     2919  744828585010143232   \n",
      "10    2920  744816995846107136   \n",
      "11    2921  744815279411073028   \n",
      "12    2921  744815279411073028   \n",
      "13    2921  744815279411073028   \n",
      "14    2931  743386006402048000   \n",
      "15    2932  743381252707856384   \n",
      "16    2932  743381252707856384   \n",
      "17    2932  743381252707856384   \n",
      "18    2932  743381252707856384   \n",
      "19    2932  743381252707856384   \n",
      "20    2932  743381252707856384   \n",
      "21    2945  742661115532972032   \n",
      "22    2946  742658898914639872   \n",
      "23    2946  742658898914639872   \n",
      "24    2947  742656369510219777   \n",
      "25    2947  742656369510219777   \n",
      "26    2948  742652933590900736   \n",
      "27    2963  741568485025796096   \n",
      "28    2963  741568485025796096   \n",
      "29    2964  741567279050149888   \n",
      "..     ...                 ...   \n",
      "296   9742  989135291565903873   \n",
      "297   9742  989135291565903873   \n",
      "298   9742  989135291565903873   \n",
      "299  12910  992218379149889536   \n",
      "300  12910  992218379149889536   \n",
      "301  12910  992218379149889536   \n",
      "302  12927  991337132642979840   \n",
      "303  16248  991311142625652737   \n",
      "304  16248  991311142625652737   \n",
      "305  16248  991311142625652737   \n",
      "306  16248  991311142625652737   \n",
      "307  16248  991311142625652737   \n",
      "308  19304  994947253776330753   \n",
      "309  19304  994947253776330753   \n",
      "310  19312  994682264528224256   \n",
      "311  19312  994682264528224256   \n",
      "312  19430  991798269239062528   \n",
      "313  19430  991798269239062528   \n",
      "314  19430  991798269239062528   \n",
      "315  19430  991798269239062528   \n",
      "316  19430  991798269239062528   \n",
      "317  19430  991798269239062528   \n",
      "318  19430  991798269239062528   \n",
      "319  19430  991798269239062528   \n",
      "320  19430  991798269239062528   \n",
      "321  19430  991798269239062528   \n",
      "322  19430  991798269239062528   \n",
      "323  19430  991798269239062528   \n",
      "324  19430  991798269239062528   \n",
      "325  19430  991798269239062528   \n",
      "\n",
      "                                                 TWEET       SYNONYMS  \\\n",
      "0    Spring Bank's SB-9200 begins phase II global t...        SB-9200   \n",
      "1    Spring Bank's SB-9200 begins phase II global t...        SB-9200   \n",
      "2    Spring Bank's SB-9200 begins phase II global t...        SB-9200   \n",
      "3    Frontier Biotech's AB-001 shows safety and eff...         AB-001   \n",
      "4      Curis starts phase I trial of CA-170 for cancer         CA-170   \n",
      "5    ApeX files IND to start phase I US trial of AP...       APX-3330   \n",
      "6    Inovio and GeneOne get green light to start ph...       GLS-5700   \n",
      "7    US FDA clears Sangamo's IND for SB-913 phase I...         SB-913   \n",
      "8    TiGenix's AlloCSC-01 shows interim acute &amp ...     AlloCSC-01   \n",
      "9    TiGenix's AlloCSC-01 shows interim acute &amp ...     AlloCSC-01   \n",
      "10   Nippon Chemiphar and Kyusyu University start p...        NC-2600   \n",
      "11   Poxel's oral type 2 diabetes candidate PXL-770...        PXL-770   \n",
      "12   Poxel's oral type 2 diabetes candidate PXL-770...        PXL-770   \n",
      "13   Poxel's oral type 2 diabetes candidate PXL-770...        PXL-770   \n",
      "14   Zenith Epigenetics' ZEN-3694 begins phase I tr...       ZEN-3694   \n",
      "15   Cellceutix starts phase II trial of topical br...       PMX30063   \n",
      "16   Cellceutix starts phase II trial of topical br...       PMX30063   \n",
      "17   Cellceutix starts phase II trial of topical br...       PMX30063   \n",
      "18   Cellceutix starts phase II trial of topical br...       PMX30063   \n",
      "19   Cellceutix starts phase II trial of topical br...     BRILACIDIN   \n",
      "20   Cellceutix starts phase II trial of topical br...     BRILACIDIN   \n",
      "21   Tyme's SM-88 begins phase Ib/II trial for pros...          SM-88   \n",
      "22   Fibrocell's FCX-007 starts phase I/II trial fo...        FCX-007   \n",
      "23   Fibrocell's FCX-007 starts phase I/II trial fo...        FCX-007   \n",
      "24   Marinus' ganaxolone capsules fail to meet effi...     GANAXOLONE   \n",
      "25   Marinus' ganaxolone capsules fail to meet effi...     GANAXOLONE   \n",
      "26   Eleven Biotherapeutics files US IND to start p...        EBI-031   \n",
      "27   Short term treatment with Gilead's GS5745 well...         GS5745   \n",
      "28   Short term treatment with Gilead's GS5745 well...         GS5745   \n",
      "29   Sirukumab efficacy in phase 3 study in active ...      SIRUKUMAB   \n",
      "..                                                 ...            ...   \n",
      "296  After mega-round investment ADC Therapeutics c...           HER2   \n",
      "297  After mega-round investment ADC Therapeutics c...           HER2   \n",
      "298  After mega-round investment ADC Therapeutics c...           HER2   \n",
      "299  Live at #ARVO2018 phase I/II data for DSP-Visu...     PREDNISONE   \n",
      "300  Live at #ARVO2018 phase I/II data for DSP-Visu...     PREDNISONE   \n",
      "301  Live at #ARVO2018 phase I/II data for DSP-Visu...     PREDNISONE   \n",
      "302  AbbVie has filed risankizumab in the EU for mo...   RISANKIZUMAB   \n",
      "303  It's bad --\\nIDO rout Bristol-Myers Merck and ...  Bristol-Myers   \n",
      "304  It's bad --\\nIDO rout Bristol-Myers Merck and ...  Bristol-Myers   \n",
      "305  It's bad --\\nIDO rout Bristol-Myers Merck and ...  Bristol-Myers   \n",
      "306  It's bad --\\nIDO rout Bristol-Myers Merck and ...  Bristol-Myers   \n",
      "307  It's bad --\\nIDO rout Bristol-Myers Merck and ...  Bristol-Myers   \n",
      "308   @AstraZeneca Weighs Expanding Fasenra to #COP...        FASENRA   \n",
      "309   @AstraZeneca Weighs Expanding Fasenra to #COP...        FASENRA   \n",
      "310  WIth planned $16B $ARMO acquisition @LillyPad ...         AM0010   \n",
      "311  WIth planned $16B $ARMO acquisition @LillyPad ...         AM0010   \n",
      "312  Study by @TheCrick investigators may explain w...      LAPATINIB   \n",
      "313  Study by @TheCrick investigators may explain w...      LAPATINIB   \n",
      "314  Study by @TheCrick investigators may explain w...      LAPATINIB   \n",
      "315  Study by @TheCrick investigators may explain w...      LAPATINIB   \n",
      "316  Study by @TheCrick investigators may explain w...      LAPATINIB   \n",
      "317  Study by @TheCrick investigators may explain w...      LAPATINIB   \n",
      "318  Study by @TheCrick investigators may explain w...      LAPATINIB   \n",
      "319  Study by @TheCrick investigators may explain w...      LAPATINIB   \n",
      "320  Study by @TheCrick investigators may explain w...      LAPATINIB   \n",
      "321  Study by @TheCrick investigators may explain w...      LAPATINIB   \n",
      "322  Study by @TheCrick investigators may explain w...      LAPATINIB   \n",
      "323  Study by @TheCrick investigators may explain w...      LAPATINIB   \n",
      "324  Study by @TheCrick investigators may explain w...      LAPATINIB   \n",
      "325  Study by @TheCrick investigators may explain w...      LAPATINIB   \n",
      "\n",
      "    MOLREGNO_1 ACRONYM       NCT_ID      PHASE  N_PHASES      OUTCOME  \\\n",
      "0    Not found    Null  NCT02751996    Phase 2         1  IN PROGRESS   \n",
      "1    Not found    Null  NCT02751996    Phase 2         1  IN PROGRESS   \n",
      "2    Not found    Null  NCT02751996    Phase 2         1  IN PROGRESS   \n",
      "3    Not found    Null  NCT03474640    Phase 2         1      SUCCESS   \n",
      "4    Not found    Null  NCT02812875    Phase 1         1  IN PROGRESS   \n",
      "5    Not found    Null  NCT03375086    Phase 1         1  IN PROGRESS   \n",
      "6    Not found    Null  NCT02809443    Phase 1         1  IN PROGRESS   \n",
      "7    Not found    Null  NCT03041324  Phase 1/2         1  IN PROGRESS   \n",
      "8    Not found    Null  NCT02439398  Phase 1/2         1      SUCCESS   \n",
      "9    Not found    Null  NCT02439398  Phase 1/2         1      SUCCESS   \n",
      "10   Not found    Null         Null    Phase 1         2  IN PROGRESS   \n",
      "11   Not found    Null  NCT03395470    Phase 1         1      SUCCESS   \n",
      "12   Not found    Null  NCT03395470    Phase 1         1      SUCCESS   \n",
      "13   Not found    Null  NCT03395470    Phase 1         1      SUCCESS   \n",
      "14   Not found    Null         Null    Phase 1         2  IN PROGRESS   \n",
      "15     1449217    Null  NCT02324335    Phase 2         2  IN PROGRESS   \n",
      "16     1449217    Null  NCT02324335    Phase 2         2  IN PROGRESS   \n",
      "17     1449224    Null  NCT02324335    Phase 2         2  IN PROGRESS   \n",
      "18     1449224    Null  NCT02324335    Phase 2         2  IN PROGRESS   \n",
      "19     1449217    Null  NCT02324335    Phase 2         2  IN PROGRESS   \n",
      "20     1449217    Null  NCT02324335    Phase 2         2  IN PROGRESS   \n",
      "21   Not found    Null  NCT03512756  Phase 1/2         1  IN PROGRESS   \n",
      "22   Not found    Null  NCT02810951  Phase 1/2         2  IN PROGRESS   \n",
      "23   Not found    Null  NCT02810951  Phase 1/2         2  IN PROGRESS   \n",
      "24      992582    Null  NCT03460756    Phase 3         1         FAIL   \n",
      "25      992582    Null  NCT03460756    Phase 3         1         FAIL   \n",
      "26   Not found    Null  NCT02842541    Phase 1         1  IN PROGRESS   \n",
      "27   Not found    Null  NCT02759562    Phase 1         1  IN PROGRESS   \n",
      "28   Not found    Null  NCT02759562    Phase 1         1  IN PROGRESS   \n",
      "29     1121942    Null  NCT00718718    Phase 3         1  IN PROGRESS   \n",
      "..         ...     ...          ...        ...       ...          ...   \n",
      "296       Null    Null  NCT03199885    Phase 1         1      STOPPED   \n",
      "297       Null    Null  NCT03199885    Phase 1         1      STOPPED   \n",
      "298       Null    Null  NCT03199885    Phase 1         1      STOPPED   \n",
      "299      27229    Null  NCT01393730  Phase 1/2         1  IN PROGRESS   \n",
      "300      27229    Null  NCT01393730  Phase 1/2         1  IN PROGRESS   \n",
      "301      27229    Null  NCT01393730  Phase 1/2         1  IN PROGRESS   \n",
      "302    2197900    Null  NCT03047395    Phase 3         2      STOPPED   \n",
      "303  Not found    Null  NCT02582697       Null         2         FAIL   \n",
      "304  Not found    Null  NCT02582697       Null         2         FAIL   \n",
      "305  Not found    Null  NCT02582697       Null         2         FAIL   \n",
      "306  Not found    Null  NCT02582697       Null         2         FAIL   \n",
      "307  Not found    Null  NCT02582697       Null         2         FAIL   \n",
      "308    1121862    Null  NCT03473977    Phase 3         1         FAIL   \n",
      "309    1121862    Null  NCT03473977    Phase 3         1         FAIL   \n",
      "310    2197863    Null  NCT03382899    Phase 3         2  IN PROGRESS   \n",
      "311    2197863    Null  NCT03382899    Phase 3         2  IN PROGRESS   \n",
      "312      14805    Null  NCT00404066       Null         0         FAIL   \n",
      "313      14805    Null  NCT00404066       Null         0         FAIL   \n",
      "314      14805    Null  NCT00404066       Null         0         FAIL   \n",
      "315      14805    Null  NCT00404066       Null         0         FAIL   \n",
      "316      14805    Null  NCT00404066       Null         0         FAIL   \n",
      "317      14805    Null  NCT00404066       Null         0         FAIL   \n",
      "318      14805    Null  NCT00404066       Null         0         FAIL   \n",
      "319      14805    Null  NCT00404066       Null         0         FAIL   \n",
      "320     675130    Null  NCT00404066       Null         0         FAIL   \n",
      "321     675130    Null  NCT00404066       Null         0         FAIL   \n",
      "322     675130    Null  NCT00404066       Null         0         FAIL   \n",
      "323     675130    Null  NCT00404066       Null         0         FAIL   \n",
      "324     675130    Null  NCT00404066       Null         0         FAIL   \n",
      "325     675130    Null  NCT00404066       Null         0         FAIL   \n",
      "\n",
      "            ...         COMPANY_SCORE  \\\n",
      "0           ...                     1   \n",
      "1           ...                     1   \n",
      "2           ...                     1   \n",
      "3           ...                  Null   \n",
      "4           ...                     1   \n",
      "5           ...                  Null   \n",
      "6           ...                     1   \n",
      "7           ...                     1   \n",
      "8           ...                     1   \n",
      "9           ...                     1   \n",
      "10          ...                     1   \n",
      "11          ...                     1   \n",
      "12          ...                     1   \n",
      "13          ...                     1   \n",
      "14          ...                  Null   \n",
      "15          ...                     1   \n",
      "16          ...                     1   \n",
      "17          ...                     1   \n",
      "18          ...                     1   \n",
      "19          ...                     1   \n",
      "20          ...                     1   \n",
      "21          ...                  Null   \n",
      "22          ...                     1   \n",
      "23          ...                     1   \n",
      "24          ...                  Null   \n",
      "25          ...                  Null   \n",
      "26          ...                     1   \n",
      "27          ...                     1   \n",
      "28          ...                     1   \n",
      "29          ...                  Null   \n",
      "..          ...                   ...   \n",
      "296         ...                     1   \n",
      "297         ...                     1   \n",
      "298         ...                     1   \n",
      "299         ...                  Null   \n",
      "300         ...                  Null   \n",
      "301         ...                  Null   \n",
      "302         ...                     1   \n",
      "303         ...                     1   \n",
      "304         ...                     1   \n",
      "305         ...                     1   \n",
      "306         ...                     1   \n",
      "307         ...                     1   \n",
      "308         ...                  Null   \n",
      "309         ...                  Null   \n",
      "310         ...                  Null   \n",
      "311         ...                  Null   \n",
      "312         ...                  Null   \n",
      "313         ...                  Null   \n",
      "314         ...                  Null   \n",
      "315         ...                  Null   \n",
      "316         ...                  Null   \n",
      "317         ...                  Null   \n",
      "318         ...                  Null   \n",
      "319         ...                  Null   \n",
      "320         ...                  Null   \n",
      "321         ...                  Null   \n",
      "322         ...                  Null   \n",
      "323         ...                  Null   \n",
      "324         ...                  Null   \n",
      "325         ...                  Null   \n",
      "\n",
      "                                   INDICATION INDICATION_ID  \\\n",
      "0                                   Hepatitis       D006505   \n",
      "1                                   Hepatitis       D006505   \n",
      "2                                   Hepatitis       D006505   \n",
      "3                               Low Back Pain       D017116   \n",
      "4                                   Carcinoma       D002277   \n",
      "5                                   Carcinoma       D002277   \n",
      "6                        Zika Virus Infection       DX90254   \n",
      "7                    Mucopolysaccharidosis II       D016532   \n",
      "8                       Myocardial Infarction       D009203   \n",
      "9                       Myocardial Infarction       D009203   \n",
      "10                           Neuropathic Pain       DX90161   \n",
      "11                   Type 2 Diabetes Mellitus       D003924   \n",
      "12                   Type 2 Diabetes Mellitus       D003924   \n",
      "13                   Type 2 Diabetes Mellitus       D003924   \n",
      "14   Castration-Resistant Prostatic Neoplasms       D064129   \n",
      "15                                  Mucositis       D052016   \n",
      "16                                  Mucositis       D052016   \n",
      "17                                  Mucositis       D052016   \n",
      "18                                  Mucositis       D052016   \n",
      "19                                  Mucositis       D052016   \n",
      "20                                  Mucositis       D052016   \n",
      "21                        Prostatic Neoplasms       D011471   \n",
      "22          Epidermolysis Bullosa Dystrophica       D016108   \n",
      "23          Epidermolysis Bullosa Dystrophica       D016108   \n",
      "24                             Mood Disorders       D019964   \n",
      "25                             Mood Disorders       D019964   \n",
      "26                                       Null          Null   \n",
      "27                         Ulcerative Colitis       D003093   \n",
      "28                         Ulcerative Colitis       D003093   \n",
      "29                     Polymyalgia Rheumatica       D011111   \n",
      "..                                        ...           ...   \n",
      "296                                      Null          Null   \n",
      "297                                      Null          Null   \n",
      "298                                      Null          Null   \n",
      "299                                 Carcinoma       D002277   \n",
      "300                                 Carcinoma       D002277   \n",
      "301                                 Carcinoma       D002277   \n",
      "302                                 Psoriasis       D011565   \n",
      "303                                      Null          Null   \n",
      "304                                      Null          Null   \n",
      "305                                      Null          Null   \n",
      "306                                      Null          Null   \n",
      "307                                      Null          Null   \n",
      "308     Chronic Obstructive Pulmonary Disease       D029424   \n",
      "309     Chronic Obstructive Pulmonary Disease       D029424   \n",
      "310                                 Carcinoma       D002277   \n",
      "311                                 Carcinoma       D002277   \n",
      "312                         Colonic Neoplasms       D003110   \n",
      "313                         Colonic Neoplasms       D003110   \n",
      "314                         Colonic Neoplasms       D003110   \n",
      "315                         Colonic Neoplasms       D003110   \n",
      "316                         Colonic Neoplasms       D003110   \n",
      "317                         Colonic Neoplasms       D003110   \n",
      "318                         Colonic Neoplasms       D003110   \n",
      "319                         Colonic Neoplasms       D003110   \n",
      "320                         Colonic Neoplasms       D003110   \n",
      "321                         Colonic Neoplasms       D003110   \n",
      "322                         Colonic Neoplasms       D003110   \n",
      "323                         Colonic Neoplasms       D003110   \n",
      "324                         Colonic Neoplasms       D003110   \n",
      "325                         Colonic Neoplasms       D003110   \n",
      "\n",
      "    INDICATION_NONAMBIG INDICATION_SCORE INTERVENTION_TYPE  \\\n",
      "0                     1                1              Drug   \n",
      "1                     1                1              Drug   \n",
      "2                     1                1              Drug   \n",
      "3                     1                1        Biological   \n",
      "4                     1                1              Drug   \n",
      "5                     1                1              Drug   \n",
      "6                     1                1        Biological   \n",
      "7                     1                1        Biological   \n",
      "8                     1                1             Other   \n",
      "9                     1                1        Biological   \n",
      "10                    1                1              Null   \n",
      "11                    1                1              Drug   \n",
      "12                    1                1              Drug   \n",
      "13                    1                1              Drug   \n",
      "14                    1                1              Null   \n",
      "15                    1                1              Drug   \n",
      "16                    1                1             Other   \n",
      "17                    1                1              Drug   \n",
      "18                    1                1             Other   \n",
      "19                    1                1              Drug   \n",
      "20                    1                1             Other   \n",
      "21                    1                1              Drug   \n",
      "22                    1                1           Genetic   \n",
      "23                    1                1              Drug   \n",
      "24                    1                1              Drug   \n",
      "25                    1                1              Drug   \n",
      "26                 Null             Null              Drug   \n",
      "27                    1                1              Drug   \n",
      "28                    1                1              Drug   \n",
      "29                    1                1              Drug   \n",
      "..                  ...              ...               ...   \n",
      "296                Null             Null             Other   \n",
      "297                Null             Null             Other   \n",
      "298                Null             Null        Biological   \n",
      "299                   1                1              Drug   \n",
      "300                   1                1              Drug   \n",
      "301                   1                1              Drug   \n",
      "302                   1                1        Biological   \n",
      "303                Null             Null              Drug   \n",
      "304                Null             Null              Drug   \n",
      "305                Null             Null              Drug   \n",
      "306                Null             Null              Drug   \n",
      "307                Null             Null              Drug   \n",
      "308                   1                1        Biological   \n",
      "309                   1                1        Biological   \n",
      "310                   1                1        Biological   \n",
      "311                   1                1              Drug   \n",
      "312                   1                1              Drug   \n",
      "313                   1                1              Drug   \n",
      "314                   1                1              Drug   \n",
      "315                   1                1              Drug   \n",
      "316                   1                1              Drug   \n",
      "317                   1                1              Drug   \n",
      "318                   1                1              Drug   \n",
      "319                   1                1              Drug   \n",
      "320                   1                1              Drug   \n",
      "321                   1                1              Drug   \n",
      "322                   1                1              Drug   \n",
      "323                   1                1              Drug   \n",
      "324                   1                1              Drug   \n",
      "325                   1                1              Drug   \n",
      "\n",
      "                                     INTERVENTION_NAME  \\\n",
      "0                                              SB 9200   \n",
      "1                                              Placebo   \n",
      "2                                            Tenofovir   \n",
      "3    TAB001, Recombinant Humanized anti-PD-1 Monocl...   \n",
      "4                                               CA-170   \n",
      "5                                              APX3330   \n",
      "6                                             GLS-5700   \n",
      "7                                               SB-913   \n",
      "8                           Human Serum Albumin-HSA 5%   \n",
      "9           Allogeneic human cardiac stem cells (CSCs)   \n",
      "10                                                Null   \n",
      "11                                             Placebo   \n",
      "12                                        Rosuvastatin   \n",
      "13                                              PXL770   \n",
      "14                                                Null   \n",
      "15                                          Brilacidin   \n",
      "16                                             Placebo   \n",
      "17                                          Brilacidin   \n",
      "18                                             Placebo   \n",
      "19                                          Brilacidin   \n",
      "20                                             Placebo   \n",
      "21   Combination of metyrosine-derivative with low-...   \n",
      "22                                             FCX-007   \n",
      "23                                      Sterile Saline   \n",
      "24                                          Ganaxolone   \n",
      "25                                             Placebo   \n",
      "26                                             EBI-031   \n",
      "27                                       Andecaliximab   \n",
      "28                                             Placebo   \n",
      "29                                             Placebo   \n",
      "..                                                 ...   \n",
      "296                                            Placebo   \n",
      "297                         Quality-of-Life Assessment   \n",
      "298                                        Trastuzumab   \n",
      "299                                Abiraterone acetate   \n",
      "300                                        Dutasteride   \n",
      "301                                         Prednisone   \n",
      "302                                       risankizumab   \n",
      "303                    Pegylated G-CSF (Pegfilgrastim)   \n",
      "304                                         Filgrastim   \n",
      "305         Bleomycin (active name: Bleomycin Sulfate)   \n",
      "306                                          Etoposide   \n",
      "307                                          Cisplatin   \n",
      "308                                       Benralizumab   \n",
      "309                                            Placebo   \n",
      "310                                             AM0010   \n",
      "311                                      Pembrolizumab   \n",
      "312                                          Docetaxel   \n",
      "313                                          Lapatinib   \n",
      "314                                        Doxorubicin   \n",
      "315                                   Cyclophosphamide   \n",
      "316                                      Pegfilgrastim   \n",
      "317                                         Filgrastim   \n",
      "318                                      Dexamethasone   \n",
      "319                                        Trastuzumab   \n",
      "320                                          Docetaxel   \n",
      "321                                          Lapatinib   \n",
      "322                                        Doxorubicin   \n",
      "323                                   Cyclophosphamide   \n",
      "324                                      Pegfilgrastim   \n",
      "325                                         Filgrastim   \n",
      "\n",
      "                                          DESCRIPTIONS  \\\n",
      "0                                              SB 9200   \n",
      "1                                                 Null   \n",
      "2                                                 Null   \n",
      "3    TAB001 is a programmed death-1 (PD-1) immune c...   \n",
      "4    Dose escalation stage (Phase 1a) accelerated t...   \n",
      "5    APX3330 will be supplied as 60 and 120 mg oral...   \n",
      "6    GLS-5700 contains a single plasmid containing ...   \n",
      "7    Single dose of each of the 3 components of SB-...   \n",
      "8    Human Serum Albumin (HSA) is a well-known phys...   \n",
      "9    Allogeneic human CSCs is a new cell medicine b...   \n",
      "10                                                Null   \n",
      "11                                                 MAD   \n",
      "12                                                 DDI   \n",
      "13                                                 MAD   \n",
      "14                                                Null   \n",
      "15           Oral Rinse used 3 times daily for 7 weeks   \n",
      "16                                                Null   \n",
      "17           Oral Rinse used 3 times daily for 7 weeks   \n",
      "18                                                Null   \n",
      "19           Oral Rinse used 3 times daily for 7 weeks   \n",
      "20                                                Null   \n",
      "21           Daily oral combination therapy for cancer   \n",
      "22   FCX-007 is a genetically modified cell product...   \n",
      "23   In Phase II (subjects 7 through 12), FCX-007 t...   \n",
      "24                                                Oral   \n",
      "25                                                Oral   \n",
      "26                                                Null   \n",
      "27             Administered via subcutaneous injection   \n",
      "28             Administered via subcutaneous injection   \n",
      "29   Placebo will be adminstered subcutaneously as ...   \n",
      "..                                                 ...   \n",
      "296                                           Given IV   \n",
      "297                                  Ancillary studies   \n",
      "298                                           Given IV   \n",
      "299                                               Null   \n",
      "300                                               Null   \n",
      "301                                               Null   \n",
      "302  Risankizumab 150 mg administered by subcutaneo...   \n",
      "303  Standard Arm: 6 mg SCI on day 6 of a 21-day cy...   \n",
      "304  Standard Arm: 10 mcg/kg/day on day6, until pos...   \n",
      "305  Standard Arm: Bleomycin 30,000 international u...   \n",
      "306  Standard Arm: Etoposide 100 mg/m2 IV on days 1...   \n",
      "307  Standard Arm: Cisplatin 20 mg/m2 IV on days 1,...   \n",
      "308  Monoclonal antibody originally developed for t...   \n",
      "309  Placebo will be injected in 3 monthly doses of...   \n",
      "310                          AM0010 plus Pembrolizumab   \n",
      "311                                Pembrolizumab Alone   \n",
      "312  100 mg/m2, intravenously every 3 weeks for 4 c...   \n",
      "313  1250 mg, tablets, oral daily during treatment ...   \n",
      "314  60 mg/m2, intravenously every 2 weeks for 4 cy...   \n",
      "315  600 mg/m2, intravenously every 2 weeks for 4 c...   \n",
      "316  6 mg, subcutaneously on day 2 of all cytotoxic...   \n",
      "317  300 or 480 mcg, subcutaneously on days 3 to 10...   \n",
      "318  8 mg, oral taken twice a day for 3 days starti...   \n",
      "319  Loading dose 8 mg/kg, then 6 mg/kg, intravenou...   \n",
      "320  100 mg/m2, intravenously every 3 weeks for 4 c...   \n",
      "321  1250 mg, tablets, oral daily during treatment ...   \n",
      "322  60 mg/m2, intravenously every 2 weeks for 4 cy...   \n",
      "323  600 mg/m2, intravenously every 2 weeks for 4 c...   \n",
      "324  6 mg, subcutaneously on day 2 of all cytotoxic...   \n",
      "325  300 or 480 mcg, subcutaneously on days 3 to 10...   \n",
      "\n",
      "                                            OTHER_NAME INDIC_INTERVENTIONS  \n",
      "0                                               SB9200                True  \n",
      "1                                                 Null               False  \n",
      "2                                                 Null               False  \n",
      "3                                                JS001                True  \n",
      "4                                                 Null                True  \n",
      "5                                                E3330                True  \n",
      "6                                                 Null                True  \n",
      "7                                                 Null                True  \n",
      "8                                                 Null               False  \n",
      "9                                           AlloCSC-01                True  \n",
      "10                                                Null               False  \n",
      "11                                                Null               False  \n",
      "12                                                Null               False  \n",
      "13                                                Null                True  \n",
      "14                                                Null               False  \n",
      "15                                            PMX30063                True  \n",
      "16                                 Water for Injection               False  \n",
      "17                                            PMX30063                True  \n",
      "18                                 Water for Injection               False  \n",
      "19                                            PMX30063                True  \n",
      "20                                 Water for Injection               False  \n",
      "21                                               SM-88                True  \n",
      "22   Genetically-Modified Autologous Human Dermal F...                True  \n",
      "23                                             Placebo               False  \n",
      "24                                                Null                True  \n",
      "25                                                Null               False  \n",
      "26                                                Null                True  \n",
      "27                                             GS-5745                True  \n",
      "28                                                Null               False  \n",
      "29                                                Null               False  \n",
      "..                                                 ...                 ...  \n",
      "296                  placebo therapy;PLCB;sham therapy               False  \n",
      "297                         Quality of Life Assessment               False  \n",
      "298  ABP 980;Anti-c-ERB-2;Anti-c-erbB2 Monoclonal A...                True  \n",
      "299                                             CB7630               False  \n",
      "300                                            Avodart               False  \n",
      "301                                     Corticosteroid                True  \n",
      "302                                 ABBV-066 BI 655066                True  \n",
      "303  Neulasta Syringe with Automatic Needle Guard (...               False  \n",
      "304  Neupogen (Amgen);Nivestim (Hospira);Tevagrasti...               False  \n",
      "305  Blenamax (Aspen);DBL Bleomycin Sulphate (Willo...               False  \n",
      "306  DBL Etoposide Injection (Hospira);Etopophos (B...                True  \n",
      "307  Cisplatin Ebewe (Sandoz);Cisplatin injection (...               False  \n",
      "308                                            Fasenra                True  \n",
      "309                                               Null               False  \n",
      "310                                               Null                True  \n",
      "311                                               Null               False  \n",
      "312                                           Taxotere               False  \n",
      "313                                           GW572016                True  \n",
      "314                            Adriamycin;Adriablastin               False  \n",
      "315                                       Cytoxan;ASTA               False  \n",
      "316                                           Neulasta               False  \n",
      "317  Neupogen;Granulocyte Colony-Stimulating Factor...               False  \n",
      "318                                            Adexone               False  \n",
      "319                                          Herceptin               False  \n",
      "320                                           Taxotere               False  \n",
      "321                                           GW572016                True  \n",
      "322                            Adriamycin;Adriablastin               False  \n",
      "323                                       Cytoxan;ASTA               False  \n",
      "324                                           Neulasta               False  \n",
      "325  Neupogen;Granulocyte Colony-Stimulating Factor...               False  \n",
      "\n",
      "[326 rows x 25 columns],        TWID             TWEET_ID  \\\n",
      "0     19430   991798269239062528   \n",
      "1     19430   991798269239062528   \n",
      "2     19477   990612942524690432   \n",
      "3     19477   990612942524690432   \n",
      "4     19522   989608833084477440   \n",
      "5     19522   989608833084477440   \n",
      "6     19526   989502325533310976   \n",
      "7     19526   989502325533310976   \n",
      "8     19565   988521674436960258   \n",
      "9     19712   985222431202795521   \n",
      "10    19772   983810627549519873   \n",
      "11    19778   983712108683644928   \n",
      "12    19796   983048102453137408   \n",
      "13    19830   982361076615516161   \n",
      "14    19830   982361076615516161   \n",
      "15    19830   982361076615516161   \n",
      "16    19830   982361076615516161   \n",
      "17    19830   982361076615516161   \n",
      "18    19830   982361076615516161   \n",
      "19    19830   982361076615516161   \n",
      "20    19830   982361076615516161   \n",
      "21    19830   982361076615516161   \n",
      "22    19830   982361076615516161   \n",
      "23    19830   982361076615516161   \n",
      "24    19830   982361076615516161   \n",
      "25    19830   982361076615516161   \n",
      "26    19830   982361076615516161   \n",
      "27    19830   982361076615516161   \n",
      "28    19836   982255437188775937   \n",
      "29    19920   980103708926205952   \n",
      "..      ...                  ...   \n",
      "297   71177  1008721334027931649   \n",
      "298   71184  1008400157065515010   \n",
      "299   71184  1008400157065515010   \n",
      "300   71184  1008400157065515010   \n",
      "301   71206  1007992469328416768   \n",
      "302   71214  1007728226167328768   \n",
      "303   71214  1007728226167328768   \n",
      "304   71214  1007728226167328768   \n",
      "305   71218  1007626689931894784   \n",
      "306   71239  1007003456375263233   \n",
      "307   71268  1006339070421798915   \n",
      "308   71277  1006185066576347136   \n",
      "309   74381  1009078221005033472   \n",
      "310  116396  1011617239773208578   \n",
      "311  116399  1011457286303354880   \n",
      "312  116409  1010937748306481153   \n",
      "313  122871  1012333898615984129   \n",
      "314  122871  1012333898615984129   \n",
      "315  122880  1011977695536836608   \n",
      "316  122900  1011352104278155264   \n",
      "317  122900  1011352104278155264   \n",
      "318  122900  1011352104278155264   \n",
      "319  122900  1011352104278155264   \n",
      "320  122925  1010544287359086593   \n",
      "321  132553  1012453525979267077   \n",
      "322  132553  1012453525979267077   \n",
      "323  132553  1012453525979267077   \n",
      "324  135766  1012439269128986626   \n",
      "325  135766  1012439269128986626   \n",
      "326  138975  1012504783897362433   \n",
      "\n",
      "                                                 TWEET              SYNONYMS  \\\n",
      "0    Study by @TheCrick investigators may explain w...             LAPATINIB   \n",
      "1    Study by @TheCrick investigators may explain w...             LAPATINIB   \n",
      "2    Neuraltus Weighs Future of Lead Candidate NP00...                 NP001   \n",
      "3    Neuraltus Weighs Future of Lead Candidate NP00...                 NP001   \n",
      "4    Neuraltus lead candidate NP001 fails confirmat...                 NP001   \n",
      "5    Neuraltus lead candidate NP001 fails confirmat...                 NP001   \n",
      "6     Neuraltus Weighs Future of Lead Candidate NP0...                 NP001   \n",
      "7     Neuraltus Weighs Future of Lead Candidate NP0...                 NP001   \n",
      "8    After a failed Phase IIb trial and a Phase III...           AMYLOIDOSIS   \n",
      "9    vTv Therapeutics ($VTVT) Halts Trials of #Alzh...            AZELIRAGON   \n",
      "10   Shares of vTv Therapeutics ($VTVT) plunge afte...            AZELIRAGON   \n",
      "11   vTv Therapeutics ($VTVT) Halts Trials of #Alzh...            AZELIRAGON   \n",
      "12    @Incyte @Merck Halt Phase III #ClinicalTrial ...  EPACADOSTAT/KEYTRUDA   \n",
      "13   Phase III trial failure for @Incyte's Epacados...           EPACADOSTAT   \n",
      "14   Phase III trial failure for @Incyte's Epacados...           EPACADOSTAT   \n",
      "15   Phase III trial failure for @Incyte's Epacados...           EPACADOSTAT   \n",
      "16   Phase III trial failure for @Incyte's Epacados...           EPACADOSTAT   \n",
      "17   Phase III trial failure for @Incyte's Epacados...           EPACADOSTAT   \n",
      "18   Phase III trial failure for @Incyte's Epacados...           EPACADOSTAT   \n",
      "19   Phase III trial failure for @Incyte's Epacados...           EPACADOSTAT   \n",
      "20   Phase III trial failure for @Incyte's Epacados...           EPACADOSTAT   \n",
      "21   Phase III trial failure for @Incyte's Epacados...           EPACADOSTAT   \n",
      "22   Phase III trial failure for @Incyte's Epacados...           EPACADOSTAT   \n",
      "23   Phase III trial failure for @Incyte's Epacados...           EPACADOSTAT   \n",
      "24   Phase III trial failure for @Incyte's Epacados...           EPACADOSTAT   \n",
      "25   Phase III trial failure for @Incyte's Epacados...           EPACADOSTAT   \n",
      "26   Phase III trial failure for @Incyte's Epacados...              KEYTRUDA   \n",
      "27   Phase III trial failure for @Incyte's Epacados...              KEYTRUDA   \n",
      "28    @Incyte @Merck Halt Phase III #ClinicalTrial ...  EPACADOSTAT/KEYTRUDA   \n",
      "29    @AblynxABLX and Protagonist Therapeutics ($PT...                  Null   \n",
      "..                                                 ...                   ...   \n",
      "297   @US_FDA Lifts Clinical Hold on @SolidBioDMD T...           GENETHERAPY   \n",
      "298  $TEVA Halts Phase III Trial of Fremanezumab in...          FREMANEZUMAB   \n",
      "299  $TEVA Halts Phase III Trial of Fremanezumab in...          FREMANEZUMAB   \n",
      "300  $TEVA Halts Phase III Trial of Fremanezumab in...          FREMANEZUMAB   \n",
      "301   @Vical Halts Development of HSV-2 Vaccine aft...                 HSV-2   \n",
      "302  Citing likely failure $TEVA halts Phase III tr...          FREMANEZUMAB   \n",
      "303  Citing likely failure $TEVA halts Phase III tr...          FREMANEZUMAB   \n",
      "304  Citing likely failure $TEVA halts Phase III tr...          FREMANEZUMAB   \n",
      "305  $TEVA Halts Phase III Trial of Fremanezumab in...              oowKWW16   \n",
      "306  Citing \"oral intolerability\" @flexpharma  halt...               FLX-787   \n",
      "307  After Phase II failure  @Vical halts developme...                 HSV-2   \n",
      "308   @Vical Halts Development of HSV-2 Vaccine aft...                 HSV-2   \n",
      "309  $SRPT I'm impressed\\n$SLDB $PFE\\n\\nA Gene Ther...          GENE THERAPY   \n",
      "310  Gossamer Bio obtains exclusive license for wor...                 HIF-1   \n",
      "311  The potential use of novel [11C]-radiolabeled ...                 PKG-1   \n",
      "312  Preclinical data for Glaceum's HSG-4112 curren...              HSG-4112   \n",
      "313   @ArsanisInc Halts Phase II Trial of #Pneumoni...                ASN100   \n",
      "314   @ArsanisInc Halts Phase II Trial of #Pneumoni...                ASN100   \n",
      "315   @Summitplc Plans Cost Cuts Stock Falls 80% af...             EZUTROMID   \n",
      "316  After Phase II failure @MerrimackPharma scraps...                MM-141   \n",
      "317  After Phase II failure @MerrimackPharma scraps...                MM-141   \n",
      "318  After Phase II failure @MerrimackPharma scraps...                MM-141   \n",
      "319  After Phase II failure @MerrimackPharma scraps...                MM-141   \n",
      "320   @US_FDA Lifts Clinical Hold on @SolidBioDMD T...           GENETHERAPY   \n",
      "321  Finally Celgene wins Anemia drug luspatercept ...          LUSPATERCEPT   \n",
      "322  Finally Celgene wins Anemia drug luspatercept ...          LUSPATERCEPT   \n",
      "323  Finally Celgene wins Anemia drug luspatercept ...          LUSPATERCEPT   \n",
      "324  Anticipating failure @ArsanisInc ends Phase II...                ASN100   \n",
      "325  Anticipating failure @ArsanisInc ends Phase II...                ASN100   \n",
      "326  RT @adamfeuerstein $XLRN blood disease drug hi...         PIVOTAL TRIAL   \n",
      "\n",
      "    MOLREGNO_1 ACRONYM       NCT_ID    PHASE  N_PHASES      OUTCOME  \\\n",
      "0       675130    Null  NCT00404066     Null         0         FAIL   \n",
      "1       675130    Null  NCT00404066     Null         0         FAIL   \n",
      "2    Not found    Null  NCT02794857  Phase 2         1         FAIL   \n",
      "3    Not found    Null  NCT02794857  Phase 2         1         FAIL   \n",
      "4    Not found    Null  NCT02794857  Phase 2         1         FAIL   \n",
      "5    Not found    Null  NCT02794857  Phase 2         1         FAIL   \n",
      "6    Not found    Null  NCT02794857  Phase 2         1         FAIL   \n",
      "7    Not found    Null  NCT02794857  Phase 2         1         FAIL   \n",
      "8         Null    Null         Null  Phase 3         2         FAIL   \n",
      "9      2197800    Null  NCT02916056  Phase 3         1      STOPPED   \n",
      "10     2197800    Null  NCT02916056  Phase 3         1         FAIL   \n",
      "11     2197800    Null  NCT02916056  Phase 3         1      STOPPED   \n",
      "12        Null    Null         Null  Phase 3         1         FAIL   \n",
      "13     1927218    Null  NCT03085914  Phase 3         1         FAIL   \n",
      "14     1927218    Null  NCT03085914  Phase 3         1         FAIL   \n",
      "15     1927218    Null  NCT03085914  Phase 3         1         FAIL   \n",
      "16     1927218    Null  NCT03085914  Phase 3         1         FAIL   \n",
      "17     1927218    Null  NCT03085914  Phase 3         1         FAIL   \n",
      "18     1927218    Null  NCT03085914  Phase 3         1         FAIL   \n",
      "19     1927218    Null  NCT03085914  Phase 3         1         FAIL   \n",
      "20     1927218    Null  NCT03085914  Phase 3         1         FAIL   \n",
      "21     1927218    Null  NCT03085914  Phase 3         1         FAIL   \n",
      "22     1927218    Null  NCT03085914  Phase 3         1         FAIL   \n",
      "23     1927218    Null  NCT03085914  Phase 3         1         FAIL   \n",
      "24     1927218    Null  NCT03085914  Phase 3         1         FAIL   \n",
      "25     1927218    Null  NCT03085914  Phase 3         1         FAIL   \n",
      "26     1626777    Null  NCT03362060  Phase 3         1         FAIL   \n",
      "27     1626777    Null  NCT03362060  Phase 3         1         FAIL   \n",
      "28        Null    Null         Null  Phase 3         1         FAIL   \n",
      "29        Null    PTGX         Null  Phase 2         1         FAIL   \n",
      "..         ...     ...          ...      ...       ...          ...   \n",
      "297       Null    Null  NCT01906541     Null         0  IN PROGRESS   \n",
      "298       Null    Null  NCT02945046  Phase 3         1         FAIL   \n",
      "299       Null    Null  NCT02945046  Phase 3         1         FAIL   \n",
      "300       Null    Null  NCT02945046  Phase 3         1         FAIL   \n",
      "301  Not found    Null         Null  Phase 2         1         FAIL   \n",
      "302       Null    Null  NCT02945046  Phase 3         1         FAIL   \n",
      "303       Null    Null  NCT02945046  Phase 3         1         FAIL   \n",
      "304       Null    Null  NCT02945046  Phase 3         1         FAIL   \n",
      "305  Not found    Null         Null  Phase 3         1         FAIL   \n",
      "306  Not found    Null  NCT03338114  Phase 2         1      STOPPED   \n",
      "307  Not found    Null         Null  Phase 2         1         FAIL   \n",
      "308  Not found    Null         Null  Phase 2         1         FAIL   \n",
      "309       Null    Null  NCT03507686     Null         0          N/I   \n",
      "310  Not found    Null  NCT00466583     Null         1  IN PROGRESS   \n",
      "311  Not found    Null         Null     Null         0          N/I   \n",
      "312  Not found    Null         Null  Phase 1         1  IN PROGRESS   \n",
      "313  Not found    Null  NCT02940626  Phase 2         1         FAIL   \n",
      "314  Not found    Null  NCT02940626  Phase 2         1         FAIL   \n",
      "315       Null    Null  NCT02858362  Phase 2         1         FAIL   \n",
      "316  Not found    Null  NCT02538627  Phase 2         1         FAIL   \n",
      "317  Not found    Null  NCT02538627  Phase 2         1         FAIL   \n",
      "318  Not found    Null  NCT02538627  Phase 2         1         FAIL   \n",
      "319  Not found    Null  NCT02538627  Phase 2         1         FAIL   \n",
      "320       Null    Null  NCT01906541     Null         0  IN PROGRESS   \n",
      "321    1592363    Null  NCT03342404  Phase 3         1      SUCCESS   \n",
      "322    1592363    Null  NCT03342404  Phase 3         1      SUCCESS   \n",
      "323    1592363    Null  NCT03342404  Phase 3         1      SUCCESS   \n",
      "324  Not found    Null  NCT02940626  Phase 2         1         FAIL   \n",
      "325  Not found    Null  NCT02940626  Phase 2         1         FAIL   \n",
      "326       Null    Null         Null     Null         1      SUCCESS   \n",
      "\n",
      "            ...         COMPANY_SCORE                    INDICATION  \\\n",
      "0           ...                  Null             Colonic Neoplasms   \n",
      "1           ...                  Null             Colonic Neoplasms   \n",
      "2           ...                     1             Alzheimer Disease   \n",
      "3           ...                     1             Alzheimer Disease   \n",
      "4           ...                     1             Alzheimer Disease   \n",
      "5           ...                     1             Alzheimer Disease   \n",
      "6           ...                     1             Alzheimer Disease   \n",
      "7           ...                     1             Alzheimer Disease   \n",
      "8           ...                  Null  Primary Systemic Amyloidosis   \n",
      "9           ...                     1             Alzheimer Disease   \n",
      "10          ...                     1             Alzheimer Disease   \n",
      "11          ...                     1             Alzheimer Disease   \n",
      "12          ...                     1      Female Genital Neoplasms   \n",
      "13          ...                  Null      Female Genital Neoplasms   \n",
      "14          ...                  Null      Female Genital Neoplasms   \n",
      "15          ...                  Null      Female Genital Neoplasms   \n",
      "16          ...                  Null      Female Genital Neoplasms   \n",
      "17          ...                  Null      Female Genital Neoplasms   \n",
      "18          ...                  Null      Female Genital Neoplasms   \n",
      "19          ...                  Null      Female Genital Neoplasms   \n",
      "20          ...                  Null      Female Genital Neoplasms   \n",
      "21          ...                  Null      Female Genital Neoplasms   \n",
      "22          ...                  Null      Female Genital Neoplasms   \n",
      "23          ...                  Null      Female Genital Neoplasms   \n",
      "24          ...                  Null      Female Genital Neoplasms   \n",
      "25          ...                  Null      Female Genital Neoplasms   \n",
      "26          ...                  Null      Female Genital Neoplasms   \n",
      "27          ...                  Null      Female Genital Neoplasms   \n",
      "28          ...                     1      Female Genital Neoplasms   \n",
      "29          ...                     1                          Null   \n",
      "..          ...                   ...                           ...   \n",
      "297         ...                  Null                          Null   \n",
      "298         ...                     1              Cluster Headache   \n",
      "299         ...                     1              Cluster Headache   \n",
      "300         ...                     1              Cluster Headache   \n",
      "301         ...                  Null   Herpes Simplex Encephalitis   \n",
      "302         ...                     1              Cluster Headache   \n",
      "303         ...                     1              Cluster Headache   \n",
      "304         ...                     1              Cluster Headache   \n",
      "305         ...                     1              Cluster Headache   \n",
      "306         ...                  Null                          Null   \n",
      "307         ...                  Null   Herpes Simplex Encephalitis   \n",
      "308         ...                  Null   Herpes Simplex Encephalitis   \n",
      "309         ...                  Null          Muscular Dystrophies   \n",
      "310         ...                     1                          Null   \n",
      "311         ...                  Null                  Chronic Pain   \n",
      "312         ...                  Null                       Obesity   \n",
      "313         ...                  Null      Staphylococcal Pneumonia   \n",
      "314         ...                  Null      Staphylococcal Pneumonia   \n",
      "315         ...                  Null                          Null   \n",
      "316         ...                  Null      Hepatocellular Carcinoma   \n",
      "317         ...                  Null      Hepatocellular Carcinoma   \n",
      "318         ...                  Null      Hepatocellular Carcinoma   \n",
      "319         ...                  Null      Hepatocellular Carcinoma   \n",
      "320         ...                  Null                          Null   \n",
      "321         ...                     1                   Thalassemia   \n",
      "322         ...                     1                   Thalassemia   \n",
      "323         ...                     1                   Thalassemia   \n",
      "324         ...                  Null      Staphylococcal Pneumonia   \n",
      "325         ...                  Null      Staphylococcal Pneumonia   \n",
      "326         ...                  Null          Hematologic Diseases   \n",
      "\n",
      "    INDICATION_ID INDICATION_NONAMBIG INDICATION_SCORE INTERVENTION_TYPE  \\\n",
      "0         D003110                   1                1              Drug   \n",
      "1         D003110                   1                1              Drug   \n",
      "2         D000544                   1                1              Drug   \n",
      "3         D000544                   1                1              Drug   \n",
      "4         D000544                   1                1              Drug   \n",
      "5         D000544                   1                1              Drug   \n",
      "6         D000544                   1                1              Drug   \n",
      "7         D000544                   1                1              Drug   \n",
      "8         DX90345                   1                1              Null   \n",
      "9         D000544                   1                1              Drug   \n",
      "10        D000544                   1                1              Drug   \n",
      "11        D000544                   1                1              Drug   \n",
      "12        D005833                   1                1              Null   \n",
      "13        D005833                   1                1              Drug   \n",
      "14        D005833                   1                1              Drug   \n",
      "15        D005833                   1                1              Drug   \n",
      "16        D005833                   1                1              Drug   \n",
      "17        D005833                   1                1              Drug   \n",
      "18        D005833                   1                1              Drug   \n",
      "19        D005833                   1                1              Drug   \n",
      "20        D005833                   1                1              Drug   \n",
      "21        D005833                   1                1              Drug   \n",
      "22        D005833                   1                1              Drug   \n",
      "23        D005833                   1                1              Drug   \n",
      "24        D005833                   1                1              Drug   \n",
      "25        D005833                   1                1              Drug   \n",
      "26        D005833                   1                1              Drug   \n",
      "27        D005833                   1                1        Biological   \n",
      "28        D005833                   1                1              Null   \n",
      "29           Null                Null             Null              Null   \n",
      "..            ...                 ...              ...               ...   \n",
      "297          Null                Null             Null           Genetic   \n",
      "298       D003027                   1                1              Drug   \n",
      "299       D003027                   1                1              Drug   \n",
      "300       D003027                   1                1              Drug   \n",
      "301       D020803                   0                1              Null   \n",
      "302       D003027                   1                1              Drug   \n",
      "303       D003027                   1                1              Drug   \n",
      "304       D003027                   1                1              Drug   \n",
      "305       D003027                   1                1              Null   \n",
      "306          Null                Null             Null              Drug   \n",
      "307       D020803                   0                1              Null   \n",
      "308       D020803                   0                1              Null   \n",
      "309       D009136                   1                1              Drug   \n",
      "310          Null                Null             Null              Drug   \n",
      "311       D059350                   1                1              Null   \n",
      "312       D009765                   1                1              Null   \n",
      "313       D011023                   1                1              Drug   \n",
      "314       D011023                   1                1              Drug   \n",
      "315          Null                Null             Null              Drug   \n",
      "316       D006528                   1                1              Drug   \n",
      "317       D006528                   1                1              Drug   \n",
      "318       D006528                   1                1              Drug   \n",
      "319       D006528                   1                1              Drug   \n",
      "320          Null                Null             Null           Genetic   \n",
      "321       D013789                   1                1              Drug   \n",
      "322       D013789                   1                1             Other   \n",
      "323       D013789                   1                1             Other   \n",
      "324       D011023                   1                1              Drug   \n",
      "325       D011023                   1                1              Drug   \n",
      "326       D006402                   1                1              Null   \n",
      "\n",
      "                                 INTERVENTION_NAME  \\\n",
      "0                                    Dexamethasone   \n",
      "1                                      Trastuzumab   \n",
      "2                                            NP001   \n",
      "3                                          Placebo   \n",
      "4                                            NP001   \n",
      "5                                          Placebo   \n",
      "6                                            NP001   \n",
      "7                                          Placebo   \n",
      "8                                             Null   \n",
      "9                                   Azeliragon 5mg   \n",
      "10                                  Azeliragon 5mg   \n",
      "11                                  Azeliragon 5mg   \n",
      "12                                            Null   \n",
      "13                                Cyclophosphamide   \n",
      "14                                     Carboplatin   \n",
      "15                                     Epacadostat   \n",
      "16                                   Pembrolizumab   \n",
      "17                                     Oxaliplatin   \n",
      "18                                      Leucovorin   \n",
      "19                                  5-Fluorouracil   \n",
      "20                                     Gemcitabine   \n",
      "21                                  nab-Paclitaxel   \n",
      "22                                     Carboplatin   \n",
      "23                                      Paclitaxel   \n",
      "24                                      Pemetrexed   \n",
      "25                                       Cisplatin   \n",
      "26                                   Pembrolizumab   \n",
      "27                                         PVX-410   \n",
      "28                                            Null   \n",
      "29                                            Null   \n",
      "..                                             ...   \n",
      "297                           ex-vivo gene-therapy   \n",
      "298                                        Placebo   \n",
      "299                               Fremanezumab - A   \n",
      "300                               Fremanezumab - B   \n",
      "301                                           Null   \n",
      "302                                        Placebo   \n",
      "303                               Fremanezumab - A   \n",
      "304                               Fremanezumab - B   \n",
      "305                                           Null   \n",
      "306     FLX-787-ODT (orally disintigrating tablet)   \n",
      "307                                           Null   \n",
      "308                                           Null   \n",
      "309                                      AAV2-REP1   \n",
      "310  Intravenous EZN-2968 (anti-HIF-1a LNA AS-ODN)   \n",
      "311                                           Null   \n",
      "312                                           Null   \n",
      "313                                         ASN100   \n",
      "314                                        Placebo   \n",
      "315                                      ezutromid   \n",
      "316                                         MM-151   \n",
      "317                                         MM-121   \n",
      "318                                         MM-141   \n",
      "319                                     trametinib   \n",
      "320                           ex-vivo gene-therapy   \n",
      "321                                   Luspatercept   \n",
      "322                                        Placebo   \n",
      "323                     Best Supportive Care (BSC)   \n",
      "324                                         ASN100   \n",
      "325                                        Placebo   \n",
      "326                                           Null   \n",
      "\n",
      "                                          DESCRIPTIONS       OTHER_NAME  \\\n",
      "0    8 mg, oral taken twice a day for 3 days starti...          Adexone   \n",
      "1    Loading dose 8 mg/kg, then 6 mg/kg, intravenou...        Herceptin   \n",
      "2                                                 Null             Null   \n",
      "3                                                 Null             Null   \n",
      "4                                                 Null             Null   \n",
      "5                                                 Null             Null   \n",
      "6                                                 Null             Null   \n",
      "7                                                 Null             Null   \n",
      "8                                                 Null             Null   \n",
      "9                                                 Null           TTP488   \n",
      "10                                                Null           TTP488   \n",
      "11                                                Null           TTP488   \n",
      "12                                                Null             Null   \n",
      "13            Cyclophosphamide 50 mg orally once daily             Null   \n",
      "14         Carboplatin AUC 5 IV on Day 1 every 3 weeks             Null   \n",
      "15   Epacadostat oral twice-daily continuous daily ...       INCB024360   \n",
      "16               Pembrolizumab 200 mg IV every 3 weeks             Null   \n",
      "17           Oxaliplatin 85 mg/m^2 IV on Days 1 and 15             Null   \n",
      "18           Leucovorin 400 mg/m^2 IV on Days 1 and 15             Null   \n",
      "19   5-Fluorouracil total dose of 2400 mg/m^2 on Da...             Null   \n",
      "20     Gemcitabine 1000 mg/m^2 IV on Days 1, 8, and 15             Null   \n",
      "21   nab-Paclitaxel 125 mg/m^2 IV on Days 1, 8, and 15             Null   \n",
      "22         Carboplatin AUC 6 IV on Day 1 every 3 weeks             Null   \n",
      "23     Paclitaxel 200 mg/m^2 IV on Day 1 every 3 weeks             Null   \n",
      "24     Pemetrexed 500 mg/m^2 IV on Day 1 every 3 weeks             Null   \n",
      "25          Cisplatin 75 mg/m^2 on Day 1 every 3 weeks             Null   \n",
      "26   Pembrolizumab is a monoclonal antibody checkpo...         Keytruda   \n",
      "27   PVX-410 is a type of vaccine composed of 4 9-a...             Null   \n",
      "28                                                Null             Null   \n",
      "29                                                Null             Null   \n",
      "..                                                 ...              ...   \n",
      "297  transplantation autologous CD34+ cells, transd...             Null   \n",
      "298                                   Matching placebo             Null   \n",
      "299                                        iv infusion        TEV-48125   \n",
      "300                                        iv infusion        TEV-48125   \n",
      "301                                               Null             Null   \n",
      "302                                   Matching placebo             Null   \n",
      "303                                        iv infusion        TEV-48125   \n",
      "304                                        iv infusion        TEV-48125   \n",
      "305                                               Null             Null   \n",
      "306                         Oral Disintegrating Tablet             Null   \n",
      "307                                               Null             Null   \n",
      "308                                               Null             Null   \n",
      "309  Sub-retinal injection of AAV2-REP1 after vitre...     Gene Therapy   \n",
      "310  IV infusion of EZN 2968 given in 6 week cycles...             Null   \n",
      "311                                               Null             Null   \n",
      "312                                               Null             Null   \n",
      "313  monoclonal antibody combination of ASN-1 and A...  ASN-1 and ASN-2   \n",
      "314                                            Placebo             Null   \n",
      "315                                    oral suspension         SMTC1100   \n",
      "316                                             MM-151             Null   \n",
      "317                                             MM-121             Null   \n",
      "318                                             MM-141             Null   \n",
      "319                                        trametininb         MEKINIST   \n",
      "320  transplantation autologous CD34+ cells, transd...             Null   \n",
      "321  Subjects will start with luspatercept at 1 mg/...          ACE-536   \n",
      "322               Placebo, Subcutaneous, every 21 days    normal saline   \n",
      "323                         Best Supportive Care (BSC)             Null   \n",
      "324  monoclonal antibody combination of ASN-1 and A...  ASN-1 and ASN-2   \n",
      "325                                            Placebo             Null   \n",
      "326                                               Null             Null   \n",
      "\n",
      "    INDIC_INTERVENTIONS  \n",
      "0                 False  \n",
      "1                 False  \n",
      "2                  True  \n",
      "3                 False  \n",
      "4                  True  \n",
      "5                 False  \n",
      "6                  True  \n",
      "7                 False  \n",
      "8                 False  \n",
      "9                  True  \n",
      "10                 True  \n",
      "11                 True  \n",
      "12                False  \n",
      "13                False  \n",
      "14                False  \n",
      "15                 True  \n",
      "16                False  \n",
      "17                False  \n",
      "18                False  \n",
      "19                False  \n",
      "20                False  \n",
      "21                False  \n",
      "22                False  \n",
      "23                False  \n",
      "24                False  \n",
      "25                False  \n",
      "26                 True  \n",
      "27                False  \n",
      "28                False  \n",
      "29                 True  \n",
      "..                  ...  \n",
      "297                True  \n",
      "298               False  \n",
      "299                True  \n",
      "300                True  \n",
      "301               False  \n",
      "302               False  \n",
      "303                True  \n",
      "304                True  \n",
      "305               False  \n",
      "306                True  \n",
      "307               False  \n",
      "308               False  \n",
      "309                True  \n",
      "310                True  \n",
      "311               False  \n",
      "312               False  \n",
      "313                True  \n",
      "314               False  \n",
      "315                True  \n",
      "316               False  \n",
      "317               False  \n",
      "318                True  \n",
      "319               False  \n",
      "320                True  \n",
      "321                True  \n",
      "322               False  \n",
      "323               False  \n",
      "324                True  \n",
      "325               False  \n",
      "326               False  \n",
      "\n",
      "[327 rows x 25 columns]]\n"
     ]
    }
   ],
   "source": [
    "def true_interv(chunk):\n",
    "    for i in range(len(chunk)):\n",
    "        #if synonym in the 'INTERVENTION_NAME' or in the 'OTHER_NAME'\n",
    "        res_1 = re.findall(str(chunk.loc[i, 'SYNONYMS']).lower().replace('-', ''), chunk.loc[i, 'INTERVENTION_NAME'].lower().replace('-', ''))\n",
    "        res_2 = re.findall(str(chunk.loc[i, 'SYNONYMS']).lower().replace('-', ''), chunk.loc[i, 'OTHER_NAME'].lower().replace('-', ''))\n",
    "        if len(res_1) > 0 or len(res_2) > 0: #if yes that is the row we need\n",
    "            chunk.at[i, 'INDIC_INTERVENTIONS'] = 'True' #true matching\n",
    "    return chunk\n",
    "                   \n",
    "if __name__ == '__main__': #constructor\n",
    "    p = Pool(6)\n",
    "    listik = p.map(true_interv, chunks) #main function\n",
    "    print(listik) \n",
    "    \n",
    "df = df[0:0] #a frame for the further work\n",
    "for l in range(len(listik)):\n",
    "    df = df.append(listik[l]) #add updated chunks to the main table\n",
    "    \n",
    "df.index = np.arange(len(df)) #update the indexing"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 259,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>TWID</th>\n",
       "      <th>TIMES</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>4</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>16</td>\n",
       "      <td>10</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "  TWID TIMES\n",
       "0    4     1\n",
       "1   16    10"
      ]
     },
     "execution_count": 259,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#the table with information about rows copies (with the same twid)\n",
    "#we will need it not to delete all the information about nct_id's\n",
    "twids = pd.DataFrame(columns=['TWID', 'TIMES'])\n",
    "\n",
    "twids.at[0, 'TWID'] = df.iloc[0, 0] #add the first twid\n",
    "num = 0\n",
    "\n",
    "for i in range(1, len(df)):\n",
    "    if df.iloc[i, 0] != twids.iloc[num, 0]:\n",
    "        num += 1\n",
    "        twids.at[num, 'TWID'] = df.iloc[i, 0]         \n",
    "    \n",
    "i = 0\n",
    "j = 0\n",
    "counter = 0\n",
    "while i != len(df):\n",
    "    if df.iloc[i, 0] == twids.iloc[j, 0]:\n",
    "        i += 1\n",
    "        counter += 1\n",
    "    elif df.iloc[i, 0] != twids.iloc[j, 0]:\n",
    "        twids.at[j, 'TIMES'] = counter\n",
    "        i += 1\n",
    "        j += 1\n",
    "        counter = 1 \n",
    "        \n",
    "twids[:2]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 260,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "946\n"
     ]
    }
   ],
   "source": [
    "#This is cell to clean the ones that are not correct\n",
    "cleaner = [] #list with indexes to clean\n",
    "for i in range(len(df)):\n",
    "    if str(df.loc[i, 'INDIC_INTERVENTIONS']) != 'True': #if the indicator is not true\n",
    "        for j in range(len(twids)):\n",
    "            if str(twids.loc[j, 'TWID']) == str(df.loc[i, 'TWID']): #find twid in the supplementary table\n",
    "                if twids.loc[j, 'TIMES'] > 1: #and if the there is more than one copy of this row\n",
    "                    cleaner.append(i) #add the index\n",
    "        \n",
    "df = df.drop(df.index[cleaner]) #delete not relevant ones\n",
    "df = df.drop_duplicates() #delete duplicates\n",
    "df.index = np.arange(len(df)) #update the indexing\n",
    "del df['INDIC_INTERVENTIONS'] #now we so not need this column with indicator, delete it\n",
    "print(len(df)) "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 261,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>TWID</th>\n",
       "      <th>TWEET_ID</th>\n",
       "      <th>TWEET</th>\n",
       "      <th>SYNONYMS</th>\n",
       "      <th>MOLREGNO_1</th>\n",
       "      <th>ACRONYM</th>\n",
       "      <th>NCT_ID</th>\n",
       "      <th>PHASE</th>\n",
       "      <th>N_PHASES</th>\n",
       "      <th>OUTCOME</th>\n",
       "      <th>...</th>\n",
       "      <th>COMPANY_NONAMBIG</th>\n",
       "      <th>COMPANY_SCORE</th>\n",
       "      <th>INDICATION</th>\n",
       "      <th>INDICATION_ID</th>\n",
       "      <th>INDICATION_NONAMBIG</th>\n",
       "      <th>INDICATION_SCORE</th>\n",
       "      <th>INTERVENTION_TYPE</th>\n",
       "      <th>INTERVENTION_NAME</th>\n",
       "      <th>DESCRIPTIONS</th>\n",
       "      <th>OTHER_NAME</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>4</td>\n",
       "      <td>986398045897191424</td>\n",
       "      <td>@PoseidaThera present promising results in ini...</td>\n",
       "      <td>P-BCMA-101</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT03288493</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>1</td>\n",
       "      <td>SUCCESS</td>\n",
       "      <td>...</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Multiple Myeloma</td>\n",
       "      <td>D009101</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Biological</td>\n",
       "      <td>P-BCMA-101 CAR-T cells</td>\n",
       "      <td>P-BCMA-101 is an autologous, principally Tscm,...</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>16</td>\n",
       "      <td>986219643881885698</td>\n",
       "      <td>Genentech gains a license option to Kineta's a...</td>\n",
       "      <td>ACETYLCHOLINE</td>\n",
       "      <td>27812</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT03446612</td>\n",
       "      <td>Null</td>\n",
       "      <td>0</td>\n",
       "      <td>SUCCESS</td>\n",
       "      <td>...</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Chronic Pain</td>\n",
       "      <td>D059350</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Drug</td>\n",
       "      <td>Acetylcholine</td>\n",
       "      <td>Acetylcholine will be used as a challenge agen...</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>2 rows × 24 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "   TWID            TWEET_ID  \\\n",
       "0     4  986398045897191424   \n",
       "1    16  986219643881885698   \n",
       "\n",
       "                                               TWEET       SYNONYMS  \\\n",
       "0  @PoseidaThera present promising results in ini...     P-BCMA-101   \n",
       "1  Genentech gains a license option to Kineta's a...  ACETYLCHOLINE   \n",
       "\n",
       "  MOLREGNO_1 ACRONYM       NCT_ID    PHASE  N_PHASES  OUTCOME    ...      \\\n",
       "0  Not found    Null  NCT03288493  Phase 1         1  SUCCESS    ...       \n",
       "1      27812    Null  NCT03446612     Null         0  SUCCESS    ...       \n",
       "\n",
       "  COMPANY_NONAMBIG COMPANY_SCORE        INDICATION INDICATION_ID  \\\n",
       "0             Null          Null  Multiple Myeloma       D009101   \n",
       "1                1             1      Chronic Pain       D059350   \n",
       "\n",
       "  INDICATION_NONAMBIG INDICATION_SCORE INTERVENTION_TYPE  \\\n",
       "0                   1                1        Biological   \n",
       "1                   1                1              Drug   \n",
       "\n",
       "        INTERVENTION_NAME                                       DESCRIPTIONS  \\\n",
       "0  P-BCMA-101 CAR-T cells  P-BCMA-101 is an autologous, principally Tscm,...   \n",
       "1           Acetylcholine  Acetylcholine will be used as a challenge agen...   \n",
       "\n",
       "  OTHER_NAME  \n",
       "0       Null  \n",
       "1       Null  \n",
       "\n",
       "[2 rows x 24 columns]"
      ]
     },
     "execution_count": 261,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df[:2]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 262,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "1449"
      ]
     },
     "execution_count": 262,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df = pd.merge(df, NCTID_CONDITION_EFO, how='left', on='NCT_ID') #match with the NCTID_CONDITION_EFO table by NCT_ID\n",
    "df = df.drop_duplicates() #delete full duplicates\n",
    "df.index = np.arange(len(df)) #update indexing\n",
    "del df['REDUNDANT'] #delete not needed columns\n",
    "del df['FOR_AUTOMATIC_MAPPING']\n",
    "del df['IS_INDICATION']\n",
    "\n",
    "len(df)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 263,
   "metadata": {},
   "outputs": [],
   "source": [
    "df = pd.merge(df, NCT_ID2MOLREGNO, how='left', on='NCT_ID') #match with the NCT_ID2MOLREGNO table by NCT_ID\n",
    "df = df.fillna('Null') #fill in empty cells\n",
    "del df['ARM_GROUP_TYPE'] #delete not needed colums\n",
    "del df['ARM_GROUP_LABEL']\n",
    "del df['FOR_DICTIONARY']\n",
    "del df['INTERVENTION_NAME_y']\n",
    "df = df.drop_duplicates() #drop duplicates\n",
    "df.index = np.arange(len(df)) #update the indexing"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 264,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "2754"
      ]
     },
     "execution_count": 264,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(df) #a lot of duplicates appeared because of the different conditions"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 265,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>TWID</th>\n",
       "      <th>TWEET_ID</th>\n",
       "      <th>TWEET</th>\n",
       "      <th>SYNONYMS</th>\n",
       "      <th>MOLREGNO_1</th>\n",
       "      <th>ACRONYM</th>\n",
       "      <th>NCT_ID</th>\n",
       "      <th>PHASE</th>\n",
       "      <th>N_PHASES</th>\n",
       "      <th>OUTCOME</th>\n",
       "      <th>...</th>\n",
       "      <th>INDICATION_ID</th>\n",
       "      <th>INDICATION_NONAMBIG</th>\n",
       "      <th>INDICATION_SCORE</th>\n",
       "      <th>INTERVENTION_TYPE</th>\n",
       "      <th>INTERVENTION_NAME_x</th>\n",
       "      <th>DESCRIPTIONS</th>\n",
       "      <th>OTHER_NAME</th>\n",
       "      <th>EFO_ID</th>\n",
       "      <th>CONDITION</th>\n",
       "      <th>MOLREGNO</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>4</td>\n",
       "      <td>986398045897191424</td>\n",
       "      <td>@PoseidaThera present promising results in ini...</td>\n",
       "      <td>P-BCMA-101</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT03288493</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>1</td>\n",
       "      <td>SUCCESS</td>\n",
       "      <td>...</td>\n",
       "      <td>D009101</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Biological</td>\n",
       "      <td>P-BCMA-101 CAR-T cells</td>\n",
       "      <td>P-BCMA-101 is an autologous, principally Tscm,...</td>\n",
       "      <td>Null</td>\n",
       "      <td>EFO:0001378</td>\n",
       "      <td>Multiple Myeloma</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>16</td>\n",
       "      <td>986219643881885698</td>\n",
       "      <td>Genentech gains a license option to Kineta's a...</td>\n",
       "      <td>ACETYLCHOLINE</td>\n",
       "      <td>27812</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT03446612</td>\n",
       "      <td>Null</td>\n",
       "      <td>0</td>\n",
       "      <td>SUCCESS</td>\n",
       "      <td>...</td>\n",
       "      <td>D059350</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>Drug</td>\n",
       "      <td>Acetylcholine</td>\n",
       "      <td>Acetylcholine will be used as a challenge agen...</td>\n",
       "      <td>Null</td>\n",
       "      <td>EFO:0004272</td>\n",
       "      <td>Anaemia</td>\n",
       "      <td>226851</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>2 rows × 27 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "   TWID            TWEET_ID  \\\n",
       "0     4  986398045897191424   \n",
       "1    16  986219643881885698   \n",
       "\n",
       "                                               TWEET       SYNONYMS  \\\n",
       "0  @PoseidaThera present promising results in ini...     P-BCMA-101   \n",
       "1  Genentech gains a license option to Kineta's a...  ACETYLCHOLINE   \n",
       "\n",
       "  MOLREGNO_1 ACRONYM       NCT_ID    PHASE  N_PHASES  OUTCOME   ...     \\\n",
       "0  Not found    Null  NCT03288493  Phase 1         1  SUCCESS   ...      \n",
       "1      27812    Null  NCT03446612     Null         0  SUCCESS   ...      \n",
       "\n",
       "  INDICATION_ID INDICATION_NONAMBIG INDICATION_SCORE INTERVENTION_TYPE  \\\n",
       "0       D009101                   1                1        Biological   \n",
       "1       D059350                   1                1              Drug   \n",
       "\n",
       "      INTERVENTION_NAME_x                                       DESCRIPTIONS  \\\n",
       "0  P-BCMA-101 CAR-T cells  P-BCMA-101 is an autologous, principally Tscm,...   \n",
       "1           Acetylcholine  Acetylcholine will be used as a challenge agen...   \n",
       "\n",
       "  OTHER_NAME       EFO_ID         CONDITION MOLREGNO  \n",
       "0       Null  EFO:0001378  Multiple Myeloma     Null  \n",
       "1       Null  EFO:0004272           Anaemia   226851  \n",
       "\n",
       "[2 rows x 27 columns]"
      ]
     },
     "execution_count": 265,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df[:2]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 266,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "The amount of unique tweets is 746\n"
     ]
    }
   ],
   "source": [
    "uni = 0 #count how many unique twids there are\n",
    "df.index = np.arange(len(df))\n",
    "for i in range(1, len(df)):\n",
    "    if str(df.loc[i, 'TWID']) != str(df.loc[i - 1, 'TWID']):\n",
    "        uni += 1\n",
    "        \n",
    "print('The amount of unique tweets is', uni) #585"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 267,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "2754"
      ]
     },
     "execution_count": 267,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df = pd.merge(df, efo2name, how='left', on='EFO_ID') #match with the efo2name by EFO_ID\n",
    "df = df.drop_duplicates() #drop duplicates\n",
    "df.index = np.arange(len(df)) #update indexing\n",
    "len(df)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 268,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "TWID                                                                  16\n",
      "TWEET_ID                                              986219643881885698\n",
      "TWEET                  Genentech gains a license option to Kineta's a...\n",
      "SYNONYMS                                                   ACETYLCHOLINE\n",
      "MOLREGNO_1                                                         27812\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03446612\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                          gains a license\n",
      "COMPANY                                                          Kineta®\n",
      "COMPANY_ID                                                     COMP92965\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                  Chronic Pain\n",
      "INDICATION_ID                                                    D059350\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Acetylcholine\n",
      "DESCRIPTIONS           Acetylcholine will be used as a challenge agen...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0004272\n",
      "CONDITION                                                        Anaemia\n",
      "MOLREGNO                                                          226851\n",
      "NAME_TERM                                                         anemia\n",
      "Name: 1, dtype: object\n",
      "_____\n",
      "TWID                                                                  16\n",
      "TWEET_ID                                              986219643881885698\n",
      "TWEET                  Genentech gains a license option to Kineta's a...\n",
      "SYNONYMS                                                   ACETYLCHOLINE\n",
      "MOLREGNO_1                                                         27812\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03446612\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                          gains a license\n",
      "COMPANY                                                          Kineta®\n",
      "COMPANY_ID                                                     COMP92965\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                  Chronic Pain\n",
      "INDICATION_ID                                                    D059350\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Acetylcholine\n",
      "DESCRIPTIONS           Acetylcholine will be used as a challenge agen...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0004272\n",
      "CONDITION                                                        Anaemia\n",
      "MOLREGNO                                                          425372\n",
      "NAME_TERM                                                         anemia\n",
      "Name: 2, dtype: object\n",
      "_____\n",
      "TWID                                                                  16\n",
      "TWEET_ID                                              986219643881885698\n",
      "TWEET                  Genentech gains a license option to Kineta's a...\n",
      "SYNONYMS                                                   ACETYLCHOLINE\n",
      "MOLREGNO_1                                                         27812\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03446612\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                          gains a license\n",
      "COMPANY                                                          Kineta®\n",
      "COMPANY_ID                                                     COMP92965\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                  Chronic Pain\n",
      "INDICATION_ID                                                    D059350\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Acetylcholine\n",
      "DESCRIPTIONS           Acetylcholine will be used as a challenge agen...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0004272\n",
      "CONDITION                                                        Anaemia\n",
      "MOLREGNO                                                         1926837\n",
      "NAME_TERM                                                         anemia\n",
      "Name: 4, dtype: object\n",
      "_____\n",
      "TWID                                                                  16\n",
      "TWEET_ID                                              986219643881885698\n",
      "TWEET                  Genentech gains a license option to Kineta's a...\n",
      "SYNONYMS                                                   ACETYLCHOLINE\n",
      "MOLREGNO_1                                                         27812\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03446612\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                          gains a license\n",
      "COMPANY                                                          Kineta®\n",
      "COMPANY_ID                                                     COMP92965\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                  Chronic Pain\n",
      "INDICATION_ID                                                    D059350\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Acetylcholine\n",
      "DESCRIPTIONS           Acetylcholine will be used as a challenge agen...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0004272\n",
      "CONDITION                                                        Anaemia\n",
      "MOLREGNO                                                          675493\n",
      "NAME_TERM                                                         anemia\n",
      "Name: 5, dtype: object\n",
      "_____\n",
      "TWID                                                                  16\n",
      "TWEET_ID                                              986219643881885698\n",
      "TWEET                  Genentech gains a license option to Kineta's a...\n",
      "SYNONYMS                                                   ACETYLCHOLINE\n",
      "MOLREGNO_1                                                        195974\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03446612\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                          gains a license\n",
      "COMPANY                                                          Kineta®\n",
      "COMPANY_ID                                                     COMP92965\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                  Chronic Pain\n",
      "INDICATION_ID                                                    D059350\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Acetylcholine\n",
      "DESCRIPTIONS           Acetylcholine will be used as a challenge agen...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0004272\n",
      "CONDITION                                                        Anaemia\n",
      "MOLREGNO                                                          226851\n",
      "NAME_TERM                                                         anemia\n",
      "Name: 6, dtype: object\n",
      "_____\n",
      "TWID                                                                  16\n",
      "TWEET_ID                                              986219643881885698\n",
      "TWEET                  Genentech gains a license option to Kineta's a...\n",
      "SYNONYMS                                                   ACETYLCHOLINE\n",
      "MOLREGNO_1                                                        195974\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03446612\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                          gains a license\n",
      "COMPANY                                                          Kineta®\n",
      "COMPANY_ID                                                     COMP92965\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                  Chronic Pain\n",
      "INDICATION_ID                                                    D059350\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Acetylcholine\n",
      "DESCRIPTIONS           Acetylcholine will be used as a challenge agen...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0004272\n",
      "CONDITION                                                        Anaemia\n",
      "MOLREGNO                                                          425372\n",
      "NAME_TERM                                                         anemia\n",
      "Name: 7, dtype: object\n",
      "_____\n",
      "TWID                                                                  16\n",
      "TWEET_ID                                              986219643881885698\n",
      "TWEET                  Genentech gains a license option to Kineta's a...\n",
      "SYNONYMS                                                   ACETYLCHOLINE\n",
      "MOLREGNO_1                                                        195974\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03446612\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                          gains a license\n",
      "COMPANY                                                          Kineta®\n",
      "COMPANY_ID                                                     COMP92965\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                  Chronic Pain\n",
      "INDICATION_ID                                                    D059350\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Acetylcholine\n",
      "DESCRIPTIONS           Acetylcholine will be used as a challenge agen...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0004272\n",
      "CONDITION                                                        Anaemia\n",
      "MOLREGNO                                                           27812\n",
      "NAME_TERM                                                         anemia\n",
      "Name: 8, dtype: object\n",
      "_____\n",
      "TWID                                                                  16\n",
      "TWEET_ID                                              986219643881885698\n",
      "TWEET                  Genentech gains a license option to Kineta's a...\n",
      "SYNONYMS                                                   ACETYLCHOLINE\n",
      "MOLREGNO_1                                                        195974\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03446612\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                          gains a license\n",
      "COMPANY                                                          Kineta®\n",
      "COMPANY_ID                                                     COMP92965\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                  Chronic Pain\n",
      "INDICATION_ID                                                    D059350\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Acetylcholine\n",
      "DESCRIPTIONS           Acetylcholine will be used as a challenge agen...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0004272\n",
      "CONDITION                                                        Anaemia\n",
      "MOLREGNO                                                         1926837\n",
      "NAME_TERM                                                         anemia\n",
      "Name: 9, dtype: object\n",
      "_____\n",
      "TWID                                                                  16\n",
      "TWEET_ID                                              986219643881885698\n",
      "TWEET                  Genentech gains a license option to Kineta's a...\n",
      "SYNONYMS                                                   ACETYLCHOLINE\n",
      "MOLREGNO_1                                                        195974\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03446612\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                          gains a license\n",
      "COMPANY                                                          Kineta®\n",
      "COMPANY_ID                                                     COMP92965\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                  Chronic Pain\n",
      "INDICATION_ID                                                    D059350\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Acetylcholine\n",
      "DESCRIPTIONS           Acetylcholine will be used as a challenge agen...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0004272\n",
      "CONDITION                                                        Anaemia\n",
      "MOLREGNO                                                          675493\n",
      "NAME_TERM                                                         anemia\n",
      "Name: 10, dtype: object\n",
      "_____\n",
      "TWID                                                                 106\n",
      "TWEET_ID                                              977514137046667265\n",
      "TWEET                  41 patients have been enrolled in the ongoing ...\n",
      "SYNONYMS                                                     BINIMETINIB\n",
      "MOLREGNO_1                                                       1677014\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03158103\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                     in the ongoing phase\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                          Cerebellar Neoplasms\n",
      "INDICATION_ID                                                    D002528\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                               MEK162\n",
      "DESCRIPTIONS                                  MEK162 at 30mg twice daily\n",
      "OTHER_NAME                                                   Binimetinib\n",
      "EFO_ID                                                    Orphanet:44890\n",
      "CONDITION                          Gastrointestinal Stromal Tumor (GIST)\n",
      "MOLREGNO                                                         2089491\n",
      "NAME_TERM                                 Gastrointestinal stromal tumor\n",
      "Name: 15, dtype: object\n",
      "_____\n",
      "TWID                                                                 106\n",
      "TWEET_ID                                              977514137046667265\n",
      "TWEET                  41 patients have been enrolled in the ongoing ...\n",
      "SYNONYMS                                                      RIBOCICLIB\n",
      "MOLREGNO_1                                                       2039237\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03081234\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                     in the ongoing phase\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                          Cerebellar Neoplasms\n",
      "INDICATION_ID                                                    D002528\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Ribociclib\n",
      "DESCRIPTIONS           Ribociclib 600 mg daily on days 1 to 21 of a 2...\n",
      "OTHER_NAME                                                        LEE011\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 17, dtype: object\n",
      "_____\n",
      "TWID                                                                 106\n",
      "TWEET_ID                                              977514137046667265\n",
      "TWEET                  41 patients have been enrolled in the ongoing ...\n",
      "SYNONYMS                                                      RIBOCICLIB\n",
      "MOLREGNO_1                                                       2039237\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03081234\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                     in the ongoing phase\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                          Cerebellar Neoplasms\n",
      "INDICATION_ID                                                    D002528\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Ribociclib\n",
      "DESCRIPTIONS           Ribociclib 600 mg daily on days 1 to 21 of a 2...\n",
      "OTHER_NAME                                                        LEE011\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                         1926959\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 18, dtype: object\n",
      "_____\n",
      "TWID                                                                 106\n",
      "TWEET_ID                                              977514137046667265\n",
      "TWEET                  41 patients have been enrolled in the ongoing ...\n",
      "SYNONYMS                                                      RIBOCICLIB\n",
      "MOLREGNO_1                                                       1926959\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03081234\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                     in the ongoing phase\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                          Cerebellar Neoplasms\n",
      "INDICATION_ID                                                    D002528\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Ribociclib\n",
      "DESCRIPTIONS           Ribociclib 600 mg daily on days 1 to 21 of a 2...\n",
      "OTHER_NAME                                                        LEE011\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 19, dtype: object\n",
      "_____\n",
      "TWID                                                                 184\n",
      "TWEET_ID                                              975689033983647744\n",
      "TWEET                  Phase 3 study on vibegron shows good safety an...\n",
      "SYNONYMS                                                        VIBEGRON\n",
      "MOLREGNO_1                                                       1380096\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03492281\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                             shows safety\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                    Overactive Urinary Bladder\n",
      "INDICATION_ID                                                    D053201\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                             vibegron\n",
      "DESCRIPTIONS           single daily oral dose of vibegron 75mg for 12...\n",
      "OTHER_NAME                                      RVT-901, MK4618, KRP114V\n",
      "EFO_ID                                                       EFO:1000781\n",
      "CONDITION                                             Overactive Bladder\n",
      "MOLREGNO                                                         1102940\n",
      "NAME_TERM                                             overactive bladder\n",
      "Name: 31, dtype: object\n",
      "_____\n",
      "TWID                                                                 219\n",
      "TWEET_ID                                              974573688434692096\n",
      "TWEET                  Less surgical AEs and readmissions in surgery ...\n",
      "SYNONYMS                                                       SUNITINIB\n",
      "MOLREGNO_1                                                         13048\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03379012\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME            Less surgical AEs and readmissions in surgery\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                       Thymoma\n",
      "INDICATION_ID                                                    D013945\n",
      "INDICATION_NONAMBIG                                                    2\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x    Testosterone undecanoate and sunitinib or pazo...\n",
      "DESCRIPTIONS           Testosterone undecanoate (Nebido®) 1,000 mg (4...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000681\n",
      "CONDITION                                Metastatic Renal Cell Carcinoma\n",
      "MOLREGNO                                                         1379337\n",
      "NAME_TERM                                           renal cell carcinoma\n",
      "Name: 37, dtype: object\n",
      "_____\n",
      "TWID                                                                 219\n",
      "TWEET_ID                                              974573688434692096\n",
      "TWEET                  Less surgical AEs and readmissions in surgery ...\n",
      "SYNONYMS                                                       SUNITINIB\n",
      "MOLREGNO_1                                                         13048\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03379012\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME            Less surgical AEs and readmissions in surgery\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                       Thymoma\n",
      "INDICATION_ID                                                    D013945\n",
      "INDICATION_NONAMBIG                                                    2\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x    Testosterone undecanoate and sunitinib or pazo...\n",
      "DESCRIPTIONS           Testosterone undecanoate (Nebido®) 1,000 mg (4...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000681\n",
      "CONDITION                                Metastatic Renal Cell Carcinoma\n",
      "MOLREGNO                                                          489525\n",
      "NAME_TERM                                           renal cell carcinoma\n",
      "Name: 38, dtype: object\n",
      "_____\n",
      "TWID                                                                 222\n",
      "TWEET_ID                                              973893417821528065\n",
      "TWEET                  InCARDA's InRhythm Inhaled Flecainide for card...\n",
      "SYNONYMS                                                      FLECAINIDE\n",
      "MOLREGNO_1                                                         27588\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03162120\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           Positive trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Brugada Syndrome\n",
      "INDICATION_ID                                                    D053840\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x               FlecainidE pluS Metoprolol Combination\n",
      "DESCRIPTIONS           FlecainidE pluS Metoprolol Combination in ATri...\n",
      "OTHER_NAME                                                      FM group\n",
      "EFO_ID                                                       EFO:0000275\n",
      "CONDITION                                            Atrial Fibrillation\n",
      "MOLREGNO                                                             789\n",
      "NAME_TERM                                            atrial fibrillation\n",
      "Name: 39, dtype: object\n",
      "_____\n",
      "TWID                                                                 222\n",
      "TWEET_ID                                              973893417821528065\n",
      "TWEET                  InCARDA's InRhythm Inhaled Flecainide for card...\n",
      "SYNONYMS                                                      FLECAINIDE\n",
      "MOLREGNO_1                                                         27588\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03162120\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           Positive trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Brugada Syndrome\n",
      "INDICATION_ID                                                    D053840\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x               FlecainidE pluS Metoprolol Combination\n",
      "DESCRIPTIONS           FlecainidE pluS Metoprolol Combination in ATri...\n",
      "OTHER_NAME                                                      FM group\n",
      "EFO_ID                                                       EFO:0000275\n",
      "CONDITION                                            Atrial Fibrillation\n",
      "MOLREGNO                                                          341382\n",
      "NAME_TERM                                            atrial fibrillation\n",
      "Name: 40, dtype: object\n",
      "_____\n",
      "TWID                                                                 222\n",
      "TWEET_ID                                              973893417821528065\n",
      "TWEET                  InCARDA's InRhythm Inhaled Flecainide for card...\n",
      "SYNONYMS                                                      FLECAINIDE\n",
      "MOLREGNO_1                                                         27588\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03162120\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           Positive trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Brugada Syndrome\n",
      "INDICATION_ID                                                    D053840\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x               FlecainidE pluS Metoprolol Combination\n",
      "DESCRIPTIONS           FlecainidE pluS Metoprolol Combination in ATri...\n",
      "OTHER_NAME                                                      FM group\n",
      "EFO_ID                                                   -NOT-CONDITION-\n",
      "CONDITION                                                     Recurrence\n",
      "MOLREGNO                                                             789\n",
      "NAME_TERM                                                            NaN\n",
      "Name: 42, dtype: object\n",
      "_____\n",
      "TWID                                                                 222\n",
      "TWEET_ID                                              973893417821528065\n",
      "TWEET                  InCARDA's InRhythm Inhaled Flecainide for card...\n",
      "SYNONYMS                                                      FLECAINIDE\n",
      "MOLREGNO_1                                                         27588\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03162120\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           Positive trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Brugada Syndrome\n",
      "INDICATION_ID                                                    D053840\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x               FlecainidE pluS Metoprolol Combination\n",
      "DESCRIPTIONS           FlecainidE pluS Metoprolol Combination in ATri...\n",
      "OTHER_NAME                                                      FM group\n",
      "EFO_ID                                                   -NOT-CONDITION-\n",
      "CONDITION                                                     Recurrence\n",
      "MOLREGNO                                                          341382\n",
      "NAME_TERM                                                            NaN\n",
      "Name: 43, dtype: object\n",
      "_____\n",
      "TWID                                                                 226\n",
      "TWEET_ID                                              973584058985918465\n",
      "TWEET                  #Cristal Therapeutics' nanoproduct CriPec doce...\n",
      "SYNONYMS                                                        TAXOTERE\n",
      "MOLREGNO_1                                                          9097\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03432780\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                    demonstrates efficacy\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                             Stomach Neoplasms\n",
      "INDICATION_ID                                                    D013274\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Docetaxel\n",
      "DESCRIPTIONS                                                        Null\n",
      "OTHER_NAME                                                      Taxotere\n",
      "EFO_ID                                                       EFO:0001663\n",
      "CONDITION                                       Prostate Cancer Stage IV\n",
      "MOLREGNO                                                         1927101\n",
      "NAME_TERM                                             prostate carcinoma\n",
      "Name: 49, dtype: object\n",
      "_____\n",
      "TWID                                                                 226\n",
      "TWEET_ID                                              973584058985918465\n",
      "TWEET                  #Cristal Therapeutics' nanoproduct CriPec doce...\n",
      "SYNONYMS                                                        TAXOTERE\n",
      "MOLREGNO_1                                                          9097\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03432780\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                    demonstrates efficacy\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                             Stomach Neoplasms\n",
      "INDICATION_ID                                                    D013274\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Docetaxel\n",
      "DESCRIPTIONS                                                        Null\n",
      "OTHER_NAME                                                      Taxotere\n",
      "EFO_ID                                                       EFO:0001663\n",
      "CONDITION                                      Prostate Cancer Stage III\n",
      "MOLREGNO                                                         1927101\n",
      "NAME_TERM                                             prostate carcinoma\n",
      "Name: 50, dtype: object\n",
      "_____\n",
      "TWID                                                                 258\n",
      "TWEET_ID                                              970630221702615040\n",
      "TWEET                  Santhera's Raxone shows no efficacy benefit in...\n",
      "SYNONYMS                                                          RAXONE\n",
      "MOLREGNO_1                                                        418736\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02887443\n",
      "PHASE                                                          Phase 1/2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                      no efficacy benefit\n",
      "COMPANY                                         Santhera Pharmaceuticals\n",
      "COMPANY_ID                                                     COMP91054\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                   Duchenne Muscular Dystrophy\n",
      "INDICATION_ID                                                    D020388\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                            Raxone (idebenone 150 mg)\n",
      "DESCRIPTIONS           Raxone (idebenone 300 mg t.i.d.) on days 3 and...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                   -NOT-CONDITION-\n",
      "CONDITION                                          Drug-Drug Interaction\n",
      "MOLREGNO                                                           27611\n",
      "NAME_TERM                                                            NaN\n",
      "Name: 53, dtype: object\n",
      "_____\n",
      "TWID                                                                 260\n",
      "TWEET_ID                                              970593118444752898\n",
      "TWEET                  The EMA has started an urgent review of BioGen...\n",
      "SYNONYMS                                                      DACLIZUMAB\n",
      "MOLREGNO_1                                                        675587\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01064401\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                              has started\n",
      "COMPANY                                                      Biogen IDEC\n",
      "COMPANY_ID                                                       COMP118\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                        Relapsing-Remitting Multiple Sclerosis\n",
      "INDICATION_ID                                                    D020529\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                             Biological\n",
      "INTERVENTION_NAME_x              BIIB019 (Daclizumab High Yield Process)\n",
      "DESCRIPTIONS           Daclizumab High Yield Process for subcutaneous...\n",
      "OTHER_NAME                                                       DAC HYP\n",
      "EFO_ID                                                       EFO:0003929\n",
      "CONDITION                         Relapsing-Remitting Multiple Sclerosis\n",
      "MOLREGNO                                                          675521\n",
      "NAME_TERM                         relapsing-remitting multiple sclerosis\n",
      "Name: 54, dtype: object\n",
      "_____\n",
      "TWID                                                                 260\n",
      "TWEET_ID                                              970593118444752898\n",
      "TWEET                  The EMA has started an urgent review of BioGen...\n",
      "SYNONYMS                                                      DACLIZUMAB\n",
      "MOLREGNO_1                                                        675587\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01064401\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                              has started\n",
      "COMPANY                                                      Biogen IDEC\n",
      "COMPANY_ID                                                       COMP118\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                        Relapsing-Remitting Multiple Sclerosis\n",
      "INDICATION_ID                                                    D020529\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                Daclizumab High Yield Process Placebo\n",
      "DESCRIPTIONS           Placebo to Daclizumab High Yield Process subcu...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0003929\n",
      "CONDITION                         Relapsing-Remitting Multiple Sclerosis\n",
      "MOLREGNO                                                          675521\n",
      "NAME_TERM                         relapsing-remitting multiple sclerosis\n",
      "Name: 56, dtype: object\n",
      "_____\n",
      "TWID                                                                 274\n",
      "TWEET_ID                                              967237639152787456\n",
      "TWEET                  Trastuzumab biosimilar from @ Hetero Biopharma...\n",
      "SYNONYMS                                                     TRASTUZUMAB\n",
      "MOLREGNO_1                                                        675581\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                      has progressed into clinical trials\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Nervous System Neoplasms\n",
      "INDICATION_ID                                                    D009423\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Trastuzumab\n",
      "DESCRIPTIONS           Loading dose 8 mg/kg, then 6 mg/kg, intravenou...\n",
      "OTHER_NAME                                                     Herceptin\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                          674747\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 58, dtype: object\n",
      "_____\n",
      "TWID                                                                 274\n",
      "TWEET_ID                                              967237639152787456\n",
      "TWEET                  Trastuzumab biosimilar from @ Hetero Biopharma...\n",
      "SYNONYMS                                                     TRASTUZUMAB\n",
      "MOLREGNO_1                                                        675581\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                      has progressed into clinical trials\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Nervous System Neoplasms\n",
      "INDICATION_ID                                                    D009423\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Trastuzumab\n",
      "DESCRIPTIONS           Loading dose 8 mg/kg, then 6 mg/kg, intravenou...\n",
      "OTHER_NAME                                                     Herceptin\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                           78759\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 59, dtype: object\n",
      "_____\n",
      "TWID                                                                 274\n",
      "TWEET_ID                                              967237639152787456\n",
      "TWEET                  Trastuzumab biosimilar from @ Hetero Biopharma...\n",
      "SYNONYMS                                                     TRASTUZUMAB\n",
      "MOLREGNO_1                                                        675581\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                      has progressed into clinical trials\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Nervous System Neoplasms\n",
      "INDICATION_ID                                                    D009423\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Trastuzumab\n",
      "DESCRIPTIONS           Loading dose 8 mg/kg, then 6 mg/kg, intravenou...\n",
      "OTHER_NAME                                                     Herceptin\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                          675363\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 60, dtype: object\n",
      "_____\n",
      "TWID                                                                 274\n",
      "TWEET_ID                                              967237639152787456\n",
      "TWEET                  Trastuzumab biosimilar from @ Hetero Biopharma...\n",
      "SYNONYMS                                                     TRASTUZUMAB\n",
      "MOLREGNO_1                                                        675581\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                      has progressed into clinical trials\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Nervous System Neoplasms\n",
      "INDICATION_ID                                                    D009423\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Trastuzumab\n",
      "DESCRIPTIONS           Loading dose 8 mg/kg, then 6 mg/kg, intravenou...\n",
      "OTHER_NAME                                                     Herceptin\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                          675434\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 61, dtype: object\n",
      "_____\n",
      "TWID                                                                 274\n",
      "TWEET_ID                                              967237639152787456\n",
      "TWEET                  Trastuzumab biosimilar from @ Hetero Biopharma...\n",
      "SYNONYMS                                                     TRASTUZUMAB\n",
      "MOLREGNO_1                                                        675581\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                      has progressed into clinical trials\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Nervous System Neoplasms\n",
      "INDICATION_ID                                                    D009423\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Trastuzumab\n",
      "DESCRIPTIONS           Loading dose 8 mg/kg, then 6 mg/kg, intravenou...\n",
      "OTHER_NAME                                                     Herceptin\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                          365281\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 62, dtype: object\n",
      "_____\n",
      "TWID                                                                 274\n",
      "TWEET_ID                                              967237639152787456\n",
      "TWEET                  Trastuzumab biosimilar from @ Hetero Biopharma...\n",
      "SYNONYMS                                                     TRASTUZUMAB\n",
      "MOLREGNO_1                                                        675581\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                      has progressed into clinical trials\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Nervous System Neoplasms\n",
      "INDICATION_ID                                                    D009423\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Trastuzumab\n",
      "DESCRIPTIONS           Loading dose 8 mg/kg, then 6 mg/kg, intravenou...\n",
      "OTHER_NAME                                                     Herceptin\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                           14805\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 63, dtype: object\n",
      "_____\n",
      "TWID                                                                 274\n",
      "TWEET_ID                                              967237639152787456\n",
      "TWEET                  Trastuzumab biosimilar from @ Hetero Biopharma...\n",
      "SYNONYMS                                                     TRASTUZUMAB\n",
      "MOLREGNO_1                                                        675581\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                      has progressed into clinical trials\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Nervous System Neoplasms\n",
      "INDICATION_ID                                                    D009423\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Trastuzumab\n",
      "DESCRIPTIONS           Loading dose 8 mg/kg, then 6 mg/kg, intravenou...\n",
      "OTHER_NAME                                                     Herceptin\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                         1927101\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 64, dtype: object\n",
      "_____\n",
      "TWID                                                                 274\n",
      "TWEET_ID                                              967237639152787456\n",
      "TWEET                  Trastuzumab biosimilar from @ Hetero Biopharma...\n",
      "SYNONYMS                                                     TRASTUZUMAB\n",
      "MOLREGNO_1                                                        675581\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                      has progressed into clinical trials\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Nervous System Neoplasms\n",
      "INDICATION_ID                                                    D009423\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Trastuzumab\n",
      "DESCRIPTIONS           Loading dose 8 mg/kg, then 6 mg/kg, intravenou...\n",
      "OTHER_NAME                                                     Herceptin\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                       Metastatic Breast Cancer\n",
      "MOLREGNO                                                          674747\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 66, dtype: object\n",
      "_____\n",
      "TWID                                                                 274\n",
      "TWEET_ID                                              967237639152787456\n",
      "TWEET                  Trastuzumab biosimilar from @ Hetero Biopharma...\n",
      "SYNONYMS                                                     TRASTUZUMAB\n",
      "MOLREGNO_1                                                        675581\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                      has progressed into clinical trials\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Nervous System Neoplasms\n",
      "INDICATION_ID                                                    D009423\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Trastuzumab\n",
      "DESCRIPTIONS           Loading dose 8 mg/kg, then 6 mg/kg, intravenou...\n",
      "OTHER_NAME                                                     Herceptin\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                       Metastatic Breast Cancer\n",
      "MOLREGNO                                                           78759\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 67, dtype: object\n",
      "_____\n",
      "TWID                                                                 274\n",
      "TWEET_ID                                              967237639152787456\n",
      "TWEET                  Trastuzumab biosimilar from @ Hetero Biopharma...\n",
      "SYNONYMS                                                     TRASTUZUMAB\n",
      "MOLREGNO_1                                                        675581\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                      has progressed into clinical trials\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Nervous System Neoplasms\n",
      "INDICATION_ID                                                    D009423\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Trastuzumab\n",
      "DESCRIPTIONS           Loading dose 8 mg/kg, then 6 mg/kg, intravenou...\n",
      "OTHER_NAME                                                     Herceptin\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                       Metastatic Breast Cancer\n",
      "MOLREGNO                                                          675363\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 68, dtype: object\n",
      "_____\n",
      "TWID                                                                 274\n",
      "TWEET_ID                                              967237639152787456\n",
      "TWEET                  Trastuzumab biosimilar from @ Hetero Biopharma...\n",
      "SYNONYMS                                                     TRASTUZUMAB\n",
      "MOLREGNO_1                                                        675581\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                      has progressed into clinical trials\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Nervous System Neoplasms\n",
      "INDICATION_ID                                                    D009423\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Trastuzumab\n",
      "DESCRIPTIONS           Loading dose 8 mg/kg, then 6 mg/kg, intravenou...\n",
      "OTHER_NAME                                                     Herceptin\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                       Metastatic Breast Cancer\n",
      "MOLREGNO                                                          675434\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 69, dtype: object\n",
      "_____\n",
      "TWID                                                                 274\n",
      "TWEET_ID                                              967237639152787456\n",
      "TWEET                  Trastuzumab biosimilar from @ Hetero Biopharma...\n",
      "SYNONYMS                                                     TRASTUZUMAB\n",
      "MOLREGNO_1                                                        675581\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                      has progressed into clinical trials\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Nervous System Neoplasms\n",
      "INDICATION_ID                                                    D009423\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Trastuzumab\n",
      "DESCRIPTIONS           Loading dose 8 mg/kg, then 6 mg/kg, intravenou...\n",
      "OTHER_NAME                                                     Herceptin\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                       Metastatic Breast Cancer\n",
      "MOLREGNO                                                          365281\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 70, dtype: object\n",
      "_____\n",
      "TWID                                                                 274\n",
      "TWEET_ID                                              967237639152787456\n",
      "TWEET                  Trastuzumab biosimilar from @ Hetero Biopharma...\n",
      "SYNONYMS                                                     TRASTUZUMAB\n",
      "MOLREGNO_1                                                        675581\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                      has progressed into clinical trials\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Nervous System Neoplasms\n",
      "INDICATION_ID                                                    D009423\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Trastuzumab\n",
      "DESCRIPTIONS           Loading dose 8 mg/kg, then 6 mg/kg, intravenou...\n",
      "OTHER_NAME                                                     Herceptin\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                       Metastatic Breast Cancer\n",
      "MOLREGNO                                                           14805\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 71, dtype: object\n",
      "_____\n",
      "TWID                                                                 274\n",
      "TWEET_ID                                              967237639152787456\n",
      "TWEET                  Trastuzumab biosimilar from @ Hetero Biopharma...\n",
      "SYNONYMS                                                     TRASTUZUMAB\n",
      "MOLREGNO_1                                                        675581\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                      has progressed into clinical trials\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Nervous System Neoplasms\n",
      "INDICATION_ID                                                    D009423\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Trastuzumab\n",
      "DESCRIPTIONS           Loading dose 8 mg/kg, then 6 mg/kg, intravenou...\n",
      "OTHER_NAME                                                     Herceptin\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                       Metastatic Breast Cancer\n",
      "MOLREGNO                                                         1927101\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 72, dtype: object\n",
      "_____\n",
      "TWID                                                                 289\n",
      "TWEET_ID                                              964445811290591232\n",
      "TWEET                  Daiichi Sankyo files mirogabalin for Japanese ...\n",
      "SYNONYMS                                                     MIROGABALIN\n",
      "MOLREGNO_1                                                       1926974\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02187471\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                          files for phase\n",
      "COMPANY                                                    DaiichiSankyo\n",
      "COMPANY_ID                                                       COMP199\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                              Neuropathic Pain\n",
      "INDICATION_ID                                                    DX90161\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                              DS-5565\n",
      "DESCRIPTIONS                DS-5565 15 mg QD or BID; tablet for oral use\n",
      "OTHER_NAME                                                   Mirogabalin\n",
      "EFO_ID                                                       EFO:0005687\n",
      "CONDITION                              Pain Associated With Fibromyalgia\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                   fibromyalgia\n",
      "Name: 74, dtype: object\n",
      "_____\n",
      "TWID                                                                 289\n",
      "TWEET_ID                                              964445811290591232\n",
      "TWEET                  Daiichi Sankyo files mirogabalin for Japanese ...\n",
      "SYNONYMS                                                     MIROGABALIN\n",
      "MOLREGNO_1                                                       1926974\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02187471\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                          files for phase\n",
      "COMPANY                                                    DaiichiSankyo\n",
      "COMPANY_ID                                                       COMP199\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                              Neuropathic Pain\n",
      "INDICATION_ID                                                    DX90161\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                              DS-5565\n",
      "DESCRIPTIONS                DS-5565 15 mg QD or BID; tablet for oral use\n",
      "OTHER_NAME                                                   Mirogabalin\n",
      "EFO_ID                                                       EFO:0005687\n",
      "CONDITION                              Pain Associated With Fibromyalgia\n",
      "MOLREGNO                                                          136161\n",
      "NAME_TERM                                                   fibromyalgia\n",
      "Name: 75, dtype: object\n",
      "_____\n",
      "TWID                                                                 289\n",
      "TWEET_ID                                              964445811290591232\n",
      "TWEET                  Daiichi Sankyo files mirogabalin for Japanese ...\n",
      "SYNONYMS                                                     MIROGABALIN\n",
      "MOLREGNO_1                                                       1927106\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02187471\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                          files for phase\n",
      "COMPANY                                                    DaiichiSankyo\n",
      "COMPANY_ID                                                       COMP199\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                              Neuropathic Pain\n",
      "INDICATION_ID                                                    DX90161\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                              DS-5565\n",
      "DESCRIPTIONS                DS-5565 15 mg QD or BID; tablet for oral use\n",
      "OTHER_NAME                                                   Mirogabalin\n",
      "EFO_ID                                                       EFO:0005687\n",
      "CONDITION                              Pain Associated With Fibromyalgia\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                   fibromyalgia\n",
      "Name: 77, dtype: object\n",
      "_____\n",
      "TWID                                                                 289\n",
      "TWEET_ID                                              964445811290591232\n",
      "TWEET                  Daiichi Sankyo files mirogabalin for Japanese ...\n",
      "SYNONYMS                                                     MIROGABALIN\n",
      "MOLREGNO_1                                                       1927106\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02187471\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                          files for phase\n",
      "COMPANY                                                    DaiichiSankyo\n",
      "COMPANY_ID                                                       COMP199\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                              Neuropathic Pain\n",
      "INDICATION_ID                                                    DX90161\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                              DS-5565\n",
      "DESCRIPTIONS                DS-5565 15 mg QD or BID; tablet for oral use\n",
      "OTHER_NAME                                                   Mirogabalin\n",
      "EFO_ID                                                       EFO:0005687\n",
      "CONDITION                              Pain Associated With Fibromyalgia\n",
      "MOLREGNO                                                          136161\n",
      "NAME_TERM                                                   fibromyalgia\n",
      "Name: 78, dtype: object\n",
      "_____\n",
      "TWID                                                                 289\n",
      "TWEET_ID                                              964445811290591232\n",
      "TWEET                  Daiichi Sankyo files mirogabalin for Japanese ...\n",
      "SYNONYMS                                                     MIROGABALIN\n",
      "MOLREGNO_1                                                       1927106\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02187471\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                          files for phase\n",
      "COMPANY                                                    DaiichiSankyo\n",
      "COMPANY_ID                                                       COMP199\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                              Neuropathic Pain\n",
      "INDICATION_ID                                                    DX90161\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                              DS-5565\n",
      "DESCRIPTIONS                DS-5565 15 mg QD or BID; tablet for oral use\n",
      "OTHER_NAME                                                   Mirogabalin\n",
      "EFO_ID                                                       EFO:0005687\n",
      "CONDITION                              Pain Associated With Fibromyalgia\n",
      "MOLREGNO                                                         1926974\n",
      "NAME_TERM                                                   fibromyalgia\n",
      "Name: 79, dtype: object\n",
      "_____\n",
      "TWID                                                                 296\n",
      "TWEET_ID                                              963721334361657344\n",
      "TWEET                  Merck discontinues phase 3 APECS trial for Ver...\n",
      "SYNONYMS                                                    VERUBECESTAT\n",
      "MOLREGNO_1                                                       1763563\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01739348\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                             discontinues\n",
      "COMPANY                                                            Merck\n",
      "COMPANY_ID                                                       COMP435\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                     Mild Cognitive Impairment\n",
      "INDICATION_ID                                                    D060825\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                    Verubecestat (Part I and Part II)\n",
      "DESCRIPTIONS           Single 12 mg verubecestat tablet once daily, t...\n",
      "OTHER_NAME                                                    SCH 900931\n",
      "EFO_ID                                                       EFO:0000249\n",
      "CONDITION                                            Alzheimer's Disease\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                            Alzheimer's disease\n",
      "Name: 81, dtype: object\n",
      "_____\n",
      "TWID                                                                 296\n",
      "TWEET_ID                                              963721334361657344\n",
      "TWEET                  Merck discontinues phase 3 APECS trial for Ver...\n",
      "SYNONYMS                                                    VERUBECESTAT\n",
      "MOLREGNO_1                                                       1763563\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01739348\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                             discontinues\n",
      "COMPANY                                                            Merck\n",
      "COMPANY_ID                                                       COMP435\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                     Mild Cognitive Impairment\n",
      "INDICATION_ID                                                    D060825\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                    Verubecestat (Part I and Part II)\n",
      "DESCRIPTIONS           Single 40 mg verubecestat tablet once daily, t...\n",
      "OTHER_NAME                                                    SCH 900931\n",
      "EFO_ID                                                       EFO:0000249\n",
      "CONDITION                                            Alzheimer's Disease\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                            Alzheimer's disease\n",
      "Name: 83, dtype: object\n",
      "_____\n",
      "TWID                                                                 296\n",
      "TWEET_ID                                              963721334361657344\n",
      "TWEET                  Merck discontinues phase 3 APECS trial for Ver...\n",
      "SYNONYMS                                                    VERUBECESTAT\n",
      "MOLREGNO_1                                                       1763563\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01739348\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                             discontinues\n",
      "COMPANY                                                            Merck\n",
      "COMPANY_ID                                                       COMP435\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                     Mild Cognitive Impairment\n",
      "INDICATION_ID                                                    D060825\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                    Verubecestat (Part I and Part II)\n",
      "DESCRIPTIONS           Single 60 or 40 mg verubecestat tablet once da...\n",
      "OTHER_NAME                                                    SCH 900931\n",
      "EFO_ID                                                       EFO:0000249\n",
      "CONDITION                                            Alzheimer's Disease\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                            Alzheimer's disease\n",
      "Name: 85, dtype: object\n",
      "_____\n",
      "TWID                                                                 296\n",
      "TWEET_ID                                              963721334361657344\n",
      "TWEET                  Merck discontinues phase 3 APECS trial for Ver...\n",
      "SYNONYMS                                                    VERUBECESTAT\n",
      "MOLREGNO_1                                                       1763563\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01739348\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                             discontinues\n",
      "COMPANY                                                            Merck\n",
      "COMPANY_ID                                                       COMP435\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                     Mild Cognitive Impairment\n",
      "INDICATION_ID                                                    D060825\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                               Verubecestat (Part II)\n",
      "DESCRIPTIONS           Single 40 mg verubecestat tablet once daily, t...\n",
      "OTHER_NAME                                                    SCH 900931\n",
      "EFO_ID                                                       EFO:0000249\n",
      "CONDITION                                            Alzheimer's Disease\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                            Alzheimer's disease\n",
      "Name: 87, dtype: object\n",
      "_____\n",
      "TWID                                                                 305\n",
      "TWEET_ID                                              962017919306788864\n",
      "TWEET                  VBL Therapeutics gains a milestone fee from Na...\n",
      "SYNONYMS                                          OFRANERGENE OBADENOVEC\n",
      "MOLREGNO_1                                                       2039352\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                              Null\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                              N/I\n",
      "MATCHED_OUTCOME                                      milestone triggered\n",
      "COMPANY                                                 VBL Therapeutics\n",
      "COMPANY_ID                                                     COMP92766\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                             Ovarian Neoplasms\n",
      "INDICATION_ID                                                    D010051\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Null\n",
      "INTERVENTION_NAME_x                                                 Null\n",
      "DESCRIPTIONS                                                        Null\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                              Null\n",
      "CONDITION                                                           Null\n",
      "MOLREGNO                                                            Null\n",
      "NAME_TERM                                                            NaN\n",
      "Name: 88, dtype: object\n",
      "_____\n",
      "TWID                                                                 387\n",
      "TWEET_ID                                              950941770258505730\n",
      "TWEET                  CymaBay obtains a $5 M milestone fee from Kowa...\n",
      "SYNONYMS                                                    ARHALOFENATE\n",
      "MOLREGNO_1                                                       1376094\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02252835\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                              N/I\n",
      "MATCHED_OUTCOME                                      milestone triggered\n",
      "COMPANY                                     Kowa Pharmaceuticals America\n",
      "COMPANY_ID                                                     COMP93834\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                      Type 2 Diabetes Mellitus\n",
      "INDICATION_ID                                                    D003924\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Arhalofenate\n",
      "DESCRIPTIONS                     800 mg once daily orally for four weeks\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0009104\n",
      "CONDITION                                                  Hyperuricemia\n",
      "MOLREGNO                                                          647206\n",
      "NAME_TERM                                                  hyperuricemia\n",
      "Name: 96, dtype: object\n",
      "_____\n",
      "TWID                                                                 387\n",
      "TWEET_ID                                              950941770258505730\n",
      "TWEET                  CymaBay obtains a $5 M milestone fee from Kowa...\n",
      "SYNONYMS                                                    ARHALOFENATE\n",
      "MOLREGNO_1                                                       1376094\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02252835\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                              N/I\n",
      "MATCHED_OUTCOME                                      milestone triggered\n",
      "COMPANY                                     Kowa Pharmaceuticals America\n",
      "COMPANY_ID                                                     COMP93834\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                      Type 2 Diabetes Mellitus\n",
      "INDICATION_ID                                                    D003924\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Arhalofenate\n",
      "DESCRIPTIONS                     800 mg once daily orally for four weeks\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0009104\n",
      "CONDITION                                                  Hyperuricemia\n",
      "MOLREGNO                                                           14440\n",
      "NAME_TERM                                                  hyperuricemia\n",
      "Name: 97, dtype: object\n",
      "_____\n",
      "TWID                                                                 387\n",
      "TWEET_ID                                              950941770258505730\n",
      "TWEET                  CymaBay obtains a $5 M milestone fee from Kowa...\n",
      "SYNONYMS                                                    ARHALOFENATE\n",
      "MOLREGNO_1                                                       1376094\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02252835\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                              N/I\n",
      "MATCHED_OUTCOME                                      milestone triggered\n",
      "COMPANY                                     Kowa Pharmaceuticals America\n",
      "COMPANY_ID                                                     COMP93834\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                      Type 2 Diabetes Mellitus\n",
      "INDICATION_ID                                                    D003924\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Arhalofenate\n",
      "DESCRIPTIONS                     800 mg once daily orally for four weeks\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0004274\n",
      "CONDITION                                                           Gout\n",
      "MOLREGNO                                                          647206\n",
      "NAME_TERM                                                           gout\n",
      "Name: 99, dtype: object\n",
      "_____\n",
      "TWID                                                                 387\n",
      "TWEET_ID                                              950941770258505730\n",
      "TWEET                  CymaBay obtains a $5 M milestone fee from Kowa...\n",
      "SYNONYMS                                                    ARHALOFENATE\n",
      "MOLREGNO_1                                                       1376094\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02252835\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                              N/I\n",
      "MATCHED_OUTCOME                                      milestone triggered\n",
      "COMPANY                                     Kowa Pharmaceuticals America\n",
      "COMPANY_ID                                                     COMP93834\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                      Type 2 Diabetes Mellitus\n",
      "INDICATION_ID                                                    D003924\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Arhalofenate\n",
      "DESCRIPTIONS                     800 mg once daily orally for four weeks\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0004274\n",
      "CONDITION                                                           Gout\n",
      "MOLREGNO                                                           14440\n",
      "NAME_TERM                                                           gout\n",
      "Name: 100, dtype: object\n",
      "_____\n",
      "TWID                                                                 387\n",
      "TWEET_ID                                              950941770258505730\n",
      "TWEET                  CymaBay obtains a $5 M milestone fee from Kowa...\n",
      "SYNONYMS                                                    ARHALOFENATE\n",
      "MOLREGNO_1                                                       1376094\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02252835\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                              N/I\n",
      "MATCHED_OUTCOME                                      milestone triggered\n",
      "COMPANY                                     Kowa Pharmaceuticals America\n",
      "COMPANY_ID                                                     COMP93834\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                      Type 2 Diabetes Mellitus\n",
      "INDICATION_ID                                                    D003924\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Arhalofenate\n",
      "DESCRIPTIONS                     600 mg once daily orally for four weeks\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0009104\n",
      "CONDITION                                                  Hyperuricemia\n",
      "MOLREGNO                                                          647206\n",
      "NAME_TERM                                                  hyperuricemia\n",
      "Name: 102, dtype: object\n",
      "_____\n",
      "TWID                                                                 387\n",
      "TWEET_ID                                              950941770258505730\n",
      "TWEET                  CymaBay obtains a $5 M milestone fee from Kowa...\n",
      "SYNONYMS                                                    ARHALOFENATE\n",
      "MOLREGNO_1                                                       1376094\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02252835\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                              N/I\n",
      "MATCHED_OUTCOME                                      milestone triggered\n",
      "COMPANY                                     Kowa Pharmaceuticals America\n",
      "COMPANY_ID                                                     COMP93834\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                      Type 2 Diabetes Mellitus\n",
      "INDICATION_ID                                                    D003924\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Arhalofenate\n",
      "DESCRIPTIONS                     600 mg once daily orally for four weeks\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0009104\n",
      "CONDITION                                                  Hyperuricemia\n",
      "MOLREGNO                                                           14440\n",
      "NAME_TERM                                                  hyperuricemia\n",
      "Name: 103, dtype: object\n",
      "_____\n",
      "TWID                                                                 387\n",
      "TWEET_ID                                              950941770258505730\n",
      "TWEET                  CymaBay obtains a $5 M milestone fee from Kowa...\n",
      "SYNONYMS                                                    ARHALOFENATE\n",
      "MOLREGNO_1                                                       1376094\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02252835\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                              N/I\n",
      "MATCHED_OUTCOME                                      milestone triggered\n",
      "COMPANY                                     Kowa Pharmaceuticals America\n",
      "COMPANY_ID                                                     COMP93834\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                      Type 2 Diabetes Mellitus\n",
      "INDICATION_ID                                                    D003924\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Arhalofenate\n",
      "DESCRIPTIONS                     600 mg once daily orally for four weeks\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0004274\n",
      "CONDITION                                                           Gout\n",
      "MOLREGNO                                                          647206\n",
      "NAME_TERM                                                           gout\n",
      "Name: 105, dtype: object\n",
      "_____\n",
      "TWID                                                                 387\n",
      "TWEET_ID                                              950941770258505730\n",
      "TWEET                  CymaBay obtains a $5 M milestone fee from Kowa...\n",
      "SYNONYMS                                                    ARHALOFENATE\n",
      "MOLREGNO_1                                                       1376094\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02252835\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                              N/I\n",
      "MATCHED_OUTCOME                                      milestone triggered\n",
      "COMPANY                                     Kowa Pharmaceuticals America\n",
      "COMPANY_ID                                                     COMP93834\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                      Type 2 Diabetes Mellitus\n",
      "INDICATION_ID                                                    D003924\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Arhalofenate\n",
      "DESCRIPTIONS                     600 mg once daily orally for four weeks\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0004274\n",
      "CONDITION                                                           Gout\n",
      "MOLREGNO                                                           14440\n",
      "NAME_TERM                                                           gout\n",
      "Name: 106, dtype: object\n",
      "_____\n",
      "TWID                                                                 398\n",
      "TWEET_ID                                              950714168675569666\n",
      "TWEET                  Axovant's investigational drug intepirdine to ...\n",
      "SYNONYMS                                                     INTEPIRDINE\n",
      "MOLREGNO_1                                                        630553\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                              Null\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME               failing to meet primary efficacy endpoints\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Null\n",
      "INTERVENTION_NAME_x                                                 Null\n",
      "DESCRIPTIONS                                                        Null\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                              Null\n",
      "CONDITION                                                           Null\n",
      "MOLREGNO                                                            Null\n",
      "NAME_TERM                                                            NaN\n",
      "Name: 108, dtype: object\n",
      "_____\n",
      "TWID                                                                 481\n",
      "TWEET_ID                                              939597072801681408\n",
      "TWEET                  Acalabrutinib (100 mg bid) demonstrates promis...\n",
      "SYNONYMS                                                   ACALABRUTINIB\n",
      "MOLREGNO_1                                                       2039319\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02296918\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                    demonstrates efficacy\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        acalabrutinib\n",
      "DESCRIPTIONS                               100 mg twice daily continuous\n",
      "OTHER_NAME                                                       ACP-196\n",
      "EFO_ID                                                       EFO:0000095\n",
      "CONDITION                                   Chronic Lymphocytic Leukemia\n",
      "MOLREGNO                                                         1121919\n",
      "NAME_TERM                                   chronic lymphocytic leukemia\n",
      "Name: 114, dtype: object\n",
      "_____\n",
      "TWID                                                                 481\n",
      "TWEET_ID                                              939597072801681408\n",
      "TWEET                  Acalabrutinib (100 mg bid) demonstrates promis...\n",
      "SYNONYMS                                                   ACALABRUTINIB\n",
      "MOLREGNO_1                                                       2039319\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02296918\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                    demonstrates efficacy\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        acalabrutinib\n",
      "DESCRIPTIONS                               100 mg twice daily continuous\n",
      "OTHER_NAME                                                       ACP-196\n",
      "EFO_ID                                                       EFO:0000095\n",
      "CONDITION                                   Chronic Lymphocytic Leukemia\n",
      "MOLREGNO                                                         1626740\n",
      "NAME_TERM                                   chronic lymphocytic leukemia\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Name: 116, dtype: object\n",
      "_____\n",
      "TWID                                                                 481\n",
      "TWEET_ID                                              939597072801681408\n",
      "TWEET                  Acalabrutinib (100 mg bid) demonstrates promis...\n",
      "SYNONYMS                                                   ACALABRUTINIB\n",
      "MOLREGNO_1                                                       2039319\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02296918\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                    demonstrates efficacy\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        acalabrutinib\n",
      "DESCRIPTIONS                               100 mg twice daily continuous\n",
      "OTHER_NAME                                                       ACP-196\n",
      "EFO_ID                                                       EFO:0000095\n",
      "CONDITION                                   Chronic Lymphocytic Leukemia\n",
      "MOLREGNO                                                          675578\n",
      "NAME_TERM                                   chronic lymphocytic leukemia\n",
      "Name: 117, dtype: object\n",
      "_____\n",
      "TWID                                                                 481\n",
      "TWEET_ID                                              939597072801681408\n",
      "TWEET                  Acalabrutinib (100 mg bid) demonstrates promis...\n",
      "SYNONYMS                                                   ACALABRUTINIB\n",
      "MOLREGNO_1                                                       2039319\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02296918\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                    demonstrates efficacy\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        acalabrutinib\n",
      "DESCRIPTIONS                               100 mg twice daily continuous\n",
      "OTHER_NAME                                                       ACP-196\n",
      "EFO_ID                                                       EFO:0000095\n",
      "CONDITION                                     Small Lymphocytic Lymphoma\n",
      "MOLREGNO                                                         1121919\n",
      "NAME_TERM                                   chronic lymphocytic leukemia\n",
      "Name: 118, dtype: object\n",
      "_____\n",
      "TWID                                                                 481\n",
      "TWEET_ID                                              939597072801681408\n",
      "TWEET                  Acalabrutinib (100 mg bid) demonstrates promis...\n",
      "SYNONYMS                                                   ACALABRUTINIB\n",
      "MOLREGNO_1                                                       2039319\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02296918\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                    demonstrates efficacy\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        acalabrutinib\n",
      "DESCRIPTIONS                               100 mg twice daily continuous\n",
      "OTHER_NAME                                                       ACP-196\n",
      "EFO_ID                                                       EFO:0000095\n",
      "CONDITION                                     Small Lymphocytic Lymphoma\n",
      "MOLREGNO                                                         1626740\n",
      "NAME_TERM                                   chronic lymphocytic leukemia\n",
      "Name: 120, dtype: object\n",
      "_____\n",
      "TWID                                                                 481\n",
      "TWEET_ID                                              939597072801681408\n",
      "TWEET                  Acalabrutinib (100 mg bid) demonstrates promis...\n",
      "SYNONYMS                                                   ACALABRUTINIB\n",
      "MOLREGNO_1                                                       2039319\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02296918\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                    demonstrates efficacy\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        acalabrutinib\n",
      "DESCRIPTIONS                               100 mg twice daily continuous\n",
      "OTHER_NAME                                                       ACP-196\n",
      "EFO_ID                                                       EFO:0000095\n",
      "CONDITION                                     Small Lymphocytic Lymphoma\n",
      "MOLREGNO                                                          675578\n",
      "NAME_TERM                                   chronic lymphocytic leukemia\n",
      "Name: 121, dtype: object\n",
      "_____\n",
      "TWID                                                                 481\n",
      "TWEET_ID                                              939597072801681408\n",
      "TWEET                  Acalabrutinib (100 mg bid) demonstrates promis...\n",
      "SYNONYMS                                                   ACALABRUTINIB\n",
      "MOLREGNO_1                                                       2039319\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02296918\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                    demonstrates efficacy\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        acalabrutinib\n",
      "DESCRIPTIONS                               100 mg twice daily continuous\n",
      "OTHER_NAME                                                       ACP-196\n",
      "EFO_ID                                                       EFO:0004289\n",
      "CONDITION                                        Prolymphocytic Leukemia\n",
      "MOLREGNO                                                         1121919\n",
      "NAME_TERM                                              lymphoid leukemia\n",
      "Name: 122, dtype: object\n",
      "_____\n",
      "TWID                                                                 481\n",
      "TWEET_ID                                              939597072801681408\n",
      "TWEET                  Acalabrutinib (100 mg bid) demonstrates promis...\n",
      "SYNONYMS                                                   ACALABRUTINIB\n",
      "MOLREGNO_1                                                       2039319\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02296918\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                    demonstrates efficacy\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        acalabrutinib\n",
      "DESCRIPTIONS                               100 mg twice daily continuous\n",
      "OTHER_NAME                                                       ACP-196\n",
      "EFO_ID                                                       EFO:0004289\n",
      "CONDITION                                        Prolymphocytic Leukemia\n",
      "MOLREGNO                                                         1626740\n",
      "NAME_TERM                                              lymphoid leukemia\n",
      "Name: 124, dtype: object\n",
      "_____\n",
      "TWID                                                                 481\n",
      "TWEET_ID                                              939597072801681408\n",
      "TWEET                  Acalabrutinib (100 mg bid) demonstrates promis...\n",
      "SYNONYMS                                                   ACALABRUTINIB\n",
      "MOLREGNO_1                                                       2039319\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02296918\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                    demonstrates efficacy\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        acalabrutinib\n",
      "DESCRIPTIONS                               100 mg twice daily continuous\n",
      "OTHER_NAME                                                       ACP-196\n",
      "EFO_ID                                                       EFO:0004289\n",
      "CONDITION                                        Prolymphocytic Leukemia\n",
      "MOLREGNO                                                          675578\n",
      "NAME_TERM                                              lymphoid leukemia\n",
      "Name: 125, dtype: object\n",
      "_____\n",
      "TWID                                                                 570\n",
      "TWEET_ID                                              928051270287593472\n",
      "TWEET                  LG Chem's etanercept biosimilar LBEC-0101 demo...\n",
      "SYNONYMS                                                      ETANERCEPT\n",
      "MOLREGNO_1                                                        675371\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03100253\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                 demonstrates equivalence\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                          Rheumatoid Arthritis\n",
      "INDICATION_ID                                                    D001172\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Etanercept\n",
      "DESCRIPTIONS           a. Etanercept if initial failure to monoclonal...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000685\n",
      "CONDITION                                           Rheumatoid Arthritis\n",
      "MOLREGNO                                                          675617\n",
      "NAME_TERM                                           rheumatoid arthritis\n",
      "Name: 134, dtype: object\n",
      "_____\n",
      "TWID                                                                 570\n",
      "TWEET_ID                                              928051270287593472\n",
      "TWEET                  LG Chem's etanercept biosimilar LBEC-0101 demo...\n",
      "SYNONYMS                                                      ETANERCEPT\n",
      "MOLREGNO_1                                                        675371\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03100253\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                 demonstrates equivalence\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                          Rheumatoid Arthritis\n",
      "INDICATION_ID                                                    D001172\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Etanercept\n",
      "DESCRIPTIONS           a. Etanercept if initial failure to monoclonal...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000685\n",
      "CONDITION                                           Rheumatoid Arthritis\n",
      "MOLREGNO                                                          699373\n",
      "NAME_TERM                                           rheumatoid arthritis\n",
      "Name: 135, dtype: object\n",
      "_____\n",
      "TWID                                                                 570\n",
      "TWEET_ID                                              928051270287593472\n",
      "TWEET                  LG Chem's etanercept biosimilar LBEC-0101 demo...\n",
      "SYNONYMS                                                      ETANERCEPT\n",
      "MOLREGNO_1                                                        675371\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03100253\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                 demonstrates equivalence\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                          Rheumatoid Arthritis\n",
      "INDICATION_ID                                                    D001172\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Etanercept\n",
      "DESCRIPTIONS           a. Etanercept if initial failure to monoclonal...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000685\n",
      "CONDITION                                           Rheumatoid Arthritis\n",
      "MOLREGNO                                                          675482\n",
      "NAME_TERM                                           rheumatoid arthritis\n",
      "Name: 136, dtype: object\n",
      "_____\n",
      "TWID                                                                 570\n",
      "TWEET_ID                                              928051270287593472\n",
      "TWEET                  LG Chem's etanercept biosimilar LBEC-0101 demo...\n",
      "SYNONYMS                                                      ETANERCEPT\n",
      "MOLREGNO_1                                                        675371\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03100253\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                 demonstrates equivalence\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                          Rheumatoid Arthritis\n",
      "INDICATION_ID                                                    D001172\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Etanercept\n",
      "DESCRIPTIONS           a. Etanercept if initial failure to monoclonal...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000685\n",
      "CONDITION                                           Rheumatoid Arthritis\n",
      "MOLREGNO                                                          675782\n",
      "NAME_TERM                                           rheumatoid arthritis\n",
      "Name: 137, dtype: object\n",
      "_____\n",
      "TWID                                                                 570\n",
      "TWEET_ID                                              928051270287593472\n",
      "TWEET                  LG Chem's etanercept biosimilar LBEC-0101 demo...\n",
      "SYNONYMS                                                      ETANERCEPT\n",
      "MOLREGNO_1                                                        675371\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03100253\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                 demonstrates equivalence\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                          Rheumatoid Arthritis\n",
      "INDICATION_ID                                                    D001172\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Etanercept\n",
      "DESCRIPTIONS           a. Etanercept if initial failure to monoclonal...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000685\n",
      "CONDITION                                           Rheumatoid Arthritis\n",
      "MOLREGNO                                                          675784\n",
      "NAME_TERM                                           rheumatoid arthritis\n",
      "Name: 138, dtype: object\n",
      "_____\n",
      "TWID                                                                 621\n",
      "TWEET_ID                                              924923325335441408\n",
      "TWEET                  ViiV's fostemsavir reduces HIV viral load in p...\n",
      "SYNONYMS                                                     FOSTEMSAVIR\n",
      "MOLREGNO_1                                                       1763556\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                              Null\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                       reduces viral load\n",
      "COMPANY                                                             Viiv\n",
      "COMPANY_ID                                                     COMP90935\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                HIV Infections\n",
      "INDICATION_ID                                                    D015658\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Null\n",
      "INTERVENTION_NAME_x                                                 Null\n",
      "DESCRIPTIONS                                                        Null\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                              Null\n",
      "CONDITION                                                           Null\n",
      "MOLREGNO                                                            Null\n",
      "NAME_TERM                                                            NaN\n",
      "Name: 154, dtype: object\n",
      "_____\n",
      "TWID                                                                 728\n",
      "TWEET_ID                                              920221299317854210\n",
      "TWEET                  Inovio begins phase Ib/II trial of INO-5401 in...\n",
      "SYNONYMS                                                    ATEZOLIZUMAB\n",
      "MOLREGNO_1                                                       2039198\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03359239\n",
      "PHASE                                                          Phase 1/2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                       begins phase trial\n",
      "COMPANY                                                           Inovio\n",
      "COMPANY_ID                                                     COMP90462\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                             Colonic Neoplasms\n",
      "INDICATION_ID                                                    D003110\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Atezolizumab\n",
      "DESCRIPTIONS           1200 mg administered by IV infusion every 3 we...\n",
      "OTHER_NAME                                                     TECENTRIQ\n",
      "EFO_ID                                                       EFO:0000292\n",
      "CONDITION                                 Urothelial/Bladder Cancer, Nos\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                              bladder carcinoma\n",
      "Name: 182, dtype: object\n",
      "_____\n",
      "TWID                                                                 755\n",
      "TWEET_ID                                              917695929871986688\n",
      "TWEET                  EMA accepts AstraZeneca's durvalumab MAA for l...\n",
      "SYNONYMS                                                      DURVALUMAB\n",
      "MOLREGNO_1                                                       1763549\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02352948\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME          Accepts for locally-advanced unresectable NSCLC\n",
      "COMPANY                                                      AstraZeneca\n",
      "COMPANY_ID                                                        COMP82\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                 Non-Small-Cell Lung Carcinoma\n",
      "INDICATION_ID                                                    D002289\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                MEDI4736 (durvalumab)\n",
      "DESCRIPTIONS           MEDI4736 (durvalumab) treatment by intravenous...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0003060\n",
      "CONDITION                             Non - Small Cell Lung Cancer NSCLC\n",
      "MOLREGNO                                                         1380924\n",
      "NAME_TERM                                  non-small cell lung carcinoma\n",
      "Name: 196, dtype: object\n",
      "_____\n",
      "TWID                                                                 755\n",
      "TWEET_ID                                              917695929871986688\n",
      "TWEET                  EMA accepts AstraZeneca's durvalumab MAA for l...\n",
      "SYNONYMS                                                      DURVALUMAB\n",
      "MOLREGNO_1                                                       1763549\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02352948\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME          Accepts for locally-advanced unresectable NSCLC\n",
      "COMPANY                                                      AstraZeneca\n",
      "COMPANY_ID                                                        COMP82\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                 Non-Small-Cell Lung Carcinoma\n",
      "INDICATION_ID                                                    D002289\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                MEDI4736 (durvalumab)\n",
      "DESCRIPTIONS           MEDI4736 (durvalumab) treatment by intravenous...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0003060\n",
      "CONDITION                             Non - Small Cell Lung Cancer NSCLC\n",
      "MOLREGNO                                                          560078\n",
      "NAME_TERM                                  non-small cell lung carcinoma\n",
      "Name: 198, dtype: object\n",
      "_____\n",
      "TWID                                                                 755\n",
      "TWEET_ID                                              917695929871986688\n",
      "TWEET                  EMA accepts AstraZeneca's durvalumab MAA for l...\n",
      "SYNONYMS                                                      DURVALUMAB\n",
      "MOLREGNO_1                                                       1763549\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02352948\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME          Accepts for locally-advanced unresectable NSCLC\n",
      "COMPANY                                                      AstraZeneca\n",
      "COMPANY_ID                                                        COMP82\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                 Non-Small-Cell Lung Carcinoma\n",
      "INDICATION_ID                                                    D002289\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                MEDI4736 (durvalumab)\n",
      "DESCRIPTIONS           MEDI4736 (durvalumab) treatment by intravenous...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0003060\n",
      "CONDITION                             Non - Small Cell Lung Cancer NSCLC\n",
      "MOLREGNO                                                           14785\n",
      "NAME_TERM                                  non-small cell lung carcinoma\n",
      "Name: 199, dtype: object\n",
      "_____\n",
      "TWID                                                                 755\n",
      "TWEET_ID                                              917695929871986688\n",
      "TWEET                  EMA accepts AstraZeneca's durvalumab MAA for l...\n",
      "SYNONYMS                                                      DURVALUMAB\n",
      "MOLREGNO_1                                                       1763549\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02352948\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME          Accepts for locally-advanced unresectable NSCLC\n",
      "COMPANY                                                      AstraZeneca\n",
      "COMPANY_ID                                                        COMP82\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                 Non-Small-Cell Lung Carcinoma\n",
      "INDICATION_ID                                                    D002289\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                MEDI4736 (durvalumab)\n",
      "DESCRIPTIONS           MEDI4736 (durvalumab) treatment by intravenous...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0003060\n",
      "CONDITION                             Non - Small Cell Lung Cancer NSCLC\n",
      "MOLREGNO                                                           75901\n",
      "NAME_TERM                                  non-small cell lung carcinoma\n",
      "Name: 200, dtype: object\n",
      "_____\n",
      "TWID                                                                 780\n",
      "TWEET_ID                                              915165844367388672\n",
      "TWEET                  Ablynx's caplacizumab meets efficacy primary e...\n",
      "SYNONYMS                                                    CAPLACIZUMAB\n",
      "MOLREGNO_1                                                       1382064\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03172208\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                   meets primary endpoint\n",
      "COMPANY                                                           Ablynx\n",
      "COMPANY_ID                                                     COMP93215\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                  Acquired thrombotic thrombocytopenic purpura\n",
      "INDICATION_ID                                                    C536901\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                             Biological\n",
      "INTERVENTION_NAME_x                 Caplacizumab Dose 1 iv (single-dose)\n",
      "DESCRIPTIONS           Single intravenous (iv) administration of Capl...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000761\n",
      "CONDITION                                             Healthy Volunteers\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                obsolete_normal\n",
      "Name: 206, dtype: object\n",
      "_____\n",
      "TWID                                                                 780\n",
      "TWEET_ID                                              915165844367388672\n",
      "TWEET                  Ablynx's caplacizumab meets efficacy primary e...\n",
      "SYNONYMS                                                    CAPLACIZUMAB\n",
      "MOLREGNO_1                                                       1382064\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03172208\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                   meets primary endpoint\n",
      "COMPANY                                                           Ablynx\n",
      "COMPANY_ID                                                     COMP93215\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                  Acquired thrombotic thrombocytopenic purpura\n",
      "INDICATION_ID                                                    C536901\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                             Biological\n",
      "INTERVENTION_NAME_x                 Caplacizumab Dose 2 iv (single-dose)\n",
      "DESCRIPTIONS           Single intravenous (iv) administration of Capl...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000761\n",
      "CONDITION                                             Healthy Volunteers\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                obsolete_normal\n",
      "Name: 208, dtype: object\n",
      "_____\n",
      "TWID                                                                 780\n",
      "TWEET_ID                                              915165844367388672\n",
      "TWEET                  Ablynx's caplacizumab meets efficacy primary e...\n",
      "SYNONYMS                                                    CAPLACIZUMAB\n",
      "MOLREGNO_1                                                       1382064\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03172208\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                   meets primary endpoint\n",
      "COMPANY                                                           Ablynx\n",
      "COMPANY_ID                                                     COMP93215\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                  Acquired thrombotic thrombocytopenic purpura\n",
      "INDICATION_ID                                                    C536901\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                             Biological\n",
      "INTERVENTION_NAME_x                 Caplacizumab Dose 2 sc (single-dose)\n",
      "DESCRIPTIONS           Single subcutaneous (sc) administration of Cap...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000761\n",
      "CONDITION                                             Healthy Volunteers\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                obsolete_normal\n",
      "Name: 210, dtype: object\n",
      "_____\n",
      "TWID                                                                 780\n",
      "TWEET_ID                                              915165844367388672\n",
      "TWEET                  Ablynx's caplacizumab meets efficacy primary e...\n",
      "SYNONYMS                                                    CAPLACIZUMAB\n",
      "MOLREGNO_1                                                       1382064\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03172208\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                   meets primary endpoint\n",
      "COMPANY                                                           Ablynx\n",
      "COMPANY_ID                                                     COMP93215\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                  Acquired thrombotic thrombocytopenic purpura\n",
      "INDICATION_ID                                                    C536901\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                             Biological\n",
      "INTERVENTION_NAME_x               Caplacizumab Dose 2 sc (multiple-dose)\n",
      "DESCRIPTIONS           Once daily subcutaneous (sc) administration of...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000761\n",
      "CONDITION                                             Healthy Volunteers\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                obsolete_normal\n",
      "Name: 212, dtype: object\n",
      "_____\n",
      "TWID                                                                 794\n",
      "TWEET_ID                                              913719805110374401\n",
      "TWEET                  Zynerba's ZYN-002 (cannabidiol gel) meets effi...\n",
      "SYNONYMS                                                     CANNABIDIOL\n",
      "MOLREGNO_1                                                        318390\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03164512\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                   meets primary endpoint\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Absence Epilepsy\n",
      "INDICATION_ID                                                    D004832\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                        Oral or vaporized cannabidiol\n",
      "DESCRIPTIONS                                         Acute drug exposure\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                   -NOT-CONDITION-\n",
      "CONDITION                                   Cannabidiol Pharmacokinetics\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                            NaN\n",
      "Name: 218, dtype: object\n",
      "_____\n",
      "TWID                                                                 798\n",
      "TWEET_ID                                              913397087542312962\n",
      "TWEET                  Regeneron and Sanofi's IL-4 receptor alpha ant...\n",
      "SYNONYMS                                                        DUPIXENT\n",
      "MOLREGNO_1                                                       1380941\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02260986\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               3\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                        gains EU approval\n",
      "COMPANY                                                        Regeneron\n",
      "COMPANY_ID                                                     COMP90037\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                        Asthma\n",
      "INDICATION_ID                                                    D001249\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Dupilumab\n",
      "DESCRIPTIONS           Subcutaneous injection in the different quadra...\n",
      "OTHER_NAME                                    REGN668;SAR231893;Dupixent\n",
      "EFO_ID                                                       EFO:0000274\n",
      "CONDITION                                              Atopic Dermatitis\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                  atopic eczema\n",
      "Name: 222, dtype: object\n",
      "_____\n",
      "TWID                                                                 806\n",
      "TWEET_ID                                              913342459526172672\n",
      "TWEET                  Immune's bertilimumab shows tolerability and p...\n",
      "SYNONYMS                                                    BERTILIMUMAB\n",
      "MOLREGNO_1                                                       1381369\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01671956\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                               shows preliminary efficacy\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                            Bullous Pemphigoid\n",
      "INDICATION_ID                                                    D010391\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                             Biological\n",
      "INTERVENTION_NAME_x                                         Bertilimumab\n",
      "DESCRIPTIONS           IV infusion over 30 minutes, at Day 0, Day 14 ...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000729\n",
      "CONDITION                            Ulcerative Colitis, Active Moderate\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                             ulcerative colitis\n",
      "Name: 224, dtype: object\n",
      "_____\n",
      "TWID                                                                 806\n",
      "TWEET_ID                                              913342459526172672\n",
      "TWEET                  Immune's bertilimumab shows tolerability and p...\n",
      "SYNONYMS                                                    BERTILIMUMAB\n",
      "MOLREGNO_1                                                       1381369\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01671956\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                               shows preliminary efficacy\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                            Bullous Pemphigoid\n",
      "INDICATION_ID                                                    D010391\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                             Biological\n",
      "INTERVENTION_NAME_x                                         Bertilimumab\n",
      "DESCRIPTIONS           IV infusion over 30 minutes, at Day 0, Day 14 ...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000729\n",
      "CONDITION                              Ulcerative Colitis, Active Severe\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                             ulcerative colitis\n",
      "Name: 226, dtype: object\n",
      "_____\n",
      "TWID                                                                 881\n",
      "TWEET_ID                                              907537590043201537\n",
      "TWEET                  Positive results of PATHWAY phase III trial on...\n",
      "SYNONYMS                                                     TEZEPELUMAB\n",
      "MOLREGNO_1                                                       2039200\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03406078\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           Positive trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                        Asthma\n",
      "INDICATION_ID                                                    D001249\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                             Biological\n",
      "INTERVENTION_NAME_x                                          Tezepelumab\n",
      "DESCRIPTIONS                          Tezepelumab subcutaneous injection\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000270\n",
      "CONDITION                                                         Asthma\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                         asthma\n",
      "Name: 269, dtype: object\n",
      "_____\n",
      "TWID                                                                 887\n",
      "TWEET_ID                                              907214352385757184\n",
      "TWEET                  Encouraging antitumor activity safety and effi...\n",
      "SYNONYMS                                                      DURVALUMAB\n",
      "MOLREGNO_1                                                       1763549\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02352948\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                          scores in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                   Solid Tumor\n",
      "INDICATION_ID                                                    SDI0034\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                MEDI4736 (durvalumab)\n",
      "DESCRIPTIONS           MEDI4736 (durvalumab) treatment by intravenous...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0003060\n",
      "CONDITION                             Non - Small Cell Lung Cancer NSCLC\n",
      "MOLREGNO                                                         1380924\n",
      "NAME_TERM                                  non-small cell lung carcinoma\n",
      "Name: 271, dtype: object\n",
      "_____\n",
      "TWID                                                                 887\n",
      "TWEET_ID                                              907214352385757184\n",
      "TWEET                  Encouraging antitumor activity safety and effi...\n",
      "SYNONYMS                                                      DURVALUMAB\n",
      "MOLREGNO_1                                                       1763549\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02352948\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                          scores in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                   Solid Tumor\n",
      "INDICATION_ID                                                    SDI0034\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                MEDI4736 (durvalumab)\n",
      "DESCRIPTIONS           MEDI4736 (durvalumab) treatment by intravenous...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0003060\n",
      "CONDITION                             Non - Small Cell Lung Cancer NSCLC\n",
      "MOLREGNO                                                          560078\n",
      "NAME_TERM                                  non-small cell lung carcinoma\n",
      "Name: 273, dtype: object\n",
      "_____\n",
      "TWID                                                                 887\n",
      "TWEET_ID                                              907214352385757184\n",
      "TWEET                  Encouraging antitumor activity safety and effi...\n",
      "SYNONYMS                                                      DURVALUMAB\n",
      "MOLREGNO_1                                                       1763549\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02352948\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                          scores in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                   Solid Tumor\n",
      "INDICATION_ID                                                    SDI0034\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                MEDI4736 (durvalumab)\n",
      "DESCRIPTIONS           MEDI4736 (durvalumab) treatment by intravenous...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0003060\n",
      "CONDITION                             Non - Small Cell Lung Cancer NSCLC\n",
      "MOLREGNO                                                           14785\n",
      "NAME_TERM                                  non-small cell lung carcinoma\n",
      "Name: 274, dtype: object\n",
      "_____\n",
      "TWID                                                                 887\n",
      "TWEET_ID                                              907214352385757184\n",
      "TWEET                  Encouraging antitumor activity safety and effi...\n",
      "SYNONYMS                                                      DURVALUMAB\n",
      "MOLREGNO_1                                                       1763549\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02352948\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                          scores in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                   Solid Tumor\n",
      "INDICATION_ID                                                    SDI0034\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                MEDI4736 (durvalumab)\n",
      "DESCRIPTIONS           MEDI4736 (durvalumab) treatment by intravenous...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0003060\n",
      "CONDITION                             Non - Small Cell Lung Cancer NSCLC\n",
      "MOLREGNO                                                           75901\n",
      "NAME_TERM                                  non-small cell lung carcinoma\n",
      "Name: 275, dtype: object\n",
      "_____\n",
      "TWID                                                                 969\n",
      "TWEET_ID                                              902093522945363968\n",
      "TWEET                  @pfizer presents newest safety data of apixaba...\n",
      "SYNONYMS                                                        WARFARIN\n",
      "MOLREGNO_1                                                        394165\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03395639\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                     presents safety data\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                       cardiovascular diseases\n",
      "INDICATION_ID                                                    D002318\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                               Standard of Care (SOC)\n",
      "DESCRIPTIONS           Standard of care could include low molecular w...\n",
      "OTHER_NAME                                   Warfarin/heparin;Enoxaparin\n",
      "EFO_ID                                                       EFO:0003777\n",
      "CONDITION                                                Cardiac Disease\n",
      "MOLREGNO                                                          709600\n",
      "NAME_TERM                                                  heart disease\n",
      "Name: 370, dtype: object\n",
      "_____\n",
      "TWID                                                                 969\n",
      "TWEET_ID                                              902093522945363968\n",
      "TWEET                  @pfizer presents newest safety data of apixaba...\n",
      "SYNONYMS                                                        APIXABAN\n",
      "MOLREGNO_1                                                        397524\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03129555\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                     presents safety data\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                       cardiovascular diseases\n",
      "INDICATION_ID                                                    D002318\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                 Apixaban Oral Tablet\n",
      "DESCRIPTIONS           After cluster randomization, the cluster will ...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0003827\n",
      "CONDITION                                             Pulmonary Embolism\n",
      "MOLREGNO                                                          709600\n",
      "NAME_TERM                                             pulmonary embolism\n",
      "Name: 371, dtype: object\n",
      "_____\n",
      "TWID                                                                 969\n",
      "TWEET_ID                                              902093522945363968\n",
      "TWEET                  @pfizer presents newest safety data of apixaba...\n",
      "SYNONYMS                                                        APIXABAN\n",
      "MOLREGNO_1                                                        397524\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03129555\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                     presents safety data\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                       cardiovascular diseases\n",
      "INDICATION_ID                                                    D002318\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                 Apixaban Oral Tablet\n",
      "DESCRIPTIONS           After cluster randomization, the cluster will ...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0003827\n",
      "CONDITION                                             Pulmonary Embolism\n",
      "MOLREGNO                                                          561520\n",
      "NAME_TERM                                             pulmonary embolism\n",
      "Name: 372, dtype: object\n",
      "_____\n",
      "TWID                                                                 969\n",
      "TWEET_ID                                              902093522945363968\n",
      "TWEET                  @pfizer presents newest safety data of apixaba...\n",
      "SYNONYMS                                                        APIXABAN\n",
      "MOLREGNO_1                                                        397524\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03129555\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                     presents safety data\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                       cardiovascular diseases\n",
      "INDICATION_ID                                                    D002318\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                 Apixaban Oral Tablet\n",
      "DESCRIPTIONS           After cluster randomization, the cluster will ...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0003827\n",
      "CONDITION                                             Pulmonary Embolism\n",
      "MOLREGNO                                                          328601\n",
      "NAME_TERM                                             pulmonary embolism\n",
      "Name: 373, dtype: object\n",
      "_____\n",
      "TWID                                                                 969\n",
      "TWEET_ID                                              902093522945363968\n",
      "TWEET                  @pfizer presents newest safety data of apixaba...\n",
      "SYNONYMS                                                        APIXABAN\n",
      "MOLREGNO_1                                                        397524\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03129555\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                     presents safety data\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                       cardiovascular diseases\n",
      "INDICATION_ID                                                    D002318\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                 Apixaban Oral Tablet\n",
      "DESCRIPTIONS           After cluster randomization, the cluster will ...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0003907\n",
      "CONDITION                                           Deep Vein Thrombosis\n",
      "MOLREGNO                                                          709600\n",
      "NAME_TERM                                           deep vein thrombosis\n",
      "Name: 375, dtype: object\n",
      "_____\n",
      "TWID                                                                 969\n",
      "TWEET_ID                                              902093522945363968\n",
      "TWEET                  @pfizer presents newest safety data of apixaba...\n",
      "SYNONYMS                                                        APIXABAN\n",
      "MOLREGNO_1                                                        397524\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03129555\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                     presents safety data\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                       cardiovascular diseases\n",
      "INDICATION_ID                                                    D002318\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                 Apixaban Oral Tablet\n",
      "DESCRIPTIONS           After cluster randomization, the cluster will ...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0003907\n",
      "CONDITION                                           Deep Vein Thrombosis\n",
      "MOLREGNO                                                          561520\n",
      "NAME_TERM                                           deep vein thrombosis\n",
      "Name: 376, dtype: object\n",
      "_____\n",
      "TWID                                                                 969\n",
      "TWEET_ID                                              902093522945363968\n",
      "TWEET                  @pfizer presents newest safety data of apixaba...\n",
      "SYNONYMS                                                        APIXABAN\n",
      "MOLREGNO_1                                                        397524\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03129555\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                     presents safety data\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                       cardiovascular diseases\n",
      "INDICATION_ID                                                    D002318\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                 Apixaban Oral Tablet\n",
      "DESCRIPTIONS           After cluster randomization, the cluster will ...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0003907\n",
      "CONDITION                                           Deep Vein Thrombosis\n",
      "MOLREGNO                                                          328601\n",
      "NAME_TERM                                           deep vein thrombosis\n",
      "Name: 377, dtype: object\n",
      "_____\n",
      "TWID                                                                1016\n",
      "TWEET_ID                                              898403700502175744\n",
      "TWEET                  Tetraphase files MAA for iv eravacycline for c...\n",
      "SYNONYMS                                                    ERAVACYCLINE\n",
      "MOLREGNO_1                                                       1280078\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03032510\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                         files for complicated infections\n",
      "COMPANY                                                       Tetraphase\n",
      "COMPANY_ID                                                     COMP90755\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                        Chronic Kidney Failure\n",
      "INDICATION_ID                                                    D007676\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Eravacycline\n",
      "DESCRIPTIONS                                                        Null\n",
      "OTHER_NAME                                                        TP-434\n",
      "EFO_ID                                                       EFO:0003103\n",
      "CONDITION                           Complicated Urinary Tract Infections\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                        urinary tract infection\n",
      "Name: 383, dtype: object\n",
      "_____\n",
      "TWID                                                                1016\n",
      "TWEET_ID                                              898403700502175744\n",
      "TWEET                  Tetraphase files MAA for iv eravacycline for c...\n",
      "SYNONYMS                                                    ERAVACYCLINE\n",
      "MOLREGNO_1                                                       1280078\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03032510\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                         files for complicated infections\n",
      "COMPANY                                                       Tetraphase\n",
      "COMPANY_ID                                                     COMP90755\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                        Chronic Kidney Failure\n",
      "INDICATION_ID                                                    D007676\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Eravacycline\n",
      "DESCRIPTIONS                                                        Null\n",
      "OTHER_NAME                                                        TP-434\n",
      "EFO_ID                                                       EFO:0003103\n",
      "CONDITION                           Complicated Urinary Tract Infections\n",
      "MOLREGNO                                                            1795\n",
      "NAME_TERM                                        urinary tract infection\n",
      "Name: 384, dtype: object\n",
      "_____\n",
      "TWID                                                                1016\n",
      "TWEET_ID                                              898403700502175744\n",
      "TWEET                  Tetraphase files MAA for iv eravacycline for c...\n",
      "SYNONYMS                                                    ERAVACYCLINE\n",
      "MOLREGNO_1                                                       1280078\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03032510\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                         files for complicated infections\n",
      "COMPANY                                                       Tetraphase\n",
      "COMPANY_ID                                                     COMP90755\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                        Chronic Kidney Failure\n",
      "INDICATION_ID                                                    D007676\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Eravacycline\n",
      "DESCRIPTIONS                                                        Null\n",
      "OTHER_NAME                                                        TP-434\n",
      "EFO_ID                                                       EFO:0003103\n",
      "CONDITION                           Complicated Urinary Tract Infections\n",
      "MOLREGNO                                                          304903\n",
      "NAME_TERM                                        urinary tract infection\n",
      "Name: 385, dtype: object\n",
      "_____\n",
      "TWID                                                                1021\n",
      "TWEET_ID                                              897448032064610304\n",
      "TWEET                  RT @BioWorld $REGN boots suptavumab after phas...\n",
      "SYNONYMS                                                      SUPTAVUMAB\n",
      "MOLREGNO_1                                                       2039298\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02325791\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              boots after\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                             REGN2222\n",
      "DESCRIPTIONS                                                        Null\n",
      "OTHER_NAME                                                    suptavumab\n",
      "EFO_ID                                                       EFO:1001413\n",
      "CONDITION                         Respiratory Syncytial Virus Infections\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                          Respiratory Syncytial Virus Infection\n",
      "Name: 388, dtype: object\n",
      "_____\n",
      "TWID                                                                1072\n",
      "TWEET_ID                                              890213870522040322\n",
      "TWEET                  Tetraphase's eravacycline meets primary endpoi...\n",
      "SYNONYMS                                                    ERAVACYCLINE\n",
      "MOLREGNO_1                                                       1280078\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03032510\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               3\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                   meets primary endpoint\n",
      "COMPANY                                                       Tetraphase\n",
      "COMPANY_ID                                                     COMP90755\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                        Chronic Kidney Failure\n",
      "INDICATION_ID                                                    D007676\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Eravacycline\n",
      "DESCRIPTIONS                                                        Null\n",
      "OTHER_NAME                                                        TP-434\n",
      "EFO_ID                                                       EFO:0003103\n",
      "CONDITION                           Complicated Urinary Tract Infections\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                        urinary tract infection\n",
      "Name: 401, dtype: object\n",
      "_____\n",
      "TWID                                                                1072\n",
      "TWEET_ID                                              890213870522040322\n",
      "TWEET                  Tetraphase's eravacycline meets primary endpoi...\n",
      "SYNONYMS                                                    ERAVACYCLINE\n",
      "MOLREGNO_1                                                       1280078\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03032510\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               3\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                   meets primary endpoint\n",
      "COMPANY                                                       Tetraphase\n",
      "COMPANY_ID                                                     COMP90755\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                        Chronic Kidney Failure\n",
      "INDICATION_ID                                                    D007676\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Eravacycline\n",
      "DESCRIPTIONS                                                        Null\n",
      "OTHER_NAME                                                        TP-434\n",
      "EFO_ID                                                       EFO:0003103\n",
      "CONDITION                           Complicated Urinary Tract Infections\n",
      "MOLREGNO                                                            1795\n",
      "NAME_TERM                                        urinary tract infection\n",
      "Name: 402, dtype: object\n",
      "_____\n",
      "TWID                                                                1072\n",
      "TWEET_ID                                              890213870522040322\n",
      "TWEET                  Tetraphase's eravacycline meets primary endpoi...\n",
      "SYNONYMS                                                    ERAVACYCLINE\n",
      "MOLREGNO_1                                                       1280078\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03032510\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               3\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                   meets primary endpoint\n",
      "COMPANY                                                       Tetraphase\n",
      "COMPANY_ID                                                     COMP90755\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                        Chronic Kidney Failure\n",
      "INDICATION_ID                                                    D007676\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Eravacycline\n",
      "DESCRIPTIONS                                                        Null\n",
      "OTHER_NAME                                                        TP-434\n",
      "EFO_ID                                                       EFO:0003103\n",
      "CONDITION                           Complicated Urinary Tract Infections\n",
      "MOLREGNO                                                          304903\n",
      "NAME_TERM                                        urinary tract infection\n",
      "Name: 403, dtype: object\n",
      "_____\n",
      "TWID                                                                1074\n",
      "TWEET_ID                                              890210096415899649\n",
      "TWEET                  Axsome's AXS-06 (meloxicam and esomeprazole) m...\n",
      "SYNONYMS                                                       MELOXICAM\n",
      "MOLREGNO_1                                                         20496\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03434275\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                   meets primary endpoint\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                 Low Back Pain\n",
      "INDICATION_ID                                                    D017116\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                                N1539\n",
      "DESCRIPTIONS                                                  Once Daily\n",
      "OTHER_NAME                                         Intravenous meloxicam\n",
      "EFO_ID                                                       EFO:0003843\n",
      "CONDITION                                            Pain, Postoperative\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                           pain\n",
      "Name: 406, dtype: object\n",
      "_____\n",
      "TWID                                                                1087\n",
      "TWEET_ID                                              888386831263379456\n",
      "TWEET                  Incyte begins phase III trials of itacitinib f...\n",
      "SYNONYMS                                                      ITACITINIB\n",
      "MOLREGNO_1                                                       1966506\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02257619\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                      begins phase trials\n",
      "COMPANY                                                           Incyte\n",
      "COMPANY_ID                                                       COMP328\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                         Graft vs Host Disease\n",
      "INDICATION_ID                                                    D006086\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Itacitinib\n",
      "DESCRIPTIONS           Itacitinib tablets administered orally at 400 ...\n",
      "OTHER_NAME                                                    INCB039110\n",
      "EFO_ID                                                       EFO:0003060\n",
      "CONDITION                          NSCLC (Non-small Cell Lung Carcinoma)\n",
      "MOLREGNO                                                         1927101\n",
      "NAME_TERM                                  non-small cell lung carcinoma\n",
      "Name: 409, dtype: object\n",
      "_____\n",
      "TWID                                                                1097\n",
      "TWEET_ID                                              887649643793874945\n",
      "TWEET                  Amgen/Sanofi's Leukine (recombinant GM-CSF) im...\n",
      "SYNONYMS                                                         LEUKINE\n",
      "MOLREGNO_1                                                        675569\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01265901\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                   improves MMSE in trial\n",
      "COMPANY                                                            Amgen\n",
      "COMPANY_ID                                                        COMP44\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                               Kidney Diseases\n",
      "INDICATION_ID                                                    D007674\n",
      "INDICATION_NONAMBIG                                                    0\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                             Biological\n",
      "INTERVENTION_NAME_x                                               GM-CSF\n",
      "DESCRIPTIONS                Intradermal injection of GM-CSF as adjuvant.\n",
      "OTHER_NAME             Granulocyte macrophage-colony stimulating fact...\n",
      "EFO_ID                                                       EFO:0000681\n",
      "CONDITION                                Metastatic Renal Cell Carcinoma\n",
      "MOLREGNO                                                          674747\n",
      "NAME_TERM                                           renal cell carcinoma\n",
      "Name: 412, dtype: object\n",
      "_____\n",
      "TWID                                                                1097\n",
      "TWEET_ID                                              887649643793874945\n",
      "TWEET                  Amgen/Sanofi's Leukine (recombinant GM-CSF) im...\n",
      "SYNONYMS                                                         LEUKINE\n",
      "MOLREGNO_1                                                        675569\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01265901\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                   improves MMSE in trial\n",
      "COMPANY                                                            Amgen\n",
      "COMPANY_ID                                                        COMP44\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                               Kidney Diseases\n",
      "INDICATION_ID                                                    D007674\n",
      "INDICATION_NONAMBIG                                                    0\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                             Biological\n",
      "INTERVENTION_NAME_x                                               GM-CSF\n",
      "DESCRIPTIONS                Intradermal injection of GM-CSF as adjuvant.\n",
      "OTHER_NAME             Granulocyte macrophage-colony stimulating fact...\n",
      "EFO_ID                                                       EFO:0000681\n",
      "CONDITION                                Metastatic Renal Cell Carcinoma\n",
      "MOLREGNO                                                           13048\n",
      "NAME_TERM                                           renal cell carcinoma\n",
      "Name: 413, dtype: object\n",
      "_____\n",
      "TWID                                                                1114\n",
      "TWEET_ID                                              886955701045780480\n",
      "TWEET                  Concomitant use of glycopyrrolate or trospium ...\n",
      "SYNONYMS                                                  GLYCOPYRROLATE\n",
      "MOLREGNO_1                                                        674978\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03081156\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                     reduced side effects\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                    Overactive Urinary Bladder\n",
      "INDICATION_ID                                                    D053201\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                          Glycopyrrolate / Formeterol\n",
      "DESCRIPTIONS                                          Exercise Tolerance\n",
      "OTHER_NAME                                           Bevespi Aeerosphere\n",
      "EFO_ID                                                       EFO:0000341\n",
      "CONDITION                         Pulmonary Disease, Chronic Obstructive\n",
      "MOLREGNO                                                         2197669\n",
      "NAME_TERM                          chronic obstructive pulmonary disease\n",
      "Name: 415, dtype: object\n",
      "_____\n",
      "TWID                                                                1190\n",
      "TWEET_ID                                              877171367141146625\n",
      "TWEET                  Seattle Genetics stops treatment in all Vadast...\n",
      "SYNONYMS                                           VADASTUXIMAB TALIRINE\n",
      "MOLREGNO_1                                                       2197892\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02706899\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                          stops treatment\n",
      "COMPANY                                                 Seattle Genetics\n",
      "COMPANY_ID                                                       COMP698\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                vadastuximab talirine\n",
      "DESCRIPTIONS                                                        Null\n",
      "OTHER_NAME                                                 33A;SGN-CD33A\n",
      "EFO_ID                                                       EFO:0000198\n",
      "CONDITION                                       Myelodysplastic Syndrome\n",
      "MOLREGNO                                                          418401\n",
      "NAME_TERM                                       myelodysplastic syndrome\n",
      "Name: 448, dtype: object\n",
      "_____\n",
      "TWID                                                                1190\n",
      "TWEET_ID                                              877171367141146625\n",
      "TWEET                  Seattle Genetics stops treatment in all Vadast...\n",
      "SYNONYMS                                           VADASTUXIMAB TALIRINE\n",
      "MOLREGNO_1                                                       2197892\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02706899\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                          stops treatment\n",
      "COMPANY                                                 Seattle Genetics\n",
      "COMPANY_ID                                                       COMP698\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                vadastuximab talirine\n",
      "DESCRIPTIONS                                                        Null\n",
      "OTHER_NAME                                                 33A;SGN-CD33A\n",
      "EFO_ID                                                       EFO:0000198\n",
      "CONDITION                                       Myelodysplastic Syndrome\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                       myelodysplastic syndrome\n",
      "Name: 449, dtype: object\n",
      "_____\n",
      "TWID                                                                1190\n",
      "TWEET_ID                                              877171367141146625\n",
      "TWEET                  Seattle Genetics stops treatment in all Vadast...\n",
      "SYNONYMS                                           VADASTUXIMAB TALIRINE\n",
      "MOLREGNO_1                                                       2197892\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02706899\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                          stops treatment\n",
      "COMPANY                                                 Seattle Genetics\n",
      "COMPANY_ID                                                       COMP698\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                vadastuximab talirine\n",
      "DESCRIPTIONS                                                        Null\n",
      "OTHER_NAME                                                 33A;SGN-CD33A\n",
      "EFO_ID                                                       EFO:0000198\n",
      "CONDITION                                       Myelodysplastic Syndrome\n",
      "MOLREGNO                                                         2197225\n",
      "NAME_TERM                                       myelodysplastic syndrome\n",
      "Name: 450, dtype: object\n",
      "_____\n",
      "TWID                                                                1190\n",
      "TWEET_ID                                              877171367141146625\n",
      "TWEET                  Seattle Genetics stops treatment in all Vadast...\n",
      "SYNONYMS                                                    VADASTUXIMAB\n",
      "MOLREGNO_1                                                       2197895\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02706899\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                          stops treatment\n",
      "COMPANY                                                 Seattle Genetics\n",
      "COMPANY_ID                                                       COMP698\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                vadastuximab talirine\n",
      "DESCRIPTIONS                                                        Null\n",
      "OTHER_NAME                                                 33A;SGN-CD33A\n",
      "EFO_ID                                                       EFO:0000198\n",
      "CONDITION                                       Myelodysplastic Syndrome\n",
      "MOLREGNO                                                          418401\n",
      "NAME_TERM                                       myelodysplastic syndrome\n",
      "Name: 451, dtype: object\n",
      "_____\n",
      "TWID                                                                1190\n",
      "TWEET_ID                                              877171367141146625\n",
      "TWEET                  Seattle Genetics stops treatment in all Vadast...\n",
      "SYNONYMS                                                    VADASTUXIMAB\n",
      "MOLREGNO_1                                                       2197895\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02706899\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                          stops treatment\n",
      "COMPANY                                                 Seattle Genetics\n",
      "COMPANY_ID                                                       COMP698\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                vadastuximab talirine\n",
      "DESCRIPTIONS                                                        Null\n",
      "OTHER_NAME                                                 33A;SGN-CD33A\n",
      "EFO_ID                                                       EFO:0000198\n",
      "CONDITION                                       Myelodysplastic Syndrome\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                       myelodysplastic syndrome\n",
      "Name: 452, dtype: object\n",
      "_____\n",
      "TWID                                                                1190\n",
      "TWEET_ID                                              877171367141146625\n",
      "TWEET                  Seattle Genetics stops treatment in all Vadast...\n",
      "SYNONYMS                                                    VADASTUXIMAB\n",
      "MOLREGNO_1                                                       2197895\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02706899\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                          stops treatment\n",
      "COMPANY                                                 Seattle Genetics\n",
      "COMPANY_ID                                                       COMP698\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                vadastuximab talirine\n",
      "DESCRIPTIONS                                                        Null\n",
      "OTHER_NAME                                                 33A;SGN-CD33A\n",
      "EFO_ID                                                       EFO:0000198\n",
      "CONDITION                                       Myelodysplastic Syndrome\n",
      "MOLREGNO                                                         2197225\n",
      "NAME_TERM                                       myelodysplastic syndrome\n",
      "Name: 453, dtype: object\n",
      "_____\n",
      "TWID                                                                1190\n",
      "TWEET_ID                                              877171367141146625\n",
      "TWEET                  Seattle Genetics stops treatment in all Vadast...\n",
      "SYNONYMS                                                        TALIRINE\n",
      "MOLREGNO_1                                                       2197836\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02706899\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                          stops treatment\n",
      "COMPANY                                                 Seattle Genetics\n",
      "COMPANY_ID                                                       COMP698\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                vadastuximab talirine\n",
      "DESCRIPTIONS                                                        Null\n",
      "OTHER_NAME                                                 33A;SGN-CD33A\n",
      "EFO_ID                                                       EFO:0000198\n",
      "CONDITION                                       Myelodysplastic Syndrome\n",
      "MOLREGNO                                                          418401\n",
      "NAME_TERM                                       myelodysplastic syndrome\n",
      "Name: 454, dtype: object\n",
      "_____\n",
      "TWID                                                                1190\n",
      "TWEET_ID                                              877171367141146625\n",
      "TWEET                  Seattle Genetics stops treatment in all Vadast...\n",
      "SYNONYMS                                                        TALIRINE\n",
      "MOLREGNO_1                                                       2197836\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02706899\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                          stops treatment\n",
      "COMPANY                                                 Seattle Genetics\n",
      "COMPANY_ID                                                       COMP698\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                vadastuximab talirine\n",
      "DESCRIPTIONS                                                        Null\n",
      "OTHER_NAME                                                 33A;SGN-CD33A\n",
      "EFO_ID                                                       EFO:0000198\n",
      "CONDITION                                       Myelodysplastic Syndrome\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                       myelodysplastic syndrome\n",
      "Name: 455, dtype: object\n",
      "_____\n",
      "TWID                                                                1190\n",
      "TWEET_ID                                              877171367141146625\n",
      "TWEET                  Seattle Genetics stops treatment in all Vadast...\n",
      "SYNONYMS                                                        TALIRINE\n",
      "MOLREGNO_1                                                       2197836\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02706899\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                          stops treatment\n",
      "COMPANY                                                 Seattle Genetics\n",
      "COMPANY_ID                                                       COMP698\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                vadastuximab talirine\n",
      "DESCRIPTIONS                                                        Null\n",
      "OTHER_NAME                                                 33A;SGN-CD33A\n",
      "EFO_ID                                                       EFO:0000198\n",
      "CONDITION                                       Myelodysplastic Syndrome\n",
      "MOLREGNO                                                         2197225\n",
      "NAME_TERM                                       myelodysplastic syndrome\n",
      "Name: 456, dtype: object\n",
      "_____\n",
      "TWID                                                                1258\n",
      "TWEET_ID                                              872762139932585984\n",
      "TWEET                  InCarda's InRhythm (inhaled flecainide) safe a...\n",
      "SYNONYMS                                                      FLECAINIDE\n",
      "MOLREGNO_1                                                         27588\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03162120\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            safe in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Brugada Syndrome\n",
      "INDICATION_ID                                                    D053840\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x               FlecainidE pluS Metoprolol Combination\n",
      "DESCRIPTIONS           FlecainidE pluS Metoprolol Combination in ATri...\n",
      "OTHER_NAME                                                      FM group\n",
      "EFO_ID                                                       EFO:0000275\n",
      "CONDITION                                            Atrial Fibrillation\n",
      "MOLREGNO                                                             789\n",
      "NAME_TERM                                            atrial fibrillation\n",
      "Name: 487, dtype: object\n",
      "_____\n",
      "TWID                                                                1258\n",
      "TWEET_ID                                              872762139932585984\n",
      "TWEET                  InCarda's InRhythm (inhaled flecainide) safe a...\n",
      "SYNONYMS                                                      FLECAINIDE\n",
      "MOLREGNO_1                                                         27588\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03162120\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            safe in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Brugada Syndrome\n",
      "INDICATION_ID                                                    D053840\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x               FlecainidE pluS Metoprolol Combination\n",
      "DESCRIPTIONS           FlecainidE pluS Metoprolol Combination in ATri...\n",
      "OTHER_NAME                                                      FM group\n",
      "EFO_ID                                                       EFO:0000275\n",
      "CONDITION                                            Atrial Fibrillation\n",
      "MOLREGNO                                                          341382\n",
      "NAME_TERM                                            atrial fibrillation\n",
      "Name: 488, dtype: object\n",
      "_____\n",
      "TWID                                                                1258\n",
      "TWEET_ID                                              872762139932585984\n",
      "TWEET                  InCarda's InRhythm (inhaled flecainide) safe a...\n",
      "SYNONYMS                                                      FLECAINIDE\n",
      "MOLREGNO_1                                                         27588\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03162120\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            safe in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Brugada Syndrome\n",
      "INDICATION_ID                                                    D053840\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x               FlecainidE pluS Metoprolol Combination\n",
      "DESCRIPTIONS           FlecainidE pluS Metoprolol Combination in ATri...\n",
      "OTHER_NAME                                                      FM group\n",
      "EFO_ID                                                   -NOT-CONDITION-\n",
      "CONDITION                                                     Recurrence\n",
      "MOLREGNO                                                             789\n",
      "NAME_TERM                                                            NaN\n",
      "Name: 490, dtype: object\n",
      "_____\n",
      "TWID                                                                1258\n",
      "TWEET_ID                                              872762139932585984\n",
      "TWEET                  InCarda's InRhythm (inhaled flecainide) safe a...\n",
      "SYNONYMS                                                      FLECAINIDE\n",
      "MOLREGNO_1                                                         27588\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03162120\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            safe in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Brugada Syndrome\n",
      "INDICATION_ID                                                    D053840\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x               FlecainidE pluS Metoprolol Combination\n",
      "DESCRIPTIONS           FlecainidE pluS Metoprolol Combination in ATri...\n",
      "OTHER_NAME                                                      FM group\n",
      "EFO_ID                                                   -NOT-CONDITION-\n",
      "CONDITION                                                     Recurrence\n",
      "MOLREGNO                                                          341382\n",
      "NAME_TERM                                                            NaN\n",
      "Name: 491, dtype: object\n",
      "_____\n",
      "TWID                                                                1265\n",
      "TWEET_ID                                              872195931785089024\n",
      "TWEET                  Enasidenib median overall survival reported as...\n",
      "SYNONYMS                                                      ENASIDENIB\n",
      "MOLREGNO_1                                                       2197779\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03013998\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                              N/I\n",
      "MATCHED_OUTCOME                   Overall survival reported as 93 months\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                              AG-221 (BAML-16-001-S3)\n",
      "DESCRIPTIONS           100 mg, oral, daily until time of intolerance ...\n",
      "OTHER_NAME                                                    Enasidenib\n",
      "EFO_ID                                                       EFO:0000222\n",
      "CONDITION                    Previously Untreated Acute Myeloid Leukemia\n",
      "MOLREGNO                                                         1121938\n",
      "NAME_TERM                                         acute myeloid leukemia\n",
      "Name: 551, dtype: object\n",
      "_____\n",
      "TWID                                                                1265\n",
      "TWEET_ID                                              872195931785089024\n",
      "TWEET                  Enasidenib median overall survival reported as...\n",
      "SYNONYMS                                                      ENASIDENIB\n",
      "MOLREGNO_1                                                       2197779\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03013998\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                              N/I\n",
      "MATCHED_OUTCOME                   Overall survival reported as 93 months\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                              AG-221 (BAML-16-001-S3)\n",
      "DESCRIPTIONS           100 mg, oral, daily until time of intolerance ...\n",
      "OTHER_NAME                                                    Enasidenib\n",
      "EFO_ID                                                       EFO:0000222\n",
      "CONDITION                    Previously Untreated Acute Myeloid Leukemia\n",
      "MOLREGNO                                                          675080\n",
      "NAME_TERM                                         acute myeloid leukemia\n",
      "Name: 552, dtype: object\n",
      "_____\n",
      "TWID                                                                1265\n",
      "TWEET_ID                                              872195931785089024\n",
      "TWEET                  Enasidenib median overall survival reported as...\n",
      "SYNONYMS                                                      ENASIDENIB\n",
      "MOLREGNO_1                                                       2197779\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03013998\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                              N/I\n",
      "MATCHED_OUTCOME                   Overall survival reported as 93 months\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                              AG-221 (BAML-16-001-S3)\n",
      "DESCRIPTIONS           100 mg, oral, daily until time of intolerance ...\n",
      "OTHER_NAME                                                    Enasidenib\n",
      "EFO_ID                                                       EFO:0000222\n",
      "CONDITION                    Previously Untreated Acute Myeloid Leukemia\n",
      "MOLREGNO                                                         1750027\n",
      "NAME_TERM                                         acute myeloid leukemia\n",
      "Name: 553, dtype: object\n",
      "_____\n",
      "TWID                                                                1265\n",
      "TWEET_ID                                              872195931785089024\n",
      "TWEET                  Enasidenib median overall survival reported as...\n",
      "SYNONYMS                                                      ENASIDENIB\n",
      "MOLREGNO_1                                                       2197779\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03013998\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                              N/I\n",
      "MATCHED_OUTCOME                   Overall survival reported as 93 months\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                              AG-221 (BAML-16-001-S3)\n",
      "DESCRIPTIONS           100 mg, oral, daily until time of intolerance ...\n",
      "OTHER_NAME                                                    Enasidenib\n",
      "EFO_ID                                                       EFO:0000222\n",
      "CONDITION                    Previously Untreated Acute Myeloid Leukemia\n",
      "MOLREGNO                                                          418401\n",
      "NAME_TERM                                         acute myeloid leukemia\n",
      "Name: 554, dtype: object\n",
      "_____\n",
      "TWID                                                                1265\n",
      "TWEET_ID                                              872195931785089024\n",
      "TWEET                  Enasidenib median overall survival reported as...\n",
      "SYNONYMS                                                      ENASIDENIB\n",
      "MOLREGNO_1                                                       2197779\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03013998\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                              N/I\n",
      "MATCHED_OUTCOME                   Overall survival reported as 93 months\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                              AG-221 (BAML-16-001-S3)\n",
      "DESCRIPTIONS           100 mg, oral, daily until time of intolerance ...\n",
      "OTHER_NAME                                                    Enasidenib\n",
      "EFO_ID                                                       EFO:0000222\n",
      "CONDITION                    Previously Untreated Acute Myeloid Leukemia\n",
      "MOLREGNO                                                          336913\n",
      "NAME_TERM                                         acute myeloid leukemia\n",
      "Name: 555, dtype: object\n",
      "_____\n",
      "TWID                                                                1265\n",
      "TWEET_ID                                              872195931785089024\n",
      "TWEET                  Enasidenib median overall survival reported as...\n",
      "SYNONYMS                                                      ENASIDENIB\n",
      "MOLREGNO_1                                                       2197779\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03013998\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                              N/I\n",
      "MATCHED_OUTCOME                   Overall survival reported as 93 months\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                              AG-221 (BAML-16-001-S3)\n",
      "DESCRIPTIONS           100 mg, oral, daily until time of intolerance ...\n",
      "OTHER_NAME                                                    Enasidenib\n",
      "EFO_ID                                                       EFO:0000222\n",
      "CONDITION                    Previously Untreated Acute Myeloid Leukemia\n",
      "MOLREGNO                                                           51182\n",
      "NAME_TERM                                         acute myeloid leukemia\n",
      "Name: 556, dtype: object\n",
      "_____\n",
      "TWID                                                                1265\n",
      "TWEET_ID                                              872195931785089024\n",
      "TWEET                  Enasidenib median overall survival reported as...\n",
      "SYNONYMS                                                      ENASIDENIB\n",
      "MOLREGNO_1                                                       2197779\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03013998\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                              N/I\n",
      "MATCHED_OUTCOME                   Overall survival reported as 93 months\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                              AG-221 (BAML-16-001-S3)\n",
      "DESCRIPTIONS           100 mg, oral, daily until time of intolerance ...\n",
      "OTHER_NAME                                                    Enasidenib\n",
      "EFO_ID                                                       EFO:0000222\n",
      "CONDITION                    Previously Untreated Acute Myeloid Leukemia\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                         acute myeloid leukemia\n",
      "Name: 557, dtype: object\n",
      "_____\n",
      "TWID                                                                1265\n",
      "TWEET_ID                                              872195931785089024\n",
      "TWEET                  Enasidenib median overall survival reported as...\n",
      "SYNONYMS                                                      ENASIDENIB\n",
      "MOLREGNO_1                                                       2197779\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03013998\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                              N/I\n",
      "MATCHED_OUTCOME                   Overall survival reported as 93 months\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                              AG-221 (BAML-16-001-S3)\n",
      "DESCRIPTIONS           100 mg, oral, daily until time of intolerance ...\n",
      "OTHER_NAME                                                    Enasidenib\n",
      "EFO_ID                                                       EFO:0000222\n",
      "CONDITION                    Previously Untreated Acute Myeloid Leukemia\n",
      "MOLREGNO                                                          693510\n",
      "NAME_TERM                                         acute myeloid leukemia\n",
      "Name: 558, dtype: object\n",
      "_____\n",
      "TWID                                                                1272\n",
      "TWEET_ID                                              872039138081558528\n",
      "TWEET                  Castle Creek starts phase II/II trial of CCP-0...\n",
      "SYNONYMS                                                       DIACEREIN\n",
      "MOLREGNO_1                                                         61717\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03154333\n",
      "PHASE                                                          Phase 1/2\n",
      "N_PHASES                                                               3\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                       starts phase trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                 Epidermolysis Bullosa Simplex\n",
      "INDICATION_ID                                                    D016110\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x            Diacerein 1% Ointment Topical Formulation\n",
      "DESCRIPTIONS                Diacerein 1% Ointment administered topically\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                      Orphanet:304\n",
      "CONDITION                                  Epidermolysis Bullosa Simplex\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                  Epidermolysis bullosa simplex\n",
      "Name: 559, dtype: object\n",
      "_____\n",
      "TWID                                                                1274\n",
      "TWEET_ID                                              872036041116585984\n",
      "TWEET                  AntriaBio files US IND for phase I trial of AB...\n",
      "SYNONYMS                                                         INSULIN\n",
      "MOLREGNO_1                                                        675478\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02451917\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                          files for phase\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                             Diabetes Mellitus\n",
      "INDICATION_ID                                                    D003920\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                     Glargine insulin\n",
      "DESCRIPTIONS           The initial insulin dose for those randomized ...\n",
      "OTHER_NAME                      Lantus insulin ™, Sanofi-Aventis, Brazil\n",
      "EFO_ID                                                       EFO:0001360\n",
      "CONDITION                                       Type 2 Diabetes Mellitus\n",
      "MOLREGNO                                                          675383\n",
      "NAME_TERM                                      type II diabetes mellitus\n",
      "Name: 562, dtype: object\n",
      "_____\n",
      "TWID                                                                1274\n",
      "TWEET_ID                                              872036041116585984\n",
      "TWEET                  AntriaBio files US IND for phase I trial of AB...\n",
      "SYNONYMS                                                         INSULIN\n",
      "MOLREGNO_1                                                        675478\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02451917\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                          files for phase\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                             Diabetes Mellitus\n",
      "INDICATION_ID                                                    D003920\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                     Glargine insulin\n",
      "DESCRIPTIONS           The initial insulin dose for those randomized ...\n",
      "OTHER_NAME                      Lantus insulin ™, Sanofi-Aventis, Brazil\n",
      "EFO_ID                                                       EFO:0001360\n",
      "CONDITION                                       Type 2 Diabetes Mellitus\n",
      "MOLREGNO                                                          675436\n",
      "NAME_TERM                                      type II diabetes mellitus\n",
      "Name: 563, dtype: object\n",
      "_____\n",
      "TWID                                                                1274\n",
      "TWEET_ID                                              872036041116585984\n",
      "TWEET                  AntriaBio files US IND for phase I trial of AB...\n",
      "SYNONYMS                                                         INSULIN\n",
      "MOLREGNO_1                                                        675478\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02451917\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                          files for phase\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                             Diabetes Mellitus\n",
      "INDICATION_ID                                                    D003920\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                     Glargine insulin\n",
      "DESCRIPTIONS           The initial insulin dose for those randomized ...\n",
      "OTHER_NAME                      Lantus insulin ™, Sanofi-Aventis, Brazil\n",
      "EFO_ID                                                       EFO:0003884\n",
      "CONDITION                                         Chronic Kidney Disease\n",
      "MOLREGNO                                                          675383\n",
      "NAME_TERM                                         chronic kidney disease\n",
      "Name: 564, dtype: object\n",
      "_____\n",
      "TWID                                                                1274\n",
      "TWEET_ID                                              872036041116585984\n",
      "TWEET                  AntriaBio files US IND for phase I trial of AB...\n",
      "SYNONYMS                                                         INSULIN\n",
      "MOLREGNO_1                                                        675478\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02451917\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                          files for phase\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                             Diabetes Mellitus\n",
      "INDICATION_ID                                                    D003920\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                     Glargine insulin\n",
      "DESCRIPTIONS           The initial insulin dose for those randomized ...\n",
      "OTHER_NAME                      Lantus insulin ™, Sanofi-Aventis, Brazil\n",
      "EFO_ID                                                       EFO:0003884\n",
      "CONDITION                                         Chronic Kidney Disease\n",
      "MOLREGNO                                                          675436\n",
      "NAME_TERM                                         chronic kidney disease\n",
      "Name: 565, dtype: object\n",
      "_____\n",
      "TWID                                                                1274\n",
      "TWEET_ID                                              872036041116585984\n",
      "TWEET                  AntriaBio files US IND for phase I trial of AB...\n",
      "SYNONYMS                                                         INSULIN\n",
      "MOLREGNO_1                                                        675478\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02451917\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                          files for phase\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                             Diabetes Mellitus\n",
      "INDICATION_ID                                                    D003920\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          NPH insulin\n",
      "DESCRIPTIONS           The same total daily NPH insulin dose was main...\n",
      "OTHER_NAME                                     Humulin N™, Lilly, Brazil\n",
      "EFO_ID                                                       EFO:0001360\n",
      "CONDITION                                       Type 2 Diabetes Mellitus\n",
      "MOLREGNO                                                          675383\n",
      "NAME_TERM                                      type II diabetes mellitus\n",
      "Name: 566, dtype: object\n",
      "_____\n",
      "TWID                                                                1274\n",
      "TWEET_ID                                              872036041116585984\n",
      "TWEET                  AntriaBio files US IND for phase I trial of AB...\n",
      "SYNONYMS                                                         INSULIN\n",
      "MOLREGNO_1                                                        675478\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02451917\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                          files for phase\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                             Diabetes Mellitus\n",
      "INDICATION_ID                                                    D003920\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          NPH insulin\n",
      "DESCRIPTIONS           The same total daily NPH insulin dose was main...\n",
      "OTHER_NAME                                     Humulin N™, Lilly, Brazil\n",
      "EFO_ID                                                       EFO:0001360\n",
      "CONDITION                                       Type 2 Diabetes Mellitus\n",
      "MOLREGNO                                                          675436\n",
      "NAME_TERM                                      type II diabetes mellitus\n",
      "Name: 567, dtype: object\n",
      "_____\n",
      "TWID                                                                1274\n",
      "TWEET_ID                                              872036041116585984\n",
      "TWEET                  AntriaBio files US IND for phase I trial of AB...\n",
      "SYNONYMS                                                         INSULIN\n",
      "MOLREGNO_1                                                        675478\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02451917\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                          files for phase\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                             Diabetes Mellitus\n",
      "INDICATION_ID                                                    D003920\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          NPH insulin\n",
      "DESCRIPTIONS           The same total daily NPH insulin dose was main...\n",
      "OTHER_NAME                                     Humulin N™, Lilly, Brazil\n",
      "EFO_ID                                                       EFO:0003884\n",
      "CONDITION                                         Chronic Kidney Disease\n",
      "MOLREGNO                                                          675383\n",
      "NAME_TERM                                         chronic kidney disease\n",
      "Name: 568, dtype: object\n",
      "_____\n",
      "TWID                                                                1274\n",
      "TWEET_ID                                              872036041116585984\n",
      "TWEET                  AntriaBio files US IND for phase I trial of AB...\n",
      "SYNONYMS                                                         INSULIN\n",
      "MOLREGNO_1                                                        675478\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02451917\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                          files for phase\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                             Diabetes Mellitus\n",
      "INDICATION_ID                                                    D003920\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          NPH insulin\n",
      "DESCRIPTIONS           The same total daily NPH insulin dose was main...\n",
      "OTHER_NAME                                     Humulin N™, Lilly, Brazil\n",
      "EFO_ID                                                       EFO:0003884\n",
      "CONDITION                                         Chronic Kidney Disease\n",
      "MOLREGNO                                                          675436\n",
      "NAME_TERM                                         chronic kidney disease\n",
      "Name: 569, dtype: object\n",
      "_____\n",
      "TWID                                                                1274\n",
      "TWEET_ID                                              872036041116585984\n",
      "TWEET                  AntriaBio files US IND for phase I trial of AB...\n",
      "SYNONYMS                                                         INSULIN\n",
      "MOLREGNO_1                                                        675534\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02451917\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                          files for phase\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                             Diabetes Mellitus\n",
      "INDICATION_ID                                                    D003920\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                     Glargine insulin\n",
      "DESCRIPTIONS           The initial insulin dose for those randomized ...\n",
      "OTHER_NAME                      Lantus insulin ™, Sanofi-Aventis, Brazil\n",
      "EFO_ID                                                       EFO:0001360\n",
      "CONDITION                                       Type 2 Diabetes Mellitus\n",
      "MOLREGNO                                                          675383\n",
      "NAME_TERM                                      type II diabetes mellitus\n",
      "Name: 570, dtype: object\n",
      "_____\n",
      "TWID                                                                1274\n",
      "TWEET_ID                                              872036041116585984\n",
      "TWEET                  AntriaBio files US IND for phase I trial of AB...\n",
      "SYNONYMS                                                         INSULIN\n",
      "MOLREGNO_1                                                        675534\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02451917\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                          files for phase\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                             Diabetes Mellitus\n",
      "INDICATION_ID                                                    D003920\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                     Glargine insulin\n",
      "DESCRIPTIONS           The initial insulin dose for those randomized ...\n",
      "OTHER_NAME                      Lantus insulin ™, Sanofi-Aventis, Brazil\n",
      "EFO_ID                                                       EFO:0001360\n",
      "CONDITION                                       Type 2 Diabetes Mellitus\n",
      "MOLREGNO                                                          675436\n",
      "NAME_TERM                                      type II diabetes mellitus\n",
      "Name: 571, dtype: object\n",
      "_____\n",
      "TWID                                                                1274\n",
      "TWEET_ID                                              872036041116585984\n",
      "TWEET                  AntriaBio files US IND for phase I trial of AB...\n",
      "SYNONYMS                                                         INSULIN\n",
      "MOLREGNO_1                                                        675534\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02451917\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                          files for phase\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                             Diabetes Mellitus\n",
      "INDICATION_ID                                                    D003920\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                     Glargine insulin\n",
      "DESCRIPTIONS           The initial insulin dose for those randomized ...\n",
      "OTHER_NAME                      Lantus insulin ™, Sanofi-Aventis, Brazil\n",
      "EFO_ID                                                       EFO:0003884\n",
      "CONDITION                                         Chronic Kidney Disease\n",
      "MOLREGNO                                                          675383\n",
      "NAME_TERM                                         chronic kidney disease\n",
      "Name: 572, dtype: object\n",
      "_____\n",
      "TWID                                                                1274\n",
      "TWEET_ID                                              872036041116585984\n",
      "TWEET                  AntriaBio files US IND for phase I trial of AB...\n",
      "SYNONYMS                                                         INSULIN\n",
      "MOLREGNO_1                                                        675534\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02451917\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                          files for phase\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                             Diabetes Mellitus\n",
      "INDICATION_ID                                                    D003920\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                     Glargine insulin\n",
      "DESCRIPTIONS           The initial insulin dose for those randomized ...\n",
      "OTHER_NAME                      Lantus insulin ™, Sanofi-Aventis, Brazil\n",
      "EFO_ID                                                       EFO:0003884\n",
      "CONDITION                                         Chronic Kidney Disease\n",
      "MOLREGNO                                                          675436\n",
      "NAME_TERM                                         chronic kidney disease\n",
      "Name: 573, dtype: object\n",
      "_____\n",
      "TWID                                                                1274\n",
      "TWEET_ID                                              872036041116585984\n",
      "TWEET                  AntriaBio files US IND for phase I trial of AB...\n",
      "SYNONYMS                                                         INSULIN\n",
      "MOLREGNO_1                                                        675534\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02451917\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                          files for phase\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                             Diabetes Mellitus\n",
      "INDICATION_ID                                                    D003920\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          NPH insulin\n",
      "DESCRIPTIONS           The same total daily NPH insulin dose was main...\n",
      "OTHER_NAME                                     Humulin N™, Lilly, Brazil\n",
      "EFO_ID                                                       EFO:0001360\n",
      "CONDITION                                       Type 2 Diabetes Mellitus\n",
      "MOLREGNO                                                          675383\n",
      "NAME_TERM                                      type II diabetes mellitus\n",
      "Name: 574, dtype: object\n",
      "_____\n",
      "TWID                                                                1274\n",
      "TWEET_ID                                              872036041116585984\n",
      "TWEET                  AntriaBio files US IND for phase I trial of AB...\n",
      "SYNONYMS                                                         INSULIN\n",
      "MOLREGNO_1                                                        675534\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02451917\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                          files for phase\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                             Diabetes Mellitus\n",
      "INDICATION_ID                                                    D003920\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          NPH insulin\n",
      "DESCRIPTIONS           The same total daily NPH insulin dose was main...\n",
      "OTHER_NAME                                     Humulin N™, Lilly, Brazil\n",
      "EFO_ID                                                       EFO:0001360\n",
      "CONDITION                                       Type 2 Diabetes Mellitus\n",
      "MOLREGNO                                                          675436\n",
      "NAME_TERM                                      type II diabetes mellitus\n",
      "Name: 575, dtype: object\n",
      "_____\n",
      "TWID                                                                1274\n",
      "TWEET_ID                                              872036041116585984\n",
      "TWEET                  AntriaBio files US IND for phase I trial of AB...\n",
      "SYNONYMS                                                         INSULIN\n",
      "MOLREGNO_1                                                        675534\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02451917\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                          files for phase\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                             Diabetes Mellitus\n",
      "INDICATION_ID                                                    D003920\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          NPH insulin\n",
      "DESCRIPTIONS           The same total daily NPH insulin dose was main...\n",
      "OTHER_NAME                                     Humulin N™, Lilly, Brazil\n",
      "EFO_ID                                                       EFO:0003884\n",
      "CONDITION                                         Chronic Kidney Disease\n",
      "MOLREGNO                                                          675383\n",
      "NAME_TERM                                         chronic kidney disease\n",
      "Name: 576, dtype: object\n",
      "_____\n",
      "TWID                                                                1274\n",
      "TWEET_ID                                              872036041116585984\n",
      "TWEET                  AntriaBio files US IND for phase I trial of AB...\n",
      "SYNONYMS                                                         INSULIN\n",
      "MOLREGNO_1                                                        675534\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02451917\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                          files for phase\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                             Diabetes Mellitus\n",
      "INDICATION_ID                                                    D003920\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          NPH insulin\n",
      "DESCRIPTIONS           The same total daily NPH insulin dose was main...\n",
      "OTHER_NAME                                     Humulin N™, Lilly, Brazil\n",
      "EFO_ID                                                       EFO:0003884\n",
      "CONDITION                                         Chronic Kidney Disease\n",
      "MOLREGNO                                                          675436\n",
      "NAME_TERM                                         chronic kidney disease\n",
      "Name: 577, dtype: object\n",
      "_____\n",
      "TWID                                                                1275\n",
      "TWEET_ID                                              871861256365498370\n",
      "TWEET                  Safety profile of CEA-TCB was manageable with ...\n",
      "SYNONYMS                                                    ATEZOLIZUMAB\n",
      "MOLREGNO_1                                                       2039198\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03359239\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           Safety profile\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                 Non-Small-Cell Lung Carcinoma\n",
      "INDICATION_ID                                                    D002289\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Atezolizumab\n",
      "DESCRIPTIONS           1200 mg administered by IV infusion every 3 we...\n",
      "OTHER_NAME                                                     TECENTRIQ\n",
      "EFO_ID                                                       EFO:0000292\n",
      "CONDITION                                 Urothelial/Bladder Cancer, Nos\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                              bladder carcinoma\n",
      "Name: 578, dtype: object\n",
      "_____\n",
      "TWID                                                                1277\n",
      "TWEET_ID                                              871859856638169089\n",
      "TWEET                  Glembatumumab vedotin shows encouraging antitu...\n",
      "SYNONYMS                                                         VEDOTIN\n",
      "MOLREGNO_1                                                       1540539\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03007030\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     shows encouraging antitumor activity\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                       Squamous Cell Neoplasms\n",
      "INDICATION_ID                                                    D018307\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                  Brentuximab Vedotin\n",
      "DESCRIPTIONS           Starting Dose: 2.4 mg/kg by vein over 30 minut...\n",
      "OTHER_NAME                                               SGN-35;Adcetris\n",
      "EFO_ID                                                       EFO:0000588\n",
      "CONDITION                                                   Mesothelioma\n",
      "MOLREGNO                                                         1121865\n",
      "NAME_TERM                                                   mesothelioma\n",
      "Name: 582, dtype: object\n",
      "_____\n",
      "TWID                                                                1277\n",
      "TWEET_ID                                              871859856638169089\n",
      "TWEET                  Glembatumumab vedotin shows encouraging antitu...\n",
      "SYNONYMS                                                         VEDOTIN\n",
      "MOLREGNO_1                                                       1540539\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03007030\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     shows encouraging antitumor activity\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                       Squamous Cell Neoplasms\n",
      "INDICATION_ID                                                    D018307\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                  Brentuximab Vedotin\n",
      "DESCRIPTIONS           Starting Dose: 2.4 mg/kg by vein over 30 minut...\n",
      "OTHER_NAME                                               SGN-35;Adcetris\n",
      "EFO_ID                                                       EFO:0003818\n",
      "CONDITION                           Lung Diseases Due to External Agents\n",
      "MOLREGNO                                                         1121865\n",
      "NAME_TERM                                                   lung disease\n",
      "Name: 583, dtype: object\n",
      "_____\n",
      "TWID                                                                1277\n",
      "TWEET_ID                                              871859856638169089\n",
      "TWEET                  Glembatumumab vedotin shows encouraging antitu...\n",
      "SYNONYMS                                                   GLEMBATUMUMAB\n",
      "MOLREGNO_1                                                       1380973\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03473691\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     shows encouraging antitumor activity\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                       Squamous Cell Neoplasms\n",
      "INDICATION_ID                                                    D018307\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                Glembatumumab Vedotin\n",
      "DESCRIPTIONS           Standard neo-adjuvant dose-dense doxorubicin 6...\n",
      "OTHER_NAME                                                       CDX-011\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                         1121899\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 584, dtype: object\n",
      "_____\n",
      "TWID                                                                1278\n",
      "TWEET_ID                                              871858414967820289\n",
      "TWEET                  Enfortumab vedotin was well tolerated in patie...\n",
      "SYNONYMS                                                      ENFORTUMAB\n",
      "MOLREGNO_1                                                       1763541\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02091999\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           well tolerated\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Pelvic Neoplasms\n",
      "INDICATION_ID                                                    D010386\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                   enfortumab vedotin\n",
      "DESCRIPTIONS                                   intravenous (IV) infusion\n",
      "OTHER_NAME                                     ASP7465;ASG-22CE;ASG-22ME\n",
      "EFO_ID                                                       EFO:0000311\n",
      "CONDITION              Metastatic Urothelial Cancer and Other Maligna...\n",
      "MOLREGNO                                                         1763551\n",
      "NAME_TERM                                                         cancer\n",
      "Name: 586, dtype: object\n",
      "_____\n",
      "TWID                                                                1278\n",
      "TWEET_ID                                              871858414967820289\n",
      "TWEET                  Enfortumab vedotin was well tolerated in patie...\n",
      "SYNONYMS                                                         VEDOTIN\n",
      "MOLREGNO_1                                                       1540539\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03007030\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           well tolerated\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Pelvic Neoplasms\n",
      "INDICATION_ID                                                    D010386\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                  Brentuximab Vedotin\n",
      "DESCRIPTIONS           Starting Dose: 2.4 mg/kg by vein over 30 minut...\n",
      "OTHER_NAME                                               SGN-35;Adcetris\n",
      "EFO_ID                                                       EFO:0000588\n",
      "CONDITION                                                   Mesothelioma\n",
      "MOLREGNO                                                         1121865\n",
      "NAME_TERM                                                   mesothelioma\n",
      "Name: 588, dtype: object\n",
      "_____\n",
      "TWID                                                                1278\n",
      "TWEET_ID                                              871858414967820289\n",
      "TWEET                  Enfortumab vedotin was well tolerated in patie...\n",
      "SYNONYMS                                                         VEDOTIN\n",
      "MOLREGNO_1                                                       1540539\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03007030\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           well tolerated\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Pelvic Neoplasms\n",
      "INDICATION_ID                                                    D010386\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                  Brentuximab Vedotin\n",
      "DESCRIPTIONS           Starting Dose: 2.4 mg/kg by vein over 30 minut...\n",
      "OTHER_NAME                                               SGN-35;Adcetris\n",
      "EFO_ID                                                       EFO:0003818\n",
      "CONDITION                           Lung Diseases Due to External Agents\n",
      "MOLREGNO                                                         1121865\n",
      "NAME_TERM                                                   lung disease\n",
      "Name: 589, dtype: object\n",
      "_____\n",
      "TWID                                                                1285\n",
      "TWEET_ID                                              871476260161155072\n",
      "TWEET                  Daratumumab+carfilzomib+lenalidomide+dexametha...\n",
      "SYNONYMS                                                   DEXAMETHASONE\n",
      "MOLREGNO_1                                                        365281\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           well tolerated\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Multiple Myeloma\n",
      "INDICATION_ID                                                    D009101\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Dexamethasone\n",
      "DESCRIPTIONS           8 mg, oral taken twice a day for 3 days starti...\n",
      "OTHER_NAME                                                       Adexone\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                          674747\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 630, dtype: object\n",
      "_____\n",
      "TWID                                                                1285\n",
      "TWEET_ID                                              871476260161155072\n",
      "TWEET                  Daratumumab+carfilzomib+lenalidomide+dexametha...\n",
      "SYNONYMS                                                   DEXAMETHASONE\n",
      "MOLREGNO_1                                                        365281\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           well tolerated\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Multiple Myeloma\n",
      "INDICATION_ID                                                    D009101\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Dexamethasone\n",
      "DESCRIPTIONS           8 mg, oral taken twice a day for 3 days starti...\n",
      "OTHER_NAME                                                       Adexone\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                           78759\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 631, dtype: object\n",
      "_____\n",
      "TWID                                                                1285\n",
      "TWEET_ID                                              871476260161155072\n",
      "TWEET                  Daratumumab+carfilzomib+lenalidomide+dexametha...\n",
      "SYNONYMS                                                   DEXAMETHASONE\n",
      "MOLREGNO_1                                                        365281\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           well tolerated\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Multiple Myeloma\n",
      "INDICATION_ID                                                    D009101\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Dexamethasone\n",
      "DESCRIPTIONS           8 mg, oral taken twice a day for 3 days starti...\n",
      "OTHER_NAME                                                       Adexone\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                          675363\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 632, dtype: object\n",
      "_____\n",
      "TWID                                                                1285\n",
      "TWEET_ID                                              871476260161155072\n",
      "TWEET                  Daratumumab+carfilzomib+lenalidomide+dexametha...\n",
      "SYNONYMS                                                   DEXAMETHASONE\n",
      "MOLREGNO_1                                                        365281\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           well tolerated\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Multiple Myeloma\n",
      "INDICATION_ID                                                    D009101\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Dexamethasone\n",
      "DESCRIPTIONS           8 mg, oral taken twice a day for 3 days starti...\n",
      "OTHER_NAME                                                       Adexone\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                          675434\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 633, dtype: object\n",
      "_____\n",
      "TWID                                                                1285\n",
      "TWEET_ID                                              871476260161155072\n",
      "TWEET                  Daratumumab+carfilzomib+lenalidomide+dexametha...\n",
      "SYNONYMS                                                   DEXAMETHASONE\n",
      "MOLREGNO_1                                                        365281\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           well tolerated\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Multiple Myeloma\n",
      "INDICATION_ID                                                    D009101\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Dexamethasone\n",
      "DESCRIPTIONS           8 mg, oral taken twice a day for 3 days starti...\n",
      "OTHER_NAME                                                       Adexone\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                           14805\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 635, dtype: object\n",
      "_____\n",
      "TWID                                                                1285\n",
      "TWEET_ID                                              871476260161155072\n",
      "TWEET                  Daratumumab+carfilzomib+lenalidomide+dexametha...\n",
      "SYNONYMS                                                   DEXAMETHASONE\n",
      "MOLREGNO_1                                                        365281\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           well tolerated\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Multiple Myeloma\n",
      "INDICATION_ID                                                    D009101\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Dexamethasone\n",
      "DESCRIPTIONS           8 mg, oral taken twice a day for 3 days starti...\n",
      "OTHER_NAME                                                       Adexone\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                         1927101\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 636, dtype: object\n",
      "_____\n",
      "TWID                                                                1285\n",
      "TWEET_ID                                              871476260161155072\n",
      "TWEET                  Daratumumab+carfilzomib+lenalidomide+dexametha...\n",
      "SYNONYMS                                                   DEXAMETHASONE\n",
      "MOLREGNO_1                                                        365281\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           well tolerated\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Multiple Myeloma\n",
      "INDICATION_ID                                                    D009101\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Dexamethasone\n",
      "DESCRIPTIONS           8 mg, oral taken twice a day for 3 days starti...\n",
      "OTHER_NAME                                                       Adexone\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                          675581\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 637, dtype: object\n",
      "_____\n",
      "TWID                                                                1285\n",
      "TWEET_ID                                              871476260161155072\n",
      "TWEET                  Daratumumab+carfilzomib+lenalidomide+dexametha...\n",
      "SYNONYMS                                                   DEXAMETHASONE\n",
      "MOLREGNO_1                                                        365281\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           well tolerated\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Multiple Myeloma\n",
      "INDICATION_ID                                                    D009101\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Dexamethasone\n",
      "DESCRIPTIONS           8 mg, oral taken twice a day for 3 days starti...\n",
      "OTHER_NAME                                                       Adexone\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                       Metastatic Breast Cancer\n",
      "MOLREGNO                                                          674747\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 638, dtype: object\n",
      "_____\n",
      "TWID                                                                1285\n",
      "TWEET_ID                                              871476260161155072\n",
      "TWEET                  Daratumumab+carfilzomib+lenalidomide+dexametha...\n",
      "SYNONYMS                                                   DEXAMETHASONE\n",
      "MOLREGNO_1                                                        365281\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           well tolerated\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Multiple Myeloma\n",
      "INDICATION_ID                                                    D009101\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Dexamethasone\n",
      "DESCRIPTIONS           8 mg, oral taken twice a day for 3 days starti...\n",
      "OTHER_NAME                                                       Adexone\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                       Metastatic Breast Cancer\n",
      "MOLREGNO                                                           78759\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 639, dtype: object\n",
      "_____\n",
      "TWID                                                                1285\n",
      "TWEET_ID                                              871476260161155072\n",
      "TWEET                  Daratumumab+carfilzomib+lenalidomide+dexametha...\n",
      "SYNONYMS                                                   DEXAMETHASONE\n",
      "MOLREGNO_1                                                        365281\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           well tolerated\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Multiple Myeloma\n",
      "INDICATION_ID                                                    D009101\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Dexamethasone\n",
      "DESCRIPTIONS           8 mg, oral taken twice a day for 3 days starti...\n",
      "OTHER_NAME                                                       Adexone\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                       Metastatic Breast Cancer\n",
      "MOLREGNO                                                          675363\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 640, dtype: object\n",
      "_____\n",
      "TWID                                                                1285\n",
      "TWEET_ID                                              871476260161155072\n",
      "TWEET                  Daratumumab+carfilzomib+lenalidomide+dexametha...\n",
      "SYNONYMS                                                   DEXAMETHASONE\n",
      "MOLREGNO_1                                                        365281\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           well tolerated\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Multiple Myeloma\n",
      "INDICATION_ID                                                    D009101\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Dexamethasone\n",
      "DESCRIPTIONS           8 mg, oral taken twice a day for 3 days starti...\n",
      "OTHER_NAME                                                       Adexone\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                       Metastatic Breast Cancer\n",
      "MOLREGNO                                                          675434\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 641, dtype: object\n",
      "_____\n",
      "TWID                                                                1285\n",
      "TWEET_ID                                              871476260161155072\n",
      "TWEET                  Daratumumab+carfilzomib+lenalidomide+dexametha...\n",
      "SYNONYMS                                                   DEXAMETHASONE\n",
      "MOLREGNO_1                                                        365281\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           well tolerated\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Multiple Myeloma\n",
      "INDICATION_ID                                                    D009101\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Dexamethasone\n",
      "DESCRIPTIONS           8 mg, oral taken twice a day for 3 days starti...\n",
      "OTHER_NAME                                                       Adexone\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                       Metastatic Breast Cancer\n",
      "MOLREGNO                                                           14805\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 643, dtype: object\n",
      "_____\n",
      "TWID                                                                1285\n",
      "TWEET_ID                                              871476260161155072\n",
      "TWEET                  Daratumumab+carfilzomib+lenalidomide+dexametha...\n",
      "SYNONYMS                                                   DEXAMETHASONE\n",
      "MOLREGNO_1                                                        365281\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           well tolerated\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Multiple Myeloma\n",
      "INDICATION_ID                                                    D009101\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Dexamethasone\n",
      "DESCRIPTIONS           8 mg, oral taken twice a day for 3 days starti...\n",
      "OTHER_NAME                                                       Adexone\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                       Metastatic Breast Cancer\n",
      "MOLREGNO                                                         1927101\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 644, dtype: object\n",
      "_____\n",
      "TWID                                                                1285\n",
      "TWEET_ID                                              871476260161155072\n",
      "TWEET                  Daratumumab+carfilzomib+lenalidomide+dexametha...\n",
      "SYNONYMS                                                   DEXAMETHASONE\n",
      "MOLREGNO_1                                                        365281\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           well tolerated\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Multiple Myeloma\n",
      "INDICATION_ID                                                    D009101\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Dexamethasone\n",
      "DESCRIPTIONS           8 mg, oral taken twice a day for 3 days starti...\n",
      "OTHER_NAME                                                       Adexone\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                       Metastatic Breast Cancer\n",
      "MOLREGNO                                                          675581\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 645, dtype: object\n",
      "_____\n",
      "TWID                                                                1285\n",
      "TWEET_ID                                              871476260161155072\n",
      "TWEET                  Daratumumab+carfilzomib+lenalidomide+dexametha...\n",
      "SYNONYMS                                                   DEXAMETHASONE\n",
      "MOLREGNO_1                                                        674588\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           well tolerated\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Multiple Myeloma\n",
      "INDICATION_ID                                                    D009101\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Dexamethasone\n",
      "DESCRIPTIONS           8 mg, oral taken twice a day for 3 days starti...\n",
      "OTHER_NAME                                                       Adexone\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                          674747\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 646, dtype: object\n",
      "_____\n",
      "TWID                                                                1285\n",
      "TWEET_ID                                              871476260161155072\n",
      "TWEET                  Daratumumab+carfilzomib+lenalidomide+dexametha...\n",
      "SYNONYMS                                                   DEXAMETHASONE\n",
      "MOLREGNO_1                                                        674588\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           well tolerated\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Multiple Myeloma\n",
      "INDICATION_ID                                                    D009101\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Dexamethasone\n",
      "DESCRIPTIONS           8 mg, oral taken twice a day for 3 days starti...\n",
      "OTHER_NAME                                                       Adexone\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                           78759\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 647, dtype: object\n",
      "_____\n",
      "TWID                                                                1285\n",
      "TWEET_ID                                              871476260161155072\n",
      "TWEET                  Daratumumab+carfilzomib+lenalidomide+dexametha...\n",
      "SYNONYMS                                                   DEXAMETHASONE\n",
      "MOLREGNO_1                                                        674588\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           well tolerated\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Multiple Myeloma\n",
      "INDICATION_ID                                                    D009101\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Dexamethasone\n",
      "DESCRIPTIONS           8 mg, oral taken twice a day for 3 days starti...\n",
      "OTHER_NAME                                                       Adexone\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                          675363\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 648, dtype: object\n",
      "_____\n",
      "TWID                                                                1285\n",
      "TWEET_ID                                              871476260161155072\n",
      "TWEET                  Daratumumab+carfilzomib+lenalidomide+dexametha...\n",
      "SYNONYMS                                                   DEXAMETHASONE\n",
      "MOLREGNO_1                                                        674588\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           well tolerated\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Multiple Myeloma\n",
      "INDICATION_ID                                                    D009101\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Dexamethasone\n",
      "DESCRIPTIONS           8 mg, oral taken twice a day for 3 days starti...\n",
      "OTHER_NAME                                                       Adexone\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                          675434\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 649, dtype: object\n",
      "_____\n",
      "TWID                                                                1285\n",
      "TWEET_ID                                              871476260161155072\n",
      "TWEET                  Daratumumab+carfilzomib+lenalidomide+dexametha...\n",
      "SYNONYMS                                                   DEXAMETHASONE\n",
      "MOLREGNO_1                                                        674588\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           well tolerated\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Multiple Myeloma\n",
      "INDICATION_ID                                                    D009101\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Dexamethasone\n",
      "DESCRIPTIONS           8 mg, oral taken twice a day for 3 days starti...\n",
      "OTHER_NAME                                                       Adexone\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                          365281\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 650, dtype: object\n",
      "_____\n",
      "TWID                                                                1285\n",
      "TWEET_ID                                              871476260161155072\n",
      "TWEET                  Daratumumab+carfilzomib+lenalidomide+dexametha...\n",
      "SYNONYMS                                                   DEXAMETHASONE\n",
      "MOLREGNO_1                                                        674588\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           well tolerated\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Multiple Myeloma\n",
      "INDICATION_ID                                                    D009101\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Dexamethasone\n",
      "DESCRIPTIONS           8 mg, oral taken twice a day for 3 days starti...\n",
      "OTHER_NAME                                                       Adexone\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                           14805\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 651, dtype: object\n",
      "_____\n",
      "TWID                                                                1285\n",
      "TWEET_ID                                              871476260161155072\n",
      "TWEET                  Daratumumab+carfilzomib+lenalidomide+dexametha...\n",
      "SYNONYMS                                                   DEXAMETHASONE\n",
      "MOLREGNO_1                                                        674588\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           well tolerated\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Multiple Myeloma\n",
      "INDICATION_ID                                                    D009101\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Dexamethasone\n",
      "DESCRIPTIONS           8 mg, oral taken twice a day for 3 days starti...\n",
      "OTHER_NAME                                                       Adexone\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                         1927101\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 652, dtype: object\n",
      "_____\n",
      "TWID                                                                1285\n",
      "TWEET_ID                                              871476260161155072\n",
      "TWEET                  Daratumumab+carfilzomib+lenalidomide+dexametha...\n",
      "SYNONYMS                                                   DEXAMETHASONE\n",
      "MOLREGNO_1                                                        674588\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           well tolerated\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Multiple Myeloma\n",
      "INDICATION_ID                                                    D009101\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Dexamethasone\n",
      "DESCRIPTIONS           8 mg, oral taken twice a day for 3 days starti...\n",
      "OTHER_NAME                                                       Adexone\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                          675581\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 653, dtype: object\n",
      "_____\n",
      "TWID                                                                1285\n",
      "TWEET_ID                                              871476260161155072\n",
      "TWEET                  Daratumumab+carfilzomib+lenalidomide+dexametha...\n",
      "SYNONYMS                                                   DEXAMETHASONE\n",
      "MOLREGNO_1                                                        674588\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           well tolerated\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Multiple Myeloma\n",
      "INDICATION_ID                                                    D009101\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Dexamethasone\n",
      "DESCRIPTIONS           8 mg, oral taken twice a day for 3 days starti...\n",
      "OTHER_NAME                                                       Adexone\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                       Metastatic Breast Cancer\n",
      "MOLREGNO                                                          674747\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 654, dtype: object\n",
      "_____\n",
      "TWID                                                                1285\n",
      "TWEET_ID                                              871476260161155072\n",
      "TWEET                  Daratumumab+carfilzomib+lenalidomide+dexametha...\n",
      "SYNONYMS                                                   DEXAMETHASONE\n",
      "MOLREGNO_1                                                        674588\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           well tolerated\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Multiple Myeloma\n",
      "INDICATION_ID                                                    D009101\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Dexamethasone\n",
      "DESCRIPTIONS           8 mg, oral taken twice a day for 3 days starti...\n",
      "OTHER_NAME                                                       Adexone\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                       Metastatic Breast Cancer\n",
      "MOLREGNO                                                           78759\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 655, dtype: object\n",
      "_____\n",
      "TWID                                                                1285\n",
      "TWEET_ID                                              871476260161155072\n",
      "TWEET                  Daratumumab+carfilzomib+lenalidomide+dexametha...\n",
      "SYNONYMS                                                   DEXAMETHASONE\n",
      "MOLREGNO_1                                                        674588\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           well tolerated\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Multiple Myeloma\n",
      "INDICATION_ID                                                    D009101\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Dexamethasone\n",
      "DESCRIPTIONS           8 mg, oral taken twice a day for 3 days starti...\n",
      "OTHER_NAME                                                       Adexone\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                       Metastatic Breast Cancer\n",
      "MOLREGNO                                                          675363\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 656, dtype: object\n",
      "_____\n",
      "TWID                                                                1285\n",
      "TWEET_ID                                              871476260161155072\n",
      "TWEET                  Daratumumab+carfilzomib+lenalidomide+dexametha...\n",
      "SYNONYMS                                                   DEXAMETHASONE\n",
      "MOLREGNO_1                                                        674588\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           well tolerated\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Multiple Myeloma\n",
      "INDICATION_ID                                                    D009101\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Dexamethasone\n",
      "DESCRIPTIONS           8 mg, oral taken twice a day for 3 days starti...\n",
      "OTHER_NAME                                                       Adexone\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                       Metastatic Breast Cancer\n",
      "MOLREGNO                                                          675434\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 657, dtype: object\n",
      "_____\n",
      "TWID                                                                1285\n",
      "TWEET_ID                                              871476260161155072\n",
      "TWEET                  Daratumumab+carfilzomib+lenalidomide+dexametha...\n",
      "SYNONYMS                                                   DEXAMETHASONE\n",
      "MOLREGNO_1                                                        674588\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           well tolerated\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Multiple Myeloma\n",
      "INDICATION_ID                                                    D009101\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Dexamethasone\n",
      "DESCRIPTIONS           8 mg, oral taken twice a day for 3 days starti...\n",
      "OTHER_NAME                                                       Adexone\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                       Metastatic Breast Cancer\n",
      "MOLREGNO                                                          365281\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 658, dtype: object\n",
      "_____\n",
      "TWID                                                                1285\n",
      "TWEET_ID                                              871476260161155072\n",
      "TWEET                  Daratumumab+carfilzomib+lenalidomide+dexametha...\n",
      "SYNONYMS                                                   DEXAMETHASONE\n",
      "MOLREGNO_1                                                        674588\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           well tolerated\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Multiple Myeloma\n",
      "INDICATION_ID                                                    D009101\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Dexamethasone\n",
      "DESCRIPTIONS           8 mg, oral taken twice a day for 3 days starti...\n",
      "OTHER_NAME                                                       Adexone\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                       Metastatic Breast Cancer\n",
      "MOLREGNO                                                           14805\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 659, dtype: object\n",
      "_____\n",
      "TWID                                                                1285\n",
      "TWEET_ID                                              871476260161155072\n",
      "TWEET                  Daratumumab+carfilzomib+lenalidomide+dexametha...\n",
      "SYNONYMS                                                   DEXAMETHASONE\n",
      "MOLREGNO_1                                                        674588\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           well tolerated\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Multiple Myeloma\n",
      "INDICATION_ID                                                    D009101\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Dexamethasone\n",
      "DESCRIPTIONS           8 mg, oral taken twice a day for 3 days starti...\n",
      "OTHER_NAME                                                       Adexone\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                       Metastatic Breast Cancer\n",
      "MOLREGNO                                                         1927101\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 660, dtype: object\n",
      "_____\n",
      "TWID                                                                1285\n",
      "TWEET_ID                                              871476260161155072\n",
      "TWEET                  Daratumumab+carfilzomib+lenalidomide+dexametha...\n",
      "SYNONYMS                                                   DEXAMETHASONE\n",
      "MOLREGNO_1                                                        674588\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           well tolerated\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Multiple Myeloma\n",
      "INDICATION_ID                                                    D009101\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Dexamethasone\n",
      "DESCRIPTIONS           8 mg, oral taken twice a day for 3 days starti...\n",
      "OTHER_NAME                                                       Adexone\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                       Metastatic Breast Cancer\n",
      "MOLREGNO                                                          675581\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 661, dtype: object\n",
      "_____\n",
      "TWID                                                                1285\n",
      "TWEET_ID                                              871476260161155072\n",
      "TWEET                  Daratumumab+carfilzomib+lenalidomide+dexametha...\n",
      "SYNONYMS                                                    LENALIDOMIDE\n",
      "MOLREGNO_1                                                         63649\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01863550\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           well tolerated\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Multiple Myeloma\n",
      "INDICATION_ID                                                    D009101\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Lenalidomide\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME                               CC-5013;CC5013;CDC 501;Revlimid\n",
      "EFO_ID                                                       EFO:0001378\n",
      "CONDITION                                            Plasma Cell Myeloma\n",
      "MOLREGNO                                                          365281\n",
      "NAME_TERM                                               multiple myeloma\n",
      "Name: 663, dtype: object\n",
      "_____\n",
      "TWID                                                                1285\n",
      "TWEET_ID                                              871476260161155072\n",
      "TWEET                  Daratumumab+carfilzomib+lenalidomide+dexametha...\n",
      "SYNONYMS                                                    LENALIDOMIDE\n",
      "MOLREGNO_1                                                         63649\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01863550\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           well tolerated\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Multiple Myeloma\n",
      "INDICATION_ID                                                    D009101\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Lenalidomide\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME                               CC-5013;CC5013;CDC 501;Revlimid\n",
      "EFO_ID                                                       EFO:0001378\n",
      "CONDITION                                            Plasma Cell Myeloma\n",
      "MOLREGNO                                                          187372\n",
      "NAME_TERM                                               multiple myeloma\n",
      "Name: 664, dtype: object\n",
      "_____\n",
      "TWID                                                                1285\n",
      "TWEET_ID                                              871476260161155072\n",
      "TWEET                  Daratumumab+carfilzomib+lenalidomide+dexametha...\n",
      "SYNONYMS                                                    LENALIDOMIDE\n",
      "MOLREGNO_1                                                         63649\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01863550\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           well tolerated\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Multiple Myeloma\n",
      "INDICATION_ID                                                    D009101\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Lenalidomide\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME                               CC-5013;CC5013;CDC 501;Revlimid\n",
      "EFO_ID                                                       EFO:0001378\n",
      "CONDITION                                            Plasma Cell Myeloma\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                               multiple myeloma\n",
      "Name: 665, dtype: object\n",
      "_____\n",
      "TWID                                                                1285\n",
      "TWEET_ID                                              871476260161155072\n",
      "TWEET                  Daratumumab+carfilzomib+lenalidomide+dexametha...\n",
      "SYNONYMS                                                    LENALIDOMIDE\n",
      "MOLREGNO_1                                                         63649\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01863550\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           well tolerated\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Multiple Myeloma\n",
      "INDICATION_ID                                                    D009101\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Lenalidomide\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME                               CC-5013;CC5013;CDC 501;Revlimid\n",
      "EFO_ID                                                       EFO:0001378\n",
      "CONDITION                                            Plasma Cell Myeloma\n",
      "MOLREGNO                                                          520664\n",
      "NAME_TERM                                               multiple myeloma\n",
      "Name: 666, dtype: object\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "_____\n",
      "TWID                                                                1285\n",
      "TWEET_ID                                              871476260161155072\n",
      "TWEET                  Daratumumab+carfilzomib+lenalidomide+dexametha...\n",
      "SYNONYMS                                                     DARATUMUMAB\n",
      "MOLREGNO_1                                                       1121878\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03289299\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           well tolerated\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Multiple Myeloma\n",
      "INDICATION_ID                                                    D009101\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Daratumumab\n",
      "DESCRIPTIONS           16 mg/kg IV given on days 1, 8, 15, and 22 of ...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0001378\n",
      "CONDITION                                    Smoldering Multiple Myeloma\n",
      "MOLREGNO                                                          520664\n",
      "NAME_TERM                                               multiple myeloma\n",
      "Name: 667, dtype: object\n",
      "_____\n",
      "TWID                                                                1285\n",
      "TWEET_ID                                              871476260161155072\n",
      "TWEET                  Daratumumab+carfilzomib+lenalidomide+dexametha...\n",
      "SYNONYMS                                                     DARATUMUMAB\n",
      "MOLREGNO_1                                                       1121878\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03289299\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           well tolerated\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Multiple Myeloma\n",
      "INDICATION_ID                                                    D009101\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Daratumumab\n",
      "DESCRIPTIONS           16 mg/kg IV given on days 1, 8, 15, and 22 of ...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0001378\n",
      "CONDITION                                    Smoldering Multiple Myeloma\n",
      "MOLREGNO                                                          365281\n",
      "NAME_TERM                                               multiple myeloma\n",
      "Name: 668, dtype: object\n",
      "_____\n",
      "TWID                                                                1285\n",
      "TWEET_ID                                              871476260161155072\n",
      "TWEET                  Daratumumab+carfilzomib+lenalidomide+dexametha...\n",
      "SYNONYMS                                                     DARATUMUMAB\n",
      "MOLREGNO_1                                                       1121878\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03289299\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           well tolerated\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Multiple Myeloma\n",
      "INDICATION_ID                                                    D009101\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Daratumumab\n",
      "DESCRIPTIONS           16 mg/kg IV given on days 1, 8, 15, and 22 of ...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0001378\n",
      "CONDITION                                    Smoldering Multiple Myeloma\n",
      "MOLREGNO                                                           63649\n",
      "NAME_TERM                                               multiple myeloma\n",
      "Name: 670, dtype: object\n",
      "_____\n",
      "TWID                                                                1285\n",
      "TWEET_ID                                              871476260161155072\n",
      "TWEET                  Daratumumab+carfilzomib+lenalidomide+dexametha...\n",
      "SYNONYMS                                                     CARFILZOMIB\n",
      "MOLREGNO_1                                                        520664\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01572480\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           well tolerated\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Multiple Myeloma\n",
      "INDICATION_ID                                                    D009101\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Carfilzomib\n",
      "DESCRIPTIONS           Carfilzomib (IV) 20-36 mg/m2 per dose on days ...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0001378\n",
      "CONDITION                                               Multiple Myeloma\n",
      "MOLREGNO                                                           63649\n",
      "NAME_TERM                                               multiple myeloma\n",
      "Name: 671, dtype: object\n",
      "_____\n",
      "TWID                                                                1285\n",
      "TWEET_ID                                              871476260161155072\n",
      "TWEET                  Daratumumab+carfilzomib+lenalidomide+dexametha...\n",
      "SYNONYMS                                                     CARFILZOMIB\n",
      "MOLREGNO_1                                                        520664\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01572480\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           well tolerated\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Multiple Myeloma\n",
      "INDICATION_ID                                                    D009101\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Carfilzomib\n",
      "DESCRIPTIONS           Carfilzomib (IV) 20-36 mg/m2 per dose on days ...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0001378\n",
      "CONDITION                                               Multiple Myeloma\n",
      "MOLREGNO                                                          365281\n",
      "NAME_TERM                                               multiple myeloma\n",
      "Name: 672, dtype: object\n",
      "_____\n",
      "TWID                                                                1298\n",
      "TWEET_ID                                              871080724035751936\n",
      "TWEET                  Pulse-contin dose erlotinib controlled CNS dis...\n",
      "SYNONYMS                                                       ERLOTINIB\n",
      "MOLREGNO_1                                                         14785\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00096265\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                       controlled disease\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                              Erlotinib Hydrochloride\n",
      "DESCRIPTIONS                                                Given orally\n",
      "OTHER_NAME                                    Cp-358,774;OSI-774;Tarceva\n",
      "EFO_ID                                                       EFO:0003060\n",
      "CONDITION                    Stage IV Non-Small Cell Lung Cancer AJCC v7\n",
      "MOLREGNO                                                           53686\n",
      "NAME_TERM                                  non-small cell lung carcinoma\n",
      "Name: 678, dtype: object\n",
      "_____\n",
      "TWID                                                                1298\n",
      "TWEET_ID                                              871080724035751936\n",
      "TWEET                  Pulse-contin dose erlotinib controlled CNS dis...\n",
      "SYNONYMS                                                       ERLOTINIB\n",
      "MOLREGNO_1                                                         14785\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00096265\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                       controlled disease\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                              Erlotinib Hydrochloride\n",
      "DESCRIPTIONS                                                Given orally\n",
      "OTHER_NAME                                    Cp-358,774;OSI-774;Tarceva\n",
      "EFO_ID                                                       EFO:0003060\n",
      "CONDITION                    Stage IV Non-Small Cell Lung Cancer AJCC v7\n",
      "MOLREGNO                                                          611647\n",
      "NAME_TERM                                  non-small cell lung carcinoma\n",
      "Name: 679, dtype: object\n",
      "_____\n",
      "TWID                                                                1298\n",
      "TWEET_ID                                              871080724035751936\n",
      "TWEET                  Pulse-contin dose erlotinib controlled CNS dis...\n",
      "SYNONYMS                                                       ERLOTINIB\n",
      "MOLREGNO_1                                                         14785\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00096265\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                       controlled disease\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                              Erlotinib Hydrochloride\n",
      "DESCRIPTIONS                                                Given orally\n",
      "OTHER_NAME                                    Cp-358,774;OSI-774;Tarceva\n",
      "EFO_ID                                                       EFO:0003060\n",
      "CONDITION                        Recurrent Non-Small Cell Lung Carcinoma\n",
      "MOLREGNO                                                           53686\n",
      "NAME_TERM                                  non-small cell lung carcinoma\n",
      "Name: 680, dtype: object\n",
      "_____\n",
      "TWID                                                                1298\n",
      "TWEET_ID                                              871080724035751936\n",
      "TWEET                  Pulse-contin dose erlotinib controlled CNS dis...\n",
      "SYNONYMS                                                       ERLOTINIB\n",
      "MOLREGNO_1                                                         14785\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00096265\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                       controlled disease\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                              Erlotinib Hydrochloride\n",
      "DESCRIPTIONS                                                Given orally\n",
      "OTHER_NAME                                    Cp-358,774;OSI-774;Tarceva\n",
      "EFO_ID                                                       EFO:0003060\n",
      "CONDITION                        Recurrent Non-Small Cell Lung Carcinoma\n",
      "MOLREGNO                                                          611647\n",
      "NAME_TERM                                  non-small cell lung carcinoma\n",
      "Name: 681, dtype: object\n",
      "_____\n",
      "TWID                                                                1298\n",
      "TWEET_ID                                              871080724035751936\n",
      "TWEET                  Pulse-contin dose erlotinib controlled CNS dis...\n",
      "SYNONYMS                                                       ERLOTINIB\n",
      "MOLREGNO_1                                                         14785\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00096265\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                       controlled disease\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                              Erlotinib Hydrochloride\n",
      "DESCRIPTIONS                                                Given orally\n",
      "OTHER_NAME                                    Cp-358,774;OSI-774;Tarceva\n",
      "EFO_ID                                                       EFO:0003833\n",
      "CONDITION                     Metastatic Malignant Neoplasm in the Brain\n",
      "MOLREGNO                                                           53686\n",
      "NAME_TERM                                                 brain neoplasm\n",
      "Name: 682, dtype: object\n",
      "_____\n",
      "TWID                                                                1298\n",
      "TWEET_ID                                              871080724035751936\n",
      "TWEET                  Pulse-contin dose erlotinib controlled CNS dis...\n",
      "SYNONYMS                                                       ERLOTINIB\n",
      "MOLREGNO_1                                                         14785\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00096265\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                       controlled disease\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                              Erlotinib Hydrochloride\n",
      "DESCRIPTIONS                                                Given orally\n",
      "OTHER_NAME                                    Cp-358,774;OSI-774;Tarceva\n",
      "EFO_ID                                                       EFO:0003833\n",
      "CONDITION                     Metastatic Malignant Neoplasm in the Brain\n",
      "MOLREGNO                                                          611647\n",
      "NAME_TERM                                                 brain neoplasm\n",
      "Name: 683, dtype: object\n",
      "_____\n",
      "TWID                                                                1298\n",
      "TWEET_ID                                              871080724035751936\n",
      "TWEET                  Pulse-contin dose erlotinib controlled CNS dis...\n",
      "SYNONYMS                                                       ERLOTINIB\n",
      "MOLREGNO_1                                                         14785\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00096265\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                       controlled disease\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                              Erlotinib Hydrochloride\n",
      "DESCRIPTIONS                                                Given orally\n",
      "OTHER_NAME                                    Cp-358,774;OSI-774;Tarceva\n",
      "EFO_ID                                                       EFO:0000616\n",
      "CONDITION                     Metastatic Malignant Neoplasm in the Brain\n",
      "MOLREGNO                                                           53686\n",
      "NAME_TERM                                                       neoplasm\n",
      "Name: 684, dtype: object\n",
      "_____\n",
      "TWID                                                                1298\n",
      "TWEET_ID                                              871080724035751936\n",
      "TWEET                  Pulse-contin dose erlotinib controlled CNS dis...\n",
      "SYNONYMS                                                       ERLOTINIB\n",
      "MOLREGNO_1                                                         14785\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00096265\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                       controlled disease\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                              Erlotinib Hydrochloride\n",
      "DESCRIPTIONS                                                Given orally\n",
      "OTHER_NAME                                    Cp-358,774;OSI-774;Tarceva\n",
      "EFO_ID                                                       EFO:0000616\n",
      "CONDITION                     Metastatic Malignant Neoplasm in the Brain\n",
      "MOLREGNO                                                          611647\n",
      "NAME_TERM                                                       neoplasm\n",
      "Name: 685, dtype: object\n",
      "_____\n",
      "TWID                                                                1342\n",
      "TWEET_ID                                              867405528519016448\n",
      "TWEET                  GSK's PI3K/mTOR inhibitor omipalisib (GSK21264...\n",
      "SYNONYMS                                                      GSK2126458\n",
      "MOLREGNO_1                                                        699312\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01248858\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                               shows safety/effectiveness\n",
      "COMPANY                                                  GlaxoSmithKline\n",
      "COMPANY_ID                                                       COMP286\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       0\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                 Idiopathic Pulmonary Fibrosis\n",
      "INDICATION_ID                                                    D054990\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                            GSK2126458 and GSK1120212\n",
      "DESCRIPTIONS           GSK2126458 and GSK1120212 are experimental tre...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000311\n",
      "CONDITION                                                         Cancer\n",
      "MOLREGNO                                                         1376145\n",
      "NAME_TERM                                                         cancer\n",
      "Name: 735, dtype: object\n",
      "_____\n",
      "TWID                                                                1363\n",
      "TWEET_ID                                              866771606684749824\n",
      "TWEET                  Mepolizumab meets primary and secondary endpoi...\n",
      "SYNONYMS                                                     MEPOLIZUMAB\n",
      "MOLREGNO_1                                                       1380695\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03292588\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                    meets primary and secondary endpoints\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                    Hypereosinophilic Syndrome\n",
      "INDICATION_ID                                                    D017681\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                              Placebo\n",
      "DESCRIPTIONS           Placebo at a dose of 100 mg administered every...\n",
      "OTHER_NAME                                       Placebo for Mepolizumab\n",
      "EFO_ID                                                       EFO:0000270\n",
      "CONDITION                                                         Asthma\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                         asthma\n",
      "Name: 740, dtype: object\n",
      "_____\n",
      "TWID                                                                1363\n",
      "TWEET_ID                                              866771606684749824\n",
      "TWEET                  Mepolizumab meets primary and secondary endpoi...\n",
      "SYNONYMS                                                     MEPOLIZUMAB\n",
      "MOLREGNO_1                                                       1380695\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03292588\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                    meets primary and secondary endpoints\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                    Hypereosinophilic Syndrome\n",
      "INDICATION_ID                                                    D017681\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                             Biological\n",
      "INTERVENTION_NAME_x                                          Mepolizumab\n",
      "DESCRIPTIONS           Mepolizumab at a dose of 100 mg administered e...\n",
      "OTHER_NAME             Nucala®;anti-Interleukin 5 (IL5) antagonist mo...\n",
      "EFO_ID                                                       EFO:0000270\n",
      "CONDITION                                                         Asthma\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                         asthma\n",
      "Name: 742, dtype: object\n",
      "_____\n",
      "TWID                                                                1388\n",
      "TWEET_ID                                              863048619758419968\n",
      "TWEET                  Selecta Biosciences begins phase I trial of SE...\n",
      "SYNONYMS                                                        NICOTINE\n",
      "MOLREGNO_1                                                           115\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03163303\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                       begins phase trial\n",
      "COMPANY                                                          Selecta\n",
      "COMPANY_ID                                                     COMP93512\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                       nicotine patch\n",
      "DESCRIPTIONS                             14-day supply of nicotine patch\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0003768\n",
      "CONDITION                                                        Smoking\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                            nicotine dependence\n",
      "Name: 757, dtype: object\n",
      "_____\n",
      "TWID                                                                1405\n",
      "TWEET_ID                                              862245735332540416\n",
      "TWEET                  Recro's N-1539 (iv meloxicam) shows safety in ...\n",
      "SYNONYMS                                                       MELOXICAM\n",
      "MOLREGNO_1                                                         20496\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03434275\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                             shows safety\n",
      "COMPANY                                                 Recro Pharma Inc\n",
      "COMPANY_ID                                                     COMP92886\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       0\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                 Low Back Pain\n",
      "INDICATION_ID                                                    D017116\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                                N1539\n",
      "DESCRIPTIONS                                                  Once Daily\n",
      "OTHER_NAME                                         Intravenous meloxicam\n",
      "EFO_ID                                                       EFO:0003843\n",
      "CONDITION                                            Pain, Postoperative\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                           pain\n",
      "Name: 762, dtype: object\n",
      "_____\n",
      "TWID                                                                1421\n",
      "TWEET_ID                                              861656296659046400\n",
      "TWEET                  Complement Factor B antisense oligonucleotide ...\n",
      "SYNONYMS                                                 OLIGONUCLEOTIDE\n",
      "MOLREGNO_1                                                        641789\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02406833\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           well tolerated\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                     TGF-β2 antisense oligonucleotide\n",
      "DESCRIPTIONS                                      intravitreal injection\n",
      "OTHER_NAME                                                      ISTH0036\n",
      "EFO_ID                                                       EFO:0004190\n",
      "CONDITION                                    Primary Open Angle Glaucoma\n",
      "MOLREGNO                                                            Null\n",
      "NAME_TERM                                            open-angle glaucoma\n",
      "Name: 764, dtype: object\n",
      "_____\n",
      "TWID                                                                1421\n",
      "TWEET_ID                                              861656296659046400\n",
      "TWEET                  Complement Factor B antisense oligonucleotide ...\n",
      "SYNONYMS                                                 OLIGONUCLEOTIDE\n",
      "MOLREGNO_1                                                        641788\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02406833\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           well tolerated\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                     TGF-β2 antisense oligonucleotide\n",
      "DESCRIPTIONS                                      intravitreal injection\n",
      "OTHER_NAME                                                      ISTH0036\n",
      "EFO_ID                                                       EFO:0004190\n",
      "CONDITION                                    Primary Open Angle Glaucoma\n",
      "MOLREGNO                                                            Null\n",
      "NAME_TERM                                            open-angle glaucoma\n",
      "Name: 765, dtype: object\n",
      "_____\n",
      "TWID                                                                1467\n",
      "TWEET_ID                                              857957573550538752\n",
      "TWEET                  Sage Therapeutics begins phase I trial of SAGE...\n",
      "SYNONYMS                                                            NMDA\n",
      "MOLREGNO_1                                                         64776\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02437344\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                       begins phase trial\n",
      "COMPANY                                                Sage Therapeutics\n",
      "COMPANY_ID                                                     COMP92371\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                             CI-581aa\n",
      "DESCRIPTIONS                              92 minute infusion of CI-581aa\n",
      "OTHER_NAME                                               NMDA antagonist\n",
      "EFO_ID                                                       EFO:0005611\n",
      "CONDITION                                              Opioid Dependence\n",
      "MOLREGNO                                                           21459\n",
      "NAME_TERM                                              opioid dependence\n",
      "Name: 775, dtype: object\n",
      "_____\n",
      "TWID                                                                1485\n",
      "TWEET_ID                                              857158297064964097\n",
      "TWEET                  US FDA clears Glenmark's IND to start clinical...\n",
      "SYNONYMS                                                      OMALIZUMAB\n",
      "MOLREGNO_1                                                        675485\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03280537\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         Clears for trial\n",
      "COMPANY                                         Glenmark Pharmaceuticals\n",
      "COMPANY_ID                                                     COMP92688\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                    Seasonal Allergic Rhinitis\n",
      "INDICATION_ID                                                    D006255\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Omalizumab\n",
      "DESCRIPTIONS           Omalizumab will be administered as a subcutane...\n",
      "OTHER_NAME                                                        Xolair\n",
      "EFO_ID                                                       EFO:0007486\n",
      "CONDITION                                         Chronic Rhinosinusitis\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                      sinusitis\n",
      "Name: 785, dtype: object\n",
      "_____\n",
      "TWID                                                                1485\n",
      "TWEET_ID                                              857158297064964097\n",
      "TWEET                  US FDA clears Glenmark's IND to start clinical...\n",
      "SYNONYMS                                                      OMALIZUMAB\n",
      "MOLREGNO_1                                                        675485\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03280537\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         Clears for trial\n",
      "COMPANY                                         Glenmark Pharmaceuticals\n",
      "COMPANY_ID                                                     COMP92688\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                    Seasonal Allergic Rhinitis\n",
      "INDICATION_ID                                                    D006255\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Omalizumab\n",
      "DESCRIPTIONS           Omalizumab will be administered as a subcutane...\n",
      "OTHER_NAME                                                        Xolair\n",
      "EFO_ID                                                       EFO:1000391\n",
      "CONDITION                                                   Nasal Polyps\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                             Nasal Cavity Polyp\n",
      "Name: 787, dtype: object\n",
      "_____\n",
      "TWID                                                                1488\n",
      "TWEET_ID                                              856952342041817089\n",
      "TWEET                  First data on MYSTICOL trial evaluating rimabo...\n",
      "SYNONYMS                                             RIMABOTULINUMTOXINB\n",
      "MOLREGNO_1                                                       1380976\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01930604\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                              N/I\n",
      "MATCHED_OUTCOME                                               First data\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                 Hyperhidrosis\n",
      "INDICATION_ID                                                    D006945\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x              NeuroBloc/Myobloc (rimabotulinumtoxinB)\n",
      "DESCRIPTIONS                                                        Null\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                        HP:0000975\n",
      "CONDITION                                                  Hyperhidrosis\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                  Hyperhidrosis\n",
      "Name: 790, dtype: object\n",
      "_____\n",
      "TWID                                                                1488\n",
      "TWEET_ID                                              856952342041817089\n",
      "TWEET                  First data on MYSTICOL trial evaluating rimabo...\n",
      "SYNONYMS                                             RIMABOTULINUMTOXINB\n",
      "MOLREGNO_1                                                       1380976\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01930604\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                              N/I\n",
      "MATCHED_OUTCOME                                               First data\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                 Hyperhidrosis\n",
      "INDICATION_ID                                                    D006945\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x              NeuroBloc/Myobloc (rimabotulinumtoxinB)\n",
      "DESCRIPTIONS                                                        Null\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                        HP:0000975\n",
      "CONDITION                                                  Hyperhidrosis\n",
      "MOLREGNO                                                          675387\n",
      "NAME_TERM                                                  Hyperhidrosis\n",
      "Name: 791, dtype: object\n",
      "_____\n",
      "TWID                                                                1488\n",
      "TWEET_ID                                              856952342041817089\n",
      "TWEET                  First data on MYSTICOL trial evaluating rimabo...\n",
      "SYNONYMS                                             RIMABOTULINUMTOXINB\n",
      "MOLREGNO_1                                                       1380976\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01930604\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                              N/I\n",
      "MATCHED_OUTCOME                                               First data\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                 Hyperhidrosis\n",
      "INDICATION_ID                                                    D006945\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x              NeuroBloc/Myobloc (rimabotulinumtoxinB)\n",
      "DESCRIPTIONS                                                        Null\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                        HP:0000975\n",
      "CONDITION                                                  Hyperhidrosis\n",
      "MOLREGNO                                                          675360\n",
      "NAME_TERM                                                  Hyperhidrosis\n",
      "Name: 792, dtype: object\n",
      "_____\n",
      "TWID                                                                1537\n",
      "TWEET_ID                                              854286063665328128\n",
      "TWEET                  OncoMed's tarextumab in combination with etopo...\n",
      "SYNONYMS                                                       ETOPOSIDE\n",
      "MOLREGNO_1                                                         68607\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03382561\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              trial fails\n",
      "COMPANY                                          Oncomed Pharmaceuticals\n",
      "COMPANY_ID                                                     COMP92543\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                     Small Cell Lung Carcinoma\n",
      "INDICATION_ID                                                    D055752\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Etoposide\n",
      "DESCRIPTIONS                                                    Given IV\n",
      "OTHER_NAME             Demethyl Epipodophyllotoxin Ethylidine Glucosi...\n",
      "EFO_ID                                                       EFO:0000702\n",
      "CONDITION                      Extensive Stage Small Cell Lung Carcinoma\n",
      "MOLREGNO                                                         1381004\n",
      "NAME_TERM                                      small cell lung carcinoma\n",
      "Name: 804, dtype: object\n",
      "_____\n",
      "TWID                                                                1537\n",
      "TWEET_ID                                              854286063665328128\n",
      "TWEET                  OncoMed's tarextumab in combination with etopo...\n",
      "SYNONYMS                                                       ETOPOSIDE\n",
      "MOLREGNO_1                                                         68607\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03382561\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              trial fails\n",
      "COMPANY                                          Oncomed Pharmaceuticals\n",
      "COMPANY_ID                                                     COMP92543\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                     Small Cell Lung Carcinoma\n",
      "INDICATION_ID                                                    D055752\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Etoposide\n",
      "DESCRIPTIONS                                                    Given IV\n",
      "OTHER_NAME             Demethyl Epipodophyllotoxin Ethylidine Glucosi...\n",
      "EFO_ID                                                       EFO:0000702\n",
      "CONDITION                      Extensive Stage Small Cell Lung Carcinoma\n",
      "MOLREGNO                                                            8633\n",
      "NAME_TERM                                      small cell lung carcinoma\n",
      "Name: 805, dtype: object\n",
      "_____\n",
      "TWID                                                                1537\n",
      "TWEET_ID                                              854286063665328128\n",
      "TWEET                  OncoMed's tarextumab in combination with etopo...\n",
      "SYNONYMS                                                       ETOPOSIDE\n",
      "MOLREGNO_1                                                         68607\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03382561\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              trial fails\n",
      "COMPANY                                          Oncomed Pharmaceuticals\n",
      "COMPANY_ID                                                     COMP92543\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                     Small Cell Lung Carcinoma\n",
      "INDICATION_ID                                                    D055752\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Etoposide\n",
      "DESCRIPTIONS                                                    Given IV\n",
      "OTHER_NAME             Demethyl Epipodophyllotoxin Ethylidine Glucosi...\n",
      "EFO_ID                                                       EFO:0000702\n",
      "CONDITION                      Extensive Stage Small Cell Lung Carcinoma\n",
      "MOLREGNO                                                          300022\n",
      "NAME_TERM                                      small cell lung carcinoma\n",
      "Name: 807, dtype: object\n",
      "_____\n",
      "TWID                                                                1537\n",
      "TWEET_ID                                              854286063665328128\n",
      "TWEET                  OncoMed's tarextumab in combination with etopo...\n",
      "SYNONYMS                                                       ETOPOSIDE\n",
      "MOLREGNO_1                                                         68607\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03382561\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              trial fails\n",
      "COMPANY                                          Oncomed Pharmaceuticals\n",
      "COMPANY_ID                                                     COMP92543\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                     Small Cell Lung Carcinoma\n",
      "INDICATION_ID                                                    D055752\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Etoposide\n",
      "DESCRIPTIONS                                                    Given IV\n",
      "OTHER_NAME             Demethyl Epipodophyllotoxin Ethylidine Glucosi...\n",
      "EFO_ID                                                       EFO:0000702\n",
      "CONDITION                      Extensive Stage Small Cell Lung Carcinoma\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                      small cell lung carcinoma\n",
      "Name: 808, dtype: object\n",
      "_____\n",
      "TWID                                                                1560\n",
      "TWEET_ID                                              850034277010083840\n",
      "TWEET                  Galapagos earns $10M fee from Gilead triggered...\n",
      "SYNONYMS                                                      FILGOTINIB\n",
      "MOLREGNO_1                                                       1763569\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03025308\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                                Earns fee\n",
      "COMPANY                                                           Gilead\n",
      "COMPANY_ID                                                       COMP284\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                 Crohn Disease\n",
      "INDICATION_ID                                                    D003424\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Filgotinib\n",
      "DESCRIPTIONS                    Tablet(s) administered orally once daily\n",
      "OTHER_NAME                                              GS-6034;GLPG0634\n",
      "EFO_ID                                                       EFO:0000685\n",
      "CONDITION                                           RheumatoId Arthritis\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                           rheumatoid arthritis\n",
      "Name: 812, dtype: object\n",
      "_____\n",
      "TWID                                                                1560\n",
      "TWEET_ID                                              850034277010083840\n",
      "TWEET                  Galapagos earns $10M fee from Gilead triggered...\n",
      "SYNONYMS                                                      FILGOTINIB\n",
      "MOLREGNO_1                                                       1763569\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03025308\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                                Earns fee\n",
      "COMPANY                                                           Gilead\n",
      "COMPANY_ID                                                       COMP284\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                 Crohn Disease\n",
      "INDICATION_ID                                                    D003424\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                          Placebo to match filgotinib\n",
      "DESCRIPTIONS                    Tablet(s) administered orally once daily\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000685\n",
      "CONDITION                                           RheumatoId Arthritis\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                           rheumatoid arthritis\n",
      "Name: 814, dtype: object\n",
      "_____\n",
      "TWID                                                                1561\n",
      "TWEET_ID                                              849985040369025025\n",
      "TWEET                  Zavante's Zolyd (fosfomycin inj) not inferior ...\n",
      "SYNONYMS                                                      FOSFOMYCIN\n",
      "MOLREGNO_1                                                        581859\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03151603\n",
      "PHASE                                                          Phase 2/3\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                              N/I\n",
      "MATCHED_OUTCOME                                          not inferior to\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                             Exocrine Pancreatic Insufficiency\n",
      "INDICATION_ID                                                    D010188\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Fosfomycin\n",
      "DESCRIPTIONS                           application of an antibiotic drug\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0003103\n",
      "CONDITION                                       Urinary Tract Infections\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                        urinary tract infection\n",
      "Name: 815, dtype: object\n",
      "_____\n",
      "TWID                                                                1561\n",
      "TWEET_ID                                              849985040369025025\n",
      "TWEET                  Zavante's Zolyd (fosfomycin inj) not inferior ...\n",
      "SYNONYMS                                                      FOSFOMYCIN\n",
      "MOLREGNO_1                                                        581859\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03151603\n",
      "PHASE                                                          Phase 2/3\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                              N/I\n",
      "MATCHED_OUTCOME                                          not inferior to\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                             Exocrine Pancreatic Insufficiency\n",
      "INDICATION_ID                                                    D010188\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                Placebo to Fosfomycin\n",
      "DESCRIPTIONS                        application of Placebo to Fosfomycin\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0003103\n",
      "CONDITION                                       Urinary Tract Infections\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                        urinary tract infection\n",
      "Name: 817, dtype: object\n",
      "_____\n",
      "TWID                                                                1642\n",
      "TWEET_ID                                              844918129293647873\n",
      "TWEET                  US FDA clears Akashi to resume HT-100 (halofug...\n",
      "SYNONYMS                                                    HALOFUGINONE\n",
      "MOLREGNO_1                                                        671041\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01847573\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                             resume study\n",
      "COMPANY                                              Akashi Therapeutics\n",
      "COMPANY_ID                                                     COMP92958\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       0\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                   Duchenne Muscular Dystrophy\n",
      "INDICATION_ID                                                    D020388\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                               HT-100\n",
      "DESCRIPTIONS           May be administered in either fed or fasted state\n",
      "OTHER_NAME              halofuginone hydrobromide delayed-release tablet\n",
      "EFO_ID                                                    Orphanet:98896\n",
      "CONDITION                                    Duchenne Muscular Dystrophy\n",
      "MOLREGNO                                                            Null\n",
      "NAME_TERM                                    Duchenne muscular dystrophy\n",
      "Name: 839, dtype: object\n",
      "_____\n",
      "TWID                                                                1643\n",
      "TWEET_ID                                              844917883763273728\n",
      "TWEET                  Intec's AP-CBD/THC (cannabidiol + dronabinol) ...\n",
      "SYNONYMS                                                     CANNABIDIOL\n",
      "MOLREGNO_1                                                        318390\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03164512\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                       starts phase trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                  Chronic Pain\n",
      "INDICATION_ID                                                    D059350\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                        Oral or vaporized cannabidiol\n",
      "DESCRIPTIONS                                         Acute drug exposure\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                   -NOT-CONDITION-\n",
      "CONDITION                                   Cannabidiol Pharmacokinetics\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                            NaN\n",
      "Name: 840, dtype: object\n",
      "_____\n",
      "TWID                                                                1643\n",
      "TWEET_ID                                              844917883763273728\n",
      "TWEET                  Intec's AP-CBD/THC (cannabidiol + dronabinol) ...\n",
      "SYNONYMS                                                      DRONABINOL\n",
      "MOLREGNO_1                                                          4496\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01394185\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                       starts phase trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                  Chronic Pain\n",
      "INDICATION_ID                                                    D059350\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                 Dronabinol 120mg/day\n",
      "DESCRIPTIONS           Participants receive 40mg dronabinol 3 times d...\n",
      "OTHER_NAME                                                   Marinol;THC\n",
      "EFO_ID                                                       EFO:0007191\n",
      "CONDITION                                              Marijuana Smoking\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                            cannabis dependence\n",
      "Name: 843, dtype: object\n",
      "_____\n",
      "TWID                                                                1643\n",
      "TWEET_ID                                              844917883763273728\n",
      "TWEET                  Intec's AP-CBD/THC (cannabidiol + dronabinol) ...\n",
      "SYNONYMS                                                      DRONABINOL\n",
      "MOLREGNO_1                                                          4496\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01394185\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                       starts phase trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                  Chronic Pain\n",
      "INDICATION_ID                                                    D059350\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                 Dronabinol 240mg/day\n",
      "DESCRIPTIONS           Participants receive 80mg dronabinol 3 times d...\n",
      "OTHER_NAME                                                   Marinol;THC\n",
      "EFO_ID                                                       EFO:0007191\n",
      "CONDITION                                              Marijuana Smoking\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                            cannabis dependence\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Name: 845, dtype: object\n",
      "_____\n",
      "TWID                                                                1705\n",
      "TWEET_ID                                              842712473887100928\n",
      "TWEET                  Preliminary toxicity results presented from ph...\n",
      "SYNONYMS                                                       CETUXIMAB\n",
      "MOLREGNO_1                                                        675579\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03391843\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                               toxicity results presented\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                          FOLFOXIRI+Cetuximab regimen\n",
      "DESCRIPTIONS           FOLFOXIRI+Cetuximab Irinotecan 165 mg/m² + oxa...\n",
      "OTHER_NAME                 CPT 11,CAMPTO，Eloxatin，Xelod，Eloxatin,Erbitux\n",
      "EFO_ID                                                       EFO:1000657\n",
      "CONDITION                                        Rectal Cancer Stage III\n",
      "MOLREGNO                                                          243124\n",
      "NAME_TERM                                                  rectum cancer\n",
      "Name: 869, dtype: object\n",
      "_____\n",
      "TWID                                                                1705\n",
      "TWEET_ID                                              842712473887100928\n",
      "TWEET                  Preliminary toxicity results presented from ph...\n",
      "SYNONYMS                                                       CETUXIMAB\n",
      "MOLREGNO_1                                                        675579\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03391843\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                               toxicity results presented\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                          FOLFOXIRI+Cetuximab regimen\n",
      "DESCRIPTIONS           FOLFOXIRI+Cetuximab Irinotecan 165 mg/m² + oxa...\n",
      "OTHER_NAME                 CPT 11,CAMPTO，Eloxatin，Xelod，Eloxatin,Erbitux\n",
      "EFO_ID                                                       EFO:1000657\n",
      "CONDITION                                        Rectal Cancer Stage III\n",
      "MOLREGNO                                                          368538\n",
      "NAME_TERM                                                  rectum cancer\n",
      "Name: 870, dtype: object\n",
      "_____\n",
      "TWID                                                                1705\n",
      "TWEET_ID                                              842712473887100928\n",
      "TWEET                  Preliminary toxicity results presented from ph...\n",
      "SYNONYMS                                                       CETUXIMAB\n",
      "MOLREGNO_1                                                        675579\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03391843\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                               toxicity results presented\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                          FOLFOXIRI+Cetuximab regimen\n",
      "DESCRIPTIONS           FOLFOXIRI+Cetuximab Irinotecan 165 mg/m² + oxa...\n",
      "OTHER_NAME                 CPT 11,CAMPTO，Eloxatin，Xelod，Eloxatin,Erbitux\n",
      "EFO_ID                                                       EFO:1000657\n",
      "CONDITION                                        Rectal Cancer Stage III\n",
      "MOLREGNO                                                          675089\n",
      "NAME_TERM                                                  rectum cancer\n",
      "Name: 871, dtype: object\n",
      "_____\n",
      "TWID                                                                1705\n",
      "TWEET_ID                                              842712473887100928\n",
      "TWEET                  Preliminary toxicity results presented from ph...\n",
      "SYNONYMS                                                       CETUXIMAB\n",
      "MOLREGNO_1                                                        675579\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03391843\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                               toxicity results presented\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                          FOLFOXIRI+Cetuximab regimen\n",
      "DESCRIPTIONS           FOLFOXIRI+Cetuximab Irinotecan 165 mg/m² + oxa...\n",
      "OTHER_NAME                 CPT 11,CAMPTO，Eloxatin，Xelod，Eloxatin,Erbitux\n",
      "EFO_ID                                                       EFO:1000657\n",
      "CONDITION                                        Rectal Cancer Stage III\n",
      "MOLREGNO                                                            5985\n",
      "NAME_TERM                                                  rectum cancer\n",
      "Name: 872, dtype: object\n",
      "_____\n",
      "TWID                                                                1758\n",
      "TWEET_ID                                              839436021083230208\n",
      "TWEET                  US FDA clears Glenmark's IND for phase II tria...\n",
      "SYNONYMS                                                      TIOTROPIUM\n",
      "MOLREGNO_1                                                        675258\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03395002\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         Clears for trial\n",
      "COMPANY                                         Glenmark Pharmaceuticals\n",
      "COMPANY_ID                                                     COMP92688\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                        Asthma\n",
      "INDICATION_ID                                                    D001249\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x    Tiotropium/Salmeterol/Fluticasone 9/50/500 mcg...\n",
      "DESCRIPTIONS           Tiotropium/Salmeterol/Fluticasone 9/50/500 mcg...\n",
      "OTHER_NAME                         Saltif 9/50/500 mcg Inhalation Powder\n",
      "EFO_ID                                                       EFO:0000341\n",
      "CONDITION                                                           COPD\n",
      "MOLREGNO                                                         1927030\n",
      "NAME_TERM                          chronic obstructive pulmonary disease\n",
      "Name: 877, dtype: object\n",
      "_____\n",
      "TWID                                                                1758\n",
      "TWEET_ID                                              839436021083230208\n",
      "TWEET                  US FDA clears Glenmark's IND for phase II tria...\n",
      "SYNONYMS                                                      TIOTROPIUM\n",
      "MOLREGNO_1                                                        675258\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03395002\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         Clears for trial\n",
      "COMPANY                                         Glenmark Pharmaceuticals\n",
      "COMPANY_ID                                                     COMP92688\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                        Asthma\n",
      "INDICATION_ID                                                    D001249\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x    Tiotropium/Salmeterol/Fluticasone 9/50/500 mcg...\n",
      "DESCRIPTIONS           Tiotropium/Salmeterol/Fluticasone 9/50/500 mcg...\n",
      "OTHER_NAME                         Saltif 9/50/500 mcg Inhalation Powder\n",
      "EFO_ID                                                       EFO:0000341\n",
      "CONDITION                                                           COPD\n",
      "MOLREGNO                                                          242716\n",
      "NAME_TERM                          chronic obstructive pulmonary disease\n",
      "Name: 878, dtype: object\n",
      "_____\n",
      "TWID                                                                1758\n",
      "TWEET_ID                                              839436021083230208\n",
      "TWEET                  US FDA clears Glenmark's IND for phase II tria...\n",
      "SYNONYMS                                                      TIOTROPIUM\n",
      "MOLREGNO_1                                                        675258\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03395002\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         Clears for trial\n",
      "COMPANY                                         Glenmark Pharmaceuticals\n",
      "COMPANY_ID                                                     COMP92688\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                        Asthma\n",
      "INDICATION_ID                                                    D001249\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x    Tiotropium/Salmeterol/Fluticasone 9/50/500 mcg...\n",
      "DESCRIPTIONS           Tiotropium/Salmeterol/Fluticasone 9/50/500 mcg...\n",
      "OTHER_NAME                         Saltif 9/50/500 mcg Inhalation Powder\n",
      "EFO_ID                                                       EFO:0000341\n",
      "CONDITION                                                           COPD\n",
      "MOLREGNO                                                          401141\n",
      "NAME_TERM                          chronic obstructive pulmonary disease\n",
      "Name: 879, dtype: object\n",
      "_____\n",
      "TWID                                                                1758\n",
      "TWEET_ID                                              839436021083230208\n",
      "TWEET                  US FDA clears Glenmark's IND for phase II tria...\n",
      "SYNONYMS                                                      TIOTROPIUM\n",
      "MOLREGNO_1                                                        675258\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03395002\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         Clears for trial\n",
      "COMPANY                                         Glenmark Pharmaceuticals\n",
      "COMPANY_ID                                                     COMP92688\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                        Asthma\n",
      "INDICATION_ID                                                    D001249\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                  Tiotropium 18 mcg Inhalation Powder\n",
      "DESCRIPTIONS           Tiotropium 18 mcg Inhalation Powder (1 puff) o...\n",
      "OTHER_NAME                              Spiriva 18 mcg Inhalation Powder\n",
      "EFO_ID                                                       EFO:0000341\n",
      "CONDITION                                                           COPD\n",
      "MOLREGNO                                                         1927030\n",
      "NAME_TERM                          chronic obstructive pulmonary disease\n",
      "Name: 880, dtype: object\n",
      "_____\n",
      "TWID                                                                1758\n",
      "TWEET_ID                                              839436021083230208\n",
      "TWEET                  US FDA clears Glenmark's IND for phase II tria...\n",
      "SYNONYMS                                                      TIOTROPIUM\n",
      "MOLREGNO_1                                                        675258\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03395002\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         Clears for trial\n",
      "COMPANY                                         Glenmark Pharmaceuticals\n",
      "COMPANY_ID                                                     COMP92688\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                        Asthma\n",
      "INDICATION_ID                                                    D001249\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                  Tiotropium 18 mcg Inhalation Powder\n",
      "DESCRIPTIONS           Tiotropium 18 mcg Inhalation Powder (1 puff) o...\n",
      "OTHER_NAME                              Spiriva 18 mcg Inhalation Powder\n",
      "EFO_ID                                                       EFO:0000341\n",
      "CONDITION                                                           COPD\n",
      "MOLREGNO                                                          242716\n",
      "NAME_TERM                          chronic obstructive pulmonary disease\n",
      "Name: 881, dtype: object\n",
      "_____\n",
      "TWID                                                                1758\n",
      "TWEET_ID                                              839436021083230208\n",
      "TWEET                  US FDA clears Glenmark's IND for phase II tria...\n",
      "SYNONYMS                                                      TIOTROPIUM\n",
      "MOLREGNO_1                                                        675258\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03395002\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         Clears for trial\n",
      "COMPANY                                         Glenmark Pharmaceuticals\n",
      "COMPANY_ID                                                     COMP92688\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                        Asthma\n",
      "INDICATION_ID                                                    D001249\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                  Tiotropium 18 mcg Inhalation Powder\n",
      "DESCRIPTIONS           Tiotropium 18 mcg Inhalation Powder (1 puff) o...\n",
      "OTHER_NAME                              Spiriva 18 mcg Inhalation Powder\n",
      "EFO_ID                                                       EFO:0000341\n",
      "CONDITION                                                           COPD\n",
      "MOLREGNO                                                          401141\n",
      "NAME_TERM                          chronic obstructive pulmonary disease\n",
      "Name: 882, dtype: object\n",
      "_____\n",
      "TWID                                                                1758\n",
      "TWEET_ID                                              839436021083230208\n",
      "TWEET                  US FDA clears Glenmark's IND for phase II tria...\n",
      "SYNONYMS                                                      TIOTROPIUM\n",
      "MOLREGNO_1                                                       1241099\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03395002\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         Clears for trial\n",
      "COMPANY                                         Glenmark Pharmaceuticals\n",
      "COMPANY_ID                                                     COMP92688\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                        Asthma\n",
      "INDICATION_ID                                                    D001249\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x    Tiotropium/Salmeterol/Fluticasone 9/50/500 mcg...\n",
      "DESCRIPTIONS           Tiotropium/Salmeterol/Fluticasone 9/50/500 mcg...\n",
      "OTHER_NAME                         Saltif 9/50/500 mcg Inhalation Powder\n",
      "EFO_ID                                                       EFO:0000341\n",
      "CONDITION                                                           COPD\n",
      "MOLREGNO                                                         1927030\n",
      "NAME_TERM                          chronic obstructive pulmonary disease\n",
      "Name: 883, dtype: object\n",
      "_____\n",
      "TWID                                                                1758\n",
      "TWEET_ID                                              839436021083230208\n",
      "TWEET                  US FDA clears Glenmark's IND for phase II tria...\n",
      "SYNONYMS                                                      TIOTROPIUM\n",
      "MOLREGNO_1                                                       1241099\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03395002\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         Clears for trial\n",
      "COMPANY                                         Glenmark Pharmaceuticals\n",
      "COMPANY_ID                                                     COMP92688\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                        Asthma\n",
      "INDICATION_ID                                                    D001249\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x    Tiotropium/Salmeterol/Fluticasone 9/50/500 mcg...\n",
      "DESCRIPTIONS           Tiotropium/Salmeterol/Fluticasone 9/50/500 mcg...\n",
      "OTHER_NAME                         Saltif 9/50/500 mcg Inhalation Powder\n",
      "EFO_ID                                                       EFO:0000341\n",
      "CONDITION                                                           COPD\n",
      "MOLREGNO                                                          242716\n",
      "NAME_TERM                          chronic obstructive pulmonary disease\n",
      "Name: 884, dtype: object\n",
      "_____\n",
      "TWID                                                                1758\n",
      "TWEET_ID                                              839436021083230208\n",
      "TWEET                  US FDA clears Glenmark's IND for phase II tria...\n",
      "SYNONYMS                                                      TIOTROPIUM\n",
      "MOLREGNO_1                                                       1241099\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03395002\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         Clears for trial\n",
      "COMPANY                                         Glenmark Pharmaceuticals\n",
      "COMPANY_ID                                                     COMP92688\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                        Asthma\n",
      "INDICATION_ID                                                    D001249\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x    Tiotropium/Salmeterol/Fluticasone 9/50/500 mcg...\n",
      "DESCRIPTIONS           Tiotropium/Salmeterol/Fluticasone 9/50/500 mcg...\n",
      "OTHER_NAME                         Saltif 9/50/500 mcg Inhalation Powder\n",
      "EFO_ID                                                       EFO:0000341\n",
      "CONDITION                                                           COPD\n",
      "MOLREGNO                                                          401141\n",
      "NAME_TERM                          chronic obstructive pulmonary disease\n",
      "Name: 885, dtype: object\n",
      "_____\n",
      "TWID                                                                1758\n",
      "TWEET_ID                                              839436021083230208\n",
      "TWEET                  US FDA clears Glenmark's IND for phase II tria...\n",
      "SYNONYMS                                                      TIOTROPIUM\n",
      "MOLREGNO_1                                                       1241099\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03395002\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         Clears for trial\n",
      "COMPANY                                         Glenmark Pharmaceuticals\n",
      "COMPANY_ID                                                     COMP92688\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                        Asthma\n",
      "INDICATION_ID                                                    D001249\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                  Tiotropium 18 mcg Inhalation Powder\n",
      "DESCRIPTIONS           Tiotropium 18 mcg Inhalation Powder (1 puff) o...\n",
      "OTHER_NAME                              Spiriva 18 mcg Inhalation Powder\n",
      "EFO_ID                                                       EFO:0000341\n",
      "CONDITION                                                           COPD\n",
      "MOLREGNO                                                         1927030\n",
      "NAME_TERM                          chronic obstructive pulmonary disease\n",
      "Name: 886, dtype: object\n",
      "_____\n",
      "TWID                                                                1758\n",
      "TWEET_ID                                              839436021083230208\n",
      "TWEET                  US FDA clears Glenmark's IND for phase II tria...\n",
      "SYNONYMS                                                      TIOTROPIUM\n",
      "MOLREGNO_1                                                       1241099\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03395002\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         Clears for trial\n",
      "COMPANY                                         Glenmark Pharmaceuticals\n",
      "COMPANY_ID                                                     COMP92688\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                        Asthma\n",
      "INDICATION_ID                                                    D001249\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                  Tiotropium 18 mcg Inhalation Powder\n",
      "DESCRIPTIONS           Tiotropium 18 mcg Inhalation Powder (1 puff) o...\n",
      "OTHER_NAME                              Spiriva 18 mcg Inhalation Powder\n",
      "EFO_ID                                                       EFO:0000341\n",
      "CONDITION                                                           COPD\n",
      "MOLREGNO                                                          242716\n",
      "NAME_TERM                          chronic obstructive pulmonary disease\n",
      "Name: 887, dtype: object\n",
      "_____\n",
      "TWID                                                                1758\n",
      "TWEET_ID                                              839436021083230208\n",
      "TWEET                  US FDA clears Glenmark's IND for phase II tria...\n",
      "SYNONYMS                                                      TIOTROPIUM\n",
      "MOLREGNO_1                                                       1241099\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03395002\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         Clears for trial\n",
      "COMPANY                                         Glenmark Pharmaceuticals\n",
      "COMPANY_ID                                                     COMP92688\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                        Asthma\n",
      "INDICATION_ID                                                    D001249\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                  Tiotropium 18 mcg Inhalation Powder\n",
      "DESCRIPTIONS           Tiotropium 18 mcg Inhalation Powder (1 puff) o...\n",
      "OTHER_NAME                              Spiriva 18 mcg Inhalation Powder\n",
      "EFO_ID                                                       EFO:0000341\n",
      "CONDITION                                                           COPD\n",
      "MOLREGNO                                                          401141\n",
      "NAME_TERM                          chronic obstructive pulmonary disease\n",
      "Name: 888, dtype: object\n",
      "_____\n",
      "TWID                                                                1758\n",
      "TWEET_ID                                              839436021083230208\n",
      "TWEET                  US FDA clears Glenmark's IND for phase II tria...\n",
      "SYNONYMS                                              TIOTROPIUM BROMIDE\n",
      "MOLREGNO_1                                                       1927030\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00565266\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         Clears for trial\n",
      "COMPANY                                         Glenmark Pharmaceuticals\n",
      "COMPANY_ID                                                     COMP92688\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                        Asthma\n",
      "INDICATION_ID                                                    D001249\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                   tiotropium bromide\n",
      "DESCRIPTIONS           tiotropium bromide inhalation powder 18 mcg on...\n",
      "OTHER_NAME                                          SPIRIVA® HandiHaler®\n",
      "EFO_ID                                                       EFO:0000270\n",
      "CONDITION                                                         Asthma\n",
      "MOLREGNO                                                          674451\n",
      "NAME_TERM                                                         asthma\n",
      "Name: 889, dtype: object\n",
      "_____\n",
      "TWID                                                                1758\n",
      "TWEET_ID                                              839436021083230208\n",
      "TWEET                  US FDA clears Glenmark's IND for phase II tria...\n",
      "SYNONYMS                                              TIOTROPIUM BROMIDE\n",
      "MOLREGNO_1                                                       1927030\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00565266\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         Clears for trial\n",
      "COMPANY                                         Glenmark Pharmaceuticals\n",
      "COMPANY_ID                                                     COMP92688\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                        Asthma\n",
      "INDICATION_ID                                                    D001249\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                   tiotropium bromide\n",
      "DESCRIPTIONS           tiotropium bromide inhalation powder 18 mcg on...\n",
      "OTHER_NAME                                          SPIRIVA® HandiHaler®\n",
      "EFO_ID                                                       EFO:0000270\n",
      "CONDITION                                                         Asthma\n",
      "MOLREGNO                                                          631502\n",
      "NAME_TERM                                                         asthma\n",
      "Name: 890, dtype: object\n",
      "_____\n",
      "TWID                                                                1758\n",
      "TWEET_ID                                              839436021083230208\n",
      "TWEET                  US FDA clears Glenmark's IND for phase II tria...\n",
      "SYNONYMS                                                         BROMIDE\n",
      "MOLREGNO_1                                                        693811\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00565266\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         Clears for trial\n",
      "COMPANY                                         Glenmark Pharmaceuticals\n",
      "COMPANY_ID                                                     COMP92688\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                        Asthma\n",
      "INDICATION_ID                                                    D001249\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                   tiotropium bromide\n",
      "DESCRIPTIONS           tiotropium bromide inhalation powder 18 mcg on...\n",
      "OTHER_NAME                                          SPIRIVA® HandiHaler®\n",
      "EFO_ID                                                       EFO:0000270\n",
      "CONDITION                                                         Asthma\n",
      "MOLREGNO                                                          674451\n",
      "NAME_TERM                                                         asthma\n",
      "Name: 892, dtype: object\n",
      "_____\n",
      "TWID                                                                1758\n",
      "TWEET_ID                                              839436021083230208\n",
      "TWEET                  US FDA clears Glenmark's IND for phase II tria...\n",
      "SYNONYMS                                                         BROMIDE\n",
      "MOLREGNO_1                                                        693811\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00565266\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         Clears for trial\n",
      "COMPANY                                         Glenmark Pharmaceuticals\n",
      "COMPANY_ID                                                     COMP92688\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                        Asthma\n",
      "INDICATION_ID                                                    D001249\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                   tiotropium bromide\n",
      "DESCRIPTIONS           tiotropium bromide inhalation powder 18 mcg on...\n",
      "OTHER_NAME                                          SPIRIVA® HandiHaler®\n",
      "EFO_ID                                                       EFO:0000270\n",
      "CONDITION                                                         Asthma\n",
      "MOLREGNO                                                          631502\n",
      "NAME_TERM                                                         asthma\n",
      "Name: 893, dtype: object\n",
      "_____\n",
      "TWID                                                                1758\n",
      "TWEET_ID                                              839436021083230208\n",
      "TWEET                  US FDA clears Glenmark's IND for phase II tria...\n",
      "SYNONYMS                                                         BROMIDE\n",
      "MOLREGNO_1                                                        693811\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00565266\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         Clears for trial\n",
      "COMPANY                                         Glenmark Pharmaceuticals\n",
      "COMPANY_ID                                                     COMP92688\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                        Asthma\n",
      "INDICATION_ID                                                    D001249\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                   tiotropium bromide\n",
      "DESCRIPTIONS           tiotropium bromide inhalation powder 18 mcg on...\n",
      "OTHER_NAME                                          SPIRIVA® HandiHaler®\n",
      "EFO_ID                                                       EFO:0000270\n",
      "CONDITION                                                         Asthma\n",
      "MOLREGNO                                                         1927030\n",
      "NAME_TERM                                                         asthma\n",
      "Name: 894, dtype: object\n",
      "_____\n",
      "TWID                                                                1758\n",
      "TWEET_ID                                              839436021083230208\n",
      "TWEET                  US FDA clears Glenmark's IND for phase II tria...\n",
      "SYNONYMS                                                         BROMIDE\n",
      "MOLREGNO_1                                                        308053\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00565266\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         Clears for trial\n",
      "COMPANY                                         Glenmark Pharmaceuticals\n",
      "COMPANY_ID                                                     COMP92688\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                        Asthma\n",
      "INDICATION_ID                                                    D001249\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                   tiotropium bromide\n",
      "DESCRIPTIONS           tiotropium bromide inhalation powder 18 mcg on...\n",
      "OTHER_NAME                                          SPIRIVA® HandiHaler®\n",
      "EFO_ID                                                       EFO:0000270\n",
      "CONDITION                                                         Asthma\n",
      "MOLREGNO                                                          674451\n",
      "NAME_TERM                                                         asthma\n",
      "Name: 895, dtype: object\n",
      "_____\n",
      "TWID                                                                1758\n",
      "TWEET_ID                                              839436021083230208\n",
      "TWEET                  US FDA clears Glenmark's IND for phase II tria...\n",
      "SYNONYMS                                                         BROMIDE\n",
      "MOLREGNO_1                                                        308053\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00565266\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         Clears for trial\n",
      "COMPANY                                         Glenmark Pharmaceuticals\n",
      "COMPANY_ID                                                     COMP92688\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                        Asthma\n",
      "INDICATION_ID                                                    D001249\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                   tiotropium bromide\n",
      "DESCRIPTIONS           tiotropium bromide inhalation powder 18 mcg on...\n",
      "OTHER_NAME                                          SPIRIVA® HandiHaler®\n",
      "EFO_ID                                                       EFO:0000270\n",
      "CONDITION                                                         Asthma\n",
      "MOLREGNO                                                          631502\n",
      "NAME_TERM                                                         asthma\n",
      "Name: 896, dtype: object\n",
      "_____\n",
      "TWID                                                                1758\n",
      "TWEET_ID                                              839436021083230208\n",
      "TWEET                  US FDA clears Glenmark's IND for phase II tria...\n",
      "SYNONYMS                                                         BROMIDE\n",
      "MOLREGNO_1                                                        308053\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00565266\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         Clears for trial\n",
      "COMPANY                                         Glenmark Pharmaceuticals\n",
      "COMPANY_ID                                                     COMP92688\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                        Asthma\n",
      "INDICATION_ID                                                    D001249\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                   tiotropium bromide\n",
      "DESCRIPTIONS           tiotropium bromide inhalation powder 18 mcg on...\n",
      "OTHER_NAME                                          SPIRIVA® HandiHaler®\n",
      "EFO_ID                                                       EFO:0000270\n",
      "CONDITION                                                         Asthma\n",
      "MOLREGNO                                                         1927030\n",
      "NAME_TERM                                                         asthma\n",
      "Name: 897, dtype: object\n",
      "_____\n",
      "TWID                                                                1791\n",
      "TWEET_ID                                              836468106637647872\n",
      "TWEET                  La Jolla Pharma reports positive results from ...\n",
      "SYNONYMS                                                          LA III\n",
      "MOLREGNO_1                                                           721\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                              Null\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           Positive trial\n",
      "COMPANY                                      La Jolla Pharmaceutical Co.\n",
      "COMPANY_ID                                                     COMP92521\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                   Hypotension\n",
      "INDICATION_ID                                                    D007022\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Null\n",
      "INTERVENTION_NAME_x                                                 Null\n",
      "DESCRIPTIONS                                                        Null\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                              Null\n",
      "CONDITION                                                           Null\n",
      "MOLREGNO                                                            Null\n",
      "NAME_TERM                                                            NaN\n",
      "Name: 903, dtype: object\n",
      "_____\n",
      "TWID                                                                1835\n",
      "TWEET_ID                                              831850847394893824\n",
      "TWEET                  Merck's Phase III trial of Verubecestat in Alz...\n",
      "SYNONYMS                                                    VERUBECESTAT\n",
      "MOLREGNO_1                                                       1763563\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01739348\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         Lack of efficacy\n",
      "COMPANY                                                            Merck\n",
      "COMPANY_ID                                                       COMP435\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                     Mild Cognitive Impairment\n",
      "INDICATION_ID                                                    D060825\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                    Verubecestat (Part I and Part II)\n",
      "DESCRIPTIONS           Single 12 mg verubecestat tablet once daily, t...\n",
      "OTHER_NAME                                                    SCH 900931\n",
      "EFO_ID                                                       EFO:0000249\n",
      "CONDITION                                            Alzheimer's Disease\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                            Alzheimer's disease\n",
      "Name: 911, dtype: object\n",
      "_____\n",
      "TWID                                                                1835\n",
      "TWEET_ID                                              831850847394893824\n",
      "TWEET                  Merck's Phase III trial of Verubecestat in Alz...\n",
      "SYNONYMS                                                    VERUBECESTAT\n",
      "MOLREGNO_1                                                       1763563\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01739348\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         Lack of efficacy\n",
      "COMPANY                                                            Merck\n",
      "COMPANY_ID                                                       COMP435\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                     Mild Cognitive Impairment\n",
      "INDICATION_ID                                                    D060825\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                    Verubecestat (Part I and Part II)\n",
      "DESCRIPTIONS           Single 40 mg verubecestat tablet once daily, t...\n",
      "OTHER_NAME                                                    SCH 900931\n",
      "EFO_ID                                                       EFO:0000249\n",
      "CONDITION                                            Alzheimer's Disease\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                            Alzheimer's disease\n",
      "Name: 913, dtype: object\n",
      "_____\n",
      "TWID                                                                1835\n",
      "TWEET_ID                                              831850847394893824\n",
      "TWEET                  Merck's Phase III trial of Verubecestat in Alz...\n",
      "SYNONYMS                                                    VERUBECESTAT\n",
      "MOLREGNO_1                                                       1763563\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01739348\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         Lack of efficacy\n",
      "COMPANY                                                            Merck\n",
      "COMPANY_ID                                                       COMP435\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                     Mild Cognitive Impairment\n",
      "INDICATION_ID                                                    D060825\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                    Verubecestat (Part I and Part II)\n",
      "DESCRIPTIONS           Single 60 or 40 mg verubecestat tablet once da...\n",
      "OTHER_NAME                                                    SCH 900931\n",
      "EFO_ID                                                       EFO:0000249\n",
      "CONDITION                                            Alzheimer's Disease\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                            Alzheimer's disease\n",
      "Name: 915, dtype: object\n",
      "_____\n",
      "TWID                                                                1835\n",
      "TWEET_ID                                              831850847394893824\n",
      "TWEET                  Merck's Phase III trial of Verubecestat in Alz...\n",
      "SYNONYMS                                                    VERUBECESTAT\n",
      "MOLREGNO_1                                                       1763563\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01739348\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         Lack of efficacy\n",
      "COMPANY                                                            Merck\n",
      "COMPANY_ID                                                       COMP435\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                     Mild Cognitive Impairment\n",
      "INDICATION_ID                                                    D060825\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                               Verubecestat (Part II)\n",
      "DESCRIPTIONS           Single 40 mg verubecestat tablet once daily, t...\n",
      "OTHER_NAME                                                    SCH 900931\n",
      "EFO_ID                                                       EFO:0000249\n",
      "CONDITION                                            Alzheimer's Disease\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                            Alzheimer's disease\n",
      "Name: 917, dtype: object\n",
      "_____\n",
      "TWID                                                                1852\n",
      "TWEET_ID                                              830028668428709889\n",
      "TWEET                  US FDA approves Emflaza (deflazacort) for the ...\n",
      "SYNONYMS                                                     DEFLAZACORT\n",
      "MOLREGNO_1                                                        675842\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02286635\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                             FDA approves\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                   Duchenne Muscular Dystrophy\n",
      "INDICATION_ID                                                    D020388\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                       Deflazacort and Clarithromycin\n",
      "DESCRIPTIONS           Deflazacort, a glucocorticoid with anti-inflam...\n",
      "OTHER_NAME                                                        biaxin\n",
      "EFO_ID                                                       EFO:0000761\n",
      "CONDITION                                             Healthy Volunteers\n",
      "MOLREGNO                                                          570147\n",
      "NAME_TERM                                                obsolete_normal\n",
      "Name: 929, dtype: object\n",
      "_____\n",
      "TWID                                                                1852\n",
      "TWEET_ID                                              830028668428709889\n",
      "TWEET                  US FDA approves Emflaza (deflazacort) for the ...\n",
      "SYNONYMS                                                     DEFLAZACORT\n",
      "MOLREGNO_1                                                        675842\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02286635\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                             FDA approves\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                   Duchenne Muscular Dystrophy\n",
      "INDICATION_ID                                                    D020388\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                       Deflazacort and Clarithromycin\n",
      "DESCRIPTIONS           Deflazacort, a glucocorticoid with anti-inflam...\n",
      "OTHER_NAME                                                        biaxin\n",
      "EFO_ID                                                       EFO:0000761\n",
      "CONDITION                                             Healthy Volunteers\n",
      "MOLREGNO                                                          365189\n",
      "NAME_TERM                                                obsolete_normal\n",
      "Name: 931, dtype: object\n",
      "_____\n",
      "TWID                                                                1852\n",
      "TWEET_ID                                              830028668428709889\n",
      "TWEET                  US FDA approves Emflaza (deflazacort) for the ...\n",
      "SYNONYMS                                                     DEFLAZACORT\n",
      "MOLREGNO_1                                                        675842\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02286635\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                             FDA approves\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                   Duchenne Muscular Dystrophy\n",
      "INDICATION_ID                                                    D020388\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                             Deflazacort and rifampin\n",
      "DESCRIPTIONS           Deflazacort, a glucocorticoid with anti-inflam...\n",
      "OTHER_NAME                                                           DFZ\n",
      "EFO_ID                                                       EFO:0000761\n",
      "CONDITION                                             Healthy Volunteers\n",
      "MOLREGNO                                                          570147\n",
      "NAME_TERM                                                obsolete_normal\n",
      "Name: 932, dtype: object\n",
      "_____\n",
      "TWID                                                                1852\n",
      "TWEET_ID                                              830028668428709889\n",
      "TWEET                  US FDA approves Emflaza (deflazacort) for the ...\n",
      "SYNONYMS                                                     DEFLAZACORT\n",
      "MOLREGNO_1                                                        675842\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02286635\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                             FDA approves\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                   Duchenne Muscular Dystrophy\n",
      "INDICATION_ID                                                    D020388\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                             Deflazacort and rifampin\n",
      "DESCRIPTIONS           Deflazacort, a glucocorticoid with anti-inflam...\n",
      "OTHER_NAME                                                           DFZ\n",
      "EFO_ID                                                       EFO:0000761\n",
      "CONDITION                                             Healthy Volunteers\n",
      "MOLREGNO                                                          365189\n",
      "NAME_TERM                                                obsolete_normal\n",
      "Name: 934, dtype: object\n",
      "_____\n",
      "TWID                                                                1868\n",
      "TWEET_ID                                              828554139382657024\n",
      "TWEET                  Innate Pharma's lirilumab fails to meet the pr...\n",
      "SYNONYMS                                                       LIRILUMAB\n",
      "MOLREGNO_1                                                       1381940\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02813135\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              trial fails\n",
      "COMPANY                                                    Innate Pharma\n",
      "COMPANY_ID                                                       COMP334\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Lirilumab\n",
      "DESCRIPTIONS                                                        Null\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000311\n",
      "CONDITION              Children, Adolescents and Young Adults With Re...\n",
      "MOLREGNO                                                          300022\n",
      "NAME_TERM                                                         cancer\n",
      "Name: 936, dtype: object\n",
      "_____\n",
      "TWID                                                                1868\n",
      "TWEET_ID                                              828554139382657024\n",
      "TWEET                  Innate Pharma's lirilumab fails to meet the pr...\n",
      "SYNONYMS                                                       LIRILUMAB\n",
      "MOLREGNO_1                                                       1381940\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02813135\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              trial fails\n",
      "COMPANY                                                    Innate Pharma\n",
      "COMPANY_ID                                                       COMP334\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Lirilumab\n",
      "DESCRIPTIONS                                                        Null\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000311\n",
      "CONDITION              Children, Adolescents and Young Adults With Re...\n",
      "MOLREGNO                                                         1381004\n",
      "NAME_TERM                                                         cancer\n",
      "Name: 937, dtype: object\n",
      "_____\n",
      "TWID                                                                1868\n",
      "TWEET_ID                                              828554139382657024\n",
      "TWEET                  Innate Pharma's lirilumab fails to meet the pr...\n",
      "SYNONYMS                                                       LIRILUMAB\n",
      "MOLREGNO_1                                                       1381940\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02813135\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              trial fails\n",
      "COMPANY                                                    Innate Pharma\n",
      "COMPANY_ID                                                       COMP334\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Lirilumab\n",
      "DESCRIPTIONS                                                        Null\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000311\n",
      "CONDITION              Children, Adolescents and Young Adults With Re...\n",
      "MOLREGNO                                                          456266\n",
      "NAME_TERM                                                         cancer\n",
      "Name: 938, dtype: object\n",
      "_____\n",
      "TWID                                                                1868\n",
      "TWEET_ID                                              828554139382657024\n",
      "TWEET                  Innate Pharma's lirilumab fails to meet the pr...\n",
      "SYNONYMS                                                       LIRILUMAB\n",
      "MOLREGNO_1                                                       1381940\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02813135\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              trial fails\n",
      "COMPANY                                                    Innate Pharma\n",
      "COMPANY_ID                                                       COMP334\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Lirilumab\n",
      "DESCRIPTIONS                                                        Null\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000311\n",
      "CONDITION              Children, Adolescents and Young Adults With Re...\n",
      "MOLREGNO                                                          616942\n",
      "NAME_TERM                                                         cancer\n",
      "Name: 939, dtype: object\n",
      "_____\n",
      "TWID                                                                1868\n",
      "TWEET_ID                                              828554139382657024\n",
      "TWEET                  Innate Pharma's lirilumab fails to meet the pr...\n",
      "SYNONYMS                                                       LIRILUMAB\n",
      "MOLREGNO_1                                                       1381940\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02813135\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              trial fails\n",
      "COMPANY                                                    Innate Pharma\n",
      "COMPANY_ID                                                       COMP334\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Lirilumab\n",
      "DESCRIPTIONS                                                        Null\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000311\n",
      "CONDITION              Children, Adolescents and Young Adults With Re...\n",
      "MOLREGNO                                                            5985\n",
      "NAME_TERM                                                         cancer\n",
      "Name: 940, dtype: object\n",
      "_____\n",
      "TWID                                                                1868\n",
      "TWEET_ID                                              828554139382657024\n",
      "TWEET                  Innate Pharma's lirilumab fails to meet the pr...\n",
      "SYNONYMS                                                       LIRILUMAB\n",
      "MOLREGNO_1                                                       1381940\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02813135\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              trial fails\n",
      "COMPANY                                                    Innate Pharma\n",
      "COMPANY_ID                                                       COMP334\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Lirilumab\n",
      "DESCRIPTIONS                                                        Null\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000311\n",
      "CONDITION              Children, Adolescents and Young Adults With Re...\n",
      "MOLREGNO                                                          469866\n",
      "NAME_TERM                                                         cancer\n",
      "Name: 941, dtype: object\n",
      "_____\n",
      "TWID                                                                1868\n",
      "TWEET_ID                                              828554139382657024\n",
      "TWEET                  Innate Pharma's lirilumab fails to meet the pr...\n",
      "SYNONYMS                                                       LIRILUMAB\n",
      "MOLREGNO_1                                                       1381940\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02813135\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              trial fails\n",
      "COMPANY                                                    Innate Pharma\n",
      "COMPANY_ID                                                       COMP334\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Lirilumab\n",
      "DESCRIPTIONS                                                        Null\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000311\n",
      "CONDITION              Children, Adolescents and Young Adults With Re...\n",
      "MOLREGNO                                                         1926959\n",
      "NAME_TERM                                                         cancer\n",
      "Name: 942, dtype: object\n",
      "_____\n",
      "TWID                                                                1868\n",
      "TWEET_ID                                              828554139382657024\n",
      "TWEET                  Innate Pharma's lirilumab fails to meet the pr...\n",
      "SYNONYMS                                                       LIRILUMAB\n",
      "MOLREGNO_1                                                       1381940\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02813135\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              trial fails\n",
      "COMPANY                                                    Innate Pharma\n",
      "COMPANY_ID                                                       COMP334\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Lirilumab\n",
      "DESCRIPTIONS                                                        Null\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000311\n",
      "CONDITION              Children, Adolescents and Young Adults With Re...\n",
      "MOLREGNO                                                         1297331\n",
      "NAME_TERM                                                         cancer\n",
      "Name: 943, dtype: object\n",
      "_____\n",
      "TWID                                                                1868\n",
      "TWEET_ID                                              828554139382657024\n",
      "TWEET                  Innate Pharma's lirilumab fails to meet the pr...\n",
      "SYNONYMS                                                       LIRILUMAB\n",
      "MOLREGNO_1                                                       1381940\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02813135\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              trial fails\n",
      "COMPANY                                                    Innate Pharma\n",
      "COMPANY_ID                                                       COMP334\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Lirilumab\n",
      "DESCRIPTIONS                                                        Null\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000311\n",
      "CONDITION              Children, Adolescents and Young Adults With Re...\n",
      "MOLREGNO                                                           53686\n",
      "NAME_TERM                                                         cancer\n",
      "Name: 944, dtype: object\n",
      "_____\n",
      "TWID                                                                1868\n",
      "TWEET_ID                                              828554139382657024\n",
      "TWEET                  Innate Pharma's lirilumab fails to meet the pr...\n",
      "SYNONYMS                                                       LIRILUMAB\n",
      "MOLREGNO_1                                                       1381940\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02813135\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              trial fails\n",
      "COMPANY                                                    Innate Pharma\n",
      "COMPANY_ID                                                       COMP334\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Lirilumab\n",
      "DESCRIPTIONS                                                        Null\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000311\n",
      "CONDITION              Children, Adolescents and Young Adults With Re...\n",
      "MOLREGNO                                                         1248731\n",
      "NAME_TERM                                                         cancer\n",
      "Name: 945, dtype: object\n",
      "_____\n",
      "TWID                                                                1868\n",
      "TWEET_ID                                              828554139382657024\n",
      "TWEET                  Innate Pharma's lirilumab fails to meet the pr...\n",
      "SYNONYMS                                                       LIRILUMAB\n",
      "MOLREGNO_1                                                       1381940\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02813135\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              trial fails\n",
      "COMPANY                                                    Innate Pharma\n",
      "COMPANY_ID                                                       COMP334\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Lirilumab\n",
      "DESCRIPTIONS                                                        Null\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000311\n",
      "CONDITION              Children, Adolescents and Young Adults With Re...\n",
      "MOLREGNO                                                         2197779\n",
      "NAME_TERM                                                         cancer\n",
      "Name: 946, dtype: object\n",
      "_____\n",
      "TWID                                                                1868\n",
      "TWEET_ID                                              828554139382657024\n",
      "TWEET                  Innate Pharma's lirilumab fails to meet the pr...\n",
      "SYNONYMS                                                       LIRILUMAB\n",
      "MOLREGNO_1                                                       1381940\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02813135\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              trial fails\n",
      "COMPANY                                                    Innate Pharma\n",
      "COMPANY_ID                                                       COMP334\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Lirilumab\n",
      "DESCRIPTIONS                                                        Null\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000311\n",
      "CONDITION              Children, Adolescents and Young Adults With Re...\n",
      "MOLREGNO                                                         1525993\n",
      "NAME_TERM                                                         cancer\n",
      "Name: 948, dtype: object\n",
      "_____\n",
      "TWID                                                                1868\n",
      "TWEET_ID                                              828554139382657024\n",
      "TWEET                  Innate Pharma's lirilumab fails to meet the pr...\n",
      "SYNONYMS                                                       LIRILUMAB\n",
      "MOLREGNO_1                                                       1381940\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02813135\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              trial fails\n",
      "COMPANY                                                    Innate Pharma\n",
      "COMPANY_ID                                                       COMP334\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Lirilumab\n",
      "DESCRIPTIONS                                                        Null\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000311\n",
      "CONDITION              Children, Adolescents and Young Adults With Re...\n",
      "MOLREGNO                                                         1037712\n",
      "NAME_TERM                                                         cancer\n",
      "Name: 949, dtype: object\n",
      "_____\n",
      "TWID                                                                1892\n",
      "TWEET_ID                                              825641676324495360\n",
      "TWEET                  Live at #ECCOCongress LOXO Oncology's larotrec...\n",
      "SYNONYMS                                                   LAROTRECTINIB\n",
      "MOLREGNO_1                                                       2099025\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03213704\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         In phase live at\n",
      "COMPANY                                                    Loxo Oncology\n",
      "COMPANY_ID                                                     COMP93848\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Larotrectinib\n",
      "DESCRIPTIONS                Given PO or via nasogastric- or gastric-tube\n",
      "OTHER_NAME                                    ARRY 470;LOXO 101;LOXO-101\n",
      "EFO_ID                                                       EFO:1000158\n",
      "CONDITION                     Refractory Central Nervous System Neoplasm\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                Central Nervous System Neoplasm\n",
      "Name: 951, dtype: object\n",
      "_____\n",
      "TWID                                                                1892\n",
      "TWEET_ID                                              825641676324495360\n",
      "TWEET                  Live at #ECCOCongress LOXO Oncology's larotrec...\n",
      "SYNONYMS                                                   LAROTRECTINIB\n",
      "MOLREGNO_1                                                       2099025\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03213704\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         In phase live at\n",
      "COMPANY                                                    Loxo Oncology\n",
      "COMPANY_ID                                                     COMP93848\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Larotrectinib\n",
      "DESCRIPTIONS                Given PO or via nasogastric- or gastric-tube\n",
      "OTHER_NAME                                    ARRY 470;LOXO 101;LOXO-101\n",
      "EFO_ID                                                       EFO:0000174\n",
      "CONDITION                                        Recurrent Ewing Sarcoma\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                  Ewing sarcoma\n",
      "Name: 953, dtype: object\n",
      "_____\n",
      "TWID                                                                1892\n",
      "TWEET_ID                                              825641676324495360\n",
      "TWEET                  Live at #ECCOCongress LOXO Oncology's larotrec...\n",
      "SYNONYMS                                                   LAROTRECTINIB\n",
      "MOLREGNO_1                                                       2099025\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03213704\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         In phase live at\n",
      "COMPANY                                                    Loxo Oncology\n",
      "COMPANY_ID                                                     COMP93848\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Larotrectinib\n",
      "DESCRIPTIONS                Given PO or via nasogastric- or gastric-tube\n",
      "OTHER_NAME                                    ARRY 470;LOXO 101;LOXO-101\n",
      "EFO_ID                                                       EFO:0000621\n",
      "CONDITION                                        Recurrent Neuroblastoma\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                  neuroblastoma\n",
      "Name: 955, dtype: object\n",
      "_____\n",
      "TWID                                                                1892\n",
      "TWEET_ID                                              825641676324495360\n",
      "TWEET                  Live at #ECCOCongress LOXO Oncology's larotrec...\n",
      "SYNONYMS                                                   LAROTRECTINIB\n",
      "MOLREGNO_1                                                       2099025\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03213704\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         In phase live at\n",
      "COMPANY                                                    Loxo Oncology\n",
      "COMPANY_ID                                                     COMP93848\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Larotrectinib\n",
      "DESCRIPTIONS                Given PO or via nasogastric- or gastric-tube\n",
      "OTHER_NAME                                    ARRY 470;LOXO 101;LOXO-101\n",
      "EFO_ID                                                       EFO:1000028\n",
      "CONDITION                                 Recurrent Childhood Ependymoma\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                     ependymoma\n",
      "Name: 957, dtype: object\n",
      "_____\n",
      "TWID                                                                1892\n",
      "TWEET_ID                                              825641676324495360\n",
      "TWEET                  Live at #ECCOCongress LOXO Oncology's larotrec...\n",
      "SYNONYMS                                                   LAROTRECTINIB\n",
      "MOLREGNO_1                                                       2099025\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03213704\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         In phase live at\n",
      "COMPANY                                                    Loxo Oncology\n",
      "COMPANY_ID                                                     COMP93848\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Larotrectinib\n",
      "DESCRIPTIONS                Given PO or via nasogastric- or gastric-tube\n",
      "OTHER_NAME                                    ARRY 470;LOXO 101;LOXO-101\n",
      "EFO_ID                                                       EFO:0000616\n",
      "CONDITION                            Refractory Malignant Solid Neoplasm\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                       neoplasm\n",
      "Name: 959, dtype: object\n",
      "_____\n",
      "TWID                                                                1892\n",
      "TWEET_ID                                              825641676324495360\n",
      "TWEET                  Live at #ECCOCongress LOXO Oncology's larotrec...\n",
      "SYNONYMS                                                   LAROTRECTINIB\n",
      "MOLREGNO_1                                                       2099025\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03213704\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         In phase live at\n",
      "COMPANY                                                    Loxo Oncology\n",
      "COMPANY_ID                                                     COMP93848\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Larotrectinib\n",
      "DESCRIPTIONS                Given PO or via nasogastric- or gastric-tube\n",
      "OTHER_NAME                                    ARRY 470;LOXO 101;LOXO-101\n",
      "EFO_ID                                                       EFO:0002939\n",
      "CONDITION                            Recurrent Childhood Medulloblastoma\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                medulloblastoma\n",
      "Name: 961, dtype: object\n",
      "_____\n",
      "TWID                                                                1892\n",
      "TWEET_ID                                              825641676324495360\n",
      "TWEET                  Live at #ECCOCongress LOXO Oncology's larotrec...\n",
      "SYNONYMS                                                   LAROTRECTINIB\n",
      "MOLREGNO_1                                                       2099025\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03213704\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         In phase live at\n",
      "COMPANY                                                    Loxo Oncology\n",
      "COMPANY_ID                                                     COMP93848\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Larotrectinib\n",
      "DESCRIPTIONS                Given PO or via nasogastric- or gastric-tube\n",
      "OTHER_NAME                                    ARRY 470;LOXO 101;LOXO-101\n",
      "EFO_ID                                                       EFO:0000514\n",
      "CONDITION                  Recurrent Childhood Malignant Germ Cell Tumor\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                germ cell tumor\n",
      "Name: 963, dtype: object\n",
      "_____\n",
      "TWID                                                                1892\n",
      "TWEET_ID                                              825641676324495360\n",
      "TWEET                  Live at #ECCOCongress LOXO Oncology's larotrec...\n",
      "SYNONYMS                                                   LAROTRECTINIB\n",
      "MOLREGNO_1                                                       2099025\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03213704\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         In phase live at\n",
      "COMPANY                                                    Loxo Oncology\n",
      "COMPANY_ID                                                     COMP93848\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Larotrectinib\n",
      "DESCRIPTIONS                Given PO or via nasogastric- or gastric-tube\n",
      "OTHER_NAME                                    ARRY 470;LOXO 101;LOXO-101\n",
      "EFO_ID                                                       EFO:0000616\n",
      "CONDITION                             Recurrent Malignant Solid Neoplasm\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                       neoplasm\n",
      "Name: 965, dtype: object\n",
      "_____\n",
      "TWID                                                                1892\n",
      "TWEET_ID                                              825641676324495360\n",
      "TWEET                  Live at #ECCOCongress LOXO Oncology's larotrec...\n",
      "SYNONYMS                                                   LAROTRECTINIB\n",
      "MOLREGNO_1                                                       2099025\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03213704\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         In phase live at\n",
      "COMPANY                                                    Loxo Oncology\n",
      "COMPANY_ID                                                     COMP93848\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Larotrectinib\n",
      "DESCRIPTIONS                Given PO or via nasogastric- or gastric-tube\n",
      "OTHER_NAME                                    ARRY 470;LOXO 101;LOXO-101\n",
      "EFO_ID                                                       EFO:0000616\n",
      "CONDITION                              Advanced Malignant Solid Neoplasm\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                       neoplasm\n",
      "Name: 967, dtype: object\n",
      "_____\n",
      "TWID                                                                1892\n",
      "TWEET_ID                                              825641676324495360\n",
      "TWEET                  Live at #ECCOCongress LOXO Oncology's larotrec...\n",
      "SYNONYMS                                                   LAROTRECTINIB\n",
      "MOLREGNO_1                                                       2099025\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03213704\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         In phase live at\n",
      "COMPANY                                                    Loxo Oncology\n",
      "COMPANY_ID                                                     COMP93848\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Larotrectinib\n",
      "DESCRIPTIONS                Given PO or via nasogastric- or gastric-tube\n",
      "OTHER_NAME                                    ARRY 470;LOXO 101;LOXO-101\n",
      "EFO_ID                                                       EFO:0000691\n",
      "CONDITION                        Recurrent Childhood Soft Tissue Sarcoma\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                        sarcoma\n",
      "Name: 969, dtype: object\n",
      "_____\n",
      "TWID                                                                1892\n",
      "TWEET_ID                                              825641676324495360\n",
      "TWEET                  Live at #ECCOCongress LOXO Oncology's larotrec...\n",
      "SYNONYMS                                                   LAROTRECTINIB\n",
      "MOLREGNO_1                                                       2099025\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03213704\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         In phase live at\n",
      "COMPANY                                                    Loxo Oncology\n",
      "COMPANY_ID                                                     COMP93848\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Larotrectinib\n",
      "DESCRIPTIONS                Given PO or via nasogastric- or gastric-tube\n",
      "OTHER_NAME                                    ARRY 470;LOXO 101;LOXO-101\n",
      "EFO_ID                                                       EFO:0000326\n",
      "CONDITION                                               Malignant Glioma\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                  central nervous system cancer\n",
      "Name: 971, dtype: object\n",
      "_____\n",
      "TWID                                                                1892\n",
      "TWEET_ID                                              825641676324495360\n",
      "TWEET                  Live at #ECCOCongress LOXO Oncology's larotrec...\n",
      "SYNONYMS                                                   LAROTRECTINIB\n",
      "MOLREGNO_1                                                       2099025\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03213704\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         In phase live at\n",
      "COMPANY                                                    Loxo Oncology\n",
      "COMPANY_ID                                                     COMP93848\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Larotrectinib\n",
      "DESCRIPTIONS                Given PO or via nasogastric- or gastric-tube\n",
      "OTHER_NAME                                    ARRY 470;LOXO 101;LOXO-101\n",
      "EFO_ID                                                       EFO:0000637\n",
      "CONDITION                                         Recurrent Osteosarcoma\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                   osteosarcoma\n",
      "Name: 973, dtype: object\n",
      "_____\n",
      "TWID                                                                1892\n",
      "TWEET_ID                                              825641676324495360\n",
      "TWEET                  Live at #ECCOCongress LOXO Oncology's larotrec...\n",
      "SYNONYMS                                                   LAROTRECTINIB\n",
      "MOLREGNO_1                                                       2099025\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03213704\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         In phase live at\n",
      "COMPANY                                                    Loxo Oncology\n",
      "COMPANY_ID                                                     COMP93848\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Larotrectinib\n",
      "DESCRIPTIONS                Given PO or via nasogastric- or gastric-tube\n",
      "OTHER_NAME                                    ARRY 470;LOXO 101;LOXO-101\n",
      "EFO_ID                                                       EFO:0005952\n",
      "CONDITION                       Recurrent Childhood Non-Hodgkin Lymphoma\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                          non-Hodgkins lymphoma\n",
      "Name: 975, dtype: object\n",
      "_____\n",
      "TWID                                                                1892\n",
      "TWEET_ID                                              825641676324495360\n",
      "TWEET                  Live at #ECCOCongress LOXO Oncology's larotrec...\n",
      "SYNONYMS                                                   LAROTRECTINIB\n",
      "MOLREGNO_1                                                       2099025\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03213704\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         In phase live at\n",
      "COMPANY                                                    Loxo Oncology\n",
      "COMPANY_ID                                                     COMP93848\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Larotrectinib\n",
      "DESCRIPTIONS                Given PO or via nasogastric- or gastric-tube\n",
      "OTHER_NAME                                    ARRY 470;LOXO 101;LOXO-101\n",
      "EFO_ID                                                       EFO:0005701\n",
      "CONDITION                                                 Rhabdoid Tumor\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                      malignant rhabdoid tumour\n",
      "Name: 977, dtype: object\n",
      "_____\n",
      "TWID                                                                1892\n",
      "TWEET_ID                                              825641676324495360\n",
      "TWEET                  Live at #ECCOCongress LOXO Oncology's larotrec...\n",
      "SYNONYMS                                                   LAROTRECTINIB\n",
      "MOLREGNO_1                                                       2099025\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03213704\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         In phase live at\n",
      "COMPANY                                                    Loxo Oncology\n",
      "COMPANY_ID                                                     COMP93848\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Larotrectinib\n",
      "DESCRIPTIONS                Given PO or via nasogastric- or gastric-tube\n",
      "OTHER_NAME                                    ARRY 470;LOXO 101;LOXO-101\n",
      "EFO_ID                                                      Orphanet:654\n",
      "CONDITION                                                    Wilms Tumor\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                 Nephroblastoma\n",
      "Name: 979, dtype: object\n",
      "_____\n",
      "TWID                                                                1892\n",
      "TWEET_ID                                              825641676324495360\n",
      "TWEET                  Live at #ECCOCongress LOXO Oncology's larotrec...\n",
      "SYNONYMS                                                   LAROTRECTINIB\n",
      "MOLREGNO_1                                                       2099025\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03213704\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         In phase live at\n",
      "COMPANY                                                    Loxo Oncology\n",
      "COMPANY_ID                                                     COMP93848\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Larotrectinib\n",
      "DESCRIPTIONS                Given PO or via nasogastric- or gastric-tube\n",
      "OTHER_NAME                                    ARRY 470;LOXO 101;LOXO-101\n",
      "EFO_ID                                                       EFO:1000352\n",
      "CONDITION                 Refractory Childhood Malignant Germ Cell Tumor\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                      Malignant Germ Cell Tumor\n",
      "Name: 981, dtype: object\n",
      "_____\n",
      "TWID                                                                1892\n",
      "TWEET_ID                                              825641676324495360\n",
      "TWEET                  Live at #ECCOCongress LOXO Oncology's larotrec...\n",
      "SYNONYMS                                                   LAROTRECTINIB\n",
      "MOLREGNO_1                                                       2099025\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03213704\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         In phase live at\n",
      "COMPANY                                                    Loxo Oncology\n",
      "COMPANY_ID                                                     COMP93848\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Larotrectinib\n",
      "DESCRIPTIONS                Given PO or via nasogastric- or gastric-tube\n",
      "OTHER_NAME                                    ARRY 470;LOXO 101;LOXO-101\n",
      "EFO_ID                                                       EFO:0000637\n",
      "CONDITION                                 Stage IVA Osteosarcoma AJCC v7\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                   osteosarcoma\n",
      "Name: 983, dtype: object\n",
      "_____\n",
      "TWID                                                                1892\n",
      "TWEET_ID                                              825641676324495360\n",
      "TWEET                  Live at #ECCOCongress LOXO Oncology's larotrec...\n",
      "SYNONYMS                                                   LAROTRECTINIB\n",
      "MOLREGNO_1                                                       2099025\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03213704\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         In phase live at\n",
      "COMPANY                                                    Loxo Oncology\n",
      "COMPANY_ID                                                     COMP93848\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Larotrectinib\n",
      "DESCRIPTIONS                Given PO or via nasogastric- or gastric-tube\n",
      "OTHER_NAME                                    ARRY 470;LOXO 101;LOXO-101\n",
      "EFO_ID                                                       EFO:0000637\n",
      "CONDITION                                  Stage IV Osteosarcoma AJCC v7\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                   osteosarcoma\n",
      "Name: 985, dtype: object\n",
      "_____\n",
      "TWID                                                                1892\n",
      "TWEET_ID                                              825641676324495360\n",
      "TWEET                  Live at #ECCOCongress LOXO Oncology's larotrec...\n",
      "SYNONYMS                                                   LAROTRECTINIB\n",
      "MOLREGNO_1                                                       2099025\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03213704\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         In phase live at\n",
      "COMPANY                                                    Loxo Oncology\n",
      "COMPANY_ID                                                     COMP93848\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Larotrectinib\n",
      "DESCRIPTIONS                Given PO or via nasogastric- or gastric-tube\n",
      "OTHER_NAME                                    ARRY 470;LOXO 101;LOXO-101\n",
      "EFO_ID                                                       EFO:0000637\n",
      "CONDITION                                 Stage IVB Osteosarcoma AJCC v7\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                   osteosarcoma\n",
      "Name: 987, dtype: object\n",
      "_____\n",
      "TWID                                                                1892\n",
      "TWEET_ID                                              825641676324495360\n",
      "TWEET                  Live at #ECCOCongress LOXO Oncology's larotrec...\n",
      "SYNONYMS                                                   LAROTRECTINIB\n",
      "MOLREGNO_1                                                       2099025\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03213704\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         In phase live at\n",
      "COMPANY                                                    Loxo Oncology\n",
      "COMPANY_ID                                                     COMP93848\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Larotrectinib\n",
      "DESCRIPTIONS                Given PO or via nasogastric- or gastric-tube\n",
      "OTHER_NAME                                    ARRY 470;LOXO 101;LOXO-101\n",
      "EFO_ID                                                       EFO:0000637\n",
      "CONDITION                                 Stage III Osteosarcoma AJCC v7\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                   osteosarcoma\n",
      "Name: 989, dtype: object\n",
      "_____\n",
      "TWID                                                                1892\n",
      "TWEET_ID                                              825641676324495360\n",
      "TWEET                  Live at #ECCOCongress LOXO Oncology's larotrec...\n",
      "SYNONYMS                                                   LAROTRECTINIB\n",
      "MOLREGNO_1                                                       2099025\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03213704\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         In phase live at\n",
      "COMPANY                                                    Loxo Oncology\n",
      "COMPANY_ID                                                     COMP93848\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Larotrectinib\n",
      "DESCRIPTIONS                Given PO or via nasogastric- or gastric-tube\n",
      "OTHER_NAME                                    ARRY 470;LOXO 101;LOXO-101\n",
      "EFO_ID                                                       EFO:0005235\n",
      "CONDITION              Recurrent Peripheral Primitive Neuroectodermal...\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                primitive neuroectodermal tumor\n",
      "Name: 991, dtype: object\n",
      "_____\n",
      "TWID                                                                1892\n",
      "TWEET_ID                                              825641676324495360\n",
      "TWEET                  Live at #ECCOCongress LOXO Oncology's larotrec...\n",
      "SYNONYMS                                                   LAROTRECTINIB\n",
      "MOLREGNO_1                                                       2099025\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03213704\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         In phase live at\n",
      "COMPANY                                                    Loxo Oncology\n",
      "COMPANY_ID                                                     COMP93848\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Larotrectinib\n",
      "DESCRIPTIONS                Given PO or via nasogastric- or gastric-tube\n",
      "OTHER_NAME                                    ARRY 470;LOXO 101;LOXO-101\n",
      "EFO_ID                                                       EFO:1001968\n",
      "CONDITION                           Stage IV Soft Tissue Sarcoma AJCC v7\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                            soft tissue sarcoma\n",
      "Name: 993, dtype: object\n",
      "_____\n",
      "TWID                                                                1892\n",
      "TWEET_ID                                              825641676324495360\n",
      "TWEET                  Live at #ECCOCongress LOXO Oncology's larotrec...\n",
      "SYNONYMS                                                   LAROTRECTINIB\n",
      "MOLREGNO_1                                                       2099025\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03213704\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         In phase live at\n",
      "COMPANY                                                    Loxo Oncology\n",
      "COMPANY_ID                                                     COMP93848\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Larotrectinib\n",
      "DESCRIPTIONS                Given PO or via nasogastric- or gastric-tube\n",
      "OTHER_NAME                                    ARRY 470;LOXO 101;LOXO-101\n",
      "EFO_ID                                                       EFO:1001968\n",
      "CONDITION                          Stage III Soft Tissue Sarcoma AJCC v7\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                            soft tissue sarcoma\n",
      "Name: 995, dtype: object\n",
      "_____\n",
      "TWID                                                                1892\n",
      "TWEET_ID                                              825641676324495360\n",
      "TWEET                  Live at #ECCOCongress LOXO Oncology's larotrec...\n",
      "SYNONYMS                                                   LAROTRECTINIB\n",
      "MOLREGNO_1                                                       2099025\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03213704\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         In phase live at\n",
      "COMPANY                                                    Loxo Oncology\n",
      "COMPANY_ID                                                     COMP93848\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Larotrectinib\n",
      "DESCRIPTIONS                Given PO or via nasogastric- or gastric-tube\n",
      "OTHER_NAME                                    ARRY 470;LOXO 101;LOXO-101\n",
      "EFO_ID                                                       EFO:0000621\n",
      "CONDITION                                       Refractory Neuroblastoma\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                  neuroblastoma\n",
      "Name: 997, dtype: object\n",
      "_____\n",
      "TWID                                                                1892\n",
      "TWEET_ID                                              825641676324495360\n",
      "TWEET                  Live at #ECCOCongress LOXO Oncology's larotrec...\n",
      "SYNONYMS                                                   LAROTRECTINIB\n",
      "MOLREGNO_1                                                       2099025\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03213704\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         In phase live at\n",
      "COMPANY                                                    Loxo Oncology\n",
      "COMPANY_ID                                                     COMP93848\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Larotrectinib\n",
      "DESCRIPTIONS                Given PO or via nasogastric- or gastric-tube\n",
      "OTHER_NAME                                    ARRY 470;LOXO 101;LOXO-101\n",
      "EFO_ID                                                       EFO:1000318\n",
      "CONDITION                        Recurrent Langerhans Cell Histiocytosis\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                  Langerhans Cell Histiocytosis\n",
      "Name: 999, dtype: object\n",
      "_____\n",
      "TWID                                                                1892\n",
      "TWEET_ID                                              825641676324495360\n",
      "TWEET                  Live at #ECCOCongress LOXO Oncology's larotrec...\n",
      "SYNONYMS                                                   LAROTRECTINIB\n",
      "MOLREGNO_1                                                       2099025\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03213704\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         In phase live at\n",
      "COMPANY                                                    Loxo Oncology\n",
      "COMPANY_ID                                                     COMP93848\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Larotrectinib\n",
      "DESCRIPTIONS                Given PO or via nasogastric- or gastric-tube\n",
      "OTHER_NAME                                    ARRY 470;LOXO 101;LOXO-101\n",
      "EFO_ID                                                       EFO:1000318\n",
      "CONDITION                       Refractory Langerhans Cell Histiocytosis\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                  Langerhans Cell Histiocytosis\n",
      "Name: 1001, dtype: object\n",
      "_____\n",
      "TWID                                                                1892\n",
      "TWEET_ID                                              825641676324495360\n",
      "TWEET                  Live at #ECCOCongress LOXO Oncology's larotrec...\n",
      "SYNONYMS                                                   LAROTRECTINIB\n",
      "MOLREGNO_1                                                       2099025\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03213704\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         In phase live at\n",
      "COMPANY                                                    Loxo Oncology\n",
      "COMPANY_ID                                                     COMP93848\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Larotrectinib\n",
      "DESCRIPTIONS                Given PO or via nasogastric- or gastric-tube\n",
      "OTHER_NAME                                    ARRY 470;LOXO 101;LOXO-101\n",
      "EFO_ID                                                       EFO:0005952\n",
      "CONDITION                                Refractory Non-Hodgkin Lymphoma\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                          non-Hodgkins lymphoma\n",
      "Name: 1003, dtype: object\n",
      "_____\n",
      "TWID                                                                1892\n",
      "TWEET_ID                                              825641676324495360\n",
      "TWEET                  Live at #ECCOCongress LOXO Oncology's larotrec...\n",
      "SYNONYMS                                                   LAROTRECTINIB\n",
      "MOLREGNO_1                                                       2099025\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03213704\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         In phase live at\n",
      "COMPANY                                                    Loxo Oncology\n",
      "COMPANY_ID                                                     COMP93848\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Larotrectinib\n",
      "DESCRIPTIONS                Given PO or via nasogastric- or gastric-tube\n",
      "OTHER_NAME                                    ARRY 470;LOXO 101;LOXO-101\n",
      "EFO_ID                                                       EFO:1000292\n",
      "CONDITION                                       Recurrent Hepatoblastoma\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                 Hepatoblastoma\n",
      "Name: 1005, dtype: object\n",
      "_____\n",
      "TWID                                                                1892\n",
      "TWEET_ID                                              825641676324495360\n",
      "TWEET                  Live at #ECCOCongress LOXO Oncology's larotrec...\n",
      "SYNONYMS                                                   LAROTRECTINIB\n",
      "MOLREGNO_1                                                       2099025\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03213704\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         In phase live at\n",
      "COMPANY                                                    Loxo Oncology\n",
      "COMPANY_ID                                                     COMP93848\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Larotrectinib\n",
      "DESCRIPTIONS                Given PO or via nasogastric- or gastric-tube\n",
      "OTHER_NAME                                    ARRY 470;LOXO 101;LOXO-101\n",
      "EFO_ID                                                       EFO:0000326\n",
      "CONDITION                                               Recurrent Glioma\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                  central nervous system cancer\n",
      "Name: 1007, dtype: object\n",
      "_____\n",
      "TWID                                                                1892\n",
      "TWEET_ID                                              825641676324495360\n",
      "TWEET                  Live at #ECCOCongress LOXO Oncology's larotrec...\n",
      "SYNONYMS                                                   LAROTRECTINIB\n",
      "MOLREGNO_1                                                       2099025\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03213704\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         In phase live at\n",
      "COMPANY                                                    Loxo Oncology\n",
      "COMPANY_ID                                                     COMP93848\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Larotrectinib\n",
      "DESCRIPTIONS                Given PO or via nasogastric- or gastric-tube\n",
      "OTHER_NAME                                    ARRY 470;LOXO 101;LOXO-101\n",
      "EFO_ID                                                       EFO:0002918\n",
      "CONDITION                           Recurrent Childhood Rhabdomyosarcoma\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                               rhabdomyosarcoma\n",
      "Name: 1009, dtype: object\n",
      "_____\n",
      "TWID                                                                1892\n",
      "TWEET_ID                                              825641676324495360\n",
      "TWEET                  Live at #ECCOCongress LOXO Oncology's larotrec...\n",
      "SYNONYMS                                                   LAROTRECTINIB\n",
      "MOLREGNO_1                                                       2099025\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03213704\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         In phase live at\n",
      "COMPANY                                                    Loxo Oncology\n",
      "COMPANY_ID                                                     COMP93848\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Larotrectinib\n",
      "DESCRIPTIONS                Given PO or via nasogastric- or gastric-tube\n",
      "OTHER_NAME                                    ARRY 470;LOXO 101;LOXO-101\n",
      "EFO_ID                                                       EFO:1000158\n",
      "CONDITION                      Recurrent Central Nervous System Neoplasm\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                Central Nervous System Neoplasm\n",
      "Name: 1011, dtype: object\n",
      "_____\n",
      "TWID                                                                1892\n",
      "TWEET_ID                                              825641676324495360\n",
      "TWEET                  Live at #ECCOCongress LOXO Oncology's larotrec...\n",
      "SYNONYMS                                                   LAROTRECTINIB\n",
      "MOLREGNO_1                                                       2099025\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03213704\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         In phase live at\n",
      "COMPANY                                                    Loxo Oncology\n",
      "COMPANY_ID                                                     COMP93848\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Larotrectinib\n",
      "DESCRIPTIONS                Given PO or via nasogastric- or gastric-tube\n",
      "OTHER_NAME                                    ARRY 470;LOXO 101;LOXO-101\n",
      "EFO_ID                                                       EFO:0005952\n",
      "CONDITION              Ann Arbor Stage III Childhood Non-Hodgkin Lymp...\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                          non-Hodgkins lymphoma\n",
      "Name: 1013, dtype: object\n",
      "_____\n",
      "TWID                                                                1892\n",
      "TWEET_ID                                              825641676324495360\n",
      "TWEET                  Live at #ECCOCongress LOXO Oncology's larotrec...\n",
      "SYNONYMS                                                   LAROTRECTINIB\n",
      "MOLREGNO_1                                                       2099025\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03213704\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         In phase live at\n",
      "COMPANY                                                    Loxo Oncology\n",
      "COMPANY_ID                                                     COMP93848\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Larotrectinib\n",
      "DESCRIPTIONS                Given PO or via nasogastric- or gastric-tube\n",
      "OTHER_NAME                                    ARRY 470;LOXO 101;LOXO-101\n",
      "EFO_ID                                                       EFO:0005952\n",
      "CONDITION              Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                          non-Hodgkins lymphoma\n",
      "Name: 1015, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:1001469\n",
      "CONDITION                                 Recurrent Mantle Cell Lymphoma\n",
      "MOLREGNO                                                          407354\n",
      "NAME_TERM                                           Mantle cell lymphoma\n",
      "Name: 1054, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:1001469\n",
      "CONDITION                                 Recurrent Mantle Cell Lymphoma\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                           Mantle cell lymphoma\n",
      "Name: 1055, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:1001469\n",
      "CONDITION                                 Recurrent Mantle Cell Lymphoma\n",
      "MOLREGNO                                                          624161\n",
      "NAME_TERM                                           Mantle cell lymphoma\n",
      "Name: 1056, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:1001469\n",
      "CONDITION                                 Recurrent Mantle Cell Lymphoma\n",
      "MOLREGNO                                                          386457\n",
      "NAME_TERM                                           Mantle cell lymphoma\n",
      "Name: 1057, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0000220\n",
      "CONDITION                   Recurrent Adult Acute Lymphoblastic Leukemia\n",
      "MOLREGNO                                                          407354\n",
      "NAME_TERM                                   acute lymphoblastic leukemia\n",
      "Name: 1059, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0000220\n",
      "CONDITION                   Recurrent Adult Acute Lymphoblastic Leukemia\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                   acute lymphoblastic leukemia\n",
      "Name: 1060, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0000220\n",
      "CONDITION                   Recurrent Adult Acute Lymphoblastic Leukemia\n",
      "MOLREGNO                                                          624161\n",
      "NAME_TERM                                   acute lymphoblastic leukemia\n",
      "Name: 1061, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0000220\n",
      "CONDITION                   Recurrent Adult Acute Lymphoblastic Leukemia\n",
      "MOLREGNO                                                          386457\n",
      "NAME_TERM                                   acute lymphoblastic leukemia\n",
      "Name: 1062, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0000220\n",
      "CONDITION               Recurrent Childhood Acute Lymphoblastic Leukemia\n",
      "MOLREGNO                                                          407354\n",
      "NAME_TERM                                   acute lymphoblastic leukemia\n",
      "Name: 1064, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0000220\n",
      "CONDITION               Recurrent Childhood Acute Lymphoblastic Leukemia\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                   acute lymphoblastic leukemia\n",
      "Name: 1065, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0000220\n",
      "CONDITION               Recurrent Childhood Acute Lymphoblastic Leukemia\n",
      "MOLREGNO                                                          624161\n",
      "NAME_TERM                                   acute lymphoblastic leukemia\n",
      "Name: 1066, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0000220\n",
      "CONDITION               Recurrent Childhood Acute Lymphoblastic Leukemia\n",
      "MOLREGNO                                                          386457\n",
      "NAME_TERM                                   acute lymphoblastic leukemia\n",
      "Name: 1067, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0002616\n",
      "CONDITION                                  Waldenstrom Macroglobulinemia\n",
      "MOLREGNO                                                          407354\n",
      "NAME_TERM                                              macroglobulinemia\n",
      "Name: 1069, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0002616\n",
      "CONDITION                                  Waldenstrom Macroglobulinemia\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                              macroglobulinemia\n",
      "Name: 1070, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0002616\n",
      "CONDITION                                  Waldenstrom Macroglobulinemia\n",
      "MOLREGNO                                                          624161\n",
      "NAME_TERM                                              macroglobulinemia\n",
      "Name: 1071, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0002616\n",
      "CONDITION                                  Waldenstrom Macroglobulinemia\n",
      "MOLREGNO                                                          386457\n",
      "NAME_TERM                                              macroglobulinemia\n",
      "Name: 1072, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0000222\n",
      "CONDITION                         Recurrent Adult Acute Myeloid Leukemia\n",
      "MOLREGNO                                                          407354\n",
      "NAME_TERM                                         acute myeloid leukemia\n",
      "Name: 1074, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0000222\n",
      "CONDITION                         Recurrent Adult Acute Myeloid Leukemia\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                         acute myeloid leukemia\n",
      "Name: 1075, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0000222\n",
      "CONDITION                         Recurrent Adult Acute Myeloid Leukemia\n",
      "MOLREGNO                                                          624161\n",
      "NAME_TERM                                         acute myeloid leukemia\n",
      "Name: 1076, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0000222\n",
      "CONDITION                         Recurrent Adult Acute Myeloid Leukemia\n",
      "MOLREGNO                                                          386457\n",
      "NAME_TERM                                         acute myeloid leukemia\n",
      "Name: 1077, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:1000388\n",
      "CONDITION                    Myelodysplastic/Myeloproliferative Neoplasm\n",
      "MOLREGNO                                                          407354\n",
      "NAME_TERM                    Myelodysplastic/Myeloproliferative Neoplasm\n",
      "Name: 1079, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:1000388\n",
      "CONDITION                    Myelodysplastic/Myeloproliferative Neoplasm\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                    Myelodysplastic/Myeloproliferative Neoplasm\n",
      "Name: 1080, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:1000388\n",
      "CONDITION                    Myelodysplastic/Myeloproliferative Neoplasm\n",
      "MOLREGNO                                                          624161\n",
      "NAME_TERM                    Myelodysplastic/Myeloproliferative Neoplasm\n",
      "Name: 1081, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:1000388\n",
      "CONDITION                    Myelodysplastic/Myeloproliferative Neoplasm\n",
      "MOLREGNO                                                          386457\n",
      "NAME_TERM                    Myelodysplastic/Myeloproliferative Neoplasm\n",
      "Name: 1082, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0000330\n",
      "CONDITION                     Recurrent Childhood Acute Myeloid Leukemia\n",
      "MOLREGNO                                                          407354\n",
      "NAME_TERM                               childhood acute myeloid leukemia\n",
      "Name: 1084, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0000330\n",
      "CONDITION                     Recurrent Childhood Acute Myeloid Leukemia\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                               childhood acute myeloid leukemia\n",
      "Name: 1085, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0000330\n",
      "CONDITION                     Recurrent Childhood Acute Myeloid Leukemia\n",
      "MOLREGNO                                                          624161\n",
      "NAME_TERM                               childhood acute myeloid leukemia\n",
      "Name: 1086, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0000330\n",
      "CONDITION                     Recurrent Childhood Acute Myeloid Leukemia\n",
      "MOLREGNO                                                          386457\n",
      "NAME_TERM                               childhood acute myeloid leukemia\n",
      "Name: 1087, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0000095\n",
      "CONDITION                         Recurrent Chronic Lymphocytic Leukemia\n",
      "MOLREGNO                                                          407354\n",
      "NAME_TERM                                   chronic lymphocytic leukemia\n",
      "Name: 1089, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0000095\n",
      "CONDITION                         Recurrent Chronic Lymphocytic Leukemia\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                   chronic lymphocytic leukemia\n",
      "Name: 1090, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0000095\n",
      "CONDITION                         Recurrent Chronic Lymphocytic Leukemia\n",
      "MOLREGNO                                                          624161\n",
      "NAME_TERM                                   chronic lymphocytic leukemia\n",
      "Name: 1091, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0000095\n",
      "CONDITION                         Recurrent Chronic Lymphocytic Leukemia\n",
      "MOLREGNO                                                          386457\n",
      "NAME_TERM                                   chronic lymphocytic leukemia\n",
      "Name: 1092, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0001378\n",
      "CONDITION                                  Recurrent Plasma Cell Myeloma\n",
      "MOLREGNO                                                          407354\n",
      "NAME_TERM                                               multiple myeloma\n",
      "Name: 1094, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0001378\n",
      "CONDITION                                  Recurrent Plasma Cell Myeloma\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                               multiple myeloma\n",
      "Name: 1095, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0001378\n",
      "CONDITION                                  Recurrent Plasma Cell Myeloma\n",
      "MOLREGNO                                                          624161\n",
      "NAME_TERM                                               multiple myeloma\n",
      "Name: 1096, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0001378\n",
      "CONDITION                                  Recurrent Plasma Cell Myeloma\n",
      "MOLREGNO                                                          386457\n",
      "NAME_TERM                                               multiple myeloma\n",
      "Name: 1097, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0005952\n",
      "CONDITION                                           Non-Hodgkin Lymphoma\n",
      "MOLREGNO                                                          407354\n",
      "NAME_TERM                                          non-Hodgkins lymphoma\n",
      "Name: 1099, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0005952\n",
      "CONDITION                                           Non-Hodgkin Lymphoma\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                          non-Hodgkins lymphoma\n",
      "Name: 1100, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0005952\n",
      "CONDITION                                           Non-Hodgkin Lymphoma\n",
      "MOLREGNO                                                          624161\n",
      "NAME_TERM                                          non-Hodgkins lymphoma\n",
      "Name: 1101, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0005952\n",
      "CONDITION                                           Non-Hodgkin Lymphoma\n",
      "MOLREGNO                                                          386457\n",
      "NAME_TERM                                          non-Hodgkins lymphoma\n",
      "Name: 1102, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0000339\n",
      "CONDITION              Recurrent Chronic Myelogenous Leukemia, BCR-AB...\n",
      "MOLREGNO                                                          407354\n",
      "NAME_TERM                                   chronic myelogenous leukemia\n",
      "Name: 1104, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0000339\n",
      "CONDITION              Recurrent Chronic Myelogenous Leukemia, BCR-AB...\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                   chronic myelogenous leukemia\n",
      "Name: 1105, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0000339\n",
      "CONDITION              Recurrent Chronic Myelogenous Leukemia, BCR-AB...\n",
      "MOLREGNO                                                          624161\n",
      "NAME_TERM                                   chronic myelogenous leukemia\n",
      "Name: 1106, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0000339\n",
      "CONDITION              Recurrent Chronic Myelogenous Leukemia, BCR-AB...\n",
      "MOLREGNO                                                          386457\n",
      "NAME_TERM                                   chronic myelogenous leukemia\n",
      "Name: 1107, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0000183\n",
      "CONDITION                                     Recurrent Hodgkin Lymphoma\n",
      "MOLREGNO                                                          407354\n",
      "NAME_TERM                                              Hodgkins lymphoma\n",
      "Name: 1109, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0000183\n",
      "CONDITION                                     Recurrent Hodgkin Lymphoma\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                              Hodgkins lymphoma\n",
      "Name: 1110, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0000183\n",
      "CONDITION                                     Recurrent Hodgkin Lymphoma\n",
      "MOLREGNO                                                          624161\n",
      "NAME_TERM                                              Hodgkins lymphoma\n",
      "Name: 1111, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0000183\n",
      "CONDITION                                     Recurrent Hodgkin Lymphoma\n",
      "MOLREGNO                                                          386457\n",
      "NAME_TERM                                              Hodgkins lymphoma\n",
      "Name: 1112, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0000403\n",
      "CONDITION                        Recurrent Diffuse Large B-Cell Lymphoma\n",
      "MOLREGNO                                                          407354\n",
      "NAME_TERM                                  diffuse large B-cell lymphoma\n",
      "Name: 1114, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0000403\n",
      "CONDITION                        Recurrent Diffuse Large B-Cell Lymphoma\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                  diffuse large B-cell lymphoma\n",
      "Name: 1115, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0000403\n",
      "CONDITION                        Recurrent Diffuse Large B-Cell Lymphoma\n",
      "MOLREGNO                                                          624161\n",
      "NAME_TERM                                  diffuse large B-cell lymphoma\n",
      "Name: 1116, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0000403\n",
      "CONDITION                        Recurrent Diffuse Large B-Cell Lymphoma\n",
      "MOLREGNO                                                          386457\n",
      "NAME_TERM                                  diffuse large B-cell lymphoma\n",
      "Name: 1117, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0005952\n",
      "CONDITION                                Aggressive Non-Hodgkin Lymphoma\n",
      "MOLREGNO                                                          407354\n",
      "NAME_TERM                                          non-Hodgkins lymphoma\n",
      "Name: 1119, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0005952\n",
      "CONDITION                                Aggressive Non-Hodgkin Lymphoma\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                          non-Hodgkins lymphoma\n",
      "Name: 1120, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0005952\n",
      "CONDITION                                Aggressive Non-Hodgkin Lymphoma\n",
      "MOLREGNO                                                          624161\n",
      "NAME_TERM                                          non-Hodgkins lymphoma\n",
      "Name: 1121, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0005952\n",
      "CONDITION                                Aggressive Non-Hodgkin Lymphoma\n",
      "MOLREGNO                                                          386457\n",
      "NAME_TERM                                          non-Hodgkins lymphoma\n",
      "Name: 1122, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0005952\n",
      "CONDITION                Recurrent Aggressive Adult Non-Hodgkin Lymphoma\n",
      "MOLREGNO                                                          407354\n",
      "NAME_TERM                                          non-Hodgkins lymphoma\n",
      "Name: 1124, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0005952\n",
      "CONDITION                Recurrent Aggressive Adult Non-Hodgkin Lymphoma\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                          non-Hodgkins lymphoma\n",
      "Name: 1125, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0005952\n",
      "CONDITION                Recurrent Aggressive Adult Non-Hodgkin Lymphoma\n",
      "MOLREGNO                                                          624161\n",
      "NAME_TERM                                          non-Hodgkins lymphoma\n",
      "Name: 1126, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0005952\n",
      "CONDITION                Recurrent Aggressive Adult Non-Hodgkin Lymphoma\n",
      "MOLREGNO                                                          386457\n",
      "NAME_TERM                                          non-Hodgkins lymphoma\n",
      "Name: 1127, dtype: object\n",
      "_____\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0004289\n",
      "CONDITION                                        Prolymphocytic Leukemia\n",
      "MOLREGNO                                                          407354\n",
      "NAME_TERM                                              lymphoid leukemia\n",
      "Name: 1129, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0004289\n",
      "CONDITION                                        Prolymphocytic Leukemia\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                              lymphoid leukemia\n",
      "Name: 1130, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0004289\n",
      "CONDITION                                        Prolymphocytic Leukemia\n",
      "MOLREGNO                                                          624161\n",
      "NAME_TERM                                              lymphoid leukemia\n",
      "Name: 1131, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0004289\n",
      "CONDITION                                        Prolymphocytic Leukemia\n",
      "MOLREGNO                                                          386457\n",
      "NAME_TERM                                              lymphoid leukemia\n",
      "Name: 1132, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0000095\n",
      "CONDITION                           Recurrent Small Lymphocytic Lymphoma\n",
      "MOLREGNO                                                          407354\n",
      "NAME_TERM                                   chronic lymphocytic leukemia\n",
      "Name: 1134, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0000095\n",
      "CONDITION                           Recurrent Small Lymphocytic Lymphoma\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                   chronic lymphocytic leukemia\n",
      "Name: 1135, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0000095\n",
      "CONDITION                           Recurrent Small Lymphocytic Lymphoma\n",
      "MOLREGNO                                                          624161\n",
      "NAME_TERM                                   chronic lymphocytic leukemia\n",
      "Name: 1136, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0000095\n",
      "CONDITION                           Recurrent Small Lymphocytic Lymphoma\n",
      "MOLREGNO                                                          386457\n",
      "NAME_TERM                                   chronic lymphocytic leukemia\n",
      "Name: 1137, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0005952\n",
      "CONDITION                                 Recurrent Non-Hodgkin Lymphoma\n",
      "MOLREGNO                                                          407354\n",
      "NAME_TERM                                          non-Hodgkins lymphoma\n",
      "Name: 1139, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0005952\n",
      "CONDITION                                 Recurrent Non-Hodgkin Lymphoma\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                          non-Hodgkins lymphoma\n",
      "Name: 1140, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0005952\n",
      "CONDITION                                 Recurrent Non-Hodgkin Lymphoma\n",
      "MOLREGNO                                                          624161\n",
      "NAME_TERM                                          non-Hodgkins lymphoma\n",
      "Name: 1141, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0005952\n",
      "CONDITION                                 Recurrent Non-Hodgkin Lymphoma\n",
      "MOLREGNO                                                          386457\n",
      "NAME_TERM                                          non-Hodgkins lymphoma\n",
      "Name: 1142, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                   -NOT-CONDITION-\n",
      "CONDITION              Blasts Under 5 Percent of Bone Marrow Nucleate...\n",
      "MOLREGNO                                                          407354\n",
      "NAME_TERM                                                            NaN\n",
      "Name: 1144, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                   -NOT-CONDITION-\n",
      "CONDITION              Blasts Under 5 Percent of Bone Marrow Nucleate...\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                            NaN\n",
      "Name: 1145, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                   -NOT-CONDITION-\n",
      "CONDITION              Blasts Under 5 Percent of Bone Marrow Nucleate...\n",
      "MOLREGNO                                                          624161\n",
      "NAME_TERM                                                            NaN\n",
      "Name: 1146, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                   -NOT-CONDITION-\n",
      "CONDITION              Blasts Under 5 Percent of Bone Marrow Nucleate...\n",
      "MOLREGNO                                                          386457\n",
      "NAME_TERM                                                            NaN\n",
      "Name: 1147, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0000095\n",
      "CONDITION                                   Chronic Lymphocytic Leukemia\n",
      "MOLREGNO                                                          407354\n",
      "NAME_TERM                                   chronic lymphocytic leukemia\n",
      "Name: 1149, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0000095\n",
      "CONDITION                                   Chronic Lymphocytic Leukemia\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                   chronic lymphocytic leukemia\n",
      "Name: 1150, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0000095\n",
      "CONDITION                                   Chronic Lymphocytic Leukemia\n",
      "MOLREGNO                                                          624161\n",
      "NAME_TERM                                   chronic lymphocytic leukemia\n",
      "Name: 1151, dtype: object\n",
      "_____\n",
      "TWID                                                                1969\n",
      "TWEET_ID                                              817343622941020160\n",
      "TWEET                  Novaliq's CyclAsol (ophthalmic ciclosporin) re...\n",
      "SYNONYMS                                                     CICLOSPORIN\n",
      "MOLREGNO_1                                                         72873\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01527045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     reduces corneal fluorescein staining\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cyclosporine\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             27-400;Ciclosporin;CsA;Cyclosporin;Cyclosporin...\n",
      "EFO_ID                                                       EFO:0000095\n",
      "CONDITION                                   Chronic Lymphocytic Leukemia\n",
      "MOLREGNO                                                          386457\n",
      "NAME_TERM                                   chronic lymphocytic leukemia\n",
      "Name: 1152, dtype: object\n",
      "_____\n",
      "TWID                                                                1982\n",
      "TWEET_ID                                              816359730444582912\n",
      "TWEET                  Saniona's Tesomet (tesofensine+metoprolol) sho...\n",
      "SYNONYMS                                                     TESOFENSINE\n",
      "MOLREGNO_1                                                       2197561\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03149445\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                         Positive results\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                         Prader-Willi Syndrome\n",
      "INDICATION_ID                                                    D011218\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                               Tesofensine/Metoprolol\n",
      "DESCRIPTIONS           Study medication will be administered for 91 d...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                      Orphanet:739\n",
      "CONDITION              Confirmed Genetic Diagnosis of Prader-Willi Sy...\n",
      "MOLREGNO                                                             789\n",
      "NAME_TERM                                          Prader-Willi syndrome\n",
      "Name: 1158, dtype: object\n",
      "_____\n",
      "TWID                                                                1982\n",
      "TWEET_ID                                              816359730444582912\n",
      "TWEET                  Saniona's Tesomet (tesofensine+metoprolol) sho...\n",
      "SYNONYMS                                                      METOPROLOL\n",
      "MOLREGNO_1                                                           789\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03370835\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                         Positive results\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                         Prader-Willi Syndrome\n",
      "INDICATION_ID                                                    D011218\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                              Metoprolol succinate ER\n",
      "DESCRIPTIONS                                Cardioselective beta-blocker\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000341\n",
      "CONDITION                         Pulmonary Disease, Chronic Obstructive\n",
      "MOLREGNO                                                           36662\n",
      "NAME_TERM                          chronic obstructive pulmonary disease\n",
      "Name: 1160, dtype: object\n",
      "_____\n",
      "TWID                                                                1982\n",
      "TWEET_ID                                              816359730444582912\n",
      "TWEET                  Saniona's Tesomet (tesofensine+metoprolol) sho...\n",
      "SYNONYMS                                                      METOPROLOL\n",
      "MOLREGNO_1                                                           789\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03370835\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                         Positive results\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                         Prader-Willi Syndrome\n",
      "INDICATION_ID                                                    D011218\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                              Metoprolol succinate ER\n",
      "DESCRIPTIONS                                Cardioselective beta-blocker\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000341\n",
      "CONDITION                         Pulmonary Disease, Chronic Obstructive\n",
      "MOLREGNO                                                          674288\n",
      "NAME_TERM                          chronic obstructive pulmonary disease\n",
      "Name: 1161, dtype: object\n",
      "_____\n",
      "TWID                                                                1982\n",
      "TWEET_ID                                              816359730444582912\n",
      "TWEET                  Saniona's Tesomet (tesofensine+metoprolol) sho...\n",
      "SYNONYMS                                                      METOPROLOL\n",
      "MOLREGNO_1                                                           789\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03370835\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                         Positive results\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                         Prader-Willi Syndrome\n",
      "INDICATION_ID                                                    D011218\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                              Metoprolol succinate ER\n",
      "DESCRIPTIONS                                Cardioselective beta-blocker\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                   -NOT-CONDITION-\n",
      "CONDITION              Adverse Effect of Beta-adrenoreceptor Antagonists\n",
      "MOLREGNO                                                           36662\n",
      "NAME_TERM                                                            NaN\n",
      "Name: 1162, dtype: object\n",
      "_____\n",
      "TWID                                                                1982\n",
      "TWEET_ID                                              816359730444582912\n",
      "TWEET                  Saniona's Tesomet (tesofensine+metoprolol) sho...\n",
      "SYNONYMS                                                      METOPROLOL\n",
      "MOLREGNO_1                                                           789\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03370835\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                         Positive results\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                         Prader-Willi Syndrome\n",
      "INDICATION_ID                                                    D011218\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                              Metoprolol succinate ER\n",
      "DESCRIPTIONS                                Cardioselective beta-blocker\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                   -NOT-CONDITION-\n",
      "CONDITION              Adverse Effect of Beta-adrenoreceptor Antagonists\n",
      "MOLREGNO                                                          674288\n",
      "NAME_TERM                                                            NaN\n",
      "Name: 1163, dtype: object\n",
      "_____\n",
      "TWID                                                                1982\n",
      "TWEET_ID                                              816359730444582912\n",
      "TWEET                  Saniona's Tesomet (tesofensine+metoprolol) sho...\n",
      "SYNONYMS                                                      METOPROLOL\n",
      "MOLREGNO_1                                                           789\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03370835\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                         Positive results\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                         Prader-Willi Syndrome\n",
      "INDICATION_ID                                                    D011218\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                              Metoprolol succinate ER\n",
      "DESCRIPTIONS                                Cardioselective beta-blocker\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000270\n",
      "CONDITION                                                         Asthma\n",
      "MOLREGNO                                                           36662\n",
      "NAME_TERM                                                         asthma\n",
      "Name: 1164, dtype: object\n",
      "_____\n",
      "TWID                                                                1982\n",
      "TWEET_ID                                              816359730444582912\n",
      "TWEET                  Saniona's Tesomet (tesofensine+metoprolol) sho...\n",
      "SYNONYMS                                                      METOPROLOL\n",
      "MOLREGNO_1                                                           789\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03370835\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                         Positive results\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                         Prader-Willi Syndrome\n",
      "INDICATION_ID                                                    D011218\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                              Metoprolol succinate ER\n",
      "DESCRIPTIONS                                Cardioselective beta-blocker\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000270\n",
      "CONDITION                                                         Asthma\n",
      "MOLREGNO                                                          674288\n",
      "NAME_TERM                                                         asthma\n",
      "Name: 1165, dtype: object\n",
      "_____\n",
      "TWID                                                                2010\n",
      "TWEET_ID                                              811902556146274304\n",
      "TWEET                  Concert Pharmaceuticals begins US phase II tri...\n",
      "SYNONYMS                                                       IVACAFTOR\n",
      "MOLREGNO_1                                                       1331852\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03150719\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                       begins phase trial\n",
      "COMPANY                                          Concert Pharmaceuticals\n",
      "COMPANY_ID                                                     COMP90942\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Sinusitis\n",
      "INDICATION_ID                                                    D012852\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                                  IVA\n",
      "DESCRIPTIONS                                          IVA 150 mg tablet.\n",
      "OTHER_NAME                                                     Ivacaftor\n",
      "EFO_ID                                                      Orphanet:586\n",
      "CONDITION                                                Cystic Fibrosis\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                Cystic fibrosis\n",
      "Name: 1167, dtype: object\n",
      "_____\n",
      "TWID                                                                2012\n",
      "TWEET_ID                                              811900176801480704\n",
      "TWEET                  Nano Carrier halts Japanese phase I trial of N...\n",
      "SYNONYMS                                                       CISPLATIN\n",
      "MOLREGNO_1                                                          8633\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              halts trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                       Squamous Cell Neoplasms\n",
      "INDICATION_ID                                                    D018307\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Cisplatin\n",
      "DESCRIPTIONS                            cis-diamminedichloroplatinum(II)\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                          675089\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1176, dtype: object\n",
      "_____\n",
      "TWID                                                                2012\n",
      "TWEET_ID                                              811900176801480704\n",
      "TWEET                  Nano Carrier halts Japanese phase I trial of N...\n",
      "SYNONYMS                                                       CISPLATIN\n",
      "MOLREGNO_1                                                          8633\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              halts trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                       Squamous Cell Neoplasms\n",
      "INDICATION_ID                                                    D018307\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Cisplatin\n",
      "DESCRIPTIONS                            cis-diamminedichloroplatinum(II)\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                            8062\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1177, dtype: object\n",
      "_____\n",
      "TWID                                                                2012\n",
      "TWEET_ID                                              811900176801480704\n",
      "TWEET                  Nano Carrier halts Japanese phase I trial of N...\n",
      "SYNONYMS                                                       CISPLATIN\n",
      "MOLREGNO_1                                                          8633\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              halts trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                       Squamous Cell Neoplasms\n",
      "INDICATION_ID                                                    D018307\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Cisplatin\n",
      "DESCRIPTIONS                            cis-diamminedichloroplatinum(II)\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                         1380097\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1178, dtype: object\n",
      "_____\n",
      "TWID                                                                2012\n",
      "TWEET_ID                                              811900176801480704\n",
      "TWEET                  Nano Carrier halts Japanese phase I trial of N...\n",
      "SYNONYMS                                                       CISPLATIN\n",
      "MOLREGNO_1                                                          8633\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              halts trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                       Squamous Cell Neoplasms\n",
      "INDICATION_ID                                                    D018307\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Cisplatin\n",
      "DESCRIPTIONS                            cis-diamminedichloroplatinum(II)\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                          674747\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1180, dtype: object\n",
      "_____\n",
      "TWID                                                                2012\n",
      "TWEET_ID                                              811900176801480704\n",
      "TWEET                  Nano Carrier halts Japanese phase I trial of N...\n",
      "SYNONYMS                                                       CISPLATIN\n",
      "MOLREGNO_1                                                          8633\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              halts trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                       Squamous Cell Neoplasms\n",
      "INDICATION_ID                                                    D018307\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Cisplatin\n",
      "DESCRIPTIONS                            cis-diamminedichloroplatinum(II)\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                          675483\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1181, dtype: object\n",
      "_____\n",
      "TWID                                                                2012\n",
      "TWEET_ID                                              811900176801480704\n",
      "TWEET                  Nano Carrier halts Japanese phase I trial of N...\n",
      "SYNONYMS                                                       CISPLATIN\n",
      "MOLREGNO_1                                                          8633\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              halts trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                       Squamous Cell Neoplasms\n",
      "INDICATION_ID                                                    D018307\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Cisplatin\n",
      "DESCRIPTIONS                            cis-diamminedichloroplatinum(II)\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                          368538\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1182, dtype: object\n",
      "_____\n",
      "TWID                                                                2012\n",
      "TWEET_ID                                              811900176801480704\n",
      "TWEET                  Nano Carrier halts Japanese phase I trial of N...\n",
      "SYNONYMS                                                       CISPLATIN\n",
      "MOLREGNO_1                                                          8633\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              halts trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                       Squamous Cell Neoplasms\n",
      "INDICATION_ID                                                    D018307\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Cisplatin\n",
      "DESCRIPTIONS                            cis-diamminedichloroplatinum(II)\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                         2096424\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1183, dtype: object\n",
      "_____\n",
      "TWID                                                                2012\n",
      "TWEET_ID                                              811900176801480704\n",
      "TWEET                  Nano Carrier halts Japanese phase I trial of N...\n",
      "SYNONYMS                                                       CISPLATIN\n",
      "MOLREGNO_1                                                          8633\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              halts trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                       Squamous Cell Neoplasms\n",
      "INDICATION_ID                                                    D018307\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Cisplatin\n",
      "DESCRIPTIONS                            cis-diamminedichloroplatinum(II)\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                          598447\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1184, dtype: object\n",
      "_____\n",
      "TWID                                                                2012\n",
      "TWEET_ID                                              811900176801480704\n",
      "TWEET                  Nano Carrier halts Japanese phase I trial of N...\n",
      "SYNONYMS                                                       CISPLATIN\n",
      "MOLREGNO_1                                                        328069\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              halts trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                       Squamous Cell Neoplasms\n",
      "INDICATION_ID                                                    D018307\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Cisplatin\n",
      "DESCRIPTIONS                            cis-diamminedichloroplatinum(II)\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                          675089\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1185, dtype: object\n",
      "_____\n",
      "TWID                                                                2012\n",
      "TWEET_ID                                              811900176801480704\n",
      "TWEET                  Nano Carrier halts Japanese phase I trial of N...\n",
      "SYNONYMS                                                       CISPLATIN\n",
      "MOLREGNO_1                                                        328069\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              halts trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                       Squamous Cell Neoplasms\n",
      "INDICATION_ID                                                    D018307\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Cisplatin\n",
      "DESCRIPTIONS                            cis-diamminedichloroplatinum(II)\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                            8062\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1186, dtype: object\n",
      "_____\n",
      "TWID                                                                2012\n",
      "TWEET_ID                                              811900176801480704\n",
      "TWEET                  Nano Carrier halts Japanese phase I trial of N...\n",
      "SYNONYMS                                                       CISPLATIN\n",
      "MOLREGNO_1                                                        328069\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              halts trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                       Squamous Cell Neoplasms\n",
      "INDICATION_ID                                                    D018307\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Cisplatin\n",
      "DESCRIPTIONS                            cis-diamminedichloroplatinum(II)\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                         1380097\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1187, dtype: object\n",
      "_____\n",
      "TWID                                                                2012\n",
      "TWEET_ID                                              811900176801480704\n",
      "TWEET                  Nano Carrier halts Japanese phase I trial of N...\n",
      "SYNONYMS                                                       CISPLATIN\n",
      "MOLREGNO_1                                                        328069\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              halts trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                       Squamous Cell Neoplasms\n",
      "INDICATION_ID                                                    D018307\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Cisplatin\n",
      "DESCRIPTIONS                            cis-diamminedichloroplatinum(II)\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                            8633\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1188, dtype: object\n",
      "_____\n",
      "TWID                                                                2012\n",
      "TWEET_ID                                              811900176801480704\n",
      "TWEET                  Nano Carrier halts Japanese phase I trial of N...\n",
      "SYNONYMS                                                       CISPLATIN\n",
      "MOLREGNO_1                                                        328069\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              halts trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                       Squamous Cell Neoplasms\n",
      "INDICATION_ID                                                    D018307\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Cisplatin\n",
      "DESCRIPTIONS                            cis-diamminedichloroplatinum(II)\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                          674747\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1189, dtype: object\n",
      "_____\n",
      "TWID                                                                2012\n",
      "TWEET_ID                                              811900176801480704\n",
      "TWEET                  Nano Carrier halts Japanese phase I trial of N...\n",
      "SYNONYMS                                                       CISPLATIN\n",
      "MOLREGNO_1                                                        328069\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              halts trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                       Squamous Cell Neoplasms\n",
      "INDICATION_ID                                                    D018307\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Cisplatin\n",
      "DESCRIPTIONS                            cis-diamminedichloroplatinum(II)\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                          675483\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1190, dtype: object\n",
      "_____\n",
      "TWID                                                                2012\n",
      "TWEET_ID                                              811900176801480704\n",
      "TWEET                  Nano Carrier halts Japanese phase I trial of N...\n",
      "SYNONYMS                                                       CISPLATIN\n",
      "MOLREGNO_1                                                        328069\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              halts trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                       Squamous Cell Neoplasms\n",
      "INDICATION_ID                                                    D018307\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Cisplatin\n",
      "DESCRIPTIONS                            cis-diamminedichloroplatinum(II)\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                          368538\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1191, dtype: object\n",
      "_____\n",
      "TWID                                                                2012\n",
      "TWEET_ID                                              811900176801480704\n",
      "TWEET                  Nano Carrier halts Japanese phase I trial of N...\n",
      "SYNONYMS                                                       CISPLATIN\n",
      "MOLREGNO_1                                                        328069\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              halts trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                       Squamous Cell Neoplasms\n",
      "INDICATION_ID                                                    D018307\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Cisplatin\n",
      "DESCRIPTIONS                            cis-diamminedichloroplatinum(II)\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                         2096424\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1192, dtype: object\n",
      "_____\n",
      "TWID                                                                2012\n",
      "TWEET_ID                                              811900176801480704\n",
      "TWEET                  Nano Carrier halts Japanese phase I trial of N...\n",
      "SYNONYMS                                                       CISPLATIN\n",
      "MOLREGNO_1                                                        328069\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              halts trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                       Squamous Cell Neoplasms\n",
      "INDICATION_ID                                                    D018307\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Cisplatin\n",
      "DESCRIPTIONS                            cis-diamminedichloroplatinum(II)\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                          598447\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1193, dtype: object\n",
      "_____\n",
      "TWID                                                                2012\n",
      "TWEET_ID                                              811900176801480704\n",
      "TWEET                  Nano Carrier halts Japanese phase I trial of N...\n",
      "SYNONYMS                                                       CISPLATIN\n",
      "MOLREGNO_1                                                       1358551\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              halts trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                       Squamous Cell Neoplasms\n",
      "INDICATION_ID                                                    D018307\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Cisplatin\n",
      "DESCRIPTIONS                            cis-diamminedichloroplatinum(II)\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                          675089\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1194, dtype: object\n",
      "_____\n",
      "TWID                                                                2012\n",
      "TWEET_ID                                              811900176801480704\n",
      "TWEET                  Nano Carrier halts Japanese phase I trial of N...\n",
      "SYNONYMS                                                       CISPLATIN\n",
      "MOLREGNO_1                                                       1358551\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              halts trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                       Squamous Cell Neoplasms\n",
      "INDICATION_ID                                                    D018307\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Cisplatin\n",
      "DESCRIPTIONS                            cis-diamminedichloroplatinum(II)\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                            8062\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1195, dtype: object\n",
      "_____\n",
      "TWID                                                                2012\n",
      "TWEET_ID                                              811900176801480704\n",
      "TWEET                  Nano Carrier halts Japanese phase I trial of N...\n",
      "SYNONYMS                                                       CISPLATIN\n",
      "MOLREGNO_1                                                       1358551\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              halts trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                       Squamous Cell Neoplasms\n",
      "INDICATION_ID                                                    D018307\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Cisplatin\n",
      "DESCRIPTIONS                            cis-diamminedichloroplatinum(II)\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                         1380097\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1196, dtype: object\n",
      "_____\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "TWID                                                                2012\n",
      "TWEET_ID                                              811900176801480704\n",
      "TWEET                  Nano Carrier halts Japanese phase I trial of N...\n",
      "SYNONYMS                                                       CISPLATIN\n",
      "MOLREGNO_1                                                       1358551\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              halts trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                       Squamous Cell Neoplasms\n",
      "INDICATION_ID                                                    D018307\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Cisplatin\n",
      "DESCRIPTIONS                            cis-diamminedichloroplatinum(II)\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                            8633\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1197, dtype: object\n",
      "_____\n",
      "TWID                                                                2012\n",
      "TWEET_ID                                              811900176801480704\n",
      "TWEET                  Nano Carrier halts Japanese phase I trial of N...\n",
      "SYNONYMS                                                       CISPLATIN\n",
      "MOLREGNO_1                                                       1358551\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              halts trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                       Squamous Cell Neoplasms\n",
      "INDICATION_ID                                                    D018307\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Cisplatin\n",
      "DESCRIPTIONS                            cis-diamminedichloroplatinum(II)\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                          674747\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1198, dtype: object\n",
      "_____\n",
      "TWID                                                                2012\n",
      "TWEET_ID                                              811900176801480704\n",
      "TWEET                  Nano Carrier halts Japanese phase I trial of N...\n",
      "SYNONYMS                                                       CISPLATIN\n",
      "MOLREGNO_1                                                       1358551\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              halts trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                       Squamous Cell Neoplasms\n",
      "INDICATION_ID                                                    D018307\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Cisplatin\n",
      "DESCRIPTIONS                            cis-diamminedichloroplatinum(II)\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                          675483\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1199, dtype: object\n",
      "_____\n",
      "TWID                                                                2012\n",
      "TWEET_ID                                              811900176801480704\n",
      "TWEET                  Nano Carrier halts Japanese phase I trial of N...\n",
      "SYNONYMS                                                       CISPLATIN\n",
      "MOLREGNO_1                                                       1358551\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              halts trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                       Squamous Cell Neoplasms\n",
      "INDICATION_ID                                                    D018307\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Cisplatin\n",
      "DESCRIPTIONS                            cis-diamminedichloroplatinum(II)\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                          368538\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1200, dtype: object\n",
      "_____\n",
      "TWID                                                                2012\n",
      "TWEET_ID                                              811900176801480704\n",
      "TWEET                  Nano Carrier halts Japanese phase I trial of N...\n",
      "SYNONYMS                                                       CISPLATIN\n",
      "MOLREGNO_1                                                       1358551\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              halts trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                       Squamous Cell Neoplasms\n",
      "INDICATION_ID                                                    D018307\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Cisplatin\n",
      "DESCRIPTIONS                            cis-diamminedichloroplatinum(II)\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                         2096424\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1201, dtype: object\n",
      "_____\n",
      "TWID                                                                2012\n",
      "TWEET_ID                                              811900176801480704\n",
      "TWEET                  Nano Carrier halts Japanese phase I trial of N...\n",
      "SYNONYMS                                                       CISPLATIN\n",
      "MOLREGNO_1                                                       1358551\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              halts trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                       Squamous Cell Neoplasms\n",
      "INDICATION_ID                                                    D018307\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Cisplatin\n",
      "DESCRIPTIONS                            cis-diamminedichloroplatinum(II)\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                          598447\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1202, dtype: object\n",
      "_____\n",
      "TWID                                                                2030\n",
      "TWEET_ID                                              811182185625464832\n",
      "TWEET                  Avolynt's biphasic remogliflozin etabonate sig...\n",
      "SYNONYMS                                                   REMOGLIFLOZIN\n",
      "MOLREGNO_1                                                        477908\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02537470\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            safe in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                             Diabetes Mellitus\n",
      "INDICATION_ID                                                    D003920\n",
      "INDICATION_NONAMBIG                                                    2\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                     Biphasic Remogliflozin Etabonate\n",
      "DESCRIPTIONS                                           Experimental Drug\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0001360\n",
      "CONDITION                                       Type 2 Diabetes Mellitus\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                      type II diabetes mellitus\n",
      "Name: 1203, dtype: object\n",
      "_____\n",
      "TWID                                                                2030\n",
      "TWEET_ID                                              811182185625464832\n",
      "TWEET                  Avolynt's biphasic remogliflozin etabonate sig...\n",
      "SYNONYMS                                                   REMOGLIFLOZIN\n",
      "MOLREGNO_1                                                        477908\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02537470\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            safe in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                             Diabetes Mellitus\n",
      "INDICATION_ID                                                    D003920\n",
      "INDICATION_NONAMBIG                                                    2\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                     Biphasic Remogliflozin Etabonate\n",
      "DESCRIPTIONS                                           Experimental Drug\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0001360\n",
      "CONDITION                                       Type 2 Diabetes Mellitus\n",
      "MOLREGNO                                                         1340896\n",
      "NAME_TERM                                      type II diabetes mellitus\n",
      "Name: 1204, dtype: object\n",
      "_____\n",
      "TWID                                                                2030\n",
      "TWEET_ID                                              811182185625464832\n",
      "TWEET                  Avolynt's biphasic remogliflozin etabonate sig...\n",
      "SYNONYMS                                                   REMOGLIFLOZIN\n",
      "MOLREGNO_1                                                        477908\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02537470\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            safe in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                             Diabetes Mellitus\n",
      "INDICATION_ID                                                    D003920\n",
      "INDICATION_NONAMBIG                                                    2\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                     Biphasic Remogliflozin Etabonate\n",
      "DESCRIPTIONS                                           Experimental Drug\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0001360\n",
      "CONDITION                                      Diabetes Mellitus, Type 2\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                      type II diabetes mellitus\n",
      "Name: 1205, dtype: object\n",
      "_____\n",
      "TWID                                                                2030\n",
      "TWEET_ID                                              811182185625464832\n",
      "TWEET                  Avolynt's biphasic remogliflozin etabonate sig...\n",
      "SYNONYMS                                                   REMOGLIFLOZIN\n",
      "MOLREGNO_1                                                        477908\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02537470\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            safe in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                             Diabetes Mellitus\n",
      "INDICATION_ID                                                    D003920\n",
      "INDICATION_NONAMBIG                                                    2\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                     Biphasic Remogliflozin Etabonate\n",
      "DESCRIPTIONS                                           Experimental Drug\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0001360\n",
      "CONDITION                                      Diabetes Mellitus, Type 2\n",
      "MOLREGNO                                                         1340896\n",
      "NAME_TERM                                      type II diabetes mellitus\n",
      "Name: 1206, dtype: object\n",
      "_____\n",
      "TWID                                                                2030\n",
      "TWEET_ID                                              811182185625464832\n",
      "TWEET                  Avolynt's biphasic remogliflozin etabonate sig...\n",
      "SYNONYMS                                         REMOGLIFLOZIN ETABONATE\n",
      "MOLREGNO_1                                                       1340896\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02537470\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            safe in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                             Diabetes Mellitus\n",
      "INDICATION_ID                                                    D003920\n",
      "INDICATION_NONAMBIG                                                    2\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                     Biphasic Remogliflozin Etabonate\n",
      "DESCRIPTIONS                                           Experimental Drug\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0001360\n",
      "CONDITION                                       Type 2 Diabetes Mellitus\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                      type II diabetes mellitus\n",
      "Name: 1207, dtype: object\n",
      "_____\n",
      "TWID                                                                2030\n",
      "TWEET_ID                                              811182185625464832\n",
      "TWEET                  Avolynt's biphasic remogliflozin etabonate sig...\n",
      "SYNONYMS                                         REMOGLIFLOZIN ETABONATE\n",
      "MOLREGNO_1                                                       1340896\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02537470\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            safe in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                             Diabetes Mellitus\n",
      "INDICATION_ID                                                    D003920\n",
      "INDICATION_NONAMBIG                                                    2\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                     Biphasic Remogliflozin Etabonate\n",
      "DESCRIPTIONS                                           Experimental Drug\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0001360\n",
      "CONDITION                                      Diabetes Mellitus, Type 2\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                      type II diabetes mellitus\n",
      "Name: 1209, dtype: object\n",
      "_____\n",
      "TWID                                                                2032\n",
      "TWEET_ID                                              811171033633865728\n",
      "TWEET                  DRGT's DGRT-46 and DRGT-47 (celecoxib reformul...\n",
      "SYNONYMS                                                       CELECOXIB\n",
      "MOLREGNO_1                                                         18694\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03026140\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME               demonstrate rapid absorption and potential\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                            Migraine Disorders\n",
      "INDICATION_ID                                                    D008881\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                      Celecoxib 200mg\n",
      "DESCRIPTIONS           celecoxib will be administered starting day 1 ...\n",
      "OTHER_NAME                                                      Celebrex\n",
      "EFO_ID                                                       EFO:1001950\n",
      "CONDITION                                                Colon Carcinoma\n",
      "MOLREGNO                                                         1381004\n",
      "NAME_TERM                                                colon carcinoma\n",
      "Name: 1211, dtype: object\n",
      "_____\n",
      "TWID                                                                2032\n",
      "TWEET_ID                                              811171033633865728\n",
      "TWEET                  DRGT's DGRT-46 and DRGT-47 (celecoxib reformul...\n",
      "SYNONYMS                                                       CELECOXIB\n",
      "MOLREGNO_1                                                         18694\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03026140\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME               demonstrate rapid absorption and potential\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                            Migraine Disorders\n",
      "INDICATION_ID                                                    D008881\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                      Celecoxib 200mg\n",
      "DESCRIPTIONS           celecoxib will be administered starting day 1 ...\n",
      "OTHER_NAME                                                      Celebrex\n",
      "EFO_ID                                                       EFO:1001950\n",
      "CONDITION                                                Colon Carcinoma\n",
      "MOLREGNO                                                         1153495\n",
      "NAME_TERM                                                colon carcinoma\n",
      "Name: 1212, dtype: object\n",
      "_____\n",
      "TWID                                                                2045\n",
      "TWEET_ID                                              809394183949553664\n",
      "TWEET                  Karuna's KarXT (xanomeline + trospium chloride...\n",
      "SYNONYMS                                                      XANOMELINE\n",
      "MOLREGNO_1                                                         26653\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02831231\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                           shows improved tolerability vs\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                    Overactive Urinary Bladder\n",
      "INDICATION_ID                                                    D053201\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                  xanomeline tartrate\n",
      "DESCRIPTIONS                     xanomeline tartrate, 75 mg capsule, TID\n",
      "OTHER_NAME                                                      LY246708\n",
      "EFO_ID                                                       EFO:0000692\n",
      "CONDITION                                                  Schizophrenia\n",
      "MOLREGNO                                                         1594639\n",
      "NAME_TERM                                                  schizophrenia\n",
      "Name: 1220, dtype: object\n",
      "_____\n",
      "TWID                                                                2045\n",
      "TWEET_ID                                              809394183949553664\n",
      "TWEET                  Karuna's KarXT (xanomeline + trospium chloride...\n",
      "SYNONYMS                                                      XANOMELINE\n",
      "MOLREGNO_1                                                         26653\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02831231\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                           shows improved tolerability vs\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                    Overactive Urinary Bladder\n",
      "INDICATION_ID                                                    D053201\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                  xanomeline tartrate\n",
      "DESCRIPTIONS                     xanomeline tartrate, 75 mg capsule, TID\n",
      "OTHER_NAME                                                      LY246708\n",
      "EFO_ID                                                       EFO:0000692\n",
      "CONDITION                                                  Schizophrenia\n",
      "MOLREGNO                                                         1525716\n",
      "NAME_TERM                                                  schizophrenia\n",
      "Name: 1221, dtype: object\n",
      "_____\n",
      "TWID                                                                2045\n",
      "TWEET_ID                                              809394183949553664\n",
      "TWEET                  Karuna's KarXT (xanomeline + trospium chloride...\n",
      "SYNONYMS                                               TROSPIUM CHLORIDE\n",
      "MOLREGNO_1                                                       1594639\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01166438\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                           shows improved tolerability vs\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                    Overactive Urinary Bladder\n",
      "INDICATION_ID                                                    D053201\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                    Trospium chloride\n",
      "DESCRIPTIONS           Oral Trospium chloride XR 60mg once a day for ...\n",
      "OTHER_NAME                                                      Sanctura\n",
      "EFO_ID                                                       EFO:1000781\n",
      "CONDITION                                             Overactive Bladder\n",
      "MOLREGNO                                                          675360\n",
      "NAME_TERM                                             overactive bladder\n",
      "Name: 1222, dtype: object\n",
      "_____\n",
      "TWID                                                                2045\n",
      "TWEET_ID                                              809394183949553664\n",
      "TWEET                  Karuna's KarXT (xanomeline + trospium chloride...\n",
      "SYNONYMS                                               TROSPIUM CHLORIDE\n",
      "MOLREGNO_1                                                       1594639\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01166438\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                           shows improved tolerability vs\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                    Overactive Urinary Bladder\n",
      "INDICATION_ID                                                    D053201\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                    Trospium chloride\n",
      "DESCRIPTIONS           Oral Trospium chloride XR 60mg once a day for ...\n",
      "OTHER_NAME                                                      Sanctura\n",
      "EFO_ID                                                       EFO:1000781\n",
      "CONDITION                                             Overactive Bladder\n",
      "MOLREGNO                                                          561914\n",
      "NAME_TERM                                             overactive bladder\n",
      "Name: 1223, dtype: object\n",
      "_____\n",
      "TWID                                                                2045\n",
      "TWEET_ID                                              809394183949553664\n",
      "TWEET                  Karuna's KarXT (xanomeline + trospium chloride...\n",
      "SYNONYMS                                               TROSPIUM CHLORIDE\n",
      "MOLREGNO_1                                                       1594639\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01166438\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                           shows improved tolerability vs\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                    Overactive Urinary Bladder\n",
      "INDICATION_ID                                                    D053201\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                    Trospium chloride\n",
      "DESCRIPTIONS           Oral Trospium chloride XR 60mg once a day for ...\n",
      "OTHER_NAME                                                      Sanctura\n",
      "EFO_ID                                                        HP:0000020\n",
      "CONDITION                                      Urge Urinary Incontinence\n",
      "MOLREGNO                                                          675360\n",
      "NAME_TERM                                           Urinary incontinence\n",
      "Name: 1225, dtype: object\n",
      "_____\n",
      "TWID                                                                2045\n",
      "TWEET_ID                                              809394183949553664\n",
      "TWEET                  Karuna's KarXT (xanomeline + trospium chloride...\n",
      "SYNONYMS                                               TROSPIUM CHLORIDE\n",
      "MOLREGNO_1                                                       1594639\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01166438\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                           shows improved tolerability vs\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                    Overactive Urinary Bladder\n",
      "INDICATION_ID                                                    D053201\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                    Trospium chloride\n",
      "DESCRIPTIONS           Oral Trospium chloride XR 60mg once a day for ...\n",
      "OTHER_NAME                                                      Sanctura\n",
      "EFO_ID                                                        HP:0000020\n",
      "CONDITION                                      Urge Urinary Incontinence\n",
      "MOLREGNO                                                          561914\n",
      "NAME_TERM                                           Urinary incontinence\n",
      "Name: 1226, dtype: object\n",
      "_____\n",
      "TWID                                                                2045\n",
      "TWEET_ID                                              809394183949553664\n",
      "TWEET                  Karuna's KarXT (xanomeline + trospium chloride...\n",
      "SYNONYMS                                               TROSPIUM CHLORIDE\n",
      "MOLREGNO_1                                                        674556\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01166438\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                           shows improved tolerability vs\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                    Overactive Urinary Bladder\n",
      "INDICATION_ID                                                    D053201\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                    Trospium chloride\n",
      "DESCRIPTIONS           Oral Trospium chloride XR 60mg once a day for ...\n",
      "OTHER_NAME                                                      Sanctura\n",
      "EFO_ID                                                       EFO:1000781\n",
      "CONDITION                                             Overactive Bladder\n",
      "MOLREGNO                                                          675360\n",
      "NAME_TERM                                             overactive bladder\n",
      "Name: 1228, dtype: object\n",
      "_____\n",
      "TWID                                                                2045\n",
      "TWEET_ID                                              809394183949553664\n",
      "TWEET                  Karuna's KarXT (xanomeline + trospium chloride...\n",
      "SYNONYMS                                               TROSPIUM CHLORIDE\n",
      "MOLREGNO_1                                                        674556\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01166438\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                           shows improved tolerability vs\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                    Overactive Urinary Bladder\n",
      "INDICATION_ID                                                    D053201\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                    Trospium chloride\n",
      "DESCRIPTIONS           Oral Trospium chloride XR 60mg once a day for ...\n",
      "OTHER_NAME                                                      Sanctura\n",
      "EFO_ID                                                       EFO:1000781\n",
      "CONDITION                                             Overactive Bladder\n",
      "MOLREGNO                                                          561914\n",
      "NAME_TERM                                             overactive bladder\n",
      "Name: 1229, dtype: object\n",
      "_____\n",
      "TWID                                                                2045\n",
      "TWEET_ID                                              809394183949553664\n",
      "TWEET                  Karuna's KarXT (xanomeline + trospium chloride...\n",
      "SYNONYMS                                               TROSPIUM CHLORIDE\n",
      "MOLREGNO_1                                                        674556\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01166438\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                           shows improved tolerability vs\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                    Overactive Urinary Bladder\n",
      "INDICATION_ID                                                    D053201\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                    Trospium chloride\n",
      "DESCRIPTIONS           Oral Trospium chloride XR 60mg once a day for ...\n",
      "OTHER_NAME                                                      Sanctura\n",
      "EFO_ID                                                       EFO:1000781\n",
      "CONDITION                                             Overactive Bladder\n",
      "MOLREGNO                                                         1594639\n",
      "NAME_TERM                                             overactive bladder\n",
      "Name: 1230, dtype: object\n",
      "_____\n",
      "TWID                                                                2045\n",
      "TWEET_ID                                              809394183949553664\n",
      "TWEET                  Karuna's KarXT (xanomeline + trospium chloride...\n",
      "SYNONYMS                                               TROSPIUM CHLORIDE\n",
      "MOLREGNO_1                                                        674556\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01166438\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                           shows improved tolerability vs\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                    Overactive Urinary Bladder\n",
      "INDICATION_ID                                                    D053201\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                    Trospium chloride\n",
      "DESCRIPTIONS           Oral Trospium chloride XR 60mg once a day for ...\n",
      "OTHER_NAME                                                      Sanctura\n",
      "EFO_ID                                                        HP:0000020\n",
      "CONDITION                                      Urge Urinary Incontinence\n",
      "MOLREGNO                                                          675360\n",
      "NAME_TERM                                           Urinary incontinence\n",
      "Name: 1231, dtype: object\n",
      "_____\n",
      "TWID                                                                2045\n",
      "TWEET_ID                                              809394183949553664\n",
      "TWEET                  Karuna's KarXT (xanomeline + trospium chloride...\n",
      "SYNONYMS                                               TROSPIUM CHLORIDE\n",
      "MOLREGNO_1                                                        674556\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01166438\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                           shows improved tolerability vs\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                    Overactive Urinary Bladder\n",
      "INDICATION_ID                                                    D053201\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                    Trospium chloride\n",
      "DESCRIPTIONS           Oral Trospium chloride XR 60mg once a day for ...\n",
      "OTHER_NAME                                                      Sanctura\n",
      "EFO_ID                                                        HP:0000020\n",
      "CONDITION                                      Urge Urinary Incontinence\n",
      "MOLREGNO                                                          561914\n",
      "NAME_TERM                                           Urinary incontinence\n",
      "Name: 1232, dtype: object\n",
      "_____\n",
      "TWID                                                                2045\n",
      "TWEET_ID                                              809394183949553664\n",
      "TWEET                  Karuna's KarXT (xanomeline + trospium chloride...\n",
      "SYNONYMS                                               TROSPIUM CHLORIDE\n",
      "MOLREGNO_1                                                        674556\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01166438\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                           shows improved tolerability vs\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                    Overactive Urinary Bladder\n",
      "INDICATION_ID                                                    D053201\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                    Trospium chloride\n",
      "DESCRIPTIONS           Oral Trospium chloride XR 60mg once a day for ...\n",
      "OTHER_NAME                                                      Sanctura\n",
      "EFO_ID                                                        HP:0000020\n",
      "CONDITION                                      Urge Urinary Incontinence\n",
      "MOLREGNO                                                         1594639\n",
      "NAME_TERM                                           Urinary incontinence\n",
      "Name: 1233, dtype: object\n",
      "_____\n",
      "TWID                                                                2076\n",
      "TWEET_ID                                              806243252969967616\n",
      "TWEET                  Lorlatinib displayed a potent clinical activit...\n",
      "SYNONYMS                                                      LORLATINIB\n",
      "MOLREGNO_1                                                       1757351\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03107988\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     displayed a potent clinical activity\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Lorlatinib\n",
      "DESCRIPTIONS           Lorlatinib will be given orally once daily con...\n",
      "OTHER_NAME                                                    PF06463922\n",
      "EFO_ID                                                       EFO:0000621\n",
      "CONDITION                                                  Neuroblastoma\n",
      "MOLREGNO                                                          674747\n",
      "NAME_TERM                                                  neuroblastoma\n",
      "Name: 1244, dtype: object\n",
      "_____\n",
      "TWID                                                                2076\n",
      "TWEET_ID                                              806243252969967616\n",
      "TWEET                  Lorlatinib displayed a potent clinical activit...\n",
      "SYNONYMS                                                      LORLATINIB\n",
      "MOLREGNO_1                                                       1757351\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03107988\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     displayed a potent clinical activity\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Lorlatinib\n",
      "DESCRIPTIONS           Lorlatinib will be given orally once daily con...\n",
      "OTHER_NAME                                                    PF06463922\n",
      "EFO_ID                                                       EFO:0000621\n",
      "CONDITION                                                  Neuroblastoma\n",
      "MOLREGNO                                                          456266\n",
      "NAME_TERM                                                  neuroblastoma\n",
      "Name: 1246, dtype: object\n",
      "_____\n",
      "TWID                                                                2088\n",
      "TWEET_ID                                              806028434036047872\n",
      "TWEET                  Matinas BioPharma begins phase I trial of anti...\n",
      "SYNONYMS                                                        AMIKACIN\n",
      "MOLREGNO_1                                                        333157\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03149640\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                       begins phase trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                         Chronic Obstructive Pulmonary Disease\n",
      "INDICATION_ID                                                    D029424\n",
      "INDICATION_NONAMBIG                                                    2\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                     Inhaled amikacin\n",
      "DESCRIPTIONS           Once a day, inhaled amikacin at day 4, day 5 a...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:1001865\n",
      "CONDITION                               Pneumonia, Ventilator-Associated\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                ventilator-associated pneumonia\n",
      "Name: 1249, dtype: object\n",
      "_____\n",
      "TWID                                                                2089\n",
      "TWEET_ID                                              806026278881005568\n",
      "TWEET                  Cerecor's selective kappa opioid receptor anta...\n",
      "SYNONYMS                                                        NICOTINE\n",
      "MOLREGNO_1                                                           115\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03163303\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              trial fails\n",
      "COMPANY                                                          cerecor\n",
      "COMPANY_ID                                                     COMP92596\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                       nicotine patch\n",
      "DESCRIPTIONS                             14-day supply of nicotine patch\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0003768\n",
      "CONDITION                                                        Smoking\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                            nicotine dependence\n",
      "Name: 1252, dtype: object\n",
      "_____\n",
      "TWID                                                                2090\n",
      "TWEET_ID                                              805907578798489601\n",
      "TWEET                  NEOD001 improved peripheral neuropathy in AL a...\n",
      "SYNONYMS                                                         NEOD001\n",
      "MOLREGNO_1                                                       2096396\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03168906\n",
      "PHASE                                                          Phase 1/2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                        82% response rate\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                  Primary Systemic Amyloidosis\n",
      "INDICATION_ID                                                    DX90345\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                              NEOD001\n",
      "DESCRIPTIONS           NEOD001 is a monoclonal antibody directed at s...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:1001875\n",
      "CONDITION                                                    Amyloidosis\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                    amyloidosis\n",
      "Name: 1253, dtype: object\n",
      "_____\n",
      "TWID                                                                2105\n",
      "TWEET_ID                                              805730876315213825\n",
      "TWEET                  ReNeuron reports positive phase II results for...\n",
      "SYNONYMS                                                             CTX\n",
      "MOLREGNO_1                                                        993371\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03417154\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                         Positive results\n",
      "COMPANY                                                         ReNeuron\n",
      "COMPANY_ID                                                     COMP91026\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                        Stroke\n",
      "INDICATION_ID                                                    D020521\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x       Stage 1 Arm 1: Low dose Cyclophosphamide (CTX)\n",
      "DESCRIPTIONS           Oral cyclophosphamide 50mg + nivolumab 3 mg/kg...\n",
      "OTHER_NAME                                                           CTX\n",
      "EFO_ID                                                       EFO:0000222\n",
      "CONDITION                                         Acute Myeloid Leukemia\n",
      "MOLREGNO                                                          674747\n",
      "NAME_TERM                                         acute myeloid leukemia\n",
      "Name: 1262, dtype: object\n",
      "_____\n",
      "TWID                                                                2105\n",
      "TWEET_ID                                              805730876315213825\n",
      "TWEET                  ReNeuron reports positive phase II results for...\n",
      "SYNONYMS                                                             CTX\n",
      "MOLREGNO_1                                                        993371\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03417154\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                         Positive results\n",
      "COMPANY                                                         ReNeuron\n",
      "COMPANY_ID                                                     COMP91026\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                        Stroke\n",
      "INDICATION_ID                                                    D020521\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x       Stage 1 Arm 1: Low dose Cyclophosphamide (CTX)\n",
      "DESCRIPTIONS           Oral cyclophosphamide 50mg + nivolumab 3 mg/kg...\n",
      "OTHER_NAME                                                           CTX\n",
      "EFO_ID                                                       EFO:0000222\n",
      "CONDITION                                         Acute Myeloid Leukemia\n",
      "MOLREGNO                                                         1381004\n",
      "NAME_TERM                                         acute myeloid leukemia\n",
      "Name: 1263, dtype: object\n",
      "_____\n",
      "TWID                                                                2105\n",
      "TWEET_ID                                              805730876315213825\n",
      "TWEET                  ReNeuron reports positive phase II results for...\n",
      "SYNONYMS                                                             CTX\n",
      "MOLREGNO_1                                                        993371\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03417154\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                         Positive results\n",
      "COMPANY                                                         ReNeuron\n",
      "COMPANY_ID                                                     COMP91026\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                        Stroke\n",
      "INDICATION_ID                                                    D020521\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x       Stage 1 Arm 1: Low dose Cyclophosphamide (CTX)\n",
      "DESCRIPTIONS           Oral cyclophosphamide 50mg + nivolumab 3 mg/kg...\n",
      "OTHER_NAME                                                           CTX\n",
      "EFO_ID                                                       EFO:0000198\n",
      "CONDITION                           Higher Risk Myelodysplastic Syndrome\n",
      "MOLREGNO                                                          674747\n",
      "NAME_TERM                                       myelodysplastic syndrome\n",
      "Name: 1264, dtype: object\n",
      "_____\n",
      "TWID                                                                2105\n",
      "TWEET_ID                                              805730876315213825\n",
      "TWEET                  ReNeuron reports positive phase II results for...\n",
      "SYNONYMS                                                             CTX\n",
      "MOLREGNO_1                                                        993371\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03417154\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                         Positive results\n",
      "COMPANY                                                         ReNeuron\n",
      "COMPANY_ID                                                     COMP91026\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                        Stroke\n",
      "INDICATION_ID                                                    D020521\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x       Stage 1 Arm 1: Low dose Cyclophosphamide (CTX)\n",
      "DESCRIPTIONS           Oral cyclophosphamide 50mg + nivolumab 3 mg/kg...\n",
      "OTHER_NAME                                                           CTX\n",
      "EFO_ID                                                       EFO:0000198\n",
      "CONDITION                           Higher Risk Myelodysplastic Syndrome\n",
      "MOLREGNO                                                         1381004\n",
      "NAME_TERM                                       myelodysplastic syndrome\n",
      "Name: 1265, dtype: object\n",
      "_____\n",
      "TWID                                                                2105\n",
      "TWEET_ID                                              805730876315213825\n",
      "TWEET                  ReNeuron reports positive phase II results for...\n",
      "SYNONYMS                                                             CTX\n",
      "MOLREGNO_1                                                        993371\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03417154\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                         Positive results\n",
      "COMPANY                                                         ReNeuron\n",
      "COMPANY_ID                                                     COMP91026\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                        Stroke\n",
      "INDICATION_ID                                                    D020521\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x       Stage 1 Arm 2: Low dose Cyclophosphamide (CTX)\n",
      "DESCRIPTIONS           Oral cyclophosphamide 350 mg every 7 days + ni...\n",
      "OTHER_NAME                                                           CTX\n",
      "EFO_ID                                                       EFO:0000222\n",
      "CONDITION                                         Acute Myeloid Leukemia\n",
      "MOLREGNO                                                          674747\n",
      "NAME_TERM                                         acute myeloid leukemia\n",
      "Name: 1266, dtype: object\n",
      "_____\n",
      "TWID                                                                2105\n",
      "TWEET_ID                                              805730876315213825\n",
      "TWEET                  ReNeuron reports positive phase II results for...\n",
      "SYNONYMS                                                             CTX\n",
      "MOLREGNO_1                                                        993371\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03417154\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                         Positive results\n",
      "COMPANY                                                         ReNeuron\n",
      "COMPANY_ID                                                     COMP91026\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                        Stroke\n",
      "INDICATION_ID                                                    D020521\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x       Stage 1 Arm 2: Low dose Cyclophosphamide (CTX)\n",
      "DESCRIPTIONS           Oral cyclophosphamide 350 mg every 7 days + ni...\n",
      "OTHER_NAME                                                           CTX\n",
      "EFO_ID                                                       EFO:0000222\n",
      "CONDITION                                         Acute Myeloid Leukemia\n",
      "MOLREGNO                                                         1381004\n",
      "NAME_TERM                                         acute myeloid leukemia\n",
      "Name: 1267, dtype: object\n",
      "_____\n",
      "TWID                                                                2105\n",
      "TWEET_ID                                              805730876315213825\n",
      "TWEET                  ReNeuron reports positive phase II results for...\n",
      "SYNONYMS                                                             CTX\n",
      "MOLREGNO_1                                                        993371\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03417154\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                         Positive results\n",
      "COMPANY                                                         ReNeuron\n",
      "COMPANY_ID                                                     COMP91026\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                        Stroke\n",
      "INDICATION_ID                                                    D020521\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x       Stage 1 Arm 2: Low dose Cyclophosphamide (CTX)\n",
      "DESCRIPTIONS           Oral cyclophosphamide 350 mg every 7 days + ni...\n",
      "OTHER_NAME                                                           CTX\n",
      "EFO_ID                                                       EFO:0000198\n",
      "CONDITION                           Higher Risk Myelodysplastic Syndrome\n",
      "MOLREGNO                                                          674747\n",
      "NAME_TERM                                       myelodysplastic syndrome\n",
      "Name: 1268, dtype: object\n",
      "_____\n",
      "TWID                                                                2105\n",
      "TWEET_ID                                              805730876315213825\n",
      "TWEET                  ReNeuron reports positive phase II results for...\n",
      "SYNONYMS                                                             CTX\n",
      "MOLREGNO_1                                                        993371\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03417154\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                         Positive results\n",
      "COMPANY                                                         ReNeuron\n",
      "COMPANY_ID                                                     COMP91026\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                        Stroke\n",
      "INDICATION_ID                                                    D020521\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x       Stage 1 Arm 2: Low dose Cyclophosphamide (CTX)\n",
      "DESCRIPTIONS           Oral cyclophosphamide 350 mg every 7 days + ni...\n",
      "OTHER_NAME                                                           CTX\n",
      "EFO_ID                                                       EFO:0000198\n",
      "CONDITION                           Higher Risk Myelodysplastic Syndrome\n",
      "MOLREGNO                                                         1381004\n",
      "NAME_TERM                                       myelodysplastic syndrome\n",
      "Name: 1269, dtype: object\n",
      "_____\n",
      "TWID                                                                2105\n",
      "TWEET_ID                                              805730876315213825\n",
      "TWEET                  ReNeuron reports positive phase II results for...\n",
      "SYNONYMS                                                             CTX\n",
      "MOLREGNO_1                                                        993371\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03417154\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                         Positive results\n",
      "COMPANY                                                         ReNeuron\n",
      "COMPANY_ID                                                     COMP91026\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                        Stroke\n",
      "INDICATION_ID                                                    D020521\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x             Stage 2: Low dose Cyclophosphamide (CTX)\n",
      "DESCRIPTIONS           Stage 2: Oral cyclophosphamide as assigned for...\n",
      "OTHER_NAME                                                           CTX\n",
      "EFO_ID                                                       EFO:0000222\n",
      "CONDITION                                         Acute Myeloid Leukemia\n",
      "MOLREGNO                                                          674747\n",
      "NAME_TERM                                         acute myeloid leukemia\n",
      "Name: 1270, dtype: object\n",
      "_____\n",
      "TWID                                                                2105\n",
      "TWEET_ID                                              805730876315213825\n",
      "TWEET                  ReNeuron reports positive phase II results for...\n",
      "SYNONYMS                                                             CTX\n",
      "MOLREGNO_1                                                        993371\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03417154\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                         Positive results\n",
      "COMPANY                                                         ReNeuron\n",
      "COMPANY_ID                                                     COMP91026\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                        Stroke\n",
      "INDICATION_ID                                                    D020521\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x             Stage 2: Low dose Cyclophosphamide (CTX)\n",
      "DESCRIPTIONS           Stage 2: Oral cyclophosphamide as assigned for...\n",
      "OTHER_NAME                                                           CTX\n",
      "EFO_ID                                                       EFO:0000222\n",
      "CONDITION                                         Acute Myeloid Leukemia\n",
      "MOLREGNO                                                         1381004\n",
      "NAME_TERM                                         acute myeloid leukemia\n",
      "Name: 1271, dtype: object\n",
      "_____\n",
      "TWID                                                                2105\n",
      "TWEET_ID                                              805730876315213825\n",
      "TWEET                  ReNeuron reports positive phase II results for...\n",
      "SYNONYMS                                                             CTX\n",
      "MOLREGNO_1                                                        993371\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03417154\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                         Positive results\n",
      "COMPANY                                                         ReNeuron\n",
      "COMPANY_ID                                                     COMP91026\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                        Stroke\n",
      "INDICATION_ID                                                    D020521\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x             Stage 2: Low dose Cyclophosphamide (CTX)\n",
      "DESCRIPTIONS           Stage 2: Oral cyclophosphamide as assigned for...\n",
      "OTHER_NAME                                                           CTX\n",
      "EFO_ID                                                       EFO:0000198\n",
      "CONDITION                           Higher Risk Myelodysplastic Syndrome\n",
      "MOLREGNO                                                          674747\n",
      "NAME_TERM                                       myelodysplastic syndrome\n",
      "Name: 1272, dtype: object\n",
      "_____\n",
      "TWID                                                                2105\n",
      "TWEET_ID                                              805730876315213825\n",
      "TWEET                  ReNeuron reports positive phase II results for...\n",
      "SYNONYMS                                                             CTX\n",
      "MOLREGNO_1                                                        993371\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03417154\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                         Positive results\n",
      "COMPANY                                                         ReNeuron\n",
      "COMPANY_ID                                                     COMP91026\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                        Stroke\n",
      "INDICATION_ID                                                    D020521\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x             Stage 2: Low dose Cyclophosphamide (CTX)\n",
      "DESCRIPTIONS           Stage 2: Oral cyclophosphamide as assigned for...\n",
      "OTHER_NAME                                                           CTX\n",
      "EFO_ID                                                       EFO:0000198\n",
      "CONDITION                           Higher Risk Myelodysplastic Syndrome\n",
      "MOLREGNO                                                         1381004\n",
      "NAME_TERM                                       myelodysplastic syndrome\n",
      "Name: 1273, dtype: object\n",
      "_____\n",
      "TWID                                                                2123\n",
      "TWEET_ID                                              804646924615696384\n",
      "TWEET                  Ensysce Biosciences begins phase I trials of  ...\n",
      "SYNONYMS                                                       OXYCODONE\n",
      "MOLREGNO_1                                                         27624\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03415555\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                      begins phase trials\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Pain\n",
      "INDICATION_ID                                                    D010146\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Oxycodone\n",
      "DESCRIPTIONS           Each patient, before the end of surgery, will ...\n",
      "OTHER_NAME                                            PCA with oxycodone\n",
      "EFO_ID                                                       EFO:0003843\n",
      "CONDITION                                             Postoperative Pain\n",
      "MOLREGNO                                                           16450\n",
      "NAME_TERM                                                           pain\n",
      "Name: 1296, dtype: object\n",
      "_____\n",
      "TWID                                                                2123\n",
      "TWEET_ID                                              804646924615696384\n",
      "TWEET                  Ensysce Biosciences begins phase I trials of  ...\n",
      "SYNONYMS                                                       OXYCODONE\n",
      "MOLREGNO_1                                                         27624\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03415555\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                      begins phase trials\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Pain\n",
      "INDICATION_ID                                                    D010146\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Oxycodone\n",
      "DESCRIPTIONS           Each patient, before the end of surgery, will ...\n",
      "OTHER_NAME                                            PCA with oxycodone\n",
      "EFO_ID                                                          -ABSENT-\n",
      "CONDITION                                           Mitral Valve Disease\n",
      "MOLREGNO                                                           16450\n",
      "NAME_TERM                                                            NaN\n",
      "Name: 1298, dtype: object\n",
      "_____\n",
      "TWID                                                                2137\n",
      "TWEET_ID                                              804258890879635456\n",
      "TWEET                  Pfizer's Herceptin biosimilar PF-05280014 meet...\n",
      "SYNONYMS                                                       HERCEPTIN\n",
      "MOLREGNO_1                                                        675581\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                   meets primary endpoint\n",
      "COMPANY                                                           Pfizer\n",
      "COMPANY_ID                                                       COMP570\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Trastuzumab\n",
      "DESCRIPTIONS           Loading dose 8 mg/kg, then 6 mg/kg, intravenou...\n",
      "OTHER_NAME                                                     Herceptin\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                          674747\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1307, dtype: object\n",
      "_____\n",
      "TWID                                                                2137\n",
      "TWEET_ID                                              804258890879635456\n",
      "TWEET                  Pfizer's Herceptin biosimilar PF-05280014 meet...\n",
      "SYNONYMS                                                       HERCEPTIN\n",
      "MOLREGNO_1                                                        675581\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                   meets primary endpoint\n",
      "COMPANY                                                           Pfizer\n",
      "COMPANY_ID                                                       COMP570\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Trastuzumab\n",
      "DESCRIPTIONS           Loading dose 8 mg/kg, then 6 mg/kg, intravenou...\n",
      "OTHER_NAME                                                     Herceptin\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                           78759\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1308, dtype: object\n",
      "_____\n",
      "TWID                                                                2137\n",
      "TWEET_ID                                              804258890879635456\n",
      "TWEET                  Pfizer's Herceptin biosimilar PF-05280014 meet...\n",
      "SYNONYMS                                                       HERCEPTIN\n",
      "MOLREGNO_1                                                        675581\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                   meets primary endpoint\n",
      "COMPANY                                                           Pfizer\n",
      "COMPANY_ID                                                       COMP570\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Trastuzumab\n",
      "DESCRIPTIONS           Loading dose 8 mg/kg, then 6 mg/kg, intravenou...\n",
      "OTHER_NAME                                                     Herceptin\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                          675363\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1309, dtype: object\n",
      "_____\n",
      "TWID                                                                2137\n",
      "TWEET_ID                                              804258890879635456\n",
      "TWEET                  Pfizer's Herceptin biosimilar PF-05280014 meet...\n",
      "SYNONYMS                                                       HERCEPTIN\n",
      "MOLREGNO_1                                                        675581\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                   meets primary endpoint\n",
      "COMPANY                                                           Pfizer\n",
      "COMPANY_ID                                                       COMP570\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Trastuzumab\n",
      "DESCRIPTIONS           Loading dose 8 mg/kg, then 6 mg/kg, intravenou...\n",
      "OTHER_NAME                                                     Herceptin\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                          675434\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1310, dtype: object\n",
      "_____\n",
      "TWID                                                                2137\n",
      "TWEET_ID                                              804258890879635456\n",
      "TWEET                  Pfizer's Herceptin biosimilar PF-05280014 meet...\n",
      "SYNONYMS                                                       HERCEPTIN\n",
      "MOLREGNO_1                                                        675581\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                   meets primary endpoint\n",
      "COMPANY                                                           Pfizer\n",
      "COMPANY_ID                                                       COMP570\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Trastuzumab\n",
      "DESCRIPTIONS           Loading dose 8 mg/kg, then 6 mg/kg, intravenou...\n",
      "OTHER_NAME                                                     Herceptin\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                          365281\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1311, dtype: object\n",
      "_____\n",
      "TWID                                                                2137\n",
      "TWEET_ID                                              804258890879635456\n",
      "TWEET                  Pfizer's Herceptin biosimilar PF-05280014 meet...\n",
      "SYNONYMS                                                       HERCEPTIN\n",
      "MOLREGNO_1                                                        675581\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                   meets primary endpoint\n",
      "COMPANY                                                           Pfizer\n",
      "COMPANY_ID                                                       COMP570\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Trastuzumab\n",
      "DESCRIPTIONS           Loading dose 8 mg/kg, then 6 mg/kg, intravenou...\n",
      "OTHER_NAME                                                     Herceptin\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                           14805\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1312, dtype: object\n",
      "_____\n",
      "TWID                                                                2137\n",
      "TWEET_ID                                              804258890879635456\n",
      "TWEET                  Pfizer's Herceptin biosimilar PF-05280014 meet...\n",
      "SYNONYMS                                                       HERCEPTIN\n",
      "MOLREGNO_1                                                        675581\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                   meets primary endpoint\n",
      "COMPANY                                                           Pfizer\n",
      "COMPANY_ID                                                       COMP570\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Trastuzumab\n",
      "DESCRIPTIONS           Loading dose 8 mg/kg, then 6 mg/kg, intravenou...\n",
      "OTHER_NAME                                                     Herceptin\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                         1927101\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1313, dtype: object\n",
      "_____\n",
      "TWID                                                                2137\n",
      "TWEET_ID                                              804258890879635456\n",
      "TWEET                  Pfizer's Herceptin biosimilar PF-05280014 meet...\n",
      "SYNONYMS                                                       HERCEPTIN\n",
      "MOLREGNO_1                                                        675581\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                   meets primary endpoint\n",
      "COMPANY                                                           Pfizer\n",
      "COMPANY_ID                                                       COMP570\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Trastuzumab\n",
      "DESCRIPTIONS           Loading dose 8 mg/kg, then 6 mg/kg, intravenou...\n",
      "OTHER_NAME                                                     Herceptin\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                       Metastatic Breast Cancer\n",
      "MOLREGNO                                                          674747\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1315, dtype: object\n",
      "_____\n",
      "TWID                                                                2137\n",
      "TWEET_ID                                              804258890879635456\n",
      "TWEET                  Pfizer's Herceptin biosimilar PF-05280014 meet...\n",
      "SYNONYMS                                                       HERCEPTIN\n",
      "MOLREGNO_1                                                        675581\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                   meets primary endpoint\n",
      "COMPANY                                                           Pfizer\n",
      "COMPANY_ID                                                       COMP570\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Trastuzumab\n",
      "DESCRIPTIONS           Loading dose 8 mg/kg, then 6 mg/kg, intravenou...\n",
      "OTHER_NAME                                                     Herceptin\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                       Metastatic Breast Cancer\n",
      "MOLREGNO                                                           78759\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1316, dtype: object\n",
      "_____\n",
      "TWID                                                                2137\n",
      "TWEET_ID                                              804258890879635456\n",
      "TWEET                  Pfizer's Herceptin biosimilar PF-05280014 meet...\n",
      "SYNONYMS                                                       HERCEPTIN\n",
      "MOLREGNO_1                                                        675581\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                   meets primary endpoint\n",
      "COMPANY                                                           Pfizer\n",
      "COMPANY_ID                                                       COMP570\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Trastuzumab\n",
      "DESCRIPTIONS           Loading dose 8 mg/kg, then 6 mg/kg, intravenou...\n",
      "OTHER_NAME                                                     Herceptin\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                       Metastatic Breast Cancer\n",
      "MOLREGNO                                                          675363\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1317, dtype: object\n",
      "_____\n",
      "TWID                                                                2137\n",
      "TWEET_ID                                              804258890879635456\n",
      "TWEET                  Pfizer's Herceptin biosimilar PF-05280014 meet...\n",
      "SYNONYMS                                                       HERCEPTIN\n",
      "MOLREGNO_1                                                        675581\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                   meets primary endpoint\n",
      "COMPANY                                                           Pfizer\n",
      "COMPANY_ID                                                       COMP570\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Trastuzumab\n",
      "DESCRIPTIONS           Loading dose 8 mg/kg, then 6 mg/kg, intravenou...\n",
      "OTHER_NAME                                                     Herceptin\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                       Metastatic Breast Cancer\n",
      "MOLREGNO                                                          675434\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1318, dtype: object\n",
      "_____\n",
      "TWID                                                                2137\n",
      "TWEET_ID                                              804258890879635456\n",
      "TWEET                  Pfizer's Herceptin biosimilar PF-05280014 meet...\n",
      "SYNONYMS                                                       HERCEPTIN\n",
      "MOLREGNO_1                                                        675581\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                   meets primary endpoint\n",
      "COMPANY                                                           Pfizer\n",
      "COMPANY_ID                                                       COMP570\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Trastuzumab\n",
      "DESCRIPTIONS           Loading dose 8 mg/kg, then 6 mg/kg, intravenou...\n",
      "OTHER_NAME                                                     Herceptin\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                       Metastatic Breast Cancer\n",
      "MOLREGNO                                                          365281\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1319, dtype: object\n",
      "_____\n",
      "TWID                                                                2137\n",
      "TWEET_ID                                              804258890879635456\n",
      "TWEET                  Pfizer's Herceptin biosimilar PF-05280014 meet...\n",
      "SYNONYMS                                                       HERCEPTIN\n",
      "MOLREGNO_1                                                        675581\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                   meets primary endpoint\n",
      "COMPANY                                                           Pfizer\n",
      "COMPANY_ID                                                       COMP570\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Trastuzumab\n",
      "DESCRIPTIONS           Loading dose 8 mg/kg, then 6 mg/kg, intravenou...\n",
      "OTHER_NAME                                                     Herceptin\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                       Metastatic Breast Cancer\n",
      "MOLREGNO                                                           14805\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1320, dtype: object\n",
      "_____\n",
      "TWID                                                                2137\n",
      "TWEET_ID                                              804258890879635456\n",
      "TWEET                  Pfizer's Herceptin biosimilar PF-05280014 meet...\n",
      "SYNONYMS                                                       HERCEPTIN\n",
      "MOLREGNO_1                                                        675581\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                   meets primary endpoint\n",
      "COMPANY                                                           Pfizer\n",
      "COMPANY_ID                                                       COMP570\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Trastuzumab\n",
      "DESCRIPTIONS           Loading dose 8 mg/kg, then 6 mg/kg, intravenou...\n",
      "OTHER_NAME                                                     Herceptin\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                       Metastatic Breast Cancer\n",
      "MOLREGNO                                                         1927101\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1321, dtype: object\n",
      "_____\n",
      "TWID                                                                2158\n",
      "TWEET_ID                                              803573673084846081\n",
      "TWEET                  Nivalis' cavosonstat fails to meet efficacy pr...\n",
      "SYNONYMS                                                     CAVOSONSTAT\n",
      "MOLREGNO_1                                                       2197781\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02500667\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              trial fails\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                               Cystic Fibrosis\n",
      "INDICATION_ID                                                    D003550\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                               N91115\n",
      "DESCRIPTIONS                                                  200 mg BID\n",
      "OTHER_NAME                                                   Cavosonstat\n",
      "EFO_ID                                                   -NOT-CONDITION-\n",
      "CONDITION                                  Drug Interaction Potentiation\n",
      "MOLREGNO                                                          365189\n",
      "NAME_TERM                                                            NaN\n",
      "Name: 1331, dtype: object\n",
      "_____\n",
      "TWID                                                                2169\n",
      "TWEET_ID                                              801749046729658368\n",
      "TWEET                  Eli Lilly &amp Co's Solanezumab failed phase I...\n",
      "SYNONYMS                                                     SOLANEZUMAB\n",
      "MOLREGNO_1                                                       1121943\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01127633\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                             Trial failed\n",
      "COMPANY                                                        Eli Lilly\n",
      "COMPANY_ID                                                       COMP234\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                             Alzheimer Disease\n",
      "INDICATION_ID                                                    D000544\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Solanezumab\n",
      "DESCRIPTIONS           400 mg of solanezumab administered once every ...\n",
      "OTHER_NAME                                                     LY2062430\n",
      "EFO_ID                                                       EFO:0000249\n",
      "CONDITION                                            Alzheimer's Disease\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                            Alzheimer's disease\n",
      "Name: 1335, dtype: object\n",
      "_____\n",
      "TWID                                                                2171\n",
      "TWEET_ID                                              801727363839041537\n",
      "TWEET                  Juno Therapeutics places phase II trial of JCA...\n",
      "SYNONYMS                                                         JCAR015\n",
      "MOLREGNO_1                                                       2197891\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02535364\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          STOPPED\n",
      "MATCHED_OUTCOME                                     places clinical hold\n",
      "COMPANY                                                Juno Therapeutics\n",
      "COMPANY_ID                                                     COMP93827\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                   Brain Edema\n",
      "INDICATION_ID                                                    D001929\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                             Biological\n",
      "INTERVENTION_NAME_x                  JCAR015 (CD19-targeted CAR T cells)\n",
      "DESCRIPTIONS           Part A: Following leukapheresis and concurrent...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000220\n",
      "CONDITION                                   Acute Lymphoblastic Leukemia\n",
      "MOLREGNO                                                            Null\n",
      "NAME_TERM                                   acute lymphoblastic leukemia\n",
      "Name: 1336, dtype: object\n",
      "_____\n",
      "TWID                                                                2172\n",
      "TWEET_ID                                              801477566104076288\n",
      "TWEET                  Galapagos earns $50m milestone payment from Gi...\n",
      "SYNONYMS                                                      FILGOTINIB\n",
      "MOLREGNO_1                                                       1763569\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03025308\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                              N/I\n",
      "MATCHED_OUTCOME                                      milestone triggered\n",
      "COMPANY                                                           Gilead\n",
      "COMPANY_ID                                                       COMP284\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                 Crohn Disease\n",
      "INDICATION_ID                                                    D003424\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Filgotinib\n",
      "DESCRIPTIONS                    Tablet(s) administered orally once daily\n",
      "OTHER_NAME                                              GS-6034;GLPG0634\n",
      "EFO_ID                                                       EFO:0000685\n",
      "CONDITION                                           RheumatoId Arthritis\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                           rheumatoid arthritis\n",
      "Name: 1338, dtype: object\n",
      "_____\n",
      "TWID                                                                2172\n",
      "TWEET_ID                                              801477566104076288\n",
      "TWEET                  Galapagos earns $50m milestone payment from Gi...\n",
      "SYNONYMS                                                      FILGOTINIB\n",
      "MOLREGNO_1                                                       1763569\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03025308\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                              N/I\n",
      "MATCHED_OUTCOME                                      milestone triggered\n",
      "COMPANY                                                           Gilead\n",
      "COMPANY_ID                                                       COMP284\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                 Crohn Disease\n",
      "INDICATION_ID                                                    D003424\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                          Placebo to match filgotinib\n",
      "DESCRIPTIONS                    Tablet(s) administered orally once daily\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000685\n",
      "CONDITION                                           RheumatoId Arthritis\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                           rheumatoid arthritis\n",
      "Name: 1340, dtype: object\n",
      "_____\n",
      "TWID                                                                2187\n",
      "TWEET_ID                                              799717189037105152\n",
      "TWEET                  Sevelamer carbonate (Sanofi Genzyme's Renvela)...\n",
      "SYNONYMS                                                       SEVELAMER\n",
      "MOLREGNO_1                                                        675749\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03451019\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                          seen to be safe\n",
      "COMPANY                                                          Genzyme\n",
      "COMPANY_ID                                                       COMP282\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                             Hyperphosphatemia\n",
      "INDICATION_ID                                                    D054559\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                              Sevelamer Hydrochloride\n",
      "DESCRIPTIONS           Single oral doses of lanthanum (1000 mg) or Se...\n",
      "OTHER_NAME                                                       Renagel\n",
      "EFO_ID                                                       EFO:0003884\n",
      "CONDITION                                         Chronic Kidney Disease\n",
      "MOLREGNO                                                         1369656\n",
      "NAME_TERM                                         chronic kidney disease\n",
      "Name: 1343, dtype: object\n",
      "_____\n",
      "TWID                                                                2187\n",
      "TWEET_ID                                              799717189037105152\n",
      "TWEET                  Sevelamer carbonate (Sanofi Genzyme's Renvela)...\n",
      "SYNONYMS                                                       SEVELAMER\n",
      "MOLREGNO_1                                                        675749\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03451019\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                          seen to be safe\n",
      "COMPANY                                                          Genzyme\n",
      "COMPANY_ID                                                       COMP282\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                             Hyperphosphatemia\n",
      "INDICATION_ID                                                    D054559\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                              Sevelamer Hydrochloride\n",
      "DESCRIPTIONS           Single oral doses of lanthanum (1000 mg) or Se...\n",
      "OTHER_NAME                                                       Renagel\n",
      "EFO_ID                                                       EFO:0003884\n",
      "CONDITION                                         Chronic Kidney Disease\n",
      "MOLREGNO                                                          675495\n",
      "NAME_TERM                                         chronic kidney disease\n",
      "Name: 1344, dtype: object\n",
      "_____\n",
      "TWID                                                                2187\n",
      "TWEET_ID                                              799717189037105152\n",
      "TWEET                  Sevelamer carbonate (Sanofi Genzyme's Renvela)...\n",
      "SYNONYMS                                                         RENVELA\n",
      "MOLREGNO_1                                                        675749\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01308242\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                          seen to be safe\n",
      "COMPANY                                                          Genzyme\n",
      "COMPANY_ID                                                       COMP282\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                             Hyperphosphatemia\n",
      "INDICATION_ID                                                    D054559\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                  Sevelamer Carbonate\n",
      "DESCRIPTIONS           Sevelamer 800 mg by mouth three times daily wi...\n",
      "OTHER_NAME                                                       Renvela\n",
      "EFO_ID                                                       EFO:0003884\n",
      "CONDITION                                         Chronic Kidney Disease\n",
      "MOLREGNO                                                          675750\n",
      "NAME_TERM                                         chronic kidney disease\n",
      "Name: 1346, dtype: object\n",
      "_____\n",
      "TWID                                                                2191\n",
      "TWEET_ID                                              799235688461762560\n",
      "TWEET                  Lack of efficacy causes half of phase II and p...\n",
      "SYNONYMS                                                          NATURE\n",
      "MOLREGNO_1                                                       1381144\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03081949\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         Lack of efficacy\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x         Oral Sodium Selenite 200 µg/day for 3 months\n",
      "DESCRIPTIONS           PPCM patients with selenium deficiency, who ha...\n",
      "OTHER_NAME                                  Nature's way Selenium 200mcg\n",
      "EFO_ID                                                       EFO:0002628\n",
      "CONDITION                                      Peripartum Cardiomyopathy\n",
      "MOLREGNO                                                          185238\n",
      "NAME_TERM                                      peripartum cardiomyopathy\n",
      "Name: 1348, dtype: object\n",
      "_____\n",
      "TWID                                                                2193\n",
      "TWEET_ID                                              799199484437823488\n",
      "TWEET                  Boehringer Ingelheim's bevacizumab biosimilar ...\n",
      "SYNONYMS                                                     BEVACIZUMAB\n",
      "MOLREGNO_1                                                        675483\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      SIM IN COMP\n",
      "MATCHED_OUTCOME                              Demonstrates bioequivalence\n",
      "COMPANY                                             Boehringer-Ingelheim\n",
      "COMPANY_ID                                                       COMP136\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                 Macular Edema\n",
      "INDICATION_ID                                                    D008269\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                             Biological\n",
      "INTERVENTION_NAME_x                                          bevacizumab\n",
      "DESCRIPTIONS                 Recombinant human anti-VEGF IgG1 monoclonal\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                          675089\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1350, dtype: object\n",
      "_____\n",
      "TWID                                                                2193\n",
      "TWEET_ID                                              799199484437823488\n",
      "TWEET                  Boehringer Ingelheim's bevacizumab biosimilar ...\n",
      "SYNONYMS                                                     BEVACIZUMAB\n",
      "MOLREGNO_1                                                        675483\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      SIM IN COMP\n",
      "MATCHED_OUTCOME                              Demonstrates bioequivalence\n",
      "COMPANY                                             Boehringer-Ingelheim\n",
      "COMPANY_ID                                                       COMP136\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                 Macular Edema\n",
      "INDICATION_ID                                                    D008269\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                             Biological\n",
      "INTERVENTION_NAME_x                                          bevacizumab\n",
      "DESCRIPTIONS                 Recombinant human anti-VEGF IgG1 monoclonal\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                            8062\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1351, dtype: object\n",
      "_____\n",
      "TWID                                                                2193\n",
      "TWEET_ID                                              799199484437823488\n",
      "TWEET                  Boehringer Ingelheim's bevacizumab biosimilar ...\n",
      "SYNONYMS                                                     BEVACIZUMAB\n",
      "MOLREGNO_1                                                        675483\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      SIM IN COMP\n",
      "MATCHED_OUTCOME                              Demonstrates bioequivalence\n",
      "COMPANY                                             Boehringer-Ingelheim\n",
      "COMPANY_ID                                                       COMP136\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                 Macular Edema\n",
      "INDICATION_ID                                                    D008269\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                             Biological\n",
      "INTERVENTION_NAME_x                                          bevacizumab\n",
      "DESCRIPTIONS                 Recombinant human anti-VEGF IgG1 monoclonal\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                         1380097\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1352, dtype: object\n",
      "_____\n",
      "TWID                                                                2193\n",
      "TWEET_ID                                              799199484437823488\n",
      "TWEET                  Boehringer Ingelheim's bevacizumab biosimilar ...\n",
      "SYNONYMS                                                     BEVACIZUMAB\n",
      "MOLREGNO_1                                                        675483\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      SIM IN COMP\n",
      "MATCHED_OUTCOME                              Demonstrates bioequivalence\n",
      "COMPANY                                             Boehringer-Ingelheim\n",
      "COMPANY_ID                                                       COMP136\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                 Macular Edema\n",
      "INDICATION_ID                                                    D008269\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                             Biological\n",
      "INTERVENTION_NAME_x                                          bevacizumab\n",
      "DESCRIPTIONS                 Recombinant human anti-VEGF IgG1 monoclonal\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                            8633\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1353, dtype: object\n",
      "_____\n",
      "TWID                                                                2193\n",
      "TWEET_ID                                              799199484437823488\n",
      "TWEET                  Boehringer Ingelheim's bevacizumab biosimilar ...\n",
      "SYNONYMS                                                     BEVACIZUMAB\n",
      "MOLREGNO_1                                                        675483\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      SIM IN COMP\n",
      "MATCHED_OUTCOME                              Demonstrates bioequivalence\n",
      "COMPANY                                             Boehringer-Ingelheim\n",
      "COMPANY_ID                                                       COMP136\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                 Macular Edema\n",
      "INDICATION_ID                                                    D008269\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                             Biological\n",
      "INTERVENTION_NAME_x                                          bevacizumab\n",
      "DESCRIPTIONS                 Recombinant human anti-VEGF IgG1 monoclonal\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                          674747\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1354, dtype: object\n",
      "_____\n",
      "TWID                                                                2193\n",
      "TWEET_ID                                              799199484437823488\n",
      "TWEET                  Boehringer Ingelheim's bevacizumab biosimilar ...\n",
      "SYNONYMS                                                     BEVACIZUMAB\n",
      "MOLREGNO_1                                                        675483\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      SIM IN COMP\n",
      "MATCHED_OUTCOME                              Demonstrates bioequivalence\n",
      "COMPANY                                             Boehringer-Ingelheim\n",
      "COMPANY_ID                                                       COMP136\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                 Macular Edema\n",
      "INDICATION_ID                                                    D008269\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                             Biological\n",
      "INTERVENTION_NAME_x                                          bevacizumab\n",
      "DESCRIPTIONS                 Recombinant human anti-VEGF IgG1 monoclonal\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                          368538\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1356, dtype: object\n",
      "_____\n",
      "TWID                                                                2193\n",
      "TWEET_ID                                              799199484437823488\n",
      "TWEET                  Boehringer Ingelheim's bevacizumab biosimilar ...\n",
      "SYNONYMS                                                     BEVACIZUMAB\n",
      "MOLREGNO_1                                                        675483\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      SIM IN COMP\n",
      "MATCHED_OUTCOME                              Demonstrates bioequivalence\n",
      "COMPANY                                             Boehringer-Ingelheim\n",
      "COMPANY_ID                                                       COMP136\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                 Macular Edema\n",
      "INDICATION_ID                                                    D008269\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                             Biological\n",
      "INTERVENTION_NAME_x                                          bevacizumab\n",
      "DESCRIPTIONS                 Recombinant human anti-VEGF IgG1 monoclonal\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                         2096424\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1357, dtype: object\n",
      "_____\n",
      "TWID                                                                2193\n",
      "TWEET_ID                                              799199484437823488\n",
      "TWEET                  Boehringer Ingelheim's bevacizumab biosimilar ...\n",
      "SYNONYMS                                                     BEVACIZUMAB\n",
      "MOLREGNO_1                                                        675483\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      SIM IN COMP\n",
      "MATCHED_OUTCOME                              Demonstrates bioequivalence\n",
      "COMPANY                                             Boehringer-Ingelheim\n",
      "COMPANY_ID                                                       COMP136\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                 Macular Edema\n",
      "INDICATION_ID                                                    D008269\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                             Biological\n",
      "INTERVENTION_NAME_x                                          bevacizumab\n",
      "DESCRIPTIONS                 Recombinant human anti-VEGF IgG1 monoclonal\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                          598447\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1358, dtype: object\n",
      "_____\n",
      "TWID                                                                2201\n",
      "TWEET_ID                                              798950631293665280\n",
      "TWEET                  EFFECT-HF trial of Vifor's  iv ferric carboxym...\n",
      "SYNONYMS                                           FERRIC CARBOXYMALTOSE\n",
      "MOLREGNO_1                                                       1380863\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02009943\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                              met its primary endpoint \\t\n",
      "COMPANY                                                     Vifor Pharma\n",
      "COMPANY_ID                                                     COMP92668\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                 Heart Failure\n",
      "INDICATION_ID                                                    D006333\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                Ferric carboxymaltose\n",
      "DESCRIPTIONS                                             One time dosing\n",
      "OTHER_NAME                                                    Injectafer\n",
      "EFO_ID                                                       EFO:0004272\n",
      "CONDITION                                                     ICU Anemia\n",
      "MOLREGNO                                                          674774\n",
      "NAME_TERM                                                         anemia\n",
      "Name: 1362, dtype: object\n",
      "_____\n",
      "TWID                                                                2201\n",
      "TWEET_ID                                              798950631293665280\n",
      "TWEET                  EFFECT-HF trial of Vifor's  iv ferric carboxym...\n",
      "SYNONYMS                                           FERRIC CARBOXYMALTOSE\n",
      "MOLREGNO_1                                                       1380863\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02009943\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                              met its primary endpoint \\t\n",
      "COMPANY                                                     Vifor Pharma\n",
      "COMPANY_ID                                                     COMP92668\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                 Heart Failure\n",
      "INDICATION_ID                                                    D006333\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                Ferric carboxymaltose\n",
      "DESCRIPTIONS                                             One time dosing\n",
      "OTHER_NAME                                                    Injectafer\n",
      "EFO_ID                                                          -ABSENT-\n",
      "CONDITION                                     Functional Iron Deficiency\n",
      "MOLREGNO                                                          674774\n",
      "NAME_TERM                                                            NaN\n",
      "Name: 1364, dtype: object\n",
      "_____\n",
      "TWID                                                                2205\n",
      "TWEET_ID                                              798685053962158080\n",
      "TWEET                  @AstraZeneca drug AZD-7325 increases test stim...\n",
      "SYNONYMS                                                              2H\n",
      "MOLREGNO_1                                                        694656\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03051711\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         In phase live at\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                            Fragile X Syndrome\n",
      "INDICATION_ID                                                    D005600\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                               GBT440\n",
      "DESCRIPTIONS           Capsules which contain GBT440 drug substance i...\n",
      "OTHER_NAME             2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)p...\n",
      "EFO_ID                                                              Null\n",
      "CONDITION                                                           Null\n",
      "MOLREGNO                                                            Null\n",
      "NAME_TERM                                                            NaN\n",
      "Name: 1365, dtype: object\n",
      "_____\n",
      "TWID                                                                2205\n",
      "TWEET_ID                                              798685053962158080\n",
      "TWEET                  @AstraZeneca drug AZD-7325 increases test stim...\n",
      "SYNONYMS                                                         AZD7325\n",
      "MOLREGNO_1                                                       1149947\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03140813\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         In phase live at\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                            Fragile X Syndrome\n",
      "INDICATION_ID                                                    D005600\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                  AZD7325 (High-Dose)\n",
      "DESCRIPTIONS                                                 15mg PO BID\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                      Orphanet:908\n",
      "CONDITION                                             Fragile X Syndrome\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                             Fragile X syndrome\n",
      "Name: 1367, dtype: object\n",
      "_____\n",
      "TWID                                                                2205\n",
      "TWEET_ID                                              798685053962158080\n",
      "TWEET                  @AstraZeneca drug AZD-7325 increases test stim...\n",
      "SYNONYMS                                                         AZD7325\n",
      "MOLREGNO_1                                                       1149947\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03140813\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         In phase live at\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                            Fragile X Syndrome\n",
      "INDICATION_ID                                                    D005600\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                   AZD7325 (Low-Dose)\n",
      "DESCRIPTIONS                                                  5mg PO BID\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                      Orphanet:908\n",
      "CONDITION                                             Fragile X Syndrome\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                             Fragile X syndrome\n",
      "Name: 1369, dtype: object\n",
      "_____\n",
      "TWID                                                                2211\n",
      "TWEET_ID                                              798644347449184256\n",
      "TWEET                  Results of ORION-1 phase II trial of inclisira...\n",
      "SYNONYMS                                                      INCLISIRAN\n",
      "MOLREGNO_1                                                       2197904\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03399370\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                            Initiation of\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                          Hypercholesterolemia\n",
      "INDICATION_ID                                                    D006937\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                    Inclisiran Sodium\n",
      "DESCRIPTIONS           Inclisiran is a small interfering ribonucleic ...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000319\n",
      "CONDITION                                                          ASCVD\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                         cardiovascular disease\n",
      "Name: 1375, dtype: object\n",
      "_____\n",
      "TWID                                                                2243\n",
      "TWEET_ID                                              798105296346357760\n",
      "TWEET                  Camurus and Braeburn's long-acting buprenorphi...\n",
      "SYNONYMS                                                   BUPRENORPHINE\n",
      "MOLREGNO_1                                                        556608\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03026790\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                   meets primary endpoint\n",
      "COMPANY                                         Braeburn Pharmaceuticals\n",
      "COMPANY_ID                                                     COMP92246\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       0\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                  Chronic Pain\n",
      "INDICATION_ID                                                    D059350\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                               Buprenorphine-Naloxone\n",
      "DESCRIPTIONS           Option of using buprenorphine-naloxone to assi...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0003843\n",
      "CONDITION                                                   Chronic Pain\n",
      "MOLREGNO                                                          446784\n",
      "NAME_TERM                                                           pain\n",
      "Name: 1379, dtype: object\n",
      "_____\n",
      "TWID                                                                2261\n",
      "TWEET_ID                                              797887760879206400\n",
      "TWEET                  No added advantage from rifaximin over lactulo...\n",
      "SYNONYMS                                                       LACTULOSE\n",
      "MOLREGNO_1                                                        699419\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03148002\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                              N/I\n",
      "MATCHED_OUTCOME                                       No added advantage\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Irritable Bowel Syndrome\n",
      "INDICATION_ID                                                    D043183\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x             Current Bowel Protocol (senna/lactulose)\n",
      "DESCRIPTIONS                            Stimulant and Osmotic Laxatives.\n",
      "OTHER_NAME             Senna;Lactulose;Sennosides;DIN 02242814;DIN: 0...\n",
      "EFO_ID                                                        HP:0002019\n",
      "CONDITION                                                   Constipation\n",
      "MOLREGNO                                                         1380824\n",
      "NAME_TERM                                                   constipation\n",
      "Name: 1386, dtype: object\n",
      "_____\n",
      "TWID                                                                2261\n",
      "TWEET_ID                                              797887760879206400\n",
      "TWEET                  No added advantage from rifaximin over lactulo...\n",
      "SYNONYMS                                                       LACTULOSE\n",
      "MOLREGNO_1                                                        699419\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03148002\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                              N/I\n",
      "MATCHED_OUTCOME                                       No added advantage\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Irritable Bowel Syndrome\n",
      "INDICATION_ID                                                    D043183\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x             Current Bowel Protocol (senna/lactulose)\n",
      "DESCRIPTIONS                            Stimulant and Osmotic Laxatives.\n",
      "OTHER_NAME             Senna;Lactulose;Sennosides;DIN 02242814;DIN: 0...\n",
      "EFO_ID                                                        HP:0002019\n",
      "CONDITION                                                   Constipation\n",
      "MOLREGNO                                                          675520\n",
      "NAME_TERM                                                   constipation\n",
      "Name: 1387, dtype: object\n",
      "_____\n",
      "TWID                                                                2261\n",
      "TWEET_ID                                              797887760879206400\n",
      "TWEET                  No added advantage from rifaximin over lactulo...\n",
      "SYNONYMS                                                       LACTULOSE\n",
      "MOLREGNO_1                                                        699419\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03148002\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                              N/I\n",
      "MATCHED_OUTCOME                                       No added advantage\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Irritable Bowel Syndrome\n",
      "INDICATION_ID                                                    D043183\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x             Current Bowel Protocol (senna/lactulose)\n",
      "DESCRIPTIONS                            Stimulant and Osmotic Laxatives.\n",
      "OTHER_NAME             Senna;Lactulose;Sennosides;DIN 02242814;DIN: 0...\n",
      "EFO_ID                                                   -NOT-CONDITION-\n",
      "CONDITION                               Peritoneal Dialysis Complication\n",
      "MOLREGNO                                                         1380824\n",
      "NAME_TERM                                                            NaN\n",
      "Name: 1389, dtype: object\n",
      "_____\n",
      "TWID                                                                2261\n",
      "TWEET_ID                                              797887760879206400\n",
      "TWEET                  No added advantage from rifaximin over lactulo...\n",
      "SYNONYMS                                                       LACTULOSE\n",
      "MOLREGNO_1                                                        699419\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03148002\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                              N/I\n",
      "MATCHED_OUTCOME                                       No added advantage\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Irritable Bowel Syndrome\n",
      "INDICATION_ID                                                    D043183\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x             Current Bowel Protocol (senna/lactulose)\n",
      "DESCRIPTIONS                            Stimulant and Osmotic Laxatives.\n",
      "OTHER_NAME             Senna;Lactulose;Sennosides;DIN 02242814;DIN: 0...\n",
      "EFO_ID                                                   -NOT-CONDITION-\n",
      "CONDITION                               Peritoneal Dialysis Complication\n",
      "MOLREGNO                                                          675520\n",
      "NAME_TERM                                                            NaN\n",
      "Name: 1390, dtype: object\n",
      "_____\n",
      "TWID                                                                2261\n",
      "TWEET_ID                                              797887760879206400\n",
      "TWEET                  No added advantage from rifaximin over lactulo...\n",
      "SYNONYMS                                                       LACTULOSE\n",
      "MOLREGNO_1                                                        699419\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03148002\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                              N/I\n",
      "MATCHED_OUTCOME                                       No added advantage\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Irritable Bowel Syndrome\n",
      "INDICATION_ID                                                    D043183\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                   PEG Bowel Protocol (PEG/lactulose)\n",
      "DESCRIPTIONS                                          Osmotic Laxatives.\n",
      "OTHER_NAME             PEG;Lax-A-Day;Pegalax;DIN: 02328232;Restoralax...\n",
      "EFO_ID                                                        HP:0002019\n",
      "CONDITION                                                   Constipation\n",
      "MOLREGNO                                                         1380824\n",
      "NAME_TERM                                                   constipation\n",
      "Name: 1392, dtype: object\n",
      "_____\n",
      "TWID                                                                2261\n",
      "TWEET_ID                                              797887760879206400\n",
      "TWEET                  No added advantage from rifaximin over lactulo...\n",
      "SYNONYMS                                                       LACTULOSE\n",
      "MOLREGNO_1                                                        699419\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03148002\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                              N/I\n",
      "MATCHED_OUTCOME                                       No added advantage\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Irritable Bowel Syndrome\n",
      "INDICATION_ID                                                    D043183\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                   PEG Bowel Protocol (PEG/lactulose)\n",
      "DESCRIPTIONS                                          Osmotic Laxatives.\n",
      "OTHER_NAME             PEG;Lax-A-Day;Pegalax;DIN: 02328232;Restoralax...\n",
      "EFO_ID                                                        HP:0002019\n",
      "CONDITION                                                   Constipation\n",
      "MOLREGNO                                                          675520\n",
      "NAME_TERM                                                   constipation\n",
      "Name: 1393, dtype: object\n",
      "_____\n",
      "TWID                                                                2261\n",
      "TWEET_ID                                              797887760879206400\n",
      "TWEET                  No added advantage from rifaximin over lactulo...\n",
      "SYNONYMS                                                       LACTULOSE\n",
      "MOLREGNO_1                                                        699419\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03148002\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                              N/I\n",
      "MATCHED_OUTCOME                                       No added advantage\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Irritable Bowel Syndrome\n",
      "INDICATION_ID                                                    D043183\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                   PEG Bowel Protocol (PEG/lactulose)\n",
      "DESCRIPTIONS                                          Osmotic Laxatives.\n",
      "OTHER_NAME             PEG;Lax-A-Day;Pegalax;DIN: 02328232;Restoralax...\n",
      "EFO_ID                                                   -NOT-CONDITION-\n",
      "CONDITION                               Peritoneal Dialysis Complication\n",
      "MOLREGNO                                                         1380824\n",
      "NAME_TERM                                                            NaN\n",
      "Name: 1395, dtype: object\n",
      "_____\n",
      "TWID                                                                2261\n",
      "TWEET_ID                                              797887760879206400\n",
      "TWEET                  No added advantage from rifaximin over lactulo...\n",
      "SYNONYMS                                                       LACTULOSE\n",
      "MOLREGNO_1                                                        699419\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03148002\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                              N/I\n",
      "MATCHED_OUTCOME                                       No added advantage\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Irritable Bowel Syndrome\n",
      "INDICATION_ID                                                    D043183\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                   PEG Bowel Protocol (PEG/lactulose)\n",
      "DESCRIPTIONS                                          Osmotic Laxatives.\n",
      "OTHER_NAME             PEG;Lax-A-Day;Pegalax;DIN: 02328232;Restoralax...\n",
      "EFO_ID                                                   -NOT-CONDITION-\n",
      "CONDITION                               Peritoneal Dialysis Complication\n",
      "MOLREGNO                                                          675520\n",
      "NAME_TERM                                                            NaN\n",
      "Name: 1396, dtype: object\n",
      "_____\n",
      "TWID                                                                2261\n",
      "TWEET_ID                                              797887760879206400\n",
      "TWEET                  No added advantage from rifaximin over lactulo...\n",
      "SYNONYMS                                                       RIFAXIMIN\n",
      "MOLREGNO_1                                                        466768\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03069131\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                              N/I\n",
      "MATCHED_OUTCOME                                       No added advantage\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Irritable Bowel Syndrome\n",
      "INDICATION_ID                                                    D043183\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Rifaximin\n",
      "DESCRIPTIONS           twice daily administration of 1 tablet contain...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0001422\n",
      "CONDITION                                                      Cirrhosis\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                             cirrhosis of liver\n",
      "Name: 1397, dtype: object\n",
      "_____\n",
      "TWID                                                                2261\n",
      "TWEET_ID                                              797887760879206400\n",
      "TWEET                  No added advantage from rifaximin over lactulo...\n",
      "SYNONYMS                                                       RIFAXIMIN\n",
      "MOLREGNO_1                                                        466768\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03069131\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                              N/I\n",
      "MATCHED_OUTCOME                                       No added advantage\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Irritable Bowel Syndrome\n",
      "INDICATION_ID                                                    D043183\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Rifaximin\n",
      "DESCRIPTIONS           twice daily administration of 1 tablet contain...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0008588\n",
      "CONDITION                                                    Peritonitis\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                    peritonitis\n",
      "Name: 1399, dtype: object\n",
      "_____\n",
      "TWID                                                                2261\n",
      "TWEET_ID                                              797887760879206400\n",
      "TWEET                  No added advantage from rifaximin over lactulo...\n",
      "SYNONYMS                                                       RIFAXIMIN\n",
      "MOLREGNO_1                                                        466768\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03069131\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                              N/I\n",
      "MATCHED_OUTCOME                                       No added advantage\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Irritable Bowel Syndrome\n",
      "INDICATION_ID                                                    D043183\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Rifaximin\n",
      "DESCRIPTIONS           twice daily administration of 1 tablet contain...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                        HP:0001541\n",
      "CONDITION                                                        Ascites\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                        Ascites\n",
      "Name: 1401, dtype: object\n",
      "_____\n",
      "TWID                                                                2288\n",
      "TWEET_ID                                              795962947423989760\n",
      "TWEET                  Opexa reduces 40% workforce following negative...\n",
      "SYNONYMS                                                          TCELNA\n",
      "MOLREGNO_1                                                       1449231\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01684761\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                   Negative phase results\n",
      "COMPANY                                                            Opexa\n",
      "COMPANY_ID                                                     COMP90274\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                       Atrophy\n",
      "INDICATION_ID                                                    D001284\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                             Biological\n",
      "INTERVENTION_NAME_x                                               Tcelna\n",
      "DESCRIPTIONS           Autologous pool of myelin reactive T-cells (MR...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0008522\n",
      "CONDITION                       Secondary Progressive Multiple Sclerosis\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                       secondary progressive multiple sclerosis\n",
      "Name: 1407, dtype: object\n",
      "_____\n",
      "TWID                                                                2288\n",
      "TWEET_ID                                              795962947423989760\n",
      "TWEET                  Opexa reduces 40% workforce following negative...\n",
      "SYNONYMS                                                          TCELNA\n",
      "MOLREGNO_1                                                       1449231\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01684761\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                   Negative phase results\n",
      "COMPANY                                                            Opexa\n",
      "COMPANY_ID                                                     COMP90274\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                       Atrophy\n",
      "INDICATION_ID                                                    D001284\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                             Biological\n",
      "INTERVENTION_NAME_x                                               Tcelna\n",
      "DESCRIPTIONS           Autologous pool of myelin reactive T-cells (MR...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0003885\n",
      "CONDITION                                             Multiple Sclerosis\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                             multiple sclerosis\n",
      "Name: 1408, dtype: object\n",
      "_____\n",
      "TWID                                                                2288\n",
      "TWEET_ID                                              795962947423989760\n",
      "TWEET                  Opexa reduces 40% workforce following negative...\n",
      "SYNONYMS                                                          TCELNA\n",
      "MOLREGNO_1                                                       1449231\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01684761\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                   Negative phase results\n",
      "COMPANY                                                            Opexa\n",
      "COMPANY_ID                                                     COMP90274\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                       Atrophy\n",
      "INDICATION_ID                                                    D001284\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                             Biological\n",
      "INTERVENTION_NAME_x                                               Tcelna\n",
      "DESCRIPTIONS           Autologous pool of myelin reactive T-cells (MR...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000618\n",
      "CONDITION                      Autoimmune Diseases of the Nervous System\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                         nervous system disease\n",
      "Name: 1409, dtype: object\n",
      "_____\n",
      "TWID                                                                2288\n",
      "TWEET_ID                                              795962947423989760\n",
      "TWEET                  Opexa reduces 40% workforce following negative...\n",
      "SYNONYMS                                                          TCELNA\n",
      "MOLREGNO_1                                                       1449231\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01684761\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                   Negative phase results\n",
      "COMPANY                                                            Opexa\n",
      "COMPANY_ID                                                     COMP90274\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                       Atrophy\n",
      "INDICATION_ID                                                    D001284\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                             Biological\n",
      "INTERVENTION_NAME_x                                               Tcelna\n",
      "DESCRIPTIONS           Autologous pool of myelin reactive T-cells (MR...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0005140\n",
      "CONDITION                      Autoimmune Diseases of the Nervous System\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                             autoimmune disease\n",
      "Name: 1410, dtype: object\n",
      "_____\n",
      "TWID                                                                2288\n",
      "TWEET_ID                                              795962947423989760\n",
      "TWEET                  Opexa reduces 40% workforce following negative...\n",
      "SYNONYMS                                                          TCELNA\n",
      "MOLREGNO_1                                                       1449231\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01684761\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                   Negative phase results\n",
      "COMPANY                                                            Opexa\n",
      "COMPANY_ID                                                     COMP90274\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                       Atrophy\n",
      "INDICATION_ID                                                    D001284\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                             Biological\n",
      "INTERVENTION_NAME_x                                               Tcelna\n",
      "DESCRIPTIONS           Autologous pool of myelin reactive T-cells (MR...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                   -NOT-CONDITION-\n",
      "CONDITION                                            Disease Progression\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                            NaN\n",
      "Name: 1411, dtype: object\n",
      "_____\n",
      "TWID                                                                2288\n",
      "TWEET_ID                                              795962947423989760\n",
      "TWEET                  Opexa reduces 40% workforce following negative...\n",
      "SYNONYMS                                                          TCELNA\n",
      "MOLREGNO_1                                                       1449231\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01684761\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                   Negative phase results\n",
      "COMPANY                                                            Opexa\n",
      "COMPANY_ID                                                     COMP90274\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                       Atrophy\n",
      "INDICATION_ID                                                    D001284\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                             Biological\n",
      "INTERVENTION_NAME_x                                               Tcelna\n",
      "DESCRIPTIONS           Autologous pool of myelin reactive T-cells (MR...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                        HP:0012444\n",
      "CONDITION                                                  Brain Atrophy\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM              Brain atrophy {http://www.co-ode.org/patterns#...\n",
      "Name: 1412, dtype: object\n",
      "_____\n",
      "TWID                                                                2304\n",
      "TWEET_ID                                              794105763002191872\n",
      "TWEET                  Phase I pharmacokinetic safety and immunogenic...\n",
      "SYNONYMS                                                       ABATACEPT\n",
      "MOLREGNO_1                                                        675774\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00442611\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                          Trial initiated\n",
      "COMPANY                                                            Mylan\n",
      "COMPANY_ID                                                     COMP90048\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                            Sjogren's Syndrome\n",
      "INDICATION_ID                                                    D012859\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Abatacept\n",
      "DESCRIPTIONS                                                        Null\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000404\n",
      "CONDITION                                           Scleroderma, Diffuse\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                            diffuse scleroderma\n",
      "Name: 1415, dtype: object\n",
      "_____\n",
      "TWID                                                                2304\n",
      "TWEET_ID                                              794105763002191872\n",
      "TWEET                  Phase I pharmacokinetic safety and immunogenic...\n",
      "SYNONYMS                                                       ABATACEPT\n",
      "MOLREGNO_1                                                        675774\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00442611\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                          Trial initiated\n",
      "COMPANY                                                            Mylan\n",
      "COMPANY_ID                                                     COMP90048\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                            Sjogren's Syndrome\n",
      "INDICATION_ID                                                    D012859\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Abatacept\n",
      "DESCRIPTIONS                                                        Null\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000717\n",
      "CONDITION                                          Scleroderma, Systemic\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                           systemic scleroderma\n",
      "Name: 1417, dtype: object\n",
      "_____\n",
      "TWID                                                                2308\n",
      "TWEET_ID                                              793755656234729472\n",
      "TWEET                  Palatin's bremelanotide meets coprimary effica...\n",
      "SYNONYMS                                                   BREMELANOTIDE\n",
      "MOLREGNO_1                                                       1360388\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02338960\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                       meets coprimary efficacy endpoints\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                             Hypoactive sexual desire disorder\n",
      "INDICATION_ID                                                    SDI0266\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Bremelanotide\n",
      "DESCRIPTIONS           A melanocortin agonist and synthetic peptide a...\n",
      "OTHER_NAME                                                    BMT;PT-141\n",
      "EFO_ID                                                       EFO:0004714\n",
      "CONDITION                              Hypoactive Sexual Desire Disorder\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                             sexual dysfunction\n",
      "Name: 1419, dtype: object\n",
      "_____\n",
      "TWID                                                                2313\n",
      "TWEET_ID                                              793349824020033536\n",
      "TWEET                  Phase III clinical trial begins in US for Eisa...\n",
      "SYNONYMS                                                           E2609\n",
      "MOLREGNO_1                                                       2096360\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03055962\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                       begins phase trial\n",
      "COMPANY                                                      Biogen IDEC\n",
      "COMPANY_ID                                                       COMP118\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                             Alzheimer Disease\n",
      "INDICATION_ID                                                    D000544\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                                E2609\n",
      "DESCRIPTIONS                                                      tablet\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000761\n",
      "CONDITION                                           Healthy Participants\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                obsolete_normal\n",
      "Name: 1423, dtype: object\n",
      "_____\n",
      "TWID                                                                2322\n",
      "TWEET_ID                                              791931974327767040\n",
      "TWEET                  Alexion's ALXN-1210 begins phase III trials fo...\n",
      "SYNONYMS                                                        ALXN1210\n",
      "MOLREGNO_1                                                       2197857\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02605993\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                      begins phase trials\n",
      "COMPANY                                                          Alexion\n",
      "COMPANY_ID                                                        COMP30\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                            Atypical Hemolytic Uremic Syndrome\n",
      "INDICATION_ID                                                    D065766\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                             Biological\n",
      "INTERVENTION_NAME_x                                             ALXN1210\n",
      "DESCRIPTIONS                                                        Null\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                      Orphanet:447\n",
      "CONDITION                                                            PNH\n",
      "MOLREGNO                                                            Null\n",
      "NAME_TERM                            Paroxysmal nocturnal hemoglobinuria\n",
      "Name: 1431, dtype: object\n",
      "_____\n",
      "TWID                                                                2322\n",
      "TWEET_ID                                              791931974327767040\n",
      "TWEET                  Alexion's ALXN-1210 begins phase III trials fo...\n",
      "SYNONYMS                                                        ALXN1210\n",
      "MOLREGNO_1                                                       2197857\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02605993\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                      begins phase trials\n",
      "COMPANY                                                          Alexion\n",
      "COMPANY_ID                                                        COMP30\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                            Atypical Hemolytic Uremic Syndrome\n",
      "INDICATION_ID                                                    D065766\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                             Biological\n",
      "INTERVENTION_NAME_x                                             ALXN1210\n",
      "DESCRIPTIONS                                                        Null\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                      Orphanet:447\n",
      "CONDITION                            Paroxysmal Nocturnal Hemoglobinuria\n",
      "MOLREGNO                                                            Null\n",
      "NAME_TERM                            Paroxysmal nocturnal hemoglobinuria\n",
      "Name: 1432, dtype: object\n",
      "_____\n",
      "TWID                                                                2336\n",
      "TWEET_ID                                              791213908883152896\n",
      "TWEET                  Dipexium's Locilex (pexiganan acetate) fails t...\n",
      "SYNONYMS                                                       PEXIGANAN\n",
      "MOLREGNO_1                                                        711762\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01590758\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              trial fails\n",
      "COMPANY                                         Dipexium Pharmaceuticals\n",
      "COMPANY_ID                                                     COMP91194\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                 Diabetic Foot\n",
      "INDICATION_ID                                                    D017719\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                         Topical pexiganan cream 0.8%\n",
      "DESCRIPTIONS                                        14 days of treatment\n",
      "OTHER_NAME                                                        MSI-78\n",
      "EFO_ID                                                       EFO:0000544\n",
      "CONDITION                                        Diabetic Foot Infection\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                      infection\n",
      "Name: 1441, dtype: object\n",
      "_____\n",
      "TWID                                                                2370\n",
      "TWEET_ID                                              788436408587341824\n",
      "TWEET                  89Zr ImmunoPET provides valuable data on biodi...\n",
      "SYNONYMS                                                    CERGUTUZUMAB\n",
      "MOLREGNO_1                                                       2197886\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02350673\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                              N/I\n",
      "MATCHED_OUTCOME                                   Provides valuable data\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                             Cergutuzumab Amunaleukin\n",
      "DESCRIPTIONS           Participants will receive cergutuzumab amunale...\n",
      "OTHER_NAME                                           RO6895882, CEA-IL2v\n",
      "EFO_ID                                                       EFO:0000616\n",
      "CONDITION                                                   Solid Tumors\n",
      "MOLREGNO                                                         2197222\n",
      "NAME_TERM                                                       neoplasm\n",
      "Name: 1449, dtype: object\n",
      "_____\n",
      "TWID                                                                2370\n",
      "TWEET_ID                                              788436408587341824\n",
      "TWEET                  89Zr ImmunoPET provides valuable data on biodi...\n",
      "SYNONYMS                                                    CERGUTUZUMAB\n",
      "MOLREGNO_1                                                       2197886\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02350673\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                              N/I\n",
      "MATCHED_OUTCOME                                   Provides valuable data\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                             Cergutuzumab Amunaleukin\n",
      "DESCRIPTIONS           Participants will receive cergutuzumab amunale...\n",
      "OTHER_NAME                                           RO6895882, CEA-IL2v\n",
      "EFO_ID                                                       EFO:0000616\n",
      "CONDITION                                                   Solid Tumors\n",
      "MOLREGNO                                                         2039198\n",
      "NAME_TERM                                                       neoplasm\n",
      "Name: 1450, dtype: object\n",
      "_____\n",
      "TWID                                                                2370\n",
      "TWEET_ID                                              788436408587341824\n",
      "TWEET                  89Zr ImmunoPET provides valuable data on biodi...\n",
      "SYNONYMS                                        CERGUTUZUMAB AMUNALEUKIN\n",
      "MOLREGNO_1                                                       2197889\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02350673\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                              N/I\n",
      "MATCHED_OUTCOME                                   Provides valuable data\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                             Cergutuzumab Amunaleukin\n",
      "DESCRIPTIONS           Participants will receive cergutuzumab amunale...\n",
      "OTHER_NAME                                           RO6895882, CEA-IL2v\n",
      "EFO_ID                                                       EFO:0000616\n",
      "CONDITION                                                   Solid Tumors\n",
      "MOLREGNO                                                         2197222\n",
      "NAME_TERM                                                       neoplasm\n",
      "Name: 1451, dtype: object\n",
      "_____\n",
      "TWID                                                                2370\n",
      "TWEET_ID                                              788436408587341824\n",
      "TWEET                  89Zr ImmunoPET provides valuable data on biodi...\n",
      "SYNONYMS                                        CERGUTUZUMAB AMUNALEUKIN\n",
      "MOLREGNO_1                                                       2197889\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02350673\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                              N/I\n",
      "MATCHED_OUTCOME                                   Provides valuable data\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                             Cergutuzumab Amunaleukin\n",
      "DESCRIPTIONS           Participants will receive cergutuzumab amunale...\n",
      "OTHER_NAME                                           RO6895882, CEA-IL2v\n",
      "EFO_ID                                                       EFO:0000616\n",
      "CONDITION                                                   Solid Tumors\n",
      "MOLREGNO                                                         2039198\n",
      "NAME_TERM                                                       neoplasm\n",
      "Name: 1452, dtype: object\n",
      "_____\n",
      "TWID                                                                2370\n",
      "TWEET_ID                                              788436408587341824\n",
      "TWEET                  89Zr ImmunoPET provides valuable data on biodi...\n",
      "SYNONYMS                                                           ROCHE\n",
      "MOLREGNO_1                                                        469217\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03448666\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                              N/I\n",
      "MATCHED_OUTCOME                                   Provides valuable data\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                    Combination Product\n",
      "INTERVENTION_NAME_x                                        Pembrolizumab\n",
      "DESCRIPTIONS           Electrochemotherapy will be performed with the...\n",
      "OTHER_NAME                                           Electrochemotherapy\n",
      "EFO_ID                                                       EFO:0000756\n",
      "CONDITION                                             Malignant Melanoma\n",
      "MOLREGNO                                                         1626777\n",
      "NAME_TERM                                                       melanoma\n",
      "Name: 1453, dtype: object\n",
      "_____\n",
      "TWID                                                                2374\n",
      "TWEET_ID                                              788266575656722433\n",
      "TWEET                  US FDA places hold on phase 2b trial of Regene...\n",
      "SYNONYMS                                                       FASINUMAB\n",
      "MOLREGNO_1                                                       1381968\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03161093\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                            hold on trial\n",
      "COMPANY                                                        Regeneron\n",
      "COMPANY_ID                                                     COMP90037\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                           Knee Osteoarthritis\n",
      "INDICATION_ID                                                    D020370\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Fasinumab\n",
      "DESCRIPTIONS                Solution for injection in pre-filled syringe\n",
      "OTHER_NAME                                                       REGN475\n",
      "EFO_ID                                                       EFO:0002506\n",
      "CONDITION                                           Osteoarthritis, Knee\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                 osteoarthritis\n",
      "Name: 1455, dtype: object\n",
      "_____\n",
      "TWID                                                                2374\n",
      "TWEET_ID                                              788266575656722433\n",
      "TWEET                  US FDA places hold on phase 2b trial of Regene...\n",
      "SYNONYMS                                                       FASINUMAB\n",
      "MOLREGNO_1                                                       1381968\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03161093\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                            hold on trial\n",
      "COMPANY                                                        Regeneron\n",
      "COMPANY_ID                                                     COMP90037\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                           Knee Osteoarthritis\n",
      "INDICATION_ID                                                    D020370\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Fasinumab\n",
      "DESCRIPTIONS                Solution for injection in pre-filled syringe\n",
      "OTHER_NAME                                                       REGN475\n",
      "EFO_ID                                                       EFO:0002506\n",
      "CONDITION                                           Osteoarthritis, Knee\n",
      "MOLREGNO                                                           51056\n",
      "NAME_TERM                                                 osteoarthritis\n",
      "Name: 1457, dtype: object\n",
      "_____\n",
      "TWID                                                                2374\n",
      "TWEET_ID                                              788266575656722433\n",
      "TWEET                  US FDA places hold on phase 2b trial of Regene...\n",
      "SYNONYMS                                                       FASINUMAB\n",
      "MOLREGNO_1                                                       1381968\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03161093\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                            hold on trial\n",
      "COMPANY                                                        Regeneron\n",
      "COMPANY_ID                                                     COMP90037\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                           Knee Osteoarthritis\n",
      "INDICATION_ID                                                    D020370\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Fasinumab\n",
      "DESCRIPTIONS                Solution for injection in pre-filled syringe\n",
      "OTHER_NAME                                                       REGN475\n",
      "EFO_ID                                                       EFO:1000786\n",
      "CONDITION                                            Osteoarthritis, Hip\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                            osteoarthritis, hip\n",
      "Name: 1458, dtype: object\n",
      "_____\n",
      "TWID                                                                2374\n",
      "TWEET_ID                                              788266575656722433\n",
      "TWEET                  US FDA places hold on phase 2b trial of Regene...\n",
      "SYNONYMS                                                       FASINUMAB\n",
      "MOLREGNO_1                                                       1381968\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03161093\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                            hold on trial\n",
      "COMPANY                                                        Regeneron\n",
      "COMPANY_ID                                                     COMP90037\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                           Knee Osteoarthritis\n",
      "INDICATION_ID                                                    D020370\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Fasinumab\n",
      "DESCRIPTIONS                Solution for injection in pre-filled syringe\n",
      "OTHER_NAME                                                       REGN475\n",
      "EFO_ID                                                       EFO:1000786\n",
      "CONDITION                                            Osteoarthritis, Hip\n",
      "MOLREGNO                                                           51056\n",
      "NAME_TERM                                            osteoarthritis, hip\n",
      "Name: 1460, dtype: object\n",
      "_____\n",
      "TWID                                                                2374\n",
      "TWEET_ID                                              788266575656722433\n",
      "TWEET                  US FDA places hold on phase 2b trial of Regene...\n",
      "SYNONYMS                                                       FASINUMAB\n",
      "MOLREGNO_1                                                       1381968\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03161093\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                            hold on trial\n",
      "COMPANY                                                        Regeneron\n",
      "COMPANY_ID                                                     COMP90037\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                           Knee Osteoarthritis\n",
      "INDICATION_ID                                                    D020370\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                           Fasinumab-matching placebo\n",
      "DESCRIPTIONS                Solution for injection in pre-filled syringe\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0002506\n",
      "CONDITION                                           Osteoarthritis, Knee\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                 osteoarthritis\n",
      "Name: 1461, dtype: object\n",
      "_____\n",
      "TWID                                                                2374\n",
      "TWEET_ID                                              788266575656722433\n",
      "TWEET                  US FDA places hold on phase 2b trial of Regene...\n",
      "SYNONYMS                                                       FASINUMAB\n",
      "MOLREGNO_1                                                       1381968\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03161093\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                            hold on trial\n",
      "COMPANY                                                        Regeneron\n",
      "COMPANY_ID                                                     COMP90037\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                           Knee Osteoarthritis\n",
      "INDICATION_ID                                                    D020370\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                           Fasinumab-matching placebo\n",
      "DESCRIPTIONS                Solution for injection in pre-filled syringe\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0002506\n",
      "CONDITION                                           Osteoarthritis, Knee\n",
      "MOLREGNO                                                           51056\n",
      "NAME_TERM                                                 osteoarthritis\n",
      "Name: 1463, dtype: object\n",
      "_____\n",
      "TWID                                                                2374\n",
      "TWEET_ID                                              788266575656722433\n",
      "TWEET                  US FDA places hold on phase 2b trial of Regene...\n",
      "SYNONYMS                                                       FASINUMAB\n",
      "MOLREGNO_1                                                       1381968\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03161093\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                            hold on trial\n",
      "COMPANY                                                        Regeneron\n",
      "COMPANY_ID                                                     COMP90037\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                           Knee Osteoarthritis\n",
      "INDICATION_ID                                                    D020370\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                           Fasinumab-matching placebo\n",
      "DESCRIPTIONS                Solution for injection in pre-filled syringe\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:1000786\n",
      "CONDITION                                            Osteoarthritis, Hip\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                            osteoarthritis, hip\n",
      "Name: 1464, dtype: object\n",
      "_____\n",
      "TWID                                                                2374\n",
      "TWEET_ID                                              788266575656722433\n",
      "TWEET                  US FDA places hold on phase 2b trial of Regene...\n",
      "SYNONYMS                                                       FASINUMAB\n",
      "MOLREGNO_1                                                       1381968\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03161093\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                            hold on trial\n",
      "COMPANY                                                        Regeneron\n",
      "COMPANY_ID                                                     COMP90037\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                           Knee Osteoarthritis\n",
      "INDICATION_ID                                                    D020370\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                           Fasinumab-matching placebo\n",
      "DESCRIPTIONS                Solution for injection in pre-filled syringe\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:1000786\n",
      "CONDITION                                            Osteoarthritis, Hip\n",
      "MOLREGNO                                                           51056\n",
      "NAME_TERM                                            osteoarthritis, hip\n",
      "Name: 1466, dtype: object\n",
      "_____\n",
      "TWID                                                                2384\n",
      "TWEET_ID                                              787903040976150528\n",
      "TWEET                  Clementia Pharmaceuticals' palovarotene demons...\n",
      "SYNONYMS                                                    PALOVAROTENE\n",
      "MOLREGNO_1                                                       1377918\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03442985\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           Positive trial\n",
      "COMPANY                                        Clementia Pharmaceuticals\n",
      "COMPANY_ID                                                     COMP92796\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                 Multiple Hereditary Exostoses\n",
      "INDICATION_ID                                                    D005097\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                  Palovarotene 2.5 mg\n",
      "DESCRIPTIONS           Subjects will receive a weight-adjusted dose e...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                              Null\n",
      "CONDITION                                                           Null\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                            NaN\n",
      "Name: 1470, dtype: object\n",
      "_____\n",
      "TWID                                                                2384\n",
      "TWEET_ID                                              787903040976150528\n",
      "TWEET                  Clementia Pharmaceuticals' palovarotene demons...\n",
      "SYNONYMS                                                    PALOVAROTENE\n",
      "MOLREGNO_1                                                       1377918\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03442985\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           Positive trial\n",
      "COMPANY                                        Clementia Pharmaceuticals\n",
      "COMPANY_ID                                                     COMP92796\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                 Multiple Hereditary Exostoses\n",
      "INDICATION_ID                                                    D005097\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                  Palovarotene 5.0 mg\n",
      "DESCRIPTIONS           Subjects will receive a weight-adjusted dose e...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                              Null\n",
      "CONDITION                                                           Null\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                            NaN\n",
      "Name: 1472, dtype: object\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "_____\n",
      "TWID                                                                2410\n",
      "TWEET_ID                                              785725187224240128\n",
      "TWEET                  Clinically meaningful improvements reported in...\n",
      "SYNONYMS                                                      BRILACIDIN\n",
      "MOLREGNO_1                                                       1449217\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02324335\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                         meaningful improvements reported\n",
      "COMPANY                                                       Cellceutix\n",
      "COMPANY_ID                                                     COMP90493\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Mucositis\n",
      "INDICATION_ID                                                    D052016\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Brilacidin\n",
      "DESCRIPTIONS                   Oral Rinse used 3 times daily for 7 weeks\n",
      "OTHER_NAME                                                      PMX30063\n",
      "EFO_ID                                                       EFO:1001898\n",
      "CONDITION                                                      Mucositis\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                      mucositis\n",
      "Name: 1481, dtype: object\n",
      "_____\n",
      "TWID                                                                2410\n",
      "TWEET_ID                                              785725187224240128\n",
      "TWEET                  Clinically meaningful improvements reported in...\n",
      "SYNONYMS                                                      BRILACIDIN\n",
      "MOLREGNO_1                                                       1449217\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02324335\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                         meaningful improvements reported\n",
      "COMPANY                                                       Cellceutix\n",
      "COMPANY_ID                                                     COMP90493\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Mucositis\n",
      "INDICATION_ID                                                    D052016\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Brilacidin\n",
      "DESCRIPTIONS                   Oral Rinse used 3 times daily for 7 weeks\n",
      "OTHER_NAME                                                      PMX30063\n",
      "EFO_ID                                                       EFO:0004284\n",
      "CONDITION                                        Head and Neck Neoplasms\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                             upper aerodigestive tract neoplasm\n",
      "Name: 1483, dtype: object\n",
      "_____\n",
      "TWID                                                                2430\n",
      "TWEET_ID                                              783256816029270016\n",
      "TWEET                  AstraZeneca's Brilinta fails to show benefit o...\n",
      "SYNONYMS                                                     CLOPIDOGREL\n",
      "MOLREGNO_1                                                        598402\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03381742\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              trial fails\n",
      "COMPANY                                                      AstraZeneca\n",
      "COMPANY_ID                                                        COMP82\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                        Stroke\n",
      "INDICATION_ID                                                    D020521\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          clopidogrel\n",
      "DESCRIPTIONS           standard-dose clopidogrel treatment (300 mg lo...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0005672\n",
      "CONDITION                                        Acute Coronary Syndrome\n",
      "MOLREGNO                                                          416772\n",
      "NAME_TERM                                        acute coronary syndrome\n",
      "Name: 1486, dtype: object\n",
      "_____\n",
      "TWID                                                                2430\n",
      "TWEET_ID                                              783256816029270016\n",
      "TWEET                  AstraZeneca's Brilinta fails to show benefit o...\n",
      "SYNONYMS                                                        BRILINTA\n",
      "MOLREGNO_1                                                        416772\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03161678\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              trial fails\n",
      "COMPANY                                                      AstraZeneca\n",
      "COMPANY_ID                                                        COMP82\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                        Stroke\n",
      "INDICATION_ID                                                    D020521\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Ticagrelor\n",
      "DESCRIPTIONS           Ticagrelor (90 mg twice daily for 8 days) will...\n",
      "OTHER_NAME                                                      Brilinta\n",
      "EFO_ID                                                       EFO:0000612\n",
      "CONDITION                                          Myocardial Infarction\n",
      "MOLREGNO                                                          598402\n",
      "NAME_TERM                                          myocardial infarction\n",
      "Name: 1489, dtype: object\n",
      "_____\n",
      "TWID                                                                2430\n",
      "TWEET_ID                                              783256816029270016\n",
      "TWEET                  AstraZeneca's Brilinta fails to show benefit o...\n",
      "SYNONYMS                                                        BRILINTA\n",
      "MOLREGNO_1                                                        416772\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03161678\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              trial fails\n",
      "COMPANY                                                      AstraZeneca\n",
      "COMPANY_ID                                                        COMP82\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                        Stroke\n",
      "INDICATION_ID                                                    D020521\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Ticagrelor\n",
      "DESCRIPTIONS           Ticagrelor (90 mg twice daily for 8 days) will...\n",
      "OTHER_NAME                                                      Brilinta\n",
      "EFO_ID                                                        HP:0004936\n",
      "CONDITION                                                     Thrombosis\n",
      "MOLREGNO                                                          598402\n",
      "NAME_TERM                                              Venous thrombosis\n",
      "Name: 1491, dtype: object\n",
      "_____\n",
      "TWID                                                                2487\n",
      "TWEET_ID                                              780346129506377728\n",
      "TWEET                  Janssen's AL-335 in combination with odalasvir...\n",
      "SYNONYMS                                                       ODALASVIR\n",
      "MOLREGNO_1                                                       1926826\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03059303\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                             achieves 100% SVR12 in phase\n",
      "COMPANY                                                          Janssen\n",
      "COMPANY_ID                                                       COMP354\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                           Renal Insufficiency\n",
      "INDICATION_ID                                                    D051437\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                      Odalasvir 75 mg\n",
      "DESCRIPTIONS           Part 2: ODV 75 mg taken orally as a component ...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000761\n",
      "CONDITION                                                        Healthy\n",
      "MOLREGNO                                                            5975\n",
      "NAME_TERM                                                obsolete_normal\n",
      "Name: 1509, dtype: object\n",
      "_____\n",
      "TWID                                                                2487\n",
      "TWEET_ID                                              780346129506377728\n",
      "TWEET                  Janssen's AL-335 in combination with odalasvir...\n",
      "SYNONYMS                                                       ODALASVIR\n",
      "MOLREGNO_1                                                       1926826\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03059303\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                             achieves 100% SVR12 in phase\n",
      "COMPANY                                                          Janssen\n",
      "COMPANY_ID                                                       COMP354\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                           Renal Insufficiency\n",
      "INDICATION_ID                                                    D051437\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                      Odalasvir 75 mg\n",
      "DESCRIPTIONS           Part 2: ODV 75 mg taken orally as a component ...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000761\n",
      "CONDITION                                                        Healthy\n",
      "MOLREGNO                                                          419601\n",
      "NAME_TERM                                                obsolete_normal\n",
      "Name: 1511, dtype: object\n",
      "_____\n",
      "TWID                                                                2487\n",
      "TWEET_ID                                              780346129506377728\n",
      "TWEET                  Janssen's AL-335 in combination with odalasvir...\n",
      "SYNONYMS                                                       ODALASVIR\n",
      "MOLREGNO_1                                                       1926826\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03059303\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                             achieves 100% SVR12 in phase\n",
      "COMPANY                                                          Janssen\n",
      "COMPANY_ID                                                       COMP354\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                           Renal Insufficiency\n",
      "INDICATION_ID                                                    D051437\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                      Odalasvir 75 mg\n",
      "DESCRIPTIONS           Part 2: ODV 75 mg taken orally as a component ...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000761\n",
      "CONDITION                                                        Healthy\n",
      "MOLREGNO                                                          451744\n",
      "NAME_TERM                                                obsolete_normal\n",
      "Name: 1512, dtype: object\n",
      "_____\n",
      "TWID                                                                2487\n",
      "TWEET_ID                                              780346129506377728\n",
      "TWEET                  Janssen's AL-335 in combination with odalasvir...\n",
      "SYNONYMS                                                       ODALASVIR\n",
      "MOLREGNO_1                                                       1926826\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03059303\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                             achieves 100% SVR12 in phase\n",
      "COMPANY                                                          Janssen\n",
      "COMPANY_ID                                                       COMP354\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                           Renal Insufficiency\n",
      "INDICATION_ID                                                    D051437\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                      Odalasvir 25 mg\n",
      "DESCRIPTIONS           Part 1: Odalasvir (ODV) 25 mg taken orally as ...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000761\n",
      "CONDITION                                                        Healthy\n",
      "MOLREGNO                                                            5975\n",
      "NAME_TERM                                                obsolete_normal\n",
      "Name: 1513, dtype: object\n",
      "_____\n",
      "TWID                                                                2487\n",
      "TWEET_ID                                              780346129506377728\n",
      "TWEET                  Janssen's AL-335 in combination with odalasvir...\n",
      "SYNONYMS                                                       ODALASVIR\n",
      "MOLREGNO_1                                                       1926826\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03059303\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                             achieves 100% SVR12 in phase\n",
      "COMPANY                                                          Janssen\n",
      "COMPANY_ID                                                       COMP354\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                           Renal Insufficiency\n",
      "INDICATION_ID                                                    D051437\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                      Odalasvir 25 mg\n",
      "DESCRIPTIONS           Part 1: Odalasvir (ODV) 25 mg taken orally as ...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000761\n",
      "CONDITION                                                        Healthy\n",
      "MOLREGNO                                                          419601\n",
      "NAME_TERM                                                obsolete_normal\n",
      "Name: 1515, dtype: object\n",
      "_____\n",
      "TWID                                                                2487\n",
      "TWEET_ID                                              780346129506377728\n",
      "TWEET                  Janssen's AL-335 in combination with odalasvir...\n",
      "SYNONYMS                                                       ODALASVIR\n",
      "MOLREGNO_1                                                       1926826\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03059303\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                             achieves 100% SVR12 in phase\n",
      "COMPANY                                                          Janssen\n",
      "COMPANY_ID                                                       COMP354\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                           Renal Insufficiency\n",
      "INDICATION_ID                                                    D051437\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                      Odalasvir 25 mg\n",
      "DESCRIPTIONS           Part 1: Odalasvir (ODV) 25 mg taken orally as ...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000761\n",
      "CONDITION                                                        Healthy\n",
      "MOLREGNO                                                          451744\n",
      "NAME_TERM                                                obsolete_normal\n",
      "Name: 1516, dtype: object\n",
      "_____\n",
      "TWID                                                                2487\n",
      "TWEET_ID                                              780346129506377728\n",
      "TWEET                  Janssen's AL-335 in combination with odalasvir...\n",
      "SYNONYMS                                                       ODALASVIR\n",
      "MOLREGNO_1                                                       1926826\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03059303\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                             achieves 100% SVR12 in phase\n",
      "COMPANY                                                          Janssen\n",
      "COMPANY_ID                                                       COMP354\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                           Renal Insufficiency\n",
      "INDICATION_ID                                                    D051437\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                    Odalasvir 12.5 mg\n",
      "DESCRIPTIONS           Part 1: ODV 12.5 mg taken orally as a componen...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000761\n",
      "CONDITION                                                        Healthy\n",
      "MOLREGNO                                                            5975\n",
      "NAME_TERM                                                obsolete_normal\n",
      "Name: 1517, dtype: object\n",
      "_____\n",
      "TWID                                                                2487\n",
      "TWEET_ID                                              780346129506377728\n",
      "TWEET                  Janssen's AL-335 in combination with odalasvir...\n",
      "SYNONYMS                                                       ODALASVIR\n",
      "MOLREGNO_1                                                       1926826\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03059303\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                             achieves 100% SVR12 in phase\n",
      "COMPANY                                                          Janssen\n",
      "COMPANY_ID                                                       COMP354\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                           Renal Insufficiency\n",
      "INDICATION_ID                                                    D051437\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                    Odalasvir 12.5 mg\n",
      "DESCRIPTIONS           Part 1: ODV 12.5 mg taken orally as a componen...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000761\n",
      "CONDITION                                                        Healthy\n",
      "MOLREGNO                                                          419601\n",
      "NAME_TERM                                                obsolete_normal\n",
      "Name: 1519, dtype: object\n",
      "_____\n",
      "TWID                                                                2487\n",
      "TWEET_ID                                              780346129506377728\n",
      "TWEET                  Janssen's AL-335 in combination with odalasvir...\n",
      "SYNONYMS                                                       ODALASVIR\n",
      "MOLREGNO_1                                                       1926826\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03059303\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                             achieves 100% SVR12 in phase\n",
      "COMPANY                                                          Janssen\n",
      "COMPANY_ID                                                       COMP354\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                           Renal Insufficiency\n",
      "INDICATION_ID                                                    D051437\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                    Odalasvir 12.5 mg\n",
      "DESCRIPTIONS           Part 1: ODV 12.5 mg taken orally as a componen...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000761\n",
      "CONDITION                                                        Healthy\n",
      "MOLREGNO                                                          451744\n",
      "NAME_TERM                                                obsolete_normal\n",
      "Name: 1520, dtype: object\n",
      "_____\n",
      "TWID                                                                2487\n",
      "TWEET_ID                                              780346129506377728\n",
      "TWEET                  Janssen's AL-335 in combination with odalasvir...\n",
      "SYNONYMS                                                      SIMEPREVIR\n",
      "MOLREGNO_1                                                        451744\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03069001\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                             achieves 100% SVR12 in phase\n",
      "COMPANY                                                          Janssen\n",
      "COMPANY_ID                                                       COMP354\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                           Renal Insufficiency\n",
      "INDICATION_ID                                                    D051437\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                Sofosbuvir-Simeprevir\n",
      "DESCRIPTIONS           -Sofosbuvir-Simeprevir group included 50 patie...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0003047\n",
      "CONDITION                                                            HCV\n",
      "MOLREGNO                                                          708075\n",
      "NAME_TERM                                          hepatitis C infection\n",
      "Name: 1521, dtype: object\n",
      "_____\n",
      "TWID                                                                2487\n",
      "TWEET_ID                                              780346129506377728\n",
      "TWEET                  Janssen's AL-335 in combination with odalasvir...\n",
      "SYNONYMS                                                      SIMEPREVIR\n",
      "MOLREGNO_1                                                        451744\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03069001\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                             achieves 100% SVR12 in phase\n",
      "COMPANY                                                          Janssen\n",
      "COMPANY_ID                                                       COMP354\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                           Renal Insufficiency\n",
      "INDICATION_ID                                                    D051437\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                Sofosbuvir-Simeprevir\n",
      "DESCRIPTIONS           -Sofosbuvir-Simeprevir group included 50 patie...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0003047\n",
      "CONDITION                                                            HCV\n",
      "MOLREGNO                                                          485738\n",
      "NAME_TERM                                          hepatitis C infection\n",
      "Name: 1522, dtype: object\n",
      "_____\n",
      "TWID                                                                2517\n",
      "TWEET_ID                                              778170849761329152\n",
      "TWEET                  Shandong Taibang receives CFDA approval to sta...\n",
      "SYNONYMS                                   COAGULATION FACTOR IX (HUMAN)\n",
      "MOLREGNO_1                                                        675421\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                              Null\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                    start clinical trials\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                  Hemophilia B\n",
      "INDICATION_ID                                                    D002836\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Null\n",
      "INTERVENTION_NAME_x                                                 Null\n",
      "DESCRIPTIONS                                                        Null\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                              Null\n",
      "CONDITION                                                           Null\n",
      "MOLREGNO                                                            Null\n",
      "NAME_TERM                                                            NaN\n",
      "Name: 1545, dtype: object\n",
      "_____\n",
      "TWID                                                                2521\n",
      "TWEET_ID                                              777774748382040064\n",
      "TWEET                  Pfizer's PF-06438179 (a biosimilar to Remicade...\n",
      "SYNONYMS                                                        REMICADE\n",
      "MOLREGNO_1                                                        675617\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03006393\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                   meets primary endpoint\n",
      "COMPANY                                                           Pfizer\n",
      "COMPANY_ID                                                       COMP570\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                               Behcet Syndrome\n",
      "INDICATION_ID                                                    D001528\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Infliximab\n",
      "DESCRIPTIONS           One infusion of Infliximab (Remicade) will be ...\n",
      "OTHER_NAME                                                      Remicade\n",
      "EFO_ID                                                       EFO:0003761\n",
      "CONDITION                                                     Depression\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                            unipolar depression\n",
      "Name: 1548, dtype: object\n",
      "_____\n",
      "TWID                                                                2546\n",
      "TWEET_ID                                              776339035451105280\n",
      "TWEET                  US FDA clears Inhibikase's Abelson tyrosine ki...\n",
      "SYNONYMS                                                        TYROSINE\n",
      "MOLREGNO_1                                                         84482\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02761057\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                    start clinical trials\n",
      "COMPANY                                          Inhibikase Therapeutics\n",
      "COMPANY_ID                                                     COMP92933\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                   Secondary Parkinson Disease\n",
      "INDICATION_ID                                                    D010302\n",
      "INDICATION_NONAMBIG                                                    0\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Crizotinib\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             MET Tyrosine Kinase Inhibitor PF-02341066;PF-0...\n",
      "EFO_ID                                                       EFO:0000640\n",
      "CONDITION                          Type 2 Papillary Renal Cell Carcinoma\n",
      "MOLREGNO                                                          602271\n",
      "NAME_TERM                                 papillary renal cell carcinoma\n",
      "Name: 1564, dtype: object\n",
      "_____\n",
      "TWID                                                                2546\n",
      "TWEET_ID                                              776339035451105280\n",
      "TWEET                  US FDA clears Inhibikase's Abelson tyrosine ki...\n",
      "SYNONYMS                                                        TYROSINE\n",
      "MOLREGNO_1                                                         84482\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02761057\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                    start clinical trials\n",
      "COMPANY                                          Inhibikase Therapeutics\n",
      "COMPANY_ID                                                     COMP92933\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                   Secondary Parkinson Disease\n",
      "INDICATION_ID                                                    D010302\n",
      "INDICATION_NONAMBIG                                                    0\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Crizotinib\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             MET Tyrosine Kinase Inhibitor PF-02341066;PF-0...\n",
      "EFO_ID                                                       EFO:0000640\n",
      "CONDITION                          Type 2 Papillary Renal Cell Carcinoma\n",
      "MOLREGNO                                                          450864\n",
      "NAME_TERM                                 papillary renal cell carcinoma\n",
      "Name: 1565, dtype: object\n",
      "_____\n",
      "TWID                                                                2546\n",
      "TWEET_ID                                              776339035451105280\n",
      "TWEET                  US FDA clears Inhibikase's Abelson tyrosine ki...\n",
      "SYNONYMS                                                        TYROSINE\n",
      "MOLREGNO_1                                                         84482\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02761057\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                    start clinical trials\n",
      "COMPANY                                          Inhibikase Therapeutics\n",
      "COMPANY_ID                                                     COMP92933\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                   Secondary Parkinson Disease\n",
      "INDICATION_ID                                                    D010302\n",
      "INDICATION_NONAMBIG                                                    0\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Crizotinib\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             MET Tyrosine Kinase Inhibitor PF-02341066;PF-0...\n",
      "EFO_ID                                                       EFO:0000640\n",
      "CONDITION                          Type 2 Papillary Renal Cell Carcinoma\n",
      "MOLREGNO                                                         1376138\n",
      "NAME_TERM                                 papillary renal cell carcinoma\n",
      "Name: 1566, dtype: object\n",
      "_____\n",
      "TWID                                                                2546\n",
      "TWEET_ID                                              776339035451105280\n",
      "TWEET                  US FDA clears Inhibikase's Abelson tyrosine ki...\n",
      "SYNONYMS                                                        TYROSINE\n",
      "MOLREGNO_1                                                         84482\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02761057\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                    start clinical trials\n",
      "COMPANY                                          Inhibikase Therapeutics\n",
      "COMPANY_ID                                                     COMP92933\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                   Secondary Parkinson Disease\n",
      "INDICATION_ID                                                    D010302\n",
      "INDICATION_NONAMBIG                                                    0\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Crizotinib\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             MET Tyrosine Kinase Inhibitor PF-02341066;PF-0...\n",
      "EFO_ID                                                       EFO:0000640\n",
      "CONDITION                          Type 2 Papillary Renal Cell Carcinoma\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                 papillary renal cell carcinoma\n",
      "Name: 1567, dtype: object\n",
      "_____\n",
      "TWID                                                                2546\n",
      "TWEET_ID                                              776339035451105280\n",
      "TWEET                  US FDA clears Inhibikase's Abelson tyrosine ki...\n",
      "SYNONYMS                                                        TYROSINE\n",
      "MOLREGNO_1                                                         84482\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02761057\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                    start clinical trials\n",
      "COMPANY                                          Inhibikase Therapeutics\n",
      "COMPANY_ID                                                     COMP92933\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                   Secondary Parkinson Disease\n",
      "INDICATION_ID                                                    D010302\n",
      "INDICATION_NONAMBIG                                                    0\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Crizotinib\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             MET Tyrosine Kinase Inhibitor PF-02341066;PF-0...\n",
      "EFO_ID                                                       EFO:0000640\n",
      "CONDITION                          Type 1 Papillary Renal Cell Carcinoma\n",
      "MOLREGNO                                                          602271\n",
      "NAME_TERM                                 papillary renal cell carcinoma\n",
      "Name: 1568, dtype: object\n",
      "_____\n",
      "TWID                                                                2546\n",
      "TWEET_ID                                              776339035451105280\n",
      "TWEET                  US FDA clears Inhibikase's Abelson tyrosine ki...\n",
      "SYNONYMS                                                        TYROSINE\n",
      "MOLREGNO_1                                                         84482\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02761057\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                    start clinical trials\n",
      "COMPANY                                          Inhibikase Therapeutics\n",
      "COMPANY_ID                                                     COMP92933\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                   Secondary Parkinson Disease\n",
      "INDICATION_ID                                                    D010302\n",
      "INDICATION_NONAMBIG                                                    0\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Crizotinib\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             MET Tyrosine Kinase Inhibitor PF-02341066;PF-0...\n",
      "EFO_ID                                                       EFO:0000640\n",
      "CONDITION                          Type 1 Papillary Renal Cell Carcinoma\n",
      "MOLREGNO                                                          450864\n",
      "NAME_TERM                                 papillary renal cell carcinoma\n",
      "Name: 1569, dtype: object\n",
      "_____\n",
      "TWID                                                                2546\n",
      "TWEET_ID                                              776339035451105280\n",
      "TWEET                  US FDA clears Inhibikase's Abelson tyrosine ki...\n",
      "SYNONYMS                                                        TYROSINE\n",
      "MOLREGNO_1                                                         84482\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02761057\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                    start clinical trials\n",
      "COMPANY                                          Inhibikase Therapeutics\n",
      "COMPANY_ID                                                     COMP92933\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                   Secondary Parkinson Disease\n",
      "INDICATION_ID                                                    D010302\n",
      "INDICATION_NONAMBIG                                                    0\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Crizotinib\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             MET Tyrosine Kinase Inhibitor PF-02341066;PF-0...\n",
      "EFO_ID                                                       EFO:0000640\n",
      "CONDITION                          Type 1 Papillary Renal Cell Carcinoma\n",
      "MOLREGNO                                                         1376138\n",
      "NAME_TERM                                 papillary renal cell carcinoma\n",
      "Name: 1570, dtype: object\n",
      "_____\n",
      "TWID                                                                2546\n",
      "TWEET_ID                                              776339035451105280\n",
      "TWEET                  US FDA clears Inhibikase's Abelson tyrosine ki...\n",
      "SYNONYMS                                                        TYROSINE\n",
      "MOLREGNO_1                                                         84482\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02761057\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                    start clinical trials\n",
      "COMPANY                                          Inhibikase Therapeutics\n",
      "COMPANY_ID                                                     COMP92933\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                   Secondary Parkinson Disease\n",
      "INDICATION_ID                                                    D010302\n",
      "INDICATION_NONAMBIG                                                    0\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Crizotinib\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             MET Tyrosine Kinase Inhibitor PF-02341066;PF-0...\n",
      "EFO_ID                                                       EFO:0000640\n",
      "CONDITION                          Type 1 Papillary Renal Cell Carcinoma\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                 papillary renal cell carcinoma\n",
      "Name: 1571, dtype: object\n",
      "_____\n",
      "TWID                                                                2546\n",
      "TWEET_ID                                              776339035451105280\n",
      "TWEET                  US FDA clears Inhibikase's Abelson tyrosine ki...\n",
      "SYNONYMS                                                        TYROSINE\n",
      "MOLREGNO_1                                                         84482\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02761057\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                    start clinical trials\n",
      "COMPANY                                          Inhibikase Therapeutics\n",
      "COMPANY_ID                                                     COMP92933\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                   Secondary Parkinson Disease\n",
      "INDICATION_ID                                                    D010302\n",
      "INDICATION_NONAMBIG                                                    0\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Crizotinib\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             MET Tyrosine Kinase Inhibitor PF-02341066;PF-0...\n",
      "EFO_ID                                                       EFO:0000681\n",
      "CONDITION                             Stage IV Renal Cell Cancer AJCC v7\n",
      "MOLREGNO                                                          602271\n",
      "NAME_TERM                                           renal cell carcinoma\n",
      "Name: 1572, dtype: object\n",
      "_____\n",
      "TWID                                                                2546\n",
      "TWEET_ID                                              776339035451105280\n",
      "TWEET                  US FDA clears Inhibikase's Abelson tyrosine ki...\n",
      "SYNONYMS                                                        TYROSINE\n",
      "MOLREGNO_1                                                         84482\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02761057\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                    start clinical trials\n",
      "COMPANY                                          Inhibikase Therapeutics\n",
      "COMPANY_ID                                                     COMP92933\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                   Secondary Parkinson Disease\n",
      "INDICATION_ID                                                    D010302\n",
      "INDICATION_NONAMBIG                                                    0\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Crizotinib\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             MET Tyrosine Kinase Inhibitor PF-02341066;PF-0...\n",
      "EFO_ID                                                       EFO:0000681\n",
      "CONDITION                             Stage IV Renal Cell Cancer AJCC v7\n",
      "MOLREGNO                                                          450864\n",
      "NAME_TERM                                           renal cell carcinoma\n",
      "Name: 1573, dtype: object\n",
      "_____\n",
      "TWID                                                                2546\n",
      "TWEET_ID                                              776339035451105280\n",
      "TWEET                  US FDA clears Inhibikase's Abelson tyrosine ki...\n",
      "SYNONYMS                                                        TYROSINE\n",
      "MOLREGNO_1                                                         84482\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02761057\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                    start clinical trials\n",
      "COMPANY                                          Inhibikase Therapeutics\n",
      "COMPANY_ID                                                     COMP92933\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                   Secondary Parkinson Disease\n",
      "INDICATION_ID                                                    D010302\n",
      "INDICATION_NONAMBIG                                                    0\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Crizotinib\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             MET Tyrosine Kinase Inhibitor PF-02341066;PF-0...\n",
      "EFO_ID                                                       EFO:0000681\n",
      "CONDITION                             Stage IV Renal Cell Cancer AJCC v7\n",
      "MOLREGNO                                                         1376138\n",
      "NAME_TERM                                           renal cell carcinoma\n",
      "Name: 1574, dtype: object\n",
      "_____\n",
      "TWID                                                                2546\n",
      "TWEET_ID                                              776339035451105280\n",
      "TWEET                  US FDA clears Inhibikase's Abelson tyrosine ki...\n",
      "SYNONYMS                                                        TYROSINE\n",
      "MOLREGNO_1                                                         84482\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02761057\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                    start clinical trials\n",
      "COMPANY                                          Inhibikase Therapeutics\n",
      "COMPANY_ID                                                     COMP92933\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                   Secondary Parkinson Disease\n",
      "INDICATION_ID                                                    D010302\n",
      "INDICATION_NONAMBIG                                                    0\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Crizotinib\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             MET Tyrosine Kinase Inhibitor PF-02341066;PF-0...\n",
      "EFO_ID                                                       EFO:0000681\n",
      "CONDITION                             Stage IV Renal Cell Cancer AJCC v7\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                           renal cell carcinoma\n",
      "Name: 1575, dtype: object\n",
      "_____\n",
      "TWID                                                                2546\n",
      "TWEET_ID                                              776339035451105280\n",
      "TWEET                  US FDA clears Inhibikase's Abelson tyrosine ki...\n",
      "SYNONYMS                                                        TYROSINE\n",
      "MOLREGNO_1                                                         84482\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02761057\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                    start clinical trials\n",
      "COMPANY                                          Inhibikase Therapeutics\n",
      "COMPANY_ID                                                     COMP92933\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                   Secondary Parkinson Disease\n",
      "INDICATION_ID                                                    D010302\n",
      "INDICATION_NONAMBIG                                                    0\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Crizotinib\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             MET Tyrosine Kinase Inhibitor PF-02341066;PF-0...\n",
      "EFO_ID                                                       EFO:0000681\n",
      "CONDITION                            Stage III Renal Cell Cancer AJCC v7\n",
      "MOLREGNO                                                          602271\n",
      "NAME_TERM                                           renal cell carcinoma\n",
      "Name: 1576, dtype: object\n",
      "_____\n",
      "TWID                                                                2546\n",
      "TWEET_ID                                              776339035451105280\n",
      "TWEET                  US FDA clears Inhibikase's Abelson tyrosine ki...\n",
      "SYNONYMS                                                        TYROSINE\n",
      "MOLREGNO_1                                                         84482\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02761057\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                    start clinical trials\n",
      "COMPANY                                          Inhibikase Therapeutics\n",
      "COMPANY_ID                                                     COMP92933\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                   Secondary Parkinson Disease\n",
      "INDICATION_ID                                                    D010302\n",
      "INDICATION_NONAMBIG                                                    0\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Crizotinib\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             MET Tyrosine Kinase Inhibitor PF-02341066;PF-0...\n",
      "EFO_ID                                                       EFO:0000681\n",
      "CONDITION                            Stage III Renal Cell Cancer AJCC v7\n",
      "MOLREGNO                                                          450864\n",
      "NAME_TERM                                           renal cell carcinoma\n",
      "Name: 1577, dtype: object\n",
      "_____\n",
      "TWID                                                                2546\n",
      "TWEET_ID                                              776339035451105280\n",
      "TWEET                  US FDA clears Inhibikase's Abelson tyrosine ki...\n",
      "SYNONYMS                                                        TYROSINE\n",
      "MOLREGNO_1                                                         84482\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02761057\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                    start clinical trials\n",
      "COMPANY                                          Inhibikase Therapeutics\n",
      "COMPANY_ID                                                     COMP92933\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                   Secondary Parkinson Disease\n",
      "INDICATION_ID                                                    D010302\n",
      "INDICATION_NONAMBIG                                                    0\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Crizotinib\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             MET Tyrosine Kinase Inhibitor PF-02341066;PF-0...\n",
      "EFO_ID                                                       EFO:0000681\n",
      "CONDITION                            Stage III Renal Cell Cancer AJCC v7\n",
      "MOLREGNO                                                         1376138\n",
      "NAME_TERM                                           renal cell carcinoma\n",
      "Name: 1578, dtype: object\n",
      "_____\n",
      "TWID                                                                2546\n",
      "TWEET_ID                                              776339035451105280\n",
      "TWEET                  US FDA clears Inhibikase's Abelson tyrosine ki...\n",
      "SYNONYMS                                                        TYROSINE\n",
      "MOLREGNO_1                                                         84482\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02761057\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                    start clinical trials\n",
      "COMPANY                                          Inhibikase Therapeutics\n",
      "COMPANY_ID                                                     COMP92933\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                   Secondary Parkinson Disease\n",
      "INDICATION_ID                                                    D010302\n",
      "INDICATION_NONAMBIG                                                    0\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Crizotinib\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME             MET Tyrosine Kinase Inhibitor PF-02341066;PF-0...\n",
      "EFO_ID                                                       EFO:0000681\n",
      "CONDITION                            Stage III Renal Cell Cancer AJCC v7\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                           renal cell carcinoma\n",
      "Name: 1579, dtype: object\n",
      "_____\n",
      "TWID                                                                2547\n",
      "TWEET_ID                                              776336829867892738\n",
      "TWEET                  Azevan Pharmaceuticals' SRX-246 meets primary ...\n",
      "SYNONYMS                                                          SRX246\n",
      "MOLREGNO_1                                                        391061\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03036397\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                   meets primary endpoint\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                             Anxiety Disorders\n",
      "INDICATION_ID                                                    D001008\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                               SRX246\n",
      "DESCRIPTIONS                           180mg qam/ 120mg qhs for 5-7 days\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0005230\n",
      "CONDITION                                               Anxiety Disorder\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                        anxiety\n",
      "Name: 1580, dtype: object\n",
      "_____\n",
      "TWID                                                                2554\n",
      "TWEET_ID                                              776064650668482560\n",
      "TWEET                  Sanofi's new dual peptide SAR425899 efficientl...\n",
      "SYNONYMS                                                         GLUCOSE\n",
      "MOLREGNO_1                                                       1037865\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03039673\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            safe in trial\n",
      "COMPANY                                                    SanofiAventis\n",
      "COMPANY_ID                                                       COMP657\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                            5% glucose water solution\n",
      "DESCRIPTIONS           The placebo consists of 5% glucose water solut...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000253\n",
      "CONDITION                                  Amyotrophic Lateral Sclerosis\n",
      "MOLREGNO                                                          627419\n",
      "NAME_TERM                                  amyotrophic lateral sclerosis\n",
      "Name: 1582, dtype: object\n",
      "_____\n",
      "TWID                                                                2554\n",
      "TWEET_ID                                              776064650668482560\n",
      "TWEET                  Sanofi's new dual peptide SAR425899 efficientl...\n",
      "SYNONYMS                                                         GLUCOSE\n",
      "MOLREGNO_1                                                       1037865\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03039673\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            safe in trial\n",
      "COMPANY                                                    SanofiAventis\n",
      "COMPANY_ID                                                       COMP657\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                            5% glucose water solution\n",
      "DESCRIPTIONS           The placebo consists of 5% glucose water solut...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000253\n",
      "CONDITION                                  Amyotrophic Lateral Sclerosis\n",
      "MOLREGNO                                                          675456\n",
      "NAME_TERM                                  amyotrophic lateral sclerosis\n",
      "Name: 1584, dtype: object\n",
      "_____\n",
      "TWID                                                                2554\n",
      "TWEET_ID                                              776064650668482560\n",
      "TWEET                  Sanofi's new dual peptide SAR425899 efficientl...\n",
      "SYNONYMS                                                         GLUCOSE\n",
      "MOLREGNO_1                                                       1037865\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03039673\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            safe in trial\n",
      "COMPANY                                                    SanofiAventis\n",
      "COMPANY_ID                                                       COMP657\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                            5% glucose water solution\n",
      "DESCRIPTIONS           The placebo consists of 5% glucose water solut...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000253\n",
      "CONDITION                                  Amyotrophic Lateral Sclerosis\n",
      "MOLREGNO                                                           38898\n",
      "NAME_TERM                                  amyotrophic lateral sclerosis\n",
      "Name: 1585, dtype: object\n",
      "_____\n",
      "TWID                                                                2554\n",
      "TWEET_ID                                              776064650668482560\n",
      "TWEET                  Sanofi's new dual peptide SAR425899 efficientl...\n",
      "SYNONYMS                                                         GLUCOSE\n",
      "MOLREGNO_1                                                        688684\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03039673\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            safe in trial\n",
      "COMPANY                                                    SanofiAventis\n",
      "COMPANY_ID                                                       COMP657\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                            5% glucose water solution\n",
      "DESCRIPTIONS           The placebo consists of 5% glucose water solut...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000253\n",
      "CONDITION                                  Amyotrophic Lateral Sclerosis\n",
      "MOLREGNO                                                          627419\n",
      "NAME_TERM                                  amyotrophic lateral sclerosis\n",
      "Name: 1586, dtype: object\n",
      "_____\n",
      "TWID                                                                2554\n",
      "TWEET_ID                                              776064650668482560\n",
      "TWEET                  Sanofi's new dual peptide SAR425899 efficientl...\n",
      "SYNONYMS                                                         GLUCOSE\n",
      "MOLREGNO_1                                                        688684\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03039673\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            safe in trial\n",
      "COMPANY                                                    SanofiAventis\n",
      "COMPANY_ID                                                       COMP657\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                            5% glucose water solution\n",
      "DESCRIPTIONS           The placebo consists of 5% glucose water solut...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000253\n",
      "CONDITION                                  Amyotrophic Lateral Sclerosis\n",
      "MOLREGNO                                                         1037865\n",
      "NAME_TERM                                  amyotrophic lateral sclerosis\n",
      "Name: 1587, dtype: object\n",
      "_____\n",
      "TWID                                                                2554\n",
      "TWEET_ID                                              776064650668482560\n",
      "TWEET                  Sanofi's new dual peptide SAR425899 efficientl...\n",
      "SYNONYMS                                                         GLUCOSE\n",
      "MOLREGNO_1                                                        688684\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03039673\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            safe in trial\n",
      "COMPANY                                                    SanofiAventis\n",
      "COMPANY_ID                                                       COMP657\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                            5% glucose water solution\n",
      "DESCRIPTIONS           The placebo consists of 5% glucose water solut...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000253\n",
      "CONDITION                                  Amyotrophic Lateral Sclerosis\n",
      "MOLREGNO                                                          675456\n",
      "NAME_TERM                                  amyotrophic lateral sclerosis\n",
      "Name: 1588, dtype: object\n",
      "_____\n",
      "TWID                                                                2554\n",
      "TWEET_ID                                              776064650668482560\n",
      "TWEET                  Sanofi's new dual peptide SAR425899 efficientl...\n",
      "SYNONYMS                                                         GLUCOSE\n",
      "MOLREGNO_1                                                        688684\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03039673\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            safe in trial\n",
      "COMPANY                                                    SanofiAventis\n",
      "COMPANY_ID                                                       COMP657\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                            5% glucose water solution\n",
      "DESCRIPTIONS           The placebo consists of 5% glucose water solut...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000253\n",
      "CONDITION                                  Amyotrophic Lateral Sclerosis\n",
      "MOLREGNO                                                           38898\n",
      "NAME_TERM                                  amyotrophic lateral sclerosis\n",
      "Name: 1589, dtype: object\n",
      "_____\n",
      "TWID                                                                2576\n",
      "TWEET_ID                                              775265471578968064\n",
      "TWEET                  Karuna begins phase I tolerability POC study o...\n",
      "SYNONYMS                                                      XANOMELINE\n",
      "MOLREGNO_1                                                         26653\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02831231\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                             Begins study\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                    Overactive Urinary Bladder\n",
      "INDICATION_ID                                                    D053201\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                  xanomeline tartrate\n",
      "DESCRIPTIONS                     xanomeline tartrate, 75 mg capsule, TID\n",
      "OTHER_NAME                                                      LY246708\n",
      "EFO_ID                                                       EFO:0000692\n",
      "CONDITION                                                  Schizophrenia\n",
      "MOLREGNO                                                         1594639\n",
      "NAME_TERM                                                  schizophrenia\n",
      "Name: 1605, dtype: object\n",
      "_____\n",
      "TWID                                                                2576\n",
      "TWEET_ID                                              775265471578968064\n",
      "TWEET                  Karuna begins phase I tolerability POC study o...\n",
      "SYNONYMS                                                      XANOMELINE\n",
      "MOLREGNO_1                                                         26653\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02831231\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                             Begins study\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                    Overactive Urinary Bladder\n",
      "INDICATION_ID                                                    D053201\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                  xanomeline tartrate\n",
      "DESCRIPTIONS                     xanomeline tartrate, 75 mg capsule, TID\n",
      "OTHER_NAME                                                      LY246708\n",
      "EFO_ID                                                       EFO:0000692\n",
      "CONDITION                                                  Schizophrenia\n",
      "MOLREGNO                                                         1525716\n",
      "NAME_TERM                                                  schizophrenia\n",
      "Name: 1606, dtype: object\n",
      "_____\n",
      "TWID                                                                2576\n",
      "TWEET_ID                                              775265471578968064\n",
      "TWEET                  Karuna begins phase I tolerability POC study o...\n",
      "SYNONYMS                                               TROSPIUM CHLORIDE\n",
      "MOLREGNO_1                                                        674556\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01166438\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                             Begins study\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                    Overactive Urinary Bladder\n",
      "INDICATION_ID                                                    D053201\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                    Trospium chloride\n",
      "DESCRIPTIONS           Oral Trospium chloride XR 60mg once a day for ...\n",
      "OTHER_NAME                                                      Sanctura\n",
      "EFO_ID                                                       EFO:1000781\n",
      "CONDITION                                             Overactive Bladder\n",
      "MOLREGNO                                                          675360\n",
      "NAME_TERM                                             overactive bladder\n",
      "Name: 1607, dtype: object\n",
      "_____\n",
      "TWID                                                                2576\n",
      "TWEET_ID                                              775265471578968064\n",
      "TWEET                  Karuna begins phase I tolerability POC study o...\n",
      "SYNONYMS                                               TROSPIUM CHLORIDE\n",
      "MOLREGNO_1                                                        674556\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01166438\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                             Begins study\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                    Overactive Urinary Bladder\n",
      "INDICATION_ID                                                    D053201\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                    Trospium chloride\n",
      "DESCRIPTIONS           Oral Trospium chloride XR 60mg once a day for ...\n",
      "OTHER_NAME                                                      Sanctura\n",
      "EFO_ID                                                       EFO:1000781\n",
      "CONDITION                                             Overactive Bladder\n",
      "MOLREGNO                                                          561914\n",
      "NAME_TERM                                             overactive bladder\n",
      "Name: 1608, dtype: object\n",
      "_____\n",
      "TWID                                                                2576\n",
      "TWEET_ID                                              775265471578968064\n",
      "TWEET                  Karuna begins phase I tolerability POC study o...\n",
      "SYNONYMS                                               TROSPIUM CHLORIDE\n",
      "MOLREGNO_1                                                        674556\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01166438\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                             Begins study\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                    Overactive Urinary Bladder\n",
      "INDICATION_ID                                                    D053201\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                    Trospium chloride\n",
      "DESCRIPTIONS           Oral Trospium chloride XR 60mg once a day for ...\n",
      "OTHER_NAME                                                      Sanctura\n",
      "EFO_ID                                                       EFO:1000781\n",
      "CONDITION                                             Overactive Bladder\n",
      "MOLREGNO                                                         1594639\n",
      "NAME_TERM                                             overactive bladder\n",
      "Name: 1609, dtype: object\n",
      "_____\n",
      "TWID                                                                2576\n",
      "TWEET_ID                                              775265471578968064\n",
      "TWEET                  Karuna begins phase I tolerability POC study o...\n",
      "SYNONYMS                                               TROSPIUM CHLORIDE\n",
      "MOLREGNO_1                                                        674556\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01166438\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                             Begins study\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                    Overactive Urinary Bladder\n",
      "INDICATION_ID                                                    D053201\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                    Trospium chloride\n",
      "DESCRIPTIONS           Oral Trospium chloride XR 60mg once a day for ...\n",
      "OTHER_NAME                                                      Sanctura\n",
      "EFO_ID                                                        HP:0000020\n",
      "CONDITION                                      Urge Urinary Incontinence\n",
      "MOLREGNO                                                          675360\n",
      "NAME_TERM                                           Urinary incontinence\n",
      "Name: 1610, dtype: object\n",
      "_____\n",
      "TWID                                                                2576\n",
      "TWEET_ID                                              775265471578968064\n",
      "TWEET                  Karuna begins phase I tolerability POC study o...\n",
      "SYNONYMS                                               TROSPIUM CHLORIDE\n",
      "MOLREGNO_1                                                        674556\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01166438\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                             Begins study\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                    Overactive Urinary Bladder\n",
      "INDICATION_ID                                                    D053201\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                    Trospium chloride\n",
      "DESCRIPTIONS           Oral Trospium chloride XR 60mg once a day for ...\n",
      "OTHER_NAME                                                      Sanctura\n",
      "EFO_ID                                                        HP:0000020\n",
      "CONDITION                                      Urge Urinary Incontinence\n",
      "MOLREGNO                                                          561914\n",
      "NAME_TERM                                           Urinary incontinence\n",
      "Name: 1611, dtype: object\n",
      "_____\n",
      "TWID                                                                2576\n",
      "TWEET_ID                                              775265471578968064\n",
      "TWEET                  Karuna begins phase I tolerability POC study o...\n",
      "SYNONYMS                                               TROSPIUM CHLORIDE\n",
      "MOLREGNO_1                                                        674556\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01166438\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                             Begins study\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                    Overactive Urinary Bladder\n",
      "INDICATION_ID                                                    D053201\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                    Trospium chloride\n",
      "DESCRIPTIONS           Oral Trospium chloride XR 60mg once a day for ...\n",
      "OTHER_NAME                                                      Sanctura\n",
      "EFO_ID                                                        HP:0000020\n",
      "CONDITION                                      Urge Urinary Incontinence\n",
      "MOLREGNO                                                         1594639\n",
      "NAME_TERM                                           Urinary incontinence\n",
      "Name: 1612, dtype: object\n",
      "_____\n",
      "TWID                                                                2576\n",
      "TWEET_ID                                              775265471578968064\n",
      "TWEET                  Karuna begins phase I tolerability POC study o...\n",
      "SYNONYMS                                               TROSPIUM CHLORIDE\n",
      "MOLREGNO_1                                                       1594639\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01166438\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                             Begins study\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                    Overactive Urinary Bladder\n",
      "INDICATION_ID                                                    D053201\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                    Trospium chloride\n",
      "DESCRIPTIONS           Oral Trospium chloride XR 60mg once a day for ...\n",
      "OTHER_NAME                                                      Sanctura\n",
      "EFO_ID                                                       EFO:1000781\n",
      "CONDITION                                             Overactive Bladder\n",
      "MOLREGNO                                                          675360\n",
      "NAME_TERM                                             overactive bladder\n",
      "Name: 1613, dtype: object\n",
      "_____\n",
      "TWID                                                                2576\n",
      "TWEET_ID                                              775265471578968064\n",
      "TWEET                  Karuna begins phase I tolerability POC study o...\n",
      "SYNONYMS                                               TROSPIUM CHLORIDE\n",
      "MOLREGNO_1                                                       1594639\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01166438\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                             Begins study\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                    Overactive Urinary Bladder\n",
      "INDICATION_ID                                                    D053201\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                    Trospium chloride\n",
      "DESCRIPTIONS           Oral Trospium chloride XR 60mg once a day for ...\n",
      "OTHER_NAME                                                      Sanctura\n",
      "EFO_ID                                                       EFO:1000781\n",
      "CONDITION                                             Overactive Bladder\n",
      "MOLREGNO                                                          561914\n",
      "NAME_TERM                                             overactive bladder\n",
      "Name: 1614, dtype: object\n",
      "_____\n",
      "TWID                                                                2576\n",
      "TWEET_ID                                              775265471578968064\n",
      "TWEET                  Karuna begins phase I tolerability POC study o...\n",
      "SYNONYMS                                               TROSPIUM CHLORIDE\n",
      "MOLREGNO_1                                                       1594639\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01166438\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                             Begins study\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                    Overactive Urinary Bladder\n",
      "INDICATION_ID                                                    D053201\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                    Trospium chloride\n",
      "DESCRIPTIONS           Oral Trospium chloride XR 60mg once a day for ...\n",
      "OTHER_NAME                                                      Sanctura\n",
      "EFO_ID                                                        HP:0000020\n",
      "CONDITION                                      Urge Urinary Incontinence\n",
      "MOLREGNO                                                          675360\n",
      "NAME_TERM                                           Urinary incontinence\n",
      "Name: 1616, dtype: object\n",
      "_____\n",
      "TWID                                                                2576\n",
      "TWEET_ID                                              775265471578968064\n",
      "TWEET                  Karuna begins phase I tolerability POC study o...\n",
      "SYNONYMS                                               TROSPIUM CHLORIDE\n",
      "MOLREGNO_1                                                       1594639\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01166438\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                             Begins study\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                    Overactive Urinary Bladder\n",
      "INDICATION_ID                                                    D053201\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                    Trospium chloride\n",
      "DESCRIPTIONS           Oral Trospium chloride XR 60mg once a day for ...\n",
      "OTHER_NAME                                                      Sanctura\n",
      "EFO_ID                                                        HP:0000020\n",
      "CONDITION                                      Urge Urinary Incontinence\n",
      "MOLREGNO                                                          561914\n",
      "NAME_TERM                                           Urinary incontinence\n",
      "Name: 1617, dtype: object\n",
      "_____\n",
      "TWID                                                                2589\n",
      "TWEET_ID                                              773563458168074240\n",
      "TWEET                  @Patara's inhaled cromolyn formulation PA-101 ...\n",
      "SYNONYMS                                                        CROMOLYN\n",
      "MOLREGNO_1                                                          6480\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03167216\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                       reduces cough rate\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                        Stroke\n",
      "INDICATION_ID                                                    D020521\n",
      "INDICATION_NONAMBIG                                                    2\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                      Cromolyn Sodium\n",
      "DESCRIPTIONS                                        Mast cell stabilizer\n",
      "OTHER_NAME                                                    Gastrocrom\n",
      "EFO_ID                                                       EFO:0003830\n",
      "CONDITION              Chronic Prostatitis With Chronic Pelvic Pain S...\n",
      "MOLREGNO                                                         1031157\n",
      "NAME_TERM                                                    prostatitis\n",
      "Name: 1626, dtype: object\n",
      "_____\n",
      "TWID                                                                2600\n",
      "TWEET_ID                                              773110212102201344\n",
      "TWEET                  Phase III trial initiated in US for Hisamitsu ...\n",
      "SYNONYMS                                                       ASENAPINE\n",
      "MOLREGNO_1                                                       1676656\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02876900\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                          Trial initiated\n",
      "COMPANY                                                        Hisamitsu\n",
      "COMPANY_ID                                                     COMP90497\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                 Schizophrenia\n",
      "INDICATION_ID                                                    D012559\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x    Asenapine maleate, transdermal patch (Low Dosage)\n",
      "DESCRIPTIONS           The study will evaluate a low dose version of ...\n",
      "OTHER_NAME                                             Transdermal patch\n",
      "EFO_ID                                                       EFO:0000692\n",
      "CONDITION                                                  Schizophrenia\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                  schizophrenia\n",
      "Name: 1630, dtype: object\n",
      "_____\n",
      "TWID                                                                2600\n",
      "TWEET_ID                                              773110212102201344\n",
      "TWEET                  Phase III trial initiated in US for Hisamitsu ...\n",
      "SYNONYMS                                                       ASENAPINE\n",
      "MOLREGNO_1                                                       1676656\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02876900\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                          Trial initiated\n",
      "COMPANY                                                        Hisamitsu\n",
      "COMPANY_ID                                                     COMP90497\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                 Schizophrenia\n",
      "INDICATION_ID                                                    D012559\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x    Asenapine maleate, transdermal patch (Low Dosage)\n",
      "DESCRIPTIONS           The study will evaluate a low dose version of ...\n",
      "OTHER_NAME                                             Transdermal patch\n",
      "EFO_ID                                                       EFO:0000692\n",
      "CONDITION                                                  Schizophrenia\n",
      "MOLREGNO                                                         1926823\n",
      "NAME_TERM                                                  schizophrenia\n",
      "Name: 1631, dtype: object\n",
      "_____\n",
      "TWID                                                                2600\n",
      "TWEET_ID                                              773110212102201344\n",
      "TWEET                  Phase III trial initiated in US for Hisamitsu ...\n",
      "SYNONYMS                                                       ASENAPINE\n",
      "MOLREGNO_1                                                       1676656\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02876900\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                          Trial initiated\n",
      "COMPANY                                                        Hisamitsu\n",
      "COMPANY_ID                                                     COMP90497\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                 Schizophrenia\n",
      "INDICATION_ID                                                    D012559\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x    Asenapine maleate, transdermal patch (High Dos...\n",
      "DESCRIPTIONS           The study will evaluate high dose version of t...\n",
      "OTHER_NAME                                             Transdermal patch\n",
      "EFO_ID                                                       EFO:0000692\n",
      "CONDITION                                                  Schizophrenia\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                  schizophrenia\n",
      "Name: 1632, dtype: object\n",
      "_____\n",
      "TWID                                                                2600\n",
      "TWEET_ID                                              773110212102201344\n",
      "TWEET                  Phase III trial initiated in US for Hisamitsu ...\n",
      "SYNONYMS                                                       ASENAPINE\n",
      "MOLREGNO_1                                                       1676656\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02876900\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                          Trial initiated\n",
      "COMPANY                                                        Hisamitsu\n",
      "COMPANY_ID                                                     COMP90497\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                 Schizophrenia\n",
      "INDICATION_ID                                                    D012559\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x    Asenapine maleate, transdermal patch (High Dos...\n",
      "DESCRIPTIONS           The study will evaluate high dose version of t...\n",
      "OTHER_NAME                                             Transdermal patch\n",
      "EFO_ID                                                       EFO:0000692\n",
      "CONDITION                                                  Schizophrenia\n",
      "MOLREGNO                                                         1926823\n",
      "NAME_TERM                                                  schizophrenia\n",
      "Name: 1633, dtype: object\n",
      "_____\n",
      "TWID                                                                2600\n",
      "TWEET_ID                                              773110212102201344\n",
      "TWEET                  Phase III trial initiated in US for Hisamitsu ...\n",
      "SYNONYMS                                               ASENAPINE MALEATE\n",
      "MOLREGNO_1                                                       1926823\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02876900\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                          Trial initiated\n",
      "COMPANY                                                        Hisamitsu\n",
      "COMPANY_ID                                                     COMP90497\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                 Schizophrenia\n",
      "INDICATION_ID                                                    D012559\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x    Asenapine maleate, transdermal patch (Low Dosage)\n",
      "DESCRIPTIONS           The study will evaluate a low dose version of ...\n",
      "OTHER_NAME                                             Transdermal patch\n",
      "EFO_ID                                                       EFO:0000692\n",
      "CONDITION                                                  Schizophrenia\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                  schizophrenia\n",
      "Name: 1634, dtype: object\n",
      "_____\n",
      "TWID                                                                2600\n",
      "TWEET_ID                                              773110212102201344\n",
      "TWEET                  Phase III trial initiated in US for Hisamitsu ...\n",
      "SYNONYMS                                               ASENAPINE MALEATE\n",
      "MOLREGNO_1                                                       1926823\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02876900\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                          Trial initiated\n",
      "COMPANY                                                        Hisamitsu\n",
      "COMPANY_ID                                                     COMP90497\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                 Schizophrenia\n",
      "INDICATION_ID                                                    D012559\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x    Asenapine maleate, transdermal patch (High Dos...\n",
      "DESCRIPTIONS           The study will evaluate high dose version of t...\n",
      "OTHER_NAME                                             Transdermal patch\n",
      "EFO_ID                                                       EFO:0000692\n",
      "CONDITION                                                  Schizophrenia\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                  schizophrenia\n",
      "Name: 1636, dtype: object\n",
      "_____\n",
      "TWID                                                                2642\n",
      "TWEET_ID                                              769871051022925824\n",
      "TWEET                  Apixaban may be as good as warfarin in atrial ...\n",
      "SYNONYMS                                                        APIXABAN\n",
      "MOLREGNO_1                                                        397524\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03129555\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           may be as good\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                       cardiovascular diseases\n",
      "INDICATION_ID                                                    D002318\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                 Apixaban Oral Tablet\n",
      "DESCRIPTIONS           After cluster randomization, the cluster will ...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0003827\n",
      "CONDITION                                             Pulmonary Embolism\n",
      "MOLREGNO                                                          709600\n",
      "NAME_TERM                                             pulmonary embolism\n",
      "Name: 1644, dtype: object\n",
      "_____\n",
      "TWID                                                                2642\n",
      "TWEET_ID                                              769871051022925824\n",
      "TWEET                  Apixaban may be as good as warfarin in atrial ...\n",
      "SYNONYMS                                                        APIXABAN\n",
      "MOLREGNO_1                                                        397524\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03129555\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           may be as good\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                       cardiovascular diseases\n",
      "INDICATION_ID                                                    D002318\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                 Apixaban Oral Tablet\n",
      "DESCRIPTIONS           After cluster randomization, the cluster will ...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0003827\n",
      "CONDITION                                             Pulmonary Embolism\n",
      "MOLREGNO                                                          561520\n",
      "NAME_TERM                                             pulmonary embolism\n",
      "Name: 1645, dtype: object\n",
      "_____\n",
      "TWID                                                                2642\n",
      "TWEET_ID                                              769871051022925824\n",
      "TWEET                  Apixaban may be as good as warfarin in atrial ...\n",
      "SYNONYMS                                                        APIXABAN\n",
      "MOLREGNO_1                                                        397524\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03129555\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           may be as good\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                       cardiovascular diseases\n",
      "INDICATION_ID                                                    D002318\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                 Apixaban Oral Tablet\n",
      "DESCRIPTIONS           After cluster randomization, the cluster will ...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0003827\n",
      "CONDITION                                             Pulmonary Embolism\n",
      "MOLREGNO                                                          328601\n",
      "NAME_TERM                                             pulmonary embolism\n",
      "Name: 1646, dtype: object\n",
      "_____\n",
      "TWID                                                                2642\n",
      "TWEET_ID                                              769871051022925824\n",
      "TWEET                  Apixaban may be as good as warfarin in atrial ...\n",
      "SYNONYMS                                                        APIXABAN\n",
      "MOLREGNO_1                                                        397524\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03129555\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           may be as good\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                       cardiovascular diseases\n",
      "INDICATION_ID                                                    D002318\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                 Apixaban Oral Tablet\n",
      "DESCRIPTIONS           After cluster randomization, the cluster will ...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0003907\n",
      "CONDITION                                           Deep Vein Thrombosis\n",
      "MOLREGNO                                                          709600\n",
      "NAME_TERM                                           deep vein thrombosis\n",
      "Name: 1648, dtype: object\n",
      "_____\n",
      "TWID                                                                2642\n",
      "TWEET_ID                                              769871051022925824\n",
      "TWEET                  Apixaban may be as good as warfarin in atrial ...\n",
      "SYNONYMS                                                        APIXABAN\n",
      "MOLREGNO_1                                                        397524\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03129555\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           may be as good\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                       cardiovascular diseases\n",
      "INDICATION_ID                                                    D002318\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                 Apixaban Oral Tablet\n",
      "DESCRIPTIONS           After cluster randomization, the cluster will ...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0003907\n",
      "CONDITION                                           Deep Vein Thrombosis\n",
      "MOLREGNO                                                          561520\n",
      "NAME_TERM                                           deep vein thrombosis\n",
      "Name: 1649, dtype: object\n",
      "_____\n",
      "TWID                                                                2642\n",
      "TWEET_ID                                              769871051022925824\n",
      "TWEET                  Apixaban may be as good as warfarin in atrial ...\n",
      "SYNONYMS                                                        APIXABAN\n",
      "MOLREGNO_1                                                        397524\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03129555\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           may be as good\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                       cardiovascular diseases\n",
      "INDICATION_ID                                                    D002318\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                 Apixaban Oral Tablet\n",
      "DESCRIPTIONS           After cluster randomization, the cluster will ...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0003907\n",
      "CONDITION                                           Deep Vein Thrombosis\n",
      "MOLREGNO                                                          328601\n",
      "NAME_TERM                                           deep vein thrombosis\n",
      "Name: 1650, dtype: object\n",
      "_____\n",
      "TWID                                                                2642\n",
      "TWEET_ID                                              769871051022925824\n",
      "TWEET                  Apixaban may be as good as warfarin in atrial ...\n",
      "SYNONYMS                                                        WARFARIN\n",
      "MOLREGNO_1                                                        394165\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03395639\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           may be as good\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                       cardiovascular diseases\n",
      "INDICATION_ID                                                    D002318\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                               Standard of Care (SOC)\n",
      "DESCRIPTIONS           Standard of care could include low molecular w...\n",
      "OTHER_NAME                                   Warfarin/heparin;Enoxaparin\n",
      "EFO_ID                                                       EFO:0003777\n",
      "CONDITION                                                Cardiac Disease\n",
      "MOLREGNO                                                          709600\n",
      "NAME_TERM                                                  heart disease\n",
      "Name: 1652, dtype: object\n",
      "_____\n",
      "TWID                                                                2666\n",
      "TWEET_ID                                              768020140088623104\n",
      "TWEET                  DeuteRx receives US approval for phase I trial...\n",
      "SYNONYMS                                                    PIOGLITAZONE\n",
      "MOLREGNO_1                                                         19737\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00231894\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                     receives US approval\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                            Insulin Resistance\n",
      "INDICATION_ID                                                    D007333\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Pioglitazone\n",
      "DESCRIPTIONS                                   pioglitazone 30-45 mg/day\n",
      "OTHER_NAME                                                         Actos\n",
      "EFO_ID                                                       EFO:0002614\n",
      "CONDITION                                             Insulin Resistance\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                             insulin resistance\n",
      "Name: 1655, dtype: object\n",
      "_____\n",
      "TWID                                                                2666\n",
      "TWEET_ID                                              768020140088623104\n",
      "TWEET                  DeuteRx receives US approval for phase I trial...\n",
      "SYNONYMS                                                    PIOGLITAZONE\n",
      "MOLREGNO_1                                                         19737\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00231894\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                     receives US approval\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                            Insulin Resistance\n",
      "INDICATION_ID                                                    D007333\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Pioglitazone\n",
      "DESCRIPTIONS                                   pioglitazone 30-45 mg/day\n",
      "OTHER_NAME                                                         Actos\n",
      "EFO_ID                                                        HP:0100543\n",
      "CONDITION                                           Cognitive Impairment\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                           cognitive impairment\n",
      "Name: 1657, dtype: object\n",
      "_____\n",
      "TWID                                                                2666\n",
      "TWEET_ID                                              768020140088623104\n",
      "TWEET                  DeuteRx receives US approval for phase I trial...\n",
      "SYNONYMS                                                    PIOGLITAZONE\n",
      "MOLREGNO_1                                                         19737\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00231894\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                     receives US approval\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                            Insulin Resistance\n",
      "INDICATION_ID                                                    D007333\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Pioglitazone\n",
      "DESCRIPTIONS                                   pioglitazone 30-45 mg/day\n",
      "OTHER_NAME                                                         Actos\n",
      "EFO_ID                                                       EFO:0000692\n",
      "CONDITION                                                  Schizophrenia\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                  schizophrenia\n",
      "Name: 1659, dtype: object\n",
      "_____\n",
      "TWID                                                                2666\n",
      "TWEET_ID                                              768020140088623104\n",
      "TWEET                  DeuteRx receives US approval for phase I trial...\n",
      "SYNONYMS                                                    PIOGLITAZONE\n",
      "MOLREGNO_1                                                         19737\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00231894\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                     receives US approval\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                            Insulin Resistance\n",
      "INDICATION_ID                                                    D007333\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Pioglitazone\n",
      "DESCRIPTIONS                                   pioglitazone 30-45 mg/day\n",
      "OTHER_NAME                                                         Actos\n",
      "EFO_ID                                                       EFO:0000400\n",
      "CONDITION                                                       Diabetes\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                              diabetes mellitus\n",
      "Name: 1661, dtype: object\n",
      "_____\n",
      "TWID                                                                2694\n",
      "TWEET_ID                                              765469666588459008\n",
      "TWEET                  Aurinia Pharmaceuticals' voclosporin demonstra...\n",
      "SYNONYMS                                                     VOCLOSPORIN\n",
      "MOLREGNO_1                                                       1449192\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03021499\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                     demonstrates significant improvement\n",
      "COMPANY                                          Aurinia Pharmaceuticals\n",
      "COMPANY_ID                                                     COMP92678\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                               Lupus Nephritis\n",
      "INDICATION_ID                                                    D008181\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Voclosporin\n",
      "DESCRIPTIONS                                       calcineurin inhibitor\n",
      "OTHER_NAME                                                        ISA247\n",
      "EFO_ID                                                       EFO:0005761\n",
      "CONDITION                                                Lupus Nephritis\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                lupus nephritis\n",
      "Name: 1664, dtype: object\n",
      "_____\n",
      "TWID                                                                2719\n",
      "TWEET_ID                                              763315891304009728\n",
      "TWEET                  Ablynx reports topline phase IIb results for v...\n",
      "SYNONYMS                                                   VOBARILIZUMAB\n",
      "MOLREGNO_1                                                       2096394\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                              Null\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                            reports topline phase results\n",
      "COMPANY                                                           Ablynx\n",
      "COMPANY_ID                                                     COMP93215\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Null\n",
      "INTERVENTION_NAME_x                                                 Null\n",
      "DESCRIPTIONS                                                        Null\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                              Null\n",
      "CONDITION                                                           Null\n",
      "MOLREGNO                                                            Null\n",
      "NAME_TERM                                                            NaN\n",
      "Name: 1687, dtype: object\n",
      "_____\n",
      "TWID                                                                2731\n",
      "TWEET_ID                                              761400111456931840\n",
      "TWEET                  Momenta's necuparanib fails to show sufficient...\n",
      "SYNONYMS                                                     NECUPARANIB\n",
      "MOLREGNO_1                                                       1763532\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01621243\n",
      "PHASE                                                          Phase 1/2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              trial fails\n",
      "COMPANY                                          Momenta Pharmaceuticals\n",
      "COMPANY_ID                                                     COMP90053\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       0\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                           Neoplasm Metastasis\n",
      "INDICATION_ID                                                    D009362\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Necuparanib\n",
      "DESCRIPTIONS                             Necuparanib will be dosed daily\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0002618\n",
      "CONDITION                                   Metastatic Pancreatic Cancer\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                           pancreatic carcinoma\n",
      "Name: 1696, dtype: object\n",
      "_____\n",
      "TWID                                                                2731\n",
      "TWEET_ID                                              761400111456931840\n",
      "TWEET                  Momenta's necuparanib fails to show sufficient...\n",
      "SYNONYMS                                                     NECUPARANIB\n",
      "MOLREGNO_1                                                       1763532\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01621243\n",
      "PHASE                                                          Phase 1/2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              trial fails\n",
      "COMPANY                                          Momenta Pharmaceuticals\n",
      "COMPANY_ID                                                     COMP90053\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       0\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                           Neoplasm Metastasis\n",
      "INDICATION_ID                                                    D009362\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Necuparanib\n",
      "DESCRIPTIONS                             Necuparanib will be dosed daily\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0002618\n",
      "CONDITION                                   Metastatic Pancreatic Cancer\n",
      "MOLREGNO                                                            8062\n",
      "NAME_TERM                                           pancreatic carcinoma\n",
      "Name: 1697, dtype: object\n",
      "_____\n",
      "TWID                                                                2731\n",
      "TWEET_ID                                              761400111456931840\n",
      "TWEET                  Momenta's necuparanib fails to show sufficient...\n",
      "SYNONYMS                                                     NECUPARANIB\n",
      "MOLREGNO_1                                                       1763532\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01621243\n",
      "PHASE                                                          Phase 1/2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              trial fails\n",
      "COMPANY                                          Momenta Pharmaceuticals\n",
      "COMPANY_ID                                                     COMP90053\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       0\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                           Neoplasm Metastasis\n",
      "INDICATION_ID                                                    D009362\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Necuparanib\n",
      "DESCRIPTIONS                             Necuparanib will be dosed daily\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0002618\n",
      "CONDITION                                   Metastatic Pancreatic Cancer\n",
      "MOLREGNO                                                           75901\n",
      "NAME_TERM                                           pancreatic carcinoma\n",
      "Name: 1699, dtype: object\n",
      "_____\n",
      "TWID                                                                2749\n",
      "TWEET_ID                                              759933566792835072\n",
      "TWEET                  Edge Therapeutics starts phase III trial of EG...\n",
      "SYNONYMS                                                      NIMODIPINE\n",
      "MOLREGNO_1                                                        421116\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03150524\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                       starts phase trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                       Subarachnoid Hemorrhage\n",
      "INDICATION_ID                                                    D013345\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Nimodipine\n",
      "DESCRIPTIONS           Participants will be administered nimodipine e...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                              Null\n",
      "CONDITION                                                           Null\n",
      "MOLREGNO                                                          365248\n",
      "NAME_TERM                                                            NaN\n",
      "Name: 1705, dtype: object\n",
      "_____\n",
      "TWID                                                                2749\n",
      "TWEET_ID                                              759933566792835072\n",
      "TWEET                  Edge Therapeutics starts phase III trial of EG...\n",
      "SYNONYMS                                                      NIMODIPINE\n",
      "MOLREGNO_1                                                        421116\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03150524\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                       starts phase trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                       Subarachnoid Hemorrhage\n",
      "INDICATION_ID                                                    D013345\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Nimodipine\n",
      "DESCRIPTIONS           Participants will be administered nimodipine e...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                              Null\n",
      "CONDITION                                                           Null\n",
      "MOLREGNO                                                            1219\n",
      "NAME_TERM                                                            NaN\n",
      "Name: 1706, dtype: object\n",
      "_____\n",
      "TWID                                                                2749\n",
      "TWEET_ID                                              759933566792835072\n",
      "TWEET                  Edge Therapeutics starts phase III trial of EG...\n",
      "SYNONYMS                                                      NIMODIPINE\n",
      "MOLREGNO_1                                                        421116\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03150524\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                       starts phase trial\n",
      "COMPANY                                                Edge Therapeutics\n",
      "COMPANY_ID                                                     COMP92360\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Nimodipine\n",
      "DESCRIPTIONS           Participants will be administered nimodipine e...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                              Null\n",
      "CONDITION                                                           Null\n",
      "MOLREGNO                                                          365248\n",
      "NAME_TERM                                                            NaN\n",
      "Name: 1707, dtype: object\n",
      "_____\n",
      "TWID                                                                2749\n",
      "TWEET_ID                                              759933566792835072\n",
      "TWEET                  Edge Therapeutics starts phase III trial of EG...\n",
      "SYNONYMS                                                      NIMODIPINE\n",
      "MOLREGNO_1                                                        421116\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03150524\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                       starts phase trial\n",
      "COMPANY                                                Edge Therapeutics\n",
      "COMPANY_ID                                                     COMP92360\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Nimodipine\n",
      "DESCRIPTIONS           Participants will be administered nimodipine e...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                              Null\n",
      "CONDITION                                                           Null\n",
      "MOLREGNO                                                            1219\n",
      "NAME_TERM                                                            NaN\n",
      "Name: 1708, dtype: object\n",
      "_____\n",
      "TWID                                                                2749\n",
      "TWEET_ID                                              759933566792835072\n",
      "TWEET                  Edge Therapeutics starts phase III trial of EG...\n",
      "SYNONYMS                                                      NIMODIPINE\n",
      "MOLREGNO_1                                                        365248\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03150524\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                       starts phase trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                       Subarachnoid Hemorrhage\n",
      "INDICATION_ID                                                    D013345\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Nimodipine\n",
      "DESCRIPTIONS           Participants will be administered nimodipine e...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                              Null\n",
      "CONDITION                                                           Null\n",
      "MOLREGNO                                                            1219\n",
      "NAME_TERM                                                            NaN\n",
      "Name: 1710, dtype: object\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "_____\n",
      "TWID                                                                2749\n",
      "TWEET_ID                                              759933566792835072\n",
      "TWEET                  Edge Therapeutics starts phase III trial of EG...\n",
      "SYNONYMS                                                      NIMODIPINE\n",
      "MOLREGNO_1                                                        365248\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03150524\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                       starts phase trial\n",
      "COMPANY                                                Edge Therapeutics\n",
      "COMPANY_ID                                                     COMP92360\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Nimodipine\n",
      "DESCRIPTIONS           Participants will be administered nimodipine e...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                              Null\n",
      "CONDITION                                                           Null\n",
      "MOLREGNO                                                            1219\n",
      "NAME_TERM                                                            NaN\n",
      "Name: 1712, dtype: object\n",
      "_____\n",
      "TWID                                                                2797\n",
      "TWEET_ID                                              753511740898439168\n",
      "TWEET                  Phase I first-in-human trial begins for Aptiny...\n",
      "SYNONYMS                                                            NMDA\n",
      "MOLREGNO_1                                                         64776\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02437344\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                       begins phase trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                             CI-581aa\n",
      "DESCRIPTIONS                              92 minute infusion of CI-581aa\n",
      "OTHER_NAME                                               NMDA antagonist\n",
      "EFO_ID                                                       EFO:0005611\n",
      "CONDITION                                              Opioid Dependence\n",
      "MOLREGNO                                                           21459\n",
      "NAME_TERM                                              opioid dependence\n",
      "Name: 1724, dtype: object\n",
      "_____\n",
      "TWID                                                                2798\n",
      "TWEET_ID                                              753510740674347009\n",
      "TWEET                  Enteris BioPharma initiates phase I clinical t...\n",
      "SYNONYMS                                                      TOBRAMYCIN\n",
      "MOLREGNO_1                                                        577488\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02873806\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                          initiates trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                               Cystic Fibrosis\n",
      "INDICATION_ID                                                    D003550\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Tobramycin\n",
      "DESCRIPTIONS           Topical antibiotic (tobramycin):\\n1 drop four ...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0004190\n",
      "CONDITION                                            Open-angle Glaucoma\n",
      "MOLREGNO                                                          674750\n",
      "NAME_TERM                                            open-angle glaucoma\n",
      "Name: 1725, dtype: object\n",
      "_____\n",
      "TWID                                                                2798\n",
      "TWEET_ID                                              753510740674347009\n",
      "TWEET                  Enteris BioPharma initiates phase I clinical t...\n",
      "SYNONYMS                                                      TOBRAMYCIN\n",
      "MOLREGNO_1                                                        577488\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02873806\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                          initiates trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                               Cystic Fibrosis\n",
      "INDICATION_ID                                                    D003550\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Tobramycin\n",
      "DESCRIPTIONS           Topical antibiotic (tobramycin):\\n1 drop four ...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0004190\n",
      "CONDITION                                            Open-angle Glaucoma\n",
      "MOLREGNO                                                          365281\n",
      "NAME_TERM                                            open-angle glaucoma\n",
      "Name: 1727, dtype: object\n",
      "_____\n",
      "TWID                                                                2813\n",
      "TWEET_ID                                              752516080552308736\n",
      "TWEET                  Sucampo discontinue cobiprostone development a...\n",
      "SYNONYMS                                                    COBIPROSTONE\n",
      "MOLREGNO_1                                                       1376069\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02542215\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                  discontinue development\n",
      "COMPANY                                                          Sucampo\n",
      "COMPANY_ID                                                     COMP90477\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                    Stomatitis\n",
      "INDICATION_ID                                                    D013280\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Cobiprostone\n",
      "DESCRIPTIONS                                                        Null\n",
      "OTHER_NAME                                                      SPI-8811\n",
      "EFO_ID                                                       EFO:1001904\n",
      "CONDITION                                                 Oral Mucositis\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                 oral mucositis\n",
      "Name: 1730, dtype: object\n",
      "_____\n",
      "TWID                                                                2843\n",
      "TWEET_ID                                              750581784837062660\n",
      "TWEET                  Can-Fite's CF-101 fails to meet primary effica...\n",
      "SYNONYMS                                                           CF101\n",
      "MOLREGNO_1                                                       2197744\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03168256\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              trial fails\n",
      "COMPANY                                               Can-Fite Biopharma\n",
      "COMPANY_ID                                                     COMP92837\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       0\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            CF101 2mg\n",
      "DESCRIPTIONS                         CF101 tablets, 2mg BID for 16 weeks\n",
      "OTHER_NAME                                                       IB-MECA\n",
      "EFO_ID                                                       EFO:0000676\n",
      "CONDITION                                               Plaque Psoriasis\n",
      "MOLREGNO                                                          194619\n",
      "NAME_TERM                                                      psoriasis\n",
      "Name: 1735, dtype: object\n",
      "_____\n",
      "TWID                                                                2843\n",
      "TWEET_ID                                              750581784837062660\n",
      "TWEET                  Can-Fite's CF-101 fails to meet primary effica...\n",
      "SYNONYMS                                                           CF101\n",
      "MOLREGNO_1                                                       2197744\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03168256\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              trial fails\n",
      "COMPANY                                               Can-Fite Biopharma\n",
      "COMPANY_ID                                                     COMP92837\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       0\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            CF101 2mg\n",
      "DESCRIPTIONS                         CF101 tablets, 2mg BID for 16 weeks\n",
      "OTHER_NAME                                                       IB-MECA\n",
      "EFO_ID                                                       EFO:0000676\n",
      "CONDITION                                               Plaque Psoriasis\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                      psoriasis\n",
      "Name: 1736, dtype: object\n",
      "_____\n",
      "TWID                                                                2843\n",
      "TWEET_ID                                              750581784837062660\n",
      "TWEET                  Can-Fite's CF-101 fails to meet primary effica...\n",
      "SYNONYMS                                                           CF101\n",
      "MOLREGNO_1                                                       2197744\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03168256\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              trial fails\n",
      "COMPANY                                               Can-Fite Biopharma\n",
      "COMPANY_ID                                                     COMP92837\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       0\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            CF101 2mg\n",
      "DESCRIPTIONS                         CF101 tablets, 2mg BID for 16 weeks\n",
      "OTHER_NAME                                                       IB-MECA\n",
      "EFO_ID                                                       EFO:0000676\n",
      "CONDITION                                               Plaque Psoriasis\n",
      "MOLREGNO                                                          458773\n",
      "NAME_TERM                                                      psoriasis\n",
      "Name: 1737, dtype: object\n",
      "_____\n",
      "TWID                                                                2843\n",
      "TWEET_ID                                              750581784837062660\n",
      "TWEET                  Can-Fite's CF-101 fails to meet primary effica...\n",
      "SYNONYMS                                                           CF101\n",
      "MOLREGNO_1                                                       2197744\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03168256\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              trial fails\n",
      "COMPANY                                               Can-Fite Biopharma\n",
      "COMPANY_ID                                                     COMP92837\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       0\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            CF101 3mg\n",
      "DESCRIPTIONS                         CF101 tablets, 3mg BID for 16 weeks\n",
      "OTHER_NAME                                                       IB-MECA\n",
      "EFO_ID                                                       EFO:0000676\n",
      "CONDITION                                               Plaque Psoriasis\n",
      "MOLREGNO                                                          194619\n",
      "NAME_TERM                                                      psoriasis\n",
      "Name: 1738, dtype: object\n",
      "_____\n",
      "TWID                                                                2843\n",
      "TWEET_ID                                              750581784837062660\n",
      "TWEET                  Can-Fite's CF-101 fails to meet primary effica...\n",
      "SYNONYMS                                                           CF101\n",
      "MOLREGNO_1                                                       2197744\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03168256\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              trial fails\n",
      "COMPANY                                               Can-Fite Biopharma\n",
      "COMPANY_ID                                                     COMP92837\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       0\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            CF101 3mg\n",
      "DESCRIPTIONS                         CF101 tablets, 3mg BID for 16 weeks\n",
      "OTHER_NAME                                                       IB-MECA\n",
      "EFO_ID                                                       EFO:0000676\n",
      "CONDITION                                               Plaque Psoriasis\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                      psoriasis\n",
      "Name: 1739, dtype: object\n",
      "_____\n",
      "TWID                                                                2843\n",
      "TWEET_ID                                              750581784837062660\n",
      "TWEET                  Can-Fite's CF-101 fails to meet primary effica...\n",
      "SYNONYMS                                                           CF101\n",
      "MOLREGNO_1                                                       2197744\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03168256\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              trial fails\n",
      "COMPANY                                               Can-Fite Biopharma\n",
      "COMPANY_ID                                                     COMP92837\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       0\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            CF101 3mg\n",
      "DESCRIPTIONS                         CF101 tablets, 3mg BID for 16 weeks\n",
      "OTHER_NAME                                                       IB-MECA\n",
      "EFO_ID                                                       EFO:0000676\n",
      "CONDITION                                               Plaque Psoriasis\n",
      "MOLREGNO                                                          458773\n",
      "NAME_TERM                                                      psoriasis\n",
      "Name: 1740, dtype: object\n",
      "_____\n",
      "TWID                                                                2845\n",
      "TWEET_ID                                              750523022398746624\n",
      "TWEET                  Nippon Kayaku's NK-105 (paclitaxel micelles) f...\n",
      "SYNONYMS                                                      PACLITAXEL\n",
      "MOLREGNO_1                                                          8062\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              trial fails\n",
      "COMPANY                                                Nippon Kayaku Co.\n",
      "COMPANY_ID                                                       COMP491\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                         Prostatic Hyperplasia\n",
      "INDICATION_ID                                                    D011470\n",
      "INDICATION_NONAMBIG                                                    2\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                       nab-Paclitaxel\n",
      "DESCRIPTIONS           Benzenepropanoic acid, β-(benzoylamino)-α-hydr...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                          675089\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1742, dtype: object\n",
      "_____\n",
      "TWID                                                                2845\n",
      "TWEET_ID                                              750523022398746624\n",
      "TWEET                  Nippon Kayaku's NK-105 (paclitaxel micelles) f...\n",
      "SYNONYMS                                                      PACLITAXEL\n",
      "MOLREGNO_1                                                          8062\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              trial fails\n",
      "COMPANY                                                Nippon Kayaku Co.\n",
      "COMPANY_ID                                                       COMP491\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                         Prostatic Hyperplasia\n",
      "INDICATION_ID                                                    D011470\n",
      "INDICATION_NONAMBIG                                                    2\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                       nab-Paclitaxel\n",
      "DESCRIPTIONS           Benzenepropanoic acid, β-(benzoylamino)-α-hydr...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                         1380097\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1744, dtype: object\n",
      "_____\n",
      "TWID                                                                2845\n",
      "TWEET_ID                                              750523022398746624\n",
      "TWEET                  Nippon Kayaku's NK-105 (paclitaxel micelles) f...\n",
      "SYNONYMS                                                      PACLITAXEL\n",
      "MOLREGNO_1                                                          8062\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              trial fails\n",
      "COMPANY                                                Nippon Kayaku Co.\n",
      "COMPANY_ID                                                       COMP491\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                         Prostatic Hyperplasia\n",
      "INDICATION_ID                                                    D011470\n",
      "INDICATION_NONAMBIG                                                    2\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                       nab-Paclitaxel\n",
      "DESCRIPTIONS           Benzenepropanoic acid, β-(benzoylamino)-α-hydr...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                            8633\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1745, dtype: object\n",
      "_____\n",
      "TWID                                                                2845\n",
      "TWEET_ID                                              750523022398746624\n",
      "TWEET                  Nippon Kayaku's NK-105 (paclitaxel micelles) f...\n",
      "SYNONYMS                                                      PACLITAXEL\n",
      "MOLREGNO_1                                                          8062\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              trial fails\n",
      "COMPANY                                                Nippon Kayaku Co.\n",
      "COMPANY_ID                                                       COMP491\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                         Prostatic Hyperplasia\n",
      "INDICATION_ID                                                    D011470\n",
      "INDICATION_NONAMBIG                                                    2\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                       nab-Paclitaxel\n",
      "DESCRIPTIONS           Benzenepropanoic acid, β-(benzoylamino)-α-hydr...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                          674747\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1746, dtype: object\n",
      "_____\n",
      "TWID                                                                2845\n",
      "TWEET_ID                                              750523022398746624\n",
      "TWEET                  Nippon Kayaku's NK-105 (paclitaxel micelles) f...\n",
      "SYNONYMS                                                      PACLITAXEL\n",
      "MOLREGNO_1                                                          8062\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              trial fails\n",
      "COMPANY                                                Nippon Kayaku Co.\n",
      "COMPANY_ID                                                       COMP491\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                         Prostatic Hyperplasia\n",
      "INDICATION_ID                                                    D011470\n",
      "INDICATION_NONAMBIG                                                    2\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                       nab-Paclitaxel\n",
      "DESCRIPTIONS           Benzenepropanoic acid, β-(benzoylamino)-α-hydr...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                          675483\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1747, dtype: object\n",
      "_____\n",
      "TWID                                                                2845\n",
      "TWEET_ID                                              750523022398746624\n",
      "TWEET                  Nippon Kayaku's NK-105 (paclitaxel micelles) f...\n",
      "SYNONYMS                                                      PACLITAXEL\n",
      "MOLREGNO_1                                                          8062\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              trial fails\n",
      "COMPANY                                                Nippon Kayaku Co.\n",
      "COMPANY_ID                                                       COMP491\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                         Prostatic Hyperplasia\n",
      "INDICATION_ID                                                    D011470\n",
      "INDICATION_NONAMBIG                                                    2\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                       nab-Paclitaxel\n",
      "DESCRIPTIONS           Benzenepropanoic acid, β-(benzoylamino)-α-hydr...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                          368538\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1748, dtype: object\n",
      "_____\n",
      "TWID                                                                2845\n",
      "TWEET_ID                                              750523022398746624\n",
      "TWEET                  Nippon Kayaku's NK-105 (paclitaxel micelles) f...\n",
      "SYNONYMS                                                      PACLITAXEL\n",
      "MOLREGNO_1                                                          8062\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              trial fails\n",
      "COMPANY                                                Nippon Kayaku Co.\n",
      "COMPANY_ID                                                       COMP491\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                         Prostatic Hyperplasia\n",
      "INDICATION_ID                                                    D011470\n",
      "INDICATION_NONAMBIG                                                    2\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                       nab-Paclitaxel\n",
      "DESCRIPTIONS           Benzenepropanoic acid, β-(benzoylamino)-α-hydr...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                         2096424\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1749, dtype: object\n",
      "_____\n",
      "TWID                                                                2845\n",
      "TWEET_ID                                              750523022398746624\n",
      "TWEET                  Nippon Kayaku's NK-105 (paclitaxel micelles) f...\n",
      "SYNONYMS                                                      PACLITAXEL\n",
      "MOLREGNO_1                                                          8062\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              trial fails\n",
      "COMPANY                                                Nippon Kayaku Co.\n",
      "COMPANY_ID                                                       COMP491\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                         Prostatic Hyperplasia\n",
      "INDICATION_ID                                                    D011470\n",
      "INDICATION_NONAMBIG                                                    2\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                       nab-Paclitaxel\n",
      "DESCRIPTIONS           Benzenepropanoic acid, β-(benzoylamino)-α-hydr...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                          598447\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1750, dtype: object\n",
      "_____\n",
      "TWID                                                                2850\n",
      "TWEET_ID                                              750264707999727616\n",
      "TWEET                  Cinfa Biotech's pegfilgrastim biosimilar B-120...\n",
      "SYNONYMS                                                   PEGFILGRASTIM\n",
      "MOLREGNO_1                                                        675363\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                               meets equivalence endpoint\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Breast Neoplasms\n",
      "INDICATION_ID                                                    D001943\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Pegfilgrastim\n",
      "DESCRIPTIONS           6 mg, subcutaneously on day 2 of all cytotoxic...\n",
      "OTHER_NAME                                                      Neulasta\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                          674747\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1751, dtype: object\n",
      "_____\n",
      "TWID                                                                2850\n",
      "TWEET_ID                                              750264707999727616\n",
      "TWEET                  Cinfa Biotech's pegfilgrastim biosimilar B-120...\n",
      "SYNONYMS                                                   PEGFILGRASTIM\n",
      "MOLREGNO_1                                                        675363\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                               meets equivalence endpoint\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Breast Neoplasms\n",
      "INDICATION_ID                                                    D001943\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Pegfilgrastim\n",
      "DESCRIPTIONS           6 mg, subcutaneously on day 2 of all cytotoxic...\n",
      "OTHER_NAME                                                      Neulasta\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                           78759\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1752, dtype: object\n",
      "_____\n",
      "TWID                                                                2850\n",
      "TWEET_ID                                              750264707999727616\n",
      "TWEET                  Cinfa Biotech's pegfilgrastim biosimilar B-120...\n",
      "SYNONYMS                                                   PEGFILGRASTIM\n",
      "MOLREGNO_1                                                        675363\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                               meets equivalence endpoint\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Breast Neoplasms\n",
      "INDICATION_ID                                                    D001943\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Pegfilgrastim\n",
      "DESCRIPTIONS           6 mg, subcutaneously on day 2 of all cytotoxic...\n",
      "OTHER_NAME                                                      Neulasta\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                          675434\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1754, dtype: object\n",
      "_____\n",
      "TWID                                                                2850\n",
      "TWEET_ID                                              750264707999727616\n",
      "TWEET                  Cinfa Biotech's pegfilgrastim biosimilar B-120...\n",
      "SYNONYMS                                                   PEGFILGRASTIM\n",
      "MOLREGNO_1                                                        675363\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                               meets equivalence endpoint\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Breast Neoplasms\n",
      "INDICATION_ID                                                    D001943\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Pegfilgrastim\n",
      "DESCRIPTIONS           6 mg, subcutaneously on day 2 of all cytotoxic...\n",
      "OTHER_NAME                                                      Neulasta\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                          365281\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1755, dtype: object\n",
      "_____\n",
      "TWID                                                                2850\n",
      "TWEET_ID                                              750264707999727616\n",
      "TWEET                  Cinfa Biotech's pegfilgrastim biosimilar B-120...\n",
      "SYNONYMS                                                   PEGFILGRASTIM\n",
      "MOLREGNO_1                                                        675363\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                               meets equivalence endpoint\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Breast Neoplasms\n",
      "INDICATION_ID                                                    D001943\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Pegfilgrastim\n",
      "DESCRIPTIONS           6 mg, subcutaneously on day 2 of all cytotoxic...\n",
      "OTHER_NAME                                                      Neulasta\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                           14805\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1756, dtype: object\n",
      "_____\n",
      "TWID                                                                2850\n",
      "TWEET_ID                                              750264707999727616\n",
      "TWEET                  Cinfa Biotech's pegfilgrastim biosimilar B-120...\n",
      "SYNONYMS                                                   PEGFILGRASTIM\n",
      "MOLREGNO_1                                                        675363\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                               meets equivalence endpoint\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Breast Neoplasms\n",
      "INDICATION_ID                                                    D001943\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Pegfilgrastim\n",
      "DESCRIPTIONS           6 mg, subcutaneously on day 2 of all cytotoxic...\n",
      "OTHER_NAME                                                      Neulasta\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                         1927101\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1757, dtype: object\n",
      "_____\n",
      "TWID                                                                2850\n",
      "TWEET_ID                                              750264707999727616\n",
      "TWEET                  Cinfa Biotech's pegfilgrastim biosimilar B-120...\n",
      "SYNONYMS                                                   PEGFILGRASTIM\n",
      "MOLREGNO_1                                                        675363\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                               meets equivalence endpoint\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Breast Neoplasms\n",
      "INDICATION_ID                                                    D001943\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Pegfilgrastim\n",
      "DESCRIPTIONS           6 mg, subcutaneously on day 2 of all cytotoxic...\n",
      "OTHER_NAME                                                      Neulasta\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                          675581\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1758, dtype: object\n",
      "_____\n",
      "TWID                                                                2850\n",
      "TWEET_ID                                              750264707999727616\n",
      "TWEET                  Cinfa Biotech's pegfilgrastim biosimilar B-120...\n",
      "SYNONYMS                                                   PEGFILGRASTIM\n",
      "MOLREGNO_1                                                        675363\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                               meets equivalence endpoint\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Breast Neoplasms\n",
      "INDICATION_ID                                                    D001943\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Pegfilgrastim\n",
      "DESCRIPTIONS           6 mg, subcutaneously on day 2 of all cytotoxic...\n",
      "OTHER_NAME                                                      Neulasta\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                       Metastatic Breast Cancer\n",
      "MOLREGNO                                                          674747\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1759, dtype: object\n",
      "_____\n",
      "TWID                                                                2850\n",
      "TWEET_ID                                              750264707999727616\n",
      "TWEET                  Cinfa Biotech's pegfilgrastim biosimilar B-120...\n",
      "SYNONYMS                                                   PEGFILGRASTIM\n",
      "MOLREGNO_1                                                        675363\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                               meets equivalence endpoint\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Breast Neoplasms\n",
      "INDICATION_ID                                                    D001943\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Pegfilgrastim\n",
      "DESCRIPTIONS           6 mg, subcutaneously on day 2 of all cytotoxic...\n",
      "OTHER_NAME                                                      Neulasta\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                       Metastatic Breast Cancer\n",
      "MOLREGNO                                                           78759\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1760, dtype: object\n",
      "_____\n",
      "TWID                                                                2850\n",
      "TWEET_ID                                              750264707999727616\n",
      "TWEET                  Cinfa Biotech's pegfilgrastim biosimilar B-120...\n",
      "SYNONYMS                                                   PEGFILGRASTIM\n",
      "MOLREGNO_1                                                        675363\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                               meets equivalence endpoint\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Breast Neoplasms\n",
      "INDICATION_ID                                                    D001943\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Pegfilgrastim\n",
      "DESCRIPTIONS           6 mg, subcutaneously on day 2 of all cytotoxic...\n",
      "OTHER_NAME                                                      Neulasta\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                       Metastatic Breast Cancer\n",
      "MOLREGNO                                                          675434\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1762, dtype: object\n",
      "_____\n",
      "TWID                                                                2850\n",
      "TWEET_ID                                              750264707999727616\n",
      "TWEET                  Cinfa Biotech's pegfilgrastim biosimilar B-120...\n",
      "SYNONYMS                                                   PEGFILGRASTIM\n",
      "MOLREGNO_1                                                        675363\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                               meets equivalence endpoint\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Breast Neoplasms\n",
      "INDICATION_ID                                                    D001943\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Pegfilgrastim\n",
      "DESCRIPTIONS           6 mg, subcutaneously on day 2 of all cytotoxic...\n",
      "OTHER_NAME                                                      Neulasta\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                       Metastatic Breast Cancer\n",
      "MOLREGNO                                                          365281\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1763, dtype: object\n",
      "_____\n",
      "TWID                                                                2850\n",
      "TWEET_ID                                              750264707999727616\n",
      "TWEET                  Cinfa Biotech's pegfilgrastim biosimilar B-120...\n",
      "SYNONYMS                                                   PEGFILGRASTIM\n",
      "MOLREGNO_1                                                        675363\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                               meets equivalence endpoint\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Breast Neoplasms\n",
      "INDICATION_ID                                                    D001943\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Pegfilgrastim\n",
      "DESCRIPTIONS           6 mg, subcutaneously on day 2 of all cytotoxic...\n",
      "OTHER_NAME                                                      Neulasta\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                       Metastatic Breast Cancer\n",
      "MOLREGNO                                                           14805\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1764, dtype: object\n",
      "_____\n",
      "TWID                                                                2850\n",
      "TWEET_ID                                              750264707999727616\n",
      "TWEET                  Cinfa Biotech's pegfilgrastim biosimilar B-120...\n",
      "SYNONYMS                                                   PEGFILGRASTIM\n",
      "MOLREGNO_1                                                        675363\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                               meets equivalence endpoint\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Breast Neoplasms\n",
      "INDICATION_ID                                                    D001943\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Pegfilgrastim\n",
      "DESCRIPTIONS           6 mg, subcutaneously on day 2 of all cytotoxic...\n",
      "OTHER_NAME                                                      Neulasta\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                       Metastatic Breast Cancer\n",
      "MOLREGNO                                                         1927101\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1765, dtype: object\n",
      "_____\n",
      "TWID                                                                2850\n",
      "TWEET_ID                                              750264707999727616\n",
      "TWEET                  Cinfa Biotech's pegfilgrastim biosimilar B-120...\n",
      "SYNONYMS                                                   PEGFILGRASTIM\n",
      "MOLREGNO_1                                                        675363\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                               meets equivalence endpoint\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Breast Neoplasms\n",
      "INDICATION_ID                                                    D001943\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Pegfilgrastim\n",
      "DESCRIPTIONS           6 mg, subcutaneously on day 2 of all cytotoxic...\n",
      "OTHER_NAME                                                      Neulasta\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                       Metastatic Breast Cancer\n",
      "MOLREGNO                                                          675581\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1766, dtype: object\n",
      "_____\n",
      "TWID                                                                2932\n",
      "TWEET_ID                                              743381252707856384\n",
      "TWEET                  Cellceutix starts phase II trial of topical br...\n",
      "SYNONYMS                                                        PMX30063\n",
      "MOLREGNO_1                                                       1449217\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02324335\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                       starts phase trial\n",
      "COMPANY                                                       Cellceutix\n",
      "COMPANY_ID                                                     COMP90493\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Mucositis\n",
      "INDICATION_ID                                                    D052016\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Brilacidin\n",
      "DESCRIPTIONS                   Oral Rinse used 3 times daily for 7 weeks\n",
      "OTHER_NAME                                                      PMX30063\n",
      "EFO_ID                                                       EFO:1001898\n",
      "CONDITION                                                      Mucositis\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                      mucositis\n",
      "Name: 1810, dtype: object\n",
      "_____\n",
      "TWID                                                                2932\n",
      "TWEET_ID                                              743381252707856384\n",
      "TWEET                  Cellceutix starts phase II trial of topical br...\n",
      "SYNONYMS                                                        PMX30063\n",
      "MOLREGNO_1                                                       1449217\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02324335\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                       starts phase trial\n",
      "COMPANY                                                       Cellceutix\n",
      "COMPANY_ID                                                     COMP90493\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Mucositis\n",
      "INDICATION_ID                                                    D052016\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Brilacidin\n",
      "DESCRIPTIONS                   Oral Rinse used 3 times daily for 7 weeks\n",
      "OTHER_NAME                                                      PMX30063\n",
      "EFO_ID                                                       EFO:0004284\n",
      "CONDITION                                        Head and Neck Neoplasms\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                             upper aerodigestive tract neoplasm\n",
      "Name: 1812, dtype: object\n",
      "_____\n",
      "TWID                                                                2932\n",
      "TWEET_ID                                              743381252707856384\n",
      "TWEET                  Cellceutix starts phase II trial of topical br...\n",
      "SYNONYMS                                                        PMX30063\n",
      "MOLREGNO_1                                                       1449224\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02324335\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                       starts phase trial\n",
      "COMPANY                                                       Cellceutix\n",
      "COMPANY_ID                                                     COMP90493\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Mucositis\n",
      "INDICATION_ID                                                    D052016\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Brilacidin\n",
      "DESCRIPTIONS                   Oral Rinse used 3 times daily for 7 weeks\n",
      "OTHER_NAME                                                      PMX30063\n",
      "EFO_ID                                                       EFO:1001898\n",
      "CONDITION                                                      Mucositis\n",
      "MOLREGNO                                                         1449217\n",
      "NAME_TERM                                                      mucositis\n",
      "Name: 1813, dtype: object\n",
      "_____\n",
      "TWID                                                                2932\n",
      "TWEET_ID                                              743381252707856384\n",
      "TWEET                  Cellceutix starts phase II trial of topical br...\n",
      "SYNONYMS                                                        PMX30063\n",
      "MOLREGNO_1                                                       1449224\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02324335\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                       starts phase trial\n",
      "COMPANY                                                       Cellceutix\n",
      "COMPANY_ID                                                     COMP90493\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Mucositis\n",
      "INDICATION_ID                                                    D052016\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Brilacidin\n",
      "DESCRIPTIONS                   Oral Rinse used 3 times daily for 7 weeks\n",
      "OTHER_NAME                                                      PMX30063\n",
      "EFO_ID                                                       EFO:1001898\n",
      "CONDITION                                                      Mucositis\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                      mucositis\n",
      "Name: 1814, dtype: object\n",
      "_____\n",
      "TWID                                                                2932\n",
      "TWEET_ID                                              743381252707856384\n",
      "TWEET                  Cellceutix starts phase II trial of topical br...\n",
      "SYNONYMS                                                        PMX30063\n",
      "MOLREGNO_1                                                       1449224\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02324335\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                       starts phase trial\n",
      "COMPANY                                                       Cellceutix\n",
      "COMPANY_ID                                                     COMP90493\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Mucositis\n",
      "INDICATION_ID                                                    D052016\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Brilacidin\n",
      "DESCRIPTIONS                   Oral Rinse used 3 times daily for 7 weeks\n",
      "OTHER_NAME                                                      PMX30063\n",
      "EFO_ID                                                       EFO:0004284\n",
      "CONDITION                                        Head and Neck Neoplasms\n",
      "MOLREGNO                                                         1449217\n",
      "NAME_TERM                             upper aerodigestive tract neoplasm\n",
      "Name: 1815, dtype: object\n",
      "_____\n",
      "TWID                                                                2932\n",
      "TWEET_ID                                              743381252707856384\n",
      "TWEET                  Cellceutix starts phase II trial of topical br...\n",
      "SYNONYMS                                                        PMX30063\n",
      "MOLREGNO_1                                                       1449224\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02324335\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                       starts phase trial\n",
      "COMPANY                                                       Cellceutix\n",
      "COMPANY_ID                                                     COMP90493\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Mucositis\n",
      "INDICATION_ID                                                    D052016\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Brilacidin\n",
      "DESCRIPTIONS                   Oral Rinse used 3 times daily for 7 weeks\n",
      "OTHER_NAME                                                      PMX30063\n",
      "EFO_ID                                                       EFO:0004284\n",
      "CONDITION                                        Head and Neck Neoplasms\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                             upper aerodigestive tract neoplasm\n",
      "Name: 1816, dtype: object\n",
      "_____\n",
      "TWID                                                                2932\n",
      "TWEET_ID                                              743381252707856384\n",
      "TWEET                  Cellceutix starts phase II trial of topical br...\n",
      "SYNONYMS                                                      BRILACIDIN\n",
      "MOLREGNO_1                                                       1449217\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02324335\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                       starts phase trial\n",
      "COMPANY                                                       Cellceutix\n",
      "COMPANY_ID                                                     COMP90493\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Mucositis\n",
      "INDICATION_ID                                                    D052016\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Brilacidin\n",
      "DESCRIPTIONS                   Oral Rinse used 3 times daily for 7 weeks\n",
      "OTHER_NAME                                                      PMX30063\n",
      "EFO_ID                                                       EFO:1001898\n",
      "CONDITION                                                      Mucositis\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                      mucositis\n",
      "Name: 1818, dtype: object\n",
      "_____\n",
      "TWID                                                                2932\n",
      "TWEET_ID                                              743381252707856384\n",
      "TWEET                  Cellceutix starts phase II trial of topical br...\n",
      "SYNONYMS                                                      BRILACIDIN\n",
      "MOLREGNO_1                                                       1449217\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02324335\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                       starts phase trial\n",
      "COMPANY                                                       Cellceutix\n",
      "COMPANY_ID                                                     COMP90493\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Mucositis\n",
      "INDICATION_ID                                                    D052016\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Brilacidin\n",
      "DESCRIPTIONS                   Oral Rinse used 3 times daily for 7 weeks\n",
      "OTHER_NAME                                                      PMX30063\n",
      "EFO_ID                                                       EFO:0004284\n",
      "CONDITION                                        Head and Neck Neoplasms\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                             upper aerodigestive tract neoplasm\n",
      "Name: 1820, dtype: object\n",
      "_____\n",
      "TWID                                                                2947\n",
      "TWEET_ID                                              742656369510219777\n",
      "TWEET                  Marinus' ganaxolone capsules fail to meet effi...\n",
      "SYNONYMS                                                      GANAXOLONE\n",
      "MOLREGNO_1                                                        992582\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03460756\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                           fail to meet efficacy endpoint\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                Mood Disorders\n",
      "INDICATION_ID                                                    D019964\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Ganaxolone\n",
      "DESCRIPTIONS                                                        Oral\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000677\n",
      "CONDITION                                                Mental Disorder\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                 mental or behavioural disorder\n",
      "Name: 1827, dtype: object\n",
      "_____\n",
      "TWID                                                                2947\n",
      "TWEET_ID                                              742656369510219777\n",
      "TWEET                  Marinus' ganaxolone capsules fail to meet effi...\n",
      "SYNONYMS                                                      GANAXOLONE\n",
      "MOLREGNO_1                                                        992582\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03460756\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                           fail to meet efficacy endpoint\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                Mood Disorders\n",
      "INDICATION_ID                                                    D019964\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Ganaxolone\n",
      "DESCRIPTIONS                                                        Oral\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0002950\n",
      "CONDITION                                        Pregnancy Complications\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                      pregnancy\n",
      "Name: 1829, dtype: object\n",
      "_____\n",
      "TWID                                                                2947\n",
      "TWEET_ID                                              742656369510219777\n",
      "TWEET                  Marinus' ganaxolone capsules fail to meet effi...\n",
      "SYNONYMS                                                      GANAXOLONE\n",
      "MOLREGNO_1                                                        992582\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03460756\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                           fail to meet efficacy endpoint\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                Mood Disorders\n",
      "INDICATION_ID                                                    D019964\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Ganaxolone\n",
      "DESCRIPTIONS                                                        Oral\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0003761\n",
      "CONDITION                                                     Depression\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                            unipolar depression\n",
      "Name: 1831, dtype: object\n",
      "_____\n",
      "TWID                                                                2947\n",
      "TWEET_ID                                              742656369510219777\n",
      "TWEET                  Marinus' ganaxolone capsules fail to meet effi...\n",
      "SYNONYMS                                                      GANAXOLONE\n",
      "MOLREGNO_1                                                        992582\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03460756\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                           fail to meet efficacy endpoint\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                Mood Disorders\n",
      "INDICATION_ID                                                    D019964\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Ganaxolone\n",
      "DESCRIPTIONS                                                        Oral\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0004247\n",
      "CONDITION                                                 Mood Disorders\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                  mood disorder\n",
      "Name: 1833, dtype: object\n",
      "_____\n",
      "TWID                                                                2947\n",
      "TWEET_ID                                              742656369510219777\n",
      "TWEET                  Marinus' ganaxolone capsules fail to meet effi...\n",
      "SYNONYMS                                                      GANAXOLONE\n",
      "MOLREGNO_1                                                        992582\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03460756\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                           fail to meet efficacy endpoint\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                Mood Disorders\n",
      "INDICATION_ID                                                    D019964\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Ganaxolone\n",
      "DESCRIPTIONS                                                        Oral\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0003761\n",
      "CONDITION                                            Depressive Disorder\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                            unipolar depression\n",
      "Name: 1835, dtype: object\n",
      "_____\n",
      "TWID                                                                2947\n",
      "TWEET_ID                                              742656369510219777\n",
      "TWEET                  Marinus' ganaxolone capsules fail to meet effi...\n",
      "SYNONYMS                                                      GANAXOLONE\n",
      "MOLREGNO_1                                                        992582\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03460756\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                           fail to meet efficacy endpoint\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                Mood Disorders\n",
      "INDICATION_ID                                                    D019964\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Ganaxolone\n",
      "DESCRIPTIONS                                                        Oral\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0007453\n",
      "CONDITION                                         Depression, Postpartum\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                          postpartum depression\n",
      "Name: 1837, dtype: object\n",
      "_____\n",
      "TWID                                                                2964\n",
      "TWEET_ID                                              741567279050149888\n",
      "TWEET                  Sirukumab efficacy in phase 3 study in active ...\n",
      "SYNONYMS                                                       SIRUKUMAB\n",
      "MOLREGNO_1                                                       1121942\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00718718\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         In phase live at\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                        Polymyalgia Rheumatica\n",
      "INDICATION_ID                                                    D011111\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                      CNTO 136 100 mg\n",
      "DESCRIPTIONS           CNTO 136 100 mg will be administered subcutane...\n",
      "OTHER_NAME                                                     Sirukumab\n",
      "EFO_ID                                                       EFO:0000685\n",
      "CONDITION                                          Arthritis, Rheumatoid\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                           rheumatoid arthritis\n",
      "Name: 1842, dtype: object\n",
      "_____\n",
      "TWID                                                                2964\n",
      "TWEET_ID                                              741567279050149888\n",
      "TWEET                  Sirukumab efficacy in phase 3 study in active ...\n",
      "SYNONYMS                                                       SIRUKUMAB\n",
      "MOLREGNO_1                                                       1121942\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00718718\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         In phase live at\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                        Polymyalgia Rheumatica\n",
      "INDICATION_ID                                                    D011111\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                      CNTO 136 100 mg\n",
      "DESCRIPTIONS           CNTO 136 100 mg will be administered subcutane...\n",
      "OTHER_NAME                                                     Sirukumab\n",
      "EFO_ID                                                       EFO:0000685\n",
      "CONDITION                                          Arthritis, Rheumatoid\n",
      "MOLREGNO                                                           49931\n",
      "NAME_TERM                                           rheumatoid arthritis\n",
      "Name: 1843, dtype: object\n",
      "_____\n",
      "TWID                                                                2964\n",
      "TWEET_ID                                              741567279050149888\n",
      "TWEET                  Sirukumab efficacy in phase 3 study in active ...\n",
      "SYNONYMS                                                       SIRUKUMAB\n",
      "MOLREGNO_1                                                       1121942\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00718718\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         In phase live at\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                        Polymyalgia Rheumatica\n",
      "INDICATION_ID                                                    D011111\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                       CNTO 136 50 mg\n",
      "DESCRIPTIONS           CNTO 136 50 mg will be administered subcutaneo...\n",
      "OTHER_NAME                                                     Sirukumab\n",
      "EFO_ID                                                       EFO:0000685\n",
      "CONDITION                                          Arthritis, Rheumatoid\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                           rheumatoid arthritis\n",
      "Name: 1845, dtype: object\n",
      "_____\n",
      "TWID                                                                2964\n",
      "TWEET_ID                                              741567279050149888\n",
      "TWEET                  Sirukumab efficacy in phase 3 study in active ...\n",
      "SYNONYMS                                                       SIRUKUMAB\n",
      "MOLREGNO_1                                                       1121942\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00718718\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         In phase live at\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                        Polymyalgia Rheumatica\n",
      "INDICATION_ID                                                    D011111\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                       CNTO 136 50 mg\n",
      "DESCRIPTIONS           CNTO 136 50 mg will be administered subcutaneo...\n",
      "OTHER_NAME                                                     Sirukumab\n",
      "EFO_ID                                                       EFO:0000685\n",
      "CONDITION                                          Arthritis, Rheumatoid\n",
      "MOLREGNO                                                           49931\n",
      "NAME_TERM                                           rheumatoid arthritis\n",
      "Name: 1846, dtype: object\n",
      "_____\n",
      "TWID                                                                2964\n",
      "TWEET_ID                                              741567279050149888\n",
      "TWEET                  Sirukumab efficacy in phase 3 study in active ...\n",
      "SYNONYMS                                                       SIRUKUMAB\n",
      "MOLREGNO_1                                                       1121942\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00718718\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         In phase live at\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                        Polymyalgia Rheumatica\n",
      "INDICATION_ID                                                    D011111\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                       CNTO 136 25 mg\n",
      "DESCRIPTIONS           CNTO 136 25 mg will be administered subcutaneo...\n",
      "OTHER_NAME                                                     Sirukumab\n",
      "EFO_ID                                                       EFO:0000685\n",
      "CONDITION                                          Arthritis, Rheumatoid\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                           rheumatoid arthritis\n",
      "Name: 1848, dtype: object\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "_____\n",
      "TWID                                                                2964\n",
      "TWEET_ID                                              741567279050149888\n",
      "TWEET                  Sirukumab efficacy in phase 3 study in active ...\n",
      "SYNONYMS                                                       SIRUKUMAB\n",
      "MOLREGNO_1                                                       1121942\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00718718\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         In phase live at\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                        Polymyalgia Rheumatica\n",
      "INDICATION_ID                                                    D011111\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                       CNTO 136 25 mg\n",
      "DESCRIPTIONS           CNTO 136 25 mg will be administered subcutaneo...\n",
      "OTHER_NAME                                                     Sirukumab\n",
      "EFO_ID                                                       EFO:0000685\n",
      "CONDITION                                          Arthritis, Rheumatoid\n",
      "MOLREGNO                                                           49931\n",
      "NAME_TERM                                           rheumatoid arthritis\n",
      "Name: 1849, dtype: object\n",
      "_____\n",
      "TWID                                                                2973\n",
      "TWEET_ID                                              741208998939136000\n",
      "TWEET                  Macrogenics presents good phase 1 safety data ...\n",
      "SYNONYMS                                                     MACROGENICS\n",
      "MOLREGNO_1                                                       1927222\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                              Null\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                     presents safety data\n",
      "COMPANY                                                      Macrogenics\n",
      "COMPANY_ID                                                       COMP415\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                   Hepatitis A\n",
      "INDICATION_ID                                                    D006506\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Null\n",
      "INTERVENTION_NAME_x                                                 Null\n",
      "DESCRIPTIONS                                                        Null\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                              Null\n",
      "CONDITION                                                           Null\n",
      "MOLREGNO                                                            Null\n",
      "NAME_TERM                                                            NaN\n",
      "Name: 1850, dtype: object\n",
      "_____\n",
      "TWID                                                                2983\n",
      "TWEET_ID                                              740966552451883008\n",
      "TWEET                  Milatuzumab suppresses disease activity in mod...\n",
      "SYNONYMS                                                     MILATUZUMAB\n",
      "MOLREGNO_1                                                       1121911\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00989586\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                              suppresses disease activity\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                  Systemic Lupus Erythematosus\n",
      "INDICATION_ID                                                    D008180\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                             Biological\n",
      "INTERVENTION_NAME_x                                          milatuzumab\n",
      "DESCRIPTIONS           Patient will receive milatuzumab weekly for 4 ...\n",
      "OTHER_NAME                                           monoclonal antibody\n",
      "EFO_ID                                                       EFO:0000574\n",
      "CONDITION                                                       Lymphoma\n",
      "MOLREGNO                                                         1121959\n",
      "NAME_TERM                                                       lymphoma\n",
      "Name: 1855, dtype: object\n",
      "_____\n",
      "TWID                                                                2983\n",
      "TWEET_ID                                              740966552451883008\n",
      "TWEET                  Milatuzumab suppresses disease activity in mod...\n",
      "SYNONYMS                                                     MILATUZUMAB\n",
      "MOLREGNO_1                                                       1121911\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00989586\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                              suppresses disease activity\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                  Systemic Lupus Erythematosus\n",
      "INDICATION_ID                                                    D008180\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                             Biological\n",
      "INTERVENTION_NAME_x                                          milatuzumab\n",
      "DESCRIPTIONS           Patient will receive milatuzumab weekly for 4 ...\n",
      "OTHER_NAME                                           monoclonal antibody\n",
      "EFO_ID                                                       EFO:0000574\n",
      "CONDITION                                                       Lymphoma\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                       lymphoma\n",
      "Name: 1856, dtype: object\n",
      "_____\n",
      "TWID                                                                2983\n",
      "TWEET_ID                                              740966552451883008\n",
      "TWEET                  Milatuzumab suppresses disease activity in mod...\n",
      "SYNONYMS                                                     MILATUZUMAB\n",
      "MOLREGNO_1                                                       1121911\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00989586\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                              suppresses disease activity\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                  Systemic Lupus Erythematosus\n",
      "INDICATION_ID                                                    D008180\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                             Biological\n",
      "INTERVENTION_NAME_x                           veltuzumab and milatuzumab\n",
      "DESCRIPTIONS           Patient will receive veltuzumab and milatuzuma...\n",
      "OTHER_NAME                                           monoclonal antibody\n",
      "EFO_ID                                                       EFO:0000574\n",
      "CONDITION                                                       Lymphoma\n",
      "MOLREGNO                                                         1121959\n",
      "NAME_TERM                                                       lymphoma\n",
      "Name: 1858, dtype: object\n",
      "_____\n",
      "TWID                                                                2983\n",
      "TWEET_ID                                              740966552451883008\n",
      "TWEET                  Milatuzumab suppresses disease activity in mod...\n",
      "SYNONYMS                                                     MILATUZUMAB\n",
      "MOLREGNO_1                                                       1121911\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00989586\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                              suppresses disease activity\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                  Systemic Lupus Erythematosus\n",
      "INDICATION_ID                                                    D008180\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                             Biological\n",
      "INTERVENTION_NAME_x                           veltuzumab and milatuzumab\n",
      "DESCRIPTIONS           Patient will receive veltuzumab and milatuzuma...\n",
      "OTHER_NAME                                           monoclonal antibody\n",
      "EFO_ID                                                       EFO:0000574\n",
      "CONDITION                                                       Lymphoma\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                       lymphoma\n",
      "Name: 1859, dtype: object\n",
      "_____\n",
      "TWID                                                                3021\n",
      "TWEET_ID                                              739994307940225024\n",
      "TWEET                  trastuzumab biosimilar MYL-1401O shows similar...\n",
      "SYNONYMS                                                       HERCEPTIN\n",
      "MOLREGNO_1                                                        675581\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                             shows safety\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Nervous System Neoplasms\n",
      "INDICATION_ID                                                    D009423\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Trastuzumab\n",
      "DESCRIPTIONS           Loading dose 8 mg/kg, then 6 mg/kg, intravenou...\n",
      "OTHER_NAME                                                     Herceptin\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                          674747\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1866, dtype: object\n",
      "_____\n",
      "TWID                                                                3021\n",
      "TWEET_ID                                              739994307940225024\n",
      "TWEET                  trastuzumab biosimilar MYL-1401O shows similar...\n",
      "SYNONYMS                                                       HERCEPTIN\n",
      "MOLREGNO_1                                                        675581\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                             shows safety\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Nervous System Neoplasms\n",
      "INDICATION_ID                                                    D009423\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Trastuzumab\n",
      "DESCRIPTIONS           Loading dose 8 mg/kg, then 6 mg/kg, intravenou...\n",
      "OTHER_NAME                                                     Herceptin\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                           78759\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1867, dtype: object\n",
      "_____\n",
      "TWID                                                                3021\n",
      "TWEET_ID                                              739994307940225024\n",
      "TWEET                  trastuzumab biosimilar MYL-1401O shows similar...\n",
      "SYNONYMS                                                       HERCEPTIN\n",
      "MOLREGNO_1                                                        675581\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                             shows safety\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Nervous System Neoplasms\n",
      "INDICATION_ID                                                    D009423\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Trastuzumab\n",
      "DESCRIPTIONS           Loading dose 8 mg/kg, then 6 mg/kg, intravenou...\n",
      "OTHER_NAME                                                     Herceptin\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                          675363\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1868, dtype: object\n",
      "_____\n",
      "TWID                                                                3021\n",
      "TWEET_ID                                              739994307940225024\n",
      "TWEET                  trastuzumab biosimilar MYL-1401O shows similar...\n",
      "SYNONYMS                                                       HERCEPTIN\n",
      "MOLREGNO_1                                                        675581\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                             shows safety\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Nervous System Neoplasms\n",
      "INDICATION_ID                                                    D009423\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Trastuzumab\n",
      "DESCRIPTIONS           Loading dose 8 mg/kg, then 6 mg/kg, intravenou...\n",
      "OTHER_NAME                                                     Herceptin\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                          675434\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1869, dtype: object\n",
      "_____\n",
      "TWID                                                                3021\n",
      "TWEET_ID                                              739994307940225024\n",
      "TWEET                  trastuzumab biosimilar MYL-1401O shows similar...\n",
      "SYNONYMS                                                       HERCEPTIN\n",
      "MOLREGNO_1                                                        675581\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                             shows safety\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Nervous System Neoplasms\n",
      "INDICATION_ID                                                    D009423\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Trastuzumab\n",
      "DESCRIPTIONS           Loading dose 8 mg/kg, then 6 mg/kg, intravenou...\n",
      "OTHER_NAME                                                     Herceptin\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                          365281\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1870, dtype: object\n",
      "_____\n",
      "TWID                                                                3021\n",
      "TWEET_ID                                              739994307940225024\n",
      "TWEET                  trastuzumab biosimilar MYL-1401O shows similar...\n",
      "SYNONYMS                                                       HERCEPTIN\n",
      "MOLREGNO_1                                                        675581\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                             shows safety\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Nervous System Neoplasms\n",
      "INDICATION_ID                                                    D009423\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Trastuzumab\n",
      "DESCRIPTIONS           Loading dose 8 mg/kg, then 6 mg/kg, intravenou...\n",
      "OTHER_NAME                                                     Herceptin\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                           14805\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1871, dtype: object\n",
      "_____\n",
      "TWID                                                                3021\n",
      "TWEET_ID                                              739994307940225024\n",
      "TWEET                  trastuzumab biosimilar MYL-1401O shows similar...\n",
      "SYNONYMS                                                       HERCEPTIN\n",
      "MOLREGNO_1                                                        675581\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                             shows safety\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Nervous System Neoplasms\n",
      "INDICATION_ID                                                    D009423\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Trastuzumab\n",
      "DESCRIPTIONS           Loading dose 8 mg/kg, then 6 mg/kg, intravenou...\n",
      "OTHER_NAME                                                     Herceptin\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                         1927101\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1872, dtype: object\n",
      "_____\n",
      "TWID                                                                3021\n",
      "TWEET_ID                                              739994307940225024\n",
      "TWEET                  trastuzumab biosimilar MYL-1401O shows similar...\n",
      "SYNONYMS                                                       HERCEPTIN\n",
      "MOLREGNO_1                                                        675581\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                             shows safety\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Nervous System Neoplasms\n",
      "INDICATION_ID                                                    D009423\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Trastuzumab\n",
      "DESCRIPTIONS           Loading dose 8 mg/kg, then 6 mg/kg, intravenou...\n",
      "OTHER_NAME                                                     Herceptin\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                       Metastatic Breast Cancer\n",
      "MOLREGNO                                                          674747\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1874, dtype: object\n",
      "_____\n",
      "TWID                                                                3021\n",
      "TWEET_ID                                              739994307940225024\n",
      "TWEET                  trastuzumab biosimilar MYL-1401O shows similar...\n",
      "SYNONYMS                                                       HERCEPTIN\n",
      "MOLREGNO_1                                                        675581\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                             shows safety\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Nervous System Neoplasms\n",
      "INDICATION_ID                                                    D009423\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Trastuzumab\n",
      "DESCRIPTIONS           Loading dose 8 mg/kg, then 6 mg/kg, intravenou...\n",
      "OTHER_NAME                                                     Herceptin\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                       Metastatic Breast Cancer\n",
      "MOLREGNO                                                           78759\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1875, dtype: object\n",
      "_____\n",
      "TWID                                                                3021\n",
      "TWEET_ID                                              739994307940225024\n",
      "TWEET                  trastuzumab biosimilar MYL-1401O shows similar...\n",
      "SYNONYMS                                                       HERCEPTIN\n",
      "MOLREGNO_1                                                        675581\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                             shows safety\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Nervous System Neoplasms\n",
      "INDICATION_ID                                                    D009423\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Trastuzumab\n",
      "DESCRIPTIONS           Loading dose 8 mg/kg, then 6 mg/kg, intravenou...\n",
      "OTHER_NAME                                                     Herceptin\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                       Metastatic Breast Cancer\n",
      "MOLREGNO                                                          675363\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1876, dtype: object\n",
      "_____\n",
      "TWID                                                                3021\n",
      "TWEET_ID                                              739994307940225024\n",
      "TWEET                  trastuzumab biosimilar MYL-1401O shows similar...\n",
      "SYNONYMS                                                       HERCEPTIN\n",
      "MOLREGNO_1                                                        675581\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                             shows safety\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Nervous System Neoplasms\n",
      "INDICATION_ID                                                    D009423\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Trastuzumab\n",
      "DESCRIPTIONS           Loading dose 8 mg/kg, then 6 mg/kg, intravenou...\n",
      "OTHER_NAME                                                     Herceptin\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                       Metastatic Breast Cancer\n",
      "MOLREGNO                                                          675434\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1877, dtype: object\n",
      "_____\n",
      "TWID                                                                3021\n",
      "TWEET_ID                                              739994307940225024\n",
      "TWEET                  trastuzumab biosimilar MYL-1401O shows similar...\n",
      "SYNONYMS                                                       HERCEPTIN\n",
      "MOLREGNO_1                                                        675581\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                             shows safety\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Nervous System Neoplasms\n",
      "INDICATION_ID                                                    D009423\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Trastuzumab\n",
      "DESCRIPTIONS           Loading dose 8 mg/kg, then 6 mg/kg, intravenou...\n",
      "OTHER_NAME                                                     Herceptin\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                       Metastatic Breast Cancer\n",
      "MOLREGNO                                                          365281\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1878, dtype: object\n",
      "_____\n",
      "TWID                                                                3021\n",
      "TWEET_ID                                              739994307940225024\n",
      "TWEET                  trastuzumab biosimilar MYL-1401O shows similar...\n",
      "SYNONYMS                                                       HERCEPTIN\n",
      "MOLREGNO_1                                                        675581\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                             shows safety\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Nervous System Neoplasms\n",
      "INDICATION_ID                                                    D009423\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Trastuzumab\n",
      "DESCRIPTIONS           Loading dose 8 mg/kg, then 6 mg/kg, intravenou...\n",
      "OTHER_NAME                                                     Herceptin\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                       Metastatic Breast Cancer\n",
      "MOLREGNO                                                           14805\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1879, dtype: object\n",
      "_____\n",
      "TWID                                                                3021\n",
      "TWEET_ID                                              739994307940225024\n",
      "TWEET                  trastuzumab biosimilar MYL-1401O shows similar...\n",
      "SYNONYMS                                                       HERCEPTIN\n",
      "MOLREGNO_1                                                        675581\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                             shows safety\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Nervous System Neoplasms\n",
      "INDICATION_ID                                                    D009423\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Trastuzumab\n",
      "DESCRIPTIONS           Loading dose 8 mg/kg, then 6 mg/kg, intravenou...\n",
      "OTHER_NAME                                                     Herceptin\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                       Metastatic Breast Cancer\n",
      "MOLREGNO                                                         1927101\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1880, dtype: object\n",
      "_____\n",
      "TWID                                                                3021\n",
      "TWEET_ID                                              739994307940225024\n",
      "TWEET                  trastuzumab biosimilar MYL-1401O shows similar...\n",
      "SYNONYMS                                                     TRASTUZUMAB\n",
      "MOLREGNO_1                                                        675581\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                             shows safety\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Nervous System Neoplasms\n",
      "INDICATION_ID                                                    D009423\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Trastuzumab\n",
      "DESCRIPTIONS           Loading dose 8 mg/kg, then 6 mg/kg, intravenou...\n",
      "OTHER_NAME                                                     Herceptin\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                          674747\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1882, dtype: object\n",
      "_____\n",
      "TWID                                                                3021\n",
      "TWEET_ID                                              739994307940225024\n",
      "TWEET                  trastuzumab biosimilar MYL-1401O shows similar...\n",
      "SYNONYMS                                                     TRASTUZUMAB\n",
      "MOLREGNO_1                                                        675581\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                             shows safety\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Nervous System Neoplasms\n",
      "INDICATION_ID                                                    D009423\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Trastuzumab\n",
      "DESCRIPTIONS           Loading dose 8 mg/kg, then 6 mg/kg, intravenou...\n",
      "OTHER_NAME                                                     Herceptin\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                           78759\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1883, dtype: object\n",
      "_____\n",
      "TWID                                                                3021\n",
      "TWEET_ID                                              739994307940225024\n",
      "TWEET                  trastuzumab biosimilar MYL-1401O shows similar...\n",
      "SYNONYMS                                                     TRASTUZUMAB\n",
      "MOLREGNO_1                                                        675581\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                             shows safety\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Nervous System Neoplasms\n",
      "INDICATION_ID                                                    D009423\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Trastuzumab\n",
      "DESCRIPTIONS           Loading dose 8 mg/kg, then 6 mg/kg, intravenou...\n",
      "OTHER_NAME                                                     Herceptin\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                          675363\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1884, dtype: object\n",
      "_____\n",
      "TWID                                                                3021\n",
      "TWEET_ID                                              739994307940225024\n",
      "TWEET                  trastuzumab biosimilar MYL-1401O shows similar...\n",
      "SYNONYMS                                                     TRASTUZUMAB\n",
      "MOLREGNO_1                                                        675581\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                             shows safety\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Nervous System Neoplasms\n",
      "INDICATION_ID                                                    D009423\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Trastuzumab\n",
      "DESCRIPTIONS           Loading dose 8 mg/kg, then 6 mg/kg, intravenou...\n",
      "OTHER_NAME                                                     Herceptin\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                          675434\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1885, dtype: object\n",
      "_____\n",
      "TWID                                                                3021\n",
      "TWEET_ID                                              739994307940225024\n",
      "TWEET                  trastuzumab biosimilar MYL-1401O shows similar...\n",
      "SYNONYMS                                                     TRASTUZUMAB\n",
      "MOLREGNO_1                                                        675581\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                             shows safety\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Nervous System Neoplasms\n",
      "INDICATION_ID                                                    D009423\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Trastuzumab\n",
      "DESCRIPTIONS           Loading dose 8 mg/kg, then 6 mg/kg, intravenou...\n",
      "OTHER_NAME                                                     Herceptin\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                          365281\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1886, dtype: object\n",
      "_____\n",
      "TWID                                                                3021\n",
      "TWEET_ID                                              739994307940225024\n",
      "TWEET                  trastuzumab biosimilar MYL-1401O shows similar...\n",
      "SYNONYMS                                                     TRASTUZUMAB\n",
      "MOLREGNO_1                                                        675581\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                             shows safety\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Nervous System Neoplasms\n",
      "INDICATION_ID                                                    D009423\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Trastuzumab\n",
      "DESCRIPTIONS           Loading dose 8 mg/kg, then 6 mg/kg, intravenou...\n",
      "OTHER_NAME                                                     Herceptin\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                           14805\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1887, dtype: object\n",
      "_____\n",
      "TWID                                                                3021\n",
      "TWEET_ID                                              739994307940225024\n",
      "TWEET                  trastuzumab biosimilar MYL-1401O shows similar...\n",
      "SYNONYMS                                                     TRASTUZUMAB\n",
      "MOLREGNO_1                                                        675581\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                             shows safety\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Nervous System Neoplasms\n",
      "INDICATION_ID                                                    D009423\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Trastuzumab\n",
      "DESCRIPTIONS           Loading dose 8 mg/kg, then 6 mg/kg, intravenou...\n",
      "OTHER_NAME                                                     Herceptin\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                         1927101\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1888, dtype: object\n",
      "_____\n",
      "TWID                                                                3021\n",
      "TWEET_ID                                              739994307940225024\n",
      "TWEET                  trastuzumab biosimilar MYL-1401O shows similar...\n",
      "SYNONYMS                                                     TRASTUZUMAB\n",
      "MOLREGNO_1                                                        675581\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                             shows safety\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Nervous System Neoplasms\n",
      "INDICATION_ID                                                    D009423\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Trastuzumab\n",
      "DESCRIPTIONS           Loading dose 8 mg/kg, then 6 mg/kg, intravenou...\n",
      "OTHER_NAME                                                     Herceptin\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                       Metastatic Breast Cancer\n",
      "MOLREGNO                                                          674747\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1890, dtype: object\n",
      "_____\n",
      "TWID                                                                3021\n",
      "TWEET_ID                                              739994307940225024\n",
      "TWEET                  trastuzumab biosimilar MYL-1401O shows similar...\n",
      "SYNONYMS                                                     TRASTUZUMAB\n",
      "MOLREGNO_1                                                        675581\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                             shows safety\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Nervous System Neoplasms\n",
      "INDICATION_ID                                                    D009423\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Trastuzumab\n",
      "DESCRIPTIONS           Loading dose 8 mg/kg, then 6 mg/kg, intravenou...\n",
      "OTHER_NAME                                                     Herceptin\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                       Metastatic Breast Cancer\n",
      "MOLREGNO                                                           78759\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1891, dtype: object\n",
      "_____\n",
      "TWID                                                                3021\n",
      "TWEET_ID                                              739994307940225024\n",
      "TWEET                  trastuzumab biosimilar MYL-1401O shows similar...\n",
      "SYNONYMS                                                     TRASTUZUMAB\n",
      "MOLREGNO_1                                                        675581\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                             shows safety\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Nervous System Neoplasms\n",
      "INDICATION_ID                                                    D009423\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Trastuzumab\n",
      "DESCRIPTIONS           Loading dose 8 mg/kg, then 6 mg/kg, intravenou...\n",
      "OTHER_NAME                                                     Herceptin\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                       Metastatic Breast Cancer\n",
      "MOLREGNO                                                          675363\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1892, dtype: object\n",
      "_____\n",
      "TWID                                                                3021\n",
      "TWEET_ID                                              739994307940225024\n",
      "TWEET                  trastuzumab biosimilar MYL-1401O shows similar...\n",
      "SYNONYMS                                                     TRASTUZUMAB\n",
      "MOLREGNO_1                                                        675581\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                             shows safety\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Nervous System Neoplasms\n",
      "INDICATION_ID                                                    D009423\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Trastuzumab\n",
      "DESCRIPTIONS           Loading dose 8 mg/kg, then 6 mg/kg, intravenou...\n",
      "OTHER_NAME                                                     Herceptin\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                       Metastatic Breast Cancer\n",
      "MOLREGNO                                                          675434\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1893, dtype: object\n",
      "_____\n",
      "TWID                                                                3021\n",
      "TWEET_ID                                              739994307940225024\n",
      "TWEET                  trastuzumab biosimilar MYL-1401O shows similar...\n",
      "SYNONYMS                                                     TRASTUZUMAB\n",
      "MOLREGNO_1                                                        675581\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                             shows safety\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Nervous System Neoplasms\n",
      "INDICATION_ID                                                    D009423\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Trastuzumab\n",
      "DESCRIPTIONS           Loading dose 8 mg/kg, then 6 mg/kg, intravenou...\n",
      "OTHER_NAME                                                     Herceptin\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                       Metastatic Breast Cancer\n",
      "MOLREGNO                                                          365281\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1894, dtype: object\n",
      "_____\n",
      "TWID                                                                3021\n",
      "TWEET_ID                                              739994307940225024\n",
      "TWEET                  trastuzumab biosimilar MYL-1401O shows similar...\n",
      "SYNONYMS                                                     TRASTUZUMAB\n",
      "MOLREGNO_1                                                        675581\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                             shows safety\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Nervous System Neoplasms\n",
      "INDICATION_ID                                                    D009423\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Trastuzumab\n",
      "DESCRIPTIONS           Loading dose 8 mg/kg, then 6 mg/kg, intravenou...\n",
      "OTHER_NAME                                                     Herceptin\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                       Metastatic Breast Cancer\n",
      "MOLREGNO                                                           14805\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1895, dtype: object\n",
      "_____\n",
      "TWID                                                                3021\n",
      "TWEET_ID                                              739994307940225024\n",
      "TWEET                  trastuzumab biosimilar MYL-1401O shows similar...\n",
      "SYNONYMS                                                     TRASTUZUMAB\n",
      "MOLREGNO_1                                                        675581\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                             shows safety\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Nervous System Neoplasms\n",
      "INDICATION_ID                                                    D009423\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Trastuzumab\n",
      "DESCRIPTIONS           Loading dose 8 mg/kg, then 6 mg/kg, intravenou...\n",
      "OTHER_NAME                                                     Herceptin\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                       Metastatic Breast Cancer\n",
      "MOLREGNO                                                         1927101\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1896, dtype: object\n",
      "_____\n",
      "TWID                                                                3031\n",
      "TWEET_ID                                              739585828142383104\n",
      "TWEET                  Safety profile of BI860585 monotherapy &amp in...\n",
      "SYNONYMS                                                      PACLITAXEL\n",
      "MOLREGNO_1                                                          8062\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           Safety profile\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                         Prostatic Hyperplasia\n",
      "INDICATION_ID                                                    D011470\n",
      "INDICATION_NONAMBIG                                                    2\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                       nab-Paclitaxel\n",
      "DESCRIPTIONS           Benzenepropanoic acid, β-(benzoylamino)-α-hydr...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                          675089\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1924, dtype: object\n",
      "_____\n",
      "TWID                                                                3031\n",
      "TWEET_ID                                              739585828142383104\n",
      "TWEET                  Safety profile of BI860585 monotherapy &amp in...\n",
      "SYNONYMS                                                      PACLITAXEL\n",
      "MOLREGNO_1                                                          8062\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           Safety profile\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                         Prostatic Hyperplasia\n",
      "INDICATION_ID                                                    D011470\n",
      "INDICATION_NONAMBIG                                                    2\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                       nab-Paclitaxel\n",
      "DESCRIPTIONS           Benzenepropanoic acid, β-(benzoylamino)-α-hydr...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                         1380097\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1926, dtype: object\n",
      "_____\n",
      "TWID                                                                3031\n",
      "TWEET_ID                                              739585828142383104\n",
      "TWEET                  Safety profile of BI860585 monotherapy &amp in...\n",
      "SYNONYMS                                                      PACLITAXEL\n",
      "MOLREGNO_1                                                          8062\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           Safety profile\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                         Prostatic Hyperplasia\n",
      "INDICATION_ID                                                    D011470\n",
      "INDICATION_NONAMBIG                                                    2\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                       nab-Paclitaxel\n",
      "DESCRIPTIONS           Benzenepropanoic acid, β-(benzoylamino)-α-hydr...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                            8633\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1927, dtype: object\n",
      "_____\n",
      "TWID                                                                3031\n",
      "TWEET_ID                                              739585828142383104\n",
      "TWEET                  Safety profile of BI860585 monotherapy &amp in...\n",
      "SYNONYMS                                                      PACLITAXEL\n",
      "MOLREGNO_1                                                          8062\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           Safety profile\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                         Prostatic Hyperplasia\n",
      "INDICATION_ID                                                    D011470\n",
      "INDICATION_NONAMBIG                                                    2\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                       nab-Paclitaxel\n",
      "DESCRIPTIONS           Benzenepropanoic acid, β-(benzoylamino)-α-hydr...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                          674747\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1928, dtype: object\n",
      "_____\n",
      "TWID                                                                3031\n",
      "TWEET_ID                                              739585828142383104\n",
      "TWEET                  Safety profile of BI860585 monotherapy &amp in...\n",
      "SYNONYMS                                                      PACLITAXEL\n",
      "MOLREGNO_1                                                          8062\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           Safety profile\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                         Prostatic Hyperplasia\n",
      "INDICATION_ID                                                    D011470\n",
      "INDICATION_NONAMBIG                                                    2\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                       nab-Paclitaxel\n",
      "DESCRIPTIONS           Benzenepropanoic acid, β-(benzoylamino)-α-hydr...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                          675483\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1929, dtype: object\n",
      "_____\n",
      "TWID                                                                3031\n",
      "TWEET_ID                                              739585828142383104\n",
      "TWEET                  Safety profile of BI860585 monotherapy &amp in...\n",
      "SYNONYMS                                                      PACLITAXEL\n",
      "MOLREGNO_1                                                          8062\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           Safety profile\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                         Prostatic Hyperplasia\n",
      "INDICATION_ID                                                    D011470\n",
      "INDICATION_NONAMBIG                                                    2\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                       nab-Paclitaxel\n",
      "DESCRIPTIONS           Benzenepropanoic acid, β-(benzoylamino)-α-hydr...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                          368538\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1930, dtype: object\n",
      "_____\n",
      "TWID                                                                3031\n",
      "TWEET_ID                                              739585828142383104\n",
      "TWEET                  Safety profile of BI860585 monotherapy &amp in...\n",
      "SYNONYMS                                                      PACLITAXEL\n",
      "MOLREGNO_1                                                          8062\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           Safety profile\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                         Prostatic Hyperplasia\n",
      "INDICATION_ID                                                    D011470\n",
      "INDICATION_NONAMBIG                                                    2\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                       nab-Paclitaxel\n",
      "DESCRIPTIONS           Benzenepropanoic acid, β-(benzoylamino)-α-hydr...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                         2096424\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1931, dtype: object\n",
      "_____\n",
      "TWID                                                                3031\n",
      "TWEET_ID                                              739585828142383104\n",
      "TWEET                  Safety profile of BI860585 monotherapy &amp in...\n",
      "SYNONYMS                                                      PACLITAXEL\n",
      "MOLREGNO_1                                                          8062\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           Safety profile\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                         Prostatic Hyperplasia\n",
      "INDICATION_ID                                                    D011470\n",
      "INDICATION_NONAMBIG                                                    2\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                       nab-Paclitaxel\n",
      "DESCRIPTIONS           Benzenepropanoic acid, β-(benzoylamino)-α-hydr...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                          598447\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1932, dtype: object\n",
      "_____\n",
      "TWID                                                                3031\n",
      "TWEET_ID                                              739585828142383104\n",
      "TWEET                  Safety profile of BI860585 monotherapy &amp in...\n",
      "SYNONYMS                                                      EXEMESTANE\n",
      "MOLREGNO_1                                                        674325\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03024580\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           Safety profile\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                         Prostatic Hyperplasia\n",
      "INDICATION_ID                                                    D011470\n",
      "INDICATION_NONAMBIG                                                    2\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                     Exemestane 25 MG\n",
      "DESCRIPTIONS                                   Exemestane 25 mg PO daily\n",
      "OTHER_NAME                                                    Exemestane\n",
      "EFO_ID                                                       EFO:0003869\n",
      "CONDITION                                                Breast Neoplasm\n",
      "MOLREGNO                                                          304798\n",
      "NAME_TERM                                                breast neoplasm\n",
      "Name: 1933, dtype: object\n",
      "_____\n",
      "TWID                                                                3031\n",
      "TWEET_ID                                              739585828142383104\n",
      "TWEET                  Safety profile of BI860585 monotherapy &amp in...\n",
      "SYNONYMS                                                      EXEMESTANE\n",
      "MOLREGNO_1                                                        674325\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03024580\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           Safety profile\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                         Prostatic Hyperplasia\n",
      "INDICATION_ID                                                    D011470\n",
      "INDICATION_NONAMBIG                                                    2\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                     Exemestane 25 MG\n",
      "DESCRIPTIONS                                   Exemestane 25 mg PO daily\n",
      "OTHER_NAME                                                    Exemestane\n",
      "EFO_ID                                                       EFO:0003869\n",
      "CONDITION                                                Breast Neoplasm\n",
      "MOLREGNO                                                          337366\n",
      "NAME_TERM                                                breast neoplasm\n",
      "Name: 1935, dtype: object\n",
      "_____\n",
      "TWID                                                                3031\n",
      "TWEET_ID                                              739585828142383104\n",
      "TWEET                  Safety profile of BI860585 monotherapy &amp in...\n",
      "SYNONYMS                                                      EXEMESTANE\n",
      "MOLREGNO_1                                                        674325\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03024580\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           Safety profile\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                         Prostatic Hyperplasia\n",
      "INDICATION_ID                                                    D011470\n",
      "INDICATION_NONAMBIG                                                    2\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                     Exemestane 25 MG\n",
      "DESCRIPTIONS                                   Exemestane 25 mg PO daily\n",
      "OTHER_NAME                                                    Exemestane\n",
      "EFO_ID                                                       EFO:0003869\n",
      "CONDITION                                                Breast Neoplasm\n",
      "MOLREGNO                                                          675090\n",
      "NAME_TERM                                                breast neoplasm\n",
      "Name: 1936, dtype: object\n",
      "_____\n",
      "TWID                                                                3031\n",
      "TWEET_ID                                              739585828142383104\n",
      "TWEET                  Safety profile of BI860585 monotherapy &amp in...\n",
      "SYNONYMS                                                      EXEMESTANE\n",
      "MOLREGNO_1                                                        674325\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03024580\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           Safety profile\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                         Prostatic Hyperplasia\n",
      "INDICATION_ID                                                    D011470\n",
      "INDICATION_NONAMBIG                                                    2\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                     Exemestane 25 MG\n",
      "DESCRIPTIONS                                   Exemestane 25 mg PO daily\n",
      "OTHER_NAME                                                    Exemestane\n",
      "EFO_ID                                                       EFO:0003869\n",
      "CONDITION                                                Breast Neoplasm\n",
      "MOLREGNO                                                          374548\n",
      "NAME_TERM                                                breast neoplasm\n",
      "Name: 1937, dtype: object\n",
      "_____\n",
      "TWID                                                                3031\n",
      "TWEET_ID                                              739585828142383104\n",
      "TWEET                  Safety profile of BI860585 monotherapy &amp in...\n",
      "SYNONYMS                                                      EXEMESTANE\n",
      "MOLREGNO_1                                                        674325\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03024580\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           Safety profile\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                         Prostatic Hyperplasia\n",
      "INDICATION_ID                                                    D011470\n",
      "INDICATION_NONAMBIG                                                    2\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                     Exemestane 25 MG\n",
      "DESCRIPTIONS                                   Exemestane 25 mg PO daily\n",
      "OTHER_NAME                                                    Exemestane\n",
      "EFO_ID                                                       EFO:0003869\n",
      "CONDITION                                                Breast Neoplasm\n",
      "MOLREGNO                                                           47340\n",
      "NAME_TERM                                                breast neoplasm\n",
      "Name: 1938, dtype: object\n",
      "_____\n",
      "TWID                                                                3033\n",
      "TWEET_ID                                              739496653829341184\n",
      "TWEET                  BI's IGF ligand Ab BI836845 tolerable in P1 tr...\n",
      "SYNONYMS                                                      EXEMESTANE\n",
      "MOLREGNO_1                                                        674325\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03024580\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                       Tolerable in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                     Exemestane 25 MG\n",
      "DESCRIPTIONS                                   Exemestane 25 mg PO daily\n",
      "OTHER_NAME                                                    Exemestane\n",
      "EFO_ID                                                       EFO:0003869\n",
      "CONDITION                                                Breast Neoplasm\n",
      "MOLREGNO                                                          304798\n",
      "NAME_TERM                                                breast neoplasm\n",
      "Name: 1940, dtype: object\n",
      "_____\n",
      "TWID                                                                3033\n",
      "TWEET_ID                                              739496653829341184\n",
      "TWEET                  BI's IGF ligand Ab BI836845 tolerable in P1 tr...\n",
      "SYNONYMS                                                      EXEMESTANE\n",
      "MOLREGNO_1                                                        674325\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03024580\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                       Tolerable in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                     Exemestane 25 MG\n",
      "DESCRIPTIONS                                   Exemestane 25 mg PO daily\n",
      "OTHER_NAME                                                    Exemestane\n",
      "EFO_ID                                                       EFO:0003869\n",
      "CONDITION                                                Breast Neoplasm\n",
      "MOLREGNO                                                          337366\n",
      "NAME_TERM                                                breast neoplasm\n",
      "Name: 1942, dtype: object\n",
      "_____\n",
      "TWID                                                                3033\n",
      "TWEET_ID                                              739496653829341184\n",
      "TWEET                  BI's IGF ligand Ab BI836845 tolerable in P1 tr...\n",
      "SYNONYMS                                                      EXEMESTANE\n",
      "MOLREGNO_1                                                        674325\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03024580\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                       Tolerable in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                     Exemestane 25 MG\n",
      "DESCRIPTIONS                                   Exemestane 25 mg PO daily\n",
      "OTHER_NAME                                                    Exemestane\n",
      "EFO_ID                                                       EFO:0003869\n",
      "CONDITION                                                Breast Neoplasm\n",
      "MOLREGNO                                                          675090\n",
      "NAME_TERM                                                breast neoplasm\n",
      "Name: 1943, dtype: object\n",
      "_____\n",
      "TWID                                                                3033\n",
      "TWEET_ID                                              739496653829341184\n",
      "TWEET                  BI's IGF ligand Ab BI836845 tolerable in P1 tr...\n",
      "SYNONYMS                                                      EXEMESTANE\n",
      "MOLREGNO_1                                                        674325\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03024580\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                       Tolerable in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                     Exemestane 25 MG\n",
      "DESCRIPTIONS                                   Exemestane 25 mg PO daily\n",
      "OTHER_NAME                                                    Exemestane\n",
      "EFO_ID                                                       EFO:0003869\n",
      "CONDITION                                                Breast Neoplasm\n",
      "MOLREGNO                                                          374548\n",
      "NAME_TERM                                                breast neoplasm\n",
      "Name: 1944, dtype: object\n",
      "_____\n",
      "TWID                                                                3033\n",
      "TWEET_ID                                              739496653829341184\n",
      "TWEET                  BI's IGF ligand Ab BI836845 tolerable in P1 tr...\n",
      "SYNONYMS                                                      EXEMESTANE\n",
      "MOLREGNO_1                                                        674325\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03024580\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                       Tolerable in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                     Exemestane 25 MG\n",
      "DESCRIPTIONS                                   Exemestane 25 mg PO daily\n",
      "OTHER_NAME                                                    Exemestane\n",
      "EFO_ID                                                       EFO:0003869\n",
      "CONDITION                                                Breast Neoplasm\n",
      "MOLREGNO                                                           47340\n",
      "NAME_TERM                                                breast neoplasm\n",
      "Name: 1945, dtype: object\n",
      "_____\n",
      "TWID                                                                3043\n",
      "TWEET_ID                                              739152277424873472\n",
      "TWEET                  DHP107 first oral paclitaxel to demonstrate ef...\n",
      "SYNONYMS                                                      PACLITAXEL\n",
      "MOLREGNO_1                                                          8062\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               3\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                           to demonstrate efficacy safety\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                             Stomach Neoplasms\n",
      "INDICATION_ID                                                    D013274\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                       nab-Paclitaxel\n",
      "DESCRIPTIONS           Benzenepropanoic acid, β-(benzoylamino)-α-hydr...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                          675089\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1947, dtype: object\n",
      "_____\n",
      "TWID                                                                3043\n",
      "TWEET_ID                                              739152277424873472\n",
      "TWEET                  DHP107 first oral paclitaxel to demonstrate ef...\n",
      "SYNONYMS                                                      PACLITAXEL\n",
      "MOLREGNO_1                                                          8062\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               3\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                           to demonstrate efficacy safety\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                             Stomach Neoplasms\n",
      "INDICATION_ID                                                    D013274\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                       nab-Paclitaxel\n",
      "DESCRIPTIONS           Benzenepropanoic acid, β-(benzoylamino)-α-hydr...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                         1380097\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1949, dtype: object\n",
      "_____\n",
      "TWID                                                                3043\n",
      "TWEET_ID                                              739152277424873472\n",
      "TWEET                  DHP107 first oral paclitaxel to demonstrate ef...\n",
      "SYNONYMS                                                      PACLITAXEL\n",
      "MOLREGNO_1                                                          8062\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               3\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                           to demonstrate efficacy safety\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                             Stomach Neoplasms\n",
      "INDICATION_ID                                                    D013274\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                       nab-Paclitaxel\n",
      "DESCRIPTIONS           Benzenepropanoic acid, β-(benzoylamino)-α-hydr...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                            8633\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1950, dtype: object\n",
      "_____\n",
      "TWID                                                                3043\n",
      "TWEET_ID                                              739152277424873472\n",
      "TWEET                  DHP107 first oral paclitaxel to demonstrate ef...\n",
      "SYNONYMS                                                      PACLITAXEL\n",
      "MOLREGNO_1                                                          8062\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               3\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                           to demonstrate efficacy safety\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                             Stomach Neoplasms\n",
      "INDICATION_ID                                                    D013274\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                       nab-Paclitaxel\n",
      "DESCRIPTIONS           Benzenepropanoic acid, β-(benzoylamino)-α-hydr...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                          674747\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1951, dtype: object\n",
      "_____\n",
      "TWID                                                                3043\n",
      "TWEET_ID                                              739152277424873472\n",
      "TWEET                  DHP107 first oral paclitaxel to demonstrate ef...\n",
      "SYNONYMS                                                      PACLITAXEL\n",
      "MOLREGNO_1                                                          8062\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               3\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                           to demonstrate efficacy safety\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                             Stomach Neoplasms\n",
      "INDICATION_ID                                                    D013274\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                       nab-Paclitaxel\n",
      "DESCRIPTIONS           Benzenepropanoic acid, β-(benzoylamino)-α-hydr...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                          675483\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1952, dtype: object\n",
      "_____\n",
      "TWID                                                                3043\n",
      "TWEET_ID                                              739152277424873472\n",
      "TWEET                  DHP107 first oral paclitaxel to demonstrate ef...\n",
      "SYNONYMS                                                      PACLITAXEL\n",
      "MOLREGNO_1                                                          8062\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               3\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                           to demonstrate efficacy safety\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                             Stomach Neoplasms\n",
      "INDICATION_ID                                                    D013274\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                       nab-Paclitaxel\n",
      "DESCRIPTIONS           Benzenepropanoic acid, β-(benzoylamino)-α-hydr...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                          368538\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1953, dtype: object\n",
      "_____\n",
      "TWID                                                                3043\n",
      "TWEET_ID                                              739152277424873472\n",
      "TWEET                  DHP107 first oral paclitaxel to demonstrate ef...\n",
      "SYNONYMS                                                      PACLITAXEL\n",
      "MOLREGNO_1                                                          8062\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               3\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                           to demonstrate efficacy safety\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                             Stomach Neoplasms\n",
      "INDICATION_ID                                                    D013274\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                       nab-Paclitaxel\n",
      "DESCRIPTIONS           Benzenepropanoic acid, β-(benzoylamino)-α-hydr...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                         2096424\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1954, dtype: object\n",
      "_____\n",
      "TWID                                                                3043\n",
      "TWEET_ID                                              739152277424873472\n",
      "TWEET                  DHP107 first oral paclitaxel to demonstrate ef...\n",
      "SYNONYMS                                                      PACLITAXEL\n",
      "MOLREGNO_1                                                          8062\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               3\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                           to demonstrate efficacy safety\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                             Stomach Neoplasms\n",
      "INDICATION_ID                                                    D013274\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                       nab-Paclitaxel\n",
      "DESCRIPTIONS           Benzenepropanoic acid, β-(benzoylamino)-α-hydr...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                          598447\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 1955, dtype: object\n",
      "_____\n",
      "TWID                                                                3063\n",
      "TWEET_ID                                              738303510509441026\n",
      "TWEET                  Dermira's DRM-04 (glycopyrronium tosylate) sho...\n",
      "SYNONYMS                                                  GLYCOPYRRONIUM\n",
      "MOLREGNO_1                                                        675286\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03256552\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                             shows safety\n",
      "COMPANY                                                          Dermira\n",
      "COMPANY_ID                                                     COMP93745\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                             Diabetes Mellitus\n",
      "INDICATION_ID                                                    D003920\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                   Glycopyrronium MDI 28.8 micrograms\n",
      "DESCRIPTIONS                          Glycopyrronium MDI 28.8 micrograms\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000341\n",
      "CONDITION                          Chronic Obstructive Pulmonary Disease\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                          chronic obstructive pulmonary disease\n",
      "Name: 1957, dtype: object\n",
      "_____\n",
      "TWID                                                                3063\n",
      "TWEET_ID                                              738303510509441026\n",
      "TWEET                  Dermira's DRM-04 (glycopyrronium tosylate) sho...\n",
      "SYNONYMS                                                  GLYCOPYRRONIUM\n",
      "MOLREGNO_1                                                        675286\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03256552\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                             shows safety\n",
      "COMPANY                                                          Dermira\n",
      "COMPANY_ID                                                     COMP93745\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                             Diabetes Mellitus\n",
      "INDICATION_ID                                                    D003920\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                   Glycopyrronium MDI 14.4 micrograms\n",
      "DESCRIPTIONS                          Glycopyrronium MDI 14.4 micrograms\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000341\n",
      "CONDITION                          Chronic Obstructive Pulmonary Disease\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                          chronic obstructive pulmonary disease\n",
      "Name: 1959, dtype: object\n",
      "_____\n",
      "TWID                                                                3063\n",
      "TWEET_ID                                              738303510509441026\n",
      "TWEET                  Dermira's DRM-04 (glycopyrronium tosylate) sho...\n",
      "SYNONYMS                                                  GLYCOPYRRONIUM\n",
      "MOLREGNO_1                                                        675286\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03256552\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                             shows safety\n",
      "COMPANY                                                          Dermira\n",
      "COMPANY_ID                                                     COMP93745\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                             Diabetes Mellitus\n",
      "INDICATION_ID                                                    D003920\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                    Glycopyrronium MDI 7.2 micrograms\n",
      "DESCRIPTIONS                           Glycopyrronium MDI 7.2 micrograms\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000341\n",
      "CONDITION                          Chronic Obstructive Pulmonary Disease\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                          chronic obstructive pulmonary disease\n",
      "Name: 1961, dtype: object\n",
      "_____\n",
      "TWID                                                                3109\n",
      "TWEET_ID                                              735385772770111489\n",
      "TWEET                  TaiMed's ibalizumab meets primary efficacy end...\n",
      "SYNONYMS                                                             OCT\n",
      "MOLREGNO_1                                                        195734\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03370913\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                   meets primary endpoint\n",
      "COMPANY                                                           TaiMed\n",
      "COMPANY_ID                                                     COMP93542\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                            Acquired Immunodeficiency Syndrome\n",
      "INDICATION_ID                                                    D000163\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                             Biological\n",
      "INTERVENTION_NAME_x                           valoctocogene roxaparvovec\n",
      "DESCRIPTIONS           Adeno-Associated Virus Vector-Mediated Gene Tr...\n",
      "OTHER_NAME                                                       BMN 270\n",
      "EFO_ID                                                    Orphanet:98878\n",
      "CONDITION                                                   Hemophilia A\n",
      "MOLREGNO                                                            Null\n",
      "NAME_TERM                                                   Hemophilia A\n",
      "Name: 1967, dtype: object\n",
      "_____\n",
      "TWID                                                                3128\n",
      "TWEET_ID                                              734790021136277504\n",
      "TWEET                  Mixed results for Novartis' KRP-203\\nin phase ...\n",
      "SYNONYMS                                                          KRP203\n",
      "MOLREGNO_1                                                       1926950\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01294774\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                              N/I\n",
      "MATCHED_OUTCOME                                            Mixed results\n",
      "COMPANY                                                         Novartis\n",
      "COMPANY_ID                                                       COMP504\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                         Hematologic Neoplasms\n",
      "INDICATION_ID                                                    D019337\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                       KRP203 - 1.2mg\n",
      "DESCRIPTIONS                                                        Null\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0003834\n",
      "CONDITION                         Subacute Cutaneous Lupus Erythematosus\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                  cutaneous lupus erythematosus\n",
      "Name: 1972, dtype: object\n",
      "_____\n",
      "TWID                                                                3128\n",
      "TWEET_ID                                              734790021136277504\n",
      "TWEET                  Mixed results for Novartis' KRP-203\\nin phase ...\n",
      "SYNONYMS                                                          KRP203\n",
      "MOLREGNO_1                                                       1926950\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01294774\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                              N/I\n",
      "MATCHED_OUTCOME                                            Mixed results\n",
      "COMPANY                                                         Novartis\n",
      "COMPANY_ID                                                       COMP504\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                         Hematologic Neoplasms\n",
      "INDICATION_ID                                                    D019337\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                           Placebo to KRP203 - 1.2 mg\n",
      "DESCRIPTIONS                                                        Null\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0003834\n",
      "CONDITION                         Subacute Cutaneous Lupus Erythematosus\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                  cutaneous lupus erythematosus\n",
      "Name: 1974, dtype: object\n",
      "_____\n",
      "TWID                                                                3151\n",
      "TWEET_ID                                              733582898612178944\n",
      "TWEET                  Tonix's TNX-102 SL (sublingual cyclobenzaprine...\n",
      "SYNONYMS                                                 CYCLOBENZAPRINE\n",
      "MOLREGNO_1                                                         28119\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03443960\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                             shows safety\n",
      "COMPANY                                            TONIX Pharmaceuticals\n",
      "COMPANY_ID                                                     COMP90805\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       0\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                               Post-Traumatic Stress Disorders\n",
      "INDICATION_ID                                                    D013313\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                    TNX-102 SL 5.6 mg\n",
      "DESCRIPTIONS           Subjects randomly assigned to this treatment w...\n",
      "OTHER_NAME                                           cyclobenzaprine HCl\n",
      "EFO_ID                                                       EFO:0000761\n",
      "CONDITION                                               Healthy Subjects\n",
      "MOLREGNO                                                          674587\n",
      "NAME_TERM                                                obsolete_normal\n",
      "Name: 1980, dtype: object\n",
      "_____\n",
      "TWID                                                                3151\n",
      "TWEET_ID                                              733582898612178944\n",
      "TWEET                  Tonix's TNX-102 SL (sublingual cyclobenzaprine...\n",
      "SYNONYMS                                                 CYCLOBENZAPRINE\n",
      "MOLREGNO_1                                                         28119\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03443960\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                             shows safety\n",
      "COMPANY                                            TONIX Pharmaceuticals\n",
      "COMPANY_ID                                                     COMP90805\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       0\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                               Post-Traumatic Stress Disorders\n",
      "INDICATION_ID                                                    D013313\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Amrix 30 mg\n",
      "DESCRIPTIONS           Subjects randomly assigned to this treatment w...\n",
      "OTHER_NAME                                           cyclobenzaprine HCl\n",
      "EFO_ID                                                       EFO:0000761\n",
      "CONDITION                                               Healthy Subjects\n",
      "MOLREGNO                                                          674587\n",
      "NAME_TERM                                                obsolete_normal\n",
      "Name: 1981, dtype: object\n",
      "_____\n",
      "TWID                                                                3172\n",
      "TWEET_ID                                              732864899995557888\n",
      "TWEET                  Theranexus's THN-102 meets primary efficacy en...\n",
      "SYNONYMS                                                       MODAFINIL\n",
      "MOLREGNO_1                                                        317124\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01778010\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                   meets primary endpoint\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                       Fatigue\n",
      "INDICATION_ID                                                    D005221\n",
      "INDICATION_NONAMBIG                                                    0\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                       Modafinil 0 mg\n",
      "DESCRIPTIONS                                        Modafinil (0 mg/day)\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0002610\n",
      "CONDITION                                             Cocaine Dependence\n",
      "MOLREGNO                                                          333370\n",
      "NAME_TERM                                             cocaine dependence\n",
      "Name: 1985, dtype: object\n",
      "_____\n",
      "TWID                                                                3172\n",
      "TWEET_ID                                              732864899995557888\n",
      "TWEET                  Theranexus's THN-102 meets primary efficacy en...\n",
      "SYNONYMS                                                       MODAFINIL\n",
      "MOLREGNO_1                                                        317124\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01778010\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                   meets primary endpoint\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                       Fatigue\n",
      "INDICATION_ID                                                    D005221\n",
      "INDICATION_NONAMBIG                                                    0\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                       Modafinil 0 mg\n",
      "DESCRIPTIONS                                        Modafinil (0 mg/day)\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0002610\n",
      "CONDITION                                             Cocaine Dependence\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                             cocaine dependence\n",
      "Name: 1986, dtype: object\n",
      "_____\n",
      "TWID                                                                3172\n",
      "TWEET_ID                                              732864899995557888\n",
      "TWEET                  Theranexus's THN-102 meets primary efficacy en...\n",
      "SYNONYMS                                                       MODAFINIL\n",
      "MOLREGNO_1                                                        317124\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01778010\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                   meets primary endpoint\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                       Fatigue\n",
      "INDICATION_ID                                                    D005221\n",
      "INDICATION_NONAMBIG                                                    0\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                     Modafinil 200 mg\n",
      "DESCRIPTIONS                                      Modafinil (200 mg/day)\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0002610\n",
      "CONDITION                                             Cocaine Dependence\n",
      "MOLREGNO                                                          333370\n",
      "NAME_TERM                                             cocaine dependence\n",
      "Name: 1988, dtype: object\n",
      "_____\n",
      "TWID                                                                3172\n",
      "TWEET_ID                                              732864899995557888\n",
      "TWEET                  Theranexus's THN-102 meets primary efficacy en...\n",
      "SYNONYMS                                                       MODAFINIL\n",
      "MOLREGNO_1                                                        317124\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01778010\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                   meets primary endpoint\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                       Fatigue\n",
      "INDICATION_ID                                                    D005221\n",
      "INDICATION_NONAMBIG                                                    0\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                     Modafinil 200 mg\n",
      "DESCRIPTIONS                                      Modafinil (200 mg/day)\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0002610\n",
      "CONDITION                                             Cocaine Dependence\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                             cocaine dependence\n",
      "Name: 1989, dtype: object\n",
      "_____\n",
      "TWID                                                                3172\n",
      "TWEET_ID                                              732864899995557888\n",
      "TWEET                  Theranexus's THN-102 meets primary efficacy en...\n",
      "SYNONYMS                                                       MODAFINIL\n",
      "MOLREGNO_1                                                        317124\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01778010\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                   meets primary endpoint\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                       Fatigue\n",
      "INDICATION_ID                                                    D005221\n",
      "INDICATION_NONAMBIG                                                    0\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                     Modafinil 400 mg\n",
      "DESCRIPTIONS                                      Modafinil (400 mg/day)\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0002610\n",
      "CONDITION                                             Cocaine Dependence\n",
      "MOLREGNO                                                          333370\n",
      "NAME_TERM                                             cocaine dependence\n",
      "Name: 1991, dtype: object\n",
      "_____\n",
      "TWID                                                                3172\n",
      "TWEET_ID                                              732864899995557888\n",
      "TWEET                  Theranexus's THN-102 meets primary efficacy en...\n",
      "SYNONYMS                                                       MODAFINIL\n",
      "MOLREGNO_1                                                        317124\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01778010\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                   meets primary endpoint\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                       Fatigue\n",
      "INDICATION_ID                                                    D005221\n",
      "INDICATION_NONAMBIG                                                    0\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                     Modafinil 400 mg\n",
      "DESCRIPTIONS                                      Modafinil (400 mg/day)\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0002610\n",
      "CONDITION                                             Cocaine Dependence\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                             cocaine dependence\n",
      "Name: 1992, dtype: object\n",
      "_____\n",
      "TWID                                                                3195\n",
      "TWEET_ID                                              732155522942681088\n",
      "TWEET                  Ziarco Pharma's histamine H4 antagonist ZPL-38...\n",
      "SYNONYMS                                                       HISTAMINE\n",
      "MOLREGNO_1                                                          8910\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01481532\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                   Decreases inflammation\n",
      "COMPANY                                                           Ziarco\n",
      "COMPANY_ID                                                     COMP93584\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                  Inflammation\n",
      "INDICATION_ID                                                    D007249\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                             Crotoxin\n",
      "DESCRIPTIONS                               Intra patient dose escalation\n",
      "OTHER_NAME                                                 antihistamine\n",
      "EFO_ID                                                       EFO:0000311\n",
      "CONDITION                                                         Cancer\n",
      "MOLREGNO                                                            Null\n",
      "NAME_TERM                                                         cancer\n",
      "Name: 1993, dtype: object\n",
      "_____\n",
      "TWID                                                                3212\n",
      "TWEET_ID                                              730403305575337984\n",
      "TWEET                  MacroGenics gains $2m milestone payment from P...\n",
      "SYNONYMS                                                     MACROGENICS\n",
      "MOLREGNO_1                                                       1927222\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                              Null\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                              N/I\n",
      "MATCHED_OUTCOME                                      milestone triggered\n",
      "COMPANY                                                           Pfizer\n",
      "COMPANY_ID                                                       COMP570\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                   Solid Tumor\n",
      "INDICATION_ID                                                    SDI0034\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Null\n",
      "INTERVENTION_NAME_x                                                 Null\n",
      "DESCRIPTIONS                                                        Null\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                              Null\n",
      "CONDITION                                                           Null\n",
      "MOLREGNO                                                            Null\n",
      "NAME_TERM                                                            NaN\n",
      "Name: 1999, dtype: object\n",
      "_____\n",
      "TWID                                                                3223\n",
      "TWEET_ID                                              730012064756989952\n",
      "TWEET                  Pfenex announces positive bioequivalence data ...\n",
      "SYNONYMS                                                    TERIPARATIDE\n",
      "MOLREGNO_1                                                        500007\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03133195\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           Positive trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                 Hip Fractures\n",
      "INDICATION_ID                                                    D006620\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Teriparatide\n",
      "DESCRIPTIONS           Teriparatide 20 μg subcutaneous once daily for...\n",
      "OTHER_NAME                                   r-Human parathyroid hormone\n",
      "EFO_ID                                                       EFO:0003964\n",
      "CONDITION                            Unstable Intertrochanteric Fracture\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                   hip fracture\n",
      "Name: 2004, dtype: object\n",
      "_____\n",
      "TWID                                                                3223\n",
      "TWEET_ID                                              730012064756989952\n",
      "TWEET                  Pfenex announces positive bioequivalence data ...\n",
      "SYNONYMS                                                    TERIPARATIDE\n",
      "MOLREGNO_1                                                        500007\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03133195\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           Positive trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                 Hip Fractures\n",
      "INDICATION_ID                                                    D006620\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Teriparatide\n",
      "DESCRIPTIONS           Teriparatide 20 μg subcutaneous once daily for...\n",
      "OTHER_NAME                                   r-Human parathyroid hormone\n",
      "EFO_ID                                                       EFO:0003964\n",
      "CONDITION                            Unstable Intertrochanteric Fracture\n",
      "MOLREGNO                                                          430124\n",
      "NAME_TERM                                                   hip fracture\n",
      "Name: 2006, dtype: object\n",
      "_____\n",
      "TWID                                                                3223\n",
      "TWEET_ID                                              730012064756989952\n",
      "TWEET                  Pfenex announces positive bioequivalence data ...\n",
      "SYNONYMS                                                    TERIPARATIDE\n",
      "MOLREGNO_1                                                        500007\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03133195\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           Positive trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                 Hip Fractures\n",
      "INDICATION_ID                                                    D006620\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Teriparatide\n",
      "DESCRIPTIONS           Teriparatide 20 μg subcutaneous once daily for...\n",
      "OTHER_NAME                                   r-Human parathyroid hormone\n",
      "EFO_ID                                                       EFO:0003964\n",
      "CONDITION                            Unstable Intertrochanteric Fracture\n",
      "MOLREGNO                                                         1418072\n",
      "NAME_TERM                                                   hip fracture\n",
      "Name: 2007, dtype: object\n",
      "_____\n",
      "TWID                                                                3566\n",
      "TWEET_ID                                              980124389881638915\n",
      "TWEET                  @roncohenshair \\nHere are some stats for you O...\n",
      "SYNONYMS                                                              11\n",
      "MOLREGNO_1                                                       1540473\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01371981\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Cytarabine\n",
      "DESCRIPTIONS                                              Given IT or IV\n",
      "OTHER_NAME             .beta.-Cytosine arabinoside;1-.beta.-D-Arabino...\n",
      "EFO_ID                                                       EFO:0002427\n",
      "CONDITION                           Untreated Childhood Myeloid Neoplasm\n",
      "MOLREGNO                                                          840903\n",
      "NAME_TERM                                               myeloid neoplasm\n",
      "Name: 2012, dtype: object\n",
      "_____\n",
      "TWID                                                                3566\n",
      "TWEET_ID                                              980124389881638915\n",
      "TWEET                  @roncohenshair \\nHere are some stats for you O...\n",
      "SYNONYMS                                                              11\n",
      "MOLREGNO_1                                                       1540473\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01371981\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Cytarabine\n",
      "DESCRIPTIONS                                              Given IT or IV\n",
      "OTHER_NAME             .beta.-Cytosine arabinoside;1-.beta.-D-Arabino...\n",
      "EFO_ID                                                       EFO:0002427\n",
      "CONDITION                           Untreated Childhood Myeloid Neoplasm\n",
      "MOLREGNO                                                          446279\n",
      "NAME_TERM                                               myeloid neoplasm\n",
      "Name: 2013, dtype: object\n",
      "_____\n",
      "TWID                                                                3566\n",
      "TWEET_ID                                              980124389881638915\n",
      "TWEET                  @roncohenshair \\nHere are some stats for you O...\n",
      "SYNONYMS                                                              11\n",
      "MOLREGNO_1                                                       1540473\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01371981\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Cytarabine\n",
      "DESCRIPTIONS                                              Given IT or IV\n",
      "OTHER_NAME             .beta.-Cytosine arabinoside;1-.beta.-D-Arabino...\n",
      "EFO_ID                                                       EFO:0002427\n",
      "CONDITION                           Untreated Childhood Myeloid Neoplasm\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                               myeloid neoplasm\n",
      "Name: 2014, dtype: object\n",
      "_____\n",
      "TWID                                                                3566\n",
      "TWEET_ID                                              980124389881638915\n",
      "TWEET                  @roncohenshair \\nHere are some stats for you O...\n",
      "SYNONYMS                                                              11\n",
      "MOLREGNO_1                                                       1540473\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01371981\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Cytarabine\n",
      "DESCRIPTIONS                                              Given IT or IV\n",
      "OTHER_NAME             .beta.-Cytosine arabinoside;1-.beta.-D-Arabino...\n",
      "EFO_ID                                                       EFO:0002427\n",
      "CONDITION                           Untreated Childhood Myeloid Neoplasm\n",
      "MOLREGNO                                                           51182\n",
      "NAME_TERM                                               myeloid neoplasm\n",
      "Name: 2015, dtype: object\n",
      "_____\n",
      "TWID                                                                3566\n",
      "TWEET_ID                                              980124389881638915\n",
      "TWEET                  @roncohenshair \\nHere are some stats for you O...\n",
      "SYNONYMS                                                              11\n",
      "MOLREGNO_1                                                       1540473\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01371981\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Cytarabine\n",
      "DESCRIPTIONS                                              Given IT or IV\n",
      "OTHER_NAME             .beta.-Cytosine arabinoside;1-.beta.-D-Arabino...\n",
      "EFO_ID                                                       EFO:0002427\n",
      "CONDITION                           Untreated Childhood Myeloid Neoplasm\n",
      "MOLREGNO                                                          187372\n",
      "NAME_TERM                                               myeloid neoplasm\n",
      "Name: 2016, dtype: object\n",
      "_____\n",
      "TWID                                                                3566\n",
      "TWEET_ID                                              980124389881638915\n",
      "TWEET                  @roncohenshair \\nHere are some stats for you O...\n",
      "SYNONYMS                                                              11\n",
      "MOLREGNO_1                                                       1540473\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01371981\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Cytarabine\n",
      "DESCRIPTIONS                                              Given IT or IV\n",
      "OTHER_NAME             .beta.-Cytosine arabinoside;1-.beta.-D-Arabino...\n",
      "EFO_ID                                                       EFO:0002427\n",
      "CONDITION                           Untreated Childhood Myeloid Neoplasm\n",
      "MOLREGNO                                                          674436\n",
      "NAME_TERM                                               myeloid neoplasm\n",
      "Name: 2017, dtype: object\n",
      "_____\n",
      "TWID                                                                3566\n",
      "TWEET_ID                                              980124389881638915\n",
      "TWEET                  @roncohenshair \\nHere are some stats for you O...\n",
      "SYNONYMS                                                              11\n",
      "MOLREGNO_1                                                       1540473\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01371981\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Cytarabine\n",
      "DESCRIPTIONS                                              Given IT or IV\n",
      "OTHER_NAME             .beta.-Cytosine arabinoside;1-.beta.-D-Arabino...\n",
      "EFO_ID                                                       EFO:0002427\n",
      "CONDITION                           Untreated Childhood Myeloid Neoplasm\n",
      "MOLREGNO                                                         1381255\n",
      "NAME_TERM                                               myeloid neoplasm\n",
      "Name: 2018, dtype: object\n",
      "_____\n",
      "TWID                                                                3566\n",
      "TWEET_ID                                              980124389881638915\n",
      "TWEET                  @roncohenshair \\nHere are some stats for you O...\n",
      "SYNONYMS                                                              11\n",
      "MOLREGNO_1                                                       1540473\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01371981\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Cytarabine\n",
      "DESCRIPTIONS                                              Given IT or IV\n",
      "OTHER_NAME             .beta.-Cytosine arabinoside;1-.beta.-D-Arabino...\n",
      "EFO_ID                                                       EFO:0002427\n",
      "CONDITION                           Untreated Childhood Myeloid Neoplasm\n",
      "MOLREGNO                                                           68607\n",
      "NAME_TERM                                               myeloid neoplasm\n",
      "Name: 2019, dtype: object\n",
      "_____\n",
      "TWID                                                                3566\n",
      "TWEET_ID                                              980124389881638915\n",
      "TWEET                  @roncohenshair \\nHere are some stats for you O...\n",
      "SYNONYMS                                                              11\n",
      "MOLREGNO_1                                                       1540473\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01371981\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Cytarabine\n",
      "DESCRIPTIONS                                              Given IT or IV\n",
      "OTHER_NAME             .beta.-Cytosine arabinoside;1-.beta.-D-Arabino...\n",
      "EFO_ID                                                       EFO:1001052\n",
      "CONDITION                                                Myeloid Sarcoma\n",
      "MOLREGNO                                                          840903\n",
      "NAME_TERM                                                myeloid sarcoma\n",
      "Name: 2020, dtype: object\n",
      "_____\n",
      "TWID                                                                3566\n",
      "TWEET_ID                                              980124389881638915\n",
      "TWEET                  @roncohenshair \\nHere are some stats for you O...\n",
      "SYNONYMS                                                              11\n",
      "MOLREGNO_1                                                       1540473\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01371981\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Cytarabine\n",
      "DESCRIPTIONS                                              Given IT or IV\n",
      "OTHER_NAME             .beta.-Cytosine arabinoside;1-.beta.-D-Arabino...\n",
      "EFO_ID                                                       EFO:1001052\n",
      "CONDITION                                                Myeloid Sarcoma\n",
      "MOLREGNO                                                          446279\n",
      "NAME_TERM                                                myeloid sarcoma\n",
      "Name: 2021, dtype: object\n",
      "_____\n",
      "TWID                                                                3566\n",
      "TWEET_ID                                              980124389881638915\n",
      "TWEET                  @roncohenshair \\nHere are some stats for you O...\n",
      "SYNONYMS                                                              11\n",
      "MOLREGNO_1                                                       1540473\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01371981\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Cytarabine\n",
      "DESCRIPTIONS                                              Given IT or IV\n",
      "OTHER_NAME             .beta.-Cytosine arabinoside;1-.beta.-D-Arabino...\n",
      "EFO_ID                                                       EFO:1001052\n",
      "CONDITION                                                Myeloid Sarcoma\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                myeloid sarcoma\n",
      "Name: 2022, dtype: object\n",
      "_____\n",
      "TWID                                                                3566\n",
      "TWEET_ID                                              980124389881638915\n",
      "TWEET                  @roncohenshair \\nHere are some stats for you O...\n",
      "SYNONYMS                                                              11\n",
      "MOLREGNO_1                                                       1540473\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01371981\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Cytarabine\n",
      "DESCRIPTIONS                                              Given IT or IV\n",
      "OTHER_NAME             .beta.-Cytosine arabinoside;1-.beta.-D-Arabino...\n",
      "EFO_ID                                                       EFO:1001052\n",
      "CONDITION                                                Myeloid Sarcoma\n",
      "MOLREGNO                                                           51182\n",
      "NAME_TERM                                                myeloid sarcoma\n",
      "Name: 2023, dtype: object\n",
      "_____\n",
      "TWID                                                                3566\n",
      "TWEET_ID                                              980124389881638915\n",
      "TWEET                  @roncohenshair \\nHere are some stats for you O...\n",
      "SYNONYMS                                                              11\n",
      "MOLREGNO_1                                                       1540473\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01371981\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Cytarabine\n",
      "DESCRIPTIONS                                              Given IT or IV\n",
      "OTHER_NAME             .beta.-Cytosine arabinoside;1-.beta.-D-Arabino...\n",
      "EFO_ID                                                       EFO:1001052\n",
      "CONDITION                                                Myeloid Sarcoma\n",
      "MOLREGNO                                                          187372\n",
      "NAME_TERM                                                myeloid sarcoma\n",
      "Name: 2024, dtype: object\n",
      "_____\n",
      "TWID                                                                3566\n",
      "TWEET_ID                                              980124389881638915\n",
      "TWEET                  @roncohenshair \\nHere are some stats for you O...\n",
      "SYNONYMS                                                              11\n",
      "MOLREGNO_1                                                       1540473\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01371981\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Cytarabine\n",
      "DESCRIPTIONS                                              Given IT or IV\n",
      "OTHER_NAME             .beta.-Cytosine arabinoside;1-.beta.-D-Arabino...\n",
      "EFO_ID                                                       EFO:1001052\n",
      "CONDITION                                                Myeloid Sarcoma\n",
      "MOLREGNO                                                          674436\n",
      "NAME_TERM                                                myeloid sarcoma\n",
      "Name: 2025, dtype: object\n",
      "_____\n",
      "TWID                                                                3566\n",
      "TWEET_ID                                              980124389881638915\n",
      "TWEET                  @roncohenshair \\nHere are some stats for you O...\n",
      "SYNONYMS                                                              11\n",
      "MOLREGNO_1                                                       1540473\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01371981\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Cytarabine\n",
      "DESCRIPTIONS                                              Given IT or IV\n",
      "OTHER_NAME             .beta.-Cytosine arabinoside;1-.beta.-D-Arabino...\n",
      "EFO_ID                                                       EFO:1001052\n",
      "CONDITION                                                Myeloid Sarcoma\n",
      "MOLREGNO                                                         1381255\n",
      "NAME_TERM                                                myeloid sarcoma\n",
      "Name: 2026, dtype: object\n",
      "_____\n",
      "TWID                                                                3566\n",
      "TWEET_ID                                              980124389881638915\n",
      "TWEET                  @roncohenshair \\nHere are some stats for you O...\n",
      "SYNONYMS                                                              11\n",
      "MOLREGNO_1                                                       1540473\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01371981\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Cytarabine\n",
      "DESCRIPTIONS                                              Given IT or IV\n",
      "OTHER_NAME             .beta.-Cytosine arabinoside;1-.beta.-D-Arabino...\n",
      "EFO_ID                                                       EFO:1001052\n",
      "CONDITION                                                Myeloid Sarcoma\n",
      "MOLREGNO                                                           68607\n",
      "NAME_TERM                                                myeloid sarcoma\n",
      "Name: 2027, dtype: object\n",
      "_____\n",
      "TWID                                                                3566\n",
      "TWEET_ID                                              980124389881638915\n",
      "TWEET                  @roncohenshair \\nHere are some stats for you O...\n",
      "SYNONYMS                                                              11\n",
      "MOLREGNO_1                                                       1540473\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01371981\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Cytarabine\n",
      "DESCRIPTIONS                                              Given IT or IV\n",
      "OTHER_NAME             .beta.-Cytosine arabinoside;1-.beta.-D-Arabino...\n",
      "EFO_ID                                                       EFO:0000222\n",
      "CONDITION                         Untreated Adult Acute Myeloid Leukemia\n",
      "MOLREGNO                                                          840903\n",
      "NAME_TERM                                         acute myeloid leukemia\n",
      "Name: 2028, dtype: object\n",
      "_____\n",
      "TWID                                                                3566\n",
      "TWEET_ID                                              980124389881638915\n",
      "TWEET                  @roncohenshair \\nHere are some stats for you O...\n",
      "SYNONYMS                                                              11\n",
      "MOLREGNO_1                                                       1540473\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01371981\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Cytarabine\n",
      "DESCRIPTIONS                                              Given IT or IV\n",
      "OTHER_NAME             .beta.-Cytosine arabinoside;1-.beta.-D-Arabino...\n",
      "EFO_ID                                                       EFO:0000222\n",
      "CONDITION                         Untreated Adult Acute Myeloid Leukemia\n",
      "MOLREGNO                                                          446279\n",
      "NAME_TERM                                         acute myeloid leukemia\n",
      "Name: 2029, dtype: object\n",
      "_____\n",
      "TWID                                                                3566\n",
      "TWEET_ID                                              980124389881638915\n",
      "TWEET                  @roncohenshair \\nHere are some stats for you O...\n",
      "SYNONYMS                                                              11\n",
      "MOLREGNO_1                                                       1540473\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01371981\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Cytarabine\n",
      "DESCRIPTIONS                                              Given IT or IV\n",
      "OTHER_NAME             .beta.-Cytosine arabinoside;1-.beta.-D-Arabino...\n",
      "EFO_ID                                                       EFO:0000222\n",
      "CONDITION                         Untreated Adult Acute Myeloid Leukemia\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                         acute myeloid leukemia\n",
      "Name: 2030, dtype: object\n",
      "_____\n",
      "TWID                                                                3566\n",
      "TWEET_ID                                              980124389881638915\n",
      "TWEET                  @roncohenshair \\nHere are some stats for you O...\n",
      "SYNONYMS                                                              11\n",
      "MOLREGNO_1                                                       1540473\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01371981\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Cytarabine\n",
      "DESCRIPTIONS                                              Given IT or IV\n",
      "OTHER_NAME             .beta.-Cytosine arabinoside;1-.beta.-D-Arabino...\n",
      "EFO_ID                                                       EFO:0000222\n",
      "CONDITION                         Untreated Adult Acute Myeloid Leukemia\n",
      "MOLREGNO                                                           51182\n",
      "NAME_TERM                                         acute myeloid leukemia\n",
      "Name: 2031, dtype: object\n",
      "_____\n",
      "TWID                                                                3566\n",
      "TWEET_ID                                              980124389881638915\n",
      "TWEET                  @roncohenshair \\nHere are some stats for you O...\n",
      "SYNONYMS                                                              11\n",
      "MOLREGNO_1                                                       1540473\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01371981\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Cytarabine\n",
      "DESCRIPTIONS                                              Given IT or IV\n",
      "OTHER_NAME             .beta.-Cytosine arabinoside;1-.beta.-D-Arabino...\n",
      "EFO_ID                                                       EFO:0000222\n",
      "CONDITION                         Untreated Adult Acute Myeloid Leukemia\n",
      "MOLREGNO                                                          187372\n",
      "NAME_TERM                                         acute myeloid leukemia\n",
      "Name: 2032, dtype: object\n",
      "_____\n",
      "TWID                                                                3566\n",
      "TWEET_ID                                              980124389881638915\n",
      "TWEET                  @roncohenshair \\nHere are some stats for you O...\n",
      "SYNONYMS                                                              11\n",
      "MOLREGNO_1                                                       1540473\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01371981\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Cytarabine\n",
      "DESCRIPTIONS                                              Given IT or IV\n",
      "OTHER_NAME             .beta.-Cytosine arabinoside;1-.beta.-D-Arabino...\n",
      "EFO_ID                                                       EFO:0000222\n",
      "CONDITION                         Untreated Adult Acute Myeloid Leukemia\n",
      "MOLREGNO                                                          674436\n",
      "NAME_TERM                                         acute myeloid leukemia\n",
      "Name: 2033, dtype: object\n",
      "_____\n",
      "TWID                                                                3566\n",
      "TWEET_ID                                              980124389881638915\n",
      "TWEET                  @roncohenshair \\nHere are some stats for you O...\n",
      "SYNONYMS                                                              11\n",
      "MOLREGNO_1                                                       1540473\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01371981\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Cytarabine\n",
      "DESCRIPTIONS                                              Given IT or IV\n",
      "OTHER_NAME             .beta.-Cytosine arabinoside;1-.beta.-D-Arabino...\n",
      "EFO_ID                                                       EFO:0000222\n",
      "CONDITION                         Untreated Adult Acute Myeloid Leukemia\n",
      "MOLREGNO                                                         1381255\n",
      "NAME_TERM                                         acute myeloid leukemia\n",
      "Name: 2034, dtype: object\n",
      "_____\n",
      "TWID                                                                3566\n",
      "TWEET_ID                                              980124389881638915\n",
      "TWEET                  @roncohenshair \\nHere are some stats for you O...\n",
      "SYNONYMS                                                              11\n",
      "MOLREGNO_1                                                       1540473\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01371981\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Cytarabine\n",
      "DESCRIPTIONS                                              Given IT or IV\n",
      "OTHER_NAME             .beta.-Cytosine arabinoside;1-.beta.-D-Arabino...\n",
      "EFO_ID                                                       EFO:0000222\n",
      "CONDITION                         Untreated Adult Acute Myeloid Leukemia\n",
      "MOLREGNO                                                           68607\n",
      "NAME_TERM                                         acute myeloid leukemia\n",
      "Name: 2035, dtype: object\n",
      "_____\n",
      "TWID                                                                3566\n",
      "TWEET_ID                                              980124389881638915\n",
      "TWEET                  @roncohenshair \\nHere are some stats for you O...\n",
      "SYNONYMS                                                              11\n",
      "MOLREGNO_1                                                       1540473\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01371981\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Cytarabine\n",
      "DESCRIPTIONS                                              Given IT or IV\n",
      "OTHER_NAME             .beta.-Cytosine arabinoside;1-.beta.-D-Arabino...\n",
      "EFO_ID                                                       EFO:0000222\n",
      "CONDITION                                         Acute Myeloid Leukemia\n",
      "MOLREGNO                                                          840903\n",
      "NAME_TERM                                         acute myeloid leukemia\n",
      "Name: 2036, dtype: object\n",
      "_____\n",
      "TWID                                                                3566\n",
      "TWEET_ID                                              980124389881638915\n",
      "TWEET                  @roncohenshair \\nHere are some stats for you O...\n",
      "SYNONYMS                                                              11\n",
      "MOLREGNO_1                                                       1540473\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01371981\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Cytarabine\n",
      "DESCRIPTIONS                                              Given IT or IV\n",
      "OTHER_NAME             .beta.-Cytosine arabinoside;1-.beta.-D-Arabino...\n",
      "EFO_ID                                                       EFO:0000222\n",
      "CONDITION                                         Acute Myeloid Leukemia\n",
      "MOLREGNO                                                          446279\n",
      "NAME_TERM                                         acute myeloid leukemia\n",
      "Name: 2037, dtype: object\n",
      "_____\n",
      "TWID                                                                3566\n",
      "TWEET_ID                                              980124389881638915\n",
      "TWEET                  @roncohenshair \\nHere are some stats for you O...\n",
      "SYNONYMS                                                              11\n",
      "MOLREGNO_1                                                       1540473\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01371981\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Cytarabine\n",
      "DESCRIPTIONS                                              Given IT or IV\n",
      "OTHER_NAME             .beta.-Cytosine arabinoside;1-.beta.-D-Arabino...\n",
      "EFO_ID                                                       EFO:0000222\n",
      "CONDITION                                         Acute Myeloid Leukemia\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                         acute myeloid leukemia\n",
      "Name: 2038, dtype: object\n",
      "_____\n",
      "TWID                                                                3566\n",
      "TWEET_ID                                              980124389881638915\n",
      "TWEET                  @roncohenshair \\nHere are some stats for you O...\n",
      "SYNONYMS                                                              11\n",
      "MOLREGNO_1                                                       1540473\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01371981\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Cytarabine\n",
      "DESCRIPTIONS                                              Given IT or IV\n",
      "OTHER_NAME             .beta.-Cytosine arabinoside;1-.beta.-D-Arabino...\n",
      "EFO_ID                                                       EFO:0000222\n",
      "CONDITION                                         Acute Myeloid Leukemia\n",
      "MOLREGNO                                                           51182\n",
      "NAME_TERM                                         acute myeloid leukemia\n",
      "Name: 2039, dtype: object\n",
      "_____\n",
      "TWID                                                                3566\n",
      "TWEET_ID                                              980124389881638915\n",
      "TWEET                  @roncohenshair \\nHere are some stats for you O...\n",
      "SYNONYMS                                                              11\n",
      "MOLREGNO_1                                                       1540473\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01371981\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Cytarabine\n",
      "DESCRIPTIONS                                              Given IT or IV\n",
      "OTHER_NAME             .beta.-Cytosine arabinoside;1-.beta.-D-Arabino...\n",
      "EFO_ID                                                       EFO:0000222\n",
      "CONDITION                                         Acute Myeloid Leukemia\n",
      "MOLREGNO                                                          187372\n",
      "NAME_TERM                                         acute myeloid leukemia\n",
      "Name: 2040, dtype: object\n",
      "_____\n",
      "TWID                                                                3566\n",
      "TWEET_ID                                              980124389881638915\n",
      "TWEET                  @roncohenshair \\nHere are some stats for you O...\n",
      "SYNONYMS                                                              11\n",
      "MOLREGNO_1                                                       1540473\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01371981\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Cytarabine\n",
      "DESCRIPTIONS                                              Given IT or IV\n",
      "OTHER_NAME             .beta.-Cytosine arabinoside;1-.beta.-D-Arabino...\n",
      "EFO_ID                                                       EFO:0000222\n",
      "CONDITION                                         Acute Myeloid Leukemia\n",
      "MOLREGNO                                                          674436\n",
      "NAME_TERM                                         acute myeloid leukemia\n",
      "Name: 2041, dtype: object\n",
      "_____\n",
      "TWID                                                                3566\n",
      "TWEET_ID                                              980124389881638915\n",
      "TWEET                  @roncohenshair \\nHere are some stats for you O...\n",
      "SYNONYMS                                                              11\n",
      "MOLREGNO_1                                                       1540473\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01371981\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Cytarabine\n",
      "DESCRIPTIONS                                              Given IT or IV\n",
      "OTHER_NAME             .beta.-Cytosine arabinoside;1-.beta.-D-Arabino...\n",
      "EFO_ID                                                       EFO:0000222\n",
      "CONDITION                                         Acute Myeloid Leukemia\n",
      "MOLREGNO                                                         1381255\n",
      "NAME_TERM                                         acute myeloid leukemia\n",
      "Name: 2042, dtype: object\n",
      "_____\n",
      "TWID                                                                3566\n",
      "TWEET_ID                                              980124389881638915\n",
      "TWEET                  @roncohenshair \\nHere are some stats for you O...\n",
      "SYNONYMS                                                              11\n",
      "MOLREGNO_1                                                       1540473\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01371981\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Cytarabine\n",
      "DESCRIPTIONS                                              Given IT or IV\n",
      "OTHER_NAME             .beta.-Cytosine arabinoside;1-.beta.-D-Arabino...\n",
      "EFO_ID                                                       EFO:0000222\n",
      "CONDITION                                         Acute Myeloid Leukemia\n",
      "MOLREGNO                                                           68607\n",
      "NAME_TERM                                         acute myeloid leukemia\n",
      "Name: 2043, dtype: object\n",
      "_____\n",
      "TWID                                                                3566\n",
      "TWEET_ID                                              980124389881638915\n",
      "TWEET                  @roncohenshair \\nHere are some stats for you O...\n",
      "SYNONYMS                                                              11\n",
      "MOLREGNO_1                                                       1540473\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01371981\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Cytarabine\n",
      "DESCRIPTIONS                                              Given IT or IV\n",
      "OTHER_NAME             .beta.-Cytosine arabinoside;1-.beta.-D-Arabino...\n",
      "EFO_ID                                                       EFO:0002427\n",
      "CONDITION                                               Myeloid Neoplasm\n",
      "MOLREGNO                                                          840903\n",
      "NAME_TERM                                               myeloid neoplasm\n",
      "Name: 2044, dtype: object\n",
      "_____\n",
      "TWID                                                                3566\n",
      "TWEET_ID                                              980124389881638915\n",
      "TWEET                  @roncohenshair \\nHere are some stats for you O...\n",
      "SYNONYMS                                                              11\n",
      "MOLREGNO_1                                                       1540473\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01371981\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Cytarabine\n",
      "DESCRIPTIONS                                              Given IT or IV\n",
      "OTHER_NAME             .beta.-Cytosine arabinoside;1-.beta.-D-Arabino...\n",
      "EFO_ID                                                       EFO:0002427\n",
      "CONDITION                                               Myeloid Neoplasm\n",
      "MOLREGNO                                                          446279\n",
      "NAME_TERM                                               myeloid neoplasm\n",
      "Name: 2045, dtype: object\n",
      "_____\n",
      "TWID                                                                3566\n",
      "TWEET_ID                                              980124389881638915\n",
      "TWEET                  @roncohenshair \\nHere are some stats for you O...\n",
      "SYNONYMS                                                              11\n",
      "MOLREGNO_1                                                       1540473\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01371981\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Cytarabine\n",
      "DESCRIPTIONS                                              Given IT or IV\n",
      "OTHER_NAME             .beta.-Cytosine arabinoside;1-.beta.-D-Arabino...\n",
      "EFO_ID                                                       EFO:0002427\n",
      "CONDITION                                               Myeloid Neoplasm\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                               myeloid neoplasm\n",
      "Name: 2046, dtype: object\n",
      "_____\n",
      "TWID                                                                3566\n",
      "TWEET_ID                                              980124389881638915\n",
      "TWEET                  @roncohenshair \\nHere are some stats for you O...\n",
      "SYNONYMS                                                              11\n",
      "MOLREGNO_1                                                       1540473\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01371981\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Cytarabine\n",
      "DESCRIPTIONS                                              Given IT or IV\n",
      "OTHER_NAME             .beta.-Cytosine arabinoside;1-.beta.-D-Arabino...\n",
      "EFO_ID                                                       EFO:0002427\n",
      "CONDITION                                               Myeloid Neoplasm\n",
      "MOLREGNO                                                           51182\n",
      "NAME_TERM                                               myeloid neoplasm\n",
      "Name: 2047, dtype: object\n",
      "_____\n",
      "TWID                                                                3566\n",
      "TWEET_ID                                              980124389881638915\n",
      "TWEET                  @roncohenshair \\nHere are some stats for you O...\n",
      "SYNONYMS                                                              11\n",
      "MOLREGNO_1                                                       1540473\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01371981\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Cytarabine\n",
      "DESCRIPTIONS                                              Given IT or IV\n",
      "OTHER_NAME             .beta.-Cytosine arabinoside;1-.beta.-D-Arabino...\n",
      "EFO_ID                                                       EFO:0002427\n",
      "CONDITION                                               Myeloid Neoplasm\n",
      "MOLREGNO                                                          187372\n",
      "NAME_TERM                                               myeloid neoplasm\n",
      "Name: 2048, dtype: object\n",
      "_____\n",
      "TWID                                                                3566\n",
      "TWEET_ID                                              980124389881638915\n",
      "TWEET                  @roncohenshair \\nHere are some stats for you O...\n",
      "SYNONYMS                                                              11\n",
      "MOLREGNO_1                                                       1540473\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01371981\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Cytarabine\n",
      "DESCRIPTIONS                                              Given IT or IV\n",
      "OTHER_NAME             .beta.-Cytosine arabinoside;1-.beta.-D-Arabino...\n",
      "EFO_ID                                                       EFO:0002427\n",
      "CONDITION                                               Myeloid Neoplasm\n",
      "MOLREGNO                                                          674436\n",
      "NAME_TERM                                               myeloid neoplasm\n",
      "Name: 2049, dtype: object\n",
      "_____\n",
      "TWID                                                                3566\n",
      "TWEET_ID                                              980124389881638915\n",
      "TWEET                  @roncohenshair \\nHere are some stats for you O...\n",
      "SYNONYMS                                                              11\n",
      "MOLREGNO_1                                                       1540473\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01371981\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Cytarabine\n",
      "DESCRIPTIONS                                              Given IT or IV\n",
      "OTHER_NAME             .beta.-Cytosine arabinoside;1-.beta.-D-Arabino...\n",
      "EFO_ID                                                       EFO:0002427\n",
      "CONDITION                                               Myeloid Neoplasm\n",
      "MOLREGNO                                                         1381255\n",
      "NAME_TERM                                               myeloid neoplasm\n",
      "Name: 2050, dtype: object\n",
      "_____\n",
      "TWID                                                                3566\n",
      "TWEET_ID                                              980124389881638915\n",
      "TWEET                  @roncohenshair \\nHere are some stats for you O...\n",
      "SYNONYMS                                                              11\n",
      "MOLREGNO_1                                                       1540473\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01371981\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Cytarabine\n",
      "DESCRIPTIONS                                              Given IT or IV\n",
      "OTHER_NAME             .beta.-Cytosine arabinoside;1-.beta.-D-Arabino...\n",
      "EFO_ID                                                       EFO:0002427\n",
      "CONDITION                                               Myeloid Neoplasm\n",
      "MOLREGNO                                                           68607\n",
      "NAME_TERM                                               myeloid neoplasm\n",
      "Name: 2051, dtype: object\n",
      "_____\n",
      "TWID                                                                3566\n",
      "TWEET_ID                                              980124389881638915\n",
      "TWEET                  @roncohenshair \\nHere are some stats for you O...\n",
      "SYNONYMS                                                              11\n",
      "MOLREGNO_1                                                       1540473\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01371981\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Cytarabine\n",
      "DESCRIPTIONS                                              Given IT or IV\n",
      "OTHER_NAME             .beta.-Cytosine arabinoside;1-.beta.-D-Arabino...\n",
      "EFO_ID                                                       EFO:0000565\n",
      "CONDITION                                                 Leukemia Cutis\n",
      "MOLREGNO                                                          840903\n",
      "NAME_TERM                                                       leukemia\n",
      "Name: 2052, dtype: object\n",
      "_____\n",
      "TWID                                                                3566\n",
      "TWEET_ID                                              980124389881638915\n",
      "TWEET                  @roncohenshair \\nHere are some stats for you O...\n",
      "SYNONYMS                                                              11\n",
      "MOLREGNO_1                                                       1540473\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01371981\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Cytarabine\n",
      "DESCRIPTIONS                                              Given IT or IV\n",
      "OTHER_NAME             .beta.-Cytosine arabinoside;1-.beta.-D-Arabino...\n",
      "EFO_ID                                                       EFO:0000565\n",
      "CONDITION                                                 Leukemia Cutis\n",
      "MOLREGNO                                                          446279\n",
      "NAME_TERM                                                       leukemia\n",
      "Name: 2053, dtype: object\n",
      "_____\n",
      "TWID                                                                3566\n",
      "TWEET_ID                                              980124389881638915\n",
      "TWEET                  @roncohenshair \\nHere are some stats for you O...\n",
      "SYNONYMS                                                              11\n",
      "MOLREGNO_1                                                       1540473\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01371981\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Cytarabine\n",
      "DESCRIPTIONS                                              Given IT or IV\n",
      "OTHER_NAME             .beta.-Cytosine arabinoside;1-.beta.-D-Arabino...\n",
      "EFO_ID                                                       EFO:0000565\n",
      "CONDITION                                                 Leukemia Cutis\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                       leukemia\n",
      "Name: 2054, dtype: object\n",
      "_____\n",
      "TWID                                                                3566\n",
      "TWEET_ID                                              980124389881638915\n",
      "TWEET                  @roncohenshair \\nHere are some stats for you O...\n",
      "SYNONYMS                                                              11\n",
      "MOLREGNO_1                                                       1540473\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01371981\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Cytarabine\n",
      "DESCRIPTIONS                                              Given IT or IV\n",
      "OTHER_NAME             .beta.-Cytosine arabinoside;1-.beta.-D-Arabino...\n",
      "EFO_ID                                                       EFO:0000565\n",
      "CONDITION                                                 Leukemia Cutis\n",
      "MOLREGNO                                                           51182\n",
      "NAME_TERM                                                       leukemia\n",
      "Name: 2055, dtype: object\n",
      "_____\n",
      "TWID                                                                3566\n",
      "TWEET_ID                                              980124389881638915\n",
      "TWEET                  @roncohenshair \\nHere are some stats for you O...\n",
      "SYNONYMS                                                              11\n",
      "MOLREGNO_1                                                       1540473\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01371981\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Cytarabine\n",
      "DESCRIPTIONS                                              Given IT or IV\n",
      "OTHER_NAME             .beta.-Cytosine arabinoside;1-.beta.-D-Arabino...\n",
      "EFO_ID                                                       EFO:0000565\n",
      "CONDITION                                                 Leukemia Cutis\n",
      "MOLREGNO                                                          187372\n",
      "NAME_TERM                                                       leukemia\n",
      "Name: 2056, dtype: object\n",
      "_____\n",
      "TWID                                                                3566\n",
      "TWEET_ID                                              980124389881638915\n",
      "TWEET                  @roncohenshair \\nHere are some stats for you O...\n",
      "SYNONYMS                                                              11\n",
      "MOLREGNO_1                                                       1540473\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01371981\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Cytarabine\n",
      "DESCRIPTIONS                                              Given IT or IV\n",
      "OTHER_NAME             .beta.-Cytosine arabinoside;1-.beta.-D-Arabino...\n",
      "EFO_ID                                                       EFO:0000565\n",
      "CONDITION                                                 Leukemia Cutis\n",
      "MOLREGNO                                                          674436\n",
      "NAME_TERM                                                       leukemia\n",
      "Name: 2057, dtype: object\n",
      "_____\n",
      "TWID                                                                3566\n",
      "TWEET_ID                                              980124389881638915\n",
      "TWEET                  @roncohenshair \\nHere are some stats for you O...\n",
      "SYNONYMS                                                              11\n",
      "MOLREGNO_1                                                       1540473\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01371981\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Cytarabine\n",
      "DESCRIPTIONS                                              Given IT or IV\n",
      "OTHER_NAME             .beta.-Cytosine arabinoside;1-.beta.-D-Arabino...\n",
      "EFO_ID                                                       EFO:0000565\n",
      "CONDITION                                                 Leukemia Cutis\n",
      "MOLREGNO                                                         1381255\n",
      "NAME_TERM                                                       leukemia\n",
      "Name: 2058, dtype: object\n",
      "_____\n",
      "TWID                                                                3566\n",
      "TWEET_ID                                              980124389881638915\n",
      "TWEET                  @roncohenshair \\nHere are some stats for you O...\n",
      "SYNONYMS                                                              11\n",
      "MOLREGNO_1                                                       1540473\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01371981\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Cytarabine\n",
      "DESCRIPTIONS                                              Given IT or IV\n",
      "OTHER_NAME             .beta.-Cytosine arabinoside;1-.beta.-D-Arabino...\n",
      "EFO_ID                                                       EFO:0000565\n",
      "CONDITION                                                 Leukemia Cutis\n",
      "MOLREGNO                                                           68607\n",
      "NAME_TERM                                                       leukemia\n",
      "Name: 2059, dtype: object\n",
      "_____\n",
      "TWID                                                                4058\n",
      "TWEET_ID                                              969668024675512321\n",
      "TWEET                  #2\\nRoche Ionis herald a big win in early-stag...\n",
      "SYNONYMS                                                           ROCHE\n",
      "MOLREGNO_1                                                        469217\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03448666\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                  demonstrate disease modifying potential\n",
      "COMPANY                                                            Roche\n",
      "COMPANY_ID                                                       COMP642\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                            Huntington Disease\n",
      "INDICATION_ID                                                    D006816\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                    Combination Product\n",
      "INTERVENTION_NAME_x                                        Pembrolizumab\n",
      "DESCRIPTIONS           Electrochemotherapy will be performed with the...\n",
      "OTHER_NAME                                           Electrochemotherapy\n",
      "EFO_ID                                                       EFO:0000756\n",
      "CONDITION                                             Malignant Melanoma\n",
      "MOLREGNO                                                         1626777\n",
      "NAME_TERM                                                       melanoma\n",
      "Name: 2065, dtype: object\n",
      "_____\n",
      "TWID                                                                4078\n",
      "TWEET_ID                                              969335897853431808\n",
      "TWEET                  Roche Ionis herald a big win in early-stage Hu...\n",
      "SYNONYMS                                                           ROCHE\n",
      "MOLREGNO_1                                                        469217\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03448666\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                  demonstrate disease modifying potential\n",
      "COMPANY                                                            Roche\n",
      "COMPANY_ID                                                       COMP642\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                            Huntington Disease\n",
      "INDICATION_ID                                                    D006816\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                    Combination Product\n",
      "INTERVENTION_NAME_x                                        Pembrolizumab\n",
      "DESCRIPTIONS           Electrochemotherapy will be performed with the...\n",
      "OTHER_NAME                                           Electrochemotherapy\n",
      "EFO_ID                                                       EFO:0000756\n",
      "CONDITION                                             Malignant Melanoma\n",
      "MOLREGNO                                                         1626777\n",
      "NAME_TERM                                                       melanoma\n",
      "Name: 2066, dtype: object\n",
      "_____\n",
      "TWID                                                                4585\n",
      "TWEET_ID                                              959062798084050944\n",
      "TWEET                  Puma touts its latest advances in a basket tri...\n",
      "SYNONYMS                                                         NERLYNX\n",
      "MOLREGNO_1                                                       2197792\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01953926\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                          reject the drug\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Neratinib\n",
      "DESCRIPTIONS           240 mg administered orally, once daily with fo...\n",
      "OTHER_NAME                                                       Nerlynx\n",
      "EFO_ID                                                       EFO:0000616\n",
      "CONDITION                                          Malignant Solid Tumor\n",
      "MOLREGNO                                                          675581\n",
      "NAME_TERM                                                       neoplasm\n",
      "Name: 2077, dtype: object\n",
      "_____\n",
      "TWID                                                                4585\n",
      "TWEET_ID                                              959062798084050944\n",
      "TWEET                  Puma touts its latest advances in a basket tri...\n",
      "SYNONYMS                                                         NERLYNX\n",
      "MOLREGNO_1                                                       2197792\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01953926\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                          reject the drug\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Neratinib\n",
      "DESCRIPTIONS           240 mg administered orally, once daily with fo...\n",
      "OTHER_NAME                                                       Nerlynx\n",
      "EFO_ID                                                       EFO:0000616\n",
      "CONDITION                                          Malignant Solid Tumor\n",
      "MOLREGNO                                                            8062\n",
      "NAME_TERM                                                       neoplasm\n",
      "Name: 2078, dtype: object\n",
      "_____\n",
      "TWID                                                                4585\n",
      "TWEET_ID                                              959062798084050944\n",
      "TWEET                  Puma touts its latest advances in a basket tri...\n",
      "SYNONYMS                                                         NERLYNX\n",
      "MOLREGNO_1                                                       2197792\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01953926\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                          reject the drug\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Neratinib\n",
      "DESCRIPTIONS           240 mg administered orally, once daily with fo...\n",
      "OTHER_NAME                                                       Nerlynx\n",
      "EFO_ID                                                       EFO:0000616\n",
      "CONDITION                                          Malignant Solid Tumor\n",
      "MOLREGNO                                                          304798\n",
      "NAME_TERM                                                       neoplasm\n",
      "Name: 2079, dtype: object\n",
      "_____\n",
      "TWID                                                                4585\n",
      "TWEET_ID                                              959062798084050944\n",
      "TWEET                  Puma touts its latest advances in a basket tri...\n",
      "SYNONYMS                                                         NERLYNX\n",
      "MOLREGNO_1                                                       2197792\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01953926\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                          reject the drug\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Neratinib\n",
      "DESCRIPTIONS           240 mg administered orally, once daily with fo...\n",
      "OTHER_NAME                                                       Nerlynx\n",
      "EFO_ID                                                       EFO:0000616\n",
      "CONDITION                                          Malignant Solid Tumor\n",
      "MOLREGNO                                                          299120\n",
      "NAME_TERM                                                       neoplasm\n",
      "Name: 2080, dtype: object\n",
      "_____\n",
      "TWID                                                                4585\n",
      "TWEET_ID                                              959062798084050944\n",
      "TWEET                  Puma touts its latest advances in a basket tri...\n",
      "SYNONYMS                                                         NERLYNX\n",
      "MOLREGNO_1                                                       2197792\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01953926\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                          reject the drug\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Neratinib\n",
      "DESCRIPTIONS           240 mg administered orally, once daily with fo...\n",
      "OTHER_NAME                                                       Nerlynx\n",
      "EFO_ID                                                       EFO:1000256\n",
      "CONDITION                                        Fibrolamellar Carcinoma\n",
      "MOLREGNO                                                          675581\n",
      "NAME_TERM                                        Fibrolamellar Carcinoma\n",
      "Name: 2081, dtype: object\n",
      "_____\n",
      "TWID                                                                4585\n",
      "TWEET_ID                                              959062798084050944\n",
      "TWEET                  Puma touts its latest advances in a basket tri...\n",
      "SYNONYMS                                                         NERLYNX\n",
      "MOLREGNO_1                                                       2197792\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01953926\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                          reject the drug\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Neratinib\n",
      "DESCRIPTIONS           240 mg administered orally, once daily with fo...\n",
      "OTHER_NAME                                                       Nerlynx\n",
      "EFO_ID                                                       EFO:1000256\n",
      "CONDITION                                        Fibrolamellar Carcinoma\n",
      "MOLREGNO                                                            8062\n",
      "NAME_TERM                                        Fibrolamellar Carcinoma\n",
      "Name: 2082, dtype: object\n",
      "_____\n",
      "TWID                                                                4585\n",
      "TWEET_ID                                              959062798084050944\n",
      "TWEET                  Puma touts its latest advances in a basket tri...\n",
      "SYNONYMS                                                         NERLYNX\n",
      "MOLREGNO_1                                                       2197792\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01953926\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                          reject the drug\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Neratinib\n",
      "DESCRIPTIONS           240 mg administered orally, once daily with fo...\n",
      "OTHER_NAME                                                       Nerlynx\n",
      "EFO_ID                                                       EFO:1000256\n",
      "CONDITION                                        Fibrolamellar Carcinoma\n",
      "MOLREGNO                                                          304798\n",
      "NAME_TERM                                        Fibrolamellar Carcinoma\n",
      "Name: 2083, dtype: object\n",
      "_____\n",
      "TWID                                                                4585\n",
      "TWEET_ID                                              959062798084050944\n",
      "TWEET                  Puma touts its latest advances in a basket tri...\n",
      "SYNONYMS                                                         NERLYNX\n",
      "MOLREGNO_1                                                       2197792\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01953926\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                          reject the drug\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Neratinib\n",
      "DESCRIPTIONS           240 mg administered orally, once daily with fo...\n",
      "OTHER_NAME                                                       Nerlynx\n",
      "EFO_ID                                                       EFO:1000256\n",
      "CONDITION                                        Fibrolamellar Carcinoma\n",
      "MOLREGNO                                                          299120\n",
      "NAME_TERM                                        Fibrolamellar Carcinoma\n",
      "Name: 2084, dtype: object\n",
      "_____\n",
      "TWID                                                                4697\n",
      "TWEET_ID                                              956508440326746112\n",
      "TWEET                  GW on fire PhIII epilepsy data signals success...\n",
      "SYNONYMS                                                             CBD\n",
      "MOLREGNO_1                                                        318390\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03382561\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                              N/I\n",
      "MATCHED_OUTCOME                                               First data\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                      Epilepsy\n",
      "INDICATION_ID                                                    D004827\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Carboplatin\n",
      "DESCRIPTIONS                                                    Given IV\n",
      "OTHER_NAME             Blastocarb;Carboplat;Carboplatin Hexal;Carbopl...\n",
      "EFO_ID                                                       EFO:0000702\n",
      "CONDITION                      Extensive Stage Small Cell Lung Carcinoma\n",
      "MOLREGNO                                                         1381004\n",
      "NAME_TERM                                      small cell lung carcinoma\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Name: 2085, dtype: object\n",
      "_____\n",
      "TWID                                                                4697\n",
      "TWEET_ID                                              956508440326746112\n",
      "TWEET                  GW on fire PhIII epilepsy data signals success...\n",
      "SYNONYMS                                                             CBD\n",
      "MOLREGNO_1                                                        318390\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03382561\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                              N/I\n",
      "MATCHED_OUTCOME                                               First data\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                      Epilepsy\n",
      "INDICATION_ID                                                    D004827\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Carboplatin\n",
      "DESCRIPTIONS                                                    Given IV\n",
      "OTHER_NAME             Blastocarb;Carboplat;Carboplatin Hexal;Carbopl...\n",
      "EFO_ID                                                       EFO:0000702\n",
      "CONDITION                      Extensive Stage Small Cell Lung Carcinoma\n",
      "MOLREGNO                                                            8633\n",
      "NAME_TERM                                      small cell lung carcinoma\n",
      "Name: 2086, dtype: object\n",
      "_____\n",
      "TWID                                                                4697\n",
      "TWEET_ID                                              956508440326746112\n",
      "TWEET                  GW on fire PhIII epilepsy data signals success...\n",
      "SYNONYMS                                                             CBD\n",
      "MOLREGNO_1                                                        318390\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03382561\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                              N/I\n",
      "MATCHED_OUTCOME                                               First data\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                      Epilepsy\n",
      "INDICATION_ID                                                    D004827\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Carboplatin\n",
      "DESCRIPTIONS                                                    Given IV\n",
      "OTHER_NAME             Blastocarb;Carboplat;Carboplatin Hexal;Carbopl...\n",
      "EFO_ID                                                       EFO:0000702\n",
      "CONDITION                      Extensive Stage Small Cell Lung Carcinoma\n",
      "MOLREGNO                                                           68607\n",
      "NAME_TERM                                      small cell lung carcinoma\n",
      "Name: 2087, dtype: object\n",
      "_____\n",
      "TWID                                                                4697\n",
      "TWEET_ID                                              956508440326746112\n",
      "TWEET                  GW on fire PhIII epilepsy data signals success...\n",
      "SYNONYMS                                                             CBD\n",
      "MOLREGNO_1                                                        318390\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03382561\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                              N/I\n",
      "MATCHED_OUTCOME                                               First data\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                      Epilepsy\n",
      "INDICATION_ID                                                    D004827\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Carboplatin\n",
      "DESCRIPTIONS                                                    Given IV\n",
      "OTHER_NAME             Blastocarb;Carboplat;Carboplatin Hexal;Carbopl...\n",
      "EFO_ID                                                       EFO:0000702\n",
      "CONDITION                      Extensive Stage Small Cell Lung Carcinoma\n",
      "MOLREGNO                                                          300022\n",
      "NAME_TERM                                      small cell lung carcinoma\n",
      "Name: 2088, dtype: object\n",
      "_____\n",
      "TWID                                                                4697\n",
      "TWEET_ID                                              956508440326746112\n",
      "TWEET                  GW on fire PhIII epilepsy data signals success...\n",
      "SYNONYMS                                                             CBD\n",
      "MOLREGNO_1                                                        318390\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03382561\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                              N/I\n",
      "MATCHED_OUTCOME                                               First data\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                      Epilepsy\n",
      "INDICATION_ID                                                    D004827\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Carboplatin\n",
      "DESCRIPTIONS                                                    Given IV\n",
      "OTHER_NAME             Blastocarb;Carboplat;Carboplatin Hexal;Carbopl...\n",
      "EFO_ID                                                       EFO:0000702\n",
      "CONDITION                      Extensive Stage Small Cell Lung Carcinoma\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                      small cell lung carcinoma\n",
      "Name: 2089, dtype: object\n",
      "_____\n",
      "TWID                                                                4704\n",
      "TWEET_ID                                              956310096451178496\n",
      "TWEET                  GW on fire PhIII epilepsy data signals success...\n",
      "SYNONYMS                                                             CBD\n",
      "MOLREGNO_1                                                        318390\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03382561\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                              N/I\n",
      "MATCHED_OUTCOME                                               First data\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                      Epilepsy\n",
      "INDICATION_ID                                                    D004827\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Carboplatin\n",
      "DESCRIPTIONS                                                    Given IV\n",
      "OTHER_NAME             Blastocarb;Carboplat;Carboplatin Hexal;Carbopl...\n",
      "EFO_ID                                                       EFO:0000702\n",
      "CONDITION                      Extensive Stage Small Cell Lung Carcinoma\n",
      "MOLREGNO                                                         1381004\n",
      "NAME_TERM                                      small cell lung carcinoma\n",
      "Name: 2090, dtype: object\n",
      "_____\n",
      "TWID                                                                4704\n",
      "TWEET_ID                                              956310096451178496\n",
      "TWEET                  GW on fire PhIII epilepsy data signals success...\n",
      "SYNONYMS                                                             CBD\n",
      "MOLREGNO_1                                                        318390\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03382561\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                              N/I\n",
      "MATCHED_OUTCOME                                               First data\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                      Epilepsy\n",
      "INDICATION_ID                                                    D004827\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Carboplatin\n",
      "DESCRIPTIONS                                                    Given IV\n",
      "OTHER_NAME             Blastocarb;Carboplat;Carboplatin Hexal;Carbopl...\n",
      "EFO_ID                                                       EFO:0000702\n",
      "CONDITION                      Extensive Stage Small Cell Lung Carcinoma\n",
      "MOLREGNO                                                            8633\n",
      "NAME_TERM                                      small cell lung carcinoma\n",
      "Name: 2091, dtype: object\n",
      "_____\n",
      "TWID                                                                4704\n",
      "TWEET_ID                                              956310096451178496\n",
      "TWEET                  GW on fire PhIII epilepsy data signals success...\n",
      "SYNONYMS                                                             CBD\n",
      "MOLREGNO_1                                                        318390\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03382561\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                              N/I\n",
      "MATCHED_OUTCOME                                               First data\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                      Epilepsy\n",
      "INDICATION_ID                                                    D004827\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Carboplatin\n",
      "DESCRIPTIONS                                                    Given IV\n",
      "OTHER_NAME             Blastocarb;Carboplat;Carboplatin Hexal;Carbopl...\n",
      "EFO_ID                                                       EFO:0000702\n",
      "CONDITION                      Extensive Stage Small Cell Lung Carcinoma\n",
      "MOLREGNO                                                           68607\n",
      "NAME_TERM                                      small cell lung carcinoma\n",
      "Name: 2092, dtype: object\n",
      "_____\n",
      "TWID                                                                4704\n",
      "TWEET_ID                                              956310096451178496\n",
      "TWEET                  GW on fire PhIII epilepsy data signals success...\n",
      "SYNONYMS                                                             CBD\n",
      "MOLREGNO_1                                                        318390\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03382561\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                              N/I\n",
      "MATCHED_OUTCOME                                               First data\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                      Epilepsy\n",
      "INDICATION_ID                                                    D004827\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Carboplatin\n",
      "DESCRIPTIONS                                                    Given IV\n",
      "OTHER_NAME             Blastocarb;Carboplat;Carboplatin Hexal;Carbopl...\n",
      "EFO_ID                                                       EFO:0000702\n",
      "CONDITION                      Extensive Stage Small Cell Lung Carcinoma\n",
      "MOLREGNO                                                          300022\n",
      "NAME_TERM                                      small cell lung carcinoma\n",
      "Name: 2093, dtype: object\n",
      "_____\n",
      "TWID                                                                4704\n",
      "TWEET_ID                                              956310096451178496\n",
      "TWEET                  GW on fire PhIII epilepsy data signals success...\n",
      "SYNONYMS                                                             CBD\n",
      "MOLREGNO_1                                                        318390\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03382561\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                              N/I\n",
      "MATCHED_OUTCOME                                               First data\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                      Epilepsy\n",
      "INDICATION_ID                                                    D004827\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Carboplatin\n",
      "DESCRIPTIONS                                                    Given IV\n",
      "OTHER_NAME             Blastocarb;Carboplat;Carboplatin Hexal;Carbopl...\n",
      "EFO_ID                                                       EFO:0000702\n",
      "CONDITION                      Extensive Stage Small Cell Lung Carcinoma\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                      small cell lung carcinoma\n",
      "Name: 2094, dtype: object\n",
      "_____\n",
      "TWID                                                                5459\n",
      "TWEET_ID                                              938183051422633984\n",
      "TWEET                  Clinical trial transparency improves at (some)...\n",
      "SYNONYMS                                                         VALEANT\n",
      "MOLREGNO_1                                                        393119\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02791308\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                              improves at\n",
      "COMPANY                                                    SanofiAventis\n",
      "COMPANY_ID                                                       COMP657\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                      Pimecrolimus Cream 1% (Valeant)\n",
      "DESCRIPTIONS                                                        Null\n",
      "OTHER_NAME                    Elidel® (pimecrolimus) Cream, 1% (Valeant)\n",
      "EFO_ID                                                       EFO:0000274\n",
      "CONDITION                                              Atopic Dermatitis\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                  atopic eczema\n",
      "Name: 2099, dtype: object\n",
      "_____\n",
      "TWID                                                                5459\n",
      "TWEET_ID                                              938183051422633984\n",
      "TWEET                  Clinical trial transparency improves at (some)...\n",
      "SYNONYMS                                                         VALEANT\n",
      "MOLREGNO_1                                                        393119\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02791308\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                              improves at\n",
      "COMPANY                                                    SanofiAventis\n",
      "COMPANY_ID                                                       COMP657\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                      Pimecrolimus Cream 1% (Valeant)\n",
      "DESCRIPTIONS                                                        Null\n",
      "OTHER_NAME                    Elidel® (pimecrolimus) Cream, 1% (Valeant)\n",
      "EFO_ID                                                       EFO:0000274\n",
      "CONDITION                                              Atopic Dermatitis\n",
      "MOLREGNO                                                          674637\n",
      "NAME_TERM                                                  atopic eczema\n",
      "Name: 2100, dtype: object\n",
      "_____\n",
      "TWID                                                                6006\n",
      "TWEET_ID                                              925739775147102209\n",
      "TWEET                  $AZN asthma drug tralokinumab goes 0 for 3 in ...\n",
      "SYNONYMS                                                    TRALOKINUMAB\n",
      "MOLREGNO_1                                                       1121952\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03363854\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              trials flop\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                               Neurodermatitis\n",
      "INDICATION_ID                                                    D009450\n",
      "INDICATION_NONAMBIG                                                    0\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Tralokinumab\n",
      "DESCRIPTIONS           Tralokinumab is a human recombinant monoclonal...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000274\n",
      "CONDITION                                              Atopic Dermatitis\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                  atopic eczema\n",
      "Name: 2112, dtype: object\n",
      "_____\n",
      "TWID                                                                6016\n",
      "TWEET_ID                                              925662792950173697\n",
      "TWEET                  AstraZeneca's asthma drug tralokinumab goes 0 ...\n",
      "SYNONYMS                                                    TRALOKINUMAB\n",
      "MOLREGNO_1                                                       1121952\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03363854\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              trials flop\n",
      "COMPANY                                                      AstraZeneca\n",
      "COMPANY_ID                                                        COMP82\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                               Neurodermatitis\n",
      "INDICATION_ID                                                    D009450\n",
      "INDICATION_NONAMBIG                                                    0\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Tralokinumab\n",
      "DESCRIPTIONS           Tralokinumab is a human recombinant monoclonal...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000274\n",
      "CONDITION                                              Atopic Dermatitis\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                  atopic eczema\n",
      "Name: 2114, dtype: object\n",
      "_____\n",
      "TWID                                                                6421\n",
      "TWEET_ID                                              916224030503555072\n",
      "TWEET                  In a setback Bayer J&ampJ say their big PhIII ...\n",
      "SYNONYMS                                                         XARELTO\n",
      "MOLREGNO_1                                                        328601\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03428373\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                             Trial failed\n",
      "COMPANY                                                   Bayer-Schering\n",
      "COMPANY_ID                                                       COMP105\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                       Postthrombotic Syndrome\n",
      "INDICATION_ID                                                    D054070\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Rivaroxaban\n",
      "DESCRIPTIONS                                      Rivaroxaban 10mg daily\n",
      "OTHER_NAME                                                       Xarelto\n",
      "EFO_ID                                                       EFO:0001378\n",
      "CONDITION                                     Multiple Myeloma Stage III\n",
      "MOLREGNO                                                            1280\n",
      "NAME_TERM                                               multiple myeloma\n",
      "Name: 2126, dtype: object\n",
      "_____\n",
      "TWID                                                                6421\n",
      "TWEET_ID                                              916224030503555072\n",
      "TWEET                  In a setback Bayer J&ampJ say their big PhIII ...\n",
      "SYNONYMS                                                         XARELTO\n",
      "MOLREGNO_1                                                        328601\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03428373\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                             Trial failed\n",
      "COMPANY                                                   Bayer-Schering\n",
      "COMPANY_ID                                                       COMP105\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                       Postthrombotic Syndrome\n",
      "INDICATION_ID                                                    D054070\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Rivaroxaban\n",
      "DESCRIPTIONS                                      Rivaroxaban 10mg daily\n",
      "OTHER_NAME                                                       Xarelto\n",
      "EFO_ID                                                       EFO:0001378\n",
      "CONDITION                                   Multiple Myeloma Progression\n",
      "MOLREGNO                                                            1280\n",
      "NAME_TERM                                               multiple myeloma\n",
      "Name: 2128, dtype: object\n",
      "_____\n",
      "TWID                                                                6421\n",
      "TWEET_ID                                              916224030503555072\n",
      "TWEET                  In a setback Bayer J&ampJ say their big PhIII ...\n",
      "SYNONYMS                                                         XARELTO\n",
      "MOLREGNO_1                                                        328601\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03428373\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                             Trial failed\n",
      "COMPANY                                                   Bayer-Schering\n",
      "COMPANY_ID                                                       COMP105\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                       Postthrombotic Syndrome\n",
      "INDICATION_ID                                                    D054070\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Rivaroxaban\n",
      "DESCRIPTIONS                                      Rivaroxaban 10mg daily\n",
      "OTHER_NAME                                                       Xarelto\n",
      "EFO_ID                                                       EFO:0001378\n",
      "CONDITION                         Multiple Myeloma With Failed Remission\n",
      "MOLREGNO                                                            1280\n",
      "NAME_TERM                                               multiple myeloma\n",
      "Name: 2130, dtype: object\n",
      "_____\n",
      "TWID                                                                6421\n",
      "TWEET_ID                                              916224030503555072\n",
      "TWEET                  In a setback Bayer J&ampJ say their big PhIII ...\n",
      "SYNONYMS                                                         XARELTO\n",
      "MOLREGNO_1                                                        328601\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03428373\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                             Trial failed\n",
      "COMPANY                                                   Bayer-Schering\n",
      "COMPANY_ID                                                       COMP105\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                       Postthrombotic Syndrome\n",
      "INDICATION_ID                                                    D054070\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Rivaroxaban\n",
      "DESCRIPTIONS                                      Rivaroxaban 10mg daily\n",
      "OTHER_NAME                                                       Xarelto\n",
      "EFO_ID                                                       EFO:0001378\n",
      "CONDITION                                      Multiple Myeloma Stage II\n",
      "MOLREGNO                                                            1280\n",
      "NAME_TERM                                               multiple myeloma\n",
      "Name: 2132, dtype: object\n",
      "_____\n",
      "TWID                                                                6421\n",
      "TWEET_ID                                              916224030503555072\n",
      "TWEET                  In a setback Bayer J&ampJ say their big PhIII ...\n",
      "SYNONYMS                                                         XARELTO\n",
      "MOLREGNO_1                                                        328601\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03428373\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                             Trial failed\n",
      "COMPANY                                                   Bayer-Schering\n",
      "COMPANY_ID                                                       COMP105\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                       Postthrombotic Syndrome\n",
      "INDICATION_ID                                                    D054070\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Rivaroxaban\n",
      "DESCRIPTIONS                                      Rivaroxaban 10mg daily\n",
      "OTHER_NAME                                                       Xarelto\n",
      "EFO_ID                                                       EFO:0001378\n",
      "CONDITION                                    Multiple Myeloma in Relapse\n",
      "MOLREGNO                                                            1280\n",
      "NAME_TERM                                               multiple myeloma\n",
      "Name: 2134, dtype: object\n",
      "_____\n",
      "TWID                                                                6421\n",
      "TWEET_ID                                              916224030503555072\n",
      "TWEET                  In a setback Bayer J&ampJ say their big PhIII ...\n",
      "SYNONYMS                                                         XARELTO\n",
      "MOLREGNO_1                                                        328601\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03428373\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                             Trial failed\n",
      "COMPANY                                                   Bayer-Schering\n",
      "COMPANY_ID                                                       COMP105\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                       Postthrombotic Syndrome\n",
      "INDICATION_ID                                                    D054070\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Rivaroxaban\n",
      "DESCRIPTIONS                                      Rivaroxaban 10mg daily\n",
      "OTHER_NAME                                                       Xarelto\n",
      "EFO_ID                                                       EFO:0001378\n",
      "CONDITION                                       Multiple Myeloma Stage I\n",
      "MOLREGNO                                                            1280\n",
      "NAME_TERM                                               multiple myeloma\n",
      "Name: 2136, dtype: object\n",
      "_____\n",
      "TWID                                                                6511\n",
      "TWEET_ID                                              988994961277358081\n",
      "TWEET                  Results from EVOLVE MS-1 trial show ALKS-8700 ...\n",
      "SYNONYMS                                                        ALKS8700\n",
      "MOLREGNO_1                                                       2197815\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                              Null\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                   relapsing remitting multiple sclerosis\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                        Relapsing-Remitting Multiple Sclerosis\n",
      "INDICATION_ID                                                    D020529\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Null\n",
      "INTERVENTION_NAME_x                                                 Null\n",
      "DESCRIPTIONS                                                        Null\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                              Null\n",
      "CONDITION                                                           Null\n",
      "MOLREGNO                                                            Null\n",
      "NAME_TERM                                                            NaN\n",
      "Name: 2143, dtype: object\n",
      "_____\n",
      "TWID                                                                6536\n",
      "TWEET_ID                                              988015852086874112\n",
      "TWEET                  First efficacy and safety data from the phase ...\n",
      "SYNONYMS                                                        IMIPENEM\n",
      "MOLREGNO_1                                                         43934\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03159078\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                              N/I\n",
      "MATCHED_OUTCOME                                               First data\n",
      "COMPANY                                                            Merck\n",
      "COMPANY_ID                                                       COMP435\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Polymyxin B\n",
      "DESCRIPTIONS           Comparison of Poly B monotherapy vs Polymyxin ...\n",
      "OTHER_NAME                                          Imipenem, (Primaxin)\n",
      "EFO_ID                                                   -NOT-CONDITION-\n",
      "CONDITION                                               Critical Illness\n",
      "MOLREGNO                                                         2197609\n",
      "NAME_TERM                                                            NaN\n",
      "Name: 2175, dtype: object\n",
      "_____\n",
      "TWID                                                                6536\n",
      "TWEET_ID                                              988015852086874112\n",
      "TWEET                  First efficacy and safety data from the phase ...\n",
      "SYNONYMS                                                        IMIPENEM\n",
      "MOLREGNO_1                                                         43934\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03159078\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                              N/I\n",
      "MATCHED_OUTCOME                                               First data\n",
      "COMPANY                                                            Merck\n",
      "COMPANY_ID                                                       COMP435\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Polymyxin B\n",
      "DESCRIPTIONS           Comparison of Poly B monotherapy vs Polymyxin ...\n",
      "OTHER_NAME                                          Imipenem, (Primaxin)\n",
      "EFO_ID                                                       EFO:0000546\n",
      "CONDITION                                                         Trauma\n",
      "MOLREGNO                                                         2197609\n",
      "NAME_TERM                                                         injury\n",
      "Name: 2176, dtype: object\n",
      "_____\n",
      "TWID                                                                6536\n",
      "TWEET_ID                                              988015852086874112\n",
      "TWEET                  First efficacy and safety data from the phase ...\n",
      "SYNONYMS                                                        IMIPENEM\n",
      "MOLREGNO_1                                                         43934\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03159078\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                              N/I\n",
      "MATCHED_OUTCOME                                               First data\n",
      "COMPANY                                                            Merck\n",
      "COMPANY_ID                                                       COMP435\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Polymyxin B\n",
      "DESCRIPTIONS           Comparison of Poly B monotherapy vs Polymyxin ...\n",
      "OTHER_NAME                                          Imipenem, (Primaxin)\n",
      "EFO_ID                                                       EFO:0000544\n",
      "CONDITION                                            Resistant Infection\n",
      "MOLREGNO                                                         2197609\n",
      "NAME_TERM                                                      infection\n",
      "Name: 2177, dtype: object\n",
      "_____\n",
      "TWID                                                                6536\n",
      "TWEET_ID                                              988015852086874112\n",
      "TWEET                  First efficacy and safety data from the phase ...\n",
      "SYNONYMS                                                        IMIPENEM\n",
      "MOLREGNO_1                                                        610112\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03159078\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                              N/I\n",
      "MATCHED_OUTCOME                                               First data\n",
      "COMPANY                                                            Merck\n",
      "COMPANY_ID                                                       COMP435\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Polymyxin B\n",
      "DESCRIPTIONS           Comparison of Poly B monotherapy vs Polymyxin ...\n",
      "OTHER_NAME                                          Imipenem, (Primaxin)\n",
      "EFO_ID                                                   -NOT-CONDITION-\n",
      "CONDITION                                               Critical Illness\n",
      "MOLREGNO                                                         2197609\n",
      "NAME_TERM                                                            NaN\n",
      "Name: 2178, dtype: object\n",
      "_____\n",
      "TWID                                                                6536\n",
      "TWEET_ID                                              988015852086874112\n",
      "TWEET                  First efficacy and safety data from the phase ...\n",
      "SYNONYMS                                                        IMIPENEM\n",
      "MOLREGNO_1                                                        610112\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03159078\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                              N/I\n",
      "MATCHED_OUTCOME                                               First data\n",
      "COMPANY                                                            Merck\n",
      "COMPANY_ID                                                       COMP435\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Polymyxin B\n",
      "DESCRIPTIONS           Comparison of Poly B monotherapy vs Polymyxin ...\n",
      "OTHER_NAME                                          Imipenem, (Primaxin)\n",
      "EFO_ID                                                       EFO:0000546\n",
      "CONDITION                                                         Trauma\n",
      "MOLREGNO                                                         2197609\n",
      "NAME_TERM                                                         injury\n",
      "Name: 2179, dtype: object\n",
      "_____\n",
      "TWID                                                                6536\n",
      "TWEET_ID                                              988015852086874112\n",
      "TWEET                  First efficacy and safety data from the phase ...\n",
      "SYNONYMS                                                        IMIPENEM\n",
      "MOLREGNO_1                                                        610112\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03159078\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                              N/I\n",
      "MATCHED_OUTCOME                                               First data\n",
      "COMPANY                                                            Merck\n",
      "COMPANY_ID                                                       COMP435\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Polymyxin B\n",
      "DESCRIPTIONS           Comparison of Poly B monotherapy vs Polymyxin ...\n",
      "OTHER_NAME                                          Imipenem, (Primaxin)\n",
      "EFO_ID                                                       EFO:0000544\n",
      "CONDITION                                            Resistant Infection\n",
      "MOLREGNO                                                         2197609\n",
      "NAME_TERM                                                      infection\n",
      "Name: 2180, dtype: object\n",
      "_____\n",
      "TWID                                                                6537\n",
      "TWEET_ID                                              988010121203802112\n",
      "TWEET                  Actelion  antibiotic Cadazolid demonstrates no...\n",
      "SYNONYMS                                                       CADAZOLID\n",
      "MOLREGNO_1                                                       2039347\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03105479\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                             demonstrates non-inferiority\n",
      "COMPANY                                                         Actelion\n",
      "COMPANY_ID                                                        COMP19\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                Pseudomembranous Enterocolitis\n",
      "INDICATION_ID                                                    D004761\n",
      "INDICATION_NONAMBIG                                                    0\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Cadazolid\n",
      "DESCRIPTIONS           Granules for oral suspension to be administere...\n",
      "OTHER_NAME                                                    ACT-179811\n",
      "EFO_ID                                                       EFO:0009130\n",
      "CONDITION                                Clostridium Difficile Infection\n",
      "MOLREGNO                                                           70140\n",
      "NAME_TERM                                clostridium difficile infection\n",
      "Name: 2184, dtype: object\n",
      "_____\n",
      "TWID                                                               12910\n",
      "TWEET_ID                                              992218379149889536\n",
      "TWEET                  Live at #ARVO2018 phase I/II data for DSP-Visu...\n",
      "SYNONYMS                                                      PREDNISONE\n",
      "MOLREGNO_1                                                         27229\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01393730\n",
      "PHASE                                                          Phase 1/2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         In phase live at\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Prednisone\n",
      "DESCRIPTIONS                                                        Null\n",
      "OTHER_NAME                                                Corticosteroid\n",
      "EFO_ID                                                       EFO:0001663\n",
      "CONDITION                                                Prostate Cancer\n",
      "MOLREGNO                                                          674920\n",
      "NAME_TERM                                             prostate carcinoma\n",
      "Name: 2258, dtype: object\n",
      "_____\n",
      "TWID                                                               12910\n",
      "TWEET_ID                                              992218379149889536\n",
      "TWEET                  Live at #ARVO2018 phase I/II data for DSP-Visu...\n",
      "SYNONYMS                                                      PREDNISONE\n",
      "MOLREGNO_1                                                         27229\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01393730\n",
      "PHASE                                                          Phase 1/2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         In phase live at\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Prednisone\n",
      "DESCRIPTIONS                                                        Null\n",
      "OTHER_NAME                                                Corticosteroid\n",
      "EFO_ID                                                       EFO:0001663\n",
      "CONDITION                                                Prostate Cancer\n",
      "MOLREGNO                                                          438435\n",
      "NAME_TERM                                             prostate carcinoma\n",
      "Name: 2259, dtype: object\n",
      "_____\n",
      "TWID                                                               12927\n",
      "TWEET_ID                                              991337132642979840\n",
      "TWEET                  AbbVie has filed risankizumab in the EU for mo...\n",
      "SYNONYMS                                                    RISANKIZUMAB\n",
      "MOLREGNO_1                                                       2197900\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03047395\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          STOPPED\n",
      "MATCHED_OUTCOME                                                Has filed\n",
      "COMPANY                                                           AbbVie\n",
      "COMPANY_ID                                                     COMP92805\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                             Biological\n",
      "INTERVENTION_NAME_x                                         risankizumab\n",
      "DESCRIPTIONS           Risankizumab 150 mg administered by subcutaneo...\n",
      "OTHER_NAME                                            ABBV-066 BI 655066\n",
      "EFO_ID                                                       EFO:0000676\n",
      "CONDITION                                                      Psoriasis\n",
      "MOLREGNO                                                         2197902\n",
      "NAME_TERM                                                      psoriasis\n",
      "Name: 2260, dtype: object\n",
      "_____\n",
      "TWID                                                               19304\n",
      "TWEET_ID                                              994947253776330753\n",
      "TWEET                   @AstraZeneca Weighs Expanding Fasenra to #COP...\n",
      "SYNONYMS                                                         FASENRA\n",
      "MOLREGNO_1                                                       1121862\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03473977\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                            phase failure\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                         Chronic Obstructive Pulmonary Disease\n",
      "INDICATION_ID                                                    D029424\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                             Biological\n",
      "INTERVENTION_NAME_x                                         Benralizumab\n",
      "DESCRIPTIONS           Monoclonal antibody originally developed for t...\n",
      "OTHER_NAME                                                       Fasenra\n",
      "EFO_ID                                                       EFO:1001463\n",
      "CONDITION                      Eosinophilic Gastritis or Gastroenteritis\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                gastroenteritis\n",
      "Name: 2267, dtype: object\n",
      "_____\n",
      "TWID                                                               19304\n",
      "TWEET_ID                                              994947253776330753\n",
      "TWEET                   @AstraZeneca Weighs Expanding Fasenra to #COP...\n",
      "SYNONYMS                                                         FASENRA\n",
      "MOLREGNO_1                                                       1121862\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03473977\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                            phase failure\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                         Chronic Obstructive Pulmonary Disease\n",
      "INDICATION_ID                                                    D029424\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                             Biological\n",
      "INTERVENTION_NAME_x                                         Benralizumab\n",
      "DESCRIPTIONS           Monoclonal antibody originally developed for t...\n",
      "OTHER_NAME                                                       Fasenra\n",
      "EFO_ID                                                       EFO:0000217\n",
      "CONDITION                      Eosinophilic Gastritis or Gastroenteritis\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                      gastritis\n",
      "Name: 2269, dtype: object\n",
      "_____\n",
      "TWID                                                               19312\n",
      "TWEET_ID                                              994682264528224256\n",
      "TWEET                  WIth planned $16B $ARMO acquisition @LillyPad ...\n",
      "SYNONYMS                                                          AM0010\n",
      "MOLREGNO_1                                                       2197863\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03382899\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                             planned $16B\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                     Carcinoma\n",
      "INDICATION_ID                                                    D002277\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                             Biological\n",
      "INTERVENTION_NAME_x                                               AM0010\n",
      "DESCRIPTIONS                                   AM0010 plus Pembrolizumab\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0003060\n",
      "CONDITION                                     Non Small Cell Lung Cancer\n",
      "MOLREGNO                                                         1626777\n",
      "NAME_TERM                                  non-small cell lung carcinoma\n",
      "Name: 2270, dtype: object\n",
      "_____\n",
      "TWID                                                               19430\n",
      "TWEET_ID                                              991798269239062528\n",
      "TWEET                  Study by @TheCrick investigators may explain w...\n",
      "SYNONYMS                                                       LAPATINIB\n",
      "MOLREGNO_1                                                         14805\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                               why failed\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                             Colonic Neoplasms\n",
      "INDICATION_ID                                                    D003110\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Lapatinib\n",
      "DESCRIPTIONS           1250 mg, tablets, oral daily during treatment ...\n",
      "OTHER_NAME                                                      GW572016\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                          674747\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 2271, dtype: object\n",
      "_____\n",
      "TWID                                                               19430\n",
      "TWEET_ID                                              991798269239062528\n",
      "TWEET                  Study by @TheCrick investigators may explain w...\n",
      "SYNONYMS                                                       LAPATINIB\n",
      "MOLREGNO_1                                                         14805\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                               why failed\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                             Colonic Neoplasms\n",
      "INDICATION_ID                                                    D003110\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Lapatinib\n",
      "DESCRIPTIONS           1250 mg, tablets, oral daily during treatment ...\n",
      "OTHER_NAME                                                      GW572016\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                           78759\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 2272, dtype: object\n",
      "_____\n",
      "TWID                                                               19430\n",
      "TWEET_ID                                              991798269239062528\n",
      "TWEET                  Study by @TheCrick investigators may explain w...\n",
      "SYNONYMS                                                       LAPATINIB\n",
      "MOLREGNO_1                                                         14805\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                               why failed\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                             Colonic Neoplasms\n",
      "INDICATION_ID                                                    D003110\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Lapatinib\n",
      "DESCRIPTIONS           1250 mg, tablets, oral daily during treatment ...\n",
      "OTHER_NAME                                                      GW572016\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                          675363\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 2273, dtype: object\n",
      "_____\n",
      "TWID                                                               19430\n",
      "TWEET_ID                                              991798269239062528\n",
      "TWEET                  Study by @TheCrick investigators may explain w...\n",
      "SYNONYMS                                                       LAPATINIB\n",
      "MOLREGNO_1                                                         14805\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                               why failed\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                             Colonic Neoplasms\n",
      "INDICATION_ID                                                    D003110\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Lapatinib\n",
      "DESCRIPTIONS           1250 mg, tablets, oral daily during treatment ...\n",
      "OTHER_NAME                                                      GW572016\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                          675434\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 2274, dtype: object\n",
      "_____\n",
      "TWID                                                               19430\n",
      "TWEET_ID                                              991798269239062528\n",
      "TWEET                  Study by @TheCrick investigators may explain w...\n",
      "SYNONYMS                                                       LAPATINIB\n",
      "MOLREGNO_1                                                         14805\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                               why failed\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                             Colonic Neoplasms\n",
      "INDICATION_ID                                                    D003110\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Lapatinib\n",
      "DESCRIPTIONS           1250 mg, tablets, oral daily during treatment ...\n",
      "OTHER_NAME                                                      GW572016\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                          365281\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 2275, dtype: object\n",
      "_____\n",
      "TWID                                                               19430\n",
      "TWEET_ID                                              991798269239062528\n",
      "TWEET                  Study by @TheCrick investigators may explain w...\n",
      "SYNONYMS                                                       LAPATINIB\n",
      "MOLREGNO_1                                                         14805\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                               why failed\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                             Colonic Neoplasms\n",
      "INDICATION_ID                                                    D003110\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Lapatinib\n",
      "DESCRIPTIONS           1250 mg, tablets, oral daily during treatment ...\n",
      "OTHER_NAME                                                      GW572016\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                         1927101\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 2277, dtype: object\n",
      "_____\n",
      "TWID                                                               19430\n",
      "TWEET_ID                                              991798269239062528\n",
      "TWEET                  Study by @TheCrick investigators may explain w...\n",
      "SYNONYMS                                                       LAPATINIB\n",
      "MOLREGNO_1                                                         14805\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                               why failed\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                             Colonic Neoplasms\n",
      "INDICATION_ID                                                    D003110\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Lapatinib\n",
      "DESCRIPTIONS           1250 mg, tablets, oral daily during treatment ...\n",
      "OTHER_NAME                                                      GW572016\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                          675581\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 2278, dtype: object\n",
      "_____\n",
      "TWID                                                               19430\n",
      "TWEET_ID                                              991798269239062528\n",
      "TWEET                  Study by @TheCrick investigators may explain w...\n",
      "SYNONYMS                                                       LAPATINIB\n",
      "MOLREGNO_1                                                         14805\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                               why failed\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                             Colonic Neoplasms\n",
      "INDICATION_ID                                                    D003110\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Lapatinib\n",
      "DESCRIPTIONS           1250 mg, tablets, oral daily during treatment ...\n",
      "OTHER_NAME                                                      GW572016\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                       Metastatic Breast Cancer\n",
      "MOLREGNO                                                          674747\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 2279, dtype: object\n",
      "_____\n",
      "TWID                                                               19430\n",
      "TWEET_ID                                              991798269239062528\n",
      "TWEET                  Study by @TheCrick investigators may explain w...\n",
      "SYNONYMS                                                       LAPATINIB\n",
      "MOLREGNO_1                                                         14805\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                               why failed\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                             Colonic Neoplasms\n",
      "INDICATION_ID                                                    D003110\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Lapatinib\n",
      "DESCRIPTIONS           1250 mg, tablets, oral daily during treatment ...\n",
      "OTHER_NAME                                                      GW572016\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                       Metastatic Breast Cancer\n",
      "MOLREGNO                                                           78759\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 2280, dtype: object\n",
      "_____\n",
      "TWID                                                               19430\n",
      "TWEET_ID                                              991798269239062528\n",
      "TWEET                  Study by @TheCrick investigators may explain w...\n",
      "SYNONYMS                                                       LAPATINIB\n",
      "MOLREGNO_1                                                         14805\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                               why failed\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                             Colonic Neoplasms\n",
      "INDICATION_ID                                                    D003110\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Lapatinib\n",
      "DESCRIPTIONS           1250 mg, tablets, oral daily during treatment ...\n",
      "OTHER_NAME                                                      GW572016\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                       Metastatic Breast Cancer\n",
      "MOLREGNO                                                          675363\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 2281, dtype: object\n",
      "_____\n",
      "TWID                                                               19430\n",
      "TWEET_ID                                              991798269239062528\n",
      "TWEET                  Study by @TheCrick investigators may explain w...\n",
      "SYNONYMS                                                       LAPATINIB\n",
      "MOLREGNO_1                                                         14805\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                               why failed\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                             Colonic Neoplasms\n",
      "INDICATION_ID                                                    D003110\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Lapatinib\n",
      "DESCRIPTIONS           1250 mg, tablets, oral daily during treatment ...\n",
      "OTHER_NAME                                                      GW572016\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                       Metastatic Breast Cancer\n",
      "MOLREGNO                                                          675434\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 2282, dtype: object\n",
      "_____\n",
      "TWID                                                               19430\n",
      "TWEET_ID                                              991798269239062528\n",
      "TWEET                  Study by @TheCrick investigators may explain w...\n",
      "SYNONYMS                                                       LAPATINIB\n",
      "MOLREGNO_1                                                         14805\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                               why failed\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                             Colonic Neoplasms\n",
      "INDICATION_ID                                                    D003110\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Lapatinib\n",
      "DESCRIPTIONS           1250 mg, tablets, oral daily during treatment ...\n",
      "OTHER_NAME                                                      GW572016\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                       Metastatic Breast Cancer\n",
      "MOLREGNO                                                          365281\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 2283, dtype: object\n",
      "_____\n",
      "TWID                                                               19430\n",
      "TWEET_ID                                              991798269239062528\n",
      "TWEET                  Study by @TheCrick investigators may explain w...\n",
      "SYNONYMS                                                       LAPATINIB\n",
      "MOLREGNO_1                                                         14805\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                               why failed\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                             Colonic Neoplasms\n",
      "INDICATION_ID                                                    D003110\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Lapatinib\n",
      "DESCRIPTIONS           1250 mg, tablets, oral daily during treatment ...\n",
      "OTHER_NAME                                                      GW572016\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                       Metastatic Breast Cancer\n",
      "MOLREGNO                                                         1927101\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 2285, dtype: object\n",
      "_____\n",
      "TWID                                                               19430\n",
      "TWEET_ID                                              991798269239062528\n",
      "TWEET                  Study by @TheCrick investigators may explain w...\n",
      "SYNONYMS                                                       LAPATINIB\n",
      "MOLREGNO_1                                                         14805\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                               why failed\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                             Colonic Neoplasms\n",
      "INDICATION_ID                                                    D003110\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Lapatinib\n",
      "DESCRIPTIONS           1250 mg, tablets, oral daily during treatment ...\n",
      "OTHER_NAME                                                      GW572016\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                       Metastatic Breast Cancer\n",
      "MOLREGNO                                                          675581\n",
      "NAME_TERM                                               breast carcinoma\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Name: 2286, dtype: object\n",
      "_____\n",
      "TWID                                                               19430\n",
      "TWEET_ID                                              991798269239062528\n",
      "TWEET                  Study by @TheCrick investigators may explain w...\n",
      "SYNONYMS                                                       LAPATINIB\n",
      "MOLREGNO_1                                                        675130\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                               why failed\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                             Colonic Neoplasms\n",
      "INDICATION_ID                                                    D003110\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Lapatinib\n",
      "DESCRIPTIONS           1250 mg, tablets, oral daily during treatment ...\n",
      "OTHER_NAME                                                      GW572016\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                          674747\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 2287, dtype: object\n",
      "_____\n",
      "TWID                                                               19430\n",
      "TWEET_ID                                              991798269239062528\n",
      "TWEET                  Study by @TheCrick investigators may explain w...\n",
      "SYNONYMS                                                       LAPATINIB\n",
      "MOLREGNO_1                                                        675130\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                               why failed\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                             Colonic Neoplasms\n",
      "INDICATION_ID                                                    D003110\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Lapatinib\n",
      "DESCRIPTIONS           1250 mg, tablets, oral daily during treatment ...\n",
      "OTHER_NAME                                                      GW572016\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                           78759\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 2288, dtype: object\n",
      "_____\n",
      "TWID                                                               19430\n",
      "TWEET_ID                                              991798269239062528\n",
      "TWEET                  Study by @TheCrick investigators may explain w...\n",
      "SYNONYMS                                                       LAPATINIB\n",
      "MOLREGNO_1                                                        675130\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                               why failed\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                             Colonic Neoplasms\n",
      "INDICATION_ID                                                    D003110\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Lapatinib\n",
      "DESCRIPTIONS           1250 mg, tablets, oral daily during treatment ...\n",
      "OTHER_NAME                                                      GW572016\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                          675363\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 2289, dtype: object\n",
      "_____\n",
      "TWID                                                               19430\n",
      "TWEET_ID                                              991798269239062528\n",
      "TWEET                  Study by @TheCrick investigators may explain w...\n",
      "SYNONYMS                                                       LAPATINIB\n",
      "MOLREGNO_1                                                        675130\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                               why failed\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                             Colonic Neoplasms\n",
      "INDICATION_ID                                                    D003110\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Lapatinib\n",
      "DESCRIPTIONS           1250 mg, tablets, oral daily during treatment ...\n",
      "OTHER_NAME                                                      GW572016\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                          675434\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 2290, dtype: object\n",
      "_____\n",
      "TWID                                                               19430\n",
      "TWEET_ID                                              991798269239062528\n",
      "TWEET                  Study by @TheCrick investigators may explain w...\n",
      "SYNONYMS                                                       LAPATINIB\n",
      "MOLREGNO_1                                                        675130\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                               why failed\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                             Colonic Neoplasms\n",
      "INDICATION_ID                                                    D003110\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Lapatinib\n",
      "DESCRIPTIONS           1250 mg, tablets, oral daily during treatment ...\n",
      "OTHER_NAME                                                      GW572016\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                          365281\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 2291, dtype: object\n",
      "_____\n",
      "TWID                                                               19430\n",
      "TWEET_ID                                              991798269239062528\n",
      "TWEET                  Study by @TheCrick investigators may explain w...\n",
      "SYNONYMS                                                       LAPATINIB\n",
      "MOLREGNO_1                                                        675130\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                               why failed\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                             Colonic Neoplasms\n",
      "INDICATION_ID                                                    D003110\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Lapatinib\n",
      "DESCRIPTIONS           1250 mg, tablets, oral daily during treatment ...\n",
      "OTHER_NAME                                                      GW572016\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                           14805\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 2292, dtype: object\n",
      "_____\n",
      "TWID                                                               19430\n",
      "TWEET_ID                                              991798269239062528\n",
      "TWEET                  Study by @TheCrick investigators may explain w...\n",
      "SYNONYMS                                                       LAPATINIB\n",
      "MOLREGNO_1                                                        675130\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                               why failed\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                             Colonic Neoplasms\n",
      "INDICATION_ID                                                    D003110\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Lapatinib\n",
      "DESCRIPTIONS           1250 mg, tablets, oral daily during treatment ...\n",
      "OTHER_NAME                                                      GW572016\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                         1927101\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 2293, dtype: object\n",
      "_____\n",
      "TWID                                                               19430\n",
      "TWEET_ID                                              991798269239062528\n",
      "TWEET                  Study by @TheCrick investigators may explain w...\n",
      "SYNONYMS                                                       LAPATINIB\n",
      "MOLREGNO_1                                                        675130\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                               why failed\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                             Colonic Neoplasms\n",
      "INDICATION_ID                                                    D003110\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Lapatinib\n",
      "DESCRIPTIONS           1250 mg, tablets, oral daily during treatment ...\n",
      "OTHER_NAME                                                      GW572016\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                                  Breast Cancer\n",
      "MOLREGNO                                                          675581\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 2294, dtype: object\n",
      "_____\n",
      "TWID                                                               19430\n",
      "TWEET_ID                                              991798269239062528\n",
      "TWEET                  Study by @TheCrick investigators may explain w...\n",
      "SYNONYMS                                                       LAPATINIB\n",
      "MOLREGNO_1                                                        675130\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                               why failed\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                             Colonic Neoplasms\n",
      "INDICATION_ID                                                    D003110\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Lapatinib\n",
      "DESCRIPTIONS           1250 mg, tablets, oral daily during treatment ...\n",
      "OTHER_NAME                                                      GW572016\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                       Metastatic Breast Cancer\n",
      "MOLREGNO                                                          674747\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 2295, dtype: object\n",
      "_____\n",
      "TWID                                                               19430\n",
      "TWEET_ID                                              991798269239062528\n",
      "TWEET                  Study by @TheCrick investigators may explain w...\n",
      "SYNONYMS                                                       LAPATINIB\n",
      "MOLREGNO_1                                                        675130\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                               why failed\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                             Colonic Neoplasms\n",
      "INDICATION_ID                                                    D003110\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Lapatinib\n",
      "DESCRIPTIONS           1250 mg, tablets, oral daily during treatment ...\n",
      "OTHER_NAME                                                      GW572016\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                       Metastatic Breast Cancer\n",
      "MOLREGNO                                                           78759\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 2296, dtype: object\n",
      "_____\n",
      "TWID                                                               19430\n",
      "TWEET_ID                                              991798269239062528\n",
      "TWEET                  Study by @TheCrick investigators may explain w...\n",
      "SYNONYMS                                                       LAPATINIB\n",
      "MOLREGNO_1                                                        675130\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                               why failed\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                             Colonic Neoplasms\n",
      "INDICATION_ID                                                    D003110\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Lapatinib\n",
      "DESCRIPTIONS           1250 mg, tablets, oral daily during treatment ...\n",
      "OTHER_NAME                                                      GW572016\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                       Metastatic Breast Cancer\n",
      "MOLREGNO                                                          675363\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 2297, dtype: object\n",
      "_____\n",
      "TWID                                                               19430\n",
      "TWEET_ID                                              991798269239062528\n",
      "TWEET                  Study by @TheCrick investigators may explain w...\n",
      "SYNONYMS                                                       LAPATINIB\n",
      "MOLREGNO_1                                                        675130\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                               why failed\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                             Colonic Neoplasms\n",
      "INDICATION_ID                                                    D003110\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Lapatinib\n",
      "DESCRIPTIONS           1250 mg, tablets, oral daily during treatment ...\n",
      "OTHER_NAME                                                      GW572016\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                       Metastatic Breast Cancer\n",
      "MOLREGNO                                                          675434\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 2298, dtype: object\n",
      "_____\n",
      "TWID                                                               19430\n",
      "TWEET_ID                                              991798269239062528\n",
      "TWEET                  Study by @TheCrick investigators may explain w...\n",
      "SYNONYMS                                                       LAPATINIB\n",
      "MOLREGNO_1                                                        675130\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                               why failed\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                             Colonic Neoplasms\n",
      "INDICATION_ID                                                    D003110\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Lapatinib\n",
      "DESCRIPTIONS           1250 mg, tablets, oral daily during treatment ...\n",
      "OTHER_NAME                                                      GW572016\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                       Metastatic Breast Cancer\n",
      "MOLREGNO                                                          365281\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 2299, dtype: object\n",
      "_____\n",
      "TWID                                                               19430\n",
      "TWEET_ID                                              991798269239062528\n",
      "TWEET                  Study by @TheCrick investigators may explain w...\n",
      "SYNONYMS                                                       LAPATINIB\n",
      "MOLREGNO_1                                                        675130\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                               why failed\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                             Colonic Neoplasms\n",
      "INDICATION_ID                                                    D003110\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Lapatinib\n",
      "DESCRIPTIONS           1250 mg, tablets, oral daily during treatment ...\n",
      "OTHER_NAME                                                      GW572016\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                       Metastatic Breast Cancer\n",
      "MOLREGNO                                                           14805\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 2300, dtype: object\n",
      "_____\n",
      "TWID                                                               19430\n",
      "TWEET_ID                                              991798269239062528\n",
      "TWEET                  Study by @TheCrick investigators may explain w...\n",
      "SYNONYMS                                                       LAPATINIB\n",
      "MOLREGNO_1                                                        675130\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                               why failed\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                             Colonic Neoplasms\n",
      "INDICATION_ID                                                    D003110\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Lapatinib\n",
      "DESCRIPTIONS           1250 mg, tablets, oral daily during treatment ...\n",
      "OTHER_NAME                                                      GW572016\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                       Metastatic Breast Cancer\n",
      "MOLREGNO                                                         1927101\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 2301, dtype: object\n",
      "_____\n",
      "TWID                                                               19430\n",
      "TWEET_ID                                              991798269239062528\n",
      "TWEET                  Study by @TheCrick investigators may explain w...\n",
      "SYNONYMS                                                       LAPATINIB\n",
      "MOLREGNO_1                                                        675130\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00404066\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                               why failed\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                             Colonic Neoplasms\n",
      "INDICATION_ID                                                    D003110\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Lapatinib\n",
      "DESCRIPTIONS           1250 mg, tablets, oral daily during treatment ...\n",
      "OTHER_NAME                                                      GW572016\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                       Metastatic Breast Cancer\n",
      "MOLREGNO                                                          675581\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 2302, dtype: object\n",
      "_____\n",
      "TWID                                                               19712\n",
      "TWEET_ID                                              985222431202795521\n",
      "TWEET                  vTv Therapeutics ($VTVT) Halts Trials of #Alzh...\n",
      "SYNONYMS                                                      AZELIRAGON\n",
      "MOLREGNO_1                                                       2197800\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02916056\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          STOPPED\n",
      "MATCHED_OUTCOME                                             Halts trials\n",
      "COMPANY                                                 vTv Therapeutics\n",
      "COMPANY_ID                                                     COMP93953\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                             Alzheimer Disease\n",
      "INDICATION_ID                                                    D000544\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                       Azeliragon 5mg\n",
      "DESCRIPTIONS                                                        Null\n",
      "OTHER_NAME                                                        TTP488\n",
      "EFO_ID                                                       EFO:0000249\n",
      "CONDITION                                            Alzheimer's Disease\n",
      "MOLREGNO                                                            Null\n",
      "NAME_TERM                                            Alzheimer's disease\n",
      "Name: 2307, dtype: object\n",
      "_____\n",
      "TWID                                                               19772\n",
      "TWEET_ID                                              983810627549519873\n",
      "TWEET                  Shares of vTv Therapeutics ($VTVT) plunge afte...\n",
      "SYNONYMS                                                      AZELIRAGON\n",
      "MOLREGNO_1                                                       2197800\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02916056\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                            phase failure\n",
      "COMPANY                                                 vTv Therapeutics\n",
      "COMPANY_ID                                                     COMP93953\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                             Alzheimer Disease\n",
      "INDICATION_ID                                                    D000544\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                       Azeliragon 5mg\n",
      "DESCRIPTIONS                                                        Null\n",
      "OTHER_NAME                                                        TTP488\n",
      "EFO_ID                                                       EFO:0000249\n",
      "CONDITION                                            Alzheimer's Disease\n",
      "MOLREGNO                                                            Null\n",
      "NAME_TERM                                            Alzheimer's disease\n",
      "Name: 2308, dtype: object\n",
      "_____\n",
      "TWID                                                               19778\n",
      "TWEET_ID                                              983712108683644928\n",
      "TWEET                  vTv Therapeutics ($VTVT) Halts Trials of #Alzh...\n",
      "SYNONYMS                                                      AZELIRAGON\n",
      "MOLREGNO_1                                                       2197800\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02916056\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          STOPPED\n",
      "MATCHED_OUTCOME                                             Halts trials\n",
      "COMPANY                                                 vTv Therapeutics\n",
      "COMPANY_ID                                                     COMP93953\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                             Alzheimer Disease\n",
      "INDICATION_ID                                                    D000544\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                       Azeliragon 5mg\n",
      "DESCRIPTIONS                                                        Null\n",
      "OTHER_NAME                                                        TTP488\n",
      "EFO_ID                                                       EFO:0000249\n",
      "CONDITION                                            Alzheimer's Disease\n",
      "MOLREGNO                                                            Null\n",
      "NAME_TERM                                            Alzheimer's disease\n",
      "Name: 2309, dtype: object\n",
      "_____\n",
      "TWID                                                               19830\n",
      "TWEET_ID                                              982361076615516161\n",
      "TWEET                  Phase III trial failure for @Incyte's Epacados...\n",
      "SYNONYMS                                                     EPACADOSTAT\n",
      "MOLREGNO_1                                                       1927218\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03085914\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         failure in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Epacadostat\n",
      "DESCRIPTIONS           Epacadostat oral twice-daily continuous daily ...\n",
      "OTHER_NAME                                                    INCB024360\n",
      "EFO_ID                                                       EFO:0006859\n",
      "CONDITION                                           Head and Neck Cancer\n",
      "MOLREGNO                                                            8062\n",
      "NAME_TERM                              head and neck malignant neoplasia\n",
      "Name: 2312, dtype: object\n",
      "_____\n",
      "TWID                                                               19830\n",
      "TWEET_ID                                              982361076615516161\n",
      "TWEET                  Phase III trial failure for @Incyte's Epacados...\n",
      "SYNONYMS                                                     EPACADOSTAT\n",
      "MOLREGNO_1                                                       1927218\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03085914\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         failure in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Epacadostat\n",
      "DESCRIPTIONS           Epacadostat oral twice-daily continuous daily ...\n",
      "OTHER_NAME                                                    INCB024360\n",
      "EFO_ID                                                       EFO:0006859\n",
      "CONDITION                                           Head and Neck Cancer\n",
      "MOLREGNO                                                          374008\n",
      "NAME_TERM                              head and neck malignant neoplasia\n",
      "Name: 2313, dtype: object\n",
      "_____\n",
      "TWID                                                               19830\n",
      "TWEET_ID                                              982361076615516161\n",
      "TWEET                  Phase III trial failure for @Incyte's Epacados...\n",
      "SYNONYMS                                                     EPACADOSTAT\n",
      "MOLREGNO_1                                                       1927218\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03085914\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         failure in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Epacadostat\n",
      "DESCRIPTIONS           Epacadostat oral twice-daily continuous daily ...\n",
      "OTHER_NAME                                                    INCB024360\n",
      "EFO_ID                                                       EFO:0006859\n",
      "CONDITION                                           Head and Neck Cancer\n",
      "MOLREGNO                                                           75901\n",
      "NAME_TERM                              head and neck malignant neoplasia\n",
      "Name: 2314, dtype: object\n",
      "_____\n",
      "TWID                                                               19830\n",
      "TWEET_ID                                              982361076615516161\n",
      "TWEET                  Phase III trial failure for @Incyte's Epacados...\n",
      "SYNONYMS                                                     EPACADOSTAT\n",
      "MOLREGNO_1                                                       1927218\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03085914\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         failure in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Epacadostat\n",
      "DESCRIPTIONS           Epacadostat oral twice-daily continuous daily ...\n",
      "OTHER_NAME                                                    INCB024360\n",
      "EFO_ID                                                       EFO:0006859\n",
      "CONDITION                                           Head and Neck Cancer\n",
      "MOLREGNO                                                          675089\n",
      "NAME_TERM                              head and neck malignant neoplasia\n",
      "Name: 2315, dtype: object\n",
      "_____\n",
      "TWID                                                               19830\n",
      "TWEET_ID                                              982361076615516161\n",
      "TWEET                  Phase III trial failure for @Incyte's Epacados...\n",
      "SYNONYMS                                                     EPACADOSTAT\n",
      "MOLREGNO_1                                                       1927218\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03085914\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         failure in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Epacadostat\n",
      "DESCRIPTIONS           Epacadostat oral twice-daily continuous daily ...\n",
      "OTHER_NAME                                                    INCB024360\n",
      "EFO_ID                                                       EFO:0006859\n",
      "CONDITION                                           Head and Neck Cancer\n",
      "MOLREGNO                                                          674747\n",
      "NAME_TERM                              head and neck malignant neoplasia\n",
      "Name: 2316, dtype: object\n",
      "_____\n",
      "TWID                                                               19830\n",
      "TWEET_ID                                              982361076615516161\n",
      "TWEET                  Phase III trial failure for @Incyte's Epacados...\n",
      "SYNONYMS                                                     EPACADOSTAT\n",
      "MOLREGNO_1                                                       1927218\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03085914\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         failure in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Epacadostat\n",
      "DESCRIPTIONS           Epacadostat oral twice-daily continuous daily ...\n",
      "OTHER_NAME                                                    INCB024360\n",
      "EFO_ID                                                       EFO:0006859\n",
      "CONDITION                                           Head and Neck Cancer\n",
      "MOLREGNO                                                            8633\n",
      "NAME_TERM                              head and neck malignant neoplasia\n",
      "Name: 2317, dtype: object\n",
      "_____\n",
      "TWID                                                               19830\n",
      "TWEET_ID                                              982361076615516161\n",
      "TWEET                  Phase III trial failure for @Incyte's Epacados...\n",
      "SYNONYMS                                                     EPACADOSTAT\n",
      "MOLREGNO_1                                                       1927218\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03085914\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         failure in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Epacadostat\n",
      "DESCRIPTIONS           Epacadostat oral twice-daily continuous daily ...\n",
      "OTHER_NAME                                                    INCB024360\n",
      "EFO_ID                                                       EFO:0006859\n",
      "CONDITION                                           Head and Neck Cancer\n",
      "MOLREGNO                                                          243124\n",
      "NAME_TERM                              head and neck malignant neoplasia\n",
      "Name: 2318, dtype: object\n",
      "_____\n",
      "TWID                                                               19830\n",
      "TWEET_ID                                              982361076615516161\n",
      "TWEET                  Phase III trial failure for @Incyte's Epacados...\n",
      "SYNONYMS                                                     EPACADOSTAT\n",
      "MOLREGNO_1                                                       1927218\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03085914\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         failure in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Epacadostat\n",
      "DESCRIPTIONS           Epacadostat oral twice-daily continuous daily ...\n",
      "OTHER_NAME                                                    INCB024360\n",
      "EFO_ID                                                       EFO:0006859\n",
      "CONDITION                                           Head and Neck Cancer\n",
      "MOLREGNO                                                         1626777\n",
      "NAME_TERM                              head and neck malignant neoplasia\n",
      "Name: 2319, dtype: object\n",
      "_____\n",
      "TWID                                                               19830\n",
      "TWEET_ID                                              982361076615516161\n",
      "TWEET                  Phase III trial failure for @Incyte's Epacados...\n",
      "SYNONYMS                                                     EPACADOSTAT\n",
      "MOLREGNO_1                                                       1927218\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03085914\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         failure in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Epacadostat\n",
      "DESCRIPTIONS           Epacadostat oral twice-daily continuous daily ...\n",
      "OTHER_NAME                                                    INCB024360\n",
      "EFO_ID                                                       EFO:0006859\n",
      "CONDITION                                           Head and Neck Cancer\n",
      "MOLREGNO                                                          368538\n",
      "NAME_TERM                              head and neck malignant neoplasia\n",
      "Name: 2320, dtype: object\n",
      "_____\n",
      "TWID                                                               19830\n",
      "TWEET_ID                                              982361076615516161\n",
      "TWEET                  Phase III trial failure for @Incyte's Epacados...\n",
      "SYNONYMS                                                     EPACADOSTAT\n",
      "MOLREGNO_1                                                       1927218\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03085914\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         failure in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Epacadostat\n",
      "DESCRIPTIONS           Epacadostat oral twice-daily continuous daily ...\n",
      "OTHER_NAME                                                    INCB024360\n",
      "EFO_ID                                                       EFO:0006859\n",
      "CONDITION                                           Head and Neck Cancer\n",
      "MOLREGNO                                                          300022\n",
      "NAME_TERM                              head and neck malignant neoplasia\n",
      "Name: 2321, dtype: object\n",
      "_____\n",
      "TWID                                                               19830\n",
      "TWEET_ID                                              982361076615516161\n",
      "TWEET                  Phase III trial failure for @Incyte's Epacados...\n",
      "SYNONYMS                                                     EPACADOSTAT\n",
      "MOLREGNO_1                                                       1927218\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03085914\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         failure in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Epacadostat\n",
      "DESCRIPTIONS           Epacadostat oral twice-daily continuous daily ...\n",
      "OTHER_NAME                                                    INCB024360\n",
      "EFO_ID                                                       EFO:0000228\n",
      "CONDITION                                          Adenocarcinoma (PDAC)\n",
      "MOLREGNO                                                            8062\n",
      "NAME_TERM                                                 adenocarcinoma\n",
      "Name: 2323, dtype: object\n",
      "_____\n",
      "TWID                                                               19830\n",
      "TWEET_ID                                              982361076615516161\n",
      "TWEET                  Phase III trial failure for @Incyte's Epacados...\n",
      "SYNONYMS                                                     EPACADOSTAT\n",
      "MOLREGNO_1                                                       1927218\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03085914\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         failure in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Epacadostat\n",
      "DESCRIPTIONS           Epacadostat oral twice-daily continuous daily ...\n",
      "OTHER_NAME                                                    INCB024360\n",
      "EFO_ID                                                       EFO:0000228\n",
      "CONDITION                                          Adenocarcinoma (PDAC)\n",
      "MOLREGNO                                                          374008\n",
      "NAME_TERM                                                 adenocarcinoma\n",
      "Name: 2324, dtype: object\n",
      "_____\n",
      "TWID                                                               19830\n",
      "TWEET_ID                                              982361076615516161\n",
      "TWEET                  Phase III trial failure for @Incyte's Epacados...\n",
      "SYNONYMS                                                     EPACADOSTAT\n",
      "MOLREGNO_1                                                       1927218\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03085914\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         failure in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Epacadostat\n",
      "DESCRIPTIONS           Epacadostat oral twice-daily continuous daily ...\n",
      "OTHER_NAME                                                    INCB024360\n",
      "EFO_ID                                                       EFO:0000228\n",
      "CONDITION                                          Adenocarcinoma (PDAC)\n",
      "MOLREGNO                                                           75901\n",
      "NAME_TERM                                                 adenocarcinoma\n",
      "Name: 2325, dtype: object\n",
      "_____\n",
      "TWID                                                               19830\n",
      "TWEET_ID                                              982361076615516161\n",
      "TWEET                  Phase III trial failure for @Incyte's Epacados...\n",
      "SYNONYMS                                                     EPACADOSTAT\n",
      "MOLREGNO_1                                                       1927218\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03085914\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         failure in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Epacadostat\n",
      "DESCRIPTIONS           Epacadostat oral twice-daily continuous daily ...\n",
      "OTHER_NAME                                                    INCB024360\n",
      "EFO_ID                                                       EFO:0000228\n",
      "CONDITION                                          Adenocarcinoma (PDAC)\n",
      "MOLREGNO                                                          675089\n",
      "NAME_TERM                                                 adenocarcinoma\n",
      "Name: 2326, dtype: object\n",
      "_____\n",
      "TWID                                                               19830\n",
      "TWEET_ID                                              982361076615516161\n",
      "TWEET                  Phase III trial failure for @Incyte's Epacados...\n",
      "SYNONYMS                                                     EPACADOSTAT\n",
      "MOLREGNO_1                                                       1927218\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03085914\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         failure in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Epacadostat\n",
      "DESCRIPTIONS           Epacadostat oral twice-daily continuous daily ...\n",
      "OTHER_NAME                                                    INCB024360\n",
      "EFO_ID                                                       EFO:0000228\n",
      "CONDITION                                          Adenocarcinoma (PDAC)\n",
      "MOLREGNO                                                          674747\n",
      "NAME_TERM                                                 adenocarcinoma\n",
      "Name: 2327, dtype: object\n",
      "_____\n",
      "TWID                                                               19830\n",
      "TWEET_ID                                              982361076615516161\n",
      "TWEET                  Phase III trial failure for @Incyte's Epacados...\n",
      "SYNONYMS                                                     EPACADOSTAT\n",
      "MOLREGNO_1                                                       1927218\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03085914\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         failure in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Epacadostat\n",
      "DESCRIPTIONS           Epacadostat oral twice-daily continuous daily ...\n",
      "OTHER_NAME                                                    INCB024360\n",
      "EFO_ID                                                       EFO:0000228\n",
      "CONDITION                                          Adenocarcinoma (PDAC)\n",
      "MOLREGNO                                                            8633\n",
      "NAME_TERM                                                 adenocarcinoma\n",
      "Name: 2328, dtype: object\n",
      "_____\n",
      "TWID                                                               19830\n",
      "TWEET_ID                                              982361076615516161\n",
      "TWEET                  Phase III trial failure for @Incyte's Epacados...\n",
      "SYNONYMS                                                     EPACADOSTAT\n",
      "MOLREGNO_1                                                       1927218\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03085914\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         failure in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Epacadostat\n",
      "DESCRIPTIONS           Epacadostat oral twice-daily continuous daily ...\n",
      "OTHER_NAME                                                    INCB024360\n",
      "EFO_ID                                                       EFO:0000228\n",
      "CONDITION                                          Adenocarcinoma (PDAC)\n",
      "MOLREGNO                                                          243124\n",
      "NAME_TERM                                                 adenocarcinoma\n",
      "Name: 2329, dtype: object\n",
      "_____\n",
      "TWID                                                               19830\n",
      "TWEET_ID                                              982361076615516161\n",
      "TWEET                  Phase III trial failure for @Incyte's Epacados...\n",
      "SYNONYMS                                                     EPACADOSTAT\n",
      "MOLREGNO_1                                                       1927218\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03085914\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         failure in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Epacadostat\n",
      "DESCRIPTIONS           Epacadostat oral twice-daily continuous daily ...\n",
      "OTHER_NAME                                                    INCB024360\n",
      "EFO_ID                                                       EFO:0000228\n",
      "CONDITION                                          Adenocarcinoma (PDAC)\n",
      "MOLREGNO                                                         1626777\n",
      "NAME_TERM                                                 adenocarcinoma\n",
      "Name: 2330, dtype: object\n",
      "_____\n",
      "TWID                                                               19830\n",
      "TWEET_ID                                              982361076615516161\n",
      "TWEET                  Phase III trial failure for @Incyte's Epacados...\n",
      "SYNONYMS                                                     EPACADOSTAT\n",
      "MOLREGNO_1                                                       1927218\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03085914\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         failure in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Epacadostat\n",
      "DESCRIPTIONS           Epacadostat oral twice-daily continuous daily ...\n",
      "OTHER_NAME                                                    INCB024360\n",
      "EFO_ID                                                       EFO:0000228\n",
      "CONDITION                                          Adenocarcinoma (PDAC)\n",
      "MOLREGNO                                                          368538\n",
      "NAME_TERM                                                 adenocarcinoma\n",
      "Name: 2331, dtype: object\n",
      "_____\n",
      "TWID                                                               19830\n",
      "TWEET_ID                                              982361076615516161\n",
      "TWEET                  Phase III trial failure for @Incyte's Epacados...\n",
      "SYNONYMS                                                     EPACADOSTAT\n",
      "MOLREGNO_1                                                       1927218\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03085914\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         failure in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Epacadostat\n",
      "DESCRIPTIONS           Epacadostat oral twice-daily continuous daily ...\n",
      "OTHER_NAME                                                    INCB024360\n",
      "EFO_ID                                                       EFO:0000228\n",
      "CONDITION                                          Adenocarcinoma (PDAC)\n",
      "MOLREGNO                                                          300022\n",
      "NAME_TERM                                                 adenocarcinoma\n",
      "Name: 2332, dtype: object\n",
      "_____\n",
      "TWID                                                               19830\n",
      "TWEET_ID                                              982361076615516161\n",
      "TWEET                  Phase III trial failure for @Incyte's Epacados...\n",
      "SYNONYMS                                                     EPACADOSTAT\n",
      "MOLREGNO_1                                                       1927218\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03085914\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         failure in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Epacadostat\n",
      "DESCRIPTIONS           Epacadostat oral twice-daily continuous daily ...\n",
      "OTHER_NAME                                                    INCB024360\n",
      "EFO_ID                                                       EFO:0001071\n",
      "CONDITION                                                    Lung Cancer\n",
      "MOLREGNO                                                            8062\n",
      "NAME_TERM                                                 lung carcinoma\n",
      "Name: 2334, dtype: object\n",
      "_____\n",
      "TWID                                                               19830\n",
      "TWEET_ID                                              982361076615516161\n",
      "TWEET                  Phase III trial failure for @Incyte's Epacados...\n",
      "SYNONYMS                                                     EPACADOSTAT\n",
      "MOLREGNO_1                                                       1927218\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03085914\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         failure in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Epacadostat\n",
      "DESCRIPTIONS           Epacadostat oral twice-daily continuous daily ...\n",
      "OTHER_NAME                                                    INCB024360\n",
      "EFO_ID                                                       EFO:0001071\n",
      "CONDITION                                                    Lung Cancer\n",
      "MOLREGNO                                                          374008\n",
      "NAME_TERM                                                 lung carcinoma\n",
      "Name: 2335, dtype: object\n",
      "_____\n",
      "TWID                                                               19830\n",
      "TWEET_ID                                              982361076615516161\n",
      "TWEET                  Phase III trial failure for @Incyte's Epacados...\n",
      "SYNONYMS                                                     EPACADOSTAT\n",
      "MOLREGNO_1                                                       1927218\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03085914\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         failure in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Epacadostat\n",
      "DESCRIPTIONS           Epacadostat oral twice-daily continuous daily ...\n",
      "OTHER_NAME                                                    INCB024360\n",
      "EFO_ID                                                       EFO:0001071\n",
      "CONDITION                                                    Lung Cancer\n",
      "MOLREGNO                                                           75901\n",
      "NAME_TERM                                                 lung carcinoma\n",
      "Name: 2336, dtype: object\n",
      "_____\n",
      "TWID                                                               19830\n",
      "TWEET_ID                                              982361076615516161\n",
      "TWEET                  Phase III trial failure for @Incyte's Epacados...\n",
      "SYNONYMS                                                     EPACADOSTAT\n",
      "MOLREGNO_1                                                       1927218\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03085914\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         failure in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Epacadostat\n",
      "DESCRIPTIONS           Epacadostat oral twice-daily continuous daily ...\n",
      "OTHER_NAME                                                    INCB024360\n",
      "EFO_ID                                                       EFO:0001071\n",
      "CONDITION                                                    Lung Cancer\n",
      "MOLREGNO                                                          675089\n",
      "NAME_TERM                                                 lung carcinoma\n",
      "Name: 2337, dtype: object\n",
      "_____\n",
      "TWID                                                               19830\n",
      "TWEET_ID                                              982361076615516161\n",
      "TWEET                  Phase III trial failure for @Incyte's Epacados...\n",
      "SYNONYMS                                                     EPACADOSTAT\n",
      "MOLREGNO_1                                                       1927218\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03085914\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         failure in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Epacadostat\n",
      "DESCRIPTIONS           Epacadostat oral twice-daily continuous daily ...\n",
      "OTHER_NAME                                                    INCB024360\n",
      "EFO_ID                                                       EFO:0001071\n",
      "CONDITION                                                    Lung Cancer\n",
      "MOLREGNO                                                          674747\n",
      "NAME_TERM                                                 lung carcinoma\n",
      "Name: 2338, dtype: object\n",
      "_____\n",
      "TWID                                                               19830\n",
      "TWEET_ID                                              982361076615516161\n",
      "TWEET                  Phase III trial failure for @Incyte's Epacados...\n",
      "SYNONYMS                                                     EPACADOSTAT\n",
      "MOLREGNO_1                                                       1927218\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03085914\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         failure in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Epacadostat\n",
      "DESCRIPTIONS           Epacadostat oral twice-daily continuous daily ...\n",
      "OTHER_NAME                                                    INCB024360\n",
      "EFO_ID                                                       EFO:0001071\n",
      "CONDITION                                                    Lung Cancer\n",
      "MOLREGNO                                                            8633\n",
      "NAME_TERM                                                 lung carcinoma\n",
      "Name: 2339, dtype: object\n",
      "_____\n",
      "TWID                                                               19830\n",
      "TWEET_ID                                              982361076615516161\n",
      "TWEET                  Phase III trial failure for @Incyte's Epacados...\n",
      "SYNONYMS                                                     EPACADOSTAT\n",
      "MOLREGNO_1                                                       1927218\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03085914\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         failure in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Epacadostat\n",
      "DESCRIPTIONS           Epacadostat oral twice-daily continuous daily ...\n",
      "OTHER_NAME                                                    INCB024360\n",
      "EFO_ID                                                       EFO:0001071\n",
      "CONDITION                                                    Lung Cancer\n",
      "MOLREGNO                                                          243124\n",
      "NAME_TERM                                                 lung carcinoma\n",
      "Name: 2340, dtype: object\n",
      "_____\n",
      "TWID                                                               19830\n",
      "TWEET_ID                                              982361076615516161\n",
      "TWEET                  Phase III trial failure for @Incyte's Epacados...\n",
      "SYNONYMS                                                     EPACADOSTAT\n",
      "MOLREGNO_1                                                       1927218\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03085914\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         failure in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Epacadostat\n",
      "DESCRIPTIONS           Epacadostat oral twice-daily continuous daily ...\n",
      "OTHER_NAME                                                    INCB024360\n",
      "EFO_ID                                                       EFO:0001071\n",
      "CONDITION                                                    Lung Cancer\n",
      "MOLREGNO                                                         1626777\n",
      "NAME_TERM                                                 lung carcinoma\n",
      "Name: 2341, dtype: object\n",
      "_____\n",
      "TWID                                                               19830\n",
      "TWEET_ID                                              982361076615516161\n",
      "TWEET                  Phase III trial failure for @Incyte's Epacados...\n",
      "SYNONYMS                                                     EPACADOSTAT\n",
      "MOLREGNO_1                                                       1927218\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03085914\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         failure in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Epacadostat\n",
      "DESCRIPTIONS           Epacadostat oral twice-daily continuous daily ...\n",
      "OTHER_NAME                                                    INCB024360\n",
      "EFO_ID                                                       EFO:0001071\n",
      "CONDITION                                                    Lung Cancer\n",
      "MOLREGNO                                                          368538\n",
      "NAME_TERM                                                 lung carcinoma\n",
      "Name: 2342, dtype: object\n",
      "_____\n",
      "TWID                                                               19830\n",
      "TWEET_ID                                              982361076615516161\n",
      "TWEET                  Phase III trial failure for @Incyte's Epacados...\n",
      "SYNONYMS                                                     EPACADOSTAT\n",
      "MOLREGNO_1                                                       1927218\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03085914\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         failure in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Epacadostat\n",
      "DESCRIPTIONS           Epacadostat oral twice-daily continuous daily ...\n",
      "OTHER_NAME                                                    INCB024360\n",
      "EFO_ID                                                       EFO:0001071\n",
      "CONDITION                                                    Lung Cancer\n",
      "MOLREGNO                                                          300022\n",
      "NAME_TERM                                                 lung carcinoma\n",
      "Name: 2343, dtype: object\n",
      "_____\n",
      "TWID                                                               19830\n",
      "TWEET_ID                                              982361076615516161\n",
      "TWEET                  Phase III trial failure for @Incyte's Epacados...\n",
      "SYNONYMS                                                     EPACADOSTAT\n",
      "MOLREGNO_1                                                       1927218\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03085914\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         failure in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Epacadostat\n",
      "DESCRIPTIONS           Epacadostat oral twice-daily continuous daily ...\n",
      "OTHER_NAME                                                    INCB024360\n",
      "EFO_ID                                                       EFO:0000616\n",
      "CONDITION                                                   Solid Tumors\n",
      "MOLREGNO                                                            8062\n",
      "NAME_TERM                                                       neoplasm\n",
      "Name: 2345, dtype: object\n",
      "_____\n",
      "TWID                                                               19830\n",
      "TWEET_ID                                              982361076615516161\n",
      "TWEET                  Phase III trial failure for @Incyte's Epacados...\n",
      "SYNONYMS                                                     EPACADOSTAT\n",
      "MOLREGNO_1                                                       1927218\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03085914\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         failure in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Epacadostat\n",
      "DESCRIPTIONS           Epacadostat oral twice-daily continuous daily ...\n",
      "OTHER_NAME                                                    INCB024360\n",
      "EFO_ID                                                       EFO:0000616\n",
      "CONDITION                                                   Solid Tumors\n",
      "MOLREGNO                                                          374008\n",
      "NAME_TERM                                                       neoplasm\n",
      "Name: 2346, dtype: object\n",
      "_____\n",
      "TWID                                                               19830\n",
      "TWEET_ID                                              982361076615516161\n",
      "TWEET                  Phase III trial failure for @Incyte's Epacados...\n",
      "SYNONYMS                                                     EPACADOSTAT\n",
      "MOLREGNO_1                                                       1927218\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03085914\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         failure in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Epacadostat\n",
      "DESCRIPTIONS           Epacadostat oral twice-daily continuous daily ...\n",
      "OTHER_NAME                                                    INCB024360\n",
      "EFO_ID                                                       EFO:0000616\n",
      "CONDITION                                                   Solid Tumors\n",
      "MOLREGNO                                                           75901\n",
      "NAME_TERM                                                       neoplasm\n",
      "Name: 2347, dtype: object\n",
      "_____\n",
      "TWID                                                               19830\n",
      "TWEET_ID                                              982361076615516161\n",
      "TWEET                  Phase III trial failure for @Incyte's Epacados...\n",
      "SYNONYMS                                                     EPACADOSTAT\n",
      "MOLREGNO_1                                                       1927218\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03085914\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         failure in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Epacadostat\n",
      "DESCRIPTIONS           Epacadostat oral twice-daily continuous daily ...\n",
      "OTHER_NAME                                                    INCB024360\n",
      "EFO_ID                                                       EFO:0000616\n",
      "CONDITION                                                   Solid Tumors\n",
      "MOLREGNO                                                          675089\n",
      "NAME_TERM                                                       neoplasm\n",
      "Name: 2348, dtype: object\n",
      "_____\n",
      "TWID                                                               19830\n",
      "TWEET_ID                                              982361076615516161\n",
      "TWEET                  Phase III trial failure for @Incyte's Epacados...\n",
      "SYNONYMS                                                     EPACADOSTAT\n",
      "MOLREGNO_1                                                       1927218\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03085914\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         failure in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Epacadostat\n",
      "DESCRIPTIONS           Epacadostat oral twice-daily continuous daily ...\n",
      "OTHER_NAME                                                    INCB024360\n",
      "EFO_ID                                                       EFO:0000616\n",
      "CONDITION                                                   Solid Tumors\n",
      "MOLREGNO                                                          674747\n",
      "NAME_TERM                                                       neoplasm\n",
      "Name: 2349, dtype: object\n",
      "_____\n",
      "TWID                                                               19830\n",
      "TWEET_ID                                              982361076615516161\n",
      "TWEET                  Phase III trial failure for @Incyte's Epacados...\n",
      "SYNONYMS                                                     EPACADOSTAT\n",
      "MOLREGNO_1                                                       1927218\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03085914\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         failure in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Epacadostat\n",
      "DESCRIPTIONS           Epacadostat oral twice-daily continuous daily ...\n",
      "OTHER_NAME                                                    INCB024360\n",
      "EFO_ID                                                       EFO:0000616\n",
      "CONDITION                                                   Solid Tumors\n",
      "MOLREGNO                                                            8633\n",
      "NAME_TERM                                                       neoplasm\n",
      "Name: 2350, dtype: object\n",
      "_____\n",
      "TWID                                                               19830\n",
      "TWEET_ID                                              982361076615516161\n",
      "TWEET                  Phase III trial failure for @Incyte's Epacados...\n",
      "SYNONYMS                                                     EPACADOSTAT\n",
      "MOLREGNO_1                                                       1927218\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03085914\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         failure in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Epacadostat\n",
      "DESCRIPTIONS           Epacadostat oral twice-daily continuous daily ...\n",
      "OTHER_NAME                                                    INCB024360\n",
      "EFO_ID                                                       EFO:0000616\n",
      "CONDITION                                                   Solid Tumors\n",
      "MOLREGNO                                                          243124\n",
      "NAME_TERM                                                       neoplasm\n",
      "Name: 2351, dtype: object\n",
      "_____\n",
      "TWID                                                               19830\n",
      "TWEET_ID                                              982361076615516161\n",
      "TWEET                  Phase III trial failure for @Incyte's Epacados...\n",
      "SYNONYMS                                                     EPACADOSTAT\n",
      "MOLREGNO_1                                                       1927218\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03085914\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         failure in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Epacadostat\n",
      "DESCRIPTIONS           Epacadostat oral twice-daily continuous daily ...\n",
      "OTHER_NAME                                                    INCB024360\n",
      "EFO_ID                                                       EFO:0000616\n",
      "CONDITION                                                   Solid Tumors\n",
      "MOLREGNO                                                         1626777\n",
      "NAME_TERM                                                       neoplasm\n",
      "Name: 2352, dtype: object\n",
      "_____\n",
      "TWID                                                               19830\n",
      "TWEET_ID                                              982361076615516161\n",
      "TWEET                  Phase III trial failure for @Incyte's Epacados...\n",
      "SYNONYMS                                                     EPACADOSTAT\n",
      "MOLREGNO_1                                                       1927218\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03085914\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         failure in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Epacadostat\n",
      "DESCRIPTIONS           Epacadostat oral twice-daily continuous daily ...\n",
      "OTHER_NAME                                                    INCB024360\n",
      "EFO_ID                                                       EFO:0000616\n",
      "CONDITION                                                   Solid Tumors\n",
      "MOLREGNO                                                          368538\n",
      "NAME_TERM                                                       neoplasm\n",
      "Name: 2353, dtype: object\n",
      "_____\n",
      "TWID                                                               19830\n",
      "TWEET_ID                                              982361076615516161\n",
      "TWEET                  Phase III trial failure for @Incyte's Epacados...\n",
      "SYNONYMS                                                     EPACADOSTAT\n",
      "MOLREGNO_1                                                       1927218\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03085914\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         failure in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Epacadostat\n",
      "DESCRIPTIONS           Epacadostat oral twice-daily continuous daily ...\n",
      "OTHER_NAME                                                    INCB024360\n",
      "EFO_ID                                                       EFO:0000616\n",
      "CONDITION                                                   Solid Tumors\n",
      "MOLREGNO                                                          300022\n",
      "NAME_TERM                                                       neoplasm\n",
      "Name: 2354, dtype: object\n",
      "_____\n",
      "TWID                                                               19830\n",
      "TWEET_ID                                              982361076615516161\n",
      "TWEET                  Phase III trial failure for @Incyte's Epacados...\n",
      "SYNONYMS                                                     EPACADOSTAT\n",
      "MOLREGNO_1                                                       1927218\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03085914\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         failure in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Epacadostat\n",
      "DESCRIPTIONS           Epacadostat oral twice-daily continuous daily ...\n",
      "OTHER_NAME                                                    INCB024360\n",
      "EFO_ID                                                       EFO:0000365\n",
      "CONDITION                                        Colorectal Cancer (CRC)\n",
      "MOLREGNO                                                            8062\n",
      "NAME_TERM                                      colorectal adenocarcinoma\n",
      "Name: 2356, dtype: object\n",
      "_____\n",
      "TWID                                                               19830\n",
      "TWEET_ID                                              982361076615516161\n",
      "TWEET                  Phase III trial failure for @Incyte's Epacados...\n",
      "SYNONYMS                                                     EPACADOSTAT\n",
      "MOLREGNO_1                                                       1927218\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03085914\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         failure in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Epacadostat\n",
      "DESCRIPTIONS           Epacadostat oral twice-daily continuous daily ...\n",
      "OTHER_NAME                                                    INCB024360\n",
      "EFO_ID                                                       EFO:0000365\n",
      "CONDITION                                        Colorectal Cancer (CRC)\n",
      "MOLREGNO                                                          374008\n",
      "NAME_TERM                                      colorectal adenocarcinoma\n",
      "Name: 2357, dtype: object\n",
      "_____\n",
      "TWID                                                               19830\n",
      "TWEET_ID                                              982361076615516161\n",
      "TWEET                  Phase III trial failure for @Incyte's Epacados...\n",
      "SYNONYMS                                                     EPACADOSTAT\n",
      "MOLREGNO_1                                                       1927218\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03085914\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         failure in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Epacadostat\n",
      "DESCRIPTIONS           Epacadostat oral twice-daily continuous daily ...\n",
      "OTHER_NAME                                                    INCB024360\n",
      "EFO_ID                                                       EFO:0000365\n",
      "CONDITION                                        Colorectal Cancer (CRC)\n",
      "MOLREGNO                                                           75901\n",
      "NAME_TERM                                      colorectal adenocarcinoma\n",
      "Name: 2358, dtype: object\n",
      "_____\n",
      "TWID                                                               19830\n",
      "TWEET_ID                                              982361076615516161\n",
      "TWEET                  Phase III trial failure for @Incyte's Epacados...\n",
      "SYNONYMS                                                     EPACADOSTAT\n",
      "MOLREGNO_1                                                       1927218\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03085914\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         failure in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Epacadostat\n",
      "DESCRIPTIONS           Epacadostat oral twice-daily continuous daily ...\n",
      "OTHER_NAME                                                    INCB024360\n",
      "EFO_ID                                                       EFO:0000365\n",
      "CONDITION                                        Colorectal Cancer (CRC)\n",
      "MOLREGNO                                                          675089\n",
      "NAME_TERM                                      colorectal adenocarcinoma\n",
      "Name: 2359, dtype: object\n",
      "_____\n",
      "TWID                                                               19830\n",
      "TWEET_ID                                              982361076615516161\n",
      "TWEET                  Phase III trial failure for @Incyte's Epacados...\n",
      "SYNONYMS                                                     EPACADOSTAT\n",
      "MOLREGNO_1                                                       1927218\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03085914\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         failure in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Epacadostat\n",
      "DESCRIPTIONS           Epacadostat oral twice-daily continuous daily ...\n",
      "OTHER_NAME                                                    INCB024360\n",
      "EFO_ID                                                       EFO:0000365\n",
      "CONDITION                                        Colorectal Cancer (CRC)\n",
      "MOLREGNO                                                          674747\n",
      "NAME_TERM                                      colorectal adenocarcinoma\n",
      "Name: 2360, dtype: object\n",
      "_____\n",
      "TWID                                                               19830\n",
      "TWEET_ID                                              982361076615516161\n",
      "TWEET                  Phase III trial failure for @Incyte's Epacados...\n",
      "SYNONYMS                                                     EPACADOSTAT\n",
      "MOLREGNO_1                                                       1927218\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03085914\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         failure in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Epacadostat\n",
      "DESCRIPTIONS           Epacadostat oral twice-daily continuous daily ...\n",
      "OTHER_NAME                                                    INCB024360\n",
      "EFO_ID                                                       EFO:0000365\n",
      "CONDITION                                        Colorectal Cancer (CRC)\n",
      "MOLREGNO                                                            8633\n",
      "NAME_TERM                                      colorectal adenocarcinoma\n",
      "Name: 2361, dtype: object\n",
      "_____\n",
      "TWID                                                               19830\n",
      "TWEET_ID                                              982361076615516161\n",
      "TWEET                  Phase III trial failure for @Incyte's Epacados...\n",
      "SYNONYMS                                                     EPACADOSTAT\n",
      "MOLREGNO_1                                                       1927218\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03085914\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         failure in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Epacadostat\n",
      "DESCRIPTIONS           Epacadostat oral twice-daily continuous daily ...\n",
      "OTHER_NAME                                                    INCB024360\n",
      "EFO_ID                                                       EFO:0000365\n",
      "CONDITION                                        Colorectal Cancer (CRC)\n",
      "MOLREGNO                                                          243124\n",
      "NAME_TERM                                      colorectal adenocarcinoma\n",
      "Name: 2362, dtype: object\n",
      "_____\n",
      "TWID                                                               19830\n",
      "TWEET_ID                                              982361076615516161\n",
      "TWEET                  Phase III trial failure for @Incyte's Epacados...\n",
      "SYNONYMS                                                     EPACADOSTAT\n",
      "MOLREGNO_1                                                       1927218\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03085914\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         failure in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Epacadostat\n",
      "DESCRIPTIONS           Epacadostat oral twice-daily continuous daily ...\n",
      "OTHER_NAME                                                    INCB024360\n",
      "EFO_ID                                                       EFO:0000365\n",
      "CONDITION                                        Colorectal Cancer (CRC)\n",
      "MOLREGNO                                                         1626777\n",
      "NAME_TERM                                      colorectal adenocarcinoma\n",
      "Name: 2363, dtype: object\n",
      "_____\n",
      "TWID                                                               19830\n",
      "TWEET_ID                                              982361076615516161\n",
      "TWEET                  Phase III trial failure for @Incyte's Epacados...\n",
      "SYNONYMS                                                     EPACADOSTAT\n",
      "MOLREGNO_1                                                       1927218\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03085914\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         failure in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Epacadostat\n",
      "DESCRIPTIONS           Epacadostat oral twice-daily continuous daily ...\n",
      "OTHER_NAME                                                    INCB024360\n",
      "EFO_ID                                                       EFO:0000365\n",
      "CONDITION                                        Colorectal Cancer (CRC)\n",
      "MOLREGNO                                                          368538\n",
      "NAME_TERM                                      colorectal adenocarcinoma\n",
      "Name: 2364, dtype: object\n",
      "_____\n",
      "TWID                                                               19830\n",
      "TWEET_ID                                              982361076615516161\n",
      "TWEET                  Phase III trial failure for @Incyte's Epacados...\n",
      "SYNONYMS                                                     EPACADOSTAT\n",
      "MOLREGNO_1                                                       1927218\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03085914\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         failure in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Epacadostat\n",
      "DESCRIPTIONS           Epacadostat oral twice-daily continuous daily ...\n",
      "OTHER_NAME                                                    INCB024360\n",
      "EFO_ID                                                       EFO:0000365\n",
      "CONDITION                                        Colorectal Cancer (CRC)\n",
      "MOLREGNO                                                          300022\n",
      "NAME_TERM                                      colorectal adenocarcinoma\n",
      "Name: 2365, dtype: object\n",
      "_____\n",
      "TWID                                                               19830\n",
      "TWEET_ID                                              982361076615516161\n",
      "TWEET                  Phase III trial failure for @Incyte's Epacados...\n",
      "SYNONYMS                                                     EPACADOSTAT\n",
      "MOLREGNO_1                                                       1927218\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03085914\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         failure in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Epacadostat\n",
      "DESCRIPTIONS           Epacadostat oral twice-daily continuous daily ...\n",
      "OTHER_NAME                                                    INCB024360\n",
      "EFO_ID                                                       EFO:0003863\n",
      "CONDITION                                         UC (Urothelial Cancer)\n",
      "MOLREGNO                                                            8062\n",
      "NAME_TERM                                            urogenital neoplasm\n",
      "Name: 2367, dtype: object\n",
      "_____\n",
      "TWID                                                               19830\n",
      "TWEET_ID                                              982361076615516161\n",
      "TWEET                  Phase III trial failure for @Incyte's Epacados...\n",
      "SYNONYMS                                                     EPACADOSTAT\n",
      "MOLREGNO_1                                                       1927218\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03085914\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         failure in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Epacadostat\n",
      "DESCRIPTIONS           Epacadostat oral twice-daily continuous daily ...\n",
      "OTHER_NAME                                                    INCB024360\n",
      "EFO_ID                                                       EFO:0003863\n",
      "CONDITION                                         UC (Urothelial Cancer)\n",
      "MOLREGNO                                                          374008\n",
      "NAME_TERM                                            urogenital neoplasm\n",
      "Name: 2368, dtype: object\n",
      "_____\n",
      "TWID                                                               19830\n",
      "TWEET_ID                                              982361076615516161\n",
      "TWEET                  Phase III trial failure for @Incyte's Epacados...\n",
      "SYNONYMS                                                     EPACADOSTAT\n",
      "MOLREGNO_1                                                       1927218\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03085914\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         failure in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Epacadostat\n",
      "DESCRIPTIONS           Epacadostat oral twice-daily continuous daily ...\n",
      "OTHER_NAME                                                    INCB024360\n",
      "EFO_ID                                                       EFO:0003863\n",
      "CONDITION                                         UC (Urothelial Cancer)\n",
      "MOLREGNO                                                           75901\n",
      "NAME_TERM                                            urogenital neoplasm\n",
      "Name: 2369, dtype: object\n",
      "_____\n",
      "TWID                                                               19830\n",
      "TWEET_ID                                              982361076615516161\n",
      "TWEET                  Phase III trial failure for @Incyte's Epacados...\n",
      "SYNONYMS                                                     EPACADOSTAT\n",
      "MOLREGNO_1                                                       1927218\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03085914\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         failure in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Epacadostat\n",
      "DESCRIPTIONS           Epacadostat oral twice-daily continuous daily ...\n",
      "OTHER_NAME                                                    INCB024360\n",
      "EFO_ID                                                       EFO:0003863\n",
      "CONDITION                                         UC (Urothelial Cancer)\n",
      "MOLREGNO                                                          675089\n",
      "NAME_TERM                                            urogenital neoplasm\n",
      "Name: 2370, dtype: object\n",
      "_____\n",
      "TWID                                                               19830\n",
      "TWEET_ID                                              982361076615516161\n",
      "TWEET                  Phase III trial failure for @Incyte's Epacados...\n",
      "SYNONYMS                                                     EPACADOSTAT\n",
      "MOLREGNO_1                                                       1927218\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03085914\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         failure in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Epacadostat\n",
      "DESCRIPTIONS           Epacadostat oral twice-daily continuous daily ...\n",
      "OTHER_NAME                                                    INCB024360\n",
      "EFO_ID                                                       EFO:0003863\n",
      "CONDITION                                         UC (Urothelial Cancer)\n",
      "MOLREGNO                                                          674747\n",
      "NAME_TERM                                            urogenital neoplasm\n",
      "Name: 2371, dtype: object\n",
      "_____\n",
      "TWID                                                               19830\n",
      "TWEET_ID                                              982361076615516161\n",
      "TWEET                  Phase III trial failure for @Incyte's Epacados...\n",
      "SYNONYMS                                                     EPACADOSTAT\n",
      "MOLREGNO_1                                                       1927218\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03085914\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         failure in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Epacadostat\n",
      "DESCRIPTIONS           Epacadostat oral twice-daily continuous daily ...\n",
      "OTHER_NAME                                                    INCB024360\n",
      "EFO_ID                                                       EFO:0003863\n",
      "CONDITION                                         UC (Urothelial Cancer)\n",
      "MOLREGNO                                                            8633\n",
      "NAME_TERM                                            urogenital neoplasm\n",
      "Name: 2372, dtype: object\n",
      "_____\n",
      "TWID                                                               19830\n",
      "TWEET_ID                                              982361076615516161\n",
      "TWEET                  Phase III trial failure for @Incyte's Epacados...\n",
      "SYNONYMS                                                     EPACADOSTAT\n",
      "MOLREGNO_1                                                       1927218\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03085914\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         failure in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Epacadostat\n",
      "DESCRIPTIONS           Epacadostat oral twice-daily continuous daily ...\n",
      "OTHER_NAME                                                    INCB024360\n",
      "EFO_ID                                                       EFO:0003863\n",
      "CONDITION                                         UC (Urothelial Cancer)\n",
      "MOLREGNO                                                          243124\n",
      "NAME_TERM                                            urogenital neoplasm\n",
      "Name: 2373, dtype: object\n",
      "_____\n",
      "TWID                                                               19830\n",
      "TWEET_ID                                              982361076615516161\n",
      "TWEET                  Phase III trial failure for @Incyte's Epacados...\n",
      "SYNONYMS                                                     EPACADOSTAT\n",
      "MOLREGNO_1                                                       1927218\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03085914\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         failure in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Epacadostat\n",
      "DESCRIPTIONS           Epacadostat oral twice-daily continuous daily ...\n",
      "OTHER_NAME                                                    INCB024360\n",
      "EFO_ID                                                       EFO:0003863\n",
      "CONDITION                                         UC (Urothelial Cancer)\n",
      "MOLREGNO                                                         1626777\n",
      "NAME_TERM                                            urogenital neoplasm\n",
      "Name: 2374, dtype: object\n",
      "_____\n",
      "TWID                                                               19830\n",
      "TWEET_ID                                              982361076615516161\n",
      "TWEET                  Phase III trial failure for @Incyte's Epacados...\n",
      "SYNONYMS                                                     EPACADOSTAT\n",
      "MOLREGNO_1                                                       1927218\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03085914\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         failure in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Epacadostat\n",
      "DESCRIPTIONS           Epacadostat oral twice-daily continuous daily ...\n",
      "OTHER_NAME                                                    INCB024360\n",
      "EFO_ID                                                       EFO:0003863\n",
      "CONDITION                                         UC (Urothelial Cancer)\n",
      "MOLREGNO                                                          368538\n",
      "NAME_TERM                                            urogenital neoplasm\n",
      "Name: 2375, dtype: object\n",
      "_____\n",
      "TWID                                                               19830\n",
      "TWEET_ID                                              982361076615516161\n",
      "TWEET                  Phase III trial failure for @Incyte's Epacados...\n",
      "SYNONYMS                                                     EPACADOSTAT\n",
      "MOLREGNO_1                                                       1927218\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03085914\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         failure in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Epacadostat\n",
      "DESCRIPTIONS           Epacadostat oral twice-daily continuous daily ...\n",
      "OTHER_NAME                                                    INCB024360\n",
      "EFO_ID                                                       EFO:0003863\n",
      "CONDITION                                         UC (Urothelial Cancer)\n",
      "MOLREGNO                                                          300022\n",
      "NAME_TERM                                            urogenital neoplasm\n",
      "Name: 2376, dtype: object\n",
      "_____\n",
      "TWID                                                               20052\n",
      "TWEET_ID                                              976593086766821376\n",
      "TWEET                  #MuscularDystrophy progression slowed by tamox...\n",
      "SYNONYMS                                                      RALOXIFENE\n",
      "MOLREGNO_1                                                          6914\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03006003\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                    progression slowed by\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                 Schizophrenia\n",
      "INDICATION_ID                                                    D012559\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Raloxifene\n",
      "DESCRIPTIONS                       Raloxifene tratment more than 4 weeks\n",
      "OTHER_NAME                                                        Evista\n",
      "EFO_ID                                                       EFO:0003761\n",
      "CONDITION                                            Depressive Syndrome\n",
      "MOLREGNO                                                           70674\n",
      "NAME_TERM                                            unipolar depression\n",
      "Name: 2385, dtype: object\n",
      "_____\n",
      "TWID                                                               20052\n",
      "TWEET_ID                                              976593086766821376\n",
      "TWEET                  #MuscularDystrophy progression slowed by tamox...\n",
      "SYNONYMS                                                       TAMOXIFEN\n",
      "MOLREGNO_1                                                          6968\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03382834\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                    progression slowed by\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                 Schizophrenia\n",
      "INDICATION_ID                                                    D012559\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Tamoxifen\n",
      "DESCRIPTIONS                                                20 mg orally\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000764\n",
      "CONDITION                                                 HIV Infections\n",
      "MOLREGNO                                                           11305\n",
      "NAME_TERM                                                  HIV infection\n",
      "Name: 2387, dtype: object\n",
      "_____\n",
      "TWID                                                               20052\n",
      "TWEET_ID                                              976593086766821376\n",
      "TWEET                  #MuscularDystrophy progression slowed by tamox...\n",
      "SYNONYMS                                                       TAMOXIFEN\n",
      "MOLREGNO_1                                                          6968\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03382834\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                    progression slowed by\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                 Schizophrenia\n",
      "INDICATION_ID                                                    D012559\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Tamoxifen\n",
      "DESCRIPTIONS                                                20 mg orally\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000764\n",
      "CONDITION                                                 HIV Infections\n",
      "MOLREGNO                                                           47340\n",
      "NAME_TERM                                                  HIV infection\n",
      "Name: 2388, dtype: object\n",
      "_____\n",
      "TWID                                                               20798\n",
      "TWEET_ID                                              956661743325007872\n",
      "TWEET                  In clinical trial solanezumab did not signific...\n",
      "SYNONYMS                                                     SOLANEZUMAB\n",
      "MOLREGNO_1                                                       1121943\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01127633\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME             did not significantly slow cognitive decline\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                             Alzheimer Disease\n",
      "INDICATION_ID                                                    D000544\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Solanezumab\n",
      "DESCRIPTIONS           400 mg of solanezumab administered once every ...\n",
      "OTHER_NAME                                                     LY2062430\n",
      "EFO_ID                                                       EFO:0000249\n",
      "CONDITION                                            Alzheimer's Disease\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                            Alzheimer's disease\n",
      "Name: 2402, dtype: object\n",
      "_____\n",
      "TWID                                                               21632\n",
      "TWEET_ID                                              933091435678539777\n",
      "TWEET                  Following Phase III failure  @Cytokinetics sus...\n",
      "SYNONYMS                                                      TIRASEMTIV\n",
      "MOLREGNO_1                                                       1592347\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01709149\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                            phase failure\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                 Amyotrophic Lateral Sclerosis\n",
      "INDICATION_ID                                                    D000690\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           CK-2017357\n",
      "DESCRIPTIONS                       CK-2017357 125 mg tablets twice daily\n",
      "OTHER_NAME                                                    tirasemtiv\n",
      "EFO_ID                                                       EFO:0000253\n",
      "CONDITION                                  Amyotrophic Lateral Sclerosis\n",
      "MOLREGNO                                                           38898\n",
      "NAME_TERM                                  amyotrophic lateral sclerosis\n",
      "Name: 2410, dtype: object\n",
      "_____\n",
      "TWID                                                               21632\n",
      "TWEET_ID                                              933091435678539777\n",
      "TWEET                  Following Phase III failure  @Cytokinetics sus...\n",
      "SYNONYMS                                                      TIRASEMTIV\n",
      "MOLREGNO_1                                                       1592347\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01709149\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                            phase failure\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                 Amyotrophic Lateral Sclerosis\n",
      "INDICATION_ID                                                    D000690\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           CK-2017357\n",
      "DESCRIPTIONS                       CK-2017357 125 mg tablets twice daily\n",
      "OTHER_NAME                                                    tirasemtiv\n",
      "EFO_ID                                                       EFO:0000253\n",
      "CONDITION                                  Amyotrophic Lateral Sclerosis\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                  amyotrophic lateral sclerosis\n",
      "Name: 2411, dtype: object\n",
      "_____\n",
      "TWID                                                               21638\n",
      "TWEET_ID                                              933002813810069504\n",
      "TWEET                   @Cytokinetics Halts Development of #ALS Candi...\n",
      "SYNONYMS                                                      TIRASEMTIV\n",
      "MOLREGNO_1                                                       1592347\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01709149\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                            phase failure\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                 Amyotrophic Lateral Sclerosis\n",
      "INDICATION_ID                                                    D000690\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           CK-2017357\n",
      "DESCRIPTIONS                       CK-2017357 125 mg tablets twice daily\n",
      "OTHER_NAME                                                    tirasemtiv\n",
      "EFO_ID                                                       EFO:0000253\n",
      "CONDITION                                  Amyotrophic Lateral Sclerosis\n",
      "MOLREGNO                                                           38898\n",
      "NAME_TERM                                  amyotrophic lateral sclerosis\n",
      "Name: 2413, dtype: object\n",
      "_____\n",
      "TWID                                                               21638\n",
      "TWEET_ID                                              933002813810069504\n",
      "TWEET                   @Cytokinetics Halts Development of #ALS Candi...\n",
      "SYNONYMS                                                      TIRASEMTIV\n",
      "MOLREGNO_1                                                       1592347\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01709149\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                            phase failure\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                 Amyotrophic Lateral Sclerosis\n",
      "INDICATION_ID                                                    D000690\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           CK-2017357\n",
      "DESCRIPTIONS                       CK-2017357 125 mg tablets twice daily\n",
      "OTHER_NAME                                                    tirasemtiv\n",
      "EFO_ID                                                       EFO:0000253\n",
      "CONDITION                                  Amyotrophic Lateral Sclerosis\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                  amyotrophic lateral sclerosis\n",
      "Name: 2414, dtype: object\n",
      "_____\n",
      "TWID                                                               21901\n",
      "TWEET_ID                                              926908187193892864\n",
      "TWEET                   @AstraZeneca #Asthma Candidate Tralokinumab F...\n",
      "SYNONYMS                                                    TRALOKINUMAB\n",
      "MOLREGNO_1                                                       1121952\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03363854\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                            fails trials \n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                               Neurodermatitis\n",
      "INDICATION_ID                                                    D009450\n",
      "INDICATION_NONAMBIG                                                    0\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Tralokinumab\n",
      "DESCRIPTIONS           Tralokinumab is a human recombinant monoclonal...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000274\n",
      "CONDITION                                              Atopic Dermatitis\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                  atopic eczema\n",
      "Name: 2428, dtype: object\n",
      "_____\n",
      "TWID                                                               21953\n",
      "TWEET_ID                                              925828587814555648\n",
      "TWEET                  #Asthma candidate tralokinumab fails second an...\n",
      "SYNONYMS                                                    TRALOKINUMAB\n",
      "MOLREGNO_1                                                       1121952\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03363854\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                            fails trials \n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                               Neurodermatitis\n",
      "INDICATION_ID                                                    D009450\n",
      "INDICATION_NONAMBIG                                                    0\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Tralokinumab\n",
      "DESCRIPTIONS           Tralokinumab is a human recombinant monoclonal...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000274\n",
      "CONDITION                                              Atopic Dermatitis\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                  atopic eczema\n",
      "Name: 2430, dtype: object\n",
      "_____\n",
      "TWID                                                               21959\n",
      "TWEET_ID                                              925700954107858945\n",
      "TWEET                   @AstraZeneca #Asthma Candidate Tralokinumab F...\n",
      "SYNONYMS                                                    TRALOKINUMAB\n",
      "MOLREGNO_1                                                       1121952\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03363854\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                            fails trials \n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                               Neurodermatitis\n",
      "INDICATION_ID                                                    D009450\n",
      "INDICATION_NONAMBIG                                                    0\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Tralokinumab\n",
      "DESCRIPTIONS           Tralokinumab is a human recombinant monoclonal...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000274\n",
      "CONDITION                                              Atopic Dermatitis\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                  atopic eczema\n",
      "Name: 2432, dtype: object\n",
      "_____\n",
      "TWID                                                               22132\n",
      "TWEET_ID                                              921804560036958209\n",
      "TWEET                   @JNJNews Halts Sirukumab Development Talacotu...\n",
      "SYNONYMS                                                       SIRUKUMAB\n",
      "MOLREGNO_1                                                       1121942\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00718718\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              halts trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                        Polymyalgia Rheumatica\n",
      "INDICATION_ID                                                    D011111\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                      CNTO 136 100 mg\n",
      "DESCRIPTIONS           CNTO 136 100 mg will be administered subcutane...\n",
      "OTHER_NAME                                                     Sirukumab\n",
      "EFO_ID                                                       EFO:0000685\n",
      "CONDITION                                          Arthritis, Rheumatoid\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                           rheumatoid arthritis\n",
      "Name: 2437, dtype: object\n",
      "_____\n",
      "TWID                                                               22132\n",
      "TWEET_ID                                              921804560036958209\n",
      "TWEET                   @JNJNews Halts Sirukumab Development Talacotu...\n",
      "SYNONYMS                                                       SIRUKUMAB\n",
      "MOLREGNO_1                                                       1121942\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00718718\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              halts trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                        Polymyalgia Rheumatica\n",
      "INDICATION_ID                                                    D011111\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                      CNTO 136 100 mg\n",
      "DESCRIPTIONS           CNTO 136 100 mg will be administered subcutane...\n",
      "OTHER_NAME                                                     Sirukumab\n",
      "EFO_ID                                                       EFO:0000685\n",
      "CONDITION                                          Arthritis, Rheumatoid\n",
      "MOLREGNO                                                           49931\n",
      "NAME_TERM                                           rheumatoid arthritis\n",
      "Name: 2438, dtype: object\n",
      "_____\n",
      "TWID                                                               22132\n",
      "TWEET_ID                                              921804560036958209\n",
      "TWEET                   @JNJNews Halts Sirukumab Development Talacotu...\n",
      "SYNONYMS                                                       SIRUKUMAB\n",
      "MOLREGNO_1                                                       1121942\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00718718\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              halts trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                        Polymyalgia Rheumatica\n",
      "INDICATION_ID                                                    D011111\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                       CNTO 136 50 mg\n",
      "DESCRIPTIONS           CNTO 136 50 mg will be administered subcutaneo...\n",
      "OTHER_NAME                                                     Sirukumab\n",
      "EFO_ID                                                       EFO:0000685\n",
      "CONDITION                                          Arthritis, Rheumatoid\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                           rheumatoid arthritis\n",
      "Name: 2440, dtype: object\n",
      "_____\n",
      "TWID                                                               22132\n",
      "TWEET_ID                                              921804560036958209\n",
      "TWEET                   @JNJNews Halts Sirukumab Development Talacotu...\n",
      "SYNONYMS                                                       SIRUKUMAB\n",
      "MOLREGNO_1                                                       1121942\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00718718\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              halts trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                        Polymyalgia Rheumatica\n",
      "INDICATION_ID                                                    D011111\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                       CNTO 136 50 mg\n",
      "DESCRIPTIONS           CNTO 136 50 mg will be administered subcutaneo...\n",
      "OTHER_NAME                                                     Sirukumab\n",
      "EFO_ID                                                       EFO:0000685\n",
      "CONDITION                                          Arthritis, Rheumatoid\n",
      "MOLREGNO                                                           49931\n",
      "NAME_TERM                                           rheumatoid arthritis\n",
      "Name: 2441, dtype: object\n",
      "_____\n",
      "TWID                                                               22132\n",
      "TWEET_ID                                              921804560036958209\n",
      "TWEET                   @JNJNews Halts Sirukumab Development Talacotu...\n",
      "SYNONYMS                                                       SIRUKUMAB\n",
      "MOLREGNO_1                                                       1121942\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00718718\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              halts trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                        Polymyalgia Rheumatica\n",
      "INDICATION_ID                                                    D011111\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                       CNTO 136 25 mg\n",
      "DESCRIPTIONS           CNTO 136 25 mg will be administered subcutaneo...\n",
      "OTHER_NAME                                                     Sirukumab\n",
      "EFO_ID                                                       EFO:0000685\n",
      "CONDITION                                          Arthritis, Rheumatoid\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                           rheumatoid arthritis\n",
      "Name: 2443, dtype: object\n",
      "_____\n",
      "TWID                                                               22132\n",
      "TWEET_ID                                              921804560036958209\n",
      "TWEET                   @JNJNews Halts Sirukumab Development Talacotu...\n",
      "SYNONYMS                                                       SIRUKUMAB\n",
      "MOLREGNO_1                                                       1121942\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00718718\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              halts trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                        Polymyalgia Rheumatica\n",
      "INDICATION_ID                                                    D011111\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                       CNTO 136 25 mg\n",
      "DESCRIPTIONS           CNTO 136 25 mg will be administered subcutaneo...\n",
      "OTHER_NAME                                                     Sirukumab\n",
      "EFO_ID                                                       EFO:0000685\n",
      "CONDITION                                          Arthritis, Rheumatoid\n",
      "MOLREGNO                                                           49931\n",
      "NAME_TERM                                           rheumatoid arthritis\n",
      "Name: 2444, dtype: object\n",
      "_____\n",
      "TWID                                                               22218\n",
      "TWEET_ID                                              920292032689688576\n",
      "TWEET                   @JNJNews Halts Sirukumab Development Talacotu...\n",
      "SYNONYMS                                                       SIRUKUMAB\n",
      "MOLREGNO_1                                                       1121942\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00718718\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              halts trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                        Polymyalgia Rheumatica\n",
      "INDICATION_ID                                                    D011111\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                      CNTO 136 100 mg\n",
      "DESCRIPTIONS           CNTO 136 100 mg will be administered subcutane...\n",
      "OTHER_NAME                                                     Sirukumab\n",
      "EFO_ID                                                       EFO:0000685\n",
      "CONDITION                                          Arthritis, Rheumatoid\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                           rheumatoid arthritis\n",
      "Name: 2450, dtype: object\n",
      "_____\n",
      "TWID                                                               22218\n",
      "TWEET_ID                                              920292032689688576\n",
      "TWEET                   @JNJNews Halts Sirukumab Development Talacotu...\n",
      "SYNONYMS                                                       SIRUKUMAB\n",
      "MOLREGNO_1                                                       1121942\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00718718\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              halts trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                        Polymyalgia Rheumatica\n",
      "INDICATION_ID                                                    D011111\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                      CNTO 136 100 mg\n",
      "DESCRIPTIONS           CNTO 136 100 mg will be administered subcutane...\n",
      "OTHER_NAME                                                     Sirukumab\n",
      "EFO_ID                                                       EFO:0000685\n",
      "CONDITION                                          Arthritis, Rheumatoid\n",
      "MOLREGNO                                                           49931\n",
      "NAME_TERM                                           rheumatoid arthritis\n",
      "Name: 2451, dtype: object\n",
      "_____\n",
      "TWID                                                               22218\n",
      "TWEET_ID                                              920292032689688576\n",
      "TWEET                   @JNJNews Halts Sirukumab Development Talacotu...\n",
      "SYNONYMS                                                       SIRUKUMAB\n",
      "MOLREGNO_1                                                       1121942\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00718718\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              halts trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                        Polymyalgia Rheumatica\n",
      "INDICATION_ID                                                    D011111\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                       CNTO 136 50 mg\n",
      "DESCRIPTIONS           CNTO 136 50 mg will be administered subcutaneo...\n",
      "OTHER_NAME                                                     Sirukumab\n",
      "EFO_ID                                                       EFO:0000685\n",
      "CONDITION                                          Arthritis, Rheumatoid\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                           rheumatoid arthritis\n",
      "Name: 2453, dtype: object\n",
      "_____\n",
      "TWID                                                               22218\n",
      "TWEET_ID                                              920292032689688576\n",
      "TWEET                   @JNJNews Halts Sirukumab Development Talacotu...\n",
      "SYNONYMS                                                       SIRUKUMAB\n",
      "MOLREGNO_1                                                       1121942\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00718718\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              halts trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                        Polymyalgia Rheumatica\n",
      "INDICATION_ID                                                    D011111\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                       CNTO 136 50 mg\n",
      "DESCRIPTIONS           CNTO 136 50 mg will be administered subcutaneo...\n",
      "OTHER_NAME                                                     Sirukumab\n",
      "EFO_ID                                                       EFO:0000685\n",
      "CONDITION                                          Arthritis, Rheumatoid\n",
      "MOLREGNO                                                           49931\n",
      "NAME_TERM                                           rheumatoid arthritis\n",
      "Name: 2454, dtype: object\n",
      "_____\n",
      "TWID                                                               22218\n",
      "TWEET_ID                                              920292032689688576\n",
      "TWEET                   @JNJNews Halts Sirukumab Development Talacotu...\n",
      "SYNONYMS                                                       SIRUKUMAB\n",
      "MOLREGNO_1                                                       1121942\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00718718\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              halts trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                        Polymyalgia Rheumatica\n",
      "INDICATION_ID                                                    D011111\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                       CNTO 136 25 mg\n",
      "DESCRIPTIONS           CNTO 136 25 mg will be administered subcutaneo...\n",
      "OTHER_NAME                                                     Sirukumab\n",
      "EFO_ID                                                       EFO:0000685\n",
      "CONDITION                                          Arthritis, Rheumatoid\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                           rheumatoid arthritis\n",
      "Name: 2456, dtype: object\n",
      "_____\n",
      "TWID                                                               22218\n",
      "TWEET_ID                                              920292032689688576\n",
      "TWEET                   @JNJNews Halts Sirukumab Development Talacotu...\n",
      "SYNONYMS                                                       SIRUKUMAB\n",
      "MOLREGNO_1                                                       1121942\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00718718\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              halts trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                        Polymyalgia Rheumatica\n",
      "INDICATION_ID                                                    D011111\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                       CNTO 136 25 mg\n",
      "DESCRIPTIONS           CNTO 136 25 mg will be administered subcutaneo...\n",
      "OTHER_NAME                                                     Sirukumab\n",
      "EFO_ID                                                       EFO:0000685\n",
      "CONDITION                                          Arthritis, Rheumatoid\n",
      "MOLREGNO                                                           49931\n",
      "NAME_TERM                                           rheumatoid arthritis\n",
      "Name: 2457, dtype: object\n",
      "_____\n",
      "TWID                                                               22225\n",
      "TWEET_ID                                              920105849107959809\n",
      "TWEET                  Dupixent buoyed by positive Phase II results f...\n",
      "SYNONYMS                                                        DUPIXENT\n",
      "MOLREGNO_1                                                       1380941\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02260986\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                         Positive results\n",
      "COMPANY                                                        Regeneron\n",
      "COMPANY_ID                                                     COMP90037\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                       Peanut Hypersensitivity\n",
      "INDICATION_ID                                                    D021183\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Dupilumab\n",
      "DESCRIPTIONS           Subcutaneous injection in the different quadra...\n",
      "OTHER_NAME                                    REGN668;SAR231893;Dupixent\n",
      "EFO_ID                                                       EFO:0000274\n",
      "CONDITION                                              Atopic Dermatitis\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                  atopic eczema\n",
      "Name: 2459, dtype: object\n",
      "_____\n",
      "TWID                                                               22359\n",
      "TWEET_ID                                              917078413990559745\n",
      "TWEET                  #Xarelto Fails Phase III Trial in Embolic #Str...\n",
      "SYNONYMS                                                         XARELTO\n",
      "MOLREGNO_1                                                        328601\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03428373\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              trial fails\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                       Postthrombotic Syndrome\n",
      "INDICATION_ID                                                    D054070\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Rivaroxaban\n",
      "DESCRIPTIONS                                      Rivaroxaban 10mg daily\n",
      "OTHER_NAME                                                       Xarelto\n",
      "EFO_ID                                                       EFO:0001378\n",
      "CONDITION                                     Multiple Myeloma Stage III\n",
      "MOLREGNO                                                            1280\n",
      "NAME_TERM                                               multiple myeloma\n",
      "Name: 2462, dtype: object\n",
      "_____\n",
      "TWID                                                               22359\n",
      "TWEET_ID                                              917078413990559745\n",
      "TWEET                  #Xarelto Fails Phase III Trial in Embolic #Str...\n",
      "SYNONYMS                                                         XARELTO\n",
      "MOLREGNO_1                                                        328601\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03428373\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              trial fails\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                       Postthrombotic Syndrome\n",
      "INDICATION_ID                                                    D054070\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Rivaroxaban\n",
      "DESCRIPTIONS                                      Rivaroxaban 10mg daily\n",
      "OTHER_NAME                                                       Xarelto\n",
      "EFO_ID                                                       EFO:0001378\n",
      "CONDITION                                   Multiple Myeloma Progression\n",
      "MOLREGNO                                                            1280\n",
      "NAME_TERM                                               multiple myeloma\n",
      "Name: 2464, dtype: object\n",
      "_____\n",
      "TWID                                                               22359\n",
      "TWEET_ID                                              917078413990559745\n",
      "TWEET                  #Xarelto Fails Phase III Trial in Embolic #Str...\n",
      "SYNONYMS                                                         XARELTO\n",
      "MOLREGNO_1                                                        328601\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03428373\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              trial fails\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                       Postthrombotic Syndrome\n",
      "INDICATION_ID                                                    D054070\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Rivaroxaban\n",
      "DESCRIPTIONS                                      Rivaroxaban 10mg daily\n",
      "OTHER_NAME                                                       Xarelto\n",
      "EFO_ID                                                       EFO:0001378\n",
      "CONDITION                         Multiple Myeloma With Failed Remission\n",
      "MOLREGNO                                                            1280\n",
      "NAME_TERM                                               multiple myeloma\n",
      "Name: 2466, dtype: object\n",
      "_____\n",
      "TWID                                                               22359\n",
      "TWEET_ID                                              917078413990559745\n",
      "TWEET                  #Xarelto Fails Phase III Trial in Embolic #Str...\n",
      "SYNONYMS                                                         XARELTO\n",
      "MOLREGNO_1                                                        328601\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03428373\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              trial fails\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                       Postthrombotic Syndrome\n",
      "INDICATION_ID                                                    D054070\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Rivaroxaban\n",
      "DESCRIPTIONS                                      Rivaroxaban 10mg daily\n",
      "OTHER_NAME                                                       Xarelto\n",
      "EFO_ID                                                       EFO:0001378\n",
      "CONDITION                                      Multiple Myeloma Stage II\n",
      "MOLREGNO                                                            1280\n",
      "NAME_TERM                                               multiple myeloma\n",
      "Name: 2468, dtype: object\n",
      "_____\n",
      "TWID                                                               22359\n",
      "TWEET_ID                                              917078413990559745\n",
      "TWEET                  #Xarelto Fails Phase III Trial in Embolic #Str...\n",
      "SYNONYMS                                                         XARELTO\n",
      "MOLREGNO_1                                                        328601\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03428373\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              trial fails\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                       Postthrombotic Syndrome\n",
      "INDICATION_ID                                                    D054070\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Rivaroxaban\n",
      "DESCRIPTIONS                                      Rivaroxaban 10mg daily\n",
      "OTHER_NAME                                                       Xarelto\n",
      "EFO_ID                                                       EFO:0001378\n",
      "CONDITION                                    Multiple Myeloma in Relapse\n",
      "MOLREGNO                                                            1280\n",
      "NAME_TERM                                               multiple myeloma\n",
      "Name: 2470, dtype: object\n",
      "_____\n",
      "TWID                                                               22359\n",
      "TWEET_ID                                              917078413990559745\n",
      "TWEET                  #Xarelto Fails Phase III Trial in Embolic #Str...\n",
      "SYNONYMS                                                         XARELTO\n",
      "MOLREGNO_1                                                        328601\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03428373\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              trial fails\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                       Postthrombotic Syndrome\n",
      "INDICATION_ID                                                    D054070\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Rivaroxaban\n",
      "DESCRIPTIONS                                      Rivaroxaban 10mg daily\n",
      "OTHER_NAME                                                       Xarelto\n",
      "EFO_ID                                                       EFO:0001378\n",
      "CONDITION                                       Multiple Myeloma Stage I\n",
      "MOLREGNO                                                            1280\n",
      "NAME_TERM                                               multiple myeloma\n",
      "Name: 2472, dtype: object\n",
      "_____\n",
      "TWID                                                               22400\n",
      "TWEET_ID                                              916406489853583361\n",
      "TWEET                   @Bayer @JanssenGlobal acknowledge failure of ...\n",
      "SYNONYMS                                                         XARELTO\n",
      "MOLREGNO_1                                                        328601\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03428373\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         failure in trial\n",
      "COMPANY                                                   Bayer-Schering\n",
      "COMPANY_ID                                                       COMP105\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                       Postthrombotic Syndrome\n",
      "INDICATION_ID                                                    D054070\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Rivaroxaban\n",
      "DESCRIPTIONS                                      Rivaroxaban 10mg daily\n",
      "OTHER_NAME                                                       Xarelto\n",
      "EFO_ID                                                       EFO:0001378\n",
      "CONDITION                                     Multiple Myeloma Stage III\n",
      "MOLREGNO                                                            1280\n",
      "NAME_TERM                                               multiple myeloma\n",
      "Name: 2474, dtype: object\n",
      "_____\n",
      "TWID                                                               22400\n",
      "TWEET_ID                                              916406489853583361\n",
      "TWEET                   @Bayer @JanssenGlobal acknowledge failure of ...\n",
      "SYNONYMS                                                         XARELTO\n",
      "MOLREGNO_1                                                        328601\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03428373\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         failure in trial\n",
      "COMPANY                                                   Bayer-Schering\n",
      "COMPANY_ID                                                       COMP105\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                       Postthrombotic Syndrome\n",
      "INDICATION_ID                                                    D054070\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Rivaroxaban\n",
      "DESCRIPTIONS                                      Rivaroxaban 10mg daily\n",
      "OTHER_NAME                                                       Xarelto\n",
      "EFO_ID                                                       EFO:0001378\n",
      "CONDITION                                   Multiple Myeloma Progression\n",
      "MOLREGNO                                                            1280\n",
      "NAME_TERM                                               multiple myeloma\n",
      "Name: 2476, dtype: object\n",
      "_____\n",
      "TWID                                                               22400\n",
      "TWEET_ID                                              916406489853583361\n",
      "TWEET                   @Bayer @JanssenGlobal acknowledge failure of ...\n",
      "SYNONYMS                                                         XARELTO\n",
      "MOLREGNO_1                                                        328601\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03428373\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         failure in trial\n",
      "COMPANY                                                   Bayer-Schering\n",
      "COMPANY_ID                                                       COMP105\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                       Postthrombotic Syndrome\n",
      "INDICATION_ID                                                    D054070\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Rivaroxaban\n",
      "DESCRIPTIONS                                      Rivaroxaban 10mg daily\n",
      "OTHER_NAME                                                       Xarelto\n",
      "EFO_ID                                                       EFO:0001378\n",
      "CONDITION                         Multiple Myeloma With Failed Remission\n",
      "MOLREGNO                                                            1280\n",
      "NAME_TERM                                               multiple myeloma\n",
      "Name: 2478, dtype: object\n",
      "_____\n",
      "TWID                                                               22400\n",
      "TWEET_ID                                              916406489853583361\n",
      "TWEET                   @Bayer @JanssenGlobal acknowledge failure of ...\n",
      "SYNONYMS                                                         XARELTO\n",
      "MOLREGNO_1                                                        328601\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03428373\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         failure in trial\n",
      "COMPANY                                                   Bayer-Schering\n",
      "COMPANY_ID                                                       COMP105\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                       Postthrombotic Syndrome\n",
      "INDICATION_ID                                                    D054070\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Rivaroxaban\n",
      "DESCRIPTIONS                                      Rivaroxaban 10mg daily\n",
      "OTHER_NAME                                                       Xarelto\n",
      "EFO_ID                                                       EFO:0001378\n",
      "CONDITION                                      Multiple Myeloma Stage II\n",
      "MOLREGNO                                                            1280\n",
      "NAME_TERM                                               multiple myeloma\n",
      "Name: 2480, dtype: object\n",
      "_____\n",
      "TWID                                                               22400\n",
      "TWEET_ID                                              916406489853583361\n",
      "TWEET                   @Bayer @JanssenGlobal acknowledge failure of ...\n",
      "SYNONYMS                                                         XARELTO\n",
      "MOLREGNO_1                                                        328601\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03428373\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         failure in trial\n",
      "COMPANY                                                   Bayer-Schering\n",
      "COMPANY_ID                                                       COMP105\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                       Postthrombotic Syndrome\n",
      "INDICATION_ID                                                    D054070\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Rivaroxaban\n",
      "DESCRIPTIONS                                      Rivaroxaban 10mg daily\n",
      "OTHER_NAME                                                       Xarelto\n",
      "EFO_ID                                                       EFO:0001378\n",
      "CONDITION                                    Multiple Myeloma in Relapse\n",
      "MOLREGNO                                                            1280\n",
      "NAME_TERM                                               multiple myeloma\n",
      "Name: 2482, dtype: object\n",
      "_____\n",
      "TWID                                                               22400\n",
      "TWEET_ID                                              916406489853583361\n",
      "TWEET                   @Bayer @JanssenGlobal acknowledge failure of ...\n",
      "SYNONYMS                                                         XARELTO\n",
      "MOLREGNO_1                                                        328601\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03428373\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                         failure in trial\n",
      "COMPANY                                                   Bayer-Schering\n",
      "COMPANY_ID                                                       COMP105\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                       Postthrombotic Syndrome\n",
      "INDICATION_ID                                                    D054070\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Rivaroxaban\n",
      "DESCRIPTIONS                                      Rivaroxaban 10mg daily\n",
      "OTHER_NAME                                                       Xarelto\n",
      "EFO_ID                                                       EFO:0001378\n",
      "CONDITION                                       Multiple Myeloma Stage I\n",
      "MOLREGNO                                                            1280\n",
      "NAME_TERM                                               multiple myeloma\n",
      "Name: 2484, dtype: object\n",
      "_____\n",
      "TWID                                                               22407\n",
      "TWEET_ID                                              916310827677908993\n",
      "TWEET                  #Xarelto Fails Phase III Trial in Embolic #Str...\n",
      "SYNONYMS                                                         XARELTO\n",
      "MOLREGNO_1                                                        328601\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03428373\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              trial fails\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                       Postthrombotic Syndrome\n",
      "INDICATION_ID                                                    D054070\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Rivaroxaban\n",
      "DESCRIPTIONS                                      Rivaroxaban 10mg daily\n",
      "OTHER_NAME                                                       Xarelto\n",
      "EFO_ID                                                       EFO:0001378\n",
      "CONDITION                                     Multiple Myeloma Stage III\n",
      "MOLREGNO                                                            1280\n",
      "NAME_TERM                                               multiple myeloma\n",
      "Name: 2486, dtype: object\n",
      "_____\n",
      "TWID                                                               22407\n",
      "TWEET_ID                                              916310827677908993\n",
      "TWEET                  #Xarelto Fails Phase III Trial in Embolic #Str...\n",
      "SYNONYMS                                                         XARELTO\n",
      "MOLREGNO_1                                                        328601\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03428373\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              trial fails\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                       Postthrombotic Syndrome\n",
      "INDICATION_ID                                                    D054070\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Rivaroxaban\n",
      "DESCRIPTIONS                                      Rivaroxaban 10mg daily\n",
      "OTHER_NAME                                                       Xarelto\n",
      "EFO_ID                                                       EFO:0001378\n",
      "CONDITION                                   Multiple Myeloma Progression\n",
      "MOLREGNO                                                            1280\n",
      "NAME_TERM                                               multiple myeloma\n",
      "Name: 2488, dtype: object\n",
      "_____\n",
      "TWID                                                               22407\n",
      "TWEET_ID                                              916310827677908993\n",
      "TWEET                  #Xarelto Fails Phase III Trial in Embolic #Str...\n",
      "SYNONYMS                                                         XARELTO\n",
      "MOLREGNO_1                                                        328601\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03428373\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              trial fails\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                       Postthrombotic Syndrome\n",
      "INDICATION_ID                                                    D054070\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Rivaroxaban\n",
      "DESCRIPTIONS                                      Rivaroxaban 10mg daily\n",
      "OTHER_NAME                                                       Xarelto\n",
      "EFO_ID                                                       EFO:0001378\n",
      "CONDITION                         Multiple Myeloma With Failed Remission\n",
      "MOLREGNO                                                            1280\n",
      "NAME_TERM                                               multiple myeloma\n",
      "Name: 2490, dtype: object\n",
      "_____\n",
      "TWID                                                               22407\n",
      "TWEET_ID                                              916310827677908993\n",
      "TWEET                  #Xarelto Fails Phase III Trial in Embolic #Str...\n",
      "SYNONYMS                                                         XARELTO\n",
      "MOLREGNO_1                                                        328601\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03428373\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              trial fails\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                       Postthrombotic Syndrome\n",
      "INDICATION_ID                                                    D054070\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Rivaroxaban\n",
      "DESCRIPTIONS                                      Rivaroxaban 10mg daily\n",
      "OTHER_NAME                                                       Xarelto\n",
      "EFO_ID                                                       EFO:0001378\n",
      "CONDITION                                      Multiple Myeloma Stage II\n",
      "MOLREGNO                                                            1280\n",
      "NAME_TERM                                               multiple myeloma\n",
      "Name: 2492, dtype: object\n",
      "_____\n",
      "TWID                                                               22407\n",
      "TWEET_ID                                              916310827677908993\n",
      "TWEET                  #Xarelto Fails Phase III Trial in Embolic #Str...\n",
      "SYNONYMS                                                         XARELTO\n",
      "MOLREGNO_1                                                        328601\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03428373\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              trial fails\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                       Postthrombotic Syndrome\n",
      "INDICATION_ID                                                    D054070\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Rivaroxaban\n",
      "DESCRIPTIONS                                      Rivaroxaban 10mg daily\n",
      "OTHER_NAME                                                       Xarelto\n",
      "EFO_ID                                                       EFO:0001378\n",
      "CONDITION                                    Multiple Myeloma in Relapse\n",
      "MOLREGNO                                                            1280\n",
      "NAME_TERM                                               multiple myeloma\n",
      "Name: 2494, dtype: object\n",
      "_____\n",
      "TWID                                                               22407\n",
      "TWEET_ID                                              916310827677908993\n",
      "TWEET                  #Xarelto Fails Phase III Trial in Embolic #Str...\n",
      "SYNONYMS                                                         XARELTO\n",
      "MOLREGNO_1                                                        328601\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03428373\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                              trial fails\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                       Postthrombotic Syndrome\n",
      "INDICATION_ID                                                    D054070\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Rivaroxaban\n",
      "DESCRIPTIONS                                      Rivaroxaban 10mg daily\n",
      "OTHER_NAME                                                       Xarelto\n",
      "EFO_ID                                                       EFO:0001378\n",
      "CONDITION                                       Multiple Myeloma Stage I\n",
      "MOLREGNO                                                            1280\n",
      "NAME_TERM                                               multiple myeloma\n",
      "Name: 2496, dtype: object\n",
      "_____\n",
      "TWID                                                               25892\n",
      "TWEET_ID                                              996019340599283712\n",
      "TWEET                  China's CStone ramps up yet another PD-1 clini...\n",
      "SYNONYMS                                                             PD1\n",
      "MOLREGNO_1                                                       2197878\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03374293\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                                 Ramps up\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                   Solid Tumor\n",
      "INDICATION_ID                                                    SDI0034\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                   Anti-PD-1 Antibody\n",
      "DESCRIPTIONS           Anti-PD-1 antibody (every 2 weeks for 5 cycles...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0002618\n",
      "CONDITION                                              Pancreatic Cancer\n",
      "MOLREGNO                                                            Null\n",
      "NAME_TERM                                           pancreatic carcinoma\n",
      "Name: 2499, dtype: object\n",
      "_____\n",
      "TWID                                                               29085\n",
      "TWEET_ID                                              995716579970207750\n",
      "TWEET                   @AstraZeneca Weighs Expanding Fasenra to #COP...\n",
      "SYNONYMS                                                         FASENRA\n",
      "MOLREGNO_1                                                       1121862\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03473977\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                            phase failure\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                         Chronic Obstructive Pulmonary Disease\n",
      "INDICATION_ID                                                    D029424\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                             Biological\n",
      "INTERVENTION_NAME_x                                         Benralizumab\n",
      "DESCRIPTIONS           Monoclonal antibody originally developed for t...\n",
      "OTHER_NAME                                                       Fasenra\n",
      "EFO_ID                                                       EFO:1001463\n",
      "CONDITION                      Eosinophilic Gastritis or Gastroenteritis\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                gastroenteritis\n",
      "Name: 2501, dtype: object\n",
      "_____\n",
      "TWID                                                               29085\n",
      "TWEET_ID                                              995716579970207750\n",
      "TWEET                   @AstraZeneca Weighs Expanding Fasenra to #COP...\n",
      "SYNONYMS                                                         FASENRA\n",
      "MOLREGNO_1                                                       1121862\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03473977\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                            phase failure\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                         Chronic Obstructive Pulmonary Disease\n",
      "INDICATION_ID                                                    D029424\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                             Biological\n",
      "INTERVENTION_NAME_x                                         Benralizumab\n",
      "DESCRIPTIONS           Monoclonal antibody originally developed for t...\n",
      "OTHER_NAME                                                       Fasenra\n",
      "EFO_ID                                                       EFO:0000217\n",
      "CONDITION                      Eosinophilic Gastritis or Gastroenteritis\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                      gastritis\n",
      "Name: 2503, dtype: object\n",
      "_____\n",
      "TWID                                                               29120\n",
      "TWEET_ID                                              995044652440084480\n",
      "TWEET                  After Phase III failure @AstraZeneca awaits re...\n",
      "SYNONYMS                                                         FASENRA\n",
      "MOLREGNO_1                                                       1121862\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03473977\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               3\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                            phase failure\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                         Chronic Obstructive Pulmonary Disease\n",
      "INDICATION_ID                                                    D029424\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                             Biological\n",
      "INTERVENTION_NAME_x                                         Benralizumab\n",
      "DESCRIPTIONS           Monoclonal antibody originally developed for t...\n",
      "OTHER_NAME                                                       Fasenra\n",
      "EFO_ID                                                       EFO:1001463\n",
      "CONDITION                      Eosinophilic Gastritis or Gastroenteritis\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                gastroenteritis\n",
      "Name: 2505, dtype: object\n",
      "_____\n",
      "TWID                                                               29120\n",
      "TWEET_ID                                              995044652440084480\n",
      "TWEET                  After Phase III failure @AstraZeneca awaits re...\n",
      "SYNONYMS                                                         FASENRA\n",
      "MOLREGNO_1                                                       1121862\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03473977\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               3\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                            phase failure\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                         Chronic Obstructive Pulmonary Disease\n",
      "INDICATION_ID                                                    D029424\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                             Biological\n",
      "INTERVENTION_NAME_x                                         Benralizumab\n",
      "DESCRIPTIONS           Monoclonal antibody originally developed for t...\n",
      "OTHER_NAME                                                       Fasenra\n",
      "EFO_ID                                                       EFO:0000217\n",
      "CONDITION                      Eosinophilic Gastritis or Gastroenteritis\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                      gastritis\n",
      "Name: 2507, dtype: object\n",
      "_____\n",
      "TWID                                                               41983\n",
      "TWEET_ID                                             1003424645553557504\n",
      "TWEET                  Final overall survival data of phase 3 TAILOR ...\n",
      "SYNONYMS                                                       CETUXIMAB\n",
      "MOLREGNO_1                                                        675579\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03391843\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                  confirmed as effective standard of care\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Rectal Neoplasms\n",
      "INDICATION_ID                                                    D012004\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                          FOLFOXIRI+Cetuximab regimen\n",
      "DESCRIPTIONS           FOLFOXIRI+Cetuximab Irinotecan 165 mg/m² + oxa...\n",
      "OTHER_NAME                 CPT 11,CAMPTO，Eloxatin，Xelod，Eloxatin,Erbitux\n",
      "EFO_ID                                                       EFO:1000657\n",
      "CONDITION                                        Rectal Cancer Stage III\n",
      "MOLREGNO                                                          243124\n",
      "NAME_TERM                                                  rectum cancer\n",
      "Name: 2512, dtype: object\n",
      "_____\n",
      "TWID                                                               41983\n",
      "TWEET_ID                                             1003424645553557504\n",
      "TWEET                  Final overall survival data of phase 3 TAILOR ...\n",
      "SYNONYMS                                                       CETUXIMAB\n",
      "MOLREGNO_1                                                        675579\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03391843\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                  confirmed as effective standard of care\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Rectal Neoplasms\n",
      "INDICATION_ID                                                    D012004\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                          FOLFOXIRI+Cetuximab regimen\n",
      "DESCRIPTIONS           FOLFOXIRI+Cetuximab Irinotecan 165 mg/m² + oxa...\n",
      "OTHER_NAME                 CPT 11,CAMPTO，Eloxatin，Xelod，Eloxatin,Erbitux\n",
      "EFO_ID                                                       EFO:1000657\n",
      "CONDITION                                        Rectal Cancer Stage III\n",
      "MOLREGNO                                                          368538\n",
      "NAME_TERM                                                  rectum cancer\n",
      "Name: 2513, dtype: object\n",
      "_____\n",
      "TWID                                                               41983\n",
      "TWEET_ID                                             1003424645553557504\n",
      "TWEET                  Final overall survival data of phase 3 TAILOR ...\n",
      "SYNONYMS                                                       CETUXIMAB\n",
      "MOLREGNO_1                                                        675579\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03391843\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                  confirmed as effective standard of care\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Rectal Neoplasms\n",
      "INDICATION_ID                                                    D012004\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                          FOLFOXIRI+Cetuximab regimen\n",
      "DESCRIPTIONS           FOLFOXIRI+Cetuximab Irinotecan 165 mg/m² + oxa...\n",
      "OTHER_NAME                 CPT 11,CAMPTO，Eloxatin，Xelod，Eloxatin,Erbitux\n",
      "EFO_ID                                                       EFO:1000657\n",
      "CONDITION                                        Rectal Cancer Stage III\n",
      "MOLREGNO                                                          675089\n",
      "NAME_TERM                                                  rectum cancer\n",
      "Name: 2514, dtype: object\n",
      "_____\n",
      "TWID                                                               41983\n",
      "TWEET_ID                                             1003424645553557504\n",
      "TWEET                  Final overall survival data of phase 3 TAILOR ...\n",
      "SYNONYMS                                                       CETUXIMAB\n",
      "MOLREGNO_1                                                        675579\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03391843\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                  confirmed as effective standard of care\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Rectal Neoplasms\n",
      "INDICATION_ID                                                    D012004\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                          FOLFOXIRI+Cetuximab regimen\n",
      "DESCRIPTIONS           FOLFOXIRI+Cetuximab Irinotecan 165 mg/m² + oxa...\n",
      "OTHER_NAME                 CPT 11,CAMPTO，Eloxatin，Xelod，Eloxatin,Erbitux\n",
      "EFO_ID                                                       EFO:1000657\n",
      "CONDITION                                        Rectal Cancer Stage III\n",
      "MOLREGNO                                                            5985\n",
      "NAME_TERM                                                  rectum cancer\n",
      "Name: 2515, dtype: object\n",
      "_____\n",
      "TWID                                                               41994\n",
      "TWEET_ID                                             1003011681528754177\n",
      "TWEET                  Ivosidenib induces durable responses (ORR 42% ...\n",
      "SYNONYMS                                                      IVOSIDENIB\n",
      "MOLREGNO_1                                                       2197829\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03173248\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           well tolerated\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                        Acute Myeloid Leukemia\n",
      "INDICATION_ID                                                    D015470\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                 AG-120 (ivosidenib) with Azacitidine\n",
      "DESCRIPTIONS           Continuous 28-day cycles of AG-120 (ivosidenib...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000222\n",
      "CONDITION                                       Leukemia, Myeloid, Acute\n",
      "MOLREGNO                                                          418401\n",
      "NAME_TERM                                         acute myeloid leukemia\n",
      "Name: 2518, dtype: object\n",
      "_____\n",
      "TWID                                                               41994\n",
      "TWEET_ID                                             1003011681528754177\n",
      "TWEET                  Ivosidenib induces durable responses (ORR 42% ...\n",
      "SYNONYMS                                                      IVOSIDENIB\n",
      "MOLREGNO_1                                                       2197829\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03173248\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           well tolerated\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                        Acute Myeloid Leukemia\n",
      "INDICATION_ID                                                    D015470\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                 AG-120 (ivosidenib) with Azacitidine\n",
      "DESCRIPTIONS           Continuous 28-day cycles of AG-120 (ivosidenib...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000222\n",
      "CONDITION                                       Leukemia, Myeloid, Acute\n",
      "MOLREGNO                                                        -ABSENT-\n",
      "NAME_TERM                                         acute myeloid leukemia\n",
      "Name: 2519, dtype: object\n",
      "_____\n",
      "TWID                                                               41994\n",
      "TWEET_ID                                             1003011681528754177\n",
      "TWEET                  Ivosidenib induces durable responses (ORR 42% ...\n",
      "SYNONYMS                                                      IVOSIDENIB\n",
      "MOLREGNO_1                                                       2197829\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03173248\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           well tolerated\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                        Acute Myeloid Leukemia\n",
      "INDICATION_ID                                                    D015470\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                 AG-120 (ivosidenib) with Azacitidine\n",
      "DESCRIPTIONS           Continuous 28-day cycles of AG-120 (ivosidenib...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000222\n",
      "CONDITION                                                  Untreated AML\n",
      "MOLREGNO                                                          418401\n",
      "NAME_TERM                                         acute myeloid leukemia\n",
      "Name: 2520, dtype: object\n",
      "_____\n",
      "TWID                                                               41994\n",
      "TWEET_ID                                             1003011681528754177\n",
      "TWEET                  Ivosidenib induces durable responses (ORR 42% ...\n",
      "SYNONYMS                                                      IVOSIDENIB\n",
      "MOLREGNO_1                                                       2197829\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03173248\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           well tolerated\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                        Acute Myeloid Leukemia\n",
      "INDICATION_ID                                                    D015470\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                 AG-120 (ivosidenib) with Azacitidine\n",
      "DESCRIPTIONS           Continuous 28-day cycles of AG-120 (ivosidenib...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000222\n",
      "CONDITION                                                  Untreated AML\n",
      "MOLREGNO                                                        -ABSENT-\n",
      "NAME_TERM                                         acute myeloid leukemia\n",
      "Name: 2521, dtype: object\n",
      "_____\n",
      "TWID                                                               41994\n",
      "TWEET_ID                                             1003011681528754177\n",
      "TWEET                  Ivosidenib induces durable responses (ORR 42% ...\n",
      "SYNONYMS                                                      IVOSIDENIB\n",
      "MOLREGNO_1                                                       2197829\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03173248\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           well tolerated\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                        Acute Myeloid Leukemia\n",
      "INDICATION_ID                                                    D015470\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                 AG-120 (ivosidenib) with Azacitidine\n",
      "DESCRIPTIONS           Continuous 28-day cycles of AG-120 (ivosidenib...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000222\n",
      "CONDITION                AML Arising From Myelodysplastic Syndrome (MDS)\n",
      "MOLREGNO                                                          418401\n",
      "NAME_TERM                                         acute myeloid leukemia\n",
      "Name: 2522, dtype: object\n",
      "_____\n",
      "TWID                                                               41994\n",
      "TWEET_ID                                             1003011681528754177\n",
      "TWEET                  Ivosidenib induces durable responses (ORR 42% ...\n",
      "SYNONYMS                                                      IVOSIDENIB\n",
      "MOLREGNO_1                                                       2197829\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03173248\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           well tolerated\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                        Acute Myeloid Leukemia\n",
      "INDICATION_ID                                                    D015470\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                 AG-120 (ivosidenib) with Azacitidine\n",
      "DESCRIPTIONS           Continuous 28-day cycles of AG-120 (ivosidenib...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000222\n",
      "CONDITION                AML Arising From Myelodysplastic Syndrome (MDS)\n",
      "MOLREGNO                                                        -ABSENT-\n",
      "NAME_TERM                                         acute myeloid leukemia\n",
      "Name: 2523, dtype: object\n",
      "_____\n",
      "TWID                                                               41994\n",
      "TWEET_ID                                             1003011681528754177\n",
      "TWEET                  Ivosidenib induces durable responses (ORR 42% ...\n",
      "SYNONYMS                                                      IVOSIDENIB\n",
      "MOLREGNO_1                                                       2197829\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03173248\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           well tolerated\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                        Acute Myeloid Leukemia\n",
      "INDICATION_ID                                                    D015470\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                 AG-120 (ivosidenib) with Azacitidine\n",
      "DESCRIPTIONS           Continuous 28-day cycles of AG-120 (ivosidenib...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000222\n",
      "CONDITION                   Newly Diagnosed Acute Myeloid Leukemia (AML)\n",
      "MOLREGNO                                                          418401\n",
      "NAME_TERM                                         acute myeloid leukemia\n",
      "Name: 2524, dtype: object\n",
      "_____\n",
      "TWID                                                               41994\n",
      "TWEET_ID                                             1003011681528754177\n",
      "TWEET                  Ivosidenib induces durable responses (ORR 42% ...\n",
      "SYNONYMS                                                      IVOSIDENIB\n",
      "MOLREGNO_1                                                       2197829\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03173248\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           well tolerated\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                        Acute Myeloid Leukemia\n",
      "INDICATION_ID                                                    D015470\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                 AG-120 (ivosidenib) with Azacitidine\n",
      "DESCRIPTIONS           Continuous 28-day cycles of AG-120 (ivosidenib...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000222\n",
      "CONDITION                   Newly Diagnosed Acute Myeloid Leukemia (AML)\n",
      "MOLREGNO                                                        -ABSENT-\n",
      "NAME_TERM                                         acute myeloid leukemia\n",
      "Name: 2525, dtype: object\n",
      "_____\n",
      "TWID                                                               41995\n",
      "TWEET_ID                                             1002966782523727872\n",
      "TWEET                  Loxo Oncology's RET inhibitor LOXO292 - robust...\n",
      "SYNONYMS                                                         THYROID\n",
      "MOLREGNO_1                                                       1381144\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01950260\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           Positive trial\n",
      "COMPANY                                                    Loxo Oncology\n",
      "COMPANY_ID                                                     COMP93848\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                 Non-Small-Cell Lung Carcinoma\n",
      "INDICATION_ID                                                    D002289\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Levothyroxine\n",
      "DESCRIPTIONS           Early initiation of levothyroxine after radioa...\n",
      "OTHER_NAME                                               Thyroid hormone\n",
      "EFO_ID                                                       EFO:0004237\n",
      "CONDITION                                                Graves' Disease\n",
      "MOLREGNO                                                          469690\n",
      "NAME_TERM                                                 Graves disease\n",
      "Name: 2526, dtype: object\n",
      "_____\n",
      "TWID                                                               41995\n",
      "TWEET_ID                                             1002966782523727872\n",
      "TWEET                  Loxo Oncology's RET inhibitor LOXO292 - robust...\n",
      "SYNONYMS                                                         THYROID\n",
      "MOLREGNO_1                                                       1381144\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01950260\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                           Positive trial\n",
      "COMPANY                                                    Loxo Oncology\n",
      "COMPANY_ID                                                     COMP93848\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                 Non-Small-Cell Lung Carcinoma\n",
      "INDICATION_ID                                                    D002289\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        Levothyroxine\n",
      "DESCRIPTIONS           Early initiation of levothyroxine after radioa...\n",
      "OTHER_NAME                                               Thyroid hormone\n",
      "EFO_ID                                                       EFO:0004237\n",
      "CONDITION                                                Graves' Disease\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                 Graves disease\n",
      "Name: 2527, dtype: object\n",
      "_____\n",
      "TWID                                                               48445\n",
      "TWEET_ID                                             1002956795957129219\n",
      "TWEET                  After Second Phase III Failure Retreats from #...\n",
      "SYNONYMS                                                         FASENRA\n",
      "MOLREGNO_1                                                       1121862\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03473977\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                            phase failure\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                         Chronic Obstructive Pulmonary Disease\n",
      "INDICATION_ID                                                    D029424\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                             Biological\n",
      "INTERVENTION_NAME_x                                         Benralizumab\n",
      "DESCRIPTIONS           Monoclonal antibody originally developed for t...\n",
      "OTHER_NAME                                                       Fasenra\n",
      "EFO_ID                                                       EFO:1001463\n",
      "CONDITION                      Eosinophilic Gastritis or Gastroenteritis\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                gastroenteritis\n",
      "Name: 2534, dtype: object\n",
      "_____\n",
      "TWID                                                               48445\n",
      "TWEET_ID                                             1002956795957129219\n",
      "TWEET                  After Second Phase III Failure Retreats from #...\n",
      "SYNONYMS                                                         FASENRA\n",
      "MOLREGNO_1                                                       1121862\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03473977\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                            phase failure\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                         Chronic Obstructive Pulmonary Disease\n",
      "INDICATION_ID                                                    D029424\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                             Biological\n",
      "INTERVENTION_NAME_x                                         Benralizumab\n",
      "DESCRIPTIONS           Monoclonal antibody originally developed for t...\n",
      "OTHER_NAME                                                       Fasenra\n",
      "EFO_ID                                                       EFO:0000217\n",
      "CONDITION                      Eosinophilic Gastritis or Gastroenteritis\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                      gastritis\n",
      "Name: 2536, dtype: object\n",
      "_____\n",
      "TWID                                                               48460\n",
      "TWEET_ID                                             1002654800264204290\n",
      "TWEET                  Development of spinal muscular atrophy candida...\n",
      "SYNONYMS                                                           ROCHE\n",
      "MOLREGNO_1                                                        469217\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03448666\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          STOPPED\n",
      "MATCHED_OUTCOME                                       Development halted\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                       Spinal Muscular Atrophy\n",
      "INDICATION_ID                                                    D009134\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                    Combination Product\n",
      "INTERVENTION_NAME_x                                        Pembrolizumab\n",
      "DESCRIPTIONS           Electrochemotherapy will be performed with the...\n",
      "OTHER_NAME                                           Electrochemotherapy\n",
      "EFO_ID                                                       EFO:0000756\n",
      "CONDITION                                             Malignant Melanoma\n",
      "MOLREGNO                                                         1626777\n",
      "NAME_TERM                                                       melanoma\n",
      "Name: 2538, dtype: object\n",
      "_____\n",
      "TWID                                                               48501\n",
      "TWEET_ID                                             1001833864392839168\n",
      "TWEET                  After Second Phase III Failure @AstraZeneca Re...\n",
      "SYNONYMS                                                         FASENRA\n",
      "MOLREGNO_1                                                       1121862\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03473977\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                            phase failure\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                         Chronic Obstructive Pulmonary Disease\n",
      "INDICATION_ID                                                    D029424\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                             Biological\n",
      "INTERVENTION_NAME_x                                         Benralizumab\n",
      "DESCRIPTIONS           Monoclonal antibody originally developed for t...\n",
      "OTHER_NAME                                                       Fasenra\n",
      "EFO_ID                                                       EFO:1001463\n",
      "CONDITION                      Eosinophilic Gastritis or Gastroenteritis\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                gastroenteritis\n",
      "Name: 2541, dtype: object\n",
      "_____\n",
      "TWID                                                               48501\n",
      "TWEET_ID                                             1001833864392839168\n",
      "TWEET                  After Second Phase III Failure @AstraZeneca Re...\n",
      "SYNONYMS                                                         FASENRA\n",
      "MOLREGNO_1                                                       1121862\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03473977\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                            phase failure\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                         Chronic Obstructive Pulmonary Disease\n",
      "INDICATION_ID                                                    D029424\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                             Biological\n",
      "INTERVENTION_NAME_x                                         Benralizumab\n",
      "DESCRIPTIONS           Monoclonal antibody originally developed for t...\n",
      "OTHER_NAME                                                       Fasenra\n",
      "EFO_ID                                                       EFO:0000217\n",
      "CONDITION                      Eosinophilic Gastritis or Gastroenteritis\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                      gastritis\n",
      "Name: 2543, dtype: object\n",
      "_____\n",
      "TWID                                                               51675\n",
      "TWEET_ID                                             1005358837925400576\n",
      "TWEET                  Positive Ph2 results for ridinilazole in C Dif...\n",
      "SYNONYMS                                                     FIDAXOMICIN\n",
      "MOLREGNO_1                                                        704780\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02218372\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                         Positive results\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                Pseudomembranous Enterocolitis\n",
      "INDICATION_ID                                                    D004761\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Fidaxomicin\n",
      "DESCRIPTIONS           Oral suspension to be given to patients from b...\n",
      "OTHER_NAME                                              Dificlir;Dificid\n",
      "EFO_ID                                                        HP:0002014\n",
      "CONDITION               Clostridium Difficile-associated Diarrhea (CDAD)\n",
      "MOLREGNO                                                           70140\n",
      "NAME_TERM                                                       diarrhea\n",
      "Name: 2550, dtype: object\n",
      "_____\n",
      "TWID                                                               51675\n",
      "TWEET_ID                                             1005358837925400576\n",
      "TWEET                  Positive Ph2 results for ridinilazole in C Dif...\n",
      "SYNONYMS                                                     FIDAXOMICIN\n",
      "MOLREGNO_1                                                        704780\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02218372\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                         Positive results\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                Pseudomembranous Enterocolitis\n",
      "INDICATION_ID                                                    D004761\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Fidaxomicin\n",
      "DESCRIPTIONS           Oral suspension to be given to patients from b...\n",
      "OTHER_NAME                                              Dificlir;Dificid\n",
      "EFO_ID                                                       EFO:1000874\n",
      "CONDITION               Clostridium Difficile-associated Diarrhea (CDAD)\n",
      "MOLREGNO                                                           70140\n",
      "NAME_TERM                       commensal Clostridium infectious disease\n",
      "Name: 2552, dtype: object\n",
      "_____\n",
      "TWID                                                               51685\n",
      "TWEET_ID                                             1004677517305892870\n",
      "TWEET                  Alkermes earns $50 million fee from Biogen tri...\n",
      "SYNONYMS                                              DIROXIMEL FUMARATE\n",
      "MOLREGNO_1                                                       2197815\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                              Null\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                                Earns fee\n",
      "COMPANY                                                      Biogen IDEC\n",
      "COMPANY_ID                                                       COMP118\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                     Psoriasis\n",
      "INDICATION_ID                                                    D011565\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Null\n",
      "INTERVENTION_NAME_x                                                 Null\n",
      "DESCRIPTIONS                                                        Null\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                              Null\n",
      "CONDITION                                                           Null\n",
      "MOLREGNO                                                            Null\n",
      "NAME_TERM                                                            NaN\n",
      "Name: 2556, dtype: object\n",
      "_____\n",
      "TWID                                                               51714\n",
      "TWEET_ID                                             1003650693763301376\n",
      "TWEET                  Durvalumab + cisplatin + pemetrexed was active...\n",
      "SYNONYMS                                                      PEMETREXED\n",
      "MOLREGNO_1                                                        374008\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02039674\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                       Tolerable in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                 Non-Small-Cell Lung Carcinoma\n",
      "INDICATION_ID                                                    D002289\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Pemetrexed\n",
      "DESCRIPTIONS                            IV on Day 1 of each 3-week cycle\n",
      "OTHER_NAME                                                       ALIMTA®\n",
      "EFO_ID                                                       EFO:0003060\n",
      "CONDITION                                  Non-small Cell Lung Carcinoma\n",
      "MOLREGNO                                                          300022\n",
      "NAME_TERM                                  non-small cell lung carcinoma\n",
      "Name: 2564, dtype: object\n",
      "_____\n",
      "TWID                                                               51714\n",
      "TWEET_ID                                             1003650693763301376\n",
      "TWEET                  Durvalumab + cisplatin + pemetrexed was active...\n",
      "SYNONYMS                                                      PEMETREXED\n",
      "MOLREGNO_1                                                        374008\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02039674\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                       Tolerable in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                 Non-Small-Cell Lung Carcinoma\n",
      "INDICATION_ID                                                    D002289\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Pemetrexed\n",
      "DESCRIPTIONS                            IV on Day 1 of each 3-week cycle\n",
      "OTHER_NAME                                                       ALIMTA®\n",
      "EFO_ID                                                       EFO:0003060\n",
      "CONDITION                                  Non-small Cell Lung Carcinoma\n",
      "MOLREGNO                                                          675483\n",
      "NAME_TERM                                  non-small cell lung carcinoma\n",
      "Name: 2565, dtype: object\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "_____\n",
      "TWID                                                               51714\n",
      "TWEET_ID                                             1003650693763301376\n",
      "TWEET                  Durvalumab + cisplatin + pemetrexed was active...\n",
      "SYNONYMS                                                      PEMETREXED\n",
      "MOLREGNO_1                                                        374008\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02039674\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                       Tolerable in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                 Non-Small-Cell Lung Carcinoma\n",
      "INDICATION_ID                                                    D002289\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Pemetrexed\n",
      "DESCRIPTIONS                            IV on Day 1 of each 3-week cycle\n",
      "OTHER_NAME                                                       ALIMTA®\n",
      "EFO_ID                                                       EFO:0003060\n",
      "CONDITION                                  Non-small Cell Lung Carcinoma\n",
      "MOLREGNO                                                         1626777\n",
      "NAME_TERM                                  non-small cell lung carcinoma\n",
      "Name: 2566, dtype: object\n",
      "_____\n",
      "TWID                                                               51714\n",
      "TWEET_ID                                             1003650693763301376\n",
      "TWEET                  Durvalumab + cisplatin + pemetrexed was active...\n",
      "SYNONYMS                                                      PEMETREXED\n",
      "MOLREGNO_1                                                        374008\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02039674\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                       Tolerable in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                 Non-Small-Cell Lung Carcinoma\n",
      "INDICATION_ID                                                    D002289\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Pemetrexed\n",
      "DESCRIPTIONS                            IV on Day 1 of each 3-week cycle\n",
      "OTHER_NAME                                                       ALIMTA®\n",
      "EFO_ID                                                       EFO:0003060\n",
      "CONDITION                                  Non-small Cell Lung Carcinoma\n",
      "MOLREGNO                                                           14785\n",
      "NAME_TERM                                  non-small cell lung carcinoma\n",
      "Name: 2567, dtype: object\n",
      "_____\n",
      "TWID                                                               51714\n",
      "TWEET_ID                                             1003650693763301376\n",
      "TWEET                  Durvalumab + cisplatin + pemetrexed was active...\n",
      "SYNONYMS                                                      PEMETREXED\n",
      "MOLREGNO_1                                                        374008\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02039674\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                       Tolerable in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                 Non-Small-Cell Lung Carcinoma\n",
      "INDICATION_ID                                                    D002289\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Pemetrexed\n",
      "DESCRIPTIONS                            IV on Day 1 of each 3-week cycle\n",
      "OTHER_NAME                                                       ALIMTA®\n",
      "EFO_ID                                                       EFO:0003060\n",
      "CONDITION                                  Non-small Cell Lung Carcinoma\n",
      "MOLREGNO                                                           88232\n",
      "NAME_TERM                                  non-small cell lung carcinoma\n",
      "Name: 2569, dtype: object\n",
      "_____\n",
      "TWID                                                               51714\n",
      "TWEET_ID                                             1003650693763301376\n",
      "TWEET                  Durvalumab + cisplatin + pemetrexed was active...\n",
      "SYNONYMS                                                      PEMETREXED\n",
      "MOLREGNO_1                                                        374008\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02039674\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                       Tolerable in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                 Non-Small-Cell Lung Carcinoma\n",
      "INDICATION_ID                                                    D002289\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Pemetrexed\n",
      "DESCRIPTIONS                            IV on Day 1 of each 3-week cycle\n",
      "OTHER_NAME                                                       ALIMTA®\n",
      "EFO_ID                                                       EFO:0003060\n",
      "CONDITION                                  Non-small Cell Lung Carcinoma\n",
      "MOLREGNO                                                            8062\n",
      "NAME_TERM                                  non-small cell lung carcinoma\n",
      "Name: 2570, dtype: object\n",
      "_____\n",
      "TWID                                                               51714\n",
      "TWEET_ID                                             1003650693763301376\n",
      "TWEET                  Durvalumab + cisplatin + pemetrexed was active...\n",
      "SYNONYMS                                                      PEMETREXED\n",
      "MOLREGNO_1                                                        374008\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02039674\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                       Tolerable in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                 Non-Small-Cell Lung Carcinoma\n",
      "INDICATION_ID                                                    D002289\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                           Pemetrexed\n",
      "DESCRIPTIONS                            IV on Day 1 of each 3-week cycle\n",
      "OTHER_NAME                                                       ALIMTA®\n",
      "EFO_ID                                                       EFO:0003060\n",
      "CONDITION                                  Non-small Cell Lung Carcinoma\n",
      "MOLREGNO                                                         1153495\n",
      "NAME_TERM                                  non-small cell lung carcinoma\n",
      "Name: 2571, dtype: object\n",
      "_____\n",
      "TWID                                                               51714\n",
      "TWEET_ID                                             1003650693763301376\n",
      "TWEET                  Durvalumab + cisplatin + pemetrexed was active...\n",
      "SYNONYMS                                                      DURVALUMAB\n",
      "MOLREGNO_1                                                       1763549\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02352948\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                       Tolerable in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                 Non-Small-Cell Lung Carcinoma\n",
      "INDICATION_ID                                                    D002289\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                MEDI4736 (durvalumab)\n",
      "DESCRIPTIONS           MEDI4736 (durvalumab) treatment by intravenous...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0003060\n",
      "CONDITION                             Non - Small Cell Lung Cancer NSCLC\n",
      "MOLREGNO                                                         1380924\n",
      "NAME_TERM                                  non-small cell lung carcinoma\n",
      "Name: 2572, dtype: object\n",
      "_____\n",
      "TWID                                                               51714\n",
      "TWEET_ID                                             1003650693763301376\n",
      "TWEET                  Durvalumab + cisplatin + pemetrexed was active...\n",
      "SYNONYMS                                                      DURVALUMAB\n",
      "MOLREGNO_1                                                       1763549\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02352948\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                       Tolerable in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                 Non-Small-Cell Lung Carcinoma\n",
      "INDICATION_ID                                                    D002289\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                MEDI4736 (durvalumab)\n",
      "DESCRIPTIONS           MEDI4736 (durvalumab) treatment by intravenous...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0003060\n",
      "CONDITION                             Non - Small Cell Lung Cancer NSCLC\n",
      "MOLREGNO                                                          560078\n",
      "NAME_TERM                                  non-small cell lung carcinoma\n",
      "Name: 2574, dtype: object\n",
      "_____\n",
      "TWID                                                               51714\n",
      "TWEET_ID                                             1003650693763301376\n",
      "TWEET                  Durvalumab + cisplatin + pemetrexed was active...\n",
      "SYNONYMS                                                      DURVALUMAB\n",
      "MOLREGNO_1                                                       1763549\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02352948\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                       Tolerable in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                 Non-Small-Cell Lung Carcinoma\n",
      "INDICATION_ID                                                    D002289\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                MEDI4736 (durvalumab)\n",
      "DESCRIPTIONS           MEDI4736 (durvalumab) treatment by intravenous...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0003060\n",
      "CONDITION                             Non - Small Cell Lung Cancer NSCLC\n",
      "MOLREGNO                                                           14785\n",
      "NAME_TERM                                  non-small cell lung carcinoma\n",
      "Name: 2575, dtype: object\n",
      "_____\n",
      "TWID                                                               51714\n",
      "TWEET_ID                                             1003650693763301376\n",
      "TWEET                  Durvalumab + cisplatin + pemetrexed was active...\n",
      "SYNONYMS                                                      DURVALUMAB\n",
      "MOLREGNO_1                                                       1763549\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02352948\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                       Tolerable in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                 Non-Small-Cell Lung Carcinoma\n",
      "INDICATION_ID                                                    D002289\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                MEDI4736 (durvalumab)\n",
      "DESCRIPTIONS           MEDI4736 (durvalumab) treatment by intravenous...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0003060\n",
      "CONDITION                             Non - Small Cell Lung Cancer NSCLC\n",
      "MOLREGNO                                                           75901\n",
      "NAME_TERM                                  non-small cell lung carcinoma\n",
      "Name: 2576, dtype: object\n",
      "_____\n",
      "TWID                                                               51714\n",
      "TWEET_ID                                             1003650693763301376\n",
      "TWEET                  Durvalumab + cisplatin + pemetrexed was active...\n",
      "SYNONYMS                                                       CISPLATIN\n",
      "MOLREGNO_1                                                       1358551\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                       Tolerable in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                 Non-Small-Cell Lung Carcinoma\n",
      "INDICATION_ID                                                    D002289\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Cisplatin\n",
      "DESCRIPTIONS                            cis-diamminedichloroplatinum(II)\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                          675089\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 2577, dtype: object\n",
      "_____\n",
      "TWID                                                               51714\n",
      "TWEET_ID                                             1003650693763301376\n",
      "TWEET                  Durvalumab + cisplatin + pemetrexed was active...\n",
      "SYNONYMS                                                       CISPLATIN\n",
      "MOLREGNO_1                                                       1358551\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                       Tolerable in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                 Non-Small-Cell Lung Carcinoma\n",
      "INDICATION_ID                                                    D002289\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Cisplatin\n",
      "DESCRIPTIONS                            cis-diamminedichloroplatinum(II)\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                            8062\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 2578, dtype: object\n",
      "_____\n",
      "TWID                                                               51714\n",
      "TWEET_ID                                             1003650693763301376\n",
      "TWEET                  Durvalumab + cisplatin + pemetrexed was active...\n",
      "SYNONYMS                                                       CISPLATIN\n",
      "MOLREGNO_1                                                       1358551\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                       Tolerable in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                 Non-Small-Cell Lung Carcinoma\n",
      "INDICATION_ID                                                    D002289\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Cisplatin\n",
      "DESCRIPTIONS                            cis-diamminedichloroplatinum(II)\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                         1380097\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 2579, dtype: object\n",
      "_____\n",
      "TWID                                                               51714\n",
      "TWEET_ID                                             1003650693763301376\n",
      "TWEET                  Durvalumab + cisplatin + pemetrexed was active...\n",
      "SYNONYMS                                                       CISPLATIN\n",
      "MOLREGNO_1                                                       1358551\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                       Tolerable in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                 Non-Small-Cell Lung Carcinoma\n",
      "INDICATION_ID                                                    D002289\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Cisplatin\n",
      "DESCRIPTIONS                            cis-diamminedichloroplatinum(II)\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                            8633\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 2580, dtype: object\n",
      "_____\n",
      "TWID                                                               51714\n",
      "TWEET_ID                                             1003650693763301376\n",
      "TWEET                  Durvalumab + cisplatin + pemetrexed was active...\n",
      "SYNONYMS                                                       CISPLATIN\n",
      "MOLREGNO_1                                                       1358551\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                       Tolerable in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                 Non-Small-Cell Lung Carcinoma\n",
      "INDICATION_ID                                                    D002289\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Cisplatin\n",
      "DESCRIPTIONS                            cis-diamminedichloroplatinum(II)\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                          674747\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 2581, dtype: object\n",
      "_____\n",
      "TWID                                                               51714\n",
      "TWEET_ID                                             1003650693763301376\n",
      "TWEET                  Durvalumab + cisplatin + pemetrexed was active...\n",
      "SYNONYMS                                                       CISPLATIN\n",
      "MOLREGNO_1                                                       1358551\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                       Tolerable in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                 Non-Small-Cell Lung Carcinoma\n",
      "INDICATION_ID                                                    D002289\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Cisplatin\n",
      "DESCRIPTIONS                            cis-diamminedichloroplatinum(II)\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                          675483\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 2582, dtype: object\n",
      "_____\n",
      "TWID                                                               51714\n",
      "TWEET_ID                                             1003650693763301376\n",
      "TWEET                  Durvalumab + cisplatin + pemetrexed was active...\n",
      "SYNONYMS                                                       CISPLATIN\n",
      "MOLREGNO_1                                                       1358551\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                       Tolerable in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                 Non-Small-Cell Lung Carcinoma\n",
      "INDICATION_ID                                                    D002289\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Cisplatin\n",
      "DESCRIPTIONS                            cis-diamminedichloroplatinum(II)\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                          368538\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 2583, dtype: object\n",
      "_____\n",
      "TWID                                                               51714\n",
      "TWEET_ID                                             1003650693763301376\n",
      "TWEET                  Durvalumab + cisplatin + pemetrexed was active...\n",
      "SYNONYMS                                                       CISPLATIN\n",
      "MOLREGNO_1                                                       1358551\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                       Tolerable in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                 Non-Small-Cell Lung Carcinoma\n",
      "INDICATION_ID                                                    D002289\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Cisplatin\n",
      "DESCRIPTIONS                            cis-diamminedichloroplatinum(II)\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                         2096424\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 2584, dtype: object\n",
      "_____\n",
      "TWID                                                               51714\n",
      "TWEET_ID                                             1003650693763301376\n",
      "TWEET                  Durvalumab + cisplatin + pemetrexed was active...\n",
      "SYNONYMS                                                       CISPLATIN\n",
      "MOLREGNO_1                                                       1358551\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                       Tolerable in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                 Non-Small-Cell Lung Carcinoma\n",
      "INDICATION_ID                                                    D002289\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Cisplatin\n",
      "DESCRIPTIONS                            cis-diamminedichloroplatinum(II)\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                          598447\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 2585, dtype: object\n",
      "_____\n",
      "TWID                                                               51714\n",
      "TWEET_ID                                             1003650693763301376\n",
      "TWEET                  Durvalumab + cisplatin + pemetrexed was active...\n",
      "SYNONYMS                                                       CISPLATIN\n",
      "MOLREGNO_1                                                        328069\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                       Tolerable in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                 Non-Small-Cell Lung Carcinoma\n",
      "INDICATION_ID                                                    D002289\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Cisplatin\n",
      "DESCRIPTIONS                            cis-diamminedichloroplatinum(II)\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                          675089\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 2586, dtype: object\n",
      "_____\n",
      "TWID                                                               51714\n",
      "TWEET_ID                                             1003650693763301376\n",
      "TWEET                  Durvalumab + cisplatin + pemetrexed was active...\n",
      "SYNONYMS                                                       CISPLATIN\n",
      "MOLREGNO_1                                                        328069\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                       Tolerable in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                 Non-Small-Cell Lung Carcinoma\n",
      "INDICATION_ID                                                    D002289\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Cisplatin\n",
      "DESCRIPTIONS                            cis-diamminedichloroplatinum(II)\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                            8062\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 2587, dtype: object\n",
      "_____\n",
      "TWID                                                               51714\n",
      "TWEET_ID                                             1003650693763301376\n",
      "TWEET                  Durvalumab + cisplatin + pemetrexed was active...\n",
      "SYNONYMS                                                       CISPLATIN\n",
      "MOLREGNO_1                                                        328069\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                       Tolerable in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                 Non-Small-Cell Lung Carcinoma\n",
      "INDICATION_ID                                                    D002289\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Cisplatin\n",
      "DESCRIPTIONS                            cis-diamminedichloroplatinum(II)\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                         1380097\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 2588, dtype: object\n",
      "_____\n",
      "TWID                                                               51714\n",
      "TWEET_ID                                             1003650693763301376\n",
      "TWEET                  Durvalumab + cisplatin + pemetrexed was active...\n",
      "SYNONYMS                                                       CISPLATIN\n",
      "MOLREGNO_1                                                        328069\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                       Tolerable in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                 Non-Small-Cell Lung Carcinoma\n",
      "INDICATION_ID                                                    D002289\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Cisplatin\n",
      "DESCRIPTIONS                            cis-diamminedichloroplatinum(II)\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                            8633\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 2589, dtype: object\n",
      "_____\n",
      "TWID                                                               51714\n",
      "TWEET_ID                                             1003650693763301376\n",
      "TWEET                  Durvalumab + cisplatin + pemetrexed was active...\n",
      "SYNONYMS                                                       CISPLATIN\n",
      "MOLREGNO_1                                                        328069\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                       Tolerable in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                 Non-Small-Cell Lung Carcinoma\n",
      "INDICATION_ID                                                    D002289\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Cisplatin\n",
      "DESCRIPTIONS                            cis-diamminedichloroplatinum(II)\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                          674747\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 2590, dtype: object\n",
      "_____\n",
      "TWID                                                               51714\n",
      "TWEET_ID                                             1003650693763301376\n",
      "TWEET                  Durvalumab + cisplatin + pemetrexed was active...\n",
      "SYNONYMS                                                       CISPLATIN\n",
      "MOLREGNO_1                                                        328069\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                       Tolerable in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                 Non-Small-Cell Lung Carcinoma\n",
      "INDICATION_ID                                                    D002289\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Cisplatin\n",
      "DESCRIPTIONS                            cis-diamminedichloroplatinum(II)\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                          675483\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 2591, dtype: object\n",
      "_____\n",
      "TWID                                                               51714\n",
      "TWEET_ID                                             1003650693763301376\n",
      "TWEET                  Durvalumab + cisplatin + pemetrexed was active...\n",
      "SYNONYMS                                                       CISPLATIN\n",
      "MOLREGNO_1                                                        328069\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                       Tolerable in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                 Non-Small-Cell Lung Carcinoma\n",
      "INDICATION_ID                                                    D002289\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Cisplatin\n",
      "DESCRIPTIONS                            cis-diamminedichloroplatinum(II)\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                          368538\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 2592, dtype: object\n",
      "_____\n",
      "TWID                                                               51714\n",
      "TWEET_ID                                             1003650693763301376\n",
      "TWEET                  Durvalumab + cisplatin + pemetrexed was active...\n",
      "SYNONYMS                                                       CISPLATIN\n",
      "MOLREGNO_1                                                        328069\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                       Tolerable in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                 Non-Small-Cell Lung Carcinoma\n",
      "INDICATION_ID                                                    D002289\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Cisplatin\n",
      "DESCRIPTIONS                            cis-diamminedichloroplatinum(II)\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                         2096424\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 2593, dtype: object\n",
      "_____\n",
      "TWID                                                               51714\n",
      "TWEET_ID                                             1003650693763301376\n",
      "TWEET                  Durvalumab + cisplatin + pemetrexed was active...\n",
      "SYNONYMS                                                       CISPLATIN\n",
      "MOLREGNO_1                                                        328069\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                       Tolerable in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                 Non-Small-Cell Lung Carcinoma\n",
      "INDICATION_ID                                                    D002289\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Cisplatin\n",
      "DESCRIPTIONS                            cis-diamminedichloroplatinum(II)\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                          598447\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 2594, dtype: object\n",
      "_____\n",
      "TWID                                                               51714\n",
      "TWEET_ID                                             1003650693763301376\n",
      "TWEET                  Durvalumab + cisplatin + pemetrexed was active...\n",
      "SYNONYMS                                                       CISPLATIN\n",
      "MOLREGNO_1                                                          8633\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                       Tolerable in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                 Non-Small-Cell Lung Carcinoma\n",
      "INDICATION_ID                                                    D002289\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Cisplatin\n",
      "DESCRIPTIONS                            cis-diamminedichloroplatinum(II)\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                          675089\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 2595, dtype: object\n",
      "_____\n",
      "TWID                                                               51714\n",
      "TWEET_ID                                             1003650693763301376\n",
      "TWEET                  Durvalumab + cisplatin + pemetrexed was active...\n",
      "SYNONYMS                                                       CISPLATIN\n",
      "MOLREGNO_1                                                          8633\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                       Tolerable in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                 Non-Small-Cell Lung Carcinoma\n",
      "INDICATION_ID                                                    D002289\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Cisplatin\n",
      "DESCRIPTIONS                            cis-diamminedichloroplatinum(II)\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                            8062\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 2596, dtype: object\n",
      "_____\n",
      "TWID                                                               51714\n",
      "TWEET_ID                                             1003650693763301376\n",
      "TWEET                  Durvalumab + cisplatin + pemetrexed was active...\n",
      "SYNONYMS                                                       CISPLATIN\n",
      "MOLREGNO_1                                                          8633\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                       Tolerable in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                 Non-Small-Cell Lung Carcinoma\n",
      "INDICATION_ID                                                    D002289\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Cisplatin\n",
      "DESCRIPTIONS                            cis-diamminedichloroplatinum(II)\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                         1380097\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 2597, dtype: object\n",
      "_____\n",
      "TWID                                                               51714\n",
      "TWEET_ID                                             1003650693763301376\n",
      "TWEET                  Durvalumab + cisplatin + pemetrexed was active...\n",
      "SYNONYMS                                                       CISPLATIN\n",
      "MOLREGNO_1                                                          8633\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                       Tolerable in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                 Non-Small-Cell Lung Carcinoma\n",
      "INDICATION_ID                                                    D002289\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Cisplatin\n",
      "DESCRIPTIONS                            cis-diamminedichloroplatinum(II)\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                          674747\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 2599, dtype: object\n",
      "_____\n",
      "TWID                                                               51714\n",
      "TWEET_ID                                             1003650693763301376\n",
      "TWEET                  Durvalumab + cisplatin + pemetrexed was active...\n",
      "SYNONYMS                                                       CISPLATIN\n",
      "MOLREGNO_1                                                          8633\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                       Tolerable in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                 Non-Small-Cell Lung Carcinoma\n",
      "INDICATION_ID                                                    D002289\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Cisplatin\n",
      "DESCRIPTIONS                            cis-diamminedichloroplatinum(II)\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                          675483\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 2600, dtype: object\n",
      "_____\n",
      "TWID                                                               51714\n",
      "TWEET_ID                                             1003650693763301376\n",
      "TWEET                  Durvalumab + cisplatin + pemetrexed was active...\n",
      "SYNONYMS                                                       CISPLATIN\n",
      "MOLREGNO_1                                                          8633\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                       Tolerable in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                 Non-Small-Cell Lung Carcinoma\n",
      "INDICATION_ID                                                    D002289\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Cisplatin\n",
      "DESCRIPTIONS                            cis-diamminedichloroplatinum(II)\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                          368538\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 2601, dtype: object\n",
      "_____\n",
      "TWID                                                               51714\n",
      "TWEET_ID                                             1003650693763301376\n",
      "TWEET                  Durvalumab + cisplatin + pemetrexed was active...\n",
      "SYNONYMS                                                       CISPLATIN\n",
      "MOLREGNO_1                                                          8633\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                       Tolerable in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                 Non-Small-Cell Lung Carcinoma\n",
      "INDICATION_ID                                                    D002289\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Cisplatin\n",
      "DESCRIPTIONS                            cis-diamminedichloroplatinum(II)\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                         2096424\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 2602, dtype: object\n",
      "_____\n",
      "TWID                                                               51714\n",
      "TWEET_ID                                             1003650693763301376\n",
      "TWEET                  Durvalumab + cisplatin + pemetrexed was active...\n",
      "SYNONYMS                                                       CISPLATIN\n",
      "MOLREGNO_1                                                          8633\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03387085\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                       Tolerable in trial\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                 Non-Small-Cell Lung Carcinoma\n",
      "INDICATION_ID                                                    D002289\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Cisplatin\n",
      "DESCRIPTIONS                            cis-diamminedichloroplatinum(II)\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000305\n",
      "CONDITION                                  Triple Negative Breast Cancer\n",
      "MOLREGNO                                                          598447\n",
      "NAME_TERM                                               breast carcinoma\n",
      "Name: 2603, dtype: object\n",
      "_____\n",
      "TWID                                                               61550\n",
      "TWEET_ID                                             1004403985036529664\n",
      "TWEET                  @oncology_bg @Aiims1742 @HealthNewsRevu @sxbeg...\n",
      "SYNONYMS                                                       CERITINIB\n",
      "MOLREGNO_1                                                       1570706\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02587650\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Ceritinib\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME                                        LDK 378;LDK378;Zykadia\n",
      "EFO_ID                                                       EFO:0000389\n",
      "CONDITION                          Stage IIIC Cutaneous Melanoma AJCC v7\n",
      "MOLREGNO                                                         1677558\n",
      "NAME_TERM                                             cutaneous melanoma\n",
      "Name: 2606, dtype: object\n",
      "_____\n",
      "TWID                                                               61550\n",
      "TWEET_ID                                             1004403985036529664\n",
      "TWEET                  @oncology_bg @Aiims1742 @HealthNewsRevu @sxbeg...\n",
      "SYNONYMS                                                       CERITINIB\n",
      "MOLREGNO_1                                                       1570706\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02587650\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Ceritinib\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME                                        LDK 378;LDK378;Zykadia\n",
      "EFO_ID                                                       EFO:0000389\n",
      "CONDITION                          Stage IIIC Cutaneous Melanoma AJCC v7\n",
      "MOLREGNO                                                         1277553\n",
      "NAME_TERM                                             cutaneous melanoma\n",
      "Name: 2607, dtype: object\n",
      "_____\n",
      "TWID                                                               61550\n",
      "TWEET_ID                                             1004403985036529664\n",
      "TWEET                  @oncology_bg @Aiims1742 @HealthNewsRevu @sxbeg...\n",
      "SYNONYMS                                                       CERITINIB\n",
      "MOLREGNO_1                                                       1570706\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02587650\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Ceritinib\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME                                        LDK 378;LDK378;Zykadia\n",
      "EFO_ID                                                       EFO:0000389\n",
      "CONDITION                          Stage IIIC Cutaneous Melanoma AJCC v7\n",
      "MOLREGNO                                                         1304559\n",
      "NAME_TERM                                             cutaneous melanoma\n",
      "Name: 2608, dtype: object\n",
      "_____\n",
      "TWID                                                               61550\n",
      "TWEET_ID                                             1004403985036529664\n",
      "TWEET                  @oncology_bg @Aiims1742 @HealthNewsRevu @sxbeg...\n",
      "SYNONYMS                                                       CERITINIB\n",
      "MOLREGNO_1                                                       1570706\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02587650\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Ceritinib\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME                                        LDK 378;LDK378;Zykadia\n",
      "EFO_ID                                                       EFO:0000389\n",
      "CONDITION                          Stage IIIC Cutaneous Melanoma AJCC v7\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                             cutaneous melanoma\n",
      "Name: 2610, dtype: object\n",
      "_____\n",
      "TWID                                                               61550\n",
      "TWEET_ID                                             1004403985036529664\n",
      "TWEET                  @oncology_bg @Aiims1742 @HealthNewsRevu @sxbeg...\n",
      "SYNONYMS                                                       CERITINIB\n",
      "MOLREGNO_1                                                       1570706\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02587650\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Ceritinib\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME                                        LDK 378;LDK378;Zykadia\n",
      "EFO_ID                                                       EFO:0000756\n",
      "CONDITION                                         Invasive Skin Melanoma\n",
      "MOLREGNO                                                         1677558\n",
      "NAME_TERM                                                       melanoma\n",
      "Name: 2611, dtype: object\n",
      "_____\n",
      "TWID                                                               61550\n",
      "TWEET_ID                                             1004403985036529664\n",
      "TWEET                  @oncology_bg @Aiims1742 @HealthNewsRevu @sxbeg...\n",
      "SYNONYMS                                                       CERITINIB\n",
      "MOLREGNO_1                                                       1570706\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02587650\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Ceritinib\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME                                        LDK 378;LDK378;Zykadia\n",
      "EFO_ID                                                       EFO:0000756\n",
      "CONDITION                                         Invasive Skin Melanoma\n",
      "MOLREGNO                                                         1277553\n",
      "NAME_TERM                                                       melanoma\n",
      "Name: 2612, dtype: object\n",
      "_____\n",
      "TWID                                                               61550\n",
      "TWEET_ID                                             1004403985036529664\n",
      "TWEET                  @oncology_bg @Aiims1742 @HealthNewsRevu @sxbeg...\n",
      "SYNONYMS                                                       CERITINIB\n",
      "MOLREGNO_1                                                       1570706\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02587650\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Ceritinib\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME                                        LDK 378;LDK378;Zykadia\n",
      "EFO_ID                                                       EFO:0000756\n",
      "CONDITION                                         Invasive Skin Melanoma\n",
      "MOLREGNO                                                         1304559\n",
      "NAME_TERM                                                       melanoma\n",
      "Name: 2613, dtype: object\n",
      "_____\n",
      "TWID                                                               61550\n",
      "TWEET_ID                                             1004403985036529664\n",
      "TWEET                  @oncology_bg @Aiims1742 @HealthNewsRevu @sxbeg...\n",
      "SYNONYMS                                                       CERITINIB\n",
      "MOLREGNO_1                                                       1570706\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02587650\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Ceritinib\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME                                        LDK 378;LDK378;Zykadia\n",
      "EFO_ID                                                       EFO:0000756\n",
      "CONDITION                                         Invasive Skin Melanoma\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                       melanoma\n",
      "Name: 2615, dtype: object\n",
      "_____\n",
      "TWID                                                               61550\n",
      "TWEET_ID                                             1004403985036529664\n",
      "TWEET                  @oncology_bg @Aiims1742 @HealthNewsRevu @sxbeg...\n",
      "SYNONYMS                                                       CERITINIB\n",
      "MOLREGNO_1                                                       1570706\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02587650\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Ceritinib\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME                                        LDK 378;LDK378;Zykadia\n",
      "EFO_ID                                                       EFO:0000389\n",
      "CONDITION                          Stage IIIA Cutaneous Melanoma AJCC v7\n",
      "MOLREGNO                                                         1677558\n",
      "NAME_TERM                                             cutaneous melanoma\n",
      "Name: 2616, dtype: object\n",
      "_____\n",
      "TWID                                                               61550\n",
      "TWEET_ID                                             1004403985036529664\n",
      "TWEET                  @oncology_bg @Aiims1742 @HealthNewsRevu @sxbeg...\n",
      "SYNONYMS                                                       CERITINIB\n",
      "MOLREGNO_1                                                       1570706\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02587650\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Ceritinib\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME                                        LDK 378;LDK378;Zykadia\n",
      "EFO_ID                                                       EFO:0000389\n",
      "CONDITION                          Stage IIIA Cutaneous Melanoma AJCC v7\n",
      "MOLREGNO                                                         1277553\n",
      "NAME_TERM                                             cutaneous melanoma\n",
      "Name: 2617, dtype: object\n",
      "_____\n",
      "TWID                                                               61550\n",
      "TWEET_ID                                             1004403985036529664\n",
      "TWEET                  @oncology_bg @Aiims1742 @HealthNewsRevu @sxbeg...\n",
      "SYNONYMS                                                       CERITINIB\n",
      "MOLREGNO_1                                                       1570706\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02587650\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Ceritinib\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME                                        LDK 378;LDK378;Zykadia\n",
      "EFO_ID                                                       EFO:0000389\n",
      "CONDITION                          Stage IIIA Cutaneous Melanoma AJCC v7\n",
      "MOLREGNO                                                         1304559\n",
      "NAME_TERM                                             cutaneous melanoma\n",
      "Name: 2618, dtype: object\n",
      "_____\n",
      "TWID                                                               61550\n",
      "TWEET_ID                                             1004403985036529664\n",
      "TWEET                  @oncology_bg @Aiims1742 @HealthNewsRevu @sxbeg...\n",
      "SYNONYMS                                                       CERITINIB\n",
      "MOLREGNO_1                                                       1570706\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02587650\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Ceritinib\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME                                        LDK 378;LDK378;Zykadia\n",
      "EFO_ID                                                       EFO:0000389\n",
      "CONDITION                          Stage IIIA Cutaneous Melanoma AJCC v7\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                             cutaneous melanoma\n",
      "Name: 2620, dtype: object\n",
      "_____\n",
      "TWID                                                               61550\n",
      "TWEET_ID                                             1004403985036529664\n",
      "TWEET                  @oncology_bg @Aiims1742 @HealthNewsRevu @sxbeg...\n",
      "SYNONYMS                                                       CERITINIB\n",
      "MOLREGNO_1                                                       1570706\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02587650\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Ceritinib\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME                                        LDK 378;LDK378;Zykadia\n",
      "EFO_ID                                                       EFO:0000389\n",
      "CONDITION                          Stage IIIB Cutaneous Melanoma AJCC v7\n",
      "MOLREGNO                                                         1677558\n",
      "NAME_TERM                                             cutaneous melanoma\n",
      "Name: 2621, dtype: object\n",
      "_____\n",
      "TWID                                                               61550\n",
      "TWEET_ID                                             1004403985036529664\n",
      "TWEET                  @oncology_bg @Aiims1742 @HealthNewsRevu @sxbeg...\n",
      "SYNONYMS                                                       CERITINIB\n",
      "MOLREGNO_1                                                       1570706\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02587650\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Ceritinib\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME                                        LDK 378;LDK378;Zykadia\n",
      "EFO_ID                                                       EFO:0000389\n",
      "CONDITION                          Stage IIIB Cutaneous Melanoma AJCC v7\n",
      "MOLREGNO                                                         1277553\n",
      "NAME_TERM                                             cutaneous melanoma\n",
      "Name: 2622, dtype: object\n",
      "_____\n",
      "TWID                                                               61550\n",
      "TWEET_ID                                             1004403985036529664\n",
      "TWEET                  @oncology_bg @Aiims1742 @HealthNewsRevu @sxbeg...\n",
      "SYNONYMS                                                       CERITINIB\n",
      "MOLREGNO_1                                                       1570706\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02587650\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Ceritinib\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME                                        LDK 378;LDK378;Zykadia\n",
      "EFO_ID                                                       EFO:0000389\n",
      "CONDITION                          Stage IIIB Cutaneous Melanoma AJCC v7\n",
      "MOLREGNO                                                         1304559\n",
      "NAME_TERM                                             cutaneous melanoma\n",
      "Name: 2623, dtype: object\n",
      "_____\n",
      "TWID                                                               61550\n",
      "TWEET_ID                                             1004403985036529664\n",
      "TWEET                  @oncology_bg @Aiims1742 @HealthNewsRevu @sxbeg...\n",
      "SYNONYMS                                                       CERITINIB\n",
      "MOLREGNO_1                                                       1570706\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02587650\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Ceritinib\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME                                        LDK 378;LDK378;Zykadia\n",
      "EFO_ID                                                       EFO:0000389\n",
      "CONDITION                          Stage IIIB Cutaneous Melanoma AJCC v7\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                             cutaneous melanoma\n",
      "Name: 2625, dtype: object\n",
      "_____\n",
      "TWID                                                               61550\n",
      "TWEET_ID                                             1004403985036529664\n",
      "TWEET                  @oncology_bg @Aiims1742 @HealthNewsRevu @sxbeg...\n",
      "SYNONYMS                                                       CERITINIB\n",
      "MOLREGNO_1                                                       1570706\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02587650\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Ceritinib\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME                                        LDK 378;LDK378;Zykadia\n",
      "EFO_ID                                                       EFO:0000389\n",
      "CONDITION                     Stage IV Cutaneous Melanoma AJCC v6 and v7\n",
      "MOLREGNO                                                         1677558\n",
      "NAME_TERM                                             cutaneous melanoma\n",
      "Name: 2626, dtype: object\n",
      "_____\n",
      "TWID                                                               61550\n",
      "TWEET_ID                                             1004403985036529664\n",
      "TWEET                  @oncology_bg @Aiims1742 @HealthNewsRevu @sxbeg...\n",
      "SYNONYMS                                                       CERITINIB\n",
      "MOLREGNO_1                                                       1570706\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02587650\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Ceritinib\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME                                        LDK 378;LDK378;Zykadia\n",
      "EFO_ID                                                       EFO:0000389\n",
      "CONDITION                     Stage IV Cutaneous Melanoma AJCC v6 and v7\n",
      "MOLREGNO                                                         1277553\n",
      "NAME_TERM                                             cutaneous melanoma\n",
      "Name: 2627, dtype: object\n",
      "_____\n",
      "TWID                                                               61550\n",
      "TWEET_ID                                             1004403985036529664\n",
      "TWEET                  @oncology_bg @Aiims1742 @HealthNewsRevu @sxbeg...\n",
      "SYNONYMS                                                       CERITINIB\n",
      "MOLREGNO_1                                                       1570706\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02587650\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Ceritinib\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME                                        LDK 378;LDK378;Zykadia\n",
      "EFO_ID                                                       EFO:0000389\n",
      "CONDITION                     Stage IV Cutaneous Melanoma AJCC v6 and v7\n",
      "MOLREGNO                                                         1304559\n",
      "NAME_TERM                                             cutaneous melanoma\n",
      "Name: 2628, dtype: object\n",
      "_____\n",
      "TWID                                                               61550\n",
      "TWEET_ID                                             1004403985036529664\n",
      "TWEET                  @oncology_bg @Aiims1742 @HealthNewsRevu @sxbeg...\n",
      "SYNONYMS                                                       CERITINIB\n",
      "MOLREGNO_1                                                       1570706\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02587650\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Ceritinib\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME                                        LDK 378;LDK378;Zykadia\n",
      "EFO_ID                                                       EFO:0000389\n",
      "CONDITION                     Stage IV Cutaneous Melanoma AJCC v6 and v7\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                             cutaneous melanoma\n",
      "Name: 2630, dtype: object\n",
      "_____\n",
      "TWID                                                               61550\n",
      "TWEET_ID                                             1004403985036529664\n",
      "TWEET                  @oncology_bg @Aiims1742 @HealthNewsRevu @sxbeg...\n",
      "SYNONYMS                                                       CERITINIB\n",
      "MOLREGNO_1                                                       1570706\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02587650\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Ceritinib\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME                                        LDK 378;LDK378;Zykadia\n",
      "EFO_ID                                                       EFO:0000389\n",
      "CONDITION                           Stage III Cutaneous Melanoma AJCC v7\n",
      "MOLREGNO                                                         1677558\n",
      "NAME_TERM                                             cutaneous melanoma\n",
      "Name: 2631, dtype: object\n",
      "_____\n",
      "TWID                                                               61550\n",
      "TWEET_ID                                             1004403985036529664\n",
      "TWEET                  @oncology_bg @Aiims1742 @HealthNewsRevu @sxbeg...\n",
      "SYNONYMS                                                       CERITINIB\n",
      "MOLREGNO_1                                                       1570706\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02587650\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Ceritinib\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME                                        LDK 378;LDK378;Zykadia\n",
      "EFO_ID                                                       EFO:0000389\n",
      "CONDITION                           Stage III Cutaneous Melanoma AJCC v7\n",
      "MOLREGNO                                                         1277553\n",
      "NAME_TERM                                             cutaneous melanoma\n",
      "Name: 2632, dtype: object\n",
      "_____\n",
      "TWID                                                               61550\n",
      "TWEET_ID                                             1004403985036529664\n",
      "TWEET                  @oncology_bg @Aiims1742 @HealthNewsRevu @sxbeg...\n",
      "SYNONYMS                                                       CERITINIB\n",
      "MOLREGNO_1                                                       1570706\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02587650\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Ceritinib\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME                                        LDK 378;LDK378;Zykadia\n",
      "EFO_ID                                                       EFO:0000389\n",
      "CONDITION                           Stage III Cutaneous Melanoma AJCC v7\n",
      "MOLREGNO                                                         1304559\n",
      "NAME_TERM                                             cutaneous melanoma\n",
      "Name: 2633, dtype: object\n",
      "_____\n",
      "TWID                                                               61550\n",
      "TWEET_ID                                             1004403985036529664\n",
      "TWEET                  @oncology_bg @Aiims1742 @HealthNewsRevu @sxbeg...\n",
      "SYNONYMS                                                       CERITINIB\n",
      "MOLREGNO_1                                                       1570706\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02587650\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                            were approved\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                      Female Genital Neoplasms\n",
      "INDICATION_ID                                                    D005833\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Ceritinib\n",
      "DESCRIPTIONS                                                    Given PO\n",
      "OTHER_NAME                                        LDK 378;LDK378;Zykadia\n",
      "EFO_ID                                                       EFO:0000389\n",
      "CONDITION                           Stage III Cutaneous Melanoma AJCC v7\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                             cutaneous melanoma\n",
      "Name: 2635, dtype: object\n",
      "_____\n",
      "TWID                                                               62054\n",
      "TWEET_ID                                              999263740448124929\n",
      "TWEET                  RT @BoerseGer $ESPR Esperion Announces Third P...\n",
      "SYNONYMS                                                  BEMPEDOIC ACID\n",
      "MOLREGNO_1                                                       1927162\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03193047\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                   meets primary endpoint\n",
      "COMPANY                                            Esperion Therapeutics\n",
      "COMPANY_ID                                                     COMP91202\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                               Atherosclerosis\n",
      "INDICATION_ID                                                    D050197\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                 bempedoic acid 180mg\n",
      "DESCRIPTIONS           Daily bempedoic acid 180mg tablet in addition ...\n",
      "OTHER_NAME                                                      ETC-1002\n",
      "EFO_ID                                                        HP:0003124\n",
      "CONDITION                                           Hypercholesterolemia\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                           hypercholesterolemia\n",
      "Name: 2638, dtype: object\n",
      "_____\n",
      "TWID                                                               62054\n",
      "TWEET_ID                                              999263740448124929\n",
      "TWEET                  RT @BoerseGer $ESPR Esperion Announces Third P...\n",
      "SYNONYMS                                                  BEMPEDOIC ACID\n",
      "MOLREGNO_1                                                       1927162\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03193047\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                   meets primary endpoint\n",
      "COMPANY                                            Esperion Therapeutics\n",
      "COMPANY_ID                                                     COMP91202\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                               Atherosclerosis\n",
      "INDICATION_ID                                                    D050197\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                 bempedoic acid 180mg\n",
      "DESCRIPTIONS           Daily bempedoic acid 180mg tablet in addition ...\n",
      "OTHER_NAME                                                      ETC-1002\n",
      "EFO_ID                                                        HP:0003124\n",
      "CONDITION                                           Hypercholesterolemia\n",
      "MOLREGNO                                                         1540527\n",
      "NAME_TERM                                           hypercholesterolemia\n",
      "Name: 2640, dtype: object\n",
      "_____\n",
      "TWID                                                               62321\n",
      "TWEET_ID                                              996353651374526464\n",
      "TWEET                  RT @odibro $LLY Galcanezumab Meets Primary End...\n",
      "SYNONYMS                                                    GALCANEZUMAB\n",
      "MOLREGNO_1                                                       2039299\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03432286\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                   meets primary endpoint\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Null\n",
      "INDICATION_ID                                                       Null\n",
      "INDICATION_NONAMBIG                                                 Null\n",
      "INDICATION_SCORE                                                    Null\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Galcanezumab\n",
      "DESCRIPTIONS                                             Administered SQ\n",
      "OTHER_NAME                                                     LY2951742\n",
      "EFO_ID                                                       EFO:0003821\n",
      "CONDITION                                              Episodic Migraine\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                              migraine disorder\n",
      "Name: 2642, dtype: object\n",
      "_____\n",
      "TWID                                                               62446\n",
      "TWEET_ID                                              994921137640374272\n",
      "TWEET                  RT @BioWriterChik $AZN reports a Phase 3 failu...\n",
      "SYNONYMS                                                         FASENRA\n",
      "MOLREGNO_1                                                       1121862\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03473977\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                            phase failure\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                         Chronic Obstructive Pulmonary Disease\n",
      "INDICATION_ID                                                    D029424\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                             Biological\n",
      "INTERVENTION_NAME_x                                         Benralizumab\n",
      "DESCRIPTIONS           Monoclonal antibody originally developed for t...\n",
      "OTHER_NAME                                                       Fasenra\n",
      "EFO_ID                                                       EFO:1001463\n",
      "CONDITION                      Eosinophilic Gastritis or Gastroenteritis\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                gastroenteritis\n",
      "Name: 2644, dtype: object\n",
      "_____\n",
      "TWID                                                               62446\n",
      "TWEET_ID                                              994921137640374272\n",
      "TWEET                  RT @BioWriterChik $AZN reports a Phase 3 failu...\n",
      "SYNONYMS                                                         FASENRA\n",
      "MOLREGNO_1                                                       1121862\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03473977\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                             FAIL\n",
      "MATCHED_OUTCOME                                            phase failure\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                         Chronic Obstructive Pulmonary Disease\n",
      "INDICATION_ID                                                    D029424\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                             Biological\n",
      "INTERVENTION_NAME_x                                         Benralizumab\n",
      "DESCRIPTIONS           Monoclonal antibody originally developed for t...\n",
      "OTHER_NAME                                                       Fasenra\n",
      "EFO_ID                                                       EFO:0000217\n",
      "CONDITION                      Eosinophilic Gastritis or Gastroenteritis\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                      gastritis\n",
      "Name: 2646, dtype: object\n",
      "_____\n",
      "TWID                                                               62927\n",
      "TWEET_ID                                              989178667111796736\n",
      "TWEET                  RT @FDAadcomm 3 VOTE Has the #PRECISION trial ...\n",
      "SYNONYMS                                                        NAPROXEN\n",
      "MOLREGNO_1                                                         51056\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02139046\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                      Demonstrated safety\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Pain\n",
      "INDICATION_ID                                                    D010146\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                             Naproxen\n",
      "DESCRIPTIONS                                            Naproxen tablets\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0004274\n",
      "CONDITION                                                           Gout\n",
      "MOLREGNO                                                          647206\n",
      "NAME_TERM                                                           gout\n",
      "Name: 2647, dtype: object\n",
      "_____\n",
      "TWID                                                               62927\n",
      "TWEET_ID                                              989178667111796736\n",
      "TWEET                  RT @FDAadcomm 3 VOTE Has the #PRECISION trial ...\n",
      "SYNONYMS                                                        NAPROXEN\n",
      "MOLREGNO_1                                                         51056\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02139046\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                      Demonstrated safety\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Pain\n",
      "INDICATION_ID                                                    D010146\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                             Naproxen\n",
      "DESCRIPTIONS                                            Naproxen tablets\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0004274\n",
      "CONDITION                                                           Gout\n",
      "MOLREGNO                                                            5975\n",
      "NAME_TERM                                                           gout\n",
      "Name: 2648, dtype: object\n",
      "_____\n",
      "TWID                                                               62927\n",
      "TWEET_ID                                              989178667111796736\n",
      "TWEET                  RT @FDAadcomm 3 VOTE Has the #PRECISION trial ...\n",
      "SYNONYMS                                                        NAPROXEN\n",
      "MOLREGNO_1                                                         51056\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02139046\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                      Demonstrated safety\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Pain\n",
      "INDICATION_ID                                                    D010146\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                             Naproxen\n",
      "DESCRIPTIONS                                            Naproxen tablets\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0004274\n",
      "CONDITION                                                           Gout\n",
      "MOLREGNO                                                           14440\n",
      "NAME_TERM                                                           gout\n",
      "Name: 2650, dtype: object\n",
      "_____\n",
      "TWID                                                               62927\n",
      "TWEET_ID                                              989178667111796736\n",
      "TWEET                  RT @FDAadcomm 3 VOTE Has the #PRECISION trial ...\n",
      "SYNONYMS                                                       CELECOXIB\n",
      "MOLREGNO_1                                                         18694\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03026140\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                      Demonstrated safety\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Pain\n",
      "INDICATION_ID                                                    D010146\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                      Celecoxib 200mg\n",
      "DESCRIPTIONS           celecoxib will be administered starting day 1 ...\n",
      "OTHER_NAME                                                      Celebrex\n",
      "EFO_ID                                                       EFO:1001950\n",
      "CONDITION                                                Colon Carcinoma\n",
      "MOLREGNO                                                         1381004\n",
      "NAME_TERM                                                colon carcinoma\n",
      "Name: 2651, dtype: object\n",
      "_____\n",
      "TWID                                                               62927\n",
      "TWEET_ID                                              989178667111796736\n",
      "TWEET                  RT @FDAadcomm 3 VOTE Has the #PRECISION trial ...\n",
      "SYNONYMS                                                       CELECOXIB\n",
      "MOLREGNO_1                                                         18694\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03026140\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                      Demonstrated safety\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                                          Pain\n",
      "INDICATION_ID                                                    D010146\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                      Celecoxib 200mg\n",
      "DESCRIPTIONS           celecoxib will be administered starting day 1 ...\n",
      "OTHER_NAME                                                      Celebrex\n",
      "EFO_ID                                                       EFO:1001950\n",
      "CONDITION                                                Colon Carcinoma\n",
      "MOLREGNO                                                         1153495\n",
      "NAME_TERM                                                colon carcinoma\n",
      "Name: 2652, dtype: object\n",
      "_____\n",
      "TWID                                                               64339\n",
      "TWEET_ID                                              969579709628592131\n",
      "TWEET                  RT @JohnCendpts Roche Ionis herald a big win i...\n",
      "SYNONYMS                                                           ROCHE\n",
      "MOLREGNO_1                                                        469217\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03448666\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               0\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                  demonstrate disease modifying potential\n",
      "COMPANY                                                            Roche\n",
      "COMPANY_ID                                                       COMP642\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                            Huntington Disease\n",
      "INDICATION_ID                                                    D006816\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                    Combination Product\n",
      "INTERVENTION_NAME_x                                        Pembrolizumab\n",
      "DESCRIPTIONS           Electrochemotherapy will be performed with the...\n",
      "OTHER_NAME                                           Electrochemotherapy\n",
      "EFO_ID                                                       EFO:0000756\n",
      "CONDITION                                             Malignant Melanoma\n",
      "MOLREGNO                                                         1626777\n",
      "NAME_TERM                                                       melanoma\n",
      "Name: 2658, dtype: object\n",
      "_____\n",
      "TWID                                                               64444\n",
      "TWEET_ID                                              968464812744302595\n",
      "TWEET                  RT @AndyBiotech $AKCA -20% in PM --&gt Mgnt di...\n",
      "SYNONYMS                                                    VOLANESORSEN\n",
      "MOLREGNO_1                                                       1926843\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02527343\n",
      "PHASE                                                               Null\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                              N/I\n",
      "MATCHED_OUTCOME                                   Disclosed another case\n",
      "COMPANY                                                             Null\n",
      "COMPANY_ID                                                          Null\n",
      "COMPANY_MATCHED                                                     Null\n",
      "COMPANY_NONAMBIG                                                    Null\n",
      "COMPANY_SCORE                                                       Null\n",
      "INDICATION                                              Thrombocytopenia\n",
      "INDICATION_ID                                                    D013921\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         volanesorsen\n",
      "DESCRIPTIONS                                                        Null\n",
      "OTHER_NAME                                  ISIS 304801, IONIS-APOCIIIRx\n",
      "EFO_ID                                                    Orphanet:98306\n",
      "CONDITION                                 Familial Partial Lipodystrophy\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                 Familial partial lipodystrophy\n",
      "Name: 2659, dtype: object\n",
      "_____\n",
      "TWID                                                               64732\n",
      "TWEET_ID                                             1008058943007088642\n",
      "TWEET                  AstraZeneca's acalabrutinib induced an overall...\n",
      "SYNONYMS                                                   ACALABRUTINIB\n",
      "MOLREGNO_1                                                       2039319\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02296918\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         In phase live at\n",
      "COMPANY                                                      AstraZeneca\n",
      "COMPANY_ID                                                        COMP82\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                 Diffuse Large B-Cell Lymphoma\n",
      "INDICATION_ID                                                    D016403\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        acalabrutinib\n",
      "DESCRIPTIONS                               100 mg twice daily continuous\n",
      "OTHER_NAME                                                       ACP-196\n",
      "EFO_ID                                                       EFO:0000095\n",
      "CONDITION                                   Chronic Lymphocytic Leukemia\n",
      "MOLREGNO                                                         1121919\n",
      "NAME_TERM                                   chronic lymphocytic leukemia\n",
      "Name: 2661, dtype: object\n",
      "_____\n",
      "TWID                                                               64732\n",
      "TWEET_ID                                             1008058943007088642\n",
      "TWEET                  AstraZeneca's acalabrutinib induced an overall...\n",
      "SYNONYMS                                                   ACALABRUTINIB\n",
      "MOLREGNO_1                                                       2039319\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02296918\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         In phase live at\n",
      "COMPANY                                                      AstraZeneca\n",
      "COMPANY_ID                                                        COMP82\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                 Diffuse Large B-Cell Lymphoma\n",
      "INDICATION_ID                                                    D016403\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        acalabrutinib\n",
      "DESCRIPTIONS                               100 mg twice daily continuous\n",
      "OTHER_NAME                                                       ACP-196\n",
      "EFO_ID                                                       EFO:0000095\n",
      "CONDITION                                   Chronic Lymphocytic Leukemia\n",
      "MOLREGNO                                                         1626740\n",
      "NAME_TERM                                   chronic lymphocytic leukemia\n",
      "Name: 2663, dtype: object\n",
      "_____\n",
      "TWID                                                               64732\n",
      "TWEET_ID                                             1008058943007088642\n",
      "TWEET                  AstraZeneca's acalabrutinib induced an overall...\n",
      "SYNONYMS                                                   ACALABRUTINIB\n",
      "MOLREGNO_1                                                       2039319\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02296918\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         In phase live at\n",
      "COMPANY                                                      AstraZeneca\n",
      "COMPANY_ID                                                        COMP82\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                 Diffuse Large B-Cell Lymphoma\n",
      "INDICATION_ID                                                    D016403\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        acalabrutinib\n",
      "DESCRIPTIONS                               100 mg twice daily continuous\n",
      "OTHER_NAME                                                       ACP-196\n",
      "EFO_ID                                                       EFO:0000095\n",
      "CONDITION                                   Chronic Lymphocytic Leukemia\n",
      "MOLREGNO                                                          675578\n",
      "NAME_TERM                                   chronic lymphocytic leukemia\n",
      "Name: 2664, dtype: object\n",
      "_____\n",
      "TWID                                                               64732\n",
      "TWEET_ID                                             1008058943007088642\n",
      "TWEET                  AstraZeneca's acalabrutinib induced an overall...\n",
      "SYNONYMS                                                   ACALABRUTINIB\n",
      "MOLREGNO_1                                                       2039319\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02296918\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         In phase live at\n",
      "COMPANY                                                      AstraZeneca\n",
      "COMPANY_ID                                                        COMP82\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                 Diffuse Large B-Cell Lymphoma\n",
      "INDICATION_ID                                                    D016403\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        acalabrutinib\n",
      "DESCRIPTIONS                               100 mg twice daily continuous\n",
      "OTHER_NAME                                                       ACP-196\n",
      "EFO_ID                                                       EFO:0000095\n",
      "CONDITION                                     Small Lymphocytic Lymphoma\n",
      "MOLREGNO                                                         1121919\n",
      "NAME_TERM                                   chronic lymphocytic leukemia\n",
      "Name: 2665, dtype: object\n",
      "_____\n",
      "TWID                                                               64732\n",
      "TWEET_ID                                             1008058943007088642\n",
      "TWEET                  AstraZeneca's acalabrutinib induced an overall...\n",
      "SYNONYMS                                                   ACALABRUTINIB\n",
      "MOLREGNO_1                                                       2039319\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02296918\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         In phase live at\n",
      "COMPANY                                                      AstraZeneca\n",
      "COMPANY_ID                                                        COMP82\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                 Diffuse Large B-Cell Lymphoma\n",
      "INDICATION_ID                                                    D016403\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        acalabrutinib\n",
      "DESCRIPTIONS                               100 mg twice daily continuous\n",
      "OTHER_NAME                                                       ACP-196\n",
      "EFO_ID                                                       EFO:0000095\n",
      "CONDITION                                     Small Lymphocytic Lymphoma\n",
      "MOLREGNO                                                         1626740\n",
      "NAME_TERM                                   chronic lymphocytic leukemia\n",
      "Name: 2667, dtype: object\n",
      "_____\n",
      "TWID                                                               64732\n",
      "TWEET_ID                                             1008058943007088642\n",
      "TWEET                  AstraZeneca's acalabrutinib induced an overall...\n",
      "SYNONYMS                                                   ACALABRUTINIB\n",
      "MOLREGNO_1                                                       2039319\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02296918\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         In phase live at\n",
      "COMPANY                                                      AstraZeneca\n",
      "COMPANY_ID                                                        COMP82\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                 Diffuse Large B-Cell Lymphoma\n",
      "INDICATION_ID                                                    D016403\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        acalabrutinib\n",
      "DESCRIPTIONS                               100 mg twice daily continuous\n",
      "OTHER_NAME                                                       ACP-196\n",
      "EFO_ID                                                       EFO:0000095\n",
      "CONDITION                                     Small Lymphocytic Lymphoma\n",
      "MOLREGNO                                                          675578\n",
      "NAME_TERM                                   chronic lymphocytic leukemia\n",
      "Name: 2668, dtype: object\n",
      "_____\n",
      "TWID                                                               64732\n",
      "TWEET_ID                                             1008058943007088642\n",
      "TWEET                  AstraZeneca's acalabrutinib induced an overall...\n",
      "SYNONYMS                                                   ACALABRUTINIB\n",
      "MOLREGNO_1                                                       2039319\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02296918\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         In phase live at\n",
      "COMPANY                                                      AstraZeneca\n",
      "COMPANY_ID                                                        COMP82\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                 Diffuse Large B-Cell Lymphoma\n",
      "INDICATION_ID                                                    D016403\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        acalabrutinib\n",
      "DESCRIPTIONS                               100 mg twice daily continuous\n",
      "OTHER_NAME                                                       ACP-196\n",
      "EFO_ID                                                       EFO:0004289\n",
      "CONDITION                                        Prolymphocytic Leukemia\n",
      "MOLREGNO                                                         1121919\n",
      "NAME_TERM                                              lymphoid leukemia\n",
      "Name: 2669, dtype: object\n",
      "_____\n",
      "TWID                                                               64732\n",
      "TWEET_ID                                             1008058943007088642\n",
      "TWEET                  AstraZeneca's acalabrutinib induced an overall...\n",
      "SYNONYMS                                                   ACALABRUTINIB\n",
      "MOLREGNO_1                                                       2039319\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02296918\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         In phase live at\n",
      "COMPANY                                                      AstraZeneca\n",
      "COMPANY_ID                                                        COMP82\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                 Diffuse Large B-Cell Lymphoma\n",
      "INDICATION_ID                                                    D016403\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        acalabrutinib\n",
      "DESCRIPTIONS                               100 mg twice daily continuous\n",
      "OTHER_NAME                                                       ACP-196\n",
      "EFO_ID                                                       EFO:0004289\n",
      "CONDITION                                        Prolymphocytic Leukemia\n",
      "MOLREGNO                                                         1626740\n",
      "NAME_TERM                                              lymphoid leukemia\n",
      "Name: 2671, dtype: object\n",
      "_____\n",
      "TWID                                                               64732\n",
      "TWEET_ID                                             1008058943007088642\n",
      "TWEET                  AstraZeneca's acalabrutinib induced an overall...\n",
      "SYNONYMS                                                   ACALABRUTINIB\n",
      "MOLREGNO_1                                                       2039319\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02296918\n",
      "PHASE                                                            Phase 1\n",
      "N_PHASES                                                               2\n",
      "OUTCOME                                                      IN PROGRESS\n",
      "MATCHED_OUTCOME                                         In phase live at\n",
      "COMPANY                                                      AstraZeneca\n",
      "COMPANY_ID                                                        COMP82\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                 Diffuse Large B-Cell Lymphoma\n",
      "INDICATION_ID                                                    D016403\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                        acalabrutinib\n",
      "DESCRIPTIONS                               100 mg twice daily continuous\n",
      "OTHER_NAME                                                       ACP-196\n",
      "EFO_ID                                                       EFO:0004289\n",
      "CONDITION                                        Prolymphocytic Leukemia\n",
      "MOLREGNO                                                          675578\n",
      "NAME_TERM                                              lymphoid leukemia\n",
      "Name: 2672, dtype: object\n",
      "_____\n",
      "TWID                                                               64741\n",
      "TWEET_ID                                             1007611641922453509\n",
      "TWEET                  A post hoc analysis from three phase III studi...\n",
      "SYNONYMS                                                       ISONIAZID\n",
      "MOLREGNO_1                                                          4941\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT00931736\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                          demonstrates the hepatic safety\n",
      "COMPANY                                                        Eli Lilly\n",
      "COMPANY_ID                                                       COMP234\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                  Tuberculosis\n",
      "INDICATION_ID                                                    D014376\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                            Isoniazid\n",
      "DESCRIPTIONS           The dosage of the medication is determined acc...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                     Orphanet:3389\n",
      "CONDITION                                  Latent Tuberculosis Infection\n",
      "MOLREGNO                                                          365189\n",
      "NAME_TERM                                                   Tuberculosis\n",
      "Name: 2689, dtype: object\n",
      "_____\n",
      "TWID                                                               64749\n",
      "TWEET_ID                                             1007257361088745473\n",
      "TWEET                  Novartis' canakinumab (Ilaris) achieves the pr...\n",
      "SYNONYMS                                                     CANAKINUMAB\n",
      "MOLREGNO_1                                                        675785\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02204293\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                            achieves the primary endpoint\n",
      "COMPANY                                                         Novartis\n",
      "COMPANY_ID                                                       COMP504\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                 Non-Small-Cell Lung Carcinoma\n",
      "INDICATION_ID                                                    D002289\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Canakinumab\n",
      "DESCRIPTIONS           Canakinumab will be injected subcutaneously in...\n",
      "OTHER_NAME                                                        Ilaris\n",
      "EFO_ID                                                       EFO:0007135\n",
      "CONDITION                                    Adult-Onset Still´s Disease\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                    adult-onset Still's disease\n",
      "Name: 2704, dtype: object\n",
      "_____\n",
      "TWID                                                               64749\n",
      "TWEET_ID                                             1007257361088745473\n",
      "TWEET                  Novartis' canakinumab (Ilaris) achieves the pr...\n",
      "SYNONYMS                                                     CANAKINUMAB\n",
      "MOLREGNO_1                                                        675785\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02204293\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                            achieves the primary endpoint\n",
      "COMPANY                                                         Novartis\n",
      "COMPANY_ID                                                       COMP504\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                 Non-Small-Cell Lung Carcinoma\n",
      "INDICATION_ID                                                    D002289\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Canakinumab\n",
      "DESCRIPTIONS           For responders on week 24 possibility of open-...\n",
      "OTHER_NAME                                                        Ilaris\n",
      "EFO_ID                                                       EFO:0007135\n",
      "CONDITION                                    Adult-Onset Still´s Disease\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                    adult-onset Still's disease\n",
      "Name: 2706, dtype: object\n",
      "_____\n",
      "TWID                                                               64749\n",
      "TWEET_ID                                             1007257361088745473\n",
      "TWEET                  Novartis' canakinumab (Ilaris) achieves the pr...\n",
      "SYNONYMS                                                          ILARIS\n",
      "MOLREGNO_1                                                        675785\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02204293\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                            achieves the primary endpoint\n",
      "COMPANY                                                         Novartis\n",
      "COMPANY_ID                                                       COMP504\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                 Non-Small-Cell Lung Carcinoma\n",
      "INDICATION_ID                                                    D002289\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Canakinumab\n",
      "DESCRIPTIONS           Canakinumab will be injected subcutaneously in...\n",
      "OTHER_NAME                                                        Ilaris\n",
      "EFO_ID                                                       EFO:0007135\n",
      "CONDITION                                    Adult-Onset Still´s Disease\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                    adult-onset Still's disease\n",
      "Name: 2708, dtype: object\n",
      "_____\n",
      "TWID                                                               64749\n",
      "TWEET_ID                                             1007257361088745473\n",
      "TWEET                  Novartis' canakinumab (Ilaris) achieves the pr...\n",
      "SYNONYMS                                                          ILARIS\n",
      "MOLREGNO_1                                                        675785\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT02204293\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                            achieves the primary endpoint\n",
      "COMPANY                                                         Novartis\n",
      "COMPANY_ID                                                       COMP504\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                 Non-Small-Cell Lung Carcinoma\n",
      "INDICATION_ID                                                    D002289\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                          Canakinumab\n",
      "DESCRIPTIONS           For responders on week 24 possibility of open-...\n",
      "OTHER_NAME                                                        Ilaris\n",
      "EFO_ID                                                       EFO:0007135\n",
      "CONDITION                                    Adult-Onset Still´s Disease\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                    adult-onset Still's disease\n",
      "Name: 2710, dtype: object\n",
      "_____\n",
      "TWID                                                               64751\n",
      "TWEET_ID                                             1007241245637447680\n",
      "TWEET                  Chugai's subcutaneous formulation of tocilizum...\n",
      "SYNONYMS                                                         ACTEMRA\n",
      "MOLREGNO_1                                                        699373\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01532869\n",
      "PHASE                                                            Phase 4\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                    demonstrates efficacy\n",
      "COMPANY                                                            Roche\n",
      "COMPANY_ID                                                       COMP642\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                          Neuromyelitis Optica\n",
      "INDICATION_ID                                                    D009471\n",
      "INDICATION_NONAMBIG                                                    2\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                      tocilizumab [RoActemra/Actemra]\n",
      "DESCRIPTIONS                    162 mg subcutaneously weekly, Weeks 0-48\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000717\n",
      "CONDITION                                            Sclerosis, Systemic\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                           systemic scleroderma\n",
      "Name: 2711, dtype: object\n",
      "_____\n",
      "TWID                                                               64751\n",
      "TWEET_ID                                             1007241245637447680\n",
      "TWEET                  Chugai's subcutaneous formulation of tocilizum...\n",
      "SYNONYMS                                                         ACTEMRA\n",
      "MOLREGNO_1                                                        699373\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01532869\n",
      "PHASE                                                            Phase 4\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                    demonstrates efficacy\n",
      "COMPANY                                                            Roche\n",
      "COMPANY_ID                                                       COMP642\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                          Neuromyelitis Optica\n",
      "INDICATION_ID                                                    D009471\n",
      "INDICATION_NONAMBIG                                                    2\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                      tocilizumab [RoActemra/Actemra]\n",
      "DESCRIPTIONS                    162 mg subcutaneously weekly, Week 48-96\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000717\n",
      "CONDITION                                            Sclerosis, Systemic\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                           systemic scleroderma\n",
      "Name: 2713, dtype: object\n",
      "_____\n",
      "TWID                                                               64751\n",
      "TWEET_ID                                             1007241245637447680\n",
      "TWEET                  Chugai's subcutaneous formulation of tocilizum...\n",
      "SYNONYMS                                                     TOCILIZUMAB\n",
      "MOLREGNO_1                                                        699373\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01532869\n",
      "PHASE                                                            Phase 4\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                    demonstrates efficacy\n",
      "COMPANY                                                            Roche\n",
      "COMPANY_ID                                                       COMP642\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                          Neuromyelitis Optica\n",
      "INDICATION_ID                                                    D009471\n",
      "INDICATION_NONAMBIG                                                    2\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                      tocilizumab [RoActemra/Actemra]\n",
      "DESCRIPTIONS                    162 mg subcutaneously weekly, Weeks 0-48\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000717\n",
      "CONDITION                                            Sclerosis, Systemic\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                           systemic scleroderma\n",
      "Name: 2715, dtype: object\n",
      "_____\n",
      "TWID                                                               64751\n",
      "TWEET_ID                                             1007241245637447680\n",
      "TWEET                  Chugai's subcutaneous formulation of tocilizum...\n",
      "SYNONYMS                                                     TOCILIZUMAB\n",
      "MOLREGNO_1                                                        699373\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT01532869\n",
      "PHASE                                                            Phase 4\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                    demonstrates efficacy\n",
      "COMPANY                                                            Roche\n",
      "COMPANY_ID                                                       COMP642\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                          Neuromyelitis Optica\n",
      "INDICATION_ID                                                    D009471\n",
      "INDICATION_NONAMBIG                                                    2\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                      tocilizumab [RoActemra/Actemra]\n",
      "DESCRIPTIONS                    162 mg subcutaneously weekly, Week 48-96\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                       EFO:0000717\n",
      "CONDITION                                            Sclerosis, Systemic\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                           systemic scleroderma\n",
      "Name: 2717, dtype: object\n",
      "_____\n",
      "TWID                                                               64754\n",
      "TWEET_ID                                             1006974738747584513\n",
      "TWEET                  Corbus Pharmaceuticals' CB2 agonist lenabasum ...\n",
      "SYNONYMS                                                       LENABASUM\n",
      "MOLREGNO_1                                                        512450\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03451045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME        demonstrates a favorable long-term safety profile\n",
      "COMPANY                                           Corbus Pharmaceuticals\n",
      "COMPANY_ID                                                     COMP92922\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                          Systemic Scleroderma\n",
      "INDICATION_ID                                                    D012595\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                      Lenabasum 20 mg\n",
      "DESCRIPTIONS           Subjects will receive lenabasum 20 mg twice da...\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                      Orphanet:586\n",
      "CONDITION                                                Cystic Fibrosis\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                Cystic fibrosis\n",
      "Name: 2719, dtype: object\n",
      "_____\n",
      "TWID                                                               64754\n",
      "TWEET_ID                                             1006974738747584513\n",
      "TWEET                  Corbus Pharmaceuticals' CB2 agonist lenabasum ...\n",
      "SYNONYMS                                                       LENABASUM\n",
      "MOLREGNO_1                                                        512450\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03451045\n",
      "PHASE                                                            Phase 2\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME        demonstrates a favorable long-term safety profile\n",
      "COMPANY                                           Corbus Pharmaceuticals\n",
      "COMPANY_ID                                                     COMP92922\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                          Systemic Scleroderma\n",
      "INDICATION_ID                                                    D012595\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                       Lenabasum 5 mg\n",
      "DESCRIPTIONS           Subjects will receive lenabasum 5 mg twice daily.\n",
      "OTHER_NAME                                                          Null\n",
      "EFO_ID                                                      Orphanet:586\n",
      "CONDITION                                                Cystic Fibrosis\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                Cystic fibrosis\n",
      "Name: 2720, dtype: object\n",
      "_____\n",
      "TWID                                                              132553\n",
      "TWEET_ID                                             1012453525979267077\n",
      "TWEET                  Finally Celgene wins Anemia drug luspatercept ...\n",
      "SYNONYMS                                                    LUSPATERCEPT\n",
      "MOLREGNO_1                                                       1592363\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03342404\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                          scores in trial\n",
      "COMPANY                                                          Celgene\n",
      "COMPANY_ID                                                       COMP160\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                   Thalassemia\n",
      "INDICATION_ID                                                    D013789\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Luspatercept\n",
      "DESCRIPTIONS           Subjects will start with luspatercept at 1 mg/...\n",
      "OTHER_NAME                                                       ACE-536\n",
      "EFO_ID                                                       EFO:1001996\n",
      "CONDITION                                                    Thalassemia\n",
      "MOLREGNO                                                      -NOT-DRUG-\n",
      "NAME_TERM                                                    Thalassemia\n",
      "Name: 2748, dtype: object\n",
      "_____\n",
      "TWID                                                              132553\n",
      "TWEET_ID                                             1012453525979267077\n",
      "TWEET                  Finally Celgene wins Anemia drug luspatercept ...\n",
      "SYNONYMS                                                    LUSPATERCEPT\n",
      "MOLREGNO_1                                                       1592363\n",
      "ACRONYM                                                             Null\n",
      "NCT_ID                                                       NCT03342404\n",
      "PHASE                                                            Phase 3\n",
      "N_PHASES                                                               1\n",
      "OUTCOME                                                          SUCCESS\n",
      "MATCHED_OUTCOME                                          scores in trial\n",
      "COMPANY                                                          Celgene\n",
      "COMPANY_ID                                                       COMP160\n",
      "COMPANY_MATCHED                                              AstraZeneca\n",
      "COMPANY_NONAMBIG                                                       1\n",
      "COMPANY_SCORE                                                          1\n",
      "INDICATION                                                   Thalassemia\n",
      "INDICATION_ID                                                    D013789\n",
      "INDICATION_NONAMBIG                                                    1\n",
      "INDICATION_SCORE                                                       1\n",
      "INTERVENTION_TYPE                                                   Drug\n",
      "INTERVENTION_NAME_x                                         Luspatercept\n",
      "DESCRIPTIONS           Subjects will start with luspatercept at 1 mg/...\n",
      "OTHER_NAME                                                       ACE-536\n",
      "EFO_ID                                                       EFO:1001996\n",
      "CONDITION                                                    Thalassemia\n",
      "MOLREGNO                                          -NOT-SPECIFIED-DRUG/S-\n",
      "NAME_TERM                                                    Thalassemia\n",
      "Name: 2749, dtype: object\n",
      "_____\n"
     ]
    }
   ],
   "source": [
    "#Now we have two columns with molregnos and we can compare the relevance of tweets\n",
    "h = 0 #counter\n",
    "df.index = np.arange(len(df))\n",
    "dif_molregno = [] #list with the indexes of rows that are not correct\n",
    "for i in range(len(df)):\n",
    "    if str(df.loc[i, 'MOLREGNO_1']) != 'Not found' and str(df.loc[i, 'MOLREGNO_1']) != 'Null': #if there is MOLREGNO extracted by synonyms' table\n",
    "        if str(df.loc[i, 'MOLREGNO_1']) != str(df.loc[i, 'MOLREGNO']): #if it is not as the MOLREGNO from indications table\n",
    "            dif_molregno.append(i) #add the index to the list\n",
    "            h += 1 #add 1 to a counter\n",
    "            \n",
    "for i in range(len(dif_molregno)): #look which ones are not correct\n",
    "    print(df.loc[dif_molregno[i]])\n",
    "    print('_____')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 269,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "1656"
      ]
     },
     "execution_count": 269,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df = df.drop(df.index[dif_molregno]) #delete these ones\n",
    "df.index = np.arange(len(df)) #update the indexing\n",
    "len(df)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "<font color='blue'> Add information about MeSH: </font>"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 270,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>MESH_ID</th>\n",
       "      <th>EFO_ID</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>D002277</td>\n",
       "      <td>EFO:0000313</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>D060050</td>\n",
       "      <td>EFO:0003913</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   MESH_ID       EFO_ID\n",
       "0  D002277  EFO:0000313\n",
       "1  D060050  EFO:0003913"
      ]
     },
     "execution_count": 270,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "efo2mesh = pd.read_csv('EFO2MESH.csv', names=['MESH_ID', 'EFO_ID', 'INVALID_LINK', 'MESH_ID_COPY'])\n",
    "del efo2mesh['INVALID_LINK']\n",
    "del efo2mesh['MESH_ID_COPY']\n",
    "efo2mesh[:2]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 271,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>TWID</th>\n",
       "      <th>TWEET_ID</th>\n",
       "      <th>TWEET</th>\n",
       "      <th>SYNONYMS</th>\n",
       "      <th>MOLREGNO_1</th>\n",
       "      <th>ACRONYM</th>\n",
       "      <th>NCT_ID</th>\n",
       "      <th>PHASE</th>\n",
       "      <th>N_PHASES</th>\n",
       "      <th>OUTCOME</th>\n",
       "      <th>...</th>\n",
       "      <th>INDICATION_SCORE</th>\n",
       "      <th>INTERVENTION_TYPE</th>\n",
       "      <th>INTERVENTION_NAME_x</th>\n",
       "      <th>DESCRIPTIONS</th>\n",
       "      <th>OTHER_NAME</th>\n",
       "      <th>EFO_ID</th>\n",
       "      <th>CONDITION</th>\n",
       "      <th>MOLREGNO</th>\n",
       "      <th>NAME_TERM</th>\n",
       "      <th>MESH_ID</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>4</td>\n",
       "      <td>986398045897191424</td>\n",
       "      <td>@PoseidaThera present promising results in ini...</td>\n",
       "      <td>P-BCMA-101</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT03288493</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>1</td>\n",
       "      <td>SUCCESS</td>\n",
       "      <td>...</td>\n",
       "      <td>1</td>\n",
       "      <td>Biological</td>\n",
       "      <td>P-BCMA-101 CAR-T cells</td>\n",
       "      <td>P-BCMA-101 is an autologous, principally Tscm,...</td>\n",
       "      <td>Null</td>\n",
       "      <td>EFO:0001378</td>\n",
       "      <td>Multiple Myeloma</td>\n",
       "      <td>Null</td>\n",
       "      <td>multiple myeloma</td>\n",
       "      <td>D009101</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>1285</td>\n",
       "      <td>871476260161155072</td>\n",
       "      <td>Daratumumab+carfilzomib+lenalidomide+dexametha...</td>\n",
       "      <td>LENALIDOMIDE</td>\n",
       "      <td>63649</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT01863550</td>\n",
       "      <td>Null</td>\n",
       "      <td>0</td>\n",
       "      <td>SUCCESS</td>\n",
       "      <td>...</td>\n",
       "      <td>1</td>\n",
       "      <td>Drug</td>\n",
       "      <td>Lenalidomide</td>\n",
       "      <td>Given PO</td>\n",
       "      <td>CC-5013;CC5013;CDC 501;Revlimid</td>\n",
       "      <td>EFO:0001378</td>\n",
       "      <td>Plasma Cell Myeloma</td>\n",
       "      <td>63649</td>\n",
       "      <td>multiple myeloma</td>\n",
       "      <td>D009101</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>2 rows × 29 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "   TWID            TWEET_ID  \\\n",
       "0     4  986398045897191424   \n",
       "1  1285  871476260161155072   \n",
       "\n",
       "                                               TWEET      SYNONYMS MOLREGNO_1  \\\n",
       "0  @PoseidaThera present promising results in ini...    P-BCMA-101  Not found   \n",
       "1  Daratumumab+carfilzomib+lenalidomide+dexametha...  LENALIDOMIDE      63649   \n",
       "\n",
       "  ACRONYM       NCT_ID    PHASE  N_PHASES  OUTCOME   ...    INDICATION_SCORE  \\\n",
       "0    Null  NCT03288493  Phase 1         1  SUCCESS   ...                   1   \n",
       "1    Null  NCT01863550     Null         0  SUCCESS   ...                   1   \n",
       "\n",
       "  INTERVENTION_TYPE     INTERVENTION_NAME_x  \\\n",
       "0        Biological  P-BCMA-101 CAR-T cells   \n",
       "1              Drug            Lenalidomide   \n",
       "\n",
       "                                        DESCRIPTIONS  \\\n",
       "0  P-BCMA-101 is an autologous, principally Tscm,...   \n",
       "1                                           Given PO   \n",
       "\n",
       "                        OTHER_NAME       EFO_ID            CONDITION MOLREGNO  \\\n",
       "0                             Null  EFO:0001378     Multiple Myeloma     Null   \n",
       "1  CC-5013;CC5013;CDC 501;Revlimid  EFO:0001378  Plasma Cell Myeloma    63649   \n",
       "\n",
       "          NAME_TERM  MESH_ID  \n",
       "0  multiple myeloma  D009101  \n",
       "1  multiple myeloma  D009101  \n",
       "\n",
       "[2 rows x 29 columns]"
      ]
     },
     "execution_count": 271,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df = pd.merge(df, efo2mesh, on='EFO_ID')\n",
    "df = df.fillna('Null')\n",
    "df = df.drop_duplicates()\n",
    "df[:2]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 272,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "The amount of unique tweets is 665\n"
     ]
    }
   ],
   "source": [
    "uni = 0 #count how many unique twids there are\n",
    "for i in range(1, len(df)):\n",
    "    if str(df.loc[i, 'TWID']) != str(df.loc[i - 1, 'TWID']):\n",
    "        uni += 1\n",
    "        \n",
    "print('The amount of unique tweets is', uni) #585"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 273,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "1439"
      ]
     },
     "execution_count": 273,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(df)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## <font color='green'> Matching with original clinical trials table </font>"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 274,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "151533"
      ]
     },
     "execution_count": 274,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#open the clinicaltrials table\n",
    "clinical_trials = pd.read_csv('CLINICALTRIALS_ORIGINAL.csv', names =['NCT_ID', 'ORG_STUDY_ID', 'OVERSIGHT_INFO_AUTHORITY', \n",
    "                                                                     'OVERALL_STATUS', 'WHY_STOPPED', 'PHASES',\n",
    "                                                                     'STUDY_TYPE', 'STUDY_DESIGN', 'NUMBER_OF_ARMS',\n",
    "                                                                     'CONDITION_CT', 'START_DATE', 'COMPLETION_DATE', \n",
    "                                                                     'COMPLETION_DATA_TYPE', 'PRIMARY_COMPLETION_DATE',\n",
    "                                                                     'PRIMARY_COMPLETION_DATA_TYPE',\n",
    "                                                                     'VERIFICATION_DATE', 'LASTCHANGED_DATE', \n",
    "                                                                     'FIRSTRECEIVED_DATE', 'FIRSTRECEIVED_RESULTS_DATE', \n",
    "                                                                     'INTERVENTION_BROWSE_MESH_TERM', \n",
    "                                                                     'CONDITION_BROWSE_MESH_TERM', 'RESULTS', \n",
    "                                                                     'BRIEF_TITLE', 'OFFICIAL_TITLE', 'LEAD_SPONSOR', \n",
    "                                                                     'STUDY_FIRST_SUBMITTED', 'LAST_UPDATE_POSTED', \n",
    "                                                                     'LAST_UPDATE_POSTED_TYPE', 'RESULTS_FIRST_POSTED', \n",
    "                                                                     'RESULTS_FIRST_POSTED_TYPE', 'ACRONYMS'],\n",
    "                             index_col=False)\n",
    "\n",
    "\n",
    "len(clinical_trials)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 275,
   "metadata": {},
   "outputs": [],
   "source": [
    "#deleting not needed columns\n",
    "del clinical_trials['OVERSIGHT_INFO_AUTHORITY']\n",
    "del clinical_trials['WHY_STOPPED']\n",
    "del clinical_trials['NUMBER_OF_ARMS']\n",
    "del clinical_trials['PRIMARY_COMPLETION_DATE']\n",
    "del clinical_trials['PRIMARY_COMPLETION_DATA_TYPE']\n",
    "del clinical_trials['COMPLETION_DATA_TYPE']\n",
    "del clinical_trials['BRIEF_TITLE']\n",
    "del clinical_trials['STUDY_FIRST_SUBMITTED']\n",
    "del clinical_trials['LAST_UPDATE_POSTED']\n",
    "del clinical_trials['LAST_UPDATE_POSTED_TYPE']\n",
    "del clinical_trials['RESULTS_FIRST_POSTED']\n",
    "del clinical_trials['RESULTS_FIRST_POSTED_TYPE']\n",
    "del clinical_trials['CONDITION_BROWSE_MESH_TERM']\n",
    "del clinical_trials['INTERVENTION_BROWSE_MESH_TERM']\n",
    "del clinical_trials['FIRSTRECEIVED_RESULTS_DATE']\n",
    "del clinical_trials['FIRSTRECEIVED_DATE']\n",
    "del clinical_trials['LASTCHANGED_DATE']\n",
    "del clinical_trials['VERIFICATION_DATE']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 276,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "1470"
      ]
     },
     "execution_count": 276,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "clinical_trials = clinical_trials.fillna('Null') #fill empty cells with 'Null'\n",
    "df = pd.merge(df, clinical_trials, how='left', on='NCT_ID') #match main dataframe with clinicaltrials by NCT_ID\n",
    "df.index = np.arange(len(df)) #update indexing\n",
    "len(df)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 277,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>TWID</th>\n",
       "      <th>TWEET_ID</th>\n",
       "      <th>TWEET</th>\n",
       "      <th>SYNONYMS</th>\n",
       "      <th>MOLREGNO_1</th>\n",
       "      <th>ACRONYM</th>\n",
       "      <th>NCT_ID</th>\n",
       "      <th>PHASE</th>\n",
       "      <th>N_PHASES</th>\n",
       "      <th>OUTCOME</th>\n",
       "      <th>...</th>\n",
       "      <th>PHASES</th>\n",
       "      <th>STUDY_TYPE</th>\n",
       "      <th>STUDY_DESIGN</th>\n",
       "      <th>CONDITION_CT</th>\n",
       "      <th>START_DATE</th>\n",
       "      <th>COMPLETION_DATE</th>\n",
       "      <th>RESULTS</th>\n",
       "      <th>OFFICIAL_TITLE</th>\n",
       "      <th>LEAD_SPONSOR</th>\n",
       "      <th>ACRONYMS</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>4</td>\n",
       "      <td>986398045897191424</td>\n",
       "      <td>@PoseidaThera present promising results in ini...</td>\n",
       "      <td>P-BCMA-101</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT03288493</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>1</td>\n",
       "      <td>SUCCESS</td>\n",
       "      <td>...</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Intervention Model: Single Group Assignment, I...</td>\n",
       "      <td>Multiple Myeloma</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Open-Label, Multicenter, Single Ascending Dose...</td>\n",
       "      <td>Poseida Therapeutics, Inc.</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>1285</td>\n",
       "      <td>871476260161155072</td>\n",
       "      <td>Daratumumab+carfilzomib+lenalidomide+dexametha...</td>\n",
       "      <td>LENALIDOMIDE</td>\n",
       "      <td>63649</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT01863550</td>\n",
       "      <td>Null</td>\n",
       "      <td>0</td>\n",
       "      <td>SUCCESS</td>\n",
       "      <td>...</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Allocation: Randomized, Intervention Model: Pa...</td>\n",
       "      <td>Plasma Cell Myeloma</td>\n",
       "      <td>2013-11-01 00:00:00</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Randomized Phase III Trial of Bortezomib, LENa...</td>\n",
       "      <td>ECOG-ACRIN Cancer Research Group</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>1285</td>\n",
       "      <td>871476260161155072</td>\n",
       "      <td>Daratumumab+carfilzomib+lenalidomide+dexametha...</td>\n",
       "      <td>DARATUMUMAB</td>\n",
       "      <td>1121878</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT03289299</td>\n",
       "      <td>Null</td>\n",
       "      <td>0</td>\n",
       "      <td>SUCCESS</td>\n",
       "      <td>...</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Intervention Model: Single Group Assignment, I...</td>\n",
       "      <td>Smoldering Multiple Myeloma</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Aggressive Smoldering Curative Approach Evalua...</td>\n",
       "      <td>International Myeloma Foundation</td>\n",
       "      <td>ASCENT</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>3 rows × 41 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "   TWID            TWEET_ID  \\\n",
       "0     4  986398045897191424   \n",
       "1  1285  871476260161155072   \n",
       "2  1285  871476260161155072   \n",
       "\n",
       "                                               TWEET      SYNONYMS MOLREGNO_1  \\\n",
       "0  @PoseidaThera present promising results in ini...    P-BCMA-101  Not found   \n",
       "1  Daratumumab+carfilzomib+lenalidomide+dexametha...  LENALIDOMIDE      63649   \n",
       "2  Daratumumab+carfilzomib+lenalidomide+dexametha...   DARATUMUMAB    1121878   \n",
       "\n",
       "  ACRONYM       NCT_ID    PHASE  N_PHASES  OUTCOME   ...      PHASES  \\\n",
       "0    Null  NCT03288493  Phase 1         1  SUCCESS   ...     Phase 1   \n",
       "1    Null  NCT01863550     Null         0  SUCCESS   ...     Phase 3   \n",
       "2    Null  NCT03289299     Null         0  SUCCESS   ...     Phase 2   \n",
       "\n",
       "       STUDY_TYPE                                       STUDY_DESIGN  \\\n",
       "0  Interventional  Intervention Model: Single Group Assignment, I...   \n",
       "1  Interventional  Allocation: Randomized, Intervention Model: Pa...   \n",
       "2  Interventional  Intervention Model: Single Group Assignment, I...   \n",
       "\n",
       "                  CONDITION_CT           START_DATE COMPLETION_DATE RESULTS  \\\n",
       "0             Multiple Myeloma                 Null            Null    Null   \n",
       "1          Plasma Cell Myeloma  2013-11-01 00:00:00            Null    Null   \n",
       "2  Smoldering Multiple Myeloma                 Null            Null    Null   \n",
       "\n",
       "                                      OFFICIAL_TITLE  \\\n",
       "0  Open-Label, Multicenter, Single Ascending Dose...   \n",
       "1  Randomized Phase III Trial of Bortezomib, LENa...   \n",
       "2  Aggressive Smoldering Curative Approach Evalua...   \n",
       "\n",
       "                       LEAD_SPONSOR ACRONYMS  \n",
       "0        Poseida Therapeutics, Inc.     Null  \n",
       "1  ECOG-ACRIN Cancer Research Group     Null  \n",
       "2  International Myeloma Foundation   ASCENT  \n",
       "\n",
       "[3 rows x 41 columns]"
      ]
     },
     "execution_count": 277,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df[:3]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 278,
   "metadata": {},
   "outputs": [],
   "source": [
    "df = df.fillna('Null') #fill empty cells with 'Null'\n",
    "df = df.drop_duplicates() #delete all the suplicates\n",
    "df.index = np.arange(len(df)) #update indexes\n",
    "df.to_csv('res_table.csv', sep='\\t', encoding='utf8') #save to csv"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 279,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>TWID</th>\n",
       "      <th>TWEET_ID</th>\n",
       "      <th>TWEET</th>\n",
       "      <th>SYNONYMS</th>\n",
       "      <th>MOLREGNO_1</th>\n",
       "      <th>ACRONYM</th>\n",
       "      <th>NCT_ID</th>\n",
       "      <th>PHASE</th>\n",
       "      <th>N_PHASES</th>\n",
       "      <th>OUTCOME</th>\n",
       "      <th>...</th>\n",
       "      <th>PHASES</th>\n",
       "      <th>STUDY_TYPE</th>\n",
       "      <th>STUDY_DESIGN</th>\n",
       "      <th>CONDITION_CT</th>\n",
       "      <th>START_DATE</th>\n",
       "      <th>COMPLETION_DATE</th>\n",
       "      <th>RESULTS</th>\n",
       "      <th>OFFICIAL_TITLE</th>\n",
       "      <th>LEAD_SPONSOR</th>\n",
       "      <th>ACRONYMS</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>4</td>\n",
       "      <td>986398045897191424</td>\n",
       "      <td>@PoseidaThera present promising results in ini...</td>\n",
       "      <td>P-BCMA-101</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT03288493</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>1</td>\n",
       "      <td>SUCCESS</td>\n",
       "      <td>...</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Intervention Model: Single Group Assignment, I...</td>\n",
       "      <td>Multiple Myeloma</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Open-Label, Multicenter, Single Ascending Dose...</td>\n",
       "      <td>Poseida Therapeutics, Inc.</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>1285</td>\n",
       "      <td>871476260161155072</td>\n",
       "      <td>Daratumumab+carfilzomib+lenalidomide+dexametha...</td>\n",
       "      <td>LENALIDOMIDE</td>\n",
       "      <td>63649</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT01863550</td>\n",
       "      <td>Null</td>\n",
       "      <td>0</td>\n",
       "      <td>SUCCESS</td>\n",
       "      <td>...</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Allocation: Randomized, Intervention Model: Pa...</td>\n",
       "      <td>Plasma Cell Myeloma</td>\n",
       "      <td>2013-11-01 00:00:00</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Randomized Phase III Trial of Bortezomib, LENa...</td>\n",
       "      <td>ECOG-ACRIN Cancer Research Group</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>2 rows × 41 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "   TWID            TWEET_ID  \\\n",
       "0     4  986398045897191424   \n",
       "1  1285  871476260161155072   \n",
       "\n",
       "                                               TWEET      SYNONYMS MOLREGNO_1  \\\n",
       "0  @PoseidaThera present promising results in ini...    P-BCMA-101  Not found   \n",
       "1  Daratumumab+carfilzomib+lenalidomide+dexametha...  LENALIDOMIDE      63649   \n",
       "\n",
       "  ACRONYM       NCT_ID    PHASE  N_PHASES  OUTCOME   ...      PHASES  \\\n",
       "0    Null  NCT03288493  Phase 1         1  SUCCESS   ...     Phase 1   \n",
       "1    Null  NCT01863550     Null         0  SUCCESS   ...     Phase 3   \n",
       "\n",
       "       STUDY_TYPE                                       STUDY_DESIGN  \\\n",
       "0  Interventional  Intervention Model: Single Group Assignment, I...   \n",
       "1  Interventional  Allocation: Randomized, Intervention Model: Pa...   \n",
       "\n",
       "          CONDITION_CT           START_DATE COMPLETION_DATE RESULTS  \\\n",
       "0     Multiple Myeloma                 Null            Null    Null   \n",
       "1  Plasma Cell Myeloma  2013-11-01 00:00:00            Null    Null   \n",
       "\n",
       "                                      OFFICIAL_TITLE  \\\n",
       "0  Open-Label, Multicenter, Single Ascending Dose...   \n",
       "1  Randomized Phase III Trial of Bortezomib, LENa...   \n",
       "\n",
       "                       LEAD_SPONSOR ACRONYMS  \n",
       "0        Poseida Therapeutics, Inc.     Null  \n",
       "1  ECOG-ACRIN Cancer Research Group     Null  \n",
       "\n",
       "[2 rows x 41 columns]"
      ]
     },
     "execution_count": 279,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df[:2]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## <font color='green'> Calculations </font>"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Here would be a comparison of table."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 280,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>TWID</th>\n",
       "      <th>TWEET_ID</th>\n",
       "      <th>TWEET</th>\n",
       "      <th>SYNONYMS</th>\n",
       "      <th>MOLREGNO_1</th>\n",
       "      <th>ACRONYM</th>\n",
       "      <th>NCT_ID</th>\n",
       "      <th>PHASE</th>\n",
       "      <th>N_PHASES</th>\n",
       "      <th>OUTCOME</th>\n",
       "      <th>...</th>\n",
       "      <th>PHASES</th>\n",
       "      <th>STUDY_TYPE</th>\n",
       "      <th>STUDY_DESIGN</th>\n",
       "      <th>CONDITION_CT</th>\n",
       "      <th>START_DATE</th>\n",
       "      <th>COMPLETION_DATE</th>\n",
       "      <th>RESULTS</th>\n",
       "      <th>OFFICIAL_TITLE</th>\n",
       "      <th>LEAD_SPONSOR</th>\n",
       "      <th>ACRONYMS</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>4</td>\n",
       "      <td>986398045897191424</td>\n",
       "      <td>@PoseidaThera present promising results in ini...</td>\n",
       "      <td>P-BCMA-101</td>\n",
       "      <td>Not found</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT03288493</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>1</td>\n",
       "      <td>SUCCESS</td>\n",
       "      <td>...</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Intervention Model: Single Group Assignment, I...</td>\n",
       "      <td>Multiple Myeloma</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Open-Label, Multicenter, Single Ascending Dose...</td>\n",
       "      <td>Poseida Therapeutics, Inc.</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>1285</td>\n",
       "      <td>871476260161155072</td>\n",
       "      <td>Daratumumab+carfilzomib+lenalidomide+dexametha...</td>\n",
       "      <td>LENALIDOMIDE</td>\n",
       "      <td>63649</td>\n",
       "      <td>Null</td>\n",
       "      <td>NCT01863550</td>\n",
       "      <td>Null</td>\n",
       "      <td>0</td>\n",
       "      <td>SUCCESS</td>\n",
       "      <td>...</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Allocation: Randomized, Intervention Model: Pa...</td>\n",
       "      <td>Plasma Cell Myeloma</td>\n",
       "      <td>2013-11-01 00:00:00</td>\n",
       "      <td>Null</td>\n",
       "      <td>Null</td>\n",
       "      <td>Randomized Phase III Trial of Bortezomib, LENa...</td>\n",
       "      <td>ECOG-ACRIN Cancer Research Group</td>\n",
       "      <td>Null</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>2 rows × 41 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "   TWID            TWEET_ID  \\\n",
       "0     4  986398045897191424   \n",
       "1  1285  871476260161155072   \n",
       "\n",
       "                                               TWEET      SYNONYMS MOLREGNO_1  \\\n",
       "0  @PoseidaThera present promising results in ini...    P-BCMA-101  Not found   \n",
       "1  Daratumumab+carfilzomib+lenalidomide+dexametha...  LENALIDOMIDE      63649   \n",
       "\n",
       "  ACRONYM       NCT_ID    PHASE  N_PHASES  OUTCOME   ...      PHASES  \\\n",
       "0    Null  NCT03288493  Phase 1         1  SUCCESS   ...     Phase 1   \n",
       "1    Null  NCT01863550     Null         0  SUCCESS   ...     Phase 3   \n",
       "\n",
       "       STUDY_TYPE                                       STUDY_DESIGN  \\\n",
       "0  Interventional  Intervention Model: Single Group Assignment, I...   \n",
       "1  Interventional  Allocation: Randomized, Intervention Model: Pa...   \n",
       "\n",
       "          CONDITION_CT           START_DATE COMPLETION_DATE RESULTS  \\\n",
       "0     Multiple Myeloma                 Null            Null    Null   \n",
       "1  Plasma Cell Myeloma  2013-11-01 00:00:00            Null    Null   \n",
       "\n",
       "                                      OFFICIAL_TITLE  \\\n",
       "0  Open-Label, Multicenter, Single Ascending Dose...   \n",
       "1  Randomized Phase III Trial of Bortezomib, LENa...   \n",
       "\n",
       "                       LEAD_SPONSOR ACRONYMS  \n",
       "0        Poseida Therapeutics, Inc.     Null  \n",
       "1  ECOG-ACRIN Cancer Research Group     Null  \n",
       "\n",
       "[2 rows x 41 columns]"
      ]
     },
     "execution_count": 280,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "db = df #make a copy\n",
    "db[:2]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 281,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>TWID</th>\n",
       "      <th>TWEET_ID</th>\n",
       "      <th>TWEET</th>\n",
       "      <th>SYNONYMS</th>\n",
       "      <th>PHASE</th>\n",
       "      <th>N_PHASES</th>\n",
       "      <th>COMPANY</th>\n",
       "      <th>INDICATION</th>\n",
       "      <th>INDICATION_ID</th>\n",
       "      <th>CONDITION</th>\n",
       "      <th>MESH_ID</th>\n",
       "      <th>PHASES</th>\n",
       "      <th>CONDITION_CT</th>\n",
       "      <th>OFFICIAL_TITLE</th>\n",
       "      <th>LEAD_SPONSOR</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>4</td>\n",
       "      <td>986398045897191424</td>\n",
       "      <td>@PoseidaThera present promising results in ini...</td>\n",
       "      <td>P-BCMA-101</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>1</td>\n",
       "      <td>Null</td>\n",
       "      <td>Multiple Myeloma</td>\n",
       "      <td>D009101</td>\n",
       "      <td>Multiple Myeloma</td>\n",
       "      <td>D009101</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Multiple Myeloma</td>\n",
       "      <td>Open-Label, Multicenter, Single Ascending Dose...</td>\n",
       "      <td>Poseida Therapeutics, Inc.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>1285</td>\n",
       "      <td>871476260161155072</td>\n",
       "      <td>Daratumumab+carfilzomib+lenalidomide+dexametha...</td>\n",
       "      <td>LENALIDOMIDE</td>\n",
       "      <td>Null</td>\n",
       "      <td>0</td>\n",
       "      <td>Null</td>\n",
       "      <td>Multiple Myeloma</td>\n",
       "      <td>D009101</td>\n",
       "      <td>Plasma Cell Myeloma</td>\n",
       "      <td>D009101</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Plasma Cell Myeloma</td>\n",
       "      <td>Randomized Phase III Trial of Bortezomib, LENa...</td>\n",
       "      <td>ECOG-ACRIN Cancer Research Group</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   TWID            TWEET_ID  \\\n",
       "0     4  986398045897191424   \n",
       "1  1285  871476260161155072   \n",
       "\n",
       "                                               TWEET      SYNONYMS    PHASE  \\\n",
       "0  @PoseidaThera present promising results in ini...    P-BCMA-101  Phase 1   \n",
       "1  Daratumumab+carfilzomib+lenalidomide+dexametha...  LENALIDOMIDE     Null   \n",
       "\n",
       "   N_PHASES COMPANY        INDICATION INDICATION_ID            CONDITION  \\\n",
       "0         1    Null  Multiple Myeloma       D009101     Multiple Myeloma   \n",
       "1         0    Null  Multiple Myeloma       D009101  Plasma Cell Myeloma   \n",
       "\n",
       "   MESH_ID   PHASES         CONDITION_CT  \\\n",
       "0  D009101  Phase 1     Multiple Myeloma   \n",
       "1  D009101  Phase 3  Plasma Cell Myeloma   \n",
       "\n",
       "                                      OFFICIAL_TITLE  \\\n",
       "0  Open-Label, Multicenter, Single Ascending Dose...   \n",
       "1  Randomized Phase III Trial of Bortezomib, LENa...   \n",
       "\n",
       "                       LEAD_SPONSOR  \n",
       "0        Poseida Therapeutics, Inc.  \n",
       "1  ECOG-ACRIN Cancer Research Group  "
      ]
     },
     "execution_count": 281,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "del db['MOLREGNO_1']\n",
    "del db['ACRONYM']\n",
    "del db['NCT_ID']\n",
    "del db['OUTCOME']\n",
    "del db['STUDY_TYPE']\n",
    "del db['STUDY_DESIGN']\n",
    "del db['START_DATE']\n",
    "del db['COMPLETION_DATE']\n",
    "del db['RESULTS']\n",
    "del db['ACRONYMS']\n",
    "del db['MATCHED_OUTCOME']\n",
    "del db['COMPANY_ID']\n",
    "del db['COMPANY_MATCHED']\n",
    "del db['COMPANY_NONAMBIG']\n",
    "del db['COMPANY_SCORE']\n",
    "del db['INDICATION_NONAMBIG']\n",
    "del db['INDICATION_SCORE']\n",
    "del db['INTERVENTION_TYPE']\n",
    "del db['INTERVENTION_NAME_x']\n",
    "del db['DESCRIPTIONS']\n",
    "del db['OTHER_NAME']\n",
    "del db['EFO_ID']\n",
    "del db['MOLREGNO']\n",
    "del db['NAME_TERM']\n",
    "del db['ORG_STUDY_ID']\n",
    "del db['OVERALL_STATUS']\n",
    "db[:2]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 197,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Keys</th>\n",
       "      <th>Nan</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>oma cancer emia neoplasm myelodysplastic syndr...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                Keys  Nan\n",
       "0  oma cancer emia neoplasm myelodysplastic syndr...  NaN"
      ]
     },
     "execution_count": 197,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "keys = pd.read_csv('Key_indications.csv', encoding='utf8')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 282,
   "metadata": {},
   "outputs": [],
   "source": [
    "#create needed columns\n",
    "db['COMPARE_INDICATION'] = 'False'\n",
    "db['COMPARE_COMPANY'] = 'False'\n",
    "db['COMPARE_PHASE'] = 'False'\n",
    "\n",
    "porter = nltk.PorterStemmer() #for stemmer\n",
    "\n",
    "for i in range(len(db)):\n",
    "    #clear tweets to match \n",
    "    db.at[i, 'INDICATION'] = str(db.loc[i, 'INDICATION']).replace(';', '').replace(',', '').replace(':', '').replace('\\'s', '').replace('.', '')\n",
    "    \n",
    "    #clearing for CONDITION\n",
    "    db.at[i, 'CONDITION'] = str(db.loc[i, 'CONDITION']).replace(';', '').replace(',', '').replace(':', '').replace('\\'s', '').replace('.', '')\n",
    "    \n",
    "    #simple matching\n",
    "    ind = str(db.loc[i, 'INDICATION']).split(' ')\n",
    "    ch_indication = [] #the list to check\n",
    "    for j in range(len(ind)):            \n",
    "        comp_ind = re.findall(ind[j].lower(), str(db.loc[i, 'CONDITION']).lower())\n",
    "        if (len(comp_ind) > 0):\n",
    "            ch_indication.append(1) #if at least one time the word is in the condition add 1\n",
    "        else:\n",
    "            ch_indication.append(0)\n",
    "        \n",
    "    if 1 in ch_indication: #if at least one word in list set true\n",
    "        db.at[i, 'COMPARE_INDICATION'] = 'True'\n",
    "    elif 1 not in ch_indication: #if not - set false\n",
    "        db.at[i, 'COMPARE_INDICATION'] = 'False'\n",
    "        \n",
    "        \n",
    "    #comparing using stemmer, only main parts of words    \n",
    "    stem_x = [porter.stem(t) for t in str(db.loc[i, 'INDICATION']).split(' ')]\n",
    "    stem_y = [porter.stem(t) for t in str(db.loc[i, 'CONDITION']).split(' ')]\n",
    "    \n",
    "    x = 0\n",
    "    for k in range(len(stem_x)): #look for every word after stemming in condition\n",
    "        if stem_x[k] in stem_y:\n",
    "            x += 1\n",
    "    if x > 0:\n",
    "        db.at[i, 'COMPARE_INDICATION'] = 'True'\n",
    "    \n",
    "    #comparing indications using the key dictionary (ex. 'oma' -> 'cancer')\n",
    "    if str(db.loc[i, 'COMPARE_INDICATION']) != 'True':\n",
    "        for j in range(len(keys)):\n",
    "            keys_j = keys.loc[j, 'Keys'].split(' ')\n",
    "            res_x = 0\n",
    "            res_y = 0\n",
    "            for k in range(len(keys_j)):\n",
    "                key_x = re.findall(str(keys_j[k]).lower(), str(db.loc[i, 'INDICATION']).lower())\n",
    "                key_y = re.findall(str(keys_j[k]).lower(), str(db.loc[i, 'CONDITION']).lower())\n",
    "                if len(key_x) > 0: \n",
    "                    res_x += 1\n",
    "                if len(key_y) > 0:\n",
    "                    res_y += 1\n",
    "                \n",
    "            if res_x > 0 and res_y > 0:\n",
    "                db.at[i, 'COMPARE_INDICATION'] = 'True'\n",
    "    \n",
    "    #check indication by mesh id:\n",
    "    if str(db.loc[i, 'INDICATION_ID']) == str(db.loc[i, 'MESH_ID']):\n",
    "         db.at[i, 'COMPARE_INDICATION'] = 'True'\n",
    "        \n",
    "    #compare company\n",
    "    res_comp = re.findall(str(db.loc[i, 'COMPANY']).lower(), str(db.loc[i, 'LEAD_SPONSOR']).lower())\n",
    "    if len(res_comp) > 0:\n",
    "        db.at[i, 'COMPARE_COMPANY'] = 'True'\n",
    "            \n",
    "            \n",
    "    #compare phase\n",
    "    res_ph = re.findall(str(db.loc[i, 'PHASE']).lower(), str(db.loc[i, 'PHASES']).lower())\n",
    "    if len(res_ph) > 0:\n",
    "        db.at[i, 'COMPARE_PHASE'] = 'True'"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 283,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Rows with same phases - 558\n",
      "Rows with the same companies - 255\n",
      "Rows with the same indications - 674\n",
      "Length of the dataset is 1439\n"
     ]
    }
   ],
   "source": [
    "same_phase = 0\n",
    "same_ind = 0\n",
    "same_comp = 0\n",
    "for i in range(len(db)):\n",
    "    if str(db.loc[i, 'COMPARE_PHASE']) == 'True':\n",
    "        same_phase += 1\n",
    "    \n",
    "    if str(db.loc[i, 'COMPARE_INDICATION']) == 'True':\n",
    "        same_ind += 1\n",
    "        \n",
    "    if str(db.loc[i, 'COMPARE_COMPANY']) == 'True':\n",
    "        same_comp +=1\n",
    "        \n",
    "print('Rows with same phases -', same_phase)\n",
    "print('Rows with the same companies -', same_comp)\n",
    "print('Rows with the same indications -', same_ind)\n",
    "print('Length of the dataset is', len(db))"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.5.0"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
